FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Hur, C AF Hur, Chin TI Esophageal capsule endoscopy for Barrett's esophagus screening: A hard pill to swallow? SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Editorial Material ID CHRONIC GASTROESOPHAGEAL-REFLUX; UNITED-STATES; DIAGNOSIS; POPULATION; SURVEILLANCE; DISEASES; CANCER; YIELD; ESO C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA. RP Hur, C (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA. OI Hur, Chin/0000-0002-2819-7576 NR 19 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAR PY 2007 VL 5 IS 3 BP 307 EP 309 DI 10.1016/j.cgh.2006.11.010 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 152ZI UT WOS:000245400600009 PM 17257904 ER PT J AU Herraiz, M Barbesino, G Faquin, W Chan-Smutko, G Patel, D Shannon, KM Daniels, GH Chung, DC AF Herraiz, Maite Barbesino, Giuseppe Faquin, William Chan-Smutko, Gayun Patel, Devanshi Shannon, Kristen M. Daniels, Gilbert H. Chung, Daniel C. TI Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID COLON-CANCER; CARCINOMA; NODULES; PAPILLARY; RISK; MICROCARCINOMA; EPIDEMIOLOGY; POPULATION; MALIGNANCY; MUTATIONS AB Background & Aims: Thyroid carcinoma is an extraintestinal manifestation of familial adenomatous polyposis (FAP) syndrome, but the precise risk is unknown. The optimal approach for thyroid cancer screening has not been established. We sought to define the prevalence of thyroid cancer and the role of screening ultrasound in FAP patients. Methods: We performed a retrospective chart review of 51 patients with a proven diagnosis of FAP at a single tertiary institution. Clinical records, genetic test results, ultrasound examinations, and histopathology were reviewed. Results: Papillary thyroid cancer was diagnosed in 6 female patients (12%). The mean age of thyroid cancer diagnosis was 33 years, and mean tumor size was 12 turn. However, all patients had additional malignant foci that were small (1-9 mm), and none had suspicious features of malignancy on ultrasound. Of 28 patients who had at least one screening ultrasound, 22 (79%) had thyroid nodules, and 2 (7%) had papillary thyroid carcinoma. Of those with nodules, 68% had multinodular disease. A follow-up ultrasound in 12 patients after a mean of 15 months revealed no changes in either the number or size of nodules. Conclusions: The 12% prevalence of thyroid cancer in this series of FAP patients is significantly higher than in previous reports. Among patients undergoing screening ultrasound, 7% had thyroid cancer. Nodular thyroid disease is very common in FAP. Because small nodules (<9 mm) might also be malignant, close follow-up with ultrasound and fine-needle aspiration might be warranted. C1 Massachusetts Gen Hosp, Gastrointestinal Unit, Dept Med, Boston, MA 02114 USA. Massachusetts Gen Hosp, Thyroid Unit, Dept Med, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Canc Risk Anal, Boston, MA 02114 USA. RP Chung, DC (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, Dept Med, 50 Blossom St,GRJ 825, Boston, MA 02114 USA. EM dchung@partners.org NR 33 TC 52 Z9 55 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAR PY 2007 VL 5 IS 3 BP 367 EP 373 DI 10.1016/j.cgh.2006.10.019 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 152ZI UT WOS:000245400600019 PM 17258512 ER PT J AU Rini, BI McDermott, D Atkins, M AF Rini, Brian I. McDermott, David Atkins, Michael TI What is standard initial systemic therapy in metastatic renal cell carcinoma? SO CLINICAL GENITOURINARY CANCER LA English DT Review DE bevacizumab; clinical trials; cytokines; sorafenib; sunitinib; ternsirolimus ID ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; CARBONIC-ANHYDRASE-IX; INTERFERON-ALPHA IFN; PHASE-III TRIAL; RANDOMIZED-TRIAL; DOSE INTERLEUKIN-2; ANTITUMOR-ACTIVITY; PROGNOSTIC-FACTORS; KINASE INHIBITOR AB Historically, systemic therapies for metastatic renal cell carcinoma (RCC) have met with minimal success. Recently, an improved understanding of cancer biology has been translated into therapies that target pathways critical for RCC growth and survival and produce more robust clinical impact. The risks and benefits of several approaches 2 to systemic therapy in metastatic RCC are reviewed. The need for chronic therapy of novel agents and potential for toxicity raise questions in regard to the timing of therapy and value of combination therapy over sequential single agents. Further insight into the biology of response, resistance, and toxicity is needed to allow for rational patient selection and enhanced application of systemic therapies. As new standard therapies for metastatic RCC emerge, clinical trial conduct remains a priority to further optimize patient outcome. C1 Cleveland Clin, Taussig Canc Ctr, Dept Solid Tumor Oncol & Urol, Cleveland, OH 44195 USA. Harvard Univ, Dana Farber Canc Ctr, Renal Canc Program, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. RP Rini, BI (reprint author), Cleveland Clin, Taussig Canc Ctr, Dept Solid Tumor Oncol & Urol, 9500 Euclid Ave,Desk R35, Cleveland, OH 44195 USA. EM rinib2@ccf.org NR 45 TC 2 Z9 2 U1 0 U2 0 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 1558-7673 J9 CLIN GENITOURIN CANC JI Clin. Genitourin. Cancer PD MAR PY 2007 VL 5 IS 4 BP 256 EP 263 DI 10.3816/CGC.2007.n.001 PG 8 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 166AO UT WOS:000246349500001 PM 17553205 ER PT J AU Mandell, LA Wunderink, RG Anzueto, A Bartlett, JG Campbell, GD Dean, NC Dowell, SF File, TM Musher, DM Niederman, MS Torres, A Whitney, CG AF Mandell, Lionel A. Wunderink, Richard G. Anzueto, Antonio Bartlett, John G. Campbell, G. Douglas Dean, Nathan C. Dowell, Scott F. File, Thomas M., Jr. Musher, Daniel M. Niederman, Michael S. Torres, Antonio Whitney, Cynthia G. TI Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults SO CLINICAL INFECTIOUS DISEASES LA English DT Review ID RESISTANT STREPTOCOCCUS-PNEUMONIAE; INVASIVE PNEUMOCOCCAL DISEASE; RANDOMIZED CONTROLLED-TRIAL; LOW-RISK PATIENTS; VENTILATOR-ASSOCIATED PNEUMONIA; URINARY ANTIGEN TEST; NEURAMINIDASE INHIBITOR OSELTAMIVIR; DIAGNOSTIC FIBEROPTIC BRONCHOSCOPY; STAPHYLOCOCCUS-AUREUS INFECTIONS; TRANSTHORACIC NEEDLE ASPIRATION AB Improving the care of adult patients with community-acquired pneumonia (CAP) has been the focus of many different organizations, and several have developed guidelines for management of CAP. Two of the most widely referenced are those of the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS). In response to confusion regarding differences between their respective guidelines, the IDSA and the ATS convened a joint committee to develop a unified CAP guideline document. The guidelines are intended primarily for use by emergency medicine physicians, hospitalists, and primary care practitioners; however, the extensive literature evaluation suggests that they are also an appropriate starting point for consultation by specialists. Substantial overlap exists among the patients whom these guidelines address and those discussed in the recently published guidelines for health care-associated pneumonia (HCAP). Pneumonia in nonambulatory residents of nursing homes and other long-term care facilities epidemiologically mirrors hospital-acquired pneumonia and should be treated according to the HCAP guidelines. However, certain other patients whose conditions are included in the designation of HCAP are better served by management in accordance with CAP guidelines with concern for specific pathogens. C1 McMaster Univ, Henderson Hosp, Div Infect Dis, Hamilton, ON L8V 1C3, Canada. McMaster Univ, Sch Med, Hamilton, ON L8V 1C3, Canada. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78285 USA. Michael E DeBakey VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA. Univ Mississippi, Sch Med, Div Pulm Crit Care & Sleep Med, Jackson, MS 39216 USA. LDS Hosp, Div Pulm & Crit Care Med, Salt Lake City, UT USA. Univ Utah, Salt Lake City, UT USA. Ctr Dis Control & Prevent, Atlanta, GA USA. NW Ohio Univ, Coll Med, Rootstown, OH USA. Summa Hlth Syst, Akron, OH USA. SUNY Stony Brook, Stony Brook, NY 11794 USA. Winthrop Univ Hosp, Dept Med, Mineola, NY 11501 USA. Univ Barcelona, Fac Med, Inst Invest Biomed August Pi & Sunyer, Hosp Clin Barcelona,Cap Serv Pneumol & Allergia R, Barcelona 7, Spain. RP Mandell, LA (reprint author), McMaster Univ, Henderson Hosp, Div Infect Dis, 5th Fl,Wing 40,Rm 503,711 Concess St, Hamilton, ON L8V 1C3, Canada. EM lmandell@mcmaster.ca OI Wunderink, Richard/0000-0002-8527-4195 NR 335 TC 2280 Z9 2548 U1 50 U2 219 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 1 PY 2007 VL 44 SU 2 BP S27 EP S72 DI 10.1086/511159 PG 46 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 132FT UT WOS:000243929000001 PM 17278083 ER PT J AU Lipton, A Cook, RJ Coleman, RE Smith, MR Major, P Terpos, E Berenson, JR AF Lipton, Allan Cook, Richard J. Coleman, Robert E. Smith, Matthew R. Major, Pierre Terpos, Evangelos Berenson, James R. TI Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma SO CLINICAL LYMPHOMA & MYELOMA LA English DT Review DE bone markers; telopeptides; zoledronic acid ID CARBOXY-TERMINAL TELOPEPTIDE; ACID-PHOSPHATASE-ACTIVITY; PLACEBO-CONTROLLED TRIAL; ZOLEDRONIC ACID; RESORPTION MARKERS; DOUBLE-BLIND; CROSS-LINKS; SRANKL/OSTEOPROTEGERIN RATIO; OSTEOCLAST DIFFERENTIATION; SKELETAL METASTASES AB Osteolytic bone lesions from advanced multiple myeloma (MM) result in significant skeletal morbidity. Therefore, biochemical markers of bone metabolism, such as the N-terminal and C-terminal telopeptides of type I collagen, bone-specific alkaline phosphatase, and osteocalcin, have been investigated as tools for evaluating the extent of bone disease, risk of skeletal morbidity, and response to antiresorptive treatment. Several studies have shown that the majority of biochemical markers of bone metabolism are increased in patients with MM with osteolytic bone lesions, thus reflecting changes in bone metabolism associated with tumor growth. There is also a growing body of evidence that markers of bone metabolism correlate with the risk of skeletal complications, disease progression, and death. In addition, bone markers could potentially be used as a tool for early diagnosis of bone lesions. The aim of this review is to improve our understanding of bone markers as a clinical tool for the management of malignant bone disease in patients with MM. C1 Penn State Univ, Milton S Hershey Med Ctr, Div Oncol, Hershey, PA 17033 USA. Univ Waterloo, Waterloo, ON N2L 3G1, Canada. Weston Pk Hosp, Ctr Canc Res, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England. Massachusetts Gen Hosp, Boston, MA 02114 USA. Hamilton Reg Canc Ctr, Hamilton, ON, Canada. 251 Gen AF Hosp, Dept Hematol & Med Res, Athens, Greece. Inst Myeloma & Bone Canc Res, W Hollywood, CA USA. RP Lipton, A (reprint author), Penn State Univ, Milton S Hershey Med Ctr, Div Oncol, 500 Univ Dr,C-6830, Hershey, PA 17033 USA. EM alipton@psu.edu NR 73 TC 21 Z9 23 U1 1 U2 1 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 1557-9190 J9 CLIN LYMPHOMA MYELOM JI Clin. Lymphoma Myeloma PD MAR PY 2007 VL 7 IS 5 BP 346 EP 353 DI 10.3816/CLM.2007.n.011 PG 8 WC Oncology SC Oncology GA 162GC UT WOS:000246073800006 PM 17562244 ER PT J AU Atherton, S Church, V Locke, C Tjoelker, R AF Atherton, Sherri Church, Victoria Locke, Christy Tjoelker, Rita TI Clinical nurse specialists: Bridging the gap between evidence and practice using evidence-based fact sheets SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2007 VL 21 IS 2 BP 102 EP 102 DI 10.1097/00002800-200703000-00012 PG 1 WC Nursing SC Nursing GA 140AX UT WOS:000244475600011 ER PT J AU Brush, K AF Brush, Katie TI The role of the CNS in dissemination and implementation of collaborative standards for prevention of line-related bacteremias SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2007 VL 21 IS 2 BP 103 EP 104 DI 10.1097/00002800-200703000-00017 PG 2 WC Nursing SC Nursing GA 140AX UT WOS:000244475600016 ER PT J AU Carroll, DL Rankin, SH AF Carroll, Diane L. Rankin, Sally H. TI Collaborative intervention improves adherence in cardiac elders SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2007 VL 21 IS 2 BP 104 EP 104 DI 10.1097/00002800-200703000-00020 PG 1 WC Nursing SC Nursing GA 140AX UT WOS:000244475600019 ER PT J AU Garner, EIO Goldstein, DP Feltmate, CM Berkowitz, RS AF Garner, Elizabeth I. O. Goldstein, Donald P. Feltmate, Colleen M. Berkowitz, Ross S. TI Gestatioinal trophoblastic disease SO CLINICAL OBSTETRICS AND GYNECOLOGY LA English DT Article DE hydatidiform mole ID COMPLETE HYDATIDIFORM MOLE; FOLLOW-UP; PREGNANCY; RISK; REEVALUATION; DIAGNOSIS AB Hydatidiform mole, a disorder of fertilization, comprises complete and partial molar pregnancy. The pathologic and clinical features of complete and partial mole are well-described. Because of earlier diagnosis, however, the clinical presentation of complete molar pregnancy has significantly changed in recent years. The earlier diagnosis of complete mole is associated with more subtle pathologic findings than later molar pregnancy. The use of immunohistochemical techniques for the detection of maternally imprinted genes as ancillary testing in the diagnosis of complete and partial mole is therefore increasing. Although most molar pregnancies are sporadic, a familial syndrome of recurrent hydatidiform mole has been described. Further research will hopefully lead to identification of the gene defect responsible for this uncommon syndrome. Fortunately, patients with molar pregnancies can generally anticipate normal future reproduction. Close hCG follow-up after molar pregnancy is required to rule out development of postmolar gestational trophoblastic neoplasia. Recent studies suggest that a shorter period of postmolar follow-up may be reasonable for patients with both complete and partial molar pregnancy. C1 Brigham & Womens Hosp, Div Gynecol Oncol, Dept Obstet Gynecol & Reprod Biol, New England Trophoblast Dis Ctr, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Trophoblast Tumor Registry,Dana Farber Canc Inst,, Boston, MA 02115 USA. RP Garner, EIO (reprint author), Brigham & Womens Hosp, Div Gynecol Oncol, Dept Obstet Gynecol & Reprod Biol, New England Trophoblast Dis Ctr, 75 Francis St, Boston, MA 02115 USA. EM egarner@partners.org NR 20 TC 38 Z9 45 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-9201 J9 CLIN OBSTET GYNECOL JI Clin. Obstet. Gynecol. PD MAR PY 2007 VL 50 IS 1 BP 112 EP 122 DI 10.1097/GRF.0b013e31802f17fc PG 11 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 172BV UT WOS:000246780000009 PM 17304028 ER PT J AU O'Cleirigh, C Safren, S AF O'Cleirigh, Conall Safren, Steven TI Breaking the mold or business as usual? Meeting the challenges of HIV prevention in people with serious mental illness and substance use disorders SO CLINICAL PSYCHOLOGY-SCIENCE AND PRACTICE LA English DT Editorial Material DE cognitive-behavioral therapy; dual diagnosis; HIV/AIDS; prevention ID COGNITIVE-BEHAVIORAL THERAPY; MEDICATION ADHERENCE; PROGRESSION; EFFICACY; HAART; ABUSE; AIDS; CARE AB Meade and Weiss (2007) present a timely review of HIV sexual risk behavior in serious mental illness (SMI) and substance use disorders (SUD), and identify a critical paucity of relevant HIV prevention research. They suggest pathways by which SMI/SUD may combine to create risks for HIV. This commentary suggests that the complexities of this patient population may be better suited to hybrid models (Carroll & Rounsaville, 2003) combining the priorities of efficacy and effectiveness. We consider some recent modifications to cognitive-behavioral therapy (CBT) interventions that may provide useful tools to support HIV prevention. The challenges presented by HIV infection in this group are also considered in relation to our current work adapting traditional CBT to treat mental health and substance use issues in the context of HIV infection and/or prevention. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA. RP Safren, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, WACC 815,15 Parkman St, Boston, MA 02114 USA. EM ssafren@partners.org NR 24 TC 7 Z9 7 U1 1 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0969-5893 J9 CLIN PSYCHOL-SCI PR JI Clin. Psychol.-Sci. Pract. PD MAR PY 2007 VL 14 IS 1 BP 34 EP 38 DI 10.1111/j.1468-2850.2007.00060.x PG 5 WC Psychology, Clinical SC Psychology GA 139FX UT WOS:000244418800005 ER PT J AU Biederman, J Krishnan, S Zhang, YX McGough, JJ Findling, RL AF Biederman, Joseph Krishnan, Suma Zhang, Yuxin McGough, James J. Findling, Robert L. TI Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study SO CLINICAL THERAPEUTICS LA English DT Article; Proceedings Paper CT 19th Congress of the United States Psychiatric and Mental Health CY NOV 16-19, 2006 CL New Orleans, LA DE attention-deficit/hyperactivity disorder; NRP-104; lisdexamfetamine; stimulant AB Background: Lisdexamfetamine dimesylate (LDX) is a therapeutically inactive amphetamine prodrug. It was developed with the goal of providing an extended duration of effect that is consistent throughout the day, with a reduced potential for abuse, overdose toxicity, and drug tampering. Following ingestion, the pharmacologically active d-amphetamine molecule is gradually released by rate-limited hydrolysis. Objectives: The aims of this study were to assess the efficacy and tolerability of LDX in school-aged children with attention-deficit/hyperactivity disorder (ADHD) treated in the community, and to characterize the duration of action of LDX compared with placebo. Methods: This Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study was conducted at 40 centers across the United States. Male and female children aged 6 to 12 years with ADHD were randomly assigned to receive LDX 30, 50, or 70 mg with forced-dose titration, or placebo, PO QD for 4 weeks. Efficacy was assessed using the ADHD Rating Scale Version IV (ADHD-RS-IV), the Conners' Parent Rating Scale (CPRS), and the Clinical Global Impression of Improvement scale. Tolerability was assessed throughout the study. Results: Of the 290 randomized patients (201 boys, 89 girls; mean [SD] age, 9 [1.8] years), 230 completed the trial (LDX 30 mg, n = 56; LDX 50 mg, n = 60; LDX 70 mg, n = 60; and placebo, n = 54). The most common reasons for study discontinuation (n = 60) were lack of efficacy (LDX 30 mg, 1%; LDX 50 mg, 0%; LDX 70 mg, 1%; and placebo, 17%) and adverse events (AEs) (LDX 30 mg, 9%; LDX 50 mg, 5%; LDX 70 mg, 14%; and placebo, 1%). Significant improvements in ADHD-RS-IV scores were seen with all doses of LDX compared with placebo (all, P < 0.001), and in CPRS scores with all LDX doses versus placebo throughout the day (all, P < 0.001 for all comparisons). Efficacy was observed by the first week of treatment, and improvements were observed throughout the day up to similar to 6 PM. The most frequently reported AEs among patients receiving LDX were typical of amphetamine products: decreased appetite (39% with active treatment vs 4% with placebo), insomnia (19% vs 3%), upper abdominal pain (12% vs 6%), headache (12% vs 10%), irritability (10% vs 0%), vomiting (9% vs 4%), weight decrease (9% vs 1%), and nausea (6% vs 3%); most were mild to moderate and occurred in the first week. Conclusion: In this population of children with ADHD, treatment once daily with the prodrug LDX at doses of 30 to 70 mg appeared to be effective and had a tolerability profile similar to those of currently marketed extended-release stimulants. (Clin Ther. 2007;29:450-463) Copyright (c) 2007 Excerpta Medica, Inc. C1 Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Yawkey Ctr, Dept Pediat Psychopharmacol, Boston, MA 02114 USA. New River Pharmaceut, Blacksburg, VA USA. Xtiers Consutling, Potomac, MD USA. Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. Univ Hosp Cleveland, Cleveland, OH USA. RP Biederman, J (reprint author), Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Yawkey Ctr, Dept Pediat Psychopharmacol, Suite 6A, Boston, MA 02114 USA. EM jbiederman@partners.org NR 29 TC 138 Z9 143 U1 1 U2 12 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 J9 CLIN THER JI Clin. Ther. PD MAR PY 2007 VL 29 IS 3 BP 450 EP 463 DI 10.1016/j.clinthera.2007.03.006 PG 14 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 157DH UT WOS:000245698300007 PM 17577466 ER PT J AU Miller, DR Gardner, JA Hendricks, AM Zhang, QW Fincke, BG AF Miller, Donald R. Gardner, John A. Hendricks, Ann M. Zhang, Quanwu Fincke, Benjamin G. TI Health care resource utilization and expenditures associated with the use of insulin glargine SO CLINICAL THERAPEUTICS LA English DT Article; Proceedings Paper CT Centers-for-Disease-Control Diabetes and Obesity Conference CY MAY 16-19, 2006 CL Denver, CO SP Ctr Dis Control DE diabetes; insulin; delivery of health care; health care costs ID OF-VETERANS-AFFAIRS; DEPENDENT DIABETES-MELLITUS; HUMAN NPH INSULIN; BASAL INSULIN; HOE 901; THERAPY; COMPLICATIONS; HYPOGLYCEMIA; PROGRESSION; SYSTEM AB Background: Newer insulins, such as long-acting analogues, offer promise of better glycemic control, reduced risk for diabetes complications, and moderation of health care use and costs. Objective: We studied initiation of insulin glargine to evaluate its association with subsequent health service utilization and estimated expenditures. Methods: Patients of the Veterans Health Administration, US Department of Veterans Affairs (VA) who initiated insulin glargine (n = 5064) in 2001-2002 were compared with patients receiving other insulin (n = 69,944), matched on prescription month (index date). Inpatient and outpatient VA care in the 12 months after a patient's index date was evaluated using Tobit regression, controlling for prior utilization, demographic characteristics, comorbidities, glycosylated hemoglobin (HbA(1c)) levels, and diabetes severity. National average utilization costs and medication acquisition costs were used to estimate the value of VA expenditures. Results: Compared with other insulin users, insulin glargine initiators had higher HbA(1c) values (8.72% vs 8.16%) prior to the index date, but greater subsequent HbA(1c) reduction (-0.50% vs -0.22%). After adjustment for age, prior utilization, HbA(1c) levels, and other factors, insulin glargine initiation was associated with 2.4 (95% CI, 1.1-3.7) fewer inpatient days for patients with any hospital admission (US $820 lower costs per initiator), 1.6 (1.2-1.9) more outpatient encounters ($279 higher costs per initiator), and $374 ($362-$387) higher costs for diabetes medications. The net difference was an average lower VA cost of $166 (-$290 to $622) per patient. Conclusions: Insulin glargine use was associated with decreased inpatient days but increased outpatient care, and the value of the net change in utilization to VA offset the additional medication expenditures. Initiation of insulin glargine improves glycemic control and may reduce time in hospital without additional use of health resources. (Clin Ther. 2007;29:478-487) Copyright (c) 2007 Excerpta Medica, Inc. C1 VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA. VA Boston Healthcare Syst, Hlth Care Financing & Econ, Jamaica Plain, MA USA. Sanofi Aventis USA, Bridgewater, NJ USA. RP Miller, DR (reprint author), VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, 200 Springs Rd 152, Bedford, MA 01730 USA. EM drmiller@bu.edu NR 38 TC 6 Z9 6 U1 1 U2 3 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 J9 CLIN THER JI Clin. Ther. PD MAR PY 2007 VL 29 IS 3 BP 478 EP 487 DI 10.1016/j.clinthera.2007.03.003 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 157DH UT WOS:000245698300010 PM 17577469 ER PT J AU Fishman, JA Emery, V Freeman, R Pascual, M Rostaing, L Schlitt, HJ Sgarabotto, D Torre-Cisneros, J Uknis, ME AF Fishman, Jay A. Emery, Vincent Freeman, Richard Pascual, Manuel Rostaing, Lionel Schlitt, Hans J. Sgarabotto, Dino Torre-Cisneros, Julian Uknis, Marc E. TI Cytomegalovirus in transplantation - challenging the status quo SO CLINICAL TRANSPLANTATION LA English DT Article DE cytomegalovirus; ganciclovir; transplantation; valganciclovir; viremia ID PANCREAS-KIDNEY TRANSPLANTATION; SOLID-ORGAN TRANSPLANTATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; ORTHOTOPIC LIVER-TRANSPLANTATION; RENAL-TRANSPLANTATION; ORAL GANCICLOVIR; LUNG TRANSPLANTATION; CMV INFECTION; VALACICLOVIR PROPHYLAXIS; PREVENT CYTOMEGALOVIRUS AB Background: Cytomegalovirus (CMV) infection of solid organ transplant (SOT) recipients causes both ''direct'' and ''indirect'' effects including allograft rejection, decreased graft and patient survival, and predisposition to opportunistic infections and malignancies. Options for CMV prevention include pre-emptive therapy, whereby anti-CMV agents are administered based on sensitive viral assays, or universal prophylaxis of all at-risk patients. Each approach has advantages and disadvantages in terms of efficacy, costs, and side effects. Standards of care for prophylaxis have not been established. Methods: A committee of international experts was convened to review the available data regarding CMV prophylaxis and to compare preventative strategies for CMV after transplantation from seropositive donors or in seropositive recipients. Results: Pre-emptive therapy requires frequent monitoring with subsequent treatment of disease and associated costs, while universal prophylaxis results in greater exposure to potential toxicities and costs of drugs. The advantages of prophylaxis include suppressing asymptomatic viremia and prevention of both direct and indirect effects of CMV infection. Meta analyses reveal decreased in mortality for patients receiving CMV prophylaxis. Costs associated with prophylaxis are less than for routine monitoring and pre-emptive therapy. The optimal duration of antiviral prophylaxis remains undefined. Extended prophylaxis may improve clinical outcomes in the highest-risk patient populations including donor-seropositive/recipient-seronegative renal transplants and in CMV-infected lung and heart transplantation. Conclusions: Prophylaxis is beneficial in preventing direct and indirect effects of CMV infection in transplant recipients, affecting both allograft and patient survival. More studies are necessary to define optimal prophylaxis regimens. C1 Univ Massachusetts, Sch Med, St Barnabas Hlth Care Syst, Dept Renal & Pancreas Transplant, Livingston, NJ 07039 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. UCL Royal Free & Univ Coll Med Sch, Ctr Virol, Dept Infect, London, England. Tufts Univ New England Med Ctr, Boston, MA USA. CHU Vaudois, Transplantat Serv, CH-1011 Lausanne, Switzerland. CHU Hop Rangueil, Toulouse, France. Univ Regensburg Klinikum, Chirurg Klin & Poliklin, Regensburg, Germany. Azienda Osped Padova, Padua, Italy. Hosp Univ Reina Sofia, Cordoba, Spain. RP Uknis, ME (reprint author), Univ Massachusetts, Sch Med, St Barnabas Hlth Care Syst, Dept Renal & Pancreas Transplant, 94 Old Short Hills Rd, Livingston, NJ 07039 USA. EM muknis@sbhcs.com OI Emery, Vincent/0000-0001-5893-9756 NR 69 TC 152 Z9 161 U1 2 U2 8 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0902-0063 J9 CLIN TRANSPLANT JI Clin. Transplant. PD MAR-APR PY 2007 VL 21 IS 2 BP 149 EP 158 DI 10.1111/j.1399-0012.2006.00618.x PG 10 WC Surgery; Transplantation SC Surgery; Transplantation GA 150PX UT WOS:000245229800001 PM 17425738 ER PT J AU Agrawal, N Ugaz, VM AF Agrawal, Nitin Ugaz, Victor M. TI A buoyancy-driven compact thermocycler for rapid PCR SO CLINICS IN LABORATORY MEDICINE LA English DT Article ID POLYMERASE-CHAIN-REACTION AB The authors have designed a novel convective flow-based thermocycling system capable of performing high-speed DNA amplification via the polymerase chain reaction in a simplified and inexpensive format. Successful amplification of a 191 bp influenza-A target is demonstrated within 25 minutes using a 10 mu L reaction volume with no modification to standard laboratory protocols. The system is simple to assemble and can be readily integrated with existing laboratory instrumentation for automated operation. C1 Texas A&M Univ, Artie McFerrin Dept Chem Engn, College Stn, TX 77843 USA. Massachusetts Gen Hosp, Dept Surg, Ctr Engn Med, Boston, MA 02114 USA. Shriners Burns Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Ugaz, VM (reprint author), Texas A&M Univ, Artie McFerrin Dept Chem Engn, College Stn, TX 77843 USA. EM nagrawall@partners.org; ugaz@tamu.edu FU NHGRI NIH HHS [K22-HG02297, R01-HG003364] NR 15 TC 12 Z9 12 U1 2 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-2712 J9 CLIN LAB MED JI Clin. Lab. Med. PD MAR PY 2007 VL 27 IS 1 BP 215 EP + DI 10.1016/j.cll.2007.01.004 PG 10 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 162YF UT WOS:000246124700018 PM 17416315 ER PT J AU Keary, TA Gunstad, J Poppas, A Paul, RH Jefferson, AL Hoth, KF Sweet, LH Forman, DE Cohen, RA AF Keary, Therese Anne Gunstad, John Poppas, Athena Paul, Robert H. Jefferson, Angela L. Hoth, Karin F. Sweet, Lawrence H. Forman, Daniel E. Cohen, Ronald A. TI Blood pressure variability and dementia rating scale performance in older adults with cardiovascular disease SO COGNITIVE AND BEHAVIORAL NEUROLOGY LA English DT Article DE blood pressure; cognitive function; cardiovascular disease ID HEART-RATE-VARIABILITY; COGNITIVE FUNCTION; VASCULAR DEMENTIA; ESSENTIAL-HYPERTENSION; ALZHEIMERS-DISEASE; ALTERNATE-FORM; MEMORY; IMPAIRMENT; DAMAGE AB Objective: The present study examined the relationship between multiple indices of blood pressure (13P) and cognitive function (as measured by the Dementia Rating Scale). Background: Cardiovascular disease (CVD) is associated with cognitive dysfunction and cerebrovascular pathology in the elderly and is a known risk factor for stroke and Alzheimer disease. Yet, the mechanisms for the effects of CVD on cognitive function are not well understood. Methods: Participants were 97 nondemented older adults with CVD who underwent neuropsychologic assessment, and a 2-hour cardiovascular laboratory protocol. Results: After controlling for age and years of education, results of hierarchical linear regression analyses indicate a significant positive relationship between a function of BP variability (SD of systolic BP divided by the average diastolic BP) and cognitive function (R-2 change = 0.042, F (1, 85) = 5.434, P < 0.05). No relationship emerged between any other BP index and cognitive function. Conclusions: Contrary to expectations, greater BP variability was associated with better, not poorer, cognitive test performance. These findings suggest that the relationship between BP and cognitive function is more complicated than originally conceptualized and requires further investigation. C1 Kent State Univ, Dept Psychol, Kent, OH 44224 USA. Rhode Isl Med Ctr, Dept Cardiol, Providence, RI USA. Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI USA. Boston Univ, Sch Med, Dept Neurol, Alzheimers Dis Ctr, Boston, MA 02118 USA. Brigham & Womens Hosp, Div Cardiol, Boston, MA 02115 USA. VA Boston Healthcare Syst, Boston, MA USA. RP Keary, TA (reprint author), Kent State Univ, Dept Psychol, Kent Hall, Kent, OH 44224 USA. EM tamatthe@kent.edu FU NIA NIH HHS [F32 AG026850] NR 42 TC 9 Z9 9 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1543-3633 J9 COGN BEHAV NEUROL JI Cogn. Behav. Neurol. PD MAR PY 2007 VL 20 IS 1 BP 73 EP 77 DI 10.1097/WNN.0b013e3180335f9f PG 5 WC Behavioral Sciences; Clinical Neurology SC Behavioral Sciences; Neurosciences & Neurology GA 152QN UT WOS:000245377000013 PM 17356348 ER PT J AU Gurrera, RJ Simpson, JC Tsuang, MT AF Gurrera, Ronald J. Simpson, John C. Tsuang, Ming T. TI Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence SO COMPREHENSIVE PSYCHIATRY LA English DT Article; Proceedings Paper CT 156th Annual Meeting of the American-Psychiatric-Association CY MAY 17-22, 2003 CL SAN FRANCISCO, CA SP Amer Psychiat Assoc ID CONSECUTIVE INPATIENTS; FREQUENCY; RISK; PUBLICATION; REVIEWS AB Objective: The aim of this study was to examine published reports for sources of excessive variance in neuroleptic malignant syndrome (NMS) incidence estimates. Data Sources: An unrestricted computerized MEDLINE search was conducted with a comprehensive search logic and supplemented by secondary references and a manual search of an extensive personal library. Study Selection: Studies were analyzed if they presented original data and provided at least 2 of the following: number of NMS cases, number of patients at risk, or ratio of cases to patients at risk. Twenty-six of the 28 candidate studies met these minimal criteria. Data Extraction: Variables included incidence, year of study publication, mean year of NMS occurrence, patient population at risk, study design, diagnostic criteria, and country of origin. Data Synthesis: Standard error, which reflects study size, accounted for 90.8% of the variance (beta = .953, P <.001) in this international series of 26 NMS incidence estimates. Incidence was significantly lower in 7 studies the time end points of which were set in advance of case identification (chi(2) = 71.08, P <.001). No other variable was significantly related to incidence. Conclusions: Neuroleptic malignant syndrome incidence estimates to date are non-trivially biased such that larger study size (patients at risk) is strongly related to lower observed incidence. Future studies can minimize the contribution of this and other sources of experimental error by incorporating several very feasible recommendations. (c) 2007 Elsevier Inc. All rights reserved. C1 Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA. Harvard Univ, Dept Epidemiol, Boston, MA 02115 USA. Harvard Univ, Inst Psychiat Epidemiol & Genet, Boston, MA 02115 USA. RP Gurrera, RJ (reprint author), VA Boston Healthcare Syst, Brockton, MA 02301 USA. EM ronald.gurrera@va.gov NR 45 TC 8 Z9 8 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0010-440X J9 COMPR PSYCHIAT JI Compr. Psychiat. PD MAR-APR PY 2007 VL 48 IS 2 BP 205 EP 211 DI 10.1016/j.comppsych.2006.10.004 PG 7 WC Psychiatry SC Psychiatry GA 139DJ UT WOS:000244412200015 PM 17292713 ER PT J AU Shacter, HE Gee, RE Long, JA AF Shacter, Hannah E. Gee, Rebekah E. Long, Judith A. TI Variation in availability of emergency contraception in pharmacies SO CONTRACEPTION LA English DT Article DE emergency contraception; health policy; women's health; pharmacy availability ID CONSCIENTIOUS OBJECTION AB Objective: The availability of emergency contraception (EC) depends on pharmacy stocking practices and pharmacist willingness to dispense the medication. We aimed to describe the availability of EC in areas governed by different state policies regarding pharmacist behavior. Study Design: A telephone survey was conducted between October I and December 31, 2005, of every pharmacy listed in the metropolitan areas of Atlanta, Philadelphia and Boston. We asked whether pharmacies could fill a prescription for EC within 24 h and, if not, why not. Results: We interviewed pharmacists at 1085 pharmacies (response rate of 75%). Overall, 23% were unable to fill a prescription for EC within 24 It. The rate of being unable to fill was 35% in Atlanta, 23% in Philadelphia and 4% in Boston (p <.001). Refusal rates were low: 4% overall; 8% in Atlanta; 3% in Philadelphia and 0% in Boston. Conclusions: Variation in state policy predicted the availability of EC. The most common reason for not being able to fill a prescription within 24 h was not having the medication in stock. (c) 2007 Elsevier Inc. All rights reserved. C1 Philadelphia Vet Affairs Ctr Hlth Equ Res & Promo, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Shacter, HE (reprint author), Philadelphia Vet Affairs Ctr Hlth Equ Res & Promo, Philadelphia, PA 19104 USA. EM hshacter@gmail.com NR 17 TC 12 Z9 13 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAR PY 2007 VL 75 IS 3 BP 214 EP 217 DI 10.1016/j.contraception.2006.11.005 PG 4 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 141BB UT WOS:000244550100011 PM 17303492 ER PT J AU Amory, JK Page, ST Anawalt, BD Matsumoto, AM Bremner, WJ AF Amory, John K. Page, Stephanie T. Anawalt, Bradley D. Matsumoto, Alvin M. Bremner, William J. TI Acceptability of a combination testosterone gel and depomedroxyprogesterone acetate male contraceptive regimen SO CONTRACEPTION LA English DT Article DE spermatogenesis; sexual function; male hormonal contraception; testosterone gel ID MALE HORMONAL CONTRACEPTION; NORMALIZES ANDROGEN LEVELS; NORETHISTERONE ENANTHATE; SEXUAL FUNCTION; TRANSDERMAL TESTOSTERONE; BODY-COMPOSITION; CLINICAL-TRIAL; NORMAL MEN; UNDECANOATE; SPERMATOGENESIS AB Background: Testosterone (T) gel, administered transdermally in combination with injections of depornedroxyprogesterone acetate (DMPA) every 3 months, results in effective suppression of spermatogenesis in 90% of men. Men's attitudes regarding the daily self-administration of T-gel and the impact of such a regimen on sexual function, however, are unknown. Therefore, we questioned subjects enrolled in a combination T-gel plus DMPA male contraceptive trial regarding the acceptability of T-gel for male contraception and the impact of the T-geu DMPA regimen on sexual function and satisfaction during treatment. Study Design: Thirty-eight healthy men, ages 18-55, were treated with T-gel (100 mg daily) + DMPA (300 mg every 3 months) for 24 weeks. Sexual function was assessed using a validated questionnaire at baseline, after 12 and 24 weeks of treatment and 12 weeks into recovery. The overall acceptability of the method and attitudes regarding the daily self-administration of T-gel were assessed by a questionnaire 12 weeks into recovery. Results: Fifty percent of subjects were either satisfied or very satisfied with the T-gel-based contraceptive regimen, and 45% indicated they would use the regimen if it were commercially available. The T-gel was found to be easy to use by 76% of men, but a third of subjects felt that T-gel administration interfered with their daily routine. Sexual function was largely preserved during treatment; however, slight decreases in sexual function were noted during recovery. Conclusions: The experimental male hormonal contraceptive regimen of T-gel + DMPA is acceptable to approximately one half of study volunteers, most of whom would use the method if it were commercially available. Given its appeal to a significant proportion of men, additional studies using T-gel and DMPA for male contraception are warranted. (c) 2007 Elsevier Inc. All rights reserved. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. RP Amory, JK (reprint author), Univ Washington, Dept Med, Box 326429, Seattle, WA 98195 USA. FU NIA NIH HHS [K23 AG027238-03, K23 AG027238]; NICHD NIH HHS [K23 HD45386, U54 HD12629, U54 HD42454] NR 21 TC 18 Z9 18 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAR PY 2007 VL 75 IS 3 BP 218 EP 223 DI 10.1016/j.contraception.2006.11.003 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 141BB UT WOS:000244550100012 PM 17303493 ER PT J AU Lee, PS Waxman, AB Cotich, KL Chung, SW Perrella, MA Stossel, TP AF Lee, Po-Shun Waxman, Aaron B. Cotich, Kara L. Chung, Su Wol Perrella, Mark A. Stossel, Thomas P. TI Plasma gelsolin is a marker and therapeutic agent in animal sepsis SO CRITICAL CARE MEDICINE LA English DT Article; Proceedings Paper CT 101st International Conference of the American-Thoracic-Society CY MAY 20-25, 2005 CL San Diego, CA SP Amer Thorac Soc, Fogarty AIDS Int Training & Res Program DE septicemia; sepsis syndrome; endotoxemia; actin-binding proteins; cecal ligation and puncture; biological markers ID D-BINDING-PROTEIN; ACTIN COMPLEXES; LYSOPHOSPHATIDIC ACID; SCAVENGER SYSTEM; SHOCK; CIRCULATION; DYSFUNCTION; RESPONSES; OUTCOMES; CALCIUM AB Objective., Plasma gelsolin is a circulating actin-binding protein that serves a protective role against tissue injuries. Depletion of plasma gelsolin in systemic inflammation may contribute to adverse outcomes. We examined the role of plasma gelsolin in animal models of sepsis. Design: Animal and laboratory experiments. Setting. Academic research laboratory. Subjects. Adult male mice. Interventions. Mice subjected to endotoxin or cecal ligation and puncture (CLP) were treated with exogenous plasma gelsolin or placebo. Measurements and Main Results. We document the depletion of plasma gelsolin (25-50% of normal) in murine models of sepsis associated with the presence of circulating actin within 6 hrs of septic challenge. Repletion of plasma gelsolin leads to solubilization of circulating actin aggregates and significantly reduces mortality in endotoxemic mice (survival rates were 88% in the gelsolin group vs. 0% in the saline group, p <.001) and in CLP-challenged mice (survival rates were 30% in the gelsolin group vs. 0% in the saline group, p =.001). Plasma gelsolin repletion also shifted the cytokine profile of endotoxemic mice toward anti-inflammatory (plasma interleukin-10 levels were 205 +/- 108 pg/mL in the gelsolin group vs. 39 +/- 29 pg/mL in the saline group, p =.02). Conclusions. We propose that circulation of particulate actin is a marker for sepsis-induced cell injury, that plasma gelsolin has a crucial protective role in sepsis, and that gelsolin replacement represents a potential therapy for this common lethal condition. C1 Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA. Brigham & Womens Hosp, Translat Med Div, Boston, MA 02115 USA. Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Lee, PS (reprint author), Brigham & Womens Hosp, Div Pulm & Crit Care, 75 Francis St, Boston, MA 02115 USA. NR 36 TC 67 Z9 76 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD MAR PY 2007 VL 35 IS 3 BP 849 EP 855 DI 10.1097/01.CCM.0000253815.26311.24 PG 7 WC Critical Care Medicine SC General & Internal Medicine GA 139ZE UT WOS:000244470800023 PM 17205019 ER PT J AU Zhu, XS Bagchi, A Zhao, HL Kirschning, CJ Hajjar, RJ Chao, W Hellman, J Schmidt, U AF Zhu, Xinsheng Bagchi, Aranya Zhao, Huailong Kirschning, Carsten J. Hajjar, Roger J. Chao, Wei Hellman, Judith Schmidt, Ulrich TI Toll-like receptor 2 activation by bacterial peptidoglycan-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction SO CRITICAL CARE MEDICINE LA English DT Article DE tumor necrosis factor-alpha; peptidoglycan-associated lipoprotein; Toll-like receptor 2 ID TUMOR-NECROSIS-FACTOR; OUTER-MEMBRANE PROTEINS; TOLL-LIKE RECEPTOR-2; SEPTIC SHOCK; FACTOR-ALPHA; MYOCARDIAL DYSFUNCTION; CARDIOVASCULAR DYSFUNCTION; VENTRICULAR CONTRACTILITY; MONOCLONAL-ANTIBODY; MUREIN LIPOPROTEIN AB Objective: Although cardiac dysfunction plays an important role in the pathogenesis of sepsis, the mechanisms that underlie cardiac dysfunction in sepsis remain poorly understood. Bacterial peptidoglycan-associated lipoprotein (PAL), an outer-membrane protein of Gram-negative bacteria, was recently found to be released into the bloodstream in sepsis and to cause inflammation and death in mice. The present studies assessed the effects of PAL on cardiomyocyte function and its signal transduction in cardiomyocytes. Design: Randomized prospective animal study. Setting. Research laboratory. Subjects: Male C57BL/6 mice, B6;129S-Tnfrsf1a(tm1lmx) Tnfrsf1b(tm1lmx)/J knockout mice, Toll-like receptor 2 (TLR2) knockout mice, and myeloid differentiation factor 88 (MyD88) knockout mice. Interventions. None. Measurements and Results. Immunohistochemical staining and immunoblot analysis indicated that intravenously injected PAL bound to myocardium. Injection of PAL decreased cardiac function in vivo. Challenge with PAL altered cell shortening and Ca2+ transients in isolated mouse cardiomyocytes but not in cardiomyocytes isolated from TLR2(-/-) and MyD88(-/-) mice. Cytokine profiling arrays demonstrated that tumor necrosis factor-alpha (TNF alpha), granulocyte colony-stimulating factor, and interferon-gamma production were elevated in PAL-treated cardiomyocytes. Increased TNF alpha production was abolished in MyD88(-/-) cardiomyocytes but restored by adenovirally mediated expression of MyD88. PAL did not affect cell shortening and Ca2+ cycling in cardiomyocytes obtained from mice deficient for TNF alpha receptor (TNFR) 1 and TNFR2 (TNFR1/2(-/-)). Conclusion: Our data reveal that PAL uses the TLR2/MyD88 signaling cascade to induce cardiomyocyte dysfunction and inflammatory responses and that TNF alpha is a major mediator of PAL-induced dysfunction in cardiomyocytes. These studies suggest that circulating PAL and other TLR2 agonists may contribute to cardiac dysfuncton in sepsis. C1 Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-8000 Munich, Germany. Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA. Harvard Univ, Sch Med, Charlestown, MA USA. RP Zhu, XS (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. FU NHLBI NIH HHS [HL-04336, R01 HL71763, K08 HL69778]; PHS HHS [R01 A1058106] NR 35 TC 38 Z9 46 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD MAR PY 2007 VL 35 IS 3 BP 886 EP 892 DI 10.1097/01.CCM.0000256723.37586.A2 PG 7 WC Critical Care Medicine SC General & Internal Medicine GA 139ZE UT WOS:000244470800028 PM 17255871 ER PT J AU Zhai, RH Zhou, W Gong, MN Thompson, BT Su, L Yu, CL Kraft, P Christiani, DC AF Zhai, Rihong Zhou, Wei Gong, Michelle N. Thompson, B. Taylor Su, Li Yu, Chuling Kraft, Peter Christiani, David C. TI Inhibitor kappa B-alpha haplotype GTC is associated with susceptibility to acute respiratory distress syndrome in Caucasians SO CRITICAL CARE MEDICINE LA English DT Article DE NFKBIA; polymorphism; haplotype; acute respiratory distress syndrome; genetic susceptibility ID GENDER-DIFFERENCES; EPITHELIAL-CELLS; POLYMORPHISM; GENE; RISK; PROMOTER; INDUCTION; DISEASES; PATHWAY; COMPLEX AB Objective: The nuclear factor (NF)-kappa B regulates inflammatory responses and plays important roles in the pathogenesis of acute respiratory distress syndrome (ARDS). Inhibitor kappa B-alpha (NFKBIA) inhibits NF-kappa B and controls its activities. The objective was to determine whether polymorphisms in NFKBIA gene would be associated with ARDS development. Design: Prospective cohort of adults with clinical risk factors for ARDS. Setting: Hospital system. Patients: Patients were 1,210 critically ill Caucasian patients meeting study criteria for a defined risk factor for ARDS who were enrolled and prospectively followed for 60 days; 382 had ARDS, and 828 were controls. Interventions. Genetic polymorphisms in the NFKBIA promoter (-861A/G, -826C/T, -297C/7) were determined using TaqMan techniques. Measurements and Main Results: The three polymorphisms were in Hardy-Weinberg equilibrium. No individual genotype was significantly associated with ARDS development. In contrast, haplotypes of NFKBIA were globally associated with ARDS development (p = .02, degree of freedom = 2). The frequency of haplotype GTC (-881G/- 826T/- 297C) was significantly higher among ARDS patients (7.4%) than that among controls (5.2%) (p = .03). Crude analysis showed that the haplotype GTC was significantly associated with higher risks of ARDS in the whole cohort compared with the common haplotype ACC (-881A/-826C/-297C) (odds ratio [OR], 1.47; 95% confidence interval [CI], 1.03-2.09; p = .03), especially among male subjects (OR, 1.90; 95% CI, 1.20-2.97; p < .01). After adjustment for covariates, the haplotype GTC remained significantly associated with increased risk of ARDS in the whole cohort (OR, 1.66; 95% CI, 1.09-2.53; p = .02), particularly among male patients (OR, 1.98; 95% CI, 1.16-3.40; p = .02) and among subjects with direct pulmonary injury (OR, 1.75; 95% CI, 1.04-2.95; p = .04). Conclusions: The haplotype GTC of NFKBIA gene is associated with higher risk of ARDS in Caucasians, particularly in male patients and in patients with direct lung injury. C1 Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Pulm Crit Care Unit, Boston, MA USA. Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. Mt Sinai Sch Med, Div Pulm & Crit Care Med, New York, NY USA. RP Zhai, RH (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA. FU NHLBI NIH HHS [HL60710, K23 HL67197]; NIEHS NIH HHS [ES00002] NR 42 TC 33 Z9 36 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD MAR PY 2007 VL 35 IS 3 BP 893 EP 898 DI 10.1097/01.CCM.0000256845.92640.38 PG 6 WC Critical Care Medicine SC General & Internal Medicine GA 139ZE UT WOS:000244470800029 PM 17235259 ER PT J AU Curtis, JR Cook, DJ Sinuff, T White, DB Hill, N Keenan, SP Benditt, JO Kacmarek, R Kirchhoff, KT Levy, MM AF Curtis, J. Randall Cook, Deborah J. Sinuff, Tasnim White, Douglas B. Hill, Nicholas Keenan, Sean P. Benditt, Joshua O. Kacmarek, Robert Kirchhoff, Karin T. Levy, Mitchell M. CA Soc Critical Care Med Palliative N TI Noninvasive positive pressure ventilation in critical and palliative care settings: Understanding the goals of therapy SO CRITICAL CARE MEDICINE LA English DT Review DE intensive care; critical care; noninvasive ventilation; palliative care; end-of-life care ID ACUTE RESPIRATORY-FAILURE; OBSTRUCTIVE PULMONARY-DISEASE; OF-LIFE CARE; REFUSED ENDOTRACHEAL INTUBATION; RANDOMIZED CONTROLLED-TRIAL; NASAL VENTILATION; MECHANICAL VENTILATION; SUPPORT VENTILATION; ACUTE EXACERBATIONS; FACE MASK AB Objective: Although noninvasive positive pressure ventilation (NPPV) is a widely accepted treatment for some patients with acute respiratory failure, the use of NPPV in patients who have decided to forego endotracheal intubation is controversial. Therefore, the Society of Critical Care Medicine charged this Task Force with developing an approach for considering use of NPPV for patients who choose to forego endotracheal intubation. Data Sources and Methods: The Task Force met in person once, by conference call twice, and wrote this document during six subsequent months. We reviewed English-language literature on NPPV for acute respiratory failure. Synthesis and Overview: The use of NPPV for patients with acute respiratory failure can be classified into three categories: 1) NPPV as life support with no preset limitations on life-sustaining treatments, 2) NPPV as life support when patients and families have decided to forego endotracheal intubation, and 3) NPPV as a palliative measure when patients and families have chosen to forego all life support, receiving comfort measures only. For each category, we reviewed the rationale and evidence for NPPV, key points to communicate to patients and families, determinants of success and failure, appropriate healthcare settings, and alternative approaches if NPPV fails to achieve the original goals. Conclusions: This Task Force suggests an approach to use of NPPV for patients and families who choose to forego endotracheal intubation. NPPV should be applied after careful discussion of the goals of care, with explicit parameters for success and failure, by experienced personnel, and in appropriate healthcare settings. Future studies are needed to evaluate the clinical outcomes of using NPPV for patients who choose to forego endotracheal intubation and to examine the perspectives of patients, families, and clinicians on use of NPPV in these contexts. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. McMaster Univ, Dept Med, Hamilton, ON, Canada. Univ Toronto, Dept Med, Toronto, ON, Canada. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. Tufts Univ New England Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA USA. Univ British Columbia, Dept Med, Vancouver, BC, Canada. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesiol, Boston, MA USA. Univ Wisconsin, Sch Nursing, Madison, WI USA. Brown Univ, Rhode Isl Hosp, Dept Med, Providence, RI 02903 USA. RP Curtis, JR (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA. NR 41 TC 76 Z9 82 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD MAR PY 2007 VL 35 IS 3 BP 932 EP 939 DI 10.1097/01.CCM.0000256725.73993.74 PG 8 WC Critical Care Medicine SC General & Internal Medicine GA 139ZE UT WOS:000244470800035 PM 17255876 ER PT J AU Kuruppu, D Dorfman, JD Tanabe, KK AF Kuruppu, Darshini Dorfman, Jon D. Tanabe, Kenneth K. TI HSV-1 viral oncolysis and molecular imaging with PET SO CURRENT CANCER DRUG TARGETS LA English DT Review DE positron emission tomography; viral oncolysis; replication conditional virus; HSV-1; hrR3; rRp45; G207; NV1020; HSV-TK ID HERPES-SIMPLEX-VIRUS; POSITRON-EMISSION-TOMOGRAPHY; DIFFUSE LIVER METASTASES; REPORTER GENE-EXPRESSION; LIVING ANIMALS; CYP2B1 TRANSGENE; INVIVO BEHAVIOR; COLON-CARCINOMA; BRAIN-TUMORS; IN-VIVO AB Viral oncolysis, the destruction of cancer cells by replicating viruses, is a new modality of cancer therapy. This strategy involves use of viruses that are either genetically engineered to replicate preferentially in neoplastic cells, or use of viruses that display innate tropism for neoplastic cells. These viruses may also be modified to deliver transgenes to destroy cancer cells. While numerous viruses may be used for this form of cancer therapy, HSV-1 is an attractive vector for viral oncolysis due to several characteristics including its high infectivity, ease of genetic engineering, large transgene capacity, and the availability of an effective medical treatment for Herpes simplex virus infections. The HSV-1 viral genome has been manipulated to generate replication conditional viruses which target cancer cells. Although these viruses are programmed to replicate preferentially in cancer cells, there is some unintended replication in normal cells. Currently, biopsy is the gold standard for monitoring the therapeutic effects of viral oncolysis. However, a non-invasive test capable of serial monitoring of therapy during the treatment period is required for both preclinical and clinical studies. Positron emission tomography (PET) using HSV thymidine kinase as the PET reporter gene offers the desired qualities of a non-invasive test which can be easily repeated to determine the location and magnitude of viral replication and tumor lysis. We review viral oncolysis, focusing on HSV-1 viral oncolysis and therapeutic monitoring by PET. C1 Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA. RP Tanabe, KK (reprint author), Massachusetts Gen Hosp, Div Surg Oncol, Yawkey 7-924,55 Fruit St, Boston, MA 02114 USA. EM ktanabe@partners.org NR 37 TC 7 Z9 7 U1 0 U2 3 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1568-0096 J9 CURR CANCER DRUG TAR JI Curr. Cancer Drug Targets PD MAR PY 2007 VL 7 IS 2 BP 175 EP 180 DI 10.2174/156800907780058871 PG 6 WC Oncology SC Oncology GA 145QK UT WOS:000244879400009 PM 17346109 ER PT J AU Perlis, RH AF Perlis, Roy H. TI Use of treatment guidelines in clinical decision making in bipolar disorder: a pilot survey of clinicians SO CURRENT MEDICAL RESEARCH AND OPINION LA English DT Article DE anticonvulsant; atypical antipsychotic; bipolar disorder; CATIE; evidence-based medicine; treatment guidelines ID MEDICATION-ALGORITHM-PROJECT; PSYCHIATRY WFSBP GUIDELINES; BIOLOGICAL TREATMENT; WORLD-FEDERATION; SCHIZOPHRENIA; MANAGEMENT; SOCIETIES; QUALITY; TRIALS AB Objective: With recent attention to the importance of evidence-based medicine in psychiatry, a number of treatment guidelines have emerged to aid clinicians in clinical decision making. The objective of this study was to assess the extent to which such guidelines are used in the treatment of bipolar disorder. Methods: In November 2005, self-administered questionnaires were sent to 7000 psychiatrists who treat bipolar disorder in their clinical practice, An additional mailing of these questionnaires was done in January 2006 to a different group of 7000 psychiatrists who also treat bipolar disorder in their clinical practice. The first 312 completed surveys were analyzed. Eight questions relevant to clinical usage of, and attitudes toward, existing guidelines were asked. Results: Among the 312 respondents, 64.1% reported making routine use of treatment guidelines when making clinical decisions, including 19.6% who used the American Psychiatric Association treatment guidelines and 33.0% who used all published guidelines. Of those who did not use bipolar guidelines, the most frequently cited reason given by respondents (20.1%) was that such guidelines do not address particular features of their clinical populations. Among the different types of practice, private individual practice gave this answer most frequently (27.5%). Conclusions: These results suggest that, despite considerable efforts to develop and disseminate evidence-based guidelines, they are not widely implemented and substantial opportunities exist to educate clinicians about their value and relevance. Limitations of the study include a low response rate and possible selection bias. Nonetheless, this project was conceived of as a pilot study and these limitations do not negate the findings, but suggest other avenues for investigation. C1 Massachusetts Gen Hosp, Depress Program, Boston, MA 02114 USA. Massachusetts Gen Hosp, Bipolar Clin & Res Program, Boston, MA 02114 USA. RP Perlis, RH (reprint author), Massachusetts Gen Hosp, Depress Program, 15 Parkman St,WACC 812, Boston, MA 02114 USA. EM rperlis@partners.org NR 31 TC 22 Z9 22 U1 2 U2 2 PU LIBRAPHARM PI NEWBURY PA 29-35 VENTURE WEST, NEW GREENHAM PARK, NEWBURY RG19 6HX, BERKSHIRE, ENGLAND SN 0300-7995 J9 CURR MED RES OPIN JI Curr. Med. Res. Opin. PD MAR PY 2007 VL 23 IS 3 BP 467 EP 475 DI 10.1185/030079906X167444 PG 9 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 147OD UT WOS:000245011400001 PM 17355728 ER PT J AU Raut, CP Morgan, JA Ashley, SW AF Raut, Chandrajit P. Morgan, Jeffrey A. Ashley, Stanley W. TI Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease SO CURRENT OPINION IN GASTROENTEROLOGY LA English DT Review DE gastrointestinal stromal tumor; imatinib; KIT; sunitinib; surgery ID TYROSINE KINASE INHIBITOR; C-KIT GENE; OF-FUNCTION MUTATIONS; TERM-FOLLOW-UP; IMATINIB MESYLATE; GERMLINE MUTATION; SURGICAL-MANAGEMENT; PROGNOSTIC-FACTORS; NEUROFIBROMATOSIS TYPE-1; CONSENSUS APPROACH AB Purpose of review Few areas in oncology have witnessed the major paradigm shift that has been noted in the understanding and management of gastrointestinal stromal tumors. This review highlights the progress made over the last 2 years. Recent findings Population-based studies have provided insight into the true incidence of gastrointestinal stromal tumors. Improved understanding of the molecular biology has provided prognostic implications and may guide treatment in the future. More mature follow-up data from phase III trials have proven that the targeted tyrosine kinase inhibitor imatinib mesylate is a dramatically effective agent, but the duration of its benefits are finite, and drug resistance is an increasingly more common phenomenon. Adjuvant and neoadjuvant trials of imatinib are currently underway. A second targeted tyrosine kinase inhibitor, sunitinib malate, has been approved for the treatment of imatinib-resistant gastrointestinal stromal tumors after recent encouraging results. Finally, the success with imatinib and sunitinib has encouraged investigators to reevaluate the role of surgery in advanced gastrointestinal stromal tumors. Summary The multidisciplinary management of gastrointestinal stromal tumors serves as a model of how new targeted molecular therapies can be combined with traditional treatment modalities to improve survival in advanced malignancies. C1 Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Raut, CP (reprint author), Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA. EM craut@partners.org NR 107 TC 21 Z9 28 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0267-1379 EI 1531-7056 J9 CURR OPIN GASTROEN JI Curr. Opin. Gastroenterol. PD MAR PY 2007 VL 23 IS 2 BP 149 EP 158 DI 10.1097/MOG.0b013e32802086d0 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 138QN UT WOS:000244377400008 PM 17268243 ER PT J AU Rondon-Berrios, H Palevsky, PM AF Rondon-Berrios, Helbert Palevsky, Paul M. TI Treatment of acute kidney injury: an update on the management of renal replacement therapy SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION LA English DT Review DE acute kidney injury; hemodialysis; hemofiltration; renal replacement therapy ID CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; CONTINUOUS ARTERIOVENOUS HEMODIAFILTRATION; CONTINUOUS VENOVENOUS HEMODIAFILTRATION; FAILURE REQUIRING DIALYSIS; RANDOMIZED-TRIAL; INTERMITTENT HEMODIALYSIS; CONTINUOUS HEMOFILTRATION; CARDIAC-SURGERY; RECOVERY AB Purpose of review Renal replacement therapy remains the cornerstone of management for the patient with severe acute kidney injury. Although the technology for providing renal replacement therapy has markedly advanced over the past few decades, fundamental issues regarding its management, including timing of initiation, selection of modality and dosing of therapy, remain unresolved. Recent findings Although several retrospective and observational studies of the timing of initiation of renal replacement therapy have suggested improved survival with early initiation of treatment, the design of these studies does not allow definitive conclusions. Recent randomized trials have not demonstrated any benefit with regard to survival or recovery of renal function with continuous renal replacement therapy compared with intermittent hemodialysis. Increased intensity of renal support appears to be associated with improved survival; however more definitive studies are ongoing. Summary The optimal management of renal replacement therapy in patients with acute kidney injury remains uncertain. Appropriately designed studies evaluating timing of initiation of therapy need to be undertaken. Current data suggest that modality of therapy does not impact outcome. More intensive renal support may be associated with improved outcomes; however several large randomized controlled trials assessing this question are ongoing. C1 VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Room 7E123 111F-U,Univ Dr Div, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400; Rondon-Berrios, Helbert/0000-0002-7109-146X NR 51 TC 24 Z9 26 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1062-4821 J9 CURR OPIN NEPHROL HY JI Curr. Opin. Nephrol. Hypertens. PD MAR PY 2007 VL 16 IS 2 BP 64 EP 70 DI 10.1097/MNH.0b013e32802ef4a5 PG 7 WC Urology & Nephrology; Peripheral Vascular Disease SC Urology & Nephrology; Cardiovascular System & Cardiology GA 139WS UT WOS:000244464000002 PM 17293679 ER PT J AU Rooks, DS AF Rooks, Daniel S. TI Fibromyalgia treatment update SO CURRENT OPINION IN RHEUMATOLOGY LA English DT Review DE fibromyalgia; guidelines; self-management; treatment ID RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; MAJOR DEPRESSIVE DISORDER; QUALITY-OF-LIFE; DOUBLE-BLIND; SELF-MANAGEMENT; IMPACT QUESTIONNAIRE; NEEDLE STIMULATION; TREATMENT PROGRAM; PHYSICAL-ACTIVITY AB Purpose of review Fibromyalgia is a common chronic pain disorder characterized by complex symptomatology and few consistently effective treatments. The purpose of this review is to highlight the recent literature from April 2005 through September 2006 involving treatment options. Recent findings Prior evidence suggests that medication and self-management approaches to care can improve symptoms, function and well-being in this patient population. Recent studies examining the efficacy of two serotonin and norepinephrine-reuptake inhibitors - duloxetine and milinacipran - and the anticonvulsant pregabalin are encouraging. Studies evaluating different forms of exercise continue to support the belief that increased physical activity is an essential component of any treatment plan for the patient with fibromyalgia. Three studies added to the understanding of treatment adherence. Finally, three studies evaluating the efficacy of acupuncture in the treatment of fibromyalgia showed conflicting results, but added to the knowledge needed for clinicians to have substantive conversations with patients. Summary Recent studies support the recommendation of a multimodal approach to treatment involving individualized, evidence-based pharmacotherapy and self-management. Treatment goals should include the improvement of symptoms, primarily pain and sleep, and the promotion of positive health behaviors with the aim of improving physical function and emotional well-being. C1 BIDMC, Div Rheumatol, Boston, MA 02215 USA. Beth Israel Deaconess Med Ctr, Ctr Study Nutr Med, Boston, MA 02215 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Rooks, DS (reprint author), BIDMC, Div Rheumatol, FD 876,330 Brookline Ave, Boston, MA 02215 USA. EM drooks@bidmc.harvard.edu FU NIAMS NIH HHS [K23 AR48305] NR 65 TC 49 Z9 53 U1 2 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8711 J9 CURR OPIN RHEUMATOL JI CURR. OPIN. RHEUMATOL. PD MAR PY 2007 VL 19 IS 2 BP 111 EP 117 PG 7 WC Rheumatology SC Rheumatology GA 140AU UT WOS:000244475200005 PM 17278924 ER PT J AU Reginato, AM Olsen, BR AF Reginato, Anthony M. Olsen, Bjorn R. TI Genetics and experimental models of crystal-induced arthritis. Lessons learned from mice and men: is it crystal clear? SO CURRENT OPINION IN RHEUMATOLOGY LA English DT Review DE ANK; gout; hydroxyapatite; hyperuricemia; NALP3 inflammasome; urate transporter 1 ID CALCIUM PYROPHOSPHATE DIHYDRATE; POSTERIOR LONGITUDINAL LIGAMENT; FAMILIAL TUMORAL CALCINOSIS; CYSTIC KIDNEY-DISEASE; JUVENILE HYPERURICEMIC NEPHROPATHY; NONSPECIFIC ALKALINE-PHOSPHATASE; CELL MEMBRANE GLYCOPROTEIN-1; URATE-ANION EXCHANGER; TAMM-HORSFALL PROTEIN; URIC-ACID LEVELS AB Purpose of review We examine the major genes in mice and humans involved in the pathogenesis of monosodium urate, calcium pyrophosphate dihydrate and hydroxyapatite crystal-induced arthritis. Recent findings Several genetic causes of renal disease associated with hyperuricemia and gout provide insight into genes involved in renal urate handling. Mutations or polymorphisms in exons 4 and 5 and intron 4 of urate transporter 1 may be independent genetic markers of hyperuricemia and gout. Genetic analysis supports the role of ANKH mutations in calcium pyrophosphate dihydrate-induced arthritis. ANKH gain-of-function mutations were confirmed by functional studies; however, the crystals formed in ATD5 cells were basic calcium phosphate, not calcium pyrophosphate dihydrate, underlying the significance of chondrocyte differentiation state and the factors regulating normal and pathological mineralization. Animal models have implicated a general model of crystal-induced inflammation involving innate immunity through the NALP3 (Natch domain, leucine-rich repeat, and PYD-containing protein 3) inflammasome signaling through the interleukin-1 receptor and its signaling protein myeloid differentiation primary response protein 88. Summary Genetic analysis has elucidated genes responsible for crystal formation and animal models have unveiled mechanisms in the development of crystal-induced arthritis. Future studies will hasten understanding of the pathology of crystal-induced arthritis and provide new therapies. C1 Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. RP Reginato, AM (reprint author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, 55 Fruit St,Bulfinch 165, Boston, MA 02114 USA. EM areginato@partners.org NR 112 TC 9 Z9 10 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8711 J9 CURR OPIN RHEUMATOL JI CURR. OPIN. RHEUMATOL. PD MAR PY 2007 VL 19 IS 2 BP 134 EP 145 DI 10.1097/BOR.0b013e328040c00b PG 12 WC Rheumatology SC Rheumatology GA 140AU UT WOS:000244475200009 PM 17278928 ER PT J AU Albrecht, J Werth, VP AF Albrecht, Joerg Werth, Victoria P. TI Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus SO DERMATOLOGIC THERAPY LA English DT Article DE cutaneous lupus erythematosus; patient outcome assessment; reproducibility of results; validity ID QUALITY-OF-LIFE; DISEASE SEVERITY; ATOPIC-DERMATITIS; SKIN-DISEASE; SURFACE-AREA; INDEX; PSORIASIS; RELIABILITY; IMPACT; ECZEMA AB Skin involvement is a frequent presenting manifestation of systemic lupus erythematosus (SLE). Cutaneous lupus erythematosus (CLE), frequently occurring without SLE, may be even more common than SLE. Until recently, clinical instruments to measure skin involvement in CLE did not exist, hampering clinical research in this field. In this paper the present authors describe outcome instruments for SLE and outline the considerations underlying the design and validation of an outcome instrument for CLE, the cutaneous lupus disease area and severity index. These studies serve as a model for development and validation of standardized instruments that can be applied to other cutaneous diseases, particularly autoimmune diseases, in order to facilitate epidemiologic studies and clinical trials. C1 Univ Penn, Dept Dermatol, Philadelphia, PA 19119 USA. John H Stroger Jr Hosp Cook Cty, Dept Med, Div Dermatol, Chicago, IL USA. Philadelphia VA Med Ctr, Philadelphia VA Dermatol, Philadelphia, PA USA. RP Werth, VP (reprint author), Univ Penn, Dept Dermatol, 2 Rhodes,3600 Spruce St, Philadelphia, PA 19119 USA. EM werth@mail.med.upenn.edu NR 32 TC 25 Z9 27 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1396-0296 J9 DERMATOL THER JI Dermatol. Ther. PD MAR-APR PY 2007 VL 20 IS 2 BP 93 EP 101 DI 10.1111/j.1529-8019.2007.00117.x PG 9 WC Dermatology SC Dermatology GA 172GQ UT WOS:000246792500004 PM 17537137 ER PT J AU Panizzi, JR Jessen, JR Drummond, IA Solnica-Krezel, L AF Panizzi, Jennifer R. Jessen, Jason R. Drummond, Iain A. Solnica-Krezel, Lilianna TI New functions for a vertebrate Rho guanine nucleotide exchange factor in ciliated epithelia SO DEVELOPMENT LA English DT Article DE pronephros; left-right asymmetry; otoliths; PDZ; RhoGEF; arhgef11; cell polarity; zebrafish ID LEFT-RIGHT ASYMMETRY; CELL-SHAPE CHANGES; LEFT-RIGHT AXIS; PDZ-RHOGEF; ZEBRAFISH PRONEPHROS; KUPFFERS VESICLE; EMBRYONIC-DEVELOPMENT; EXTENSION MOVEMENTS; SIGNALING PATHWAY; ACTS DOWNSTREAM AB Human ARHGEF11, a PDZ-domain-containing Rho guanine nucleotide exchange factor (RhoGEF), has been studied primarily in tissue culture, where it exhibits transforming ability, associates with and modulates the actin cytoskeleton, regulates neurite outgrowth, and mediates activation of Rho in response to stimulation by activated G alpha 12/13 or Plexin B1. The fruit fly homolog, RhoGEF2, interacts with heterotrimeric G protein subunits to activate Rho, associates with microtubules, and is required during gastrulation for cell shape changes that mediate epithelial folding. Here, we report functional characterization of a zebrafish homolog of ARHGEF11 that is expressed ubiquitously at blastula and gastrula stages and is enriched in neural tissues and the pronephros during later embryogenesis. Similar to its human homolog, zebrafish Arhgef11 stimulated actin stress fiber formation in cultured cells, whereas overexpression in the embryo of either the zebrafish or human protein impaired gastrulation movements. Loss-of-function experiments utilizing a chromosomal deletion that encompasses the arhgef11 locus, and antisense morpholino oligonucleotides designed to block either translation or splicing, produced embryos with ventrally-curved axes and a number of other phenotypes associated with ciliated epithelia. Arhgef11-deficient embryos often exhibited altered expression of laterality markers, enlarged brain ventricles, kidney cysts, and an excess number of otoliths in the otic vesicles. Although cilia formed and were motile in these embryos, polarized distribution of F-actin and Na+/K+-ATPase in the pronephric ducts was disturbed. Our studies in zebrafish embryos have identified new, essential roles for this RhoGEF in ciliated epithelia during vertebrate development. C1 Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37235 USA. Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Nephrol, Charlestown, MA 02129 USA. RP Solnica-Krezel, L (reprint author), Vanderbilt Univ, Dept Biol Sci, 221 Kirkland Hall, Nashville, TN 37235 USA. EM lilianna.solnica-krezel@vanderbilt.edu FU NICHD NIH HHS [2T32HD07502]; NIDDK NIH HHS [DK53093]; NIGMS NIH HHS [GM77770] NR 62 TC 31 Z9 31 U1 1 U2 7 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0950-1991 J9 DEVELOPMENT JI Development PD MAR 1 PY 2007 VL 134 IS 5 BP 921 EP 931 DI 10.1242/dev.02776 PG 11 WC Developmental Biology SC Developmental Biology GA 144XX UT WOS:000244830900012 PM 17267448 ER PT J AU Kesari, S Jackson-Grusby, L Stiles, CD AF Kesari, Santosh Jackson-Grusby, Laurie Stiles, Charles D. TI "Smad"eningly erratic: Target gene methylation determines whether TGF beta promotes or suppresses malignant glioma SO DEVELOPMENTAL CELL LA English DT Editorial Material ID PROLIFERATION; GLIOBLASTOMA; CANCER; CELLS AB TGF beta functions as a tumor suppressor in some contexts and a tumor promoter in others. In a recent issue of Cancer Cell, Bruna et al. (2007) shed light on an epigenetic mechanism that underlies this schizophrenic behavior in malignant glioma. Their findings highlight a stem cell/cancer link...and a potential blind spot in large-scale cancer genome sequencing projects. C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. Childrens Hosp, Boston, MA 02115 USA. RP Stiles, CD (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. EM charles_stiles@dfci.harvard.edu RI Kesari, Santosh/E-8461-2013 FU NICHD NIH HHS [R01 HD050760] NR 10 TC 0 Z9 0 U1 1 U2 3 PU CELL PRESS PI CAMBRIDGE PA 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA SN 1534-5807 J9 DEV CELL JI Dev. Cell PD MAR PY 2007 VL 12 IS 3 BP 324 EP 325 DI 10.1016/j.devcel.2007.02.008 PG 2 WC Cell Biology; Developmental Biology SC Cell Biology; Developmental Biology GA 151LI UT WOS:000245291400004 PM 17336898 ER PT J AU Winckler, W Weedon, MN Graham, RR McCarrolll, SA Purcell, S Almgren, P Tuomi, T Gaudet, D Bostrom, KB Walker, M Hitman, G Hattersley, AT McCarthy, MI Ardlie, KG Hirschhorn, JN Daly, MJ Frayling, TM Groop, L Altshuler, D AF Winckler, Wendy Weedon, Michael N. Graham, Robert R. McCarrolll, Steven A. Purcell, Shaun Almgren, Peter Tuomi, Tiinamaija Gaudet, Daniel Bostrom, Kristina Bengtsson Walker, Mark Hitman, Graham Hattersley, Andrew T. McCarthy, Mark I. Ardlie, Kristin G. Hirschhorn, Joel N. Daly, Mark J. Frayling, Timothy M. Groop, Leif Altshuler, David TI Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes SO DIABETES LA English DT Article ID GLUCOKINASE PROMOTER VARIANT; INSULIN-SECRETION; HNF1-ALPHA GENE; CELL PROMOTER; MELLITUS; POLYMORPHISM; POPULATION; MUTATIONS; REGION; RISK AB An important question in human genetics is the extent to which genes causing monogenic forms of disease harbor common variants that may contribute to the more typical form of that disease. We aimed to comprehensively evaluate the extent to which common variation irk the six known maturity-onset diabetes of the young (MODY) genes, which cause a monogenic form of type 2 diabetes, is associated with type 2 diabetes. Specifically, we determined patterns of common sequence variation in the genes encoding Gck, lpf1, Tcf2, and NeuroD1 (MODY2 and MODY4-MODY6, respectively), selected a comprehensive set of 107 tag single nucleotide polymorphisms (SNPs) that captured common variation, and genotyped each in 4,206 patients and control subjects from Sweden, Finland, and Canada (including family-based studies and unrelated case-control subjects). All SNPs with a nominal P value < 0.1 for association to type 2 diabetes in this initial screen were then genotyped in an additional 4,470 subjects from North America and Poland. Of 30 nominally significant SNPs from the initial sample, 8 achieved consistent results in the replication sample. We found the strongest effect at rs757210 in intron 2 of TCF2, with corrected P values < 0.01 for an odds ratio (OR) of 1.13. This association was observed again in an independent sample of 5,891 unrelated case and control subjects and 500 families from the U.K., for an overall OR of 1.12 and a P value < 10(-6) in > 15,000 samples. We combined these results with our previous studies on HNF4 alpha and TCF1 and explicitly tested for gene-gene interactions among these variants and with several known type 2 diabetes susceptibility loci, and we found no genetic interactions between these six genes. We conclude that although rare variants in these six genes explain most cases of MODY, common variants in these same genes contribute very modestly, if at all, to the common form of type 2 diabetes. C1 Harvard Univ, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA. Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Genet, Cambridge, MA 02142 USA. MIT, Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter, Devon, England. Lund Univ, Univ Hosp MAS, Dept Endocrinol, Malmo, Sweden. Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland. Univ Helsinki, Folkhalsan Inst Genet, Folkhalsan Res Ctr, Helsinki, Finland. Univ Helsinki, Res Program Mol Med, Helsinki, Finland. Univ Montreal, Community Genom Ctr, Chicoutimi Hosp, Chicoutimi, PQ, Canada. Lund Univ, Univ Hosp MAS, Dept Clin Sci, Malmo, Sweden. Univ Newcastle Upon Tyne, Dept Med, Sch Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. Univ London, Dept Diabet & Metab Med, Barts & London Queen Mary Sch Med & Dent, London, England. Churchill Hosp, Dept Endocrinol & Metab, Diabet Res Labs, Oxford Ctr Diabet, Oxford OX3 7LJ, England. Genom Collaborat, Cambridge, MA USA. Childrens Hosp, Div Genet, Boston, MA 02115 USA. Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA. Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. RP Altshuler, D (reprint author), Harvard Univ, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA. EM altshuler@molbio.mgh.harvard.edu RI Altshuler, David/A-4476-2009; OI Altshuler, David/0000-0002-7250-4107; Tuomi, Tiinamaija/0000-0002-8306-6202 FU Medical Research Council [G0500070]; Wellcome Trust NR 57 TC 127 Z9 129 U1 0 U2 7 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD MAR PY 2007 VL 56 IS 3 BP 685 EP 693 DI 10.2337/db06-0202 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 144WQ UT WOS:000244827500015 PM 17327436 ER PT J AU Grant, RW Meigs, JB AF Grant, Richard W. Meigs, James B. TI Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes - An unmet challenge for cardiovascular risk reduction SO DIABETES CARE LA English DT Article ID CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; RANDOMIZED CONTROLLED-TRIAL; CLINICAL-PRACTICE; LDL CHOLESTEROL; VA-HIT; MELLITUS; GEMFIBROZIL; PREVENTION; MANAGEMENT AB OBJECTIVE - Patients with diabetes remain at high risk for cardiovascular events despiteaggressive blood pressure, LDL cholesterol, and blood glucose control. We identified prevalence and predictors of low HDL cholesterol, characterized current lipid therapy, and estimated the theoretical benefit of more effective HDL cholesterol-raising methods among patients with type 2 diabetes. RESEARCH DESIGN AND METHODS - We analyzed a primary care-based population of patients with type 2 diabetes (n = 7,692) in 12 eastern Massachusetts outpatient practices. We grouped fibrates, niacins, and n-3 fatty acid preparations as nonstatin HDL cholesterol-raising medicines, and we used published studies to estimate the potential benefit of raising HDL cholesterol levels in this population. RESULTS - Nearly half (49.5%) of patients had low HDL cholesterol (< 40 mg/dl for men, < 50 mg/dl for women). Low HDL cholesterol was independently associated with prevalent cardiovascular disease (CVD), younger age, and higher A1C levels. Nearly two-thirds of patients (63.0%) were prescribed a statin (67.6% of patients below the HDL cholesterol goal, 80.5% of patients with CVD). In contrast, only 7.9% of patients were prescribed a nonstatin HDL cholesterol-raising medication, including 16.4% of patients below the HDL cholesterol goal with CVD. Based on published studies, normalizing low HDL cholesterol in this primary care cohort would correspond to an estimated CVD mortality reduction of 42% in women and 23% in men. CONCLUSIONS - Nearly half of the patients in this large primary care cohort had low HDL cholesterol levels. In contrast to frequent statin use, few patients were prescribed currently available medicines to raise HDL cholesterol. Low HDL cholesterol represents a highly prevalent and potentially modifiable risk factor for CVD prevention in type 2 diabetes. C1 Massachusetts Gen Hosp, Gen Med Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Grant, RW (reprint author), 50-9 Staniford St, Boston, MA 02114 USA. EM rgrant@partners.org OI Grant, Richard/0000-0002-6164-8025 FU AHRQ HHS [R21 HS015785-01]; NIDDK NIH HHS [K23 DK067452, K23 DK067452-03] NR 25 TC 34 Z9 35 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAR PY 2007 VL 30 IS 3 BP 479 EP 484 DI 10.2337/dc06-1961 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 146NM UT WOS:000244941200004 PM 17327308 ER PT J AU Ritholz, MD Smaldone, A Lee, J Castillo, A Wolpert, H Weinger, K AF Ritholz, Marilyn D. Smaldone, Arlene Lee, Jarim Castillo, Astrid Wolpert, Howard Weinger, Katie TI Perceptions of psychosocial factors and the insulin pump SO DIABETES CARE LA English DT Article ID I DIABETIC-PATIENTS; QUALITY-OF-LIFE; METABOLIC-CONTROL; INFUSION CSII; THERAPY; COMPLICATIONS; ADOLESCENTS; MELLITUS; RISK AB OBJECTIVE - The purpose of this study was to identify psychosocial issues related to diabetes, approaches to self-care, self-perceptions, and social interactions among insulin pump users with type 1 diabetes. RESEARCH DESIGN AND METHODS- Adult insulin pump users participated. in. focus groups loosely formed on the basis of A1C level. Transcripts of focus group meetings were coded into themes by five reviewers using NVivo2 qualitative software. RESULTS - Thirty adults with long-term diabetes participated in five focus groups: two with low mean SD +/- A1C (6.8 +/- 0.4%), one with mid A1C (7.80 +/- 0.3%), and two with high A1C (9.1 +/- 0.5%). Three major themes were identified: impact on diabetes self-care, emotional reactions to the insulin pump, body image, and social acceptance. Participants who described the pump as a tool to meet glycemic goals also described a more active approach to diabetes and had better glycemic control; those who discussed the pump as a panacea described more passive self-care and had poorer glycemic control. Low A1C groups reported that starting the insulin pump reminded them of feelings they experienced at their initial diabetes diagnosis, whereas the high A1C groups did not report these feelings. Women were more concerned than men about body image and social acceptance with pump use. CONCLUSIONS - Active participation in self-care, realistic expectations of pump use, and emotional recall of diabetes diagnosis were associated with better glycemic control. Interventions to improve diabetes management with pump use should include evaluation and discussion of active versus passive approaches to self-care, recall of diabetes diagnosis, expectations of the pump, and pump-related self-consciousness and body image concerns. The roles of these factors in optimal diabetes management warrant further investigation. C1 Joslin Diabet Ctr, Boston, MA 02215 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Columbia Univ, Sch Nursing, New York, NY 10027 USA. RP Weinger, K (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM katie.weinger@joslin.harvard.edu FU NIDDK NIH HHS [R01 DK60115, P30 DK36836, DK07260] NR 31 TC 39 Z9 39 U1 1 U2 9 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAR PY 2007 VL 30 IS 3 BP 549 EP 554 DI 10.2337/dc06-1755 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 146NM UT WOS:000244941200015 PM 17327319 ER PT J AU Otu, HH Can, H Spentzos, D Nelson, RG Hanson, RL Looker, HC Knowler, WC Monroy, M Libermann, TA Karumanchi, SA Thadhani, R AF Otu, Hasan H. Can, Handan Spentzos, Dimitrios Nelson, Robert G. Hanson, Robert L. Looker, Helen C. Knowler, William C. Monroy, Manuel Libermann, Towia A. Karumanchi, S. Ananth Thadhani, Ravi TI Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy SO DIABETES CARE LA English DT Article ID PROSTATE-CANCER; PIMA-INDIANS; ALBUMIN EXCRETION; OVARIAN-CANCER; SERUM; MICROALBUMINURIA; MELLITUS; BENIGN; NIDDM; IDENTIFICATION AB OBJECTIVE - We examined whether proteomic technologies identify novel urine proteins associated with subsequent development of diabetic nephropathy in subjects with type 2 diabetes before evidence of microalbuminuria. RESEACH DESIGN AND METHODS - in a nested case-control study of Pima Indians with type 2 diabetes, baseline (serum creatinine < 1.2 mg/dl and urine albumin excretion < 30 mg/g) and 10-year urine samples were examined. Case subjects (n = 31) developed diabetic nephropathy (urinary albumin-to-creatinine ratio > 300 mg/g) over 10 years. Control subjects (n = 3 1) were matched to case subjects (1: 1) according to diabetes duration, age, sex, and BMI but remained normoalbuminuric (albumin-to-creatinine ratio < 30 mg/g) over the same 10 years. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) was performed on baseline urine samples, and training (14 cases:14 controls) and validation (17:17) sets were tested. RESULTS - At baseline, A1C levels differed between case and control subjects. SELDI-TOF MS detected 714 unique urine protein peaks. Of these, a 12-peak proteomic signature correctly predicted 89% of cases of diabetic nepropathy (93% sensitivity, 86% specificity) in the training set. Applying this same signature to the independent validation set yielded an accuracy rate of 74% (71% sensitivity, 76% specificity). In multivariate analyses, the 12-peak signature was independently associated with subsequent diabetic nephropathy when applied to the validation set (odds ratio [OR] 7.9 [95% CI 1.5-43.5], P = 0.017) and the entire dataset (14.5 [3.7-55.6], P = 0.001), and A1C levels were no longer significant. CONCLUSIONS - Urine proteomic, profiling identifies normoalbuminuric subjects with type 2 diabetes who subsequently develop diabetic nephropathy. Further studies are needed to characterize the specific proteins involved in this early prediction. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Renal Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Genom Ctr, Boston, MA 02114 USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, DF HCC Canc Prote Core, Boston, MA 02114 USA. Yeditepe Univ, Dept Genet & Bioengn, Istanbul, Turkey. NIDDK, Diabet Epidemiol & Clin Res Sect, Phoenix Epidemiol & Clin Res Branch, Phoenix, AZ USA. Beth Israel Deaconess Med Ctr, Div Nephrol, Dept Med, Boston, MA 02215 USA. RP Thadhani, R (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Bullfinch 127,55 Fruit St, Boston, MA 02114 USA. EM thadhani.r@mgh.harvard.edu RI Libermann, Towia/F-9866-2010; Nelson, Robert/B-1470-2012; Hanson, Robert/O-3238-2015; OI Hanson, Robert/0000-0002-4252-7068; Libermann, Towia/0000-0002-4006-8179; Otu, Hasan/0000-0002-9253-8152 FU NIDDK NIH HHS [DK 068465] NR 30 TC 74 Z9 84 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAR PY 2007 VL 30 IS 3 BP 638 EP 643 DI 10.2337/dc06-1656 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 146NM UT WOS:000244941200029 PM 17327333 ER PT J AU Cnop, M Vidal, J Hull, RL Utzschneider, KM Carr, DB Schraw, T Scherer, PE Boyko, EJ Fujimoto, WY Khan, SE AF Cnop, Miriam Vidal, Josep Hull, Rebecca L. Utzschneider, Kristina M. Carr, Darcy B. Schraw, Todd Scherer, Philipp E. Boyko, Edward J. Fujimoto, Wilfred Y. Khan, Steven E. TI Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes SO DIABETES CARE LA English DT Article ID POLYCYSTIC-OVARY-SYNDROME; LIFE-STYLE INTERVENTION; INSULIN-RESISTANCE; HIGH-RISK; FASTING GLUCOSE; FOLLOW-UP; MELLITUS; SENSITIVITY; SECRETION; DYSFUNCTION AB OBJECTIVE - The relative roles of insulin resistance and beta-cell dysfunction in the pathogenesis of impaired glucose tolerance (IGT) and type 2 diabetes are debated. First-degree relatives of individuals with type 2 diabetes are at increased risk of developing hyperglycemia. RESEARCH DESIGN AND METHODS - We evaluated the evolution of insulin sensitivity, beta-cell function, glucose effectiveness, and glucose tolerance over 7 years in 33 nondiabetic, first-degree relatives of type 2 diabetic individuals using frequently sampled tolbutamide-modified intravenous and oral glucose tolerance tests. RESULTS - Subjects gained weight, and their waist circumference increased (P < 0.05). Insulin sensitivity, the acute insulin response to glucose, and glucose effectiveness did not change significantly. However, when we accounted for the modulating effect of insulin sensitivity on insulin release, beta-cell function determined as the disposition index decreased by 22% (P < 0.05). This decrease was associated with declines in intravenous and oral glucose tolerance (P < 0.05 and P < 0.001, respectively). Of the subjects with normal glucose tolerance at the first assessment, we compared those who progressed to IGT with those who did not. The disposition index was 50% lower in the progressors than in the nonprogressors at follow-up (P < 0.05). CONCLUSIONS - The decline in glucose tolerance over time in first-degree relatives of type 2 diabetic individuals is strongly related to the loss of beta-cell function. Thus, early interventions to slow the decline in beta-cell function should be considered in high-risk individuals. C1 VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98108 USA. Univ Washington, Div Maternal Fetal Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA. Albert Einstein Coll Med, Dept Cell Biol, Ctr Diabet Res & Training, New York, NY USA. Albert Einstein Coll Med, Dept Med, Ctr Diabet Res & Training, New York, NY USA. VA Puget Sound Hlth Care Syst, Div Gen Internal Med, Dept Med, Seattle, WA 98108 USA. RP Khan, SE (reprint author), VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM skahn@u.washington.edu OI Cnop, Miriam/0000-0002-5112-1692 FU NCRR NIH HHS [RR-16066, RR-37]; NIDDK NIH HHS [DK-02654, DK-026687, DK-17047] NR 33 TC 83 Z9 90 U1 1 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAR PY 2007 VL 30 IS 3 BP 677 EP 682 DI 10.2337/dc06-1834 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 146NM UT WOS:000244941200036 PM 17327340 ER PT J AU Nathan, DM Davidson, MB DeFronzo, RA Heine, RJ Henry, RR Pratley, R Zinman, B AF Nathan, David M. Davidson, Mayer B. DeFronzo, Ralph A. Heine, Robert J. Henry, Robert R. Pratley, Richard Zinman, Bernard TI Impaired fasting glucose and impaired glucose tolerance - Implications for care SO DIABETES CARE LA English DT Article ID AMERICAN-DIABETES-ASSOCIATION; HEALTH-ORGANIZATION CRITERIA; CARDIOVASCULAR-DISEASE RISK; BETA-CELL DYSFUNCTION; INSULIN-RESISTANCE; LIFE-STYLE; DIAGNOSTIC-CRITERIA; PLASMA-GLUCOSE; PREVENTION PROGRAM; FOLLOW-UP C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Charles R Drew Univ Med & Sci, Clin Ctr Res Excellence, Los Angeles, CA 90059 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. VU Univ, Med Ctr, Ctr Diabet, Amsterdam, Netherlands. Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. Univ Vermont, Dept Med, Burlington, VT 05405 USA. Univ Toronto, Mt Sinai Hosp, Dept Endocrinol, Toronto, ON, Canada. Univ Toronto, Mt Sinai Hosp, Dept Metab, Toronto, ON, Canada. RP Nathan, DM (reprint author), Amer Diabet Assoc, 1701 N Beauregard St, Alexandria, VA 22311 USA. RI Zinman, Bernard/E-7266-2013 NR 59 TC 517 Z9 538 U1 1 U2 34 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAR PY 2007 VL 30 IS 3 BP 753 EP 759 DI 10.2337/dc07-9920 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 146NM UT WOS:000244941200051 PM 17327355 ER PT J AU Yatoh, S Akashi, T Chan, PP Kaneto, H Sharma, A Bonner-Weir, S Weir, GC AF Yatoh, Shigeru Akashi, Tomoyuki Chan, Phillip P. Kaneto, Hideaki Sharma, Arun Bonner-Weir, Susan Weir, Gordon C. TI NeuroD and reaggregation induce beta-cell specific gene expression in cultured hepatocytes SO DIABETES-METABOLISM RESEARCH AND REVIEWS LA English DT Article DE neuroD; insulin; hepatocyte; transdifferentiation; reaggregation; and beta-cell ID INSULIN-PRODUCING CELLS; EMBRYONIC STEM-CELLS; IN-VITRO; ISLET TRANSPLANTATION; PANCREATIC-CELLS; SECRETING CELLS; BONE-MARROW; FETAL LIVER; II GENE; DIFFERENTIATION AB Background Our goal was to convert adult mouse hepatocytes to pancreatic beta-cells. Methods and Results To facilitate conversion, cultured primary hepatocytes were dedifferentiated by the removal of dexamethasone (Dex) from the culture media. Removal of Dex caused detachment of hepatocytes from the culture dish, but the addition of betacellulin prevented this from happening. With the combination of lack of Dex and addition of betacellulin, albumin mRNA levels decreased. Cultured hepatocytes had a faint expression of insulin 2 mRNA, Nkx 6.1 and Pax 6 mRNA. Dedifferentiated hepatocytes were transduced with adenoviruses expressing NeuroD1, Ngn 3, or Pax 4. NeuroD1 transduction increased the insulin 2 mRNA but caused detachment of cells. However, when hepatocytes were allowed to reaggregate for 4 and 6 days in hydrophobic plates after transduction with NeuroD1, further increases of insulin 2 mRNA were found along with induction of PDX-1, IAPP, NeuroD I, Pax 4, Isl-1, PC1, PC2 and islet glucokinase. Additionally, glucagon, Ngn3, pancreatic polypeptide and somatostatin expression were induced, but neither elastase I nor insulin I mRNA could be detected. Ngn 3 and Pax 4 had effects similar to NeuroD1, but did not increase insulin 2 mRNA as much as NeuroD1. Conclusion We conclude that the combination of NeuroD1 and reaggregation promotes cultured dedifferentiated hepatocytes to differentiate towards a pancreatic beta-cell phenotype. Copyright (c) 2006 John Wiley & Sons, Ltd. C1 Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA. NJTC Venture Fund Networked Capital, Mt Laurel, NJ USA. Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka, Japan. RP Weir, GC (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, 1 Joslin Pl, Boston, MA 02215 USA. EM gordon.weir@joslin.harvard.edu FU NIDDK NIH HHS [P30 DK36836-16, U19DK6125] NR 46 TC 16 Z9 18 U1 0 U2 3 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1520-7552 J9 DIABETES-METAB RES JI Diabetes-Metab. Res. Rev. PD MAR PY 2007 VL 23 IS 3 BP 239 EP 249 DI 10.1002/dmrr.678 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 149KW UT WOS:000245146800010 PM 16921545 ER PT J AU Li, R Thorens, B Loeken, MR AF Li, R. Thorens, B. Loeken, M. R. TI Expression of the gene encoding the high-K-m glucose transporter 2 by the early postimplantation mouse embryo is essential for neural tube defects associated with diabetic embryopathy SO DIABETOLOGIA LA English DT Article DE neural tube; diabetic pregnancy; diabetic embryopathy; embryo; GLUT2; SLC2A2 ID GLUCOSE-TRANSPORTER; CONGENITAL-ANOMALIES; PREIMPLANTATION EMBRYOS; CARDIOVASCULAR MALFORMATIONS; MOLECULAR CAUSES; EARLY-PREGNANCY; RAT; IDENTIFICATION; INFANTS; MOTHERS AB Aims/hypothesis Excess glucose transport to embryos during diabetic pregnancy causes congenital malformations. The early postimplantation embryo expresses the gene encoding the high-K (m) GLUT2 (also known as SLC2A2) glucose transporter. The hypothesis tested here is that high-K (m) glucose transport by GLUT2 causes malformations resulting from maternal hyperglycaemia during diabetic pregnancy. Materials and methods Glut2 mRNA was assayed by RT-PCR. The K (m) of embryo glucose transport was determined by measuring 0.5-20 mmol/l 2-deoxy[H-3]glucose transport. To test whether the GLUT2 transporter is required for neural tube defects resulting from maternal hyperglycaemia, Glut2 (+/-) mice were crossed and transient hyperglycaemia was induced by glucose injection on day 7.5 of pregnancy. Embryos were recovered on day 10.5, and the incidence of neural tube defects in wild-type, Glut2 (+/-) and Glut2 (-/-) embryos was scored. Results Early postimplantation embryos expressed Glut2, and expression was unaffected by maternal diabetes. Moreover, glucose transport by these embryos showed Michaelis-Menten kinetics of 16.19 mmol/l, consistent with transport mediated by GLUT2. In pregnancies made hyperglycaemic on day 7.5, neural tube defects were significantly increased in wild-type embryos, but Glut2 (+/-) embryos were partially protected from neural tube defects, and Glut2 (-/-) embryos were completely protected from these defects. The frequency of occurrence of wild-type, Glut2 (+/-) and Glut2 (-/-) embryos suggests that the presence of Glut2 alleles confers a survival advantage in embryos before day 10.5. Conclusions/interpretations High-K (m) glucose transport by the GLUT2 glucose transporter during organogenesis is responsible for the embryopathic effects of maternal diabetes. C1 Joslin Diabet Ctr, Boston, MA 02215 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. Univ Lausanne, Ctr Integrated Genomics, Dept Physiol, Lausanne, Switzerland. RP Loeken, MR (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM mary.loeken@joslin.harvard.edu OI Loeken, Mary/0000-0002-8056-9816 FU NIDDK NIH HHS [DK52865, DK58300] NR 50 TC 33 Z9 33 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD MAR PY 2007 VL 50 IS 3 BP 682 EP 689 DI 10.1007/s00125-006-0579-7 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 133PT UT WOS:000244025500026 PM 17235524 ER PT J AU Anzueto, A Bishal, WR Pottumarthy, S AF Anzueto, Antonio Bishal, William R. Pottumarthy, Sudha TI Role of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitis SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE AECB; oral cephems ID OBSTRUCTIVE PULMONARY-DISEASE; RESISTANT STREPTOCOCCUS-PNEUMONIAE; ACUTE BACTERIAL EXACERBATIONS; RESPIRATORY-TRACT PATHOGENS; CEFDITOREN-PIVOXIL; ALEXANDER PROJECT; UNITED-STATES; CEFDINIR; SUSCEPTIBILITY; INFECTIONS AB Risk stratification is the recommended approach for treatment of acute exacerbation of chronic bronchitis (AECB) to optimize the chances of clinical success. The suggested oral therapy for "simple or uncomplicated" AECB, which is predominantly a result of infection due to Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, includes advanced macrolides and 2nd- or 3rd-generation cephalosporins, in addition to the older 1st-line agents (aminopenicillins, doxycycline, trimethoprim/sulfamethoxazole, and erythromycin). In light of increasing resistance of H. influenzae and S. pneumoniae to the older agents, the specific directed structural modification of the cephalosporin nucleus resulted in the development of extended-spectrum 3rd-generation oral cephems with enhanced beta-lactamase stability and improved activity against Gram-positive pathogens (penicillin-susceptible S. pneumoniae and oxacillin-susceptible Staphylococcus aureus). Analysis of results of double-blind randomized clinical trials assessing efficacy of the extended-spectrum oral cephems published since 2000 demonstrates that both cefdinir and cefditoren have similar point estimates of success in comparison to their comparators (cefuroxime, cefprozil, or Loracarbef), when either the clinical cure or the bacteriologic response was analyzed. Thus, oral extended-spectrum 3rd-generation cephems, which retain antimicrobial efficacy against the traditional respiratory pathogens despite changing resistance patterns, offer excellent coverage against the key pathogens involved in simple or uncomplicated AECB. (c) 2007 Elsevier Inc. All rights reserved. C1 Houston Dept Hlth & Human Serv, Houston, TX 77054 USA. Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21231 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA. S Texas Vet Healthcare Syst, San Antonio, TX 78284 USA. RP Pottumarthy, S (reprint author), Houston Dept Hlth & Human Serv, Houston, TX 77054 USA. EM sudha.pottumarthy@cityofhouston.net NR 43 TC 10 Z9 11 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD MAR PY 2007 VL 57 IS 3 SU S BP 31S EP 38S DI 10.1016/j.diagmicrobio.2006.12.003 PG 8 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 151KU UT WOS:000245289800005 PM 17349461 ER PT J AU Nanji, SS Roth, SI AF Nanji, Shabin S. Roth, Sanford I. TI A parathyroid myxoadenoma observed grossly SO ENDOCRINE PATHOLOGY LA English DT Article DE hyperparathyroidism; parathyroid adenoma; lipoadenomas; myxoadenoma; myxoid; tumor; stroma ID LIPOADENOMA; GLAND AB We are reporting a case of a patient with primary hyperparathyroidism because of an unusual parathyroid adenoma. The tumor had an extensive myxofibrous stroma without an identifiable lipomatous component. Though moderate to extensive myxoid alteration of the stroma has been reported in lipoadenomas, to the best of our knowledge, this is the first parathyroid adenoma in which the myxomatous component was recognized grossly and which lacked a stromal adipose component. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Nanji, SS (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. EM shabinnanji@gmail.com NR 10 TC 3 Z9 3 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1046-3976 J9 ENDOCR PATHOL JI Endocr. Pathol. PD SPR PY 2007 VL 18 IS 1 BP 53 EP 55 DI 10.1007/s12022-007-0007-7 PG 3 WC Endocrinology & Metabolism; Pathology SC Endocrinology & Metabolism; Pathology GA 186TV UT WOS:000247802000009 PM 17652802 ER PT J AU Bellinger, DC Daniel, D Trachtenberg, F Tavares, M McKinlay, S AF Bellinger, David C. Daniel, David Trachtenberg, Felicia Tavares, Mary McKinlay, Sonia TI Dental amalgam restorations and children's neuropsychological function: The New England children's amalgam trial SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE children; dental amalgam; elemental mercury; neuropsychology; randomized contolled trial ID LEVEL MERCURY EXPOSURE; OCCUPATIONAL-EXPOSURE; 6-YEAR-OLD CHILDREN; BDNF POLYMORPHISM; DENTISTS; ASSOCIATIONS; PREGNANCY; LEAD AB BACKGROUND: A concern persists that children's exposure to mercury vapor from dental amalgams produces neurotoxicicy. OBJECTIVE: Our goal was to compare the neuropsychological function of children, without prior exposure to dental amalgam, whose caries were repaired using either dental amalgam or mercury-free composite materials. METHODS: We conducted a randomized controlled trial involving 534 6- to 10-year-old urban and rural children who were assessed yearly for 5 years using a battery of tests of intelligence, achievement, language, memory, learning, visual-spatial skills, verbal fluency, fine motor function, problem solving, attention, and executive function. RESULTS: Although the mean urinary mercury concentration was greater among children in the amalgam group than the composite group (0.9 vs. 0.6 mu g/g creatinine), few significant differences were found between the test scores of children in the two groups. The differences found were inconsistent in direction. Analyses using two cumulative exposure indices-surface years of amalgam and urinary mercury concentration-produced similar results. CONCLUSIONS: Exposure to elemental mercury in amalgam at the levels experienced by the children who participated in the trial did not result in significant effects on neuropsychological function within the 5-year follow-up period. C1 New England Res Inst, Watertown, MA 02472 USA. Childrens Hosp, Dept Neurol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. Univ Maine, Dept Psychol, Farmington, ME USA. Forsyth Inst, Boston, MA USA. RP McKinlay, S (reprint author), New England Res Inst, 9 Galen St, Watertown, MA 02472 USA. EM Smckinlay@neriscience.com FU NIDCR NIH HHS [U01 DE011886, U01 DE11886] NR 37 TC 25 Z9 26 U1 0 U2 3 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD MAR PY 2007 VL 115 IS 3 BP 440 EP 446 DI 10.1289/ehp.9497 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 142LN UT WOS:000244651500039 PM 17431496 ER PT J AU Bagic, A Boudreau, EA Greenfield, J Sato, S AF Bagic, Anto Boudreau, Eilis A. Greenfield, Jacquelyn Sato, Susumu TI Electro-clinical evolution of refractory non-convulsive status epilepticus caused by West Nile virus encephalitis SO EPILEPTIC DISORDERS LA English DT Article DE West Nile virus (WNV); seizure; status epilepticus; encephalitis; arbovirus; chronic lymphocytic leukemia; nonconvulsive status epilepticus ID PROPOFOL INFUSION SYNDROME; ST-LOUIS ENCEPHALITIS; INFECTION; EPIDEMIC; CHILDREN; EEG; PATHOPHYSIOLOGY; PATHOGENESIS; ACIDOSIS; OUTBREAK AB West Nile virus (WNV) has re-emerged with a much wider geographic distribution and a higher incidence than ever. In spite of some recent reports on the neurological manifestations and EEG changes caused by WNV encephalitis, there are few data on the incidence of seizures, status epilepticus or post-encephalitic epilepsy. There is also no systematic review of EEG changes caused by WNV encephalitis that is based on a large series of patients. Here, we review the pertinent literature, and report the electroclinical evolution and therapeutic complexity of a patient with WNV encephalitis who developed refractory, non-convulsive status epilepticus. C1 NINDS, EEG Stn, NIH, Bethesda, MD 20892 USA. Portland VA Med Ctr, HSRDP, Portland, OR USA. RP Bagic, A (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Suite 811,Kaufmann Med Bldg,3471 5th Ave, Pittsburgh, PA 15213 USA. EM bagica@upmc.edu NR 33 TC 7 Z9 7 U1 1 U2 1 PU JOHN LIBBEY EUROTEXT LTD PI MONTROUGE PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE SN 1294-9361 J9 EPILEPTIC DISORD JI Epileptic Disord. PD MAR PY 2007 VL 9 IS 1 BP 98 EP 103 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 145IG UT WOS:000244857900015 PM 17307720 ER PT J AU Guerra, CE Shea, JA AF Guerra, Carmen E. Shea, Judy A. TI Health literacy and perceived health status in Latinos and African Americans SO ETHNICITY & DISEASE LA English DT Article DE African Americans; comorbidity; continental population groups; ethnic groups; health; health literacy; health status; Hispanic Americans; minority groups; quality of life ID SELF-RATED HEALTH; PREDICTING MORTALITY; REPORTED HEALTH; LOW-INCOME; CARE; COMORBIDITY; VALIDITY; PERCEPTION; OUTCOMES; ADULTS AB Objective: To determine the association between functional health literacy and physical and mental health status in a sample of Latinos and African Americans. Methods: A cross-sectional study that used a demographics questionnaire, the Short Test of Functional Health Literacy in Adults (S-TOFHLA), the physical component summary (PCS-12) and mental component summary (MCS-1 2) scales of the SF-1 2, and the Charlson Comorbidity Index in a sample of 1301 Medicaid and/or Medicare Latino and African American adult patients at four community clinics and one university-based general medicine practice in Philadelphia. Results: When stratified by inadequate, marginal, and adequate functional health literacy levels and compared to SF-12 population norm scores of 50.0, the mean (standard deviation [SD]) PCS-12 scores were 38.8 (11.2), 38.5 (11.1), 42.7 (11.4), respectively (P <.0001); the mean (SD) MCS-12 scores were 43.3 (11.2), 43.5 (10.4), 44.3 (11.7), respectively (P=39). After adjusting for sociodemographic confounders and Charlson Index score, functional health literacy was not significantly associated with physical or mental health status (P >.50 and P=.41, respectively). Conclusion: Functional health literacy is not independently associated with perceived physical health status or mental health status in a sample of ethnic minorities. C1 Univ Penn, Sch Med, Div Gen Internal Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Guerra, CE (reprint author), Univ Penn, Sch Med, Div Gen Internal Med, Dept Med, 1221 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM carmen.guerra@uphs.upenn.edu FU AHRQ HHS [R01 HS10299]; NCI NIH HHS [K01-CA097925] NR 53 TC 17 Z9 17 U1 2 U2 5 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X J9 ETHNIC DIS JI Ethn. Dis. PD SPR PY 2007 VL 17 IS 2 BP 305 EP 312 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 189SV UT WOS:000248009700019 PM 17682363 ER PT J AU Green, AR Miller, E Krupat, E White, A Taylor, WC Hirsh, DA Wilson, RP Betancourt, JR AF Green, Alexander R. Miller, Elizabeth Krupat, Edward White, Augustus Taylor, William C. Hirsh, David A. Wilson, Rebbecca P. Betancourt, Joseph R. TI Designing and implementing a cultural competence OSCE: Lessons learned from interviews with medical students SO ETHNICITY & DISEASE LA English DT Article ID EDUCATION; SKILLS; CARE AB Purpose: Objective structured clinical examinations (OSCEs) use standardized patients (SPs) to teach and evaluate medical students ' skills. Few studies describe using OSCEs for cultural competence education, now a Liaison Committee on Medical Education accreditation standard for medical schools. We designed an OSCE station emphasizing cross-cultural communication skills (ccOSCE) and interviewed students to better understand and improve upon this tool. Method: Two investigators conducted semi-structured interviews with 22 second-year Harvard medical students who completed the ccOSCE. Three investigators coded and analyzed the interview transcripts by using qualitative methods to explore students ' perspectives on the station and its focus on cultural competence. Results: Themes that emerged pertinent to design and implementation of the station were grouped into four categories: learning goals, logistical issues, faculty feedback, and SPs. Students were positive about the overall experience. They appreciated the practical focus on nonadherence. Some found the learning goals complex, and others felt the format promoted stereotypes. Logistical issues included concerns about marginalizing cross-cultural care by creating a separate station. Faculty feedback was helpful when specific about sociocultural issues students did or did not explore well. Students found SPs realistic but inconsistent in how easily they revealed information. Conclusion: Designing a ccOSCE experience is challenging but feasible. Students ' perspectives highlight a tension between presenting cultural competence in a dedicated station (potentially marginalizing the topic and promoting stereotypes) and spreading it across stations (limiting opportunity for focused teaching). Learning goals should be clear, concise, and effectively communicated to faculty and SPs so their feedback can be standardized and specific. C1 Massachusetts Gen Hosp, Dispart Solut Ctr, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Div Gen Internal Med & Primary Care, Boston, MA 02215 USA. Harvard Univ, Sch Med, Cambridge Hlth Alliance, Cambridge, MA 02138 USA. Univ Calif Davis, Med Ctr, Ctr Reducing Hlth Dispart, Sacramento, CA 95817 USA. RP Green, AR (reprint author), Massachusetts Gen Hosp, Dispart Solut Ctr, 50 Staniford St,Suite 901, Boston, MA 02114 USA. EM argreen@partners.org RI Miller, Elizabeth/E-7939-2012 NR 15 TC 11 Z9 11 U1 1 U2 4 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X J9 ETHNIC DIS JI Ethn. Dis. PD SPR PY 2007 VL 17 IS 2 BP 344 EP 350 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 189SV UT WOS:000248009700025 PM 17682369 ER PT J AU Silverberg, MS Duerr, RH Brant, SR Bromfield, G Datta, LW Jani, N Kane, SV Rotter, JI Schumm, LP Steinhart, AH Taylor, KD Yang, HY Cho, JH Rioux, JD Daly, MJ AF Silverberg, Mark S. Duerr, Richard H. Brant, Steven R. Bromfield, Gillian Datta, Lisa W. Jani, Niraj Kane, Sunanda V. Rotter, Jerome I. Schumm, L. Philip Steinhart, A. Hillary Taylor, Kent D. Yang, Huiying Cho, Judy H. Rioux, John D. Daly, Mark J. CA NIDDK IBD Genetics Consortium TI Refined genomic localization and ethnic differences observed for the IBD5 association with Crohn's disease SO EUROPEAN JOURNAL OF HUMAN GENETICS LA English DT Article DE Crohn's disease; association; IBD5; ethnicity ID INFLAMMATORY-BOWEL-DISEASE; CATION TRANSPORTER GENES; ULCERATIVE-COLITIS; SUSCEPTIBILITY LOCI; PROVIDES EVIDENCE; NOD2 VARIANTS; WIDE SEARCH; HAPLOTYPE; RISK; 5Q31 AB Although the general association of the inflammatory bowel disease (IBD) 5 region on chromosome 5q31 to Crohn's disease ( CD) has been replicated repeatedly, the identity of the precise causal variant within the region remains unknown. A recent report proposed polymorphisms in solute carrier family 22, member 4 (SLC22A4) organic cation transporter 1( OCTN1) and solute carrier family 22, member 5 (SLC22A5) (OCTN2) as responsible for the IBD5 association, but definitive, large-sample comparison of those polymorphisms with others known to be in strong linkage disequilibrium was not performed. We evaluated 1879 affected offspring and parents ascertained by a North American IBD Genetics Consortium for six IBD5 tag single nucleotide polymorphisms ( SNPs) to evaluate association localization and ethnic and subphenotypic specificity. We confirm association to the IBD5 region ( best SNP IGR2096a_1/rs12521868, P < 0.0005) and show this association to be exclusive to the non-Jewish (NJ) population (P=0.00005) ( risk allele undertransmitted in Ashkenazi Jews). Using Phase II HapMap data, we demonstrate that there are a set of polymorphisms, spanning genes from prolyl 4-hydroxylase (P4HA2) through interferon regulatory factor 1 (IRF1) with equivalent statistical evidence of association to the reported SLC22A4 variant and that each, by itself, could entirely explain the IBD5 association to CD. Additionally, the previously reported SLC22A5 SNP is rejected as the potential causal variant. No specificity of association was seen with respect to disease type and location, and a modest association to ulcerative colitis is also observed. We confirm the importance of IBD5 to CD susceptibility, demonstrate that the locus may play a role in NJ individuals only, and establish that IRF1, PDLIM, and P4HA2 may be equally as likely to contain the IBD5 causal variant as the OCTN genes. C1 Massachusetts Gen Hosp, Simches Res Ctr, Ctr Human Genet Res, Boston, MA 02114 USA. Univ Toronto, Mt Sinai Hosp, IBD Ctr, Dept Med, Toronto, ON M5G 1X5, Canada. Univ Toronto, Mt Sinai Hosp, IBD Ctr, Dept Surg, Toronto, ON M5G 1X5, Canada. Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. Johns Hopkins Univ, Sch Med, Dept Med, Meyerhoff Inflammatory Bowel Dis Ctr, Baltimore, MD 21205 USA. Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. Univ Chicago, Chicago, IL 60637 USA. Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA USA. Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. Univ Montreal, Montreal Heart Inst, Dept Med, Montreal, PQ, Canada. RP Daly, MJ (reprint author), Massachusetts Gen Hosp, Simches Res Ctr, Ctr Human Genet Res, CPZN-6818,185 Cambridge St, Boston, MA 02114 USA. EM mjdaly@chgr.mgh.harvard.edu RI Silverberg, Mark/B-4183-2008; Rioux, John/A-9599-2015; OI Rioux, John/0000-0001-7560-8326; Duerr, Richard/0000-0001-6586-3905 FU NIDDK NIH HHS [U01 DK062420, DK62413, DK62420, DK62422, DK62423, DK62429, DK62431, DK62432, U01 DK062432] NR 37 TC 60 Z9 65 U1 1 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1018-4813 J9 EUR J HUM GENET JI Eur. J. Hum. Genet. PD MAR PY 2007 VL 15 IS 3 BP 328 EP 335 DI 10.1038/sj.ejhg.5201756 PG 8 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 139BE UT WOS:000244406200011 PM 17213842 ER PT J AU Stock, P Akbari, O Berry, G Freeman, GJ DeKruyff, RH Umetsu, DT AF Stock, Philippe Akbari, Omid Berry, Gerald Freeman, Gordon J. DeKruyff, Rosemarie H. Umetsu, Dale T. TI Induction of T(H)1-like regulatory cells that express Foxp3 and protect against airway hyperreactivity SO EUROPEAN JOURNAL OF PEDIATRICS LA English DT Meeting Abstract C1 Univ Hosp Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany. Harvard Univ, Childrens Hosp, Div Immunol, Karp Labs,Med Sch, Boston, MA 02115 USA. Stanford Univ, Dept Pathol, Stanford, CA 94305 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0340-6199 J9 EUR J PEDIATR JI Eur. J. Pediatr. PD MAR PY 2007 VL 166 IS 3 BP 287 EP 288 PG 2 WC Pediatrics SC Pediatrics GA 142JH UT WOS:000244645100060 ER PT J AU Bech, P Krystal, A Walsh, J Rubens, R Caron, J Wessel, T Amato, D Roth, T McCall, WV Fava, M AF Bech, P. Krystal, A. Walsh, J. Rubens, R. Caron, J. Wessel, T. Amato, D. Roth, T. McCall, W. V. Fava, M. TI Analysis of individual items of the Hamilton depression scale in a study of eszopiclone/fluoxetine co-therapy SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 Frederikborg Gen Hosp, Psychiat Res Unit, Hillerod, Denmark. Duke Univ, Med Ctr, Durham, NC USA. St Johns St Lukes Hosp, Sleep Med & Res Ctr, St Louis, MO USA. Sepracor Inc, Marlborough, MA USA. Henry Ford Disorders Ctr, Detroit, MI USA. Wake Forest Univ Hlth Sci, Winston Salem, NC USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Krystal, Andrew/J-7109-2013 OI Krystal, Andrew/0000-0002-6702-781X NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PD MAR PY 2007 VL 22 SU 1 BP S224 EP S224 DI 10.1016/j.eurpsy.2007.01.748 PG 1 WC Psychiatry SC Psychiatry GA 153YC UT WOS:000245473000779 ER PT J AU Blier, P Trivedi, MH Rapaport, MH AF Blier, P. Trivedi, M. H. Rapaport, M. Hyman TI Contemporary approaches for an optimal treatment of major depression SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 Ottawa Inst Mental Hlth Res, Ottawa, ON, Canada. Univ Ottawa, Ottawa, ON, Canada. Univ Texas, SW Med Ctr, Dallas, TX USA. Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PD MAR PY 2007 VL 22 SU 1 BP S72 EP S72 DI 10.1016/j.eurpsy.2007.01.278 PG 1 WC Psychiatry SC Psychiatry GA 153YC UT WOS:000245473000259 ER PT J AU Montgomery, S Kinrys, G Krystal, A McCall, WV Roth, T Rubens, R Schaefer, K Roach, J Huang, H Krishnan, R Pollack, M AF Montgomery, S. Kinrys, G. Krystal, A. McCall, W. V. Roth, T. Rubens, R. Schaefer, K. Roach, J. Huang, H. Krishnan, R. Pollack, M. TI Evaluation of eszopiclone and escitalopram oxalate co-therapy in patients with generalized anxiety disorder and insomnia SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 Univ London, Imperial Coll, London, England. Cambridge Hlth Alliance & Harvard Med Sch, Boston, MA USA. Duke Univ, Med Ctr, Durham, NC USA. Wake Forest Univ Hlth Sci, Winston Salem, NC 27109 USA. Henry Ford Sleep Disorders Ctr, Detroit, MI USA. Sepracor Inc, Marlborough, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PD MAR PY 2007 VL 22 SU 1 BP S238 EP S239 DI 10.1016/j.eurpsy.2007.01.798 PG 2 WC Psychiatry SC Psychiatry GA 153YC UT WOS:000245473000829 ER PT J AU Pollack, M Stein, DJ Mangano, R Musgnung, J Entsuah, R Simon, N AF Pollack, M. Stein, D. J. Mangano, R. Musgnung, J. Entsuah, R. Simon, N. TI Predictors of clinical outcome in panic disorder: Analysis of venlafaxine XR short-term treatment studies SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Related Disorders, Boston, MA 02114 USA. Univ Cape Town, Dept Psychiat, ZA-7925 Cape Town, South Africa. Wyeth Pharmaceut, Collegeville, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PD MAR PY 2007 VL 22 SU 1 BP S240 EP S240 DI 10.1016/j.eurpsy.2007.01.802 PG 1 WC Psychiatry SC Psychiatry GA 153YC UT WOS:000245473000833 ER PT J AU Boodanos, J Karamanolakis, D Mitsiades, C Milathianakis, C Dimopoulos, T Koutsilieris, M AF Boodanos, J. Karamanolakis, D. Mitsiades, C. Milathianakis, C. Dimopoulos, T. Koutsilieris, M. TI Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases SO EUROPEAN UROLOGY SUPPLEMENTS LA English DT Meeting Abstract C1 Univ Athens, Sch Med, Dept Expt Physiol, GR-11527 Athens, Greece. Dana Farber Canc Inst, Harvard Med Sch, Dept Med Oncol, Dept Med, Boston, MA 02115 USA. METAXA Gen Hosp, Dept Urol, Piraeus, Greece. PANAGIA Gen Hosp, Dept Urol, Thessaloniki, Greece. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9056 J9 EUR UROL SUPPL JI Eur. Urol. Suppl. PD MAR PY 2007 VL 6 IS 2 BP 101 EP 101 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 139HJ UT WOS:000244422600316 ER PT J AU Negrier, S Jager, E Porta, C Mc Dermott, D Moore, MS Bellmunt, J Grimm, MO Simantov, RE Anderson, SS Escudier, B Bukowski, R AF Negrier, S. Jaeger, E. Porta, C. Mc Dermott, D. Moore, M. S. Bellmunt, J. Grimm, MO. Simantov, R. E. Anderson, S. S. Escudier, B. Bukowski, R. TI Sorafenib in patients with advanced renal cell carcinoma (RCC) and prior cytokine therapy: Subgroup analysis of targets SO EUROPEAN UROLOGY SUPPLEMENTS LA English DT Meeting Abstract C1 Ctr Leon Berard, Dept Med Oncol, F-69373 Lyon, France. Med Klin 2, Krankenhaus Nordwest, Frankfurt, Germany. San Matteo Univ Hosp, IRCCS, Pavia, Italy. Dana Farber Harvard Canc Ctr, Div Hematol Oncol, Boston, MA USA. Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada. Hosp Vall d Hebron, PSO Vall d Hebron, Med Oncol Serv, Barcelona, Spain. Tech Univ Dresden, Dept Urol, D-8027 Dresden, Germany. Bayer Pharmaceut, Global Prod Dev, West Haven, CT USA. Bayer Pharmaceut, Dept Med Affairs, West Haven, CT USA. Inst Gustave Roussy, Dept Immunothe, Villejuif, France. Cleveland Clin, Ctr Canc, Dept Solid Tumor Oncol, Cleveland, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9056 J9 EUR UROL SUPPL JI Eur. Urol. Suppl. PD MAR PY 2007 VL 6 IS 2 BP 236 EP 236 DI 10.1016/S1569-9056(07)60851-3 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 139HJ UT WOS:000244422600853 ER PT J AU Schnaker, E Schneider, MF Gorge, T Gorzelanny, C Strozyk, E Poppelmann, B Schneider, SW AF Schnaeker, E. Schneider, M. F. Goerge, T. Gorzelanny, C. Strozyk, E. Poeppelmann, B. Schneider, S. W. TI Melanoma cells adhere to human endothelial cells via luminal secreted ultra large von Willebrand fibres (ULVWF) under conditions of laminar flow SO EXPERIMENTAL DERMATOLOGY LA English DT Meeting Abstract CT 34th Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung CY MAR 08, 2004-MAR 10, 2007 CL Freiburg, GERMANY SP Arbeitsgermeinsch Dermatolog Forschung C1 Univ Munster, Dept Dermatol, D-4400 Munster, Germany. Univ Augsburg, Dept Biophys, D-8900 Augsburg, Germany. Harvard Univ, Sch Med, Dept Pathol, CBR Biomed Res Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0906-6705 J9 EXP DERMATOL JI Exp. Dermatol. PD MAR PY 2007 VL 16 IS 3 BP 265 EP 265 PG 1 WC Dermatology SC Dermatology GA 134BC UT WOS:000244056600230 ER PT J AU Goerge, T Schnaker, E Strozyk, E Poeppelmann, B Schneider, MF Gorzelanny, C Kleineruschkamp, F Schneider, SW AF Goerge, T. Schnaeker, E. Strozyk, E. Poeppelmann, B. Schneider, M. F. Gorzelanny, C. Kleinerueschkamp, F. Schneider, S. W. TI Melanoma-derived MMP-1 induces an acute prothromotic, proinflammatory and cell adhesive endothelial surface SO EXPERIMENTAL DERMATOLOGY LA English DT Meeting Abstract CT 34th Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung CY MAR 08, 2004-MAR 10, 2007 CL Freiburg, GERMANY SP Arbeitsgermeinsch Dermatolog Forschung C1 Harvard Univ, Sch Med, Dept Pathol, CBR Inst Biomed Res, Boston, MA 02115 USA. Univ Munster, Dept Dermatol, D-4400 Munster, Germany. Univ Augsburg, Dept Biophys, D-8900 Augsburg, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0906-6705 J9 EXP DERMATOL JI Exp. Dermatol. PD MAR PY 2007 VL 16 IS 3 BP 266 EP 266 PG 1 WC Dermatology SC Dermatology GA 134BC UT WOS:000244056600232 ER PT J AU Vockel, M Liew, C Kreienkamp, H Schulz, S Moll, I Brandner, JM AF Vockel, M. Liew, C. Kreienkamp, H. Schulz, S. Moll, I. Brandner, J. M. TI Somatostatin receptor 3 is regulating tight junctions via heterotrimeric G-proteins SO EXPERIMENTAL DERMATOLOGY LA English DT Meeting Abstract CT 34th Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung CY MAR 08, 2004-MAR 10, 2007 CL Freiburg, GERMANY SP Arbeitsgermeinsch Dermatolog Forschung C1 Univ Hamburg, Hosp Eppendorf, Dept Dermatol & Venerol, D-20246 Hamburg, Germany. Univ Hamburg, Hosp Eppendorf, Dept Human Genet, D-20246 Hamburg, Germany. Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. Univ Magdeburg, Dept Pharmacol Toxicol, D-39106 Magdeburg, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0906-6705 J9 EXP DERMATOL JI Exp. Dermatol. PD MAR PY 2007 VL 16 IS 3 BP 273 EP 273 PG 1 WC Dermatology SC Dermatology GA 134BC UT WOS:000244056600254 ER PT J AU Ghobrial, IM Leleu, X Hatjiharissi, E Hideshima, T Mitsiades, C Schlossman, R Anderson, KC Richardson, P AF Ghobrial, Irene M. Leleu, Xavier Hatjiharissi, Evdoxia Hideshima, Teru Mitsiades, Constantine Schlossman, Robert Anderson, Kenneth C. Richardson, Paul TI Emerging drugs in multiple myeloma SO EXPERT OPINION ON EMERGING DRUGS LA English DT Review DE multiple myeloma; novel therapy; signaling pathway ID STEM-CELL TRANSPLANTATION; THALIDOMIDE PLUS DEXAMETHASONE; NEWLY-DIAGNOSED MYELOMA; ANTITUMOR-ACTIVITY; IN-VITRO; SYNERGISTIC ACTIVITY; COMBINATION THERAPY; INHIBITOR RAPAMYCIN; REFRACTORY MYELOMA; BORTEZOMIB AB The treatment of multiple myeloma has seen significant changes from the time of the initial use of cytotoxic agents such as melphalan, to the introduction of high-dose chemotherapy and stem cell transplantation, and most recently the era of novel targeted agents. These new drugs have rapidly become the mainstay of therapy of this disease and transformed the treatment paradigm, leading to improvements in survival and quality of life. Existing therapeutic options include agents such as thalidomide, bortezomib and lenalidomide, either used alone or in combination with standard agents, including glucocorticoids, and in conjunction with high-dose chemotherapy supported with stem cell transplantation. Several other targeted agents have demonstrated exciting preclinical activity, and are presently being tested in early Phase I and II clinical trials. This review summarizes the role of novel therapeutic agents in multiple myeloma, and the promising effect of multiple new agents in development. C1 Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA 02115 USA. Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA. RP Ghobrial, IM (reprint author), Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM irene_ghobrial@dfci.harvard.edu NR 75 TC 9 Z9 9 U1 1 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1472-8214 J9 EXPERT OPIN EMERG DR JI Expert Opin Emerg. Drugs PD MAR PY 2007 VL 12 IS 1 BP 155 EP 163 DI 10.1517/14728214.12.1.155 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 182JK UT WOS:000247500700010 PM 17355220 ER PT J AU Wittenberger, MD Hagerman, RJ Sherman, SL McConkie-Rosell, A Welt, CK Rebar, RW Corrigan, EC Simpson, JL Nelson, LM AF Wittenberger, Michael D. Hagerman, Randi J. Sherman, Stephanie L. McConkie-Rosell, Allyn Welt, Corrine K. Rebar, Robert W. Corrigan, Emily C. Simpson, Joe Leigh Nelson, Lawrence M. TI The FMR1 premutation and reproduction SO FERTILITY AND STERILITY LA English DT Review DE fragile X syndrome; FMR1; premutation; spontaneous premature ovarian failure; hypergonadotropic hypogonadism; primary hypogonadism; primary ovarian insufficiency; premature menopause; hypergonadotropic amenorrhea; low response to gonadotropin stimulation; diminished ovarian reserve; fragile X-associated tremor/ataxia syndrome; FXTAS; genetic counseling ID FRAGILE-X-SYNDROME; PREMATURE OVARIAN FAILURE; TREMOR/ATAXIA SYNDROME FXTAS; MENTAL-RETARDATION PROTEIN; PREIMPLANTATION GENETIC DIAGNOSIS; CGG REPEAT; FULL-MUTATION; INTENTION TREMOR; CYSTIC-FIBROSIS; GRAY ZONE AB Objective: To update clinicians on the reproductive implications of premutations in FMR1 (fragile X mental retardation 1). Fragile X syndrome, a cause of mental retardation and autism, is due to a full mutation (> 200 CGG repeats). Initially, individuals who carried the premutation (defined as more than 55 but less than 200 CGG repeats) were not considered at risk for any clinical disorders. It is now recognized that this was incorrect, specifically with respect to female reproduction. Design and Setting: Literature review and consensus building at two multidisciplinary scientific workshops. Conclusion(s): Convincing evidence now relates the FMR1 premutation to altered ovarian function and loss of fertility. An FMR1 mRNA gain-of-function toxicity may underlie this altered ovarian function. There are major gaps in knowledge regarding the natural history of the altered ovarian function in women who carry the FMR1 premutation, making counseling about reproductive plans a challenge. Women with premature ovarian failure are at increased risk of having an FMR1 premutation and should be informed of the availability of fragile X testing. Specialists in reproductive medicine can provide a supportive environment in which to explain the implications of FMR1 premutation testing, facilitate access to testing, and make appropriate referral to genetic counselors. C1 NICHHD, NIH, CRC, Intramural Res Program,Sect Womens Hlth Res,Dev E, Bethesda, MD 20892 USA. Univ Calif Davis, Med Ctr, Dept Pediat, MIND Inst, Sacramento, CA 95817 USA. Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA USA. Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA. Massachusetts Gen Hosp, Dept Med, Reprod Endocrine Unit, Boston, MA 02114 USA. Amer Soc Reprod Med, Birmingham, AL USA. Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA. Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA. RP Nelson, LM (reprint author), NICHHD, NIH, CRC, Intramural Res Program,Sect Womens Hlth Res,Dev E, Room 1-3330,10 Ctr Dr, Bethesda, MD 20892 USA. EM Lawrence_Nelson@nih.gov OI Welt, Corrine/0000-0002-8219-5504 FU Intramural NIH HHS; PHS HHS [U10/CCU 92513] NR 101 TC 200 Z9 211 U1 6 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD MAR PY 2007 VL 87 IS 3 BP 456 EP 465 DI 10.1016/j.fertnstert.2006.09.004 PG 8 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 148OU UT WOS:000245085300002 PM 17074338 ER PT J AU Pfleger, CM Harvey, KF Yan, H Hariharan, IK AF Pfleger, Cathie M. Harvey, Kieran F. Yan, Hua Hariharan, Iswar K. TI Mutation of the gene encoding the ubiquitin activating enzyme Uba1 causes tissue overgrowth in Drosophila SO FLY LA English DT Article DE ubiquitin; E1; Uba1; Ube1; compensatory proliferation; non-autonomous overgrowth; tumor suppressor ID CANCER CELL-LINES; GROWTH-FACTOR-BETA; PROTEIN UBIQUITINATION; BREAST-CANCER; APOPTOSIS PROTEINS; TNF SUPERFAMILY; HEPATOMA-CELLS; CYCLE EXIT; IN-VITRO; EXPRESSION AB Protein ubiquitination has been shown to regulate a wide variety of cellular process including cell cycle progression, protein trafficking and apoptosis. Most regulation of ubiquitination occurs at the level of E2 or E3 enzymes and their interactions with specific substrates. In a screen for mutations that cause tissue overgrowth, we recovered multiple mutations in the Drosophila Uba1 gene that encodes the E1 enzyme that is required for the first step of most, if not all, ubiquitination reactions. Previous studies with yeast and mammalian cells have shown that disrupting E1 function results in a cell-cycle arrest. Here we show that in the developing Drosophila eye, clones of cells that are homozygous for partial loss of function alleles of Uba1 show defects in apoptosis. Moreover, clones homozygous for stronger or complete loss of function alleles of Uba1, that are predicted to have a global defect on ubiquitination, survive poorly but are able to stimulate the overgrowth of adjacent wild-type tissue. Experiments with mammalian cells show that reducing the level of RNA of the mammalian Uba1 ortholog, UBE1, also results in increased expression of specific growth factor genes. Our studies show that a reduction in E1 activity can promote tissue growth in a multicellular organism and raise the possibility that changes in E1 activity may occur during normal development or in cancer. C1 [Pfleger, Cathie M.; Harvey, Kieran F.; Hariharan, Iswar K.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA. [Pfleger, Cathie M.; Harvey, Kieran F.; Hariharan, Iswar K.] Massachusetts Gen Hosp, Massachusetts Gen Hosp Canc Ctr, Charlestown, MA USA. [Pfleger, Cathie M.; Yan, Hua] Mt Sinai Sch Med, New York, NY USA. [Harvey, Kieran F.] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia. RP Hariharan, IK (reprint author), Univ Calif Berkeley, Dept Mol & Cell Biol, 361A Life Sci Addit, Berkeley, CA 94720 USA. EM ikh@berkeley.edu RI Yan, Hua/E-5305-2011 FU NCI NIH HHS [5R24 CA095823-04]; NCRR NIH HHS [1 S10 RR09145-01]; NIGMS NIH HHS [GM61672] NR 64 TC 20 Z9 21 U1 0 U2 4 PU LANDES BIOSCIENCE PI AUSTIN PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA SN 1933-6934 J9 FLY JI Fly PD MAR-APR PY 2007 VL 1 IS 2 BP 95 EP 105 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 307WN UT WOS:000256349800005 PM 18820468 ER PT J AU Elias, FN Yuen, TJ Olson, SL Sangeorzan, BJ Ledoux, WR AF Elias, Fady N. Yuen, Tracy J. Olson, Soren L. Sangeorzan, Bruce J. Ledoux, William R. TI Correction of clawed hallux deformity: Comparison of the Jones procedure and FHL transfer in a cadaver model SO FOOT & ANKLE INTERNATIONAL LA English DT Article DE biomechanics; foot; hallux abnormalities; pressure; surgery; toes ID FOOT PRESSURE; TENDON; MANAGEMENT; ETIOLOGY; RISK AB Background: A clawed hallux is defined as extension of the first metatarsophalangeal (MTP) joint combined with flexion of the interphalangeal JP) joint. Two operative procedures, the modified Jones procedure and flexor hallucis longus (FHL) transfer, are indicated for correction. The purpose of this study were to evaluate the overall effectiveness of these two procedures in correcting both the clawed hallux deformity and its mechanical consequences and to compare their effect on postoperative plantar pressures. Methods: The modified Jones procedure and FHL transfer were done on cadaver specimens that were tested before and after surgery in a specialized footloading frame. We quantified the angular correction of the MTP and the IP joints, as well as the plantar pressures under the head of the first metatarsal and the hallux. Results: Both surgeries were equally effective in correcting the angular deformity at the MTP and IP joints (p = 0.037 and 0.0020, respectively). A significant reduction in the plantar pressure (p = 0.015) beneath the first metatarsal was observed with both the modified Jones procedure and the FHL transfer. Overall, there was no significant difference between preoperative and postoperative pressures beneath the hallux (p = 0.5); however, for the FHL overpull group there was significantly less pressure beneath the hallux after surgery (p = 0.014). Conclusions: The two surgeries produced similar results, but the FHL transfer does not require fusion of the hallux, which is considered an undesirable comorbidity of the modified Jones procedure. C1 VA Puget Sound, Seattle, WA 98108 USA. RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Dept Vet Affairs, Seattle, WA USA. Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. Univ Washington, Dept Engn Mech, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound, Ms 151,1600 S Columbian Way, Seattle, WA 98108 USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 NR 15 TC 6 Z9 6 U1 0 U2 1 PU AMER ORTHOPAEDIC FOOT & ANKLE SOC, INC PI SEATTLE PA 2517 EASTLAKE AVE EAST, STE 200, SEATTLE, WA 98102 USA SN 1071-1007 J9 FOOT ANKLE INT JI Foot Ankle Int. PD MAR PY 2007 VL 28 IS 3 BP 369 EP 376 DI 10.3113/FAI.2007.0369 PG 8 WC Orthopedics SC Orthopedics GA 140WF UT WOS:000244536700014 PM 17371661 ER PT J AU Streelman, JT Albertson, RC Kocher, TD AF Streelman, J. Todd Albertson, R. C. Kocher, T. D. TI Variation in body size and trophic morphology within and among genetically differentiated populations of the cichlid fish, Metriaclima zebra, from Lake Malawi SO FRESHWATER BIOLOGY LA English DT Article DE body size; cichlid; environmental change; jaw shape; tooth shape; trophic differentiation ID RAPID EVOLUTION; PHENOTYPIC PLASTICITY; COLOR VARIATION; DIVERGENCE; SPECIATION; SELECTION; AFRICA; MODEL; TELEOSTEI; TRAIT AB 1. The cichlid fish Metriaclima zebra, common in Lake Malawi, feeds by filtering plankton from the water and by brushing items from sediment covered substrata. It inhabits isolated rocky reefs among which community structure, resource availability and gene pools are likely to differ. We speculated that body size and trophic morphology of M. zebra might vary concomitantly. 2. We quantified the extent of genetic, body size and trophic variation within and between populations of M. zebra from southern Lake Malawi. Specifically, we tested the hypotheses that: (i) local populations are genetically differentiated, (ii) local populations differ in jaw morphology, dentition and standard length (SL), and (iii) variation in size is correlated with variation in trophic morphology. 3. Local populations of M. zebra differed in mean SL and were genetically differentiated. Moreover, populations exhibited dissimilar oral jaw morphologies and dentitions, perhaps related to differences in feeding biology. Variation in jaw shape was largely restricted to the curvature of the distal tip of the dentary. Populations were characterised by individuals with oblique, upward or downward directed gapes. Dental patterns differed in the proportion of unicuspid teeth in all rows of each jaw (dentaries and premaxillae) and the spacing of teeth in affected rows. 4. Within populations, jaw and tooth shapes were correlated with body size. Smaller individuals possessed upward curving jaws and closely packed multicusped teeth, while larger individuals exhibited relatively downward-directed jaws with increasing numbers of widely spaced unicuspid teeth. 5. Metriaclima zebra populations have increased in mean SL over the last decade, in contrast to a decline among Lake Malawi pelagic cichlids. Differences in size may contribute to variation in trophic morphology and may track local environmental dynamics in this lacustrine system. C1 Georgia Inst Technol, Sch Biol, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA. Forsyth Inst, Dept Cytokine Biol, Boston, MA USA. Univ New Hampshire, Hubbard Ctr Genome Studies, Durham, NH 03824 USA. RP Streelman, JT (reprint author), Georgia Inst Technol, Sch Biol, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA. EM todd.streelman@biology.gatech.edu RI Kocher, Thomas/B-3089-2013 NR 76 TC 10 Z9 11 U1 0 U2 19 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0046-5070 J9 FRESHWATER BIOL JI Freshw. Biol. PD MAR PY 2007 VL 52 IS 3 BP 525 EP 538 DI 10.1111/j.1365-2427.2006.01720.x PG 14 WC Marine & Freshwater Biology SC Marine & Freshwater Biology GA 134VC UT WOS:000244111400012 ER PT J AU Kudo, T Lu, H Wu, JY Ohno, T Wu, MJ Genta, RM Graham, DY Yamaoka, Y AF Kudo, Takahiko Lu, Hong Wu, Jeng-Yih Ohno, Tomoyuki Wu, Michael J. Genta, Robert M. Graham, David Y. Yamaoka, Yoshio TI Pattern of transcription factor activation in Helicobacter pylori-infected Mongolian gerbils SO GASTROENTEROLOGY LA English DT Article ID NF-KAPPA-B; GASTRIC EPITHELIAL-CELLS; TRANSIENT FOREBRAIN ISCHEMIA; PROMOTER ACTIVATION; CYTOKINE EXPRESSION; MUCOSAL CYTOKINE; CAGA GENE; INFLAMMATION; CANCER; PROTEINS AB Background & Aims: Helicobacter pylori interact with epithelial cells resulting in activation of cellular signaling pathways leading to an inflammatory response. The pattern and timing of transcription factor activation in H pylori-infected gastric mucosa remain unclear. We investigated the roles of transcription factors in the gastric mucosa of H pylori-infected gerbils over the course of the infection. Methods: Six-week-old male Mongolian gerbils were inoculated orally with H pylori TN2GF4 or isogenic cagE mutants and examined at 1, 3, 9, and 18 months. We examined the expression of 54 transcription factors using DNA/protein arrays and electrophoretic mobility shift assays. Phosphorylation status of mitogen-activated protein kinases and I kappa B were evaluated by immunoblot and immunohistochemistry. Results: Ten transcription factors were up-regulated by H pylori infection. Six of these factors, including activator protein-1 (AP-1) and cAMP responsive element binding protein (CREB), reached maximal levels at 3 months and were strongly correlated with cellular inflammation and ulceration. Phosphorylation of extracellular signal-regulated kinase correlated with activation of AP-1 and CREB. Levels of nuclear factor-kappa B and interferon-stimulated responsive element (ISRE) peaked at 18 months and correlated with the presence of severe atrophy and with phosphorylation of Jun-N-terminal kinase (JNK), p38, and I kappa B. Conclusions: The gastric mucosal transcription factors induced by H pylori infection differed according to the phase and outcome of infection; AP-1 and CREB levels were early responders related to inflammation and ulceration, whereas NF-kappa B and ISRE were late responders related to atrophy. C1 Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Digest Dis, Renji Hosp,Dept Gastroenterol, Shanghai 200030, Peoples R China. Kaohsiung Med Univ Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan. Vet Affairs N Texas Hlth Care Syst, Pathol & Lab Serv, Dallas, TX USA. RP Yamaoka, Y (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, 111D,Rm 3A-320,2002 Holcombe Blvd, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu RI Wu, Jeng-Yih/D-4520-2009 FU NIDDK NIH HHS [DK62813, P30 DK056338, R01 DK062813-03, R01 DK062813, DK56338] NR 40 TC 27 Z9 27 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD MAR PY 2007 VL 132 IS 3 BP 1024 EP 1038 DI 10.1053/j.gastro.2007.01.009 PG 15 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 149YH UT WOS:000245182300026 PM 17383425 ER PT J AU Pandol, SJ Saluja, AK Imrie, CW Banks, PA AF Pandol, Stephen J. Saluja, Ashok K. Imrie, Clement W. Banks, Peter A. TI Acute pancreatitis: Bench to the bedside SO GASTROENTEROLOGY LA English DT Review ID NF-KAPPA-B; PLATELET-ACTIVATING-FACTOR; PROTEIN-KINASE-C; SYSTEMIC INFLAMMATORY RESPONSE; ACUTE NECROTIZING PANCREATITIS; HEAT-SHOCK-PROTEIN; ACID ETHYL-ESTER; TAUROCHOLATE-INDUCED PANCREATITIS; WATER-IMMERSION STRESS; TUMOR-NECROSIS-FACTOR C1 VA Greater Los Angeles Hlth Care Syst, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA. Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland. Brigham & Womens Hosp, Dept Med, Div Gastroenterol, Boston, MA 02115 USA. RP Pandol, SJ (reprint author), VA Greater Los Angeles Hlth Care Syst, Dept Med, Bldg 258,Room 340,11301 Wilshire Blvd, Los Angeles, CA USA. EM Stephen.pandol@va.gov OI Imrie, Clem/0000-0002-1190-7084 FU NIDDK NIH HHS [DK 058694, DK 072439] NR 258 TC 266 Z9 292 U1 2 U2 22 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD MAR PY 2007 VL 132 IS 3 BP 1127 EP 1151 DI 10.1053/j.gastro.2007.01.055 PG 25 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 149YH UT WOS:000245182300034 PM 17383433 ER PT J AU Matthes, K Mino-Kenudson, M Sahani, DV Holalkere, N Fowers, KD Rathi, R Brugge, WR AF Matthes, Kai Mino-Kenudson, Mari Sahani, Dushyant V. Holalkere, Nagaraj Fowers, Kirk D. Rathi, Ramesh Brugge, William R. TI EUS-guided injection of paclitaxel (OncoGel) provides therapeutic drug concentrations in the porcine pancreas (with video) SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID POLYMERIC MICELLAR PACLITAXEL; BIODEGRADABLE BLOCK-COPOLYMERS; DELIVERY; EFFICACY; TRIAL; BIODISTRIBUTION; FEASIBILITY; FORMULATION; CARCINOMA; PROTEINS AB Background: OncoGel (ReGel/paclitaxel) is an intralesional injectable formulation of the chemotherapeutic drug, paclitaxel, for local tumor management. Objective: The aim of this study was to determine if a minimally invasive EUS-guided injection of paclitaxel, bound to a thermosensitive gel carrier, would lead to therapeutic tissue concentrations of the chemotherapeutic agent in the porcine pancreas. Design: Eight Yorkshire breed pigs were sedated by general anesthesia and OncoGel was injected, under EUS-guidance, with a 22-gauge needle into the tail of the pancreas. Main Outcome Measurements: During the 7-day (n = 4) or 14-day (n = 4) observational period, the animals were monitored by serum levels of amylase and lipase, and by a CT on day 4. The outcome was determined by gross and microscopic evidence of inflammation of the pancreas, clinical tolerance, and quantitation of tissue paclitaxel concentrations. Results: Eight pigs underwent injection of 1, 2, 3, or 4 mL OncoGel (6 mg paclitaxel per 1 mL OncoGel) (n = 2 per group). An intrapancreatic hyperechoic focus, with an average diameter of 2.1 +/- 0.8 cm, was visible by EUS, and a hypodense area in the tail of the pancreas was visible by contrast CT Clinically, the animals appeared to tolerate the procedure without sequelae. Blood levels of amylase and lipase were normal. At euthanasia, a depot of OncoGel, with an average diameter of 14.7 +/- 5.0 mm, was located both grossly and histologically in the pancreatic tail. After 14 days, clinically significant tissue concentrations of paclitaxel were detected at a distance of 30 to 50 mm from the depot in the animals that underwent an injection of 3 and 4 mL of the agent (n = 2). Conclusions: The EUS-guided injection of OncoGel into the pancreas of the pig provided high and sustained localized concentrations of paclitaxel. This technique is a potential minimally invasive local treatment option for unresectable pancreatic tumors. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, GI Endoscopy Unit,Gastrointestinal Pathol Serv,De, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. MacroMed Inc, Sandy, UT USA. RP Brugge, WR (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, GI Endoscopy Unit,Gastrointestinal Pathol Serv,De, 55 Fruit St,Blake 4, Boston, MA 02114 USA. OI Holalkere, Nagaraj/0000-0001-6324-7682 NR 18 TC 61 Z9 61 U1 0 U2 8 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2007 VL 65 IS 3 BP 448 EP 453 DI 10.1016/j.gie.2006.06.030 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 143NR UT WOS:000244729700017 PM 17173909 ER PT J AU Williams, JW Gerrity, M Holsinger, T Dobscha, S Gaynes, B Dietrich, A AF Williams, John W., Jr. Gerrity, Martha Holsinger, Tracey Dobscha, Steve Gaynes, Bradley Dietrich, Allen TI Systematic review of multifaceted interventions to improve depression care SO GENERAL HOSPITAL PSYCHIATRY LA English DT Review DE depressive disorder; care management; literature synthesis ID RANDOMIZED CONTROLLED-TRIAL; LATE-LIFE DEPRESSION; DISEASE MANAGEMENT PROGRAMS; DISSEMINATING QUALITY IMPROVEMENT; LONG-TERM OUTCOMES; COST-EFFECTIVENESS; COLLABORATIVE CARE; MAJOR DEPRESSION; CHRONIC ILLNESS; ANTIDEPRESSANT TREATMENT AB Objective: Depression is a prevalent high-impact illness with poor outcomes in primary care settings. We performed a systematic review to determine to what extent multifaceted interventions improve depression outcomes in primary care and to define key elements, patients who are likely to benefit and resources required for these interventions. Method: We searched Medline, HealthSTAR, CINAHL, PsycINFO and a specialized registry of depression trials from 1966 to February 2006; reviewed bibliographies of pertinent articles; and consulted experts. Searches were limited to the English language. We included 28 randomized controlled trials that: (a) involved primary care patients receiving acute-phase treatment; (b) tested a multicomponent intervention involving a patient-directed component; and (c) reported effects on depression severity. Pairs of investigators independently abstracted information regarding (a) setting and subjects, (b) components of the intervention and (c) outcomes. Results: Twenty of 28 interventions improved depression outcomes over 3-12 months (an 18.4% median absolute increase in patients with 50% improvement in symptoms; range, 8.3-46%). Sustained improvements at 24-57 months were demonstrated in three studies addressing acute-phase and continuation-phase treatments. All interventions involved care management and required additional resources or staff reassignment to implement; interventions were delivered exclusively or predominantly by telephone in 16 studies. The most commonly used intervention features were: patient education and self-management, monitoring of depressive symptoms and treatment adherence, decision support for medication management, a patient registry and mental health supervision of care managers. Other intervention features were highly variable. Conclusion: There is strong evidence supporting the short-term benefits of care management for depression; critical elements for successful programs are emerging. (c) 2007 Elsevier Inc. All rights reserved. C1 Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. Duke Univ, Med Ctr, Dept Med, Durham, NC 27705 USA. Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Portland, OR 97239 USA. Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA. Dartmouth Coll Sch Med, Dept Community & Family Med, Hanover, NH USA. RP Williams, JW (reprint author), Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. EM Jw.williams@duke.edu OI Gaynes, Bradley/0000-0002-8283-5030 NR 107 TC 150 Z9 152 U1 4 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD MAR-APR PY 2007 VL 29 IS 2 BP 91 EP 116 DI 10.1016/j.genhosppsych.2006.12.003 PG 26 WC Psychiatry SC Psychiatry GA 146AG UT WOS:000244906300002 PM 17336659 ER PT J AU Crosby, SS Mashour, GA Grodin, MA Jiang, YD Osterman, J AF Crosby, Sondra S. Mashour, George A. Grodin, Michael A. Jiang, Yandong Osterman, Janet TI Emergence flashback in a patient with posttraumatic stress disorder SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article ID CARE; PREVALENCE; ANESTHESIA; AWARENESS; REFUGEES; HISTORY; TORTURE C1 Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. RP Crosby, SS (reprint author), Boston Med Ctr, Sect Gen Internal Med, ACC-5, Boston, MA 02118 USA. EM scrosby@bu.edu OI Osterman, Janet/0000-0001-7952-4672; Grodin, Michael/0000-0002-0929-8929 NR 14 TC 5 Z9 5 U1 0 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD MAR-APR PY 2007 VL 29 IS 2 BP 169 EP 171 DI 10.1016/j.genhosppsych.2006.11.003 PG 3 WC Psychiatry SC Psychiatry GA 146AG UT WOS:000244906300010 PM 17336667 ER PT J AU Lang, J Hayward, N Goldgar, D Tsao, H Hogg, D Palmer, J Stark, M Tobias, ES MacKie, R AF Lang, Julie Hayward, Nicholas Goldgar, David Tsao, Hensin Hogg, David Palmer, Jane Stark, Mitchell Tobias, Edward S. MacKie, Rona TI The m531 mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestry SO GENES CHROMOSOMES & CANCER LA English DT Article ID MULTIPLE PRIMARY MELANOMAS; FAMILIAL MELANOMA; GERMLINE MUTATIONS; MALIGNANT-MELANOMA; HAPLOTYPE ANALYSIS; PHENOTYPE ANALYSIS; PRONE FAMILIES; CDK4; P16; PREVALENCE AB Germline mutations in the tumor suppressor gene CDKN2A have been shown to predispose to cutaneous malignant melanoma. The M531 mutation is the most common CDKN2A mutation identified in Scottish melanoma patients and is also found in a small number of families in other countries. The aim of this study was to determine whether the occurrence of this mutation is due to a common ancestor originating from Scotland, and if so, to estimate how long ago the mutation arose. We examined 18 families carrying the M531 mutation: six from Scotland, five from Canada, four from Australia, and three from America. Haplotypes derived from segregation of seven informative microsatellite markers flanking CDKN2A were constructed in each family. Our findings show that 14 of 18 families carry a common ancestral haplotype on which the mutation arose similar to 88 generations ago (I-LOD-unit support interval 44-198 generations). This haplotype is very rare in controls, which supports the idea that it is a common founder mutation haplotype. The four M531 families that do not share the consensus haplotype may in fact have arisen from the same founder, but this is potentially obscured by presumed replication slippage for some of the microsatellite markers tested. (c) 2006 Wiley-Liss, Inc. C1 Royal Hosp Sick Children, Duncan Guthrie Inst Med Genet, Glasgow G3 8SJ, Lanark, Scotland. Univ Glasgow, Dept Publ Hlth, Glasgow G3 8SJ, Lanark, Scotland. Univ Queensland, Royal Brisbane Hosp, Queensland Inst Med Res, Herston, Qld, Australia. Univ Utah, Dept Dermatol, Salt Lake City, UT 84112 USA. Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. Univ Toronto, Dept Med, Toronto, ON, Canada. Univ Toronto, Dept Med Biophys, Toronto, ON, Canada. RP Lang, J (reprint author), Royal Hosp Sick Children, Duncan Guthrie Inst Med Genet, Glasgow G3 8SJ, Lanark, Scotland. EM j.lang@clinmed.gla.ac.uk RI Stark, Mitchell/E-3542-2010; hayward, nicholas/C-1367-2015 OI Stark, Mitchell/0000-0002-4510-2161; hayward, nicholas/0000-0003-4760-1033 NR 37 TC 7 Z9 8 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1045-2257 J9 GENE CHROMOSOME CANC JI Gene Chromosomes Cancer PD MAR PY 2007 VL 46 IS 3 BP 277 EP 287 DI 10.1002/gcc.20410 PG 11 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA 125LL UT WOS:000243443300007 PM 17171691 ER PT J AU Lefort, K Mandinova, A Ostano, P Kolev, V Calpini, V Kolfschoten, I Devgan, V Lieb, J Raffoul, W Hohl, D Neel, V Garlick, J Chiorino, G Dotto, GP AF Lefort, Karine Mandinova, Anna Ostano, Paola Kolev, Vihren Calpini, Valerie Kolfschoten, Ingrid Devgan, Vikram Lieb, Jocelyn Raffoul, Wassim Hohl, Daniel Neel, Victor Garlick, Jonathan Chiorino, Giovanna Dotto, G. Paolo TI Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCK alpha kinases SO GENES & DEVELOPMENT LA English DT Article DE notch; p53; ROCK/MRCK; stem cells; squamous cell carcinoma; in vivo siRNA delivery ID NF-KAPPA-B; ACUTE LYMPHOBLASTIC-LEUKEMIA; MYOTONIC-DYSTROPHY KINASE; SQUAMOUS-CELL CARCINOMA; IN-VIVO; CANCER CELLS; RHO-GTPASES; TRANSCRIPTIONAL COACTIVATOR; INTERFERING RNAS; HUMAN HOMOLOG AB Little is known about the regulation and function of the Notch1 gene in negative control of human tumors. Here we show that Notch1 gene expression and activity are substantially down-modulated in keratinocyte cancer cell lines and tumors, with expression of this gene being under p53 control in these cells. Genetic suppression of Notch signaling in primary human keratinocytes is sufficient, together with activated ras, to cause aggressive squamous cell carcinoma formation. Similar tumor- promoting effects are also caused by in vivo treatment of mice, grafted with keratinocytes expressing oncogenic ras alone, with a pharmacological inhibitor of endogenous Notch signaling. These effects are linked with a lesser commitment of keratinocytes to differentiation, an expansion of stem cell populations, and a mechanism involving up-regulation of ROCK1/2 and MRCK alpha kinases, two key effectors of small Rho GTPases previously implicated in neoplastic progression. Thus, the Notch1 gene is a p53 target with a role in human tumor suppression through negative regulation of Rho effectors. C1 Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland. Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Boston, MA 02129 USA. Fondo Edo Tempia, Lab Canc Pharmacogenom, I-13900 Biella, Italy. CHU Vaudois, Dept Surg, CH-1011 Lausanne, Switzerland. CHU Vaudois, Dept Dermatol, CH-1011 Lausanne, Switzerland. Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. Tufts Univ, Sch Dent, Div Canc Biol & Tissue Engn, Boston, MA 02111 USA. RP Dotto, GP (reprint author), Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland. EM Gian-Paolo.Dotto@unil.ch RI Chiorino, Giovanna/K-5037-2016 OI Chiorino, Giovanna/0000-0002-9502-6400 FU NCI NIH HHS [CA16038, CA73796, P01 CA016038, R01 CA073796]; NIAMS NIH HHS [AR39190, R01 AR039190] NR 81 TC 174 Z9 182 U1 1 U2 16 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI WOODBURY PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA SN 0890-9369 J9 GENE DEV JI Genes Dev. PD MAR 1 PY 2007 VL 21 IS 5 BP 562 EP 577 DI 10.1101/gad.1484707 PG 16 WC Cell Biology; Developmental Biology; Genetics & Heredity SC Cell Biology; Developmental Biology; Genetics & Heredity GA 143XV UT WOS:000244760600008 PM 17344417 ER PT J AU Lamesch, P Li, N Milstein, S Fan, CY Hao, T Szabo, G Hu, ZJ Venkatesan, K Bethel, G Martin, P Rogers, J Lawlor, S McLaren, S Dricot, A Borick, H Cusick, ME Vandenhaute, J Dunham, I Hill, DE Vidal, M AF Lamesch, Philippe Li, Ning Milstein, Stuart Fan, Changyu Hao, Tong Szabo, Gabor Hu, Zhenjun Venkatesan, Kavitha Bethel, Graeme Martin, Paul Rogers, Jane Lawlor, Stephanie McLaren, Stuart Dricot, Amelie Borick, Heather Cusick, Michael E. Vandenhaute, Jean Dunham, Ian Hill, David E. Vidal, Marc TI h0RFeome v3.1: A resource of human open reading frames representing over 10,000 human genes SO GENOMICS LA English DT Article DE human ORFeome; gateway system; clone resource; MGC collection; nucleotide substitution rate; OMIM; GO slim; visant; hORFDB; high-throughput cloning ID ORFEOME VERSION 1.1; GENOME BROWSER DATABASE; FULL-LENGTH HUMAN; CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; SEQUENCE; PROTEOME; COLLECTION; CLONING; DNA AB Complete sets of cloned protein-encoding open reading frames (ORFs), or ORFeomes, tire essential tools for large-scale proteomics and systems biology studies. Here we describe human ORFeome version 3.1 (hORFeome v3.1), Currently the largest publicly available resource of full-length human ORFs (available at www.openbiosystems.com). Generated by Gateway recombinational cloning, this collection contains 12,212 ORFs, representing 10,214 human genes, and corresponds to a 51% expansion of the original hORFeome v1.1. An online human CRFeome database, hORFDB, was built and serves as the central repository for all cloned human ORFs (http://horfdb.dfci.harvard.edu). This expansion of the original ORFeome resource greatly increases the potential experimental search space for large-scale proteomics studies, which will lead to the generation of more comprehensive datasets. (c) 2006 Elsevier Inc. All rights reserved. C1 Harvard Univ, Sch Med, CCSB, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Canc Biol, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. Fac Univ Notre Dame Paix, Unite Rech Biol Mol, B-5000 Namur, Belgium. Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA. Univ Notre Dame, Ctr Complex Network Res, Notre Dame, IN 46556 USA. Boston Univ, Dept Biomed Engn, Boston, MA 02115 USA. RP Hill, DE (reprint author), Harvard Univ, Sch Med, CCSB, Boston, MA 02115 USA. EM david_hill@dfci.harvard.edu; marc_vidal@dfci.harvard.edu RI Hu, Zhenjun/B-4309-2011; Hill, David/B-6617-2011 NR 39 TC 165 Z9 172 U1 0 U2 13 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0888-7543 EI 1089-8646 J9 GENOMICS JI Genomics PD MAR PY 2007 VL 89 IS 3 BP 307 EP 315 DI 10.1016/j.ygeno.2006.11.012 PG 9 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 141IV UT WOS:000244572900001 PM 17207965 ER PT J AU Zeger, M Popken, G Zhang, JH Xuan, SH Lu, QR Schwab, MH Nave, KA Rowitch, D D'Ercole, AJ Ye, P AF Zeger, Martha Popken, Greg Zhang, Jihui Xuan, Shouhong Lu, Q. Richard Schwab, Markus H. Nave, Klaus-Armin Rowitch, David D'Ercole, A. Joseph Ye, Ping TI Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination SO GLIA LA English DT Article DE IGF-I; IGF1R; Olig1; PLP; MBP; mutant mice; oligodendrocyte precursors ID CENTRAL-NERVOUS-SYSTEM; IGF BINDING PROTEIN-1; TRANSGENIC MICE; PROTEOLIPID PROTEIN; PROGENITOR CELLS; SPINAL-CORD; MESSENGER-RNAS; MUTANT MICE; BRAIN-DEVELOPMENT; GENE-EXPRESSION AB Insulin-like growth factor-I (IGF-I) has been shown to be a potent agent in promoting the growth and differentiation of oligodendrocyte precursors, and in stimulating myelination during development and following injury. To definitively determine whether IGF-I acts directly on the cells of oligodendrocyte lineage, we generated lines of mice in which the type I IGF receptor gene (igf1r) was conditionally ablated either in Olig1 or proteolipid protein expressing cells (termed IGF1R(pre-oligo-ko) and IGF1R(oligo-ko) mice, respectively). Compared with wild type mice, IGF1R mice had a decreased volume (by 35-55%) and cell number (by 54-70%) in the corpus callosum (CC) and anterior commissure at 2 and 6 weeks of age, respectively. IGF1R(oligo-ko) mice by 25 weeks of age also showed reductions, albeit less marked, in CC volume and cell number. Unlike astrocytes, the percentage of NG(2+) oligodendrocyte precursors was decreased by similar to 13% in 2-week-old IGF1R(pre-oligo-ko) mice, while the percentage of CC1+ mature oligodendrocytes was decreased by similar to 24% in 6-week-old IGF1R pre-oligo-ko mice and similar to 25% in 25-week-old IGFR(oligo-ko) mice. The reduction in these cells is apparently a result of decreased proliferation and increased apoptosis. These results indicate that IGF-I directly affects oligodendrocytes and myelination in vivo via IGF1R, and that IGF1R signaling in the cells of oligodendrocyte lineage is required for normal oligodendrocyte development and myelination. These data also provide a fundamental basis for developing strategies with the potential to target IGF-IGF1R signaling pathways in oligodendrocyte lineage cells for the treatment of demyelinating disorders. (c) 2006 Wiley-Liss, Inc. C1 Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA. Columbia Univ, Dept Genet & Dev, New York, NY 10027 USA. Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA. Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany. RP Ye, P (reprint author), Univ N Carolina, Dept Pediat, CB 7039, Chapel Hill, NC 27599 USA. EM ping_ye@med.unc.edu RI Ye, Ping/A-7144-2009; Nave, Klaus-Armin/C-8883-2011 FU NINDS NIH HHS [R01 NS038891, R01 NS038891-04, R01 NS048868, R01 NS048868-01] NR 56 TC 90 Z9 93 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-1491 EI 1098-1136 J9 GLIA JI Glia PD MAR PY 2007 VL 55 IS 4 BP 400 EP 411 DI 10.1002/glia.20469 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 127FI UT WOS:000243570300006 PM 17186502 ER PT J AU Butt, AA Justice, AC Skanderson, M Rigsby, MO Good, CB Kwoh, CK AF Butt, Adeel A. Justice, Amy C. Skanderson, Melissa Rigsby, Michael O. Good, Chester B. Kwoh, C. Kent TI Rate and predictors of treatment prescription for hepatitis C SO GUT LA English DT Article ID INTERFERON-ALPHA-2B PLUS RIBAVIRIN; HIV-INFECTED VETERANS; VIRUS-INFECTION; PEGINTERFERON ALPHA-2A; HEPATOCELLULAR-CARCINOMA; RANDOMIZED-TRIAL; COINFECTION; RISK; COMBINATION; PREVALENCE AB Background: The true treatment rate for hepatitis C virus (HCV) in veterans is unknown. Aim: To determine the treatment prescription rates and predictors of treatment prescription for HCV in a large national population. Methods: The Department of Veterans Affairs National Patient Care Database (NPCD) was used to identify all HCV-infected people between the fiscal years 1999 and 2003 using the International classification of diseases, 9th revision codes. Demographic information, medical and psychiatric comorbidities, and drug and alcohol use diagnoses were retrieved. Pharmacy data were retrieved from the Department of Veterans Affairs Pharmacy Benefits Management (PBM) database. Logistic regression analysis was used to determine the predictors of treatment for HCV in HCV. Results: 113 927 veterans in the Department of Veterans Affairs care with a diagnosis of HCV were identified. The treatment prescription rate for HCV was 11.8%. Patients not prescribed treatment were older, more likely to be from minority races, have more alcohol and drug misuse, and have medical and psychiatric comorbid conditions. In a multivariate logistic regression model, the following factors were predictive of non-treatment for HCV: increasing age ( odds ratio ( OR) 0.77 for each 5-year increase in age; 95% confidence interval (CI) 0.76 to 0.78); black race ( OR 0.64; 95% CI 0.6 to 0.68); Hispanic race ( OR 0.88; 95% CI 0.8 to 0.96); alcohol abuse and dependence ( OR 0.62; 95% CI 0.59 to 0.65); drug abuse and dependence ( OR 0.78; 95% CI 0.74 to 0.82); anaemia ( OR 0.18; 95% CI 0.16 to 0.21); hepatitis B infection ( OR 0.72; 95% CI 0.62 to 0.83); coronary artery disease ( OR 0.9; 95% CI 0.85 to 0.97); stroke ( OR 0.75; 95% CI 0.67 to 0.85); bipolar disorder ( OR 0.64; 95% CI 0.58 to 0.70); major depression ( OR 0.72; 95% CI 0.67 to 0.77); mild depression ( OR 0.56; 95% CI 0.53 to 0.59); and schizophrenia ( OR 0.71; 95% CI 0.65 to 0.77). The following factors were associated with a higher likelihood of treatment prescription for HCV: liver cirrhosis ( OR 1.6; 95% CI 1.5 to 1.7); and diabetes ( OR 1.07; 95% CI 1.02 to 1.12). Conclusions: A small number of HCV-infected veterans were prescribed treatment for HCV. Non-treatment is associated with increasing age, non-white race, drug and alcohol abuse, and dependence and comorbid illnesses. Reasons for non-treatment need further study. C1 Univ Pittsburgh, Med Ctr, Sch Med, VA Pittsburgh Healthcare Syst,Ctr Hlth Equ Res &, Pittsburgh, PA 15213 USA. Yale Univ, Sch Med, New Haven, CT 06520 USA. VA Connecticut Healthcare Syst, West Haven, CT USA. RP Butt, AA (reprint author), Univ Pittsburgh, Med Ctr, Sch Med, VA Pittsburgh Healthcare Syst,Ctr Hlth Equ Res &, 3601 5th Ave,Suite 3A,Falk Med Bldg, Pittsburgh, PA 15213 USA. EM butta@dom.pitt.edu FU NIDA NIH HHS [DA016175-01A1, K23 DA016175] NR 31 TC 104 Z9 104 U1 4 U2 8 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 J9 GUT JI Gut PD MAR PY 2007 VL 56 IS 3 BP 385 EP 389 DI 10.1136/gut.2006.099150 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 143IT UT WOS:000244714700017 PM 17005764 ER PT J AU Obermair, A Fuller, A Lopez-Varela, E van Gorp, T Vergote, I Eaton, L Fowler, J Quinn, M Hammond, I Marsden, D Proietto, A Carter, J Davy, M Tripcony, L Abu-Rustum, N AF Obermair, Andreas Fuller, Arlan Lopez-Varela, Elisa van Gorp, Toon Vergote, Ignace Eaton, Lynne Fowler, Jeff Quinn, Michael Hammond, Ian Marsden, Donald Proietto, Anthony Carter, Jonathan Davy, Margaret Tripcony, Lee Abu-Rustum, Nadeem TI A new prognostic model for FIGO stage 1 epithelial ovarian cancer SO GYNECOLOGIC ONCOLOGY LA English DT Article DE ovarian cancer; prognosis; CA-125; staging ID RANDOMIZED PHASE-III; SERUM CA-125; CARCINOMA; CHEMOTHERAPY; TRIALS AB Background. No consensus exists which patients with surgical stage I epithelial ovarian should receive postoperative chemotherapy. The purpose of this study was to evaluate the prognostic impact of preoperative CA-125 and to establish a prognostic index to identify patients in different risk categories. Methods. Data of 600 surgically staged patients with FIGO stage 1 EOC treated in eleven gynecological cancer centers in Australia, the USA and Europe were analyzed. Eligible patients include those with invasive EOC where a preoperative CA-125 was obtained and standard surgical staging performed. Overall survival (OS) was chosen as study endpoint. Preoperative CA-125 values were compared with other prognostic factors, and univariate and multivariate Cox models were calculated. Results. Two hundred and one patients (33.5%) had preoperative CA-125 <= 30 U/ml and CA-125 levels <= 30 U/ml were associated with lower grade,substage IA and mucinous histologic cell type. Patients with elevated CA-125 levels were more likely to receive chemotherapy. OS probability was 95% and 85% for patients with pretreatment CA-125 <= 30 U/ml and > 30 U/ml, respectively (p 0.003). Multivariate analysis confirmed preoperative serum CA-125 > 30 U/ml (OR 2.7) and age at diagnosis > 70 years (OR 2.6) as the only independent predictors for overall survival. Conclusion. Pretreatment of CA-125 <= 30 U/ml dominates over histologic cell type, substage and grade to identify a subgroup of FIGO stage I patients with a genuinely good prognosis with extremely good survival and who could possibly be spared with adjuvant chemotherapy. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Queensland, Royal Brisbane Hosp, Sch Med, Queensland Ctr Gynaecol Canc, Brisbane, Qld, Australia. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Boston, MA 02115 USA. Katholieke Univ Leuven, Univ Hosp, Dept Gynaecol Oncol, Louvain, Belgium. Ohio State Univ, James Canc Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, Columbus, OH 43210 USA. Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA. King Edward Mem Hosp Women, Western Australian Gynaecol Canc Serv, Subiaco, WA 6008, Australia. Univ Western Australia, Sch Womens & Infants Hlth, Nedlands, WA 6009, Australia. Royal Hosp Women, Gynaecol Canc Ctr, Randwick, NSW, Australia. Royal Prince Alfred Hosp, Sydney Gynaecol Oncol Grp, Camperdown, NSW, Australia. Royal Adelaide Hosp, Dept Gynaecol Oncol, Adelaide, SA 5000, Australia. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. RP Obermair, A (reprint author), Royal Hosp Women, QCGC Res Gynaecol Oncol, Dept Gynaecol Oncol, Ned Hanlon Bldg,6th Floor, Melbourne, Vic, Australia. EM andreas_obemair@health.qld.gov.au RI Obermair, Andreas/B-1175-2009; Van Gorp, Toon/H-3235-2011; Obermair, Andreas/F-6670-2015; OI Van Gorp, Toon/0000-0002-1573-8716; Quinn, Michael/0000-0003-0694-3870 NR 25 TC 20 Z9 22 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD MAR PY 2007 VL 104 IS 3 BP 607 EP 611 DI 10.1016/j.ygyno.2006.09.021 PG 5 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 144LC UT WOS:000244796500018 PM 17092548 ER PT J AU Seiden, MV Burris, HA Matulonis, U Hall, JB Armstrong, DK Speyer, J Weber, JDA Muggia, F AF Seiden, M. V. Burris, H. A. Matulonis, U. Hall, J. B. Armstrong, D. K. Speyer, J. Weber, J. D. A. Muggia, F. TI A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies SO GYNECOLOGIC ONCOLOGY LA English DT Article DE ovarian cancer; epidermal growth factor receptor; monoclonal antibody; EMD72000; matuminab; phase 2 clinical trial; ovarian neoplasm; peritoneal neoplasm; anti-EGFR antibody ID GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; PEGYLATED LIPOSOMAL DOXORUBICIN; GYNECOLOGIC-ONCOLOGY-GROUP; METASTATIC BREAST-CANCER; EPITHELIAL OVARIAN; COLORECTAL-CANCER; CLINICAL-TRIAL; CARCINOMA; RECURRENT AB Objective. The primary objective of this study was to determine the rate of response to matuzumab in patients with recurrent, EGFR-positive ovarian, or primary peritoneal cancer. Secondary end points included safety and tolerability, time to tumor progression, duration of response, and overall survival. Methods. A multi-institutional single arm phase 11 trial. Results. Of 75 women screened for the study, 37 were enrolled and treated. Median age of the treated patient population was 58 years, and most patients had more than four prior lines of chemotherapy. Therapy was well tolerated, the most common toxicities being a constellation of skin toxicities, including rash, acne, dry skin, and paronychia, as well as headache, fatigue, and diarrhea. Serious adverse events were very rare but included a single episode of pancreatitis that may have been drug related. All patients completed therapy, receiving I to 30 infusions of matuzumab. There were no formal responses (RR=0%, 95% CI: 0-9.5%), although 7 patients (21%) were on therapy for more than 3 months with stable disease. Conclusions. Matuzumab at the dose and schedule selected is well tolerated. In this population of very heavily pretreated patients with epithelial ovarian and primary peritoneal malignancies, there was no evidence of significant clinical activity when matuzumab was administered as monotherapy. (c) 2006 Elsevier Inc. All rights reserved. C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Sarah Cannon Canc Ctr, Nashville, TN USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Carolinas Med Ctr, Blumenthal Canc Ctr, Charlotte, NC 28203 USA. Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA. NYU, Ctr Clin Canc, New York, NY USA. Merck KGaA, EMD, Darmstadt, Germany. RP Seiden, MV (reprint author), Massachusetts Gen Hosp, 100 Blossom St,Cox 640, Boston, MA 02114 USA. EM mseiden@partners.org OI Muggia, Franco/0000-0003-0703-9146 NR 37 TC 81 Z9 82 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD MAR PY 2007 VL 104 IS 3 BP 727 EP 731 DI 10.1016/j.ygyno.2006.10.019 PG 5 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 144LC UT WOS:000244796500039 PM 17126894 ER PT J AU Laubach, HJ Manstein, D AF Laubach, H. -J. Manstein, D. TI Fractional photothermolysis SO HAUTARZT LA German DT Article DE fractional photothermolysis; fractional resurfacing; rejuvenation; melasma; scars ID CARBON-DIOXIDE LASER; SELECTIVE PHOTOTHERMOLYSIS; SHORT-TERM; SKIN AB Fractional photothermolysis (FP) has been recently introduced as a new concept in dermatologic laser medicine. FP employs an array of small laser beams to create many microscopic areas of thermal necrosis within the skin called microscopic treatment zones (MTZ). Even though FP completely destroys the epidermis and dermis within these MTZ, the 3-dimensional pattern of damage heals quickly and with few side effects. FP is currently used to treat fine wrinkles, photodamaged skin, acne scars, and melasma. Due to its clinical efficacy and limited side effects FP has established itself in the past two years as an alternative treatment modality to the conventional ablative and non ablative laser therapy. C1 Univ Munster, Hautklin, D-48149 Munster, Germany. Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Laubach, HJ (reprint author), Univ Munster, Hautklin, Von Esmarch Str 58, D-48149 Munster, Germany. EM hlaubach@gmail.com NR 25 TC 3 Z9 5 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0017-8470 J9 HAUTARZT JI Hautarzt PD MAR PY 2007 VL 58 IS 3 BP 216 EP + DI 10.1007/s00105-007-1286-0 PG 7 WC Dermatology SC Dermatology GA 144FG UT WOS:000244780900010 PM 17318467 ER PT J AU Feldman-Stewart, D Brennenstuhl, S McIssac, K Austoker, J Charvet, A Hewitson, P Sepucha, KR Whelan, T AF Feldman-Stewart, Deb Brennenstuhl, Sarah McIssac, Kathryn Austoker, Joan Charvet, Agathe Hewitson, Paul Sepucha, Karen R. Whelan, Tim TI A systematic review of information in decision aids SO HEALTH EXPECTATIONS LA English DT Review DE decision aids; patient support techniques; shared decision-making ID RANDOMIZED CONTROLLED-TRIAL; HORMONE REPLACEMENT THERAPY; STAGE PROSTATE-CANCER; COMMUNICATING PROBABILISTIC INFORMATION; DIAGNOSED HYPERTENSIVE PATIENTS; INTERACTIVE VIDEO PROGRAM; ISCHEMIC-HEART-DISEASE; QUALITY-OF-LIFE; BREAST-CANCER; ATRIAL-FIBRILLATION AB Objective: We completed a systematic review of information reported as included in decision aids (DAs) for adult patients, to determine if it is complete, balanced and accurate. Search strategy: DAs were identified using the Cochrane Database of DAs and searches of four electronic databases using the terms: 'decision aid'; shared decision making' and 'patients'; 'multimedia or leaflets or pamphlets or videos and patients and decision making'. Additionally, publications reporting DA development and actual DAs that were reported as publicly available on the Internet were consulted. Publications were included up to May 2006. Data extraction: Data were extracted on the following variables: external groups consulted in development of the DA, type of study used, categories of information, inclusion of probabilities, use of citation lists and inclusion of patient experiences. Main results: 68 treatment DAs and 30 screening DAs were identified. 17% of treatment DAs and 47% of screening DAs did not report any external consultation and, of those that did, DA producers tended to rely more heavily on medical experts than on patients' guidance. Content evaluations showed that (i) treatment DAs frequently omit describing the procedure(s) involved in treatment options and (ii) screening DAs frequently focus on false positives but not false negatives. About 1/2 treatment DAs reported probabilities with a greater emphasis on potential benefits than harms. Similarly, screening DAs were more likely to provide false-positive than false-negative rates. Conclusions: The review led us to be concerned about completeness, balance and accuracy of information included in DAs. C1 Queens Univ, Canc Res Inst, Div Canc Care & Epidemiol, Kingston, ON K7L 3N6, Canada. Queens Univ, Dept Oncol, Kingston, ON K7L 3N6, Canada. Queens Univ, Inst Canc Res, Div Canc Care & Epidemiol, Kingston, ON K7L 3N6, Canada. Univ Oxford, Canc Res UK Primary Care Educ Res Grp, Div Publ Hlth & Primary Hlth Care, Oxford OX1 2JD, England. Geneva Univ Hosp, Geneva, Switzerland. Massachusetts Gen Hosp, Hlth Decis Res Unit, Boston, MA 02114 USA. McMaster Univ, Support Canc Care Res Unit, Juravinski Canc Ctr, Hamilton, ON L8S 4L8, Canada. RP Feldman-Stewart, D (reprint author), Queens Univ, Canc Res Inst, Div Canc Care & Epidemiol, Level 2,10 Stuart St, Kingston, ON K7L 3N6, Canada. EM deb.feldman-stewart@krcc.on.ca RI Whelan, Timothy/D-3185-2017 NR 176 TC 35 Z9 35 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1369-6513 J9 HEALTH EXPECT JI Health Expect. PD MAR PY 2007 VL 10 IS 1 BP 46 EP 61 DI 10.1111/j.1369-7625.2006.00420.x PG 16 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 139GD UT WOS:000244419400005 PM 17324194 ER PT J AU Heist, EK AF Heist, E. Kevin TI Cell therapy to treat cardiac ischemia: Angina-free and arrhythmia-free? Commentary SO HEART RHYTHM LA English DT Editorial Material ID SKELETAL MYOBLAST TRANSPLANTATION; HEMATOPOIETIC STEM-CELLS; INFARCTED MYOCARDIUM; HEART C1 Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. RP Heist, EK (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, 55 Fruit St,GRB 109, Boston, MA 02114 USA. EM kheist@partners.org NR 14 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1547-5271 J9 HEART RHYTHM JI Heart Rhythm PD MAR PY 2007 VL 4 IS 3 BP 266 EP 267 DI 10.1016/j.hrthm.2006.11.014 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 146VZ UT WOS:000244964100002 PM 17341384 ER PT J AU Napadow, V Liu, J Li, M Kettner, N Ryan, A Kwong, KK Hui, KKS Audette, JF AF Napadow, Vitaly Liu, Jing Li, Ming Kettner, Norman Ryan, Angela Kwong, Kenneth K. Hui, Kathleen K. S. Audette, Joseph F. TI Somatosensory cortical plasticity in carpal tunnel syndrome treated by acupuncture SO HUMAN BRAIN MAPPING LA English DT Article DE alternative medicine; somatotopy; neuropathy; Hebbian plasticity; nerve entrapment ID REGIONAL PAIN SYNDROME; SURFACE-BASED ANALYSIS; PHANTOM-LIMB PAIN; ADULT OWL MONKEYS; MEDIAN NERVE; TACTILE STIMULATION; COORDINATE SYSTEM; DIGIT AMPUTATION; HUMAN BRAIN; AREA 3B AB Carpal tunnel syndrome (CTS) is a common entrapment neuropathy of the median nerve characterized by paresthesias and pain in the first through fourth digits. We hypothesize that aberrant afferent input from CTS will lead to maladaptive cortical plasticity, which may be corrected by appropriate therapy. Functional MRI (fMRI) scanning and clinical testing was performed on CTS patients at baseline and after 5 weeks of acupuncture treatment. As a control, healthy adults were also tested 5 weeks apart. During fMRI, sensory stimulation was performed for median nerve innervated digit 2 (D2) and digit 3 (D3), and ulnar nerve innervated digit 5 (D5). Surface-based and region of interest (ROI)-based analyses demonstrated that while the extent of fMRI activity in contralateral Brodmann Area 1 (BA 1) and BA 4 was increased in CTS compared to healthy adults, after acupuncture there was a significant decrease in contralateral BA 1 (P < 0.005) and BA 4 (P < 0.05) activity during D3 sensory stimulation. Healthy adults demonstrated no significant test-retest differences for any digit tested. While D3/D2 separation was contracted or blurred in CTS patients compared to healthy adults, the D2 SI representation shifted laterally after acupuncture treatment, leading to increased D3/D2 separation. Increasing D3/D2 separation correlated with decreasing paresthesias in CTS patients (P < 0.05). As CTS-induced paresthesias constitute diffuse, synchronized, multidigit symptomatology, our results for maladaptive change and correction are consistent with Hebbian plasticity mechanisms. Acupuncture, a somatosensory conditioning stimulus, shows promise in inducing beneficial cortical plasticity manifested by more focused digital representations. C1 Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA. Logan Coll Chiropract, Dept Radiol, Chesterfield, MO USA. Spaulding Rehabil Hosp, Boston, MA USA. RP Napadow, V (reprint author), 149 13th St,Rm 2301, Charlestown, MA 02119 USA. EM vitaly@nmr.mgh.harvard.edu FU NCCIH NIH HHS [K01-AT002166-01, P01-AT002048-02, R21-AT001361-01]; NCRR NIH HHS [P41RR14075] NR 78 TC 49 Z9 53 U1 1 U2 7 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1065-9471 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD MAR PY 2007 VL 28 IS 3 BP 159 EP 171 DI 10.1002/hbm.20261 PG 13 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 136YD UT WOS:000244259100001 PM 16761270 ER PT J AU Tumini, E Porcellini, E Chiappelli, M Conti, CM Beraudi, A Poli, A Caciagli, F Doyle, R Conti, P Licastro, F AF Tumini, Emanuela Porcellini, Elisa Chiappelli, Martina Conti, Chiara M. Beraudi, Alina Poli, Alessandro Caciagli, Francesco Doyle, Robert Conti, Pio Licastro, Federico TI The G51S purine nucleoside phosphorylase polymorphism is associated with cognitive decline in Alzheimer's disease patients SO HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL LA English DT Article DE purine nucleoside phosphorylase; Alzheimer's disease; cognitive decline; G51S polymorphism ID CENTRAL-NERVOUS-SYSTEM; APOLIPOPROTEIN-E; DEMENTIA; CELLS; BETA; DISORDERS; MICROGLIA; APOPTOSIS; CYTOKINE; BRAIN AB Alzheimer's disease (AD) is a polygenic and multifactorial complex disease, whose etiopathology is still unclear, however several genetic factors have shown to increase the risk of developing the disease. Purine nucleotides and nucleosides play an important role in the brain. Besides their role in neurotransmission and neuromodulation, they are involved in trophic factor release, apoptosis, and inflammatory responses. These mediators may also have a pivotal role in the control of neurodegenerative processes associated with AD. In this report the distribution of the exonic G/A single nucleotide polymorphism (SNP) in purine nucleoside phosphorylase (PNP) gene, resulting in the amino acid substitution serine to glycine at position 51 (G51S), was investigated in a large population of AD patients (n=321) and non-demented control (n=208). The PNP polymorphism distribution was not different between patients and controls. The polymorphism distribution was also analyzed in AD patients stratified according to differential progressive rate of cognitive decline during a 2-year follow-up. An increased representation of the PNP AA genotype was observed in AD patients with fast cognitive deterioration in comparison with that from patients with slow deterioration rate. Our findings suggest that the G51S PNP polymorphism is associated with a faster rate of cognitive decline in AD patients, highlighting the important role of purine metabolism in the progression of this neurodegenerative disorder. Copyright (c) 2007 John Wiley & Sons, Ltd. C1 Univ Bologna, Dept Expt Pathol, I-40126 Bologna, Italy. Univ Bologna, Dept Expt & Evolutionary Biol, I-40126 Bologna, Italy. Univ G dAnnunzio, Inst Pharmacol, Chieti, Italy. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02115 USA. Univ G dAnnunzio, Div Immunol, Chieti, Italy. RP Licastro, F (reprint author), Univ Bologna, Dept Expt Pathol, Via S Giacomo 14, I-40126 Bologna, Italy. EM licastro@alma.unibo.it RI Porcellini, Elisa/K-5346-2016; Tumini, Emanuela/C-2163-2017; OI Porcellini, Elisa/0000-0003-3991-5294; Tumini, Emanuela/0000-0001-9412-9355; beraudi, alina/0000-0001-7496-5727 NR 39 TC 7 Z9 7 U1 0 U2 2 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0885-6222 J9 HUM PSYCHOPHARM CLIN JI Hum. Psychopharmacol.-Clin. Exp. PD MAR PY 2007 VL 22 IS 2 BP 75 EP 80 DI 10.1002/hup.823 PG 6 WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry; Psychology SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry; Psychology GA 153MY UT WOS:000245440800002 PM 17221831 ER PT J AU Hauser, R Meeker, JD Singh, NP Silva, MJ Ryan, L Duty, S Calafat, AM AF Hauser, R. Meeker, J. D. Singh, N. P. Silva, M. J. Ryan, L. Duty, S. Calafat, A. M. TI DNA damage in human sperm is related to urinary levels of phthalate monoester and oxidative metabolites SO HUMAN REPRODUCTION LA English DT Article DE phthalates; urinary metabolites; DNA damage; comet assay; human sperm ID EJACULATED HUMAN SPERMATOZOA; COMET ASSAY; DI(2-ETHYLHEXYL) PHTHALATE; TESTICULAR TOXICITY; EMBRYO DEVELOPMENT; BUTYL-PHTHALATE; HUMAN EXPOSURE; STRAND BREAKS; DEHP; APOPTOSIS AB BACKGROUND: The ubiquitous use of phthalate esters in plastics, personal care products and food packaging materials results in widespread general population exposure. In this report, we extend our preliminary study on the relationship between urinary concentrations of phthalate metabolites and sperm DNA damage among a larger sample of men and include measurements of mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHAIR) and mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP), two oxidative metabolites of di-(2-ethylhexyl) phthalate (DEHP). METHODS: Among 379 men from an infertility clinic, urinary concentrations of phthalate metabolites were measured using isotope-dilution high-performance liquid chromatography-tandem mass spectrometry. Sperm DNA damage measurements, assessed with the neutral comet assay, included comet extent (CE), percentage of DNA in tail (Tail%) and tail distributed moment (TDM). RESULTS: Monoethyl phthalate (MEP), a metabolite of diethyl phthalate, was associated with increased DNA damage, confirming our previous findings. Mono-(2-ethylhexyl) phthalate (MERP), a metabolite of DEHP, was associated with DNA damage after adjustment for the oxidative DEHP metabolites. After adjustment for MEHHP, for an interquartile range increase in urinary MEHP, CE increased 17.3% [95% confidence interval (CI) = 8.7-25.7%], TDM increased 14.3% (95% CI = 6.8-21.7%) and Tail% increased 17.5% (95% CI = 3.5-31.5%). CONCLUSIONS: Sperm DNA damage was associated with MEP and with MEHP after adjusting for DEHP oxidative metabolites, which may serve as phenotypic markers of DEHP metabolism to 'less toxic' metabolites. The urinary levels of phthalate metabolites among these men were similar to those reported for the US general population, suggesting that exposure to some phthalates may affect the population distribution of sperm DNA damage. C1 Harvard Univ, Sch Med, Dept Environm Hlth, Occupat Hlth Program, Boston, MA 02115 USA. Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv, Androl Lab, Boston, MA 02114 USA. Massachusetts Gen Hosp, In Vitro Fertilizat Unit, Boston, MA 02114 USA. Univ Michigan, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. Univ Washington, Dept Bioengn, Seattle, WA 98195 USA. Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. Simmons Coll, Dept Nursing, Sch Hlth Studies, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Hauser, R (reprint author), Harvard Univ, Sch Med, Dept Environm Hlth, Occupat Hlth Program, Bldg 1,Room 1405,665 Huntington Ave, Boston, MA 02115 USA. EM rhauser@hohp.harvard.edu RI Ryan, Louise/A-4562-2009; OI Ryan, Louise/0000-0001-5957-2490; Meeker, John/0000-0001-8357-5085 FU NIEHS NIH HHS [ES09718] NR 57 TC 182 Z9 203 U1 10 U2 47 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 J9 HUM REPROD JI Hum. Reprod. PD MAR PY 2007 VL 22 IS 3 BP 688 EP 695 DI 10.1093/humrep/del428 PG 8 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 147OG UT WOS:000245011700008 PM 17090632 ER PT J AU Wang, TJ Gona, P Larson, MG Levy, D Benjamin, EJ Tofler, GH Jacques, PF Meigs, JB Rifai, N Selhub, J Robins, SJ Newton-Cheh, C Vasan, RS AF Wang, Thomas J. Gona, Philimon Larson, Martin G. Levy, Daniel Benjamin, Emelia J. Tofler, Geoffrey H. Jacques, Paul F. Meigs, James B. Rifai, Nader Selhub, Jacob Robins, Sander J. Newton-Cheh, Christopher Vasan, Ramachandran S. TI Multiple biomarkers and the risk of incident hypertension SO HYPERTENSION LA English DT Article DE epidemiology; hypertension; C-reactive protein; plasminogen activator inhibitor-1; aldosterone; albuminuria ID C-REACTIVE PROTEIN; PLASMINOGEN-ACTIVATOR INHIBITOR-1; NATRIURETIC PEPTIDE LEVELS; URINARY ALBUMIN EXCRETION; BLOOD-PRESSURE TRACKING; AORTIC ENDOTHELIAL-CELLS; RENIN-ANGIOTENSIN SYSTEM; CARDIOVASCULAR RISK; PLASMA HOMOCYSTEINE; PRIMARY ALDOSTERONISM AB An understanding of mechanisms underlying the development of essential hypertension is critical for designing prevention and treatment strategies. Selected biomarkers may be elevated before the onset of hypertension, but previous studies are limited by cross-sectional designs or a focus on single biomarkers. We prospectively studied 1456 nonhypertensive individuals who had baseline measurement of 9 biomarkers: C-reactive protein (inflammation); fibrinogen (inflammation and thrombosis); plasminogen activator inhibitor-1 (fibrinolytic potential); aldosterone, renin, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide (neurohormonal activity); homocysteine (renal function and oxidant stress); and urinary albumin/creatinine ratio (glomerular endothelial function). Incident hypertension, defined as blood pressure >= 140/90 mm Hg or antihypertensive therapy, developed in 232 participants over a mean follow-up of 3 years. After adjustment for clinical risk factors, the biomarker panel was significantly associated with incident hypertension (P = 0.002). Three (of 9) biomarkers were significantly related to incident hypertension on backward elimination (multivariable-adjusted odds ratios, per SD increment in biomarker): C-reactive protein (1.26; 95% CI: 1.05 to 1.51), plasminogen activator inhibitor-1 (1.28; 95% CI: 1.05 to 1.57), and urinary albumin/creatinine ratio (1.21; 95% CI: 1.02 to 1.43). The incidence of hypertension was 4.5, 6.4, and 9.9 per 100 person years for participants with 0, 1, and >= 2 elevated biomarkers, respectively (elevation defined as >= 1 SD above the mean). The threshold of >= 2 elevated biomarkers for predicting hypertension was associated with high specificity (0.92) but low sensitivity (0.15). Biomarkers of inflammation, reduced fibrinolytic potential, and low-grade albuminuria are jointly associated with the incidence of hypertension. These data support the premise that abnormalities in multiple biological pathways antedate the onset of overt hypertension. C1 Harvard Univ, Cardiol Div, Massachusetts Gen Hosp, Sch Med,Dept Med, Boston, MA 02114 USA. Harvard Univ, Div Gen Med, Massachusetts Gen Hosp, Sch Med,Dept Med, Boston, MA 02114 USA. Framingham Heart Dis Epidemiol Study, Framingham, MA USA. Boston Univ, Dept Math & Stat, Boston, MA 02215 USA. NHLBI, Bethesda, MD 20892 USA. Royal N Shore Hosp, Sydney, NSW, Australia. Tufts Univ, Jean Mayer Dept Agr Human Nutr Res Ctr Aging, Boston, MA 02111 USA. Harvard Univ, Childrens Hosp, Sch Med, Dept Lab Med, Boston, MA 02115 USA. Boston Univ, Sch Med, Div Endocrinol Nutr & Diabet, Prevent Med Sect,Med Ctr, Boston, MA 02118 USA. Boston Univ, Sch Med, Div Endocrinol Nutr & Diabet, Cardiol Sect,Med Ctr, Boston, MA 02118 USA. RP Wang, TJ (reprint author), Harvard Univ, Cardiol Div, Massachusetts Gen Hosp, Sch Med,Dept Med, GRB-800,55 Fruit St, Boston, MA 02114 USA. EM tjwang@partners.org OI Larson, Martin/0000-0002-9631-1254; Ramachandran, Vasan/0000-0001-7357-5970; Benjamin, Emelia/0000-0003-4076-2336 FU NHLBI NIH HHS [2K24-HL-04334, K23-HL-074077, N01-HC-25195] NR 69 TC 90 Z9 99 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD MAR PY 2007 VL 49 IS 3 BP 432 EP 438 DI 10.1161/01.HYP.0000256956.61872.aa PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 136SU UT WOS:000244245200007 PM 17242302 ER PT J AU Hubel, CA Wallukat, G Wolf, M Herse, F Rajakumar, A Roberts, JM Markovic, N Thadhani, R Luft, FC Dechend, R AF Hubel, Carl A. Wallukat, Gerd Wolf, Myles Herse, Florian Rajakumar, Augustine Roberts, James M. Markovic, Nina Thadhani, Ravi Luft, Friedrich C. Dechend, Ralf TI Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia SO HYPERTENSION LA English DT Article DE angiotensin II; autoantibodies; preeclampsia; pregnancy; soluble vascular endothelial growth factor receptor-1; insulin resistance; cardiovascular disease ID CIRCULATING ANGIOGENIC FACTORS; ENDOTHELIAL GROWTH-FACTOR; LONG-TERM MORTALITY; AT(1) RECEPTOR; TYROSINE KINASE-1; AT1 RECEPTOR; MATERNAL AUTOANTIBODIES; INSULIN-RESISTANCE; TROPHOBLAST CELLS; ANTIBODIES AB Activating angiotensin II type 1 autoantibodies (AT1-AAs) develop in women with preeclampsia and may contribute to the disorder. Insulin resistance and serum concentrations of the antiangiogenic soluble fms-like tyrosine kinase 1 (sFlt-1) are also increased in women with preeclampsia compared with normal pregnancy. sFlt-1 and insulin resistance decrease substantially after delivery; however, significant group differences persist postpartum. Women who have had preeclampsia are at increased cardiovascular risk later in life. We measured AT1-AAs in groups of women with previous preeclampsia (n=29) and previous normal pregnancies (n=35) 18 +/- 9 months after the first completed pregnancy. These women had had sFlt-1, insulin resistance homeostasis model assessment score, and related cardiovascular risk factors measured. Activating antibodies were detected by the chronotropic response of cultured neonatal rat cardiomyocytes coupled with receptor-specific antagonists (losartan and prazosin). AT1-AAs were detected in 17.2% of women with previous preeclampsia versus 2.9% of women with previous uncomplicated pregnancies (P < 0.05). In contrast, there was no difference in the prevalence of autoantibodies against the alpha 1-adrenoceptor (10% of previous preeclamptic versus 14% of previous normal pregnant). Women with activating autoantibodies had significantly increased sFlt-1, reduced free vascular endothelial growth factor, and higher insulin resistance homeostasis model assessment values compared with autoantibody-negative women. These data suggest that, as with sFlt-1 and insulin resistance, the AT1-AA does not regress completely after delivery and, secondarily, that correlations exist among these variables. The impact of AT1-AA after preeclampsia, especially in the context of cardiovascular risk, remains to be determined. C1 HELIOS Klin, Franz Volhard Clin, Med Fac Charite, D-13125 Berlin, Germany. Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Magee Womens Res Inst, Pittsburgh, PA 15260 USA. Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Renal Unit, Boston, MA 02114 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. Max Delbruck Ctr Mol Med, Berlin, Germany. RP Dechend, R (reprint author), HELIOS Klin, Franz Volhard Clin, Med Fac Charite, Wiltbergstr 50, D-13125 Berlin, Germany. EM ralf.dechend@charite.de OI Herse, Florian/0000-0002-9305-8134; Luft, Friedrich/0000-0002-8635-1199 FU NCRR NIH HHS [RR017376, M01RR01066, MO1RR00056]; NICHD NIH HHS [HD049453, HD30367, HD39223] NR 38 TC 59 Z9 66 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD MAR PY 2007 VL 49 IS 3 BP 612 EP 617 DI 10.1161/01.HYP.0000256565.20983.d4 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 136SU UT WOS:000244245200032 PM 17210828 ER PT J AU Ergun, A Barbieri, R Eden, UT Wilson, MA Brown, EN AF Erguen, Ayla Barbieri, Riccardo Eden, Uri T. Wilson, Matthew A. Brown, Ernery N. TI Construction of point process adaptive filter algorithms for neural systems using sequential Monte Carlo methods SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING LA English DT Article DE adaptive filtering; hidden Markov models; point processes; sequential Monte Carlo; state estimation ID RECEPTIVE-FIELD PLASTICITY; MOTOR CORTEX; ADULT; MODEL; REPRESENTATIONS; POPULATION; PREDICTION; ENSEMBLES; PATTERNS; NEURONS AB The stochastic state point process filter (SSPPF) and steepest descent point process filter (SDPPF) are adaptive filter algorithms for state estimation from point process observations that have been used to track neural receptive field plasticity and to decode the representations of biological signals in ensemble neural spiking activity. The SSPPF and SDPPF are constructed using, respectively, Gaussian and steepest descent approximations to the standard Bayes and Chapman-Kolmogorov (BCK) system of filter equations. To extend these approaches for constructing point process adaptive filters, we develop sequential Monte Carlo (SMC) approximations to the BCK equations in which the SSPPF and SDPPF serve as the proposal densities. We term the two new SMC point process filters SMC-PPFs and SMC-PPFD, respectively. We illustrate the new filter algorithms by decoding the wind stimulus magnitude from simulated neural spiking activity in the cricket cereal system. The SMC-PPFS and SMC-PPFD provide more accurate state estimates at low number of particles than a conventional bootstrap SMC filter algorithm in which the state transition probability density is the proposal density. We also use the SMC-PPFs algorithm to track the temporal evolution of a spatial receptive field of a rat hippocampal neuron recorded while the animal foraged in an open environment. Our results suggest an approach for constructing point process adaptive filters using SMC methods. C1 Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neurosci Stat Res Lab, Boston, MA 02114 USA. Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA. Boston Univ, Dept Math & Stat, Boston, MA 02215 USA. MIT, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA. MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. Harvard Univ, MIT, Sch Med, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Ergun, A (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neurosci Stat Res Lab, Boston, MA 02114 USA. EM ayla@neuro-stat.mgh.harvard.edu; barbieri@neurostat.mgh.harvard.edu; tzvi@neurostat.mgh.harvard.edu; wilson@ai.mit.edu; brown@neurostat.gh.har-vard.edu OI Barbieri, Riccardo/0000-0001-9381-3833 FU NIDA NIH HHS [DA015644]; NIMH NIH HHS [MH59733] NR 49 TC 45 Z9 45 U1 0 U2 7 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 0018-9294 J9 IEEE T BIO-MED ENG JI IEEE Trans. Biomed. Eng. PD MAR PY 2007 VL 54 IS 3 BP 419 EP 428 DI 10.1109/TBME.2006.888821 PG 10 WC Engineering, Biomedical SC Engineering GA 140IS UT WOS:000244498800008 PM 17355053 ER PT J AU Srinivasan, L Brown, EN AF Srinivasan, Lakshminarayan Brown, Emery N. TI A state-space framework for movement control to dynamic goals through brain-driven interfaces SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING LA English DT Article DE goal-directed movement; neural prosthetic device; recursive estimation; state equation ID TARGET LOCATION; PARIETAL CORTEX; CONTROL SIGNALS; REAL; CLASSIFICATION; INTERCEPTION; RECORDINGS; DIRECTION; ENSEMBLE; DEVICES AB State-space estimation is a convenient framework for the design of brain-driven interfaces, where neural activity is used to control assistive devices for individuals with severe motor deficits. Recently, state-space approaches were developed to combine goal planning and trajectory-guiding neural activity in the control of reaching movements of an assistive device to static goals. In this paper, we extend these algorithms to allow for goals that may change over the course of the reach. Performance between static and dynamic goal state equations and a standard free movement state equation is compared in simulation. Simulated trials are also used to explore the possibility of incorporating activity from parietal areas that have previously been associated with dynamic goal position. Performance is quantified using mean-square error (MSE) of trajectory estimates. We also demonstrate the use of goal estimate MSE in evaluating algorithms for the control of goal-directed movements. Finally, we propose a framework to combine sensor data and control algorithms along with neural activity and state equations, to coordinate goal-directed movements through brain-driven interfaces. C1 MIT, Dept Elect Engn & Comp Sci, Informat & Decis Syst Lab, Cambridge, MA 02139 USA. Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neurosci Stat Res Lab, Charlestown, MA 02129 USA. MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. RP Srinivasan, L (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, Ctr Nervous Syst Repair, 50 Blossom St,EDR-410, Boston, MA 02114 USA. EM ls2@mit.edu FU NIGMS NIH HHS [T32 GM07753-27, T32 GM007753] NR 42 TC 19 Z9 19 U1 1 U2 2 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 0018-9294 J9 IEEE T BIO-MED ENG JI IEEE Trans. Biomed. Eng. PD MAR PY 2007 VL 54 IS 3 BP 526 EP 535 DI 10.1109/TBME.2006.890508 PG 10 WC Engineering, Biomedical SC Engineering GA 140IS UT WOS:000244498800021 PM 17355066 ER PT J AU Dicianno, BE Spaeth, DM Cooper, RA Fitzgerald, SG Boninger, ML Brown, KW AF Dicianno, Brad E. Spaeth, Donald M. Cooper, Rory A. Fitzgerald, Shirley G. Boninger, Michael L. Brown, Karl W. TI Force control strategies while driving electric powered wheelchairs with isometric and movement-sensing joysticks SO IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING LA English DT Article DE assistive technology; biological motor systems; force control; isometric joystick; movement disorders; rehabilitation; wheelchairs ID POSITION; MODEL AB Innovations to control interfaces for electric powered wheelchairs (EPWs) could benefit 220 000 current users and over 125 000 individuals who desire mobility but cannot use a conventional motion sensing joystick (MSJ). We developed a digital isometric joystick (IJ) with sophisticated signal processing and two control functions. In a prior study, subjects' driving accuracy with our IJ was comparable to using an MSJ. However, we observed subjects using excessive force on the IJ possibly because its rigid post provides no positional feedback. Thus, this paper examines the time-series data recorded in the previous study to characterize subjects' force control strategies since weakness is a concern. Eleven EPW users with upper limb impairments drove an EPW using an IJ with two different control functions and an MSJ in a Fitts' law paradigm. Subjects relied upon positional feedback from the MSJ and used appropriate force. In contrast, subjects using the IJ with either control function applied significantly higher force than necessary (p < 0.0001 and p = 0.0058). Using higher average force was correlated with quicker trial times but not associated with accuracy. Lack of positional feedback may result in use of excess isometric force. Modifying control functions, adjusting gain, or providing additional training or feedback might address this problem. C1 HERL, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA. Ctr Excellence Wheelchairs & Associated Rehabil E, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. RP Dicianno, BE (reprint author), HERL, Pittsburgh, PA 15206 USA. EM diciannob@herlpitt.org; spaethd@herlpitt.org; rcooper@pitt.edu; sgf9@pitt.edu; boninger@pitt.edu; brownk@herlpitt.org OI Boninger, Michael/0000-0001-6966-919X; Dicianno, Brad/0000-0003-0738-0192 FU NICHD NIH HHS [K12HD01097] NR 27 TC 14 Z9 14 U1 2 U2 4 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1534-4320 EI 1558-0210 J9 IEEE T NEUR SYS REH JI IEEE Trans. Neural Syst. Rehabil. Eng. PD MAR PY 2007 VL 15 IS 1 BP 144 EP 150 DI 10.1109/TNSRE.2007.891394 PG 7 WC Engineering, Biomedical; Rehabilitation SC Engineering; Rehabilitation GA 149ZA UT WOS:000245184200020 PM 17436887 ER PT J AU Thompson, EC Cobb, BS Sabbattini, P Meixlsperger, S Parelho, V Liberg, D Taylor, B Dillon, N Georgopoulos, K Jumaa, H Smale, ST Fisher, AG Merkenschlager, M AF Thompson, Elizabeth C. Cobb, Bradley S. Sabbattini, Pierangela Meixlsperger, Sonja Parelho, Vania Liberg, David Taylor, Benjamin Dillon, Niall Georgopoulos, Katia Jumaa, Hassan Smale, Stephen T. Fisher, Amanda G. Merkenschlager, Matthias TI Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits SO IMMUNITY LA English DT Article ID TRANSCRIPTION FACTOR; LYMPHOCYTE DEVELOPMENT; GENE; DIFFERENTIATION; HETEROCHROMATIN; FAMILY; LOCALIZATION; ACTIVATION; COMPLEXES; MECHANISM AB Ikaros DNA-binding proteins are critical for the development of lymphocytes and other hematopoietic lineages, but it remains unclear how they cooperate with other regulators of signaling and transcription to achieve ordered gene expression during development. Here, we show that Ikaros proteins regulate the pre-BCR component lambda 5 in a stage-specific manner. In pre-BI cells, Ikaros modulated lambda 5 expression in competition with the transcriptional activator EBF. This required Ikaros binding to the IgII1 (lambda 5) promoter and was abolished either by mutation of the Ikaros DNA-binding domain or by deletion of a single Ikaros site from the IgII1 promoter. At the transition from the pre-BI to pre-BI stage, the expression of the Ikaros family member Aiolos was upregulated and required for the efficient silencing of IgII1. Aiolos expression was controlled by pre-BCR signals via the adaptor protein SLP-65. Thus, pre-BCR signaling regulates Aiolos and the silencing of IgII1 via a developmental-stage-specific feedback loop. C1 Univ London Imperial Coll Sci & Technol, MRC, Ctr Clin Sci, Lymphocyte Dev Grp, London W12 0NN, England. Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. Univ London Imperial Coll Sci & Technol, MRC, Ctr Clin Sci, Gene Regulat & Chromatin Grp, London W12 0NN, England. Max Planck Inst Immunobiol, D-79108 Freiburg, Germany. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA. RP Merkenschlager, M (reprint author), Univ London Imperial Coll Sci & Technol, MRC, Ctr Clin Sci, Lymphocyte Dev Grp, Du Cane Rd, London W12 0NN, England. EM matthias.merkenschlager@csc.mrc.ac.uk OI Taylor, Benjamin/0000-0001-6101-3786; Merkenschlager, Matthias/0000-0003-2889-3288 FU Medical Research Council [MC_U120027516, MC_U120036884] NR 31 TC 105 Z9 111 U1 1 U2 3 PU CELL PRESS PI CAMBRIDGE PA 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA SN 1074-7613 J9 IMMUNITY JI Immunity PD MAR PY 2007 VL 26 IS 3 BP 335 EP 344 DI 10.1016/j.immuni.2007.02.010 PG 10 WC Immunology SC Immunology GA 150PG UT WOS:000245228100010 PM 17363301 ER PT J AU Oyoshi, MK Barthel, R Tsitsikov, EN AF Oyoshi, Michiko K. Barthel, Robert Tsitsikov, Erdyni N. TI TRAF1 regulates recruitment of lymphocytes and, to a lesser extent, neutrophils, myeloid dendritic cells and monocytes to the lung airways following lipopolysaccharide inhalation SO IMMUNOLOGY LA English DT Article DE lipopolysaccharide; lung; lymphocyte; recruitment; TRAF1 ID NECROSIS-FACTOR-ALPHA; FACTOR RECEPTOR; TNF RECEPTOR; BACTERIAL LIPOPOLYSACCHARIDE; INFLAMMATORY RESPONSE; CHEMOKINE RECEPTORS; INHALED ENDOTOXIN; ADAPTIVE IMMUNITY; EPITHELIAL-CELLS; MUTANT MICE AB Inhaled lipopolysaccharide (LPS) induces an inflammatory response that may contribute to the pathogenesis of asthma and other airway diseases. Here we investigate the role of tumour necrosis factor (TNF) receptor-associated factor 1 (TRAF1) in leucocyte recruitment using a model of LPS-induced lung inflammation in mice. TRAF1(-/-) mice are completely deficient in the recruitment of lymphocytes to the lower respiratory tract after inhalation of LPS. Although TRAF1(-/-) mice display normal early accumulation of neutrophils, dendritic cells and monocytes in the alveolar airspace, they have a significantly reduced recruitment of these cells by 24 hr after inhalation of LPS when compared to wild-type (WT) mice. Despite normal expression of the pro-inflammatory cytokines TNF, interleukin-1 (IL-1) and IL-6 after LPS treatment, TRAF1(-/ -) mice displayed decreased expression of intercellular adhesion molecule 1, vascular cell adhesion molecule 1, CCL17 and CCL20 in the lungs, when compared to LPS-treated WT mice. These results suggest that TRAF1 facilitates LPS-induced leucocyte recruitment into the lung airways by augmenting the expression of chemokines and adhesion molecules. Mice lacking TNF receptor 1 (TNFR1) but not TNFR2 show a phenotype similar to the TRAF1(-/-) mice, suggesting that TRAF1 may act downstream of TNFR1. Significantly, we use bone marrow chimeras to demonstrate that expression of TRAF1 by cells resident in the lungs, but not by circulating leucocytes, is necessary for efficient LPS-induced recruitment of leucocytes to the lung airways. C1 Harvard Univ, Sch Med, Dept Pediat, CBR Inst Biomed Res, Boston, MA 02115 USA. RP Tsitsikov, EN (reprint author), Harvard Univ, Sch Med, Dept Pediat, CBR Inst Biomed Res, 800 Huntington Ave, Boston, MA 02115 USA. EM tsitsikov@cbrinstitute.org FU NCI NIH HHS [CA095127, R01 CA095127] NR 57 TC 11 Z9 11 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0019-2805 J9 IMMUNOLOGY JI Immunology PD MAR PY 2007 VL 120 IS 3 BP 303 EP 314 DI 10.1111/j.1365-2567.2006.02499.x PG 12 WC Immunology SC Immunology GA 134BS UT WOS:000244058200004 PM 17328785 ER PT J AU Lee, VT Pukatzki, S Sato, H Kikawada, E Kazimirova, AA Huang, J Li, XH Arm, JP Frank, DW Lory, S AF Lee, Vincent T. Pukatzki, Stefan Sato, Hiromi Kikawada, Eriya Kazimirova, Anastasia A. Huang, Jin Li, Xiaohua Arm, Jonathan P. Frank, Dara W. Lory, Stephen TI Pseudolipasin A is a specific inhibitor for phospholipase A(2) activity of Pseudomonas aeruginosa cytotoxin ExoU SO INFECTION AND IMMUNITY LA English DT Article ID HUMAN GROUP-IIA; DICTYOSTELIUM-DISCOIDEUM; BACTERIAL VIRULENCE; BETA-LACTAMASE; CHO-CELLS; IN-VITRO; INFECTION; PATHOGEN; A(2); VIVO AB A number of bacterial pathogens utilize the type III secretion pathway to deliver effector proteins directly into the host cell cytoplasm. Certain strains of Pseudomonas aeruginosa associated with acute infections express a potent cytotoxin, exoenzyme U (ExoU), that is delivered via the type III secretion pathway directly into contacting host cells. Once inside the mammalian cell, ExoU rapidly lyses the intoxicated cells via its phospholipase A(2) (PLA(2)) activity. A high-throughput cell-based assay was developed to screen libraries of compounds for those capable of protecting cells against the cytotoxic effects of ExoU. A number of compounds were identified in this screen, including one group that blocks the intracellular activity of ExoU. In addition, these compounds specifically inhibited the PLA(2) activity of ExoU in vitro, whereas eukaryotic secreted PLA(2) and cytosolic PIA, were not inhibited. This novel inhibitor of ExoU-specific PLA(2) activity, named pseudolipasin A, may provide a new lead for virulence factor-based therapeutic design. C1 Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Broad Inst, Cambridge, MA 02142 USA. Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA. RP Lee, VT (reprint author), Univ Maryland, Dept Mol Genet & Cell Biol, College Pk, MD 20742 USA. EM vtlee@umd.edu OI Lee, Vincent T./0000-0002-3593-0318 FU NHLBI NIH HHS [R01 HL070946, R01-HL070946, R21 HL079393, R21-HL079393]; NIAID NIH HHS [K22 AI065828, R01 AI049577, R01-AI49577] NR 40 TC 34 Z9 35 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD MAR PY 2007 VL 75 IS 3 BP 1089 EP 1098 DI 10.1128/IAI.01184-06 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 143PD UT WOS:000244733900003 PM 17178785 ER PT J AU Beenhouwer, DO Yoo, EM Lai, CW Rocha, MA Morrison, SL AF Beenhouwer, David O. Yoo, Esther M. Lai, Chun-Wei Rocha, Miguel A. Morrison, Sherie L. TI Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection SO INFECTION AND IMMUNITY LA English DT Article ID ANTICAPSULAR MONOCLONAL-ANTIBODIES; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HUMAN IMMUNOGLOBULIN G1; FC-RECEPTOR; CAPSULAR POLYSACCHARIDE; RHEUMATOID-ARTHRITIS; PASSIVE-IMMUNIZATION; COMPLEMENT; ISOTYPE; BINDING AB The encapsulated yeast Cryptococcus neoformans is a significant cause of meningitis and death in patients with AIDS. Some murine monoclonal antibodies (MAbs) against the glucuronoxylomannan (GXM) component of the C neoformans capsular polysaccharide can prolong the lives of infected mice, while others have no effect or can even shorten survival. To date, no one has systematically compared the efficacies of antibodies with the same variable regions and different human constant regions with their unique combination of effector functions in providing protection against murine C neoformans infection. In the present study, we examined the efficacies of anti-GXM MAbs of the four human immunoglobulin G (IgG) subclasses, which have identical variable regions but differ in their capacities to bind the three types of Fc receptors for IgG (Fc gamma R), their abilities to activate complement, and their half-lives. IgG2 and IgG4 anti-GXM prolonged the lives of infected BALB/c mice, IgG3 anti-GXM did not affect animal survival, while mice treated with IgG1 anti-GXM died earlier than mice treated with phosphate-buffered saline or irrelevant isotype-matched MAbs. All NIAbs decreased serum GXM in infected animals. Effector pathways traditionally believed to be important in defense against microbes, such as opsonophagocytosis and complement binding, negatively correlated with antibody efficacy. It is generally accepted that human IgG1 has the most favorable combination of effector functions for therapeutic use against infections. Therefore, our findings have significant implications for humanization of the mouse IgG1 currently in clinical trials for cryptococcal meningitis and for the design of antibody therapeutics to treat other infectious diseases as well. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. RP Beenhouwer, DO (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, 111F,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM dbeenhou@ucla.edu FU NIAID NIH HHS [R01 AI051415, AI29470, AI51415, R37 AI029470] NR 73 TC 45 Z9 47 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD MAR PY 2007 VL 75 IS 3 BP 1424 EP 1435 DI 10.1128/IAI.01161-06 PG 12 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 143PD UT WOS:000244733900039 PM 17220317 ER PT J AU Brown, SM Eremin, SR Shlyapnikov, SA Petrova, EA Shirokova, LV Goldmann, D O'Rourke, EJ AF Brown, Samuel M. Eremin, Sergey R. Shlyapnikov, Sergey A. Petrova, Elena A. Shirokova, Ludmila V. Goldmann, Donald O'Rourke, Edward J. TI Prospective surveillance for surgical site infection in St. Petersburg, Russian Federation SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID NNIS SYSTEM REPORT; NOSOCOMIAL INFECTIONS; WOUND-INFECTION; CDC DEFINITIONS; UNITED-STATES; RATES; RISK; NETHERLANDS; HOSPITALS; PROGRAMS AB objective. To assess the risk- adjusted incidence and predictors of surgical site infections ( SSIs). design. Prospective, multicenter, observational cohort study. setting. Seven surgical departments at 3 urban academic hospitals in St. Petersburg, Russian Federation. patients. All patients had surgery performed between January 15 and May 12, 2000. A total of 1,453 surgical procedures were followed up. Medical records were unavailable for less than 3% of all patients; patients were not excluded for any other reason. The mean patient age was 49.3 years, 61% were female, and 34% had an American Society of Anesthesiologists physical status classification ( hereafter, " ASA classification") of at least 3. Surgery for 45% of the patients was emergent. results. In all, 138 patients ( 9.5%) developed SSI, for a rate that was approximately 3.5 times the risk- stratified rates in the United States. Male sex ( odds ratio [ OR], 1.54), ASA classifications of 3 ( OR, 3.7) or 4 ( OR, 5.0), longer duration of surgery ( OR, 2.2), and wound classes of 3 ( OR, 5.5) or 4 ( OR, 14.3) were associated with increased SSI risk in multivariate analysis. Endoscopic surgery was associated with a lower risk of SSI ( OR, 0.23). Antibiotic prophylaxis was used in 0%- 33% of operations, and 69% of uninfected patients received antibiotics after the operation. conclusions. The SSI rates are significantly higher than previously reported. Although this finding may be attributable to inadequate antibiotic prophylaxis, local infection control and surgical practices may also be contributors. Use of antibiotic prophylaxis should be encouraged and the effect of local practices further investigated. Active SSI surveillance should be expanded to other parts of the Russian Federation. C1 Harvard Univ, Davis Ctr Russian Studies, Cambridge, England. Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. Childrens Hosp, Dept Infect Dis, Boston, MA USA. Harvard Univ, Sch Med, Dept Infect Dis, Boston, MA 02115 USA. Mechnikov Med Acad, Dept Epidemiol, St Petersburg, Russia. Clin Railrd Hosp, Dept Surg, St Petersburg, Russia. Municipal Hosp 26th, Dept Epidemiol, St Petersburg, Russia. Municipal Hosp 4th, Dept Epidemiol, St Petersburg, Russia. RP Brown, SM (reprint author), Univ Utah, Hlth Sci Ctr, Div Resp Cirtical Care & Occupat Pulm Med, Salt Lake City, UT 84112 USA. EM Samuel.Brown@hsc.utah.edu RI Brown, Samuel/E-6846-2015; OI Brown, Samuel/0000-0003-1206-6261; Eremin, Sergey/0000-0002-0486-3255 NR 46 TC 8 Z9 8 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAR PY 2007 VL 28 IS 3 BP 319 EP 325 DI 10.1086/509849 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 205NM UT WOS:000249120800010 PM 17326023 ER PT J AU Cornia, PB Takahashi, TA Lipsky, BA AF Cornia, Paul B. Takahashi, Traci A. Lipsky, Benjamin A. TI Evaluating and treating diabetic foot infections SO INFECTIONS IN MEDICINE LA English DT Article DE diabetic foot infection; diabetic foot ulcer; antibiotic therapy ID RESISTANT STAPHYLOCOCCUS-AUREUS; OSTEOMYELITIS; ULCERS; DIAGNOSIS; ISCHEMIA; DISEASE; REVASCULARIZATION; PREVALENCE; MANAGEMENT; AMPUTATION AB In diabetic foot infections, ulceration of a neuropathic foot is typically the inciting event, followed by infection of the wound. Key components of the initial evaluation include assessing for signs of systemic infection, determining the extent of tissue involvement, and evaluating for peripheral arterial perfusion. Antibiotic therapy is usually initiated empirically. Regardless of the severity of infection, empiric regimens should always have activity against the most commonly encountered pathogens, staphylococci and streptococci. Moderate to severe infections necessitate broader-spectrum agents with activity against commonly isolated Gram-negative bacilli and, in some cases, methicillin-resistant Staphylococcus aureus and Enterococcus species. Therapy should be modified based on results of cultures of properly obtained wound specimens. Most patients also need some surgical intervention as well as proper wound care. C1 Univ Washington, Sch Med, Div Gen Internal Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Primary & Specialty Med Serv, Seattle, WA USA. RP Cornia, PB (reprint author), Univ Washington, Sch Med, Div Gen Internal Med, Seattle, WA 98195 USA. RI Lipsky, Benjamin/B-4645-2013; OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 51 TC 0 Z9 0 U1 2 U2 3 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0749-6524 J9 INFECT MED JI Infect. Med. PD MAR PY 2007 VL 24 IS 3 BP 124 EP 129 PG 6 WC Infectious Diseases SC Infectious Diseases GA 148DU UT WOS:000245055500008 ER PT J AU Berg, CJ Michelson, SE Safren, SA AF Berg, Carla J. Michelson, Susan E. Safren, Steven A. TI Behavioral aspects of HIV care: Adherence, depression, substance use, and HIV-transmission behaviors SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA LA English DT Review ID HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED-DISEASE; SELF-REPORTED ADHERENCE; DRUG-ABUSE TREATMENT; ANTIRETROVIRAL THERAPY ADHERENCE; METHADONE-MAINTENANCE TREATMENT; NEEDLE-EXCHANGE PROGRAMS; OUT-OF-TREATMENT; BISEXUAL MEN; RISK BEHAVIOR AB A variety of psychosocial stressors are involved in living with HIV, maintaining a regimen of highly active antiretroviral therapy, and negotiating necessary self-care behaviors. Because health care providers are in regular contact with HIV-infected individuals in care, these contacts allow for the opportunity to assess and intervene on important variables related to quality of life and HIV outcomes. This article reviews information about four important behavioral aspects of HIV care: treatment adherence, depression, high-risk sex, and substance abuse. Efforts by health care providers to address these factors may result in better treatment outcomes, enhanced quality of life among HIV patients, and decreased HIV transmission. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. Fenway Community Hlth, Boston, MA 02115 USA. RP Safren, SA (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 1 Bowdoin Sq BS-07B, Boston, MA 02114 USA. EM ssafren@partners.org FU NIDA NIH HHS [1 R01 DA018603-01] NR 166 TC 35 Z9 35 U1 9 U2 11 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0891-5520 J9 INFECT DIS CLIN N AM JI Infect. Dis. Clin. North Am. PD MAR PY 2007 VL 21 IS 1 BP 181 EP + DI 10.1016/j.idc.2007.01.005 PG 21 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 178AC UT WOS:000247192600010 PM 17502235 ER PT J AU Park, JM AF Park, Jin Mo TI Modulation of macrophage signalling pathways by anthrax toxin proteins SO INFLAMMATION RESEARCH LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BIRKHAUSER VERLAG AG PI BASEL PA VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND SN 1023-3830 J9 INFLAMM RES JI Inflamm. Res. PD MAR PY 2007 VL 56 SU 2 BP S124 EP S124 PG 1 WC Cell Biology; Immunology SC Cell Biology; Immunology GA 151TO UT WOS:000245313900127 ER PT J AU Franko, DL Becker, AE Thomas, JJ Herzog, DB AF Franko, Debra L. Becker, Anne E. Thomas, Jennifer J. Herzog, David B. TI Cross-ethnic differences in eating disorder symptoms and related distress SO INTERNATIONAL JOURNAL OF EATING DISORDERS LA English DT Article DE ethnicity; symptom presentation; distress; eating disorder; referral; help-seeking; screening ID ANOREXIA-NERVOSA; BODY-IMAGE; NATIVE-AMERICAN; MENTAL-HEALTH; WHITE WOMEN; HONG-KONG; BLACK; DISTURBANCES; DISSATISFACTION; BULIMIA AB Objective: This study investigated ethnic differences in the frequency of eating disorder symptoms and related distress in a U.S. college-based eating disorders screening program. Method: Responses to self-report questions and counselors' assessment were analyzed in an ethnically diverse sample (n = 5,4 3 5). Results: The frequency of binge-eating, restrictive eating, vomiting, and amenorrhea did not differ significantly across ethnic groups. However, significant between-group differences were found with respect to modes of purging. Binge correlates (e.g., eating until uncomfortably full) were significantly more frequent among Caucasian than African American participants (p < .001). Binge eating was the best predictor of distress among Caucasians, African Americans, and Latinos, whereas vomiting was the best predictor of distress among Asians. Asian participants who used laxatives were significantly less likely to receive a recommendation for further evaluation than non-Asian participants. Conclusion: Ethnic diversity in symptom prevalence and related distress was identified. Clinician recognition of this potential diversity may enhance culturally competent care for eating disorders. (c) 2006 by Wiley Periodicals, Inc. C1 Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. Northeastern Univ, Dept Counseling & Appl Educ Psychol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Social Med, Cambridge, MA 02138 USA. Yale Univ, Dept Psychol, New Haven, CT 06520 USA. RP Franko, DL (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 32 Fruit St,YAW 6900,15 Parkman St, Boston, MA 02114 USA. EM d.franko@neu.edu NR 52 TC 62 Z9 62 U1 2 U2 11 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0276-3478 J9 INT J EAT DISORDER JI Int. J. Eating Disord. PD MAR PY 2007 VL 40 IS 2 BP 156 EP 164 DI 10.1002/eat.20341 PG 9 WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology SC Psychology; Nutrition & Dietetics; Psychiatry GA 136ZR UT WOS:000244263100009 PM 17080449 ER PT J AU Nurnberg, HG Fava, M Gelenberg, AJ Hensley, PL Paine, S AF Nurnberg, H. G. Fava, M. Gelenberg, A. J. Hensley, P. L. Paine, S. TI Open-label sildenafil treatment of partial and non-responders to double-blind treatment in men with antidepressant-associated sexual dysfunction SO INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH LA English DT Article; Proceedings Paper CT 157th Annual Meeting of the American-Psychiatric-Association CY MAY 01-06, 2004 CL New York, NY SP Amer Psychiat Assoc DE antidepressant; erectile dysfunction; sexual dysfunction; sildenafil ID PLACEBO-CONTROLLED TRIAL; ERECTILE DYSFUNCTION; CITRATE VIAGRA((R)); INTERNATIONAL INDEX; DEPRESSION; EFFICACY; SCALE; VALIDITY AB Fifty partial and non-responders (Clinical Global Impression-Sexual Function (CGI-SF) score > 2), out of 76 men who completed a 6-week, double-blind, placebo-controlled trial of sildenafil treatment for serotonergic antidepressant-associated sexual dysfunction, were eligible for an additional 6-week trial of open-label sildenafil (50 mg adjustable to 100 mg) under the same protocol, with blind maintained to initial assignment. Participation (double-blind and open-label) required major depressive disorder in remission (MDD-R) and continuing antidepressant medication. Forty-three entered open-label study: 16/17 initially randomized to sildenafil (sildenafil/sildenafil) and 27/33 initially randomized to placebo (placebo/sildenafil). Thirty-five of 43 (81%) achieved full response (CGI-SF <= 2): placebo/sildenafil 23/27 (85%); sildenafil/sildenafil 12/16 (75%); P < 0.0001 for changes and P = 0.4 between groups. Secondary measures of erectile function and overall satisfaction improved in both groups (P < 0.03). Hamilton Depression Rating Scale scores improved (placebo/sildenafil; P <= 0.05) or remained stable (sildenafil/sildenafil). In men with MDD-R who maintained antidepressant adherence, 81% of double-blind partial and non-responders treated with open-label sildenafil responded fully. C1 Univ New Mexico, Sch Med, Dept Psychiat, Albuquerque, NM 87131 USA. Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. Arizona Hlth Sci Ctr, Dept Psychiat, Tucson, AZ 85724 USA. RP Nurnberg, HG (reprint author), Univ New Mexico, Sch Med, Dept Psychiat, 2400 Tucker NE, Albuquerque, NM 87131 USA. EM geon@unm.edu NR 40 TC 7 Z9 7 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0955-9930 J9 INT J IMPOT RES JI Int. J. Impot. Res. PD MAR-APR PY 2007 VL 19 IS 2 BP 167 EP 175 DI 10.1038/sj.ijir.3901502 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 146SX UT WOS:000244956100009 PM 16871270 ER PT J AU Lee, SW Moskowitz, MA Sims, JR AF Lee, Sae-Won Moskowitz, Michael A. Sims, John R. TI Sonic hedgehog inversely regulates the expression of angiopoietin-1 and angiopoietin-2 in fibroblasts SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE LA English DT Article DE hedgehog protein; angiogenesis; angiopoietin; neurovascular unit ID ENDOTHELIAL-GROWTH-FACTOR; POSTTRANSCRIPTIONAL REGULATION; CELLS; DIFFERENTIATION; ANGIOGENESIS; GENE; PROLIFERATION; VASCULATURE; MAINTENANCE; HYPOXIA AB Nerves and blood vessels have similar branching patterns and use common morphogenic molecules during development. Recent studies show that sonic hedgehog (Shh), a traditional neurogenic morphogen, is required for embryonic arterial differentiation and can induce angiogenesis. We investigated whether Shh regulates the expression of angiogenic factors. Using NIH3T3 embryonic fibroblast cells, we demonstrated that Shh increased the mRNA levels of angiopoietin-1 (Ang-1), a secreted ligand that regulates endothelial interaction with mural cells (pericytes and smooth muscle cells) and promotes blood vessel maturation. In contrast, Shh decreased mRNA levels of angiopoietin-2 (Ang-2), a negative modulator of Ang-1. By contrast, Shh did not change the expression of vascular endothelial growth factor (VEGF) mRNA, a potent endothelial mitogen. The effect of Shh appeared to be cell-type specific as the addition of Shh to neural progenitor cells or neurons did not alter Ang-1, Ang-2 or VEGF mRNA levels. The addition of cyclopamine, an inhibitor of Shh signaling, to NIH3T3 cells, suppressed the regulation of Ang-1 and Ang-2 mRNA levels in the presence of Shh. Collectively, our results suggest that Shh may contribute to blood vessel growth, maturation and stabilization in a neurovascular network by reciprocally regulating the vascular morphogens Ang-1 and Ang-2 in a cell-type specific manner. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Stroke & Neurovasc Regulat Lab, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA. RP Sims, JR (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Stroke & Neurovasc Regulat Lab, Charlestown, MA 02129 USA. EM jsims@partners.org FU NINDS NIH HHS [5 P50 NS10828, NS045776] NR 42 TC 49 Z9 53 U1 0 U2 0 PU PROFESSOR D A SPANDIDOS PI ATHENS PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE SN 1107-3756 J9 INT J MOL MED JI Int. J. Mol. Med. PD MAR PY 2007 VL 19 IS 3 BP 445 EP 451 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 136OC UT WOS:000244233000015 PM 17273793 ER PT J AU Aquino, SL Halpern, EF Kuester, LB Fischman, AJ AF Aquino, Suzanne L. Halpern, Elkan F. Kuester, Landon B. Fischman, Alan J. TI FDG-PET and CT features of non-small cell lung cancer based on tumor type SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE LA English DT Article DE lung neoplasm; carcinoma non-small cell lung; carcinoma; bronchioloalveolar; F-18-FDG; computerized emission tomography ID POSITRON-EMISSION-TOMOGRAPHY; SOLITARY PULMONARY NODULES; BRONCHIOLOALVEOLAR CARCINOMA; FLUORODEOXYGLUCOSE PET; EXPRESSION; MALIGNANCY; DIFFERENTIATION; FLUORINE-18-FDG; HEXOKINASE; METABOLISM AB We determined if specific tumor types of non-small cell lung cancer can be identified by variance in FDG-PET standard uptake value (SUV) in combination with characteristics on CT. Staging FDG-PET and CT scans of 81 patients (34 men and 47 women, average age 67 +/- 11 years) with 82 lung cancers were analyzed. Mean tumor SUV was calculated at the location of maximum FDG uptake. Tumor size, margins, and location were analyzed on CT. Statistical analysis compared SUV between tumor subtypes, assessed relationship between tumor subtype and features on CT and determined if combination of CT and SUV patterns predicted tumor type. In total 35 adenocarcinomas (AC); 15 bronchioloalveolar cell carcinomas (BAC), 23 squamous cell carcinomas and 9 large cell carcinomas were evaluated. Significant differences were found between SUV of all AC and squamous cell (p < 0.0001); between all AC and large cell (p=0.03); between non-BAC AC and squamous cell types (p=0.0005); BAC and non-BAC AC (p=0.04), BAC and squamous cell (p < 0.0001); BAC and large cell (p=0.004). Ground glass was the most significant CT feature in distinguishing tumor types, which was seen in BAC (p < 0.0003). In conclusion, SUVs for non-small cell lung cancer were most significantly different between BAC and all other NCLC cell subtypes. The presence of ground glass in a nodule on CT is a significant feature for BAC and should raise the suspicion for this tumor type despite low FDG uptake. C1 Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Fischman, AJ (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,FND 202, Boston, MA 02114 USA. EM fischman@pet.mgh.harvard.edu NR 28 TC 24 Z9 33 U1 0 U2 1 PU PROFESSOR D A SPANDIDOS PI ATHENS PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE SN 1107-3756 J9 INT J MOL MED JI Int. J. Mol. Med. PD MAR PY 2007 VL 19 IS 3 BP 495 EP 499 PG 5 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 136OC UT WOS:000244233000021 PM 17273799 ER PT J AU Littman, AJ Vitiello, MV Foster-Schubert, K Ulrich, CM Tworoger, SS Potter, JD Weigle, DS McTiernan, A AF Littman, A. J. Vitiello, M. V. Foster-Schubert, K. Ulrich, C. M. Tworoger, S. S. Potter, J. D. Weigle, D. S. McTiernan, A. TI Sleep, ghrelin, leptin and changes in body weight during a 1-year moderate-intensity physical activity intervention SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article DE physical activity; randomized trial; ghrelin; leptin; sleep; weight change ID INSOMNIA RATING-SCALE; FOOD-INTAKE; SHORT-TERM; OBESITY; DURATION; OVERWEIGHT; APPETITE; ADULTS; RISK; POPULATION AB Objective: To investigate cross-sectional and longitudinal relationships among exercise, sleep, ghrelin and leptin. Methods: We randomly assigned 173 post-menopausal sedentary overweight ( body mass index >= 24.0 kg/m(2) and > 33% body fat) women aged 50-75 years living in western Washington State to either a facility- and home-based moderate-intensity physical activity intervention or a stretching control group. Fasting plasma ghrelin, leptin, measured height, weight and self-reported sleep were assessed at baseline and 12 months. Results: There were no consistent cross-sectional patterns between self-reported sleep measures and ghrelin or leptin at baseline. The weight loss differences between exercisers and stretchers were greater for those who slept less at follow-up than at baseline compared to those whose sleep duration did not change (-3.2 kg, 95% confidence interval (CI) -5.8, -0.5). Improvements in sleep quality were associated with significantly greater differences between exercisers and stretchers for ghrelin increases ( improved vs same sleep quality: +115 pg/ml, 95% CI +25, +206) and leptin decreases ( improved vs worsened sleep quality: -5.7 ng/ml, 95% CI -9.5, -1.5). Conclusion: There was only limited evidence that changes in sleep duration or quality modified exercise-induced changes in weight, ghrelin or leptin. Moreover, the observed differences were not in the directions hypothesized. Future longitudinal studies including population-based samples using objective measures of sleep and long follow-up may help to clarify these relationships. C1 Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98104 USA. Univ Washington, Sch Med, Dept Med, Div Med Endocrinol & Nutr, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. Univ Washington, Harborview Med Ctr, Div Endocrinol, Seattle, WA 98104 USA. RP Littman, AJ (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N M4 B402,POB 19024, Seattle, WA 98109 USA. EM alittman@fhcrc.org OI Potter, John/0000-0001-5439-1500; Tworoger, Shelley/0000-0002-6986-7046; Vitiello, Michael/0000-0002-9776-0473 FU NCI NIH HHS [R25 CA94880, T32 CA090001] NR 37 TC 39 Z9 39 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 J9 INT J OBESITY JI Int. J. Obes. PD MAR PY 2007 VL 31 IS 3 BP 466 EP 475 DI 10.1038/sj.ijo.0803438 PG 10 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 140CL UT WOS:000244480100011 PM 16909130 ER PT J AU Maurovich-Horvat, P Massaro, J Fox, CS Moselewski, F O'Donnell, CJ Hoffmann, U AF Maurovich-Horvat, P. Massaro, J. Fox, C. S. Moselewski, F. O'Donnell, C. J. Hoffmann, U. TI Comparison of anthropometric, area- and volume-based assessment of abdominal subcutaneous and visceral adipose tissue volumes using multi-detector computed tomography SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article DE abdominal obesity; adipose tissue quantification; computed tomography ID CARDIOVASCULAR RISK-FACTORS; MAGNETIC-RESONANCE; INSULIN-RESISTANCE; FAT DISTRIBUTION; VASCULAR-DISEASE; BODY-COMPOSITION; FOLLOW-UP; OBESITY; MEN; WOMEN AB Purpose: Cross-sectional imaging may enable accurate localization and quantification of subcutaneous and visceral adipose tissue. The reproducibility of multi-detector computed tomography (MDCT)-based volumetric quantification of abdominal adipose tissue and the ability to depict age-and gender-related characteristics of adipose tissue deposition have not been reported. Methods: We evaluated a random subset of 100 Caucasian subjects ( age range: 37 - 83 years; 49% women) of the Framingham Heart Study offspring cohort who underwent MDCT scanning. Two readers measured subcutaneous and visceral adipose tissue volumes (SAV and VAV; cm(3)) and areas (SAA and VAA; cm(2)) as well as abdominal sagital diameter (SD) and waist circumference ( WC). Results: Inter-reader reproducibility was excellent ( relative difference: -0.34 +/- 0.52% for SAV and 0.59 +/- 0.93% for VAV, intraclass correlation (ICC) = 0.99 each). The mean SAA/VAA ratio was significantly different from the mean SAV/VAV ratio(2.0 +/- 1.2 vs 1.7 +/- 0.9; P < 0.001). The ratio of SAV/VAV was only weakly inversely associated with SD ( ICC = -0.32, P = 0.01) and not significantly associated with WC ( ICC = -0.14, P = 0.14) or body mass index ( ICC = -0.17, P = 0.09). The mean SAV/VAV ratio was significantly different between participants < 60 vs 460 years (1.9 +/- 1.0 vs 1.5 +/- 0.7; P < 0.001) and between men and women (1.2 +/- 0.5 vs 2.2 +/- 0.9; P < 0.001). Conclusion: This study demonstrates that MDCT-based volumetric quantification of abdominal adipose tissue is highly reproducible. In addition, our results suggest that volumetric measurements can depict age- and gender-related differences of visceral and subcutaneous abdominal adipose tissue deposition. Further research is warranted to assess whether volumetric measurements may substantially improve the predictive value of obesity measures for insulin resistance, type 2 diabetes mellitus and other diseases. C1 Harvard Univ, Dept Radiol, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. Semmelweis Univ, Dept Cardiovasc Surg, H-1085 Budapest, Hungary. NHLBI, Framingham Heart Dis Epidemiol Study, Framingham, MA USA. Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. Harvard Univ, Dept Med, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Hoffmann, U (reprint author), Harvard Univ, Dept Radiol, Massachusetts Gen Hosp, Sch Med, 165 Charles River Plaza 400, Boston, MA 02114 USA. EM uhoffman@partners.org OI Massaro, Joseph/0000-0002-2682-4812; Maurovich-Horvat, Pal/0000-0003-0885-736X FU NHLBI NIH HHS [N01-HC-25195] NR 46 TC 137 Z9 143 U1 2 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 J9 INT J OBESITY JI Int. J. Obes. PD MAR PY 2007 VL 31 IS 3 BP 500 EP 506 DI 10.1038/sj.ijo.0803454 PG 7 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 140CL UT WOS:000244480100016 PM 16953256 ER PT J AU Marcus, KJ Astrakas, LG Zurakowski, D Zarifi, MK Mintzopoulos, D Poussaint, TY Anthony, DC De Girolami, U Black, PM Tarbell, NJ Tzika, AA AF Marcus, Karen J. Astrakas, Loukas G. Zurakowski, David Zarifi, Maria K. Mintzopoulos, Dionyssios Poussaint, Tina Young Anthony, Douglas C. De Girolami, Umberto Black, Peter McL. Tarbell, Nancy J. Tzika, A. Aria TI Predicting survival of children with CNS tumors using proton magnetic resonance spectroscopic imaging biomarkers SO INTERNATIONAL JOURNAL OF ONCOLOGY LA English DT Article DE brain/central nervous system cancers; pediatric cancers; tumor biomarkers; survival; NMR; diagnostic imaging; magnetic resonance spectroscopic imaging ID PEDIATRIC BRAIN-TUMORS; OPERATING CHARACTERISTIC CURVES; CENTRAL-NERVOUS-SYSTEM; P-31 NMR-SPECTROSCOPY; IN-VIVO; MALIGNANT GLIOMAS; MR SPECTROSCOPY; GENE-EXPRESSION; PHOSPHOLIPID-METABOLISM; GLIOBLASTOMA-MULTIFORME AB Using brain proton magnetic resonance spectroscopic imaging (MRSI) in children with central nervous system (CNS) tumors, we tested the hypothesis that combining information from biologically important metabolites, at diagnosis and prior to treatment, would improve prediction of survival. We evaluated brain proton MRSI exams in 76 children (median age at diagnosis: 74 months) with brain tumors. Important biomarkers, choline-containing compounds (Cho), N-acetylaspartate (NAA), total creatine (tCr), lipids and/or lactate (L), were measured at the 'highest Cho region' and normalized to the tCr of surrounding healthy tissue. Neuropathological grading was performed using World Health Organization (WHO) criteria. Fifty-eight of 76 (76%) patients were alive at the end of the study period. The mean survival time for all subjects was 52 months. Univariate analysis demonstrated that Cho, L, Cho/NAA and tumor grade differed significantly between survivors and non-survivors (P <= 0.05). Multiple logistic regression and stepwise multivariate Cox regression indicated that Cho + 0.1L was the only independent predictor of survival (likelihood ratio test = 10.27, P < 0.001; Cox regression, P=0.004). The combined index Cho + 0.1L was more accurate and more specific predictor than Cho or Cho/NAA. Accuracy and specificity for Cho + 0.1L were 80% and 86%, respectively. We conclude that brain proton MRSI biomarkers predict survival of children with CNS tumors better than does standard histopathology. More accurate prediction using this non-invasive technique represents an important advance and may suggest more appropriate therapy, especially when diagnostic biopsy is not feasible. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg,NMR Surg Lab, Boston, MA 02114 USA. Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Radiat Oncol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Orthopaed Surg, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Pathol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Neurosurg, Boston, MA 02114 USA. Dept Pathol & Anat Sci Missouri, Columbia, MO USA. RP Tzika, AA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg,NMR Surg Lab, 51 Blossom St,Room 261, Boston, MA 02114 USA. EM atzika@partners.org RI Astrakas, Loukas/F-5918-2011; OI Anthony, Douglas/0000-0002-3815-2240 NR 56 TC 30 Z9 30 U1 0 U2 1 PU PROFESSOR D A SPANDIDOS PI ATHENS PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE SN 1019-6439 J9 INT J ONCOL JI Int. J. Oncol. PD MAR PY 2007 VL 30 IS 3 BP 651 EP 657 PG 7 WC Oncology SC Oncology GA 136IO UT WOS:000244216000013 PM 17273766 ER PT J AU Baeten, JM McClelland, RS Wener, MH Bankson, DD Lavreys, L Mandaliya, K Bwayo, JJ Kreiss, JK AF Baeten, Jared M. McClelland, R. Scott Wener, Mark H. Bankson, Daniel D. Lavreys, Ludo Mandaliya, Kishorchandra Bwayo, Job J. Kreiss, Joan K. TI Relationship between markers of HIV-1 disease progression and serum beta-carotene concentrations in Kenyan women SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE beta-carotene; HIV-1; acute phase response; vitamin A; micronutrient deficiency; nutritional assessment; nutritional status ID HUMAN-IMMUNODEFICIENCY-VIRUS; VITAMIN-A STATUS; RANDOMIZED-TRIAL; CARDIOVASCULAR-DISEASE; VERTICAL TRANSMISSION; LUNG-CANCER; CELL COUNTS; VIRAL LOAD; INFECTION; SUPPLEMENTATION AB Observational studies have suggested that low serum beta-carotene concentrations may influence HIV-1 disease progression. However, randomized trials have not demonstrated beneficial effects of beta-carotene supplementation. To understand this discrepancy, we conducted a cross-sectional study among 400 HIV-1-seropositive women in Mombasa, Kenya, to correlate serum beta-carotene concentrations with several measures of HIV-1 disease severity. beta-Carotene concentrations were significantly associated with biologic markers of HIV-1 disease progression (CD4 count, HIV-1 plasma viral load, serum C-reactive protein [CRP] concentration, and serum albumin level). In multivariate analysis, beta-carotene concentrations below the median were associated with elevated CRP (>1 0 mg/l, adjusted odds ratio [aOR] 3.32, 95% confidence interval [CI] 1.99-6.53, P < 0.001) and higher HIV-1 plasma viral load (for each log(10) copies/mL increase, aOR 1.38, 95% CI 1.01-1.88, P = 0.04). In the context of negative findings from randomized trials of beta-carotene supplementation in HIV-1-seropositive individuals, these results suggest that low beta-carotene concentrations primarily reflect more active HIV-1 infection rather than a deficiency amenable to intervention. C1 Univ Washington, Seattle HIV Prevent Trials Unit, Dept Med, Seattle, WA 98104 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA. Univ Washington, Dept Lab Med, Seattle, WA 98104 USA. Vet Affairs Puget Sound Hlth Care Syst, Pathol & Lab Med Serv, Seattle, WA USA. Coast Prov Gen Hosp, Mombasa, Kenya. Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya. RP Baeten, JM (reprint author), Univ Washington, Seattle HIV Prevent Trials Unit, Dept Med, UW Box 359927,901 Boren Ave,Suite 1300, Seattle, WA 98104 USA. EM jbaeten@u.washington.edu FU FIC NIH HHS [D43-TW00007]; NIAID NIH HHS [AI39996, AI43844]; NIDDK NIH HHS [DK35816] NR 31 TC 10 Z9 10 U1 0 U2 1 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 0956-4624 J9 INT J STD AIDS JI Int. J. STD AIDS PD MAR PY 2007 VL 18 IS 3 BP 202 EP 206 DI 10.1258/095646207780132541 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 155OK UT WOS:000245587000014 PM 17362556 ER PT J AU Zhong, LC Bradley, J Schubert, W Ahmed, E Adamis, AP Shima, DT Robinson, GS Ng, YS AF Zhong, Lichun Bradley, John Schubert, William Ahmed, Ednan Adamis, Anthony P. Shima, David T. Robinson, Gregory S. Ng, Yin-Shan TI Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID INDUCED APOPTOSIS; ANGIOGENIC FACTOR; OXIDATIVE STRESS; NEURONAL DEATH; EPOETIN-ALPHA; IRIS ATROPHY; BLOOD-FLOW; RAT MODEL; NEUROPROTECTION; PROTECTS AB PURPOSE. Retinal ganglion cell (RGC) loss occurs in response to increased intraocular pressure (IOP) and/or retinal ischemia in glaucoma and leads to impairment of vision. This study was undertaken to test the efficacy of erythropoietin (EPO) in providing neuroprotection to RGCs in vivo. METHODS. The neuroprotective effects of EPO were studied in the DBA/2J mouse model of glaucoma. Mice were intraperitoneally injected with control substances or various doses of EPO, starting at the age of 6 months and continuing for an additional 2, 4, or 6 months. RGCs were labeled retrogradely by a gold tracer. IOP was measured with a microelectric-mechanical system, and FPO receptor (EPOR) expression was detected by immunohistochemistry. Axonal death in the optic nerve was quantified by para-phenylenediamine staining, and a complete blood count system was used to measure the number of erythrocytes. RESULTS. In DBA/2J mice, the average number of viable RGCs significantly decreased from 4 months to 10 months, with an inverse correlation between the number of dead optic nerve axons and viable RGCs. Treatment with EPO at doses of 3000, 6000, and 12,000 U/kg body weight per week all prevented significant RGC loss, compared with untreated DBA/2J control animals. EPO effects were similar to those of memantine, a known neuroprotective agent. IOP, in contrast, was unchanged by both EPO and memantine. Finally, EPOR was expressed in the RGC layer in both DBA/2J and C57BL/6J mice. CONCLUSIONS. EPO promoted RGC survival in DBA/2J glaucomatous mice without affecting IOP. These results suggest that EPO may be a potential therapeutic neuroprotectant in glaucoma. C1 Eyetech Inc, Lexington, MA 02421 USA. Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Ng, YS (reprint author), Eyetech Inc, 35 Hartwell Ave, Lexington, MA 02421 USA. EM ys_ng@yahoo.com NR 55 TC 92 Z9 98 U1 0 U2 6 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR PY 2007 VL 48 IS 3 BP 1212 EP 1218 DI 10.1167/iovs.06-0757 PG 7 WC Ophthalmology SC Ophthalmology GA 142YF UT WOS:000244686500035 PM 17325165 ER PT J AU Hantrah, P Yamagami, S Liu, Y Zhang, Q Vora, SS Lu, B Gerard, CJ Dana, MR AF Hantrah, Pedram Yamagami, Satoru Liu, Ying Zhang, Qiang Vora, Sudhir S. Lu, Bao Gerard, Craig J. Dana, M. Reza TI Deletion of the chemokine receptor CCR1 prolongs corneal allograft survival SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID DENDRITIC CELLS; TRANSPLANT REJECTION; LYMPH-NODES; HISTOCOMPATIBILITY; ANTAGONIST; MICE; RECRUITMENT; POPULATION; RESPONSES; MODEL AB PURPOSE. Many corneal grafts undergo immune rejection, and current therapies are associated with many side effects. The purpose of this study was to identify critical chemokine pathways involved in generating the alloimmune response to corneal transplants. METHODS. Orthotopic corneal transplantation was performed in fully mismatched strains. Cytokine and chemokine receptor gene expression was determined by the RNase protection assay. Knockout (KO) strains for chemokine-chemokine receptors that are upregulated after transplantation underwent corneal transplantation. Results derived from KO murine hosts were compared with cyclosporine (Cy) therapy. In addition to graft survival, graft infiltration, allospecific delayed-type hypersensitivity (DTH), and cytokine expression were compared among the recipient groups. RESULTS. Initial experiments revealed gene upregulation of the chemokine receptors CCR1, -2, and -5 after corneal allorejection. Although CCR1 KO hosts showed a significant increase in graft survival compared with wild-type (WT) hosts, allografts in CCR5, CCR2/CCL3(MIP-1 alpha), CXCR3, CXCL10/IP-10, and CCL3/MIP-1 alpha KO mice did not show a significant improvement in graft survival. Further, CCR1 KO hosts showed a significantly higher survival rate than with systemic Cy therapy in WT hosts. Moreover, graft infiltration by leukocytes and gene expression of proinflammatory cytokines were reduced in CCR1 KO mice compared with both Cy treated and untreated WT mice, as was the induction of allospecific DTH. CONCLUSIONS. These studies provide, for the first time, evidence that targeting of specific chemokine pathways can significantly promote survival of corneal transplants, and suggest that select deletion or suppression of CCR1 can be a useful therapeutic target in corneal transplant immunity. C1 Harvard Univ, Sch Med, Schepens Eye Res Inst, Immunol Lab, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Childrens Hosp, Dept Med, Boston, MA 02114 USA. RP Dana, MR (reprint author), Harvard Univ, Sch Med, Schepens Eye Res Inst, Immunol Lab, 20 Staniford St, Boston, MA 02114 USA. EM dana@vision.eri.harvard.edu NR 44 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR PY 2007 VL 48 IS 3 BP 1228 EP 1236 DI 10.1167/iov.05-1483 PG 9 WC Ophthalmology SC Ophthalmology GA 142YF UT WOS:000244686500037 ER PT J AU Sandberg, MA Rosner, B Weigel-DiFranco, C Dryja, TP Berson, EL AF Sandberg, Michael A. Rosner, Bernard Weigel-DiFranco, Carol Dryja, Thaddeus P. Berson, Eliot L. TI Disease course of patients with X-linked retinitis pigmentosa due to RPGR gene mutations SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID VISUAL-FIELD LOSS; OPTICAL COHERENCE TOMOGRAPHY; DYSTROPHY; ACUITY; RATES; MODEL; RP2 AB PURPOSE. To measure the rates of visual acuity, visual field, and ERG loss in patients with X-linked retinitis pigmentosa due to RPGR mutations and to determine whether these rates differ from those of patients with dominant retinitis pigmentosa due to RHO mutations. METHODS. Snellen visual acuities, Goldmann visual field areas (V4e white test light), and 30 Hz (cone) full-field ERG amplitudes were recorded for an average of 9.8 years in 113 patients with RPGR mutations. After censoring data to eliminate ceiling and floor effects, we used longitudinal regression to estimate mean rates of change and to compare these rates with those of a previously studied cohort of 134 patients with dominant retinitis pigmentosa due to RHO mutations, who were followed for an average of 8.9 years. Survival analysis was used to compare the age distribution of legal blindness in these two groups. To explain group differences in visual acuity, optical coherence tomograms were recorded in some patients to visualize central retinal structure. RESULTS. Mean annual exponential rates of decline for the patients with RPGR mutations were 4.0% for visual acuity, 4.7% for visual field area, and 7.1 % for ERG amplitude. Each of these rates was significantly different from zero (P < 0.001). The rates of visual acuity and visual field loss were significantly faster than the corresponding rates in the RHO patients (1.6%, P < 0.001 and 2.9%, P = 0.002, respectively), whereas the rate of ERG amplitude loss was comparable to that in the RHO patients (7.7%, P = 0.39). The median age of legal blindness was 32 years younger in the RPGR patients than in the RHO patients, due primarily to loss of visual acuity rather than to loss of visual field. Loss of acuity in PPGR patients appeared to be associated with foveal thinning. CONCLUSIONS. Patients with X-linked retinitis pigmentosa due to RPGR mutations lose visual acuity and visual field more rapidly than do patients with dominant retinitis pigmentosa due to RHO mutations. C1 Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Ocular Mol Genet Inst, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Berman Gund Lab Study Retinal Degenerat, Boston, MA 02114 USA. RP Sandberg, MA (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Ocular Mol Genet Inst, 243 Charles St, Boston, MA 02114 USA. EM masandberg@aol.com FU NEI NIH HHS [EY14104, EY00169, EY08683] NR 19 TC 38 Z9 39 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR PY 2007 VL 48 IS 3 BP 1298 EP 1304 DI 10.1167/iovs.06-0971 PG 7 WC Ophthalmology SC Ophthalmology GA 142YF UT WOS:000244686500046 PM 17325176 ER PT J AU Lo Re, V Kostman, JR Gross, R Reddy, KR Mounzer, K Zemel, BS Rennert, H Stieritz, DD Putt, M Frank, I Strom, BL AF Lo Re, Vincent, III Kostman, Jay R. Gross, Robert Reddy, K. Rajender Mounzer, Karam Zemel, Babette S. Rennert, Hanna Stieritz, Donald D. Putt, Mary Frank, Ian Strom, Brian L. TI Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article; Proceedings Paper CT 22nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management CY AUG 24-27, 2006 CL Lisbon, PORTUGAL DE hepatitis C virus; hepatitis C virus therapy; HIV; HIV/hepatitis C virus coinfection; weight loss ID CHRONIC HEPATITIS-C; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; REVERSE-TRANSCRIPTASE INHIBITORS; ALPHA-2A PLUS RIBAVIRIN; MITOCHONDRIAL TOXICITY; ANTIRETROVIRAL-THERAPY; PEGYLATED INTERFERON-ALPHA-2B; LIPODYSTROPHY; LIVER AB Background: Clinical observations suggest that patients with HIV/hepatitis C virus (HCV) may lose body weight during dual therapy, but this has not been confirmed analytically. Objectives: To determine if the incidence and degree of weight loss among patients with HIV/HCV receiving highly active antiretroviral therapy (HAART) and pegylated (PEG)-interferon plus ribavirin were greater than in (1) HCV-monoinfected patients receiving PEG-interferon plus ribavirin and (2) HIV-monoinfected patients receiving HAART. Risk factors for weight loss among patients with HIV/HCV were also examined. Methods: A retrospective cohort study was performed among HIV/HCV-coinfected, HCV-monoinfected and HIV-monoinfected patients. Body weights were assessed up to 6 months before and up to 12 months after initiation of HCV therapy (HIV/HCV-coinfected and HCV-monoinfected subjects) and over 18 months on HAART (HIV-monoinfected subjects). The primary outcome was clinically significant weight loss (>= 5% of baseline weight). Results: Of 192 subjects, 63 had HIV/HCV, 64 had HCV alone, and 65 had HIV alone. Clinically significant weight loss occurred in 48 (76%) subjects with HIV/HCV versus 25 (39%) subjects with HCV (P < 0.001) and 2 (3%) subjects with HIV (P < 0.001), yielding adjusted hazard ratios (HRs) of 2.76 (95% confidence interval [CI]: 1.67 to 4.55) and 38.5 (95% CI: 8.5 to 174.7), respectively Receipt of more than 2 nucleoside reverse transcriptase inhibitors increased the risk of clinically significant weight loss (adjusted HR = 8.17, 95% CI: 2.37 to 28.20). Conclusions: The incidence of weight loss is greater in dually treated patients with HIV/HCV than in treated HCV- or HFV-monoinfected patients. Prospective studies should evaluate additional risk factors for weight loss and changes in body composition to elucidate the mechanism for this weight loss. C1 Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Div Infect Dis,Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Div Gastroenterol, Dept Med, Philadelphia, PA 19104 USA. Philadelphia FIGHT, Jonathan Lax Treatment Ctr, Philadelphia, PA USA. Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Pathol & Lab Med Serv, Philadelphia, PA USA. RP Lo Re, V (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Div Infect Dis,Dept Med, 711 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM vincent.lore@uphs.upenn.edu RI Zemel, Babette/D-1117-2009; Lo Re, Vincent/N-7817-2015 FU AHRQ HHS [HS 10399]; NIAID NIH HHS [P30 AI 45008, T32 AI 055435, U01 AI 32783]; NIDDK NIH HHS [F32 DK 069080]; NIMH NIH HHS [K08 MH 01584] NR 34 TC 6 Z9 6 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAR 1 PY 2007 VL 44 IS 3 BP 344 EP 350 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 141WT UT WOS:000244610400015 PM 17179767 ER PT J AU Oshima, K Grimm, CM Corrales, CE Senn, P Moneder, RM Geleoc, GSG Edge, A Holt, JR Heller, S AF Oshima, Kazuo Grimm, Christian M. Corrales, C. Eduardo Senn, Pascal Moneder, Rodrigo Martinez Geleoc, Gwenaelle S. G. Edge, Albert Holt, Jeffrey R. Heller, Stefan TI Differential distribution of stem cells in the auditory and vestibular organs of the inner ear SO JARO-JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY LA English DT Article DE cochlea; utricle; hair cell; regeneration; spiral ganglion; neurosphere ID DEVELOPING NERVOUS-SYSTEM; RNA-BINDING PROTEIN; HAIR-CELLS; DEVELOPMENTAL ACQUISITION; SENSORY EPITHELIA; SPIRAL GANGLION; MOTOR PROTEIN; EXPRESSION; MOUSE; PROLIFERATION AB The adult mammalian cochlea lacks regenerative capacity, which is the main reason for the permanence of hearing loss. Vestibular organs, in contrast, replace a small number of lost hair cells. The reason for this difference is unknown. In this work we show isolation of sphere-forming stem cells from the early postnatal organ of Corti, vestibular sensory epithelia, the spiral ganglion, and the stria vascularis. Organ of Corti and vestibular sensory epithelial stem cells give rise to cells that express multiple hair cell markers and express functional ion channels reminiscent of nascent hair cells. Spiral ganglion stem cells display features of neural stem cells and can give rise to neurons and glial cell types. We found that the ability for sphere formation in the mouse cochlea decreases about 100-fold during the second and third postnatal weeks; this decrease is substantially faster than the reduction of stem cells in vestibular organs, which maintain their stem cell population also at older ages. Coincidentally, the relative expression of developmental and progenitor cell markers in the cochlea decreases during the first 3 postnatal weeks, which is in sharp contrast to the vestibular system, where expression of progenitor cell markers remains constant or even increases during this period. Our findings indicate that the lack of regenerative capacity in the adult mammalian cochlea is either a result of an early postnatal loss of stem cells or diminishment of stem cell features of maturing cochlear cells. C1 Stanford Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Stanford, CA 94305 USA. Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA. Marine Biol Lab, Woods Hole, MA 02543 USA. Harvard Univ, Sch Med, Dept Otolaryngol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02114 USA. Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. Univ Virginia, Sch Med, Dept Neurosci, Charlottesville, VA 22908 USA. Univ Virginia, Sch Med, Dept Otolaryngol, Charlottesville, VA 22908 USA. RP Heller, S (reprint author), Stanford Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, 801 Welch Rd, Stanford, CA 94305 USA. EM hellers@stanford.edu FU NIDCD NIH HHS [DC006167, DC006182, DC006183, R01 DC006167, R01 DC006182, R03 DC006183] NR 52 TC 159 Z9 172 U1 1 U2 19 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 1525-3961 J9 JARO-J ASSOC RES OTO JI JARO PD MAR PY 2007 VL 8 IS 1 BP 18 EP 31 DI 10.1007/s10162-006-0058-3 PG 14 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 138UQ UT WOS:000244389200003 PM 17171473 ER PT J AU Smith, ZM Delgutte, B AF Smith, Zachary M. Delgutte, Bertrand TI Using evoked potentials to match interaural electrode pairs with bilateral cochlear implants SO JARO-JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY LA English DT Article DE binaural hearing; electric stimulation; neural prosthesis; cochlear implant; inferior colliculus ID INTRACOCHLEAR ELECTRICAL-STIMULATION; FREQUENCY-PLACE COMPRESSION; AUDITORY CORTICAL IMAGES; BINAURAL INTERACTION; INFERIOR COLLICULUS; SPEECH RECOGNITION; SUPERIOR OLIVE; BRAIN-STEM; CAT; CONFIGURATION AB Bilateral cochlear implantation seeks to restore the advantages of binaural hearing to the profoundly deaf by providing binaural cues normally important for accurate sound localization and speech: reception in noise. Psychophysical observations suggest that a key issue for the implementation of a successful binaural prosthesis is the ability to match the cochlear positions of stimulation channels in each ear. We used a cat model of bilateral cochlear implants with eight-electrode arrays implanted in each cochlea to develop and test a noninvasive method based on evoked potentials for matching interaural electrodes. The arrays allowed the cochlear location of stimulation to be independently varied in each ear. The binaural interaction component (BIC) of the electrically evoked auditory brainstem response (EABR) was used as an assay of binaural processing. BIC amplitude peaked for interaural electrode pairs at the same relative cochlear position and dropped with increasing cochlear separation in either direction. To test the hypothesis' that BIC amplitude peaks when electrodes from the two sides activate maximally overlapping neural populations, we measured multiunit neural activity along the tonotopic gradient of the inferior colliculus (IC) with 16-channel recording probes and determined the spatial pattern of IC activation for each stimulating electrode. We found that the interaural electrode pairings that produced the best aligned IC activation patterns were also those that yielded maximum BIC amplitude. These results suggest that EABR measurements may provide a method for assigning frequency-channel mappings in bilateral implant recipients, such as pediatric patients, for which psychophysical measures of pitch ranking or binaural fusion are unavailable. C1 Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA. Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. Harvard Univ, MIT, Speech & Hearing Biosci & Technol Program, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. MIT, Elect Res Lab, Cambridge, MA 02139 USA. RP Smith, ZM (reprint author), Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA. EM zsmith@jhu.edu RI Smith, Zachary/B-2879-2009; OI Smith, Zachary/0000-0002-0819-4562; , /0000-0003-1349-9608 FU NIDCD NIH HHS [P30 DC005209, R01 DC005775, T32 DC000038, T32 DC00038] NR 45 TC 34 Z9 36 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 1525-3961 J9 JARO-J ASSOC RES OTO JI JARO PD MAR PY 2007 VL 8 IS 1 BP 134 EP 151 DI 10.1007/s10162-006-0069-0 PG 18 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 138UQ UT WOS:000244389200011 PM 17225976 ER PT J AU Wright, TM Myrick, H Malcolm, R Randall, P Boyle, E Henderson, S Anton, R AF Wright, Tara M. Myrick, Hugh Malcolm, Robert Randall, Patrick Boyle, Elizabeth Henderson, Scott Anton, Raymond TI Impact of lifetime alcohol quit attempts and medicated detoxifications on time to relapse during an index alcohol detoxification SO JOURNAL OF ADDICTION MEDICINE LA English DT Article; Proceedings Paper CT 159th Annual Meeting of the American-Psychiatric-Association CY MAY 20-25, 2006 CL Toronto, CANADA SP Amer Psychiat Assoc DE alcohol; drinking history; alcohol withdrawal; detoxifications; relapse ID SUBSEQUENT WITHDRAWAL SEIZURES; COMPULSIVE DRINKING SCALE; KINDLING HYPOTHESIS; SEVERITY; CARBAMAZEPINE; RELIABILITY; CONSUMPTION; INSTRUMENT; EPISODES; HISTORY AB Previous work has shown that multiple medication-treated alcohol detoxifications are associated with poorer treatment outcomes during subsequent detoxifications. Little is known about the impact of nonmedicated attempts to stop drinking outside the realm of these medically supervised detoxifications on acute detoxification outcomes. This study included 58 subjects enrolled in an outpatient detoxification study. Subjects were asked why and how often they quit alcohol for 3 days or longer during their drinking lifetime using concepts derived from the Cognitive Lifetime Drinking History. The effect of previous attempts at abstinence (both medicated and nonmedicated) on time to relapse during an index detoxification was examined. After the index detoxification, older individuals relapsed later than younger individuals and the number of previous medicated detoxifications rather than total lifetime quit attempts per se was related to quicker relapse. Contrary to expectation, those who reported fewer previous nonmedicated quit attempts tended to relapse sooner than those who reported more past quit attempts. This study supports and extends previous work that suggests that the number of previous medicated detoxifications, rather than the total number of past attempts at abstinence, predicts higher and sooner risk for early relapse drinking during outpatient alcohol detoxification. C1 [Wright, Tara M.; Myrick, Hugh; Malcolm, Robert; Randall, Patrick; Boyle, Elizabeth; Henderson, Scott; Anton, Raymond] Med Univ S Carolina, Dept Psychiat & Behav Sci, Ctr Drug & Alcohol Program, Charleston, SC 29425 USA. [Myrick, Hugh] Ralph H Johnson Dept Vet Affairs Med Ctr, Res & Dev Serv, Charleston, SC USA. RP Wright, TM (reprint author), Med Univ S Carolina, Inst Psychiat 4N, 67 President St, Charleston, SC 29425 USA. EM wright@musc.edu NR 31 TC 5 Z9 5 U1 4 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1932-0620 J9 J ADDICT MED JI J. Addict. Med. PD MAR PY 2007 VL 1 IS 1 BP 15 EP 20 DI 10.1097/ADM.0b013e318044ce4f PG 6 WC Substance Abuse SC Substance Abuse GA 303FW UT WOS:000256027400004 PM 21768927 ER PT J AU Cluver, JS Miller, PM Anton, RF AF Cluver, Jeffrey S. Miller, Peter M. Anton, Raymond F. TI Case studies of the utility of serum carbohydrate-deficient transferrin (%CDT) in the clinical management of alcoholics SO JOURNAL OF ADDICTION MEDICINE LA English DT Article DE %CDT; alcohol; biomarkers ID GAMMA-GLUTAMYL-TRANSFERASE; BIOMARKER; MARKERS; SAMPLE AB A laboratory test that measures the percentage of carbohydrate-deficient transferrin (%CDT) has been approved by the FDA for the detection of heavy alcohol use. This biomarker has unique properties and has proven to be a useful tool in multiple clinical settings. It can be used for screening and monitoring purposes in patients with suspected or known alcohol use disorders. We review the use of this test in the management of 5 patients seen in the mental health and substance abuse clinics at a Department of Veterans Affairs Medical Center. C1 [Cluver, Jeffrey S.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Cluver, Jeffrey S.; Miller, Peter M.; Anton, Raymond F.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Cluver, JS (reprint author), Ralph H Johnson Vet Affairs Med Ctr, 109 Bee St, Charleston, SC 29401 USA. EM cluverj@musc.edu NR 17 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1932-0620 J9 J ADDICT MED JI J. Addict. Med. PD MAR PY 2007 VL 1 IS 1 BP 44 EP 47 DI 10.1097/ADM.0b013e3180473c00 PG 4 WC Substance Abuse SC Substance Abuse GA 303FW UT WOS:000256027400009 PM 21768932 ER PT J AU Hunninghake, GM Soto-Quiros, ME Avila, L Ly, NP Liang, C Sylvia, JS Klanderman, BJ Silverman, EK Celedon, JC AF Hunninghake, Gary M. Soto-Quiros, Manuel E. Avila, Lydiana Ly, Ngoc P. Liang, Catherine Sylvia, Jody S. Klanderman, Barbara J. Silverman, Edwin K. Celedon, Juan C. TI Sensitization to Ascaris lumbricoides and severity of childhood asthma in Costa Rica SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Ascaris; helminth; atopy; exacerbation; severity; asthma; Costa Rica ID IMMUNOGLOBULIN-E; GEOHELMINTH INFECTIONS; ALLERGIC SENSITIZATION; ANTHELMINTIC TREATMENT; IGE ANTIBODIES; RURAL AREA; CHILDREN; ATOPY; REACTIVITY; PARASITES AB Background: Little is known about sensitization (defined as a positive IgE) to helminths and disease severity in patients with asthma. Objectives: To examine the relationship between sensitization (defined as a positive IgE) to Ascaris lumbricoides and measures of asthma morbidity and severity in a Costa Rican population with low prevalence of parasitic infection but high prevalence of parasitic exposure. Methods: Cross-sectional study of 439 children (ages 6 to 14 years) with asthma. Linear regression and logistic regression were used for the multivariate statistical analysis. Results: After adjustment for parental education and other covariates, sensitization to Ascaris lumbricoides was associated with having at least 1 positive skin test to allergens (odds ratio, 5.15; 95% CI, 2.36-11.21; P < .001), increased total serum IgE and eosinophils in peripheral blood, reductions in FEV1 and FEV1/forced vital capacity, increased airway responsiveness and bronchodilator responsiveness, and hospitalizations for asthma in the previous year (odds ratio, 3.08; 95% Cl, 1.23-7.68; P = .02). Conclusion: Sensitization to Ascaris lumbricoides is associated with increased severity and morbidity of asthma among children in Costa Rica. This association is likely mediated by an increased degree of atopy among children with asthma who are sensitized to Asearis. Clinical implications: In areas with a low prevalence of helminthiasis such as Costa Rica, Ascaris sensitization may be an important marker of severe atopy and disease morbidity in children with asthma. C1 Channing Labs, Boston, MA 02115 USA. Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Hosp Nacl Ninos Dr Carlos Saenz Herrera, Div Pediat Pulmonol, San Jose, Costa Rica. Massachusetts Gen Hosp, Pediat Pulm Div, Boston, MA 02114 USA. RP Celedon, JC (reprint author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA. EM juan.celedon@channing.harvard.edu FU NHLBI NIH HHS [F32 HL083634, F32 HL083634-01, HL04370, HL66289] NR 41 TC 72 Z9 73 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD MAR PY 2007 VL 119 IS 3 BP 654 EP 661 DI 10.1016/j.jaci.2006.12.609 PG 8 WC Allergy; Immunology SC Allergy; Immunology GA 146HL UT WOS:000244925000019 PM 17336615 ER PT J AU Freyschmidt, EJ Mathias, CB MacArthur, DH Laouar, A Narasimhaswamy, M Weih, F Oettgen, HC AF Freyschmidt, Eva-Jasmin Mathias, Clinton B. MacArthur, Daniel H. Laouar, Amale Narasimhaswamy, Manjunath Weih, Falk Oettgen, Hans C. TI Skin inflammation in RelB(-/-) mice leads to defective immunity and impaired clearance of vaccinia virus SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE eczema vaccination; allergy; vaccinia virus; smallpox vaccination; viral response; cytotoxic T cells; THI/T(H)2 cells ID RESPIRATORY SYNCYTIAL VIRUS; INTERFERON-GAMMA RECEPTOR; NITRIC-OXIDE-SYNTHASE; ATOPIC-DERMATITIS; SMALLPOX VACCINATION; TARGETED DISRUPTION; TRANSGENIC MICE; T-CELLS; IN-VIVO; INTERLEUKIN-4 AB Background: Atopic dermatitis (AD) is an inflammatory skin disorder occurring in genetically predisposed individuals with a systemic T(H)2 bias. Atopic dermatitis patients exposed to the smallpox vaccine, vaccinia virus (VV), occasionally develop eczema vaccinatum (EV), an overwhelming and potentially lethal systemic infection with VV. Objective: To establish a marine model of EV and examine the effects of skin inflammation on VV immunity. Methods: The skin of ReIB-/- mice, like that of chronic AD lesions in humans, exhibits thickening, eosinophilic infiltration, hyperkeratosis, and acanthosis. RelB(-/-) and wild-type (WT) control mice were infected with VV via skin scarification. Viral spread, cytokine levels, IgG2a responses and VV-specific T cells were measured. Results: Cutaneously VV-infected RelB(-/-), but not WT mice, exhibited weight loss, markedly impaired systemic clearance of the virus and increased contiguous propagation from the inoculation site. This was associated with a dramatically impaired generation of IFN-gamma-producing CD8(+) vaccinia-specific T cells along with decreased secretion of IFN-gamma by VV-stimulated splenocytes. The T(H)2 cytokines-IL-4, IL-5, IL-13, and IL-10-on the other hand, were overproduced. When infected intraperitoneally, RelB(-/-) mice generated robust T cell responses with good IFN-gamma production. Conclusion: Allergic inflammation in RelB(-/-) mice is associated with dysregulated immunity to VV encountered via the skin. We speculate that susceptibility of AD patients to overwhelming vaccinia virus infection is similarly related to ineffective T cell responses. Clinical implications: The susceptibility of patients with AD to EV following cutaneous contact with VV is related to ineffective antiviral immune responses. C1 Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Div Immunol, Boston, MA 02115 USA. Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA. Fritz Lipmann Inst, Res Grp Immunol, Jena, Germany. RP Oettgen, HC (reprint author), Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA. EM hans.oettgen@childrens.harvard.edu OI Mathias, Clinton/0000-0002-0223-4842 NR 34 TC 18 Z9 20 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD MAR PY 2007 VL 119 IS 3 BP 671 EP 679 DI 10.1016/j.jaci.2006.12.645 PG 9 WC Allergy; Immunology SC Allergy; Immunology GA 146HL UT WOS:000244925000021 PM 17336617 ER PT J AU Da Silva, N Shum, WWC Marshansky, V Brown, D Breton, S AF Da Silva, Nicolas Shum, Winnie W. C. Marshansky, Vladimir Brown, Dennis Breton., Sylvie TI Proteomic analysis of epididymal clear cells and V-ATPase-associated proteins SO JOURNAL OF ANDROLOGY LA English DT Meeting Abstract CT 32nd Annual Meeting of the American-Society-of-Andrology CY APR 18-24, 2007 CL Tampa, FL SP Amer Soc Androl C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. Div Nephrol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC ANDROLOGY, INC PI LAWRENCE PA C/O ALLEN PRESS, INC PO BOX 368, LAWRENCE, KS 66044 USA SN 0196-3635 J9 J ANDROL JI J. Androl. PD MAR-APR PY 2007 SU S MA 11 BP 41 EP 41 PG 1 WC Andrology SC Endocrinology & Metabolism GA 142LX UT WOS:000244652500014 ER PT J AU Amory, JK Page, ST Anawalt, BD Matsumotol, AM Bremner, WJ AF Amory, John K. Page, Stephanie T. Anawalt, Bradley D. Matsumotol, Alvin M. Bremner, William J. TI Elevated serum INSL3 is associated with failure to completely suppress spermatogenesis in men receiving male hormonal contraception SO JOURNAL OF ANDROLOGY LA English DT Meeting Abstract CT 32nd Annual Meeting of the American-Society-of-Andrology CY APR 18-24, 2007 CL Tampa, FL SP Amer Soc Androl C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. Educ & Clin Ctr, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC ANDROLOGY, INC PI LAWRENCE PA C/O ALLEN PRESS, INC PO BOX 368, LAWRENCE, KS 66044 USA SN 0196-3635 J9 J ANDROL JI J. Androl. PD MAR-APR PY 2007 SU S MA 22 BP 46 EP 46 PG 1 WC Andrology SC Endocrinology & Metabolism GA 142LX UT WOS:000244652500025 ER PT J AU Shum, WWC Da Silva, N Bouley, R El Annan, J Smith, PJS Breton, S AF Shum, Winnie W. C. Da Silva, Nicolas Bouley, Richard El Annan, Jaafar Smith, Peter J. S. Breton, Sylvie TI Involvement of angiotensin II type 2 receptor (AT2) in vacuolar H+-ATPase (V-ATPase)apical insertion and V-ATPase-dependent proton secretion in epididymal clear cells SO JOURNAL OF ANDROLOGY LA English DT Meeting Abstract CT 32nd Annual Meeting of the American-Society-of-Andrology CY APR 18-24, 2007 CL Tampa, FL SP Amer Soc Androl C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Membrane Biol, Boston, MA 02114 USA. Biocurrents Res Ctr, Mol Physiol Program, MBL, Woods Hole, MA 02543 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC ANDROLOGY, INC PI LAWRENCE PA C/O ALLEN PRESS, INC PO BOX 368, LAWRENCE, KS 66044 USA SN 0196-3635 J9 J ANDROL JI J. Androl. PD MAR-APR PY 2007 SU S MA 58 BP 62 EP 62 PG 1 WC Andrology SC Endocrinology & Metabolism GA 142LX UT WOS:000244652500061 ER PT J AU Jonker, SS Zhang, LB Louey, S Giraud, GD Thornburg, KL Faber, JJ AF Jonker, Sonnet S. Zhang, Lubo Louey, Samantha Giraud, George D. Thornburg, Kent L. Faber, J. Job TI Myocyte enlargement, differentiation, and proliferation kinetics in the fetal sheep heart SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE hyperplasia; hypertrophy; terminal differentiation; apoptosis ID CARDIAC MYOCYTES; RAT HEART; MYOCARDIAL APOPTOSIS; CARDIOPLEGIC ARREST; CELL-PROLIFERATION; MOUSE HEART; STEM-CELLS; CARDIOMYOCYTES; FETUS; CORTISOL AB The generation of new myocytes is an essential process of in utero heart growth. Most, or all, cardiac myocytes lose their capacity for proliferation during the perinatal period through the process of terminal differentiation. An increasing number of studies focus on how experimental interventions affect cardiac myocyte growth in the fetal sheep. Nevertheless, fundamental questions about normal growth of the fetal heart remain unanswered. In this study, we determined that during the last third of gestation the hearts of fetal sheep grew primarily by four processes. 1) Myocyte proliferation contributed substantially to daily cardiac mass gain, and the number of cardiac myocytes continued to increase to term. 2) The (hitherto unrecognized) contribution to cardiac growth by the increase in myocyte size associated with the transition from mononucleation to binucleation (terminal differentiation) became considerable from similar to 115 days of gestational age (dGA) until term (145dGA). Because binucleation became the more frequent outcome of myocyte cell cycle activity after similar to 115dGA, the number of binucleated myocytes increased at the expense of the number of mononucleated myocytes. Both the interval between nuclear divisions and the duration of cell cycle activity in myocytes decreased substantially during this same period. Finally, cardiac growth was in part due to enlargement of 3) mononucleated and 4) binucleated myocytes, which grew in cross-sectional diameter but not length during the last third of gestation. These data on normal cardiac growth may enable a more detailed understanding of the consequences of experimental and pathological interventions in prenatal life. C1 Oregon Hlth Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Heart Res Ctr, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. Loma Linda Univ, Sch Med, Dept Pharmacol, Ctr Perinatal Biol, Loma Linda, CA 92350 USA. RP Jonker, SS (reprint author), Univ Iowa, CBRB 1270, 285 Newton Rd, Iowa City, IA 52242 USA. EM sonnet-jonker@uiowa.edu OI Jonker, Sonnet/0000-0002-1097-2562 FU NHLBI NIH HHS [HL-067745]; NICHD NIH HHS [HD-034430] NR 53 TC 58 Z9 58 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD MAR PY 2007 VL 102 IS 3 BP 1130 EP 1142 DI 10.1152/japplphysiol.00937.2006. PG 13 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 143LF UT WOS:000244722400043 PM 17122375 ER PT J AU Wen, Y Feng, J Scott, DR Marcus, EA Sachs, G AF Wen, Yi Feng, Jing Scott, David R. Marcus, Elizabeth A. Sachs, George TI The HP0165-HP0166 two-component system (ArsRS) regulates acid-induced expression of HP1186 alpha-carbonic anhydrase in Helicobacter pylori by activating the pH-dependent promoter SO JOURNAL OF BACTERIOLOGY LA English DT Article ID BACTERIAL PROMOTERS; MUTATIONAL ANALYSIS; UREASE EXPRESSION; ALLELIC EXCHANGE; GENE-EXPRESSION; RNA-POLYMERASE; RESISTANCE; ADAPTATION; INDUCTION; GENOME AB The periplasmic a-carbonic anhydrase of Helicobacter pylori is essential for buffering the periplasm at acidic pH. This enzyme is an integral component of the acid acclimation response that allows this neutralophile to colonize the stomach. Transcription of the HP1186 alpha-carbonic anhydrase gene is upregulated in response to low environmental pH. A binding site for the HP0166 response regulator (ArsR) has been identified in the promoter region of the HP1186 gene. To investigate the mechanism that regulates the expression of HP1186 in response to low pH and the role of the HP0165-HP0166 two-component system (ArsRS) in this acid-inducible regulation, Northern blot analysis was performed with RNAs isolated from two different wild-type H. pylori strains (26695 and 43504) and mutants with HP0165 histidine kinase (ArsS) deletions, after exposure to either neutral pH or low pH (pH 4.5). ArsS-dependent upregulation of HP1186 alpha-carbonic anhydrase in response to low pH was found in both strains. Western blot analysis of H. pylori membrane proteins confirmed the regulatory role of ArsS in HP1186 expression in response to low pH. Analysis of the HP1186 promoter region revealed two possible transcription start points (TSP1 and TSP2) located 43 and 11 bp 5' of the ATG start codon, respectively, suggesting that there are two promoters transcribing the HP1186 gene. Quantitative primer extension analysis showed that the promoter from TSP, (43 bp 5' of the ATG start codon) is a pH-dependent promoter and is regulated by ArsRS in combating environmental acidity, whereas the promoter from TSP2 may be responsible for control of the basal transcription of HP1186 alpha-carbonic anhydrase. C1 Univ Calif Los Angeles, Membrane Biol Lab, Dept Physiol, David Geffen Sch Med, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Wen, Y (reprint author), 11301 Wilshire Blvd,Bldg 113,Rm 324, Los Angeles, CA 90073 USA. EM ywen@ucla.edu FU NIDDK NIH HHS [R01 DK046917, DK58333, DK53462, DK46917] NR 56 TC 25 Z9 29 U1 1 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD MAR PY 2007 VL 189 IS 6 BP 2426 EP 2434 DI 10.1128/JB.01492-06 PG 9 WC Microbiology SC Microbiology GA 147EG UT WOS:000244985600025 PM 17220228 ER PT J AU Boutrus, S Greiner, C Hwu, D Chan, M Kuperwasser, C Lin, CP Georgakoudi, I AF Boutrus, Steven Greiner, Cherry Hwu, Derrick Chan, Michael Kuperwasser, Charlotte Lin, Charles P. Georgakoudi, Irene TI Portable two-color in vivo flow cytometer for real-time detection of fluorescently-labeled circulating cells SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE in vivo cytometry; confocal optics; circulating cancer cells; circulating stem cells; fluorescence; cancer; flow cytometry; confocal detection ID CANCER-CELLS AB The recent introduction of the in vivo flow cytometer for real-time, noninvasive detection and quantification of cells circulating in the vasculature of small animals has provided a powerful tool for tracking the roles of different types of cells in disease progression. We describe a portable version of the device, which provides the capability to: a) excite and detect fluorescence at two distinct colors simultaneously, and b) perform data analysis in real time. These advances improve significantly the utility of the instrument and provide a means of increasing detection specificity. As examples, we present the depletion kinetics of circulating green fluorescent protein (GFP) labeled breast cancer cells in the vasculature of mice, and the specific detection of circulating hematopoietic stem cells labeled in vivo with two antibodies. (C) 2007 Society of Photo-Optical Instrumentation Engineers. C1 Tufts Univ, Biomed Engn Dept, Medford, MA 02155 USA. Tufts Univ New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA. Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Tufts New England Med Ctr, Boston, MA 02111 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Georgakoudi, I (reprint author), Tufts Univ, Biomed Engn Dept, Medford, MA 02155 USA. EM irene.georgakoudi@tufts.edu FU NEI NIH HHS [EY14106, R01 EY014106]; NIBIB NIH HHS [EB000664, R01 EB000664, R01 EB000664-02] NR 9 TC 33 Z9 33 U1 1 U2 10 PU SPIE-SOCIETY PHOTOPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD MAR-APR PY 2007 VL 12 IS 2 AR 020507 DI 10.1117/1.2722733 PG 3 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 173FW UT WOS:000246859900006 PM 17477705 ER PT J AU Vakoc, BJ Tearney, GJ Bouma, BE AF Vakoc, Benjamin J. Tearney, Guillermo J. Bouma, Brett E. TI Real-time microscopic visualization of tissue response to laser thermal therapy SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE laser thermal therapy; tissue response; optical frequency domain; laser damage ID OPTICAL COHERENCE TOMOGRAPHY; BLOOD; SKIN AB We present methods for visualizing the dynamic response of biological samples to laser-induced heating. Our approach utilizes optical frequency-domain imaging to detect, spatially localize, and monitor unique dynamic signatures that arise within zones of active tissue denaturation. Since this information is precisely registered with high-resolution (similar to 10 mu m) cross sectional images, regions of thermally destroyed tissue can be mapped in relation to pre-existing morphology. Using porcine esophageal specimens ex vivo, we demonstrate that the extent and evolution of laser thermal damage can be assessed in real time. (C) 2007 Society of Photo-Optical Instrumentation Engineers. C1 Harvard Univ, Sch Med, Boston, MA 02114 USA. Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Vakoc, BJ (reprint author), Harvard Univ, Sch Med, 55 Fruit St BAR 703, Boston, MA 02114 USA. EM bvakoc@partners.org FU NCI NIH HHS [1R21CA125560] NR 10 TC 23 Z9 23 U1 0 U2 4 PU SPIE-SOCIETY PHOTOPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD MAR-APR PY 2007 VL 12 IS 2 AR 020501 DI 10.1117/1.2714027 PG 3 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 173FW UT WOS:000246859900001 PM 17477700 ER PT J AU Matthews, F Trentz, O Jacob, AL Kikinis, R Jupiter, JB Messmer, P AF Matthews, Felix Trentz, Otmar Jacob, Augustinus Ludwig Kikinis, Ron Jupiter, Jesse B. Messmer, Peter TI Protrusion of hardware impairs forearm rotation after olecranon fixation - A report of two cases SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID FRACTURE FIXATION; TENSION; OSTEOTOMY; ELBOW C1 Harvard Univ, Surg Planning Lab, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Zurich Hosp, Div Trauma Surg, Dept Surg, CH-8091 Zurich, Switzerland. Univ Basel Hosp, Dept Radiol, CH-4031 Basel, Switzerland. Massachusetts Gen Hosp, Hand & Upper Extrem Serv, Dept Orthopaed Surg, Boston, MA 02114 USA. RP Matthews, F (reprint author), Harvard Univ, Surg Planning Lab, Sch Med, Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. EM peter.messnier@usz.ch NR 11 TC 12 Z9 12 U1 0 U2 0 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD MAR PY 2007 VL 89A IS 3 BP 638 EP 642 DI 10.2106/JBJS.E.01238 PG 5 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 143OG UT WOS:000244731400024 PM 17332114 ER PT J AU Silver, GM Mein, MB Herndon, DN Gamelli, RL Gibran, NS Altstein, L McDonald-Smith, GP Tompkins, RG Hunt, JL AF Silver, Geoffrey M. Mein, Matthew B. Herndon, David N. Gamelli, Richard L. Gibran, Nicole S. Altstein, Lily McDonald-Smith, Grace P. Tompkins, Ronald G. Hunt, John L. CA Inflammation Host Response Trauma TI Standard operating procedures for the clinical management of patients enrolled in a prospective study of inflammation and the host response to thermal injury SO JOURNAL OF BURN CARE & RESEARCH LA English DT Article ID FLUID RESUSCITATION; INSULIN-RESISTANCE; MUSCLE AB A's part of the National Institutes of General Medical Sciences (NIGMS)-fanded Inflammation and the Host Response to Injury study, participating investigators created a database, a clinical data collection protocol, and web-based case report form. To obtain high-quality clinical endpoints for correlation with genomic data, a uniform approach to patient management between centers was required. Standard operating procedures (SOPs) were generated to minimize variability and promote a uniform standard of patient care. The SOPs are necessary to enable validation of the clinical endpoints to be used for comparison with genomic and proteomic information derived from samples of blood and tissue obtained from thermally injured patients. Participating investigators identified areas of potential practice variation and developed a set of SOPs based on available data and sound clinical principles. In the absence of sufficient clinical data to identify a single management strategy, SOPs were designed to apply the best approach to management without interfering with local standards of care. The data-collection instrument, or case report form, was constructed concurrently with the SOPs. Wherever possible, the case report form was modified to collect data that might resolve controversial management issues. Modifications in management strategies that were necessary for children are delineated as needed. Data queries and site visits were conducted to audit compliance. SOPs for 10 areas of clinical care were developed. The institution of the SOPs required minor changes in clinical practice patterns and personnel training but did not require participating centers to procure new technology or alter the utilization of clinical resources significantly. The SOPs represent current management strategies applied to the study population to reduce variation in patient management. The SOPs are easily adaptable to other burn-related clinical protocols as well as to the routine daily management burn patients. C1 Loyola Univ, Stritch Sch Med, Dept Surg, Maywood, IL 60153 USA. Univ Washington, Sch Med, Dept Surg, Harborview Med Ctr, Seattle, WA 98195 USA. Shriners Burns Hosp, Galveston, TX USA. Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA. Loyola Univ, Stritch Sch Med, Dept Surg, Maywood, IL 60153 USA. Univ Washington, Sch Med, Dept Surg, Burn Ctr Harborview,Harborview Med Ctr, Seattle, WA 98195 USA. Univ Calif San Diego, Dept Epidemiol, San Diego, CA 92103 USA. Massachusetts Gen Hosp, Dept Surg, MGH Burn Serv, Boston, MA 02114 USA. Univ Texas, SW Med Ctr, Burn Ctr, Dallas, TX USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Silver, GM (reprint author), Loyola Univ, Stritch Sch Med, Dept Surg, 2160 S 1st Ave, Maywood, IL 60153 USA. FU NIGMS NIH HHS [U54 GM062119] NR 13 TC 27 Z9 28 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1559-047X J9 J BURN CARE RES JI J. Burn Care Res. PD MAR-APR PY 2007 VL 28 IS 2 BP 222 EP 230 DI 10.1097/BCR.0B013E318031AA44 PG 9 WC Emergency Medicine; Dermatology; Surgery SC Emergency Medicine; Dermatology; Surgery GA 142BF UT WOS:000244622800004 PM 17351437 ER PT J AU Prelack, K Dwyer, J Dallal, GE Rand, WM Yu, YM Kehayias, JJ Antoon, A Sheridan, RL AF Prelack, Kathy Dwyer, Johanna Dallal, Gerry E. Rand, William M. Yu, Yong-Ming Kehayias, Joseph J. Antoon, Alia Sheridan, Robert L. TI Growth deceleration and restoration after serious burn injury SO JOURNAL OF BURN CARE & RESEARCH LA English DT Article ID CATCH-UP GROWTH; VITAMIN-D; CHILDREN; DEPLETION; DELAY AB There is a common perception that burned children are at risk for growth deceleration. However, because the prevalence, duration, and degree of this stereotypic growth are poorly described, making informed decisions about treatment is difficult. This article describes the natural history of growth after burn injury, according to the findings of a retrospective review conducted in a regional pediatric burn center. The study population comprised children younger than 13 years at the time of injury, who survived. burns involving 2 +/- 30% TBSA. Main outcome measures were height and weight; values obtained upon admission for burn injury and at all subsequent hospital admissions were converted to height-for-age and weight-for-age Z scores with use of a reference standard. Z scores were then used to determine whether baseline height and weight status (according to initial admission data) were recouped after burn injury. Medical records of 159 patients (2910 admissions) were reviewed. Children with massive burns (>= 50% TBSA) had height-for-age Z scores that were significantly below their baseline average for all years studied (mean fall in Zscore units of 0.50-0.76; P < .0001). This decline in height-for-age Z scores represented a deficit of 1.6 to 5.8 cm. Seventeen patients (11%) had height-for-age Z scores consistent with stunting. Weight-for-age Z scores were not statistically lower than the reference standard, except for patients with massive burns up to 1.5 years post-burn. In our population of burned children, only massively burned children demonstrated a decline in stature. The decline for most was modest. C1 Shriners Hosp Children, Nutr Support, Boston, MA 02114 USA. Tufts Univ, New England Med Ctr, Frances Stern Nutr Ctr, Medford, MA 02155 USA. Tufts Univ, Friedman Sch Nutr Sci & Policy, Jean Mayer USDA Human Nutr Res Ctr Aging, Medford, MA 02155 USA. Tufts Univ, Sch Med, Medford, MA 02155 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Prelack, K (reprint author), Shriners Hosp Children, Nutr Support, 51 Blossom St, Boston, MA 02114 USA. OI Dwyer, Johanna/0000-0002-0783-1769 NR 28 TC 8 Z9 9 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1559-047X J9 J BURN CARE RES JI J. Burn Care Res. PD MAR-APR PY 2007 VL 28 IS 2 BP 262 EP 268 DI 10.1097/BCR.0B013E318031A183 PG 7 WC Emergency Medicine; Dermatology; Surgery SC Emergency Medicine; Dermatology; Surgery GA 142BF UT WOS:000244622800010 PM 17351443 ER PT J AU Matloff, ET Shannon, KM Moyer, A Col, NF AF Matloff, Ellen T. Shannon, Kristen M. Moyer, Anne Col, Nananda F. TI Should menopausal women at increased risk for breast cancer use tamoxifen, raloxifene, or hormone therapy?: A framework for personalized risk assessment and counseling SO JOURNAL OF CANCER EDUCATION LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL WOMEN; DECISION-MAKING; AROMATASE INHIBITORS; REPLACEMENT THERAPY; FAMILY-HISTORY; PREVENTION; SYMPTOMS; ESTROGEN; INTERVENTION AB Background. Menopausal women with a family history of breast cancer have several treatment options, including tamoxifen, raloxifene, and hormone therapy. This complex decision should be based on each woman's risk to develop breast cancer, menopausal symptoms, preferences, and risks for other conditions. Current models in use do not include pedigree analysis, personalized risk assessment, or genetic testing in this process. Methods. We created a personalized risk assessment and genetic counseling intervention for healthy women with a first-degree relative with breast cancer. Participants were given a personalized risk assessment for breast cancer, heart disease, osteoporosis, and uterine cancer based on family history and personal health data. Counseling Model. The effectiveness of this novel genetic counseling intervention was demonstrated in a randomized trial and these results are published elsewhere. The framework for this counseling model, with case examples from the clinical trial, is outlined in this article. Conclusions. As more menopausal therapies are developed, each with its own risks and benefits, it will become even more critical to have a personalized counseling model for use in this process. Clinicians and educators can utilize the framework presented here for counseling women with a family history of breast cancer. C1 Yale Univ, Ctr Canc, Sch Med, New Haven, CT 06520 USA. Massachusetts Gen Hosp, Ctr Canc Risk Anal, Boston, MA 02114 USA. SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11794 USA. Brown Univ, Sch Med, Providence, RI 02912 USA. Rhode Isl Hosp, Providence, RI 02903 USA. RP Matloff, ET (reprint author), Yale Univ, Ctr Canc, Sch Med, 55 Church St,Suite 402, New Haven, CT 06520 USA. EM ellen.matloff@yale.edu NR 34 TC 4 Z9 4 U1 1 U2 1 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 0885-8195 J9 J CANCER EDUC JI J. Cancer Educ. PD SPR PY 2007 VL 22 IS 1 BP 10 EP 14 PG 5 WC Oncology; Education, Scientific Disciplines; Public, Environmental & Occupational Health SC Oncology; Education & Educational Research; Public, Environmental & Occupational Health GA 192XK UT WOS:000248236900005 PM 17570802 ER PT J AU Wray, RJ Stryker, JE Winer, E Emmons, KM Demetri, G AF Wray, Ricardo J. Stryker, Jo Ellen Winer, Eric Emmons, Karen M. Demetri, George TI Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations SO JOURNAL OF CANCER EDUCATION LA English DT Article ID ONCOLOGY; PERSPECTIVES; STATEMENT; QUALITY AB Background. Accepted practices of informed consent often result in suboptimal patient understanding of research studies. Methods. This pilot study aimed to assess trial-specific tailored materials, compared to a widely used generic booklet about clinical trials, randomly assigned to 118 candidates for cancer clinical trials. Study outcomes were: satisfaction with decision-making; satisfaction with materials; and subjective understanding of the clinical trial. Results. There were no major differences between groups. Participants rated tailored materials higher as a useful reference. Conclusions. Trial-specific materials hold utility for reference during clinical trials. Studies of informed consent are feasible, although important factors limit research. C1 St Louis Univ, Sch Publ Hlth, Dept Community Hlth, St Louis, MO 63104 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Emory Univ, Sch Publ Hlth, Atlanta, GA 30322 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA. RP Wray, RJ (reprint author), St Louis Univ, Sch Publ Hlth, Dept Community Hlth, 3545 Lafayette Ave,Room 411, St Louis, MO 63104 USA. EM wray@slu.edu NR 20 TC 12 Z9 12 U1 0 U2 1 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 0885-8195 J9 J CANCER EDUC JI J. Cancer Educ. PD SPR PY 2007 VL 22 IS 1 BP 21 EP 24 PG 4 WC Oncology; Education, Scientific Disciplines; Public, Environmental & Occupational Health SC Oncology; Education & Educational Research; Public, Environmental & Occupational Health GA 192XK UT WOS:000248236900007 PM 17570804 ER PT J AU Bober, SL Park, ER Schmookler, T Nancarrow, CM Diller, L AF Bober, Sharon L. Park, Elyse R. Schmookler, Terra Nancarrow, Cheryl Medeiros Diller, Lisa TI Perceptions of breast cancer risk and cancer screening: A qualitative study of young, female Hodgkin's disease survivors SO JOURNAL OF CANCER EDUCATION LA English DT Article; Proceedings Paper CT 2nd Annual Conference of the American-Psychosocial-Oncology-Society CY JAN 27-29, 2005 CL Phoenix, AZ SP Amer Psychosocial Oncol Soc ID 2ND CANCERS; CHILDHOOD; ADOLESCENCE; NEOPLASMS; WOMEN; CARE AB Background. Young female Hodgkins Disease (HD) survivors are at high risk for breast cancer following chest irradiation. We explored health perceptions, screening behaviors, and barriers of this population. Methods. Three focus groups and nine individual interviews (n = 22) were conducted. Results. Women expressed significant misperceptions about breast cancer risk and screening. Screening barriers included avoidance, insurance issues, and lack of physician support. Conclusion. Female HD survivors would likely benefit from tailored education that links current beliefs with their previous cancer experience. Education about cancer risk may be more effective if delivered in a health-promoting rather than disease -detection framework. C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Bober, SL (reprint author), Dana Farber Canc Inst, Dana 321,44 Binney St, Boston, MA 02115 USA. EM Sharon_bober@dfci.harvard.edu NR 17 TC 8 Z9 8 U1 1 U2 4 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 0885-8195 J9 J CANCER EDUC JI J. Cancer Educ. PD SPR PY 2007 VL 22 IS 1 BP 42 EP 46 PG 5 WC Oncology; Education, Scientific Disciplines; Public, Environmental & Occupational Health SC Oncology; Education & Educational Research; Public, Environmental & Occupational Health GA 192XK UT WOS:000248236900011 PM 17570808 ER PT J AU Thiagalingam, A D'Avila, A McPherson, C Malchano, Z Ruskin, J Reddy, VY AF Thiagalingam, Aravinda D'Avila, Andre McPherson, Christina Malchano, Zachary Ruskin, Jeremy Reddy, Vivek Y. TI Impedance and temperature monitoring improve the safety of closed-loop irrigated-tip radiofrequency ablation SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article DE ablation; arrhythmia; catheterization; electrophysiology; atrial fibrillation; ventricular tachycardia ID CATHETER ABLATION; LESION SIZE; ELECTRODE; HUMANS AB Introduction: Irrigated-tip catheter ablation allows larger ablation lesions to be created, but also decreases catheter temperature monitoring accuracy. It is unclear which parameters should be monitored to optimize efficacy and safety during irrigated-tip ablation. Methods and Results: Freshly excised hearts from eight male pigs were perfused and superfused using oxygenated swine blood in an ex vivo model. Ablations were performed for 1 minute using one of five different ablation protocols: (1) Temperature Control (42 degrees C 40 W), (2) Fixed Power 20 W, (3) Fixed Power 30 W, (4) Impedance Control (target 10 Omega impedance drop), and (5) Impedance Control (target 20 Omega drop). All ablations were performed with a perpendicular orientation of the catheter to the endocardial surface. Ablation lesions depth was significantly lower in the temperature control group (5.0 +/- 1.7 mm) compared with the fixed power ablation groups (6.5 +/- 1.0 mm for Power 20 W, 6.6 +/- 1.2 mm for Power 30 W). Impedance-controlled ablation created lesions intermediate in depth between fixed power and temperature controlled (6.0 +/- 1.6 for Impedance 10 Omega and 6.2 +/- 1.4 mm for Impedance 20 Omega groups). There was a significantly greater incidence of pops and thrombus formation in the Power 20 W (9/14), Power 30 W (10/14), and Impedance 20 Omega (10/16) groups than the Temperature Control (1/16) and Impedance control 10 Omega (2/16) groups. Conclusion: Temperature control improved the safety profile during irrigated-tip ablation in comparison with fixed-power ablations, but resulted in significantly smaller lesions. Impedance-controlled ablation lesions (target 10 Omega drop) created lesions of comparable size to fixed-power ablations with a significantly better safety profile. C1 Massachusetts Gen Hosp, Dept Cardiac Electrophysiol, Boston, MA 02114 USA. RP Thiagalingam, A (reprint author), Massachusetts Gen Hosp, Dept Cardiac Electrophysiol, 55 Fruit St, Boston, MA 02114 USA. EM athiagalingam@partners.org RI d'Avila, Andre Luiz/F-8009-2010; d'Avila, Andre/A-7693-2009 OI d'Avila, Andre Luiz/0000-0001-8769-1411; NR 12 TC 23 Z9 23 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1045-3873 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD MAR PY 2007 VL 18 IS 3 BP 318 EP 325 DI 10.1111/j.1540-8167.2006.00745.x PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 145UZ UT WOS:000244892600016 PM 17313656 ER PT J AU Stuart-Shor, EM Forman, DE AF Stuart-Shor, Eileen M. Forman, Daniel E. TI Progress in prevention - Resistant or difficult-to-control hypertension - An opportunity for prevention SO JOURNAL OF CARDIOVASCULAR NURSING LA English DT Editorial Material ID CARDIOVASCULAR RISK; BLOOD-PRESSURE; CORONARY; DISEASE C1 Univ Massachusetts, Boston Coll Nursing & Hlth Sci, Boston, MA 02125 USA. Beth Israel Deaconess Med Ctr, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. Brigham & Womens Hosp, New England GRECC, VA Boston Hlth Care Syst, Cardiac Rehab & Exercise Testing Lab, Boston, MA 02115 USA. RP Stuart-Shor, EM (reprint author), Univ Massachusetts, Boston Coll Nursing & Hlth Sci, 100 Morrissey Blvd, Boston, MA 02125 USA. EM eileen.stuart-shor@umb.edu NR 9 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0889-4655 J9 J CARDIOVASC NURS JI J. Cardiovasc. Nurs. PD MAR-APR PY 2007 VL 22 IS 2 BP 105 EP 106 PG 2 WC Cardiac & Cardiovascular Systems; Nursing SC Cardiovascular System & Cardiology; Nursing GA 146GD UT WOS:000244921600014 PM 17318035 ER PT J AU Hirai, M Ohbayashi, T Horiguchi, M Okawa, K Hagiwara, A Chien, KR Kita, T Nakamura, T AF Hirai, Maretoshi Ohbayashi, Tetsuya Horiguchi, Masahito Okawa, Katsuya Hagiwara, Akari Chien, Kenneth R. Kita, Toru Nakamura, Tomoyuki TI Fibulin-5/DANCE has an elastogenic organizer activity that is abrogated by proteolytic cleavage in vivo SO JOURNAL OF CELL BIOLOGY LA English DT Article ID ELASTIN-BINDING PROTEIN; LYSYL OXIDASE; FIBER; MICE; COACERVATION; TROPOELASTIN; FIBRILLIN-1; DEFICIENCY; MECHANISMS; INVITRO AB Elastic fibers are required for the elasticity and integrity of various organs. We and others previously showed that fibulin-5 (also called developing arteries and neural crest EGF-like [DANCE] or embryonic vascular EGF-like repeat - containing protein [EVEC]) is indispensable for elastogenesis by studying. bulin-5 - deficient mice, which recapitulate human aging phenotypes caused by disorganized elastic fibers (Nakamura, T., P.R. Lozano, Y. Ikeda, Y. Iwanaga, A. Hinek, S. Minamisawa, C.F. Cheng, K. Kobuke, N. Dalton, Y. Takada, et al. 2002. Nature. 415: 171 - 175; Yanagisawa, H., E.C. Davis, B.C. Starcher, T. Ouchi, M. Yanagisawa, J.A. Richardson, and E. N. Olson. 2002. Nature. 415: 168 - 171). However, the molecular mechanism by which fiblin-5 contributes to elastogenesis remains unknown. We report that fibulin-5 protein potently induces elastic fiber assembly and maturation by organizing tropoelastin and cross-linking enzymes onto microfibrils. Deposition of fibulin-5 on microfibrils promotes coacervation and alignment of tropoelastins on microfibrils, and also facilitates cross-linking of tropoelastin by tethering lysyl oxidase-like 1, 2, and 4 enzymes. Notably, recombinant fibulin-5 protein induced elastogenesis even in serum-free conditions, although elastogenesis in cell culture has been believed to be serum-dependent. Moreover, the amount of full-length fibulin-5 diminishes with age, while truncated fibulin-5, which cannot promote elastogenesis, increases. These data suggest that fibulin-5 could be a novel therapeutic target for elastic fiber regeneration. C1 Horizontal Med Res Org, Kyoto 6068501, Japan. Horizontal Med Res Org, Kyoto 6068501, Japan. Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto 6068501, Japan. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02114 USA. RP Nakamura, T (reprint author), Horizontal Med Res Org, Kyoto 6068501, Japan. EM nakatomo@kuhp.kyoto-u.ac.jp NR 31 TC 85 Z9 90 U1 0 U2 3 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA SN 0021-9525 J9 J CELL BIOL JI J. Cell Biol. PD MAR PY 2007 VL 176 IS 7 BP 1061 EP 1071 DI 10.1083/jcb.200611026 PG 11 WC Cell Biology SC Cell Biology GA 150JB UT WOS:000245211200015 PM 17371835 ER PT J AU Martini, SR Kent, TA AF Martini, Sharyl R. Kent, Thomas A. TI Hyperglycemia in acute ischemic stroke: a vascular perspective SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Review DE acute; glucose; hyperglycemia; outcome; reperfusion; stroke ID NITRIC-OXIDE SYNTHASE; PLASMINOGEN-ACTIVATOR INHIBITOR-1; FOCAL CEREBRAL-ISCHEMIA; SMOOTH-MUSCLE-CELLS; PROTEIN-KINASE-C; NF-KAPPA-B; GLUCAGON-LIKE PEPTIDE-1; HUMAN ENDOTHELIAL-CELLS; HIGH GLUCOSE-CONCENTRATIONS; BLOOD-GLUCOSE AB Admission hyperglycemia complicates approximately one- third of acute ischemic strokes and is associated with a worse clinical outcome. Both human and animal studies have showed that hyperglycemia is particularly detrimental in ischemia/ reperfusion. Decreased reperfusion blood flow has been observed after middle cerebral artery occlusion in acutely hyperglycemic animals, suggesting the vasculature as an important site of hyperglycemic reperfusion injury. This paper reviews biochemical and molecular pathways in the vasculature that are rapidly affected by hyperglycemia and concludes that these changes result in a pro- vasoconstrictive, pro- thrombotic and proinflammatory phenotype that renders the vasculature vulnerable to reperfusion injury. Understanding these pathways should lead to the development of rational therapies that reduce hyperglycemic reperfusion injury and thus improve outcome in this large subset of acute ischemic stroke patients. C1 Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Stroke Program, Houston, TX USA. RP Kent, TA (reprint author), Baylor Coll Med, Dept Neurol, 2002 Holcombe Blvd MS127, Houston, TX 77030 USA. EM tkent@bcm.tmc.edu OI Kent, Thomas/0000-0002-9877-7584 FU NINDS NIH HHS [R01 NS 42078-01A1] NR 160 TC 93 Z9 106 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD MAR PY 2007 VL 27 IS 3 BP 435 EP 451 DI 10.1038/sj.jcbfm.9600355 PG 17 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 138TX UT WOS:000244387100001 PM 16804552 ER PT J AU Tejima, E Zhao, BQ Tsuji, K Rosell, A van Leyen, K Gonzalez, RG Montaner, J Wang, XY Lo, EH AF Tejima, Emiri Zhao, Bing-Qiao Tsuji, Kiyoshi Rosell, Anna van Leyen, Klaus Gonzalez, R. Gilberto Montaner, Joan Wang, Xiaoying Lo, Eng H. TI Astrocytic induction of matrix metalloproteinase-9 and edema in brain hemorrhage SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article ID FOCAL CEREBRAL-ISCHEMIA; EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; TUFTSIN FRAGMENT 1-3; SPINAL-CORD-INJURY; GENE KNOCK-OUT; MATRIX METALLOPROTEINASES; BARRIER DISRUPTION; BLOOD-FLOW; CELL-DEATH; ACTIVATED MATRIX-METALLOPROTEINASE-9 AB We tested the hypothesis that astrocytic matrix metalloproteinase- 9 ( MMP- 9) mediates hemorrhagic brain edema. In a clinical case of hemorrhagic stroke, MMP- 9 co-localized with astrocytes and neurons in peri-hematoma areas. In a mouse model where blood was injected into striatum, MMP- 9 was colocalized with astrocytes surrounding the hemorrhagic lesion. Because MMP- 9 is present in blood as well as brain, we compared four groups of wild type (WT) and MMP- 9 knockout ( KO) mice: WT blood injected into WT brain, KO blood into KO brain, WT blood into KO brain, and KO blood into WT brain. Gel zymography showed that MMP- 9 was elevated in WT hemorrhagic brain tissue but absent from KO hemorrhagic brain tissue. Edematous water content was elevated when WT blood was injected into WT brain. However, edema was ameliorated when MMP- 9 was absent in either blood or brain or both. To further assess the mechanisms involved in astrocytic induction of MMP- 9, we next examined primary mouse astrocyte cultures. Exposure to hemoglobin rapidly upregulated MMP- 9 in conditioned media within 1 to 24 h. Hemoglobin- induced MMP- 9 was reduced by the free radical scavenger U83836E. Taken together, these data suggest that although there are large amounts of MMP- 9 in blood, hemoglobin- induced oxidative stress can trigger MMP- 9 in astrocytes and these parenchymal sources of matrix degradation may also be an important factor in the pathogenesis of hemorrhagic brain edema. C1 Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Neurol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA. Hosp Gen Valle Hebron, Lab Invest Neurovasc, Barcelona, Spain. Massachusetts Gen Hosp, Dept Radiol, Div Neuroradiol, Boston, MA 02114 USA. RP Lo, EH (reprint author), Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol, CNY 2401,East 149-2401, Charlestown, MA 02129 USA. EM Lo@helix.mgh.harvard.edu RI van Leyen, Klaus/C-9126-2013; Montaner, Joan/D-3063-2015; IBIS, NEUROVASCULAR/O-1855-2015 FU NINDS NIH HHS [R01-NS37074, P50-NS10828, R01-NS38731, R01-NS40529] NR 61 TC 87 Z9 96 U1 1 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD MAR PY 2007 VL 27 IS 3 BP 460 EP 468 DI 10.1038/sj.jcbfm.9600354 PG 9 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 138TX UT WOS:000244387100003 PM 16788715 ER PT J AU Aravagiri, M Marder, SR Pollock, B AF Aravagiri, Manickam Marder, Stephen R. Pollock, Bruce TI Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES LA English DT Article DE ziprasidone; LC-MS-MS; schizophrenia patients; plasma analysis; ziprasidone levels ID ANTIPSYCHOTIC-DRUG ZIPRASIDONE; METABOLISM; EXTRACTION; CP-88,059; EXCRETION; WEIGHT; AGENT AB An accurate, rapid and simple liquid chromatography-tandem mass spectrometry (LC-MS-MS) assay method was developed for the determination of ziprasidone (ZIP) in the plasma of schizophrenia patients. A simple one step liquid-liquid extraction with 20% methylene dichloride in pentane was used to isolate ZIP and the internal standard from the plasma matrix. The compounds were separated on a C-18 column by an isocratic elution and the eluted compounds were analyzed by a triple quadrupole mass spectrometer with a Turbolon spray interface using the positive ion atmospheric pressure electrospray ionization method and detected using multiple reaction monitoring mode. The ZIP standard calibration curve was linear over the range of 0.25-500 ng/ml when 0.5 ml of plasma was used for the analysis (r(2) > 0.998). The intra-assay (within-day) and inter-assay (between-day) variations were less than 12% for the spiked standard curve and quality control samples. The absolute extraction efficiency was 82% for ZIP and 68% for INS-RSP. The analysis time for each sample was less than 3 min and useful for high turnaround plasma level determinations. This LC-MS-MS assay method for ZIP is highly specific, sensitive, accurate and rapid and is currently being used for the plasma level determination of ZIP in schizophrenia patients treated with various daily oral doses of ZIP. The data showed large inter-individual variations. (c) 2006 Elsevier B.V. All rights reserved. C1 Univ Calif Los Angeles, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. Univ Pittsburgh, Geriatr Psychopharmacol Program, Pittsburgh, PA 15260 USA. Univ Toronto, Rotman Res Inst, Toronto, ON M4X 1K9, Canada. RP Aravagiri, M (reprint author), Univ Calif Los Angeles, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. EM kannan@ucla.edu FU NIMH NIH HHS [N01MH90001, MH064173, MH41573] NR 21 TC 18 Z9 20 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1570-0232 J9 J CHROMATOGR B JI J. Chromatogr. B PD MAR 1 PY 2007 VL 847 IS 2 BP 237 EP 244 DI 10.1016/j.jchromb.2006.10.024 PG 8 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 152UN UT WOS:000245387600022 PM 17098485 ER PT J AU Alston, TA AF Alston, Theodore A. TI Nitrous or nitric? Same difference. Molecular formulas in the 1840s SO JOURNAL OF CLINICAL ANESTHESIA LA English DT Article DE chloroform; J Dalton; JBA Dumas; nitrous oxide; JY Simpson ID OXIDE AB The molecular formulas given by James Y. Simpson for nitrous oxide, diethyl ether, and chloroform are difficult to interpret today. The organic formulas are "incorrect" today because Jean Dumas (the influential chemist who was one of the discoverers of chloroform) used John Dalton's presumption of molecular simplicity. That is, water was long presumed to be HO. The nitrous oxide formula was incorrect owing to confusion with Dalton's nitrous gas, now termed nitric oxide. The Simpson formulas illustrate that inhaled anesthesia arrived at the time of a cusp in the history of chemistry. (c) 2007 Elsevier Inc. All rights reserved. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. RP Alston, TA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. EM talston@partners.org NR 12 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0952-8180 J9 J CLIN ANESTH JI J. Clin. Anesth. PD MAR PY 2007 VL 19 IS 2 BP 159 EP 161 DI 10.1016/j.jclinane.2006.08.009 PG 3 WC Anesthesiology SC Anesthesiology GA 155WJ UT WOS:000245609000018 PM 17379133 ER PT J AU Levitsky, LL AF Levitsky, Lynne L. TI Defining the role of IGF-I therapy for short children SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Editorial Material ID GROWTH-FACTOR-I; CLINICAL ENDOCRINOLOGY; ACTION DISORDERS; RECLASSIFICATION; CONTROVERSY C1 Massachusetts Gen Hosp, Pediat Endocrine Unit Bartlett 410x, Boston, MA 02114 USA. RP Levitsky, LL (reprint author), Massachusetts Gen Hosp, Pediat Endocrine Unit Bartlett 410x, Boston, MA 02114 USA. EM llevitsky@partners.org NR 10 TC 0 Z9 0 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAR PY 2007 VL 92 IS 3 BP 813 EP 814 DI 10.1210/jc.2007-0087 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 143LA UT WOS:000244721900012 PM 17341577 ER PT J AU Fox, E Daskal, FC Stocking, C AF Fox, Ellen Daskal, Frona C. Stocking, Carol TI Ethics consultants' recommendations for life-prolonging treatment of patients in persistent vegetative state: A follow-up study SO JOURNAL OF CLINICAL ETHICS LA English DT Article ID MEDICAL ASPECTS; GOALS C1 US Dept Vet Affairs, Natl Ctr Eth Hlth Care, Washington, DC USA. Univ Chicago, MacLean Ctr Clin Med Eth, Chicago, IL 60637 USA. RP Fox, E (reprint author), US Dept Vet Affairs, Natl Ctr Eth Hlth Care, Washington, DC USA. EM Foxe2@comcast.net NR 9 TC 3 Z9 4 U1 1 U2 3 PU UNIV PUBLISHING GROUP PI HAGERSTOWN PA 138 W WASHINGTON ST, STE 403-405, HAGERSTOWN, MD 21740 USA SN 1046-7890 J9 J CLIN ETHIC JI J. Clin. Ethics PD SPR PY 2007 VL 18 IS 1 BP 64 EP 71 PG 8 WC Ethics; Social Sciences, Biomedical SC Social Sciences - Other Topics; Biomedical Social Sciences GA 170QG UT WOS:000246678400010 PM 17546936 ER PT J AU Bandipalliam, P AF Bandipalliam, Prathap TI Desmoid tumors and familial adenomatous polyposis - A tale of two syndromes SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Editorial Material ID AGGRESSIVE FIBROMATOSIS; APC GENE; COLORECTAL-CANCER; COLON-CANCER; MUTATIONS; IDENTIFICATION; EXPRESSION; RISK; AGE C1 Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA. RP Bandipalliam, P (reprint author), Dana Farber Canc Inst, Div Populat Sci, Smith 205,44 Binney St, Boston, MA 02115 USA. EM prathap_bandipalliam@dfci.harvard.edu NR 33 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD MAR PY 2007 VL 41 IS 3 BP 231 EP 236 DI 10.1097/01.mcg.0000225659.38426.e7 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 145QO UT WOS:000244879800002 PM 17426459 ER PT J AU Mizoguchi, A Ogawa, A Takedatsu, H Sugimoto, K Shimomura, Y Shirane, K Nagahama, K Nagaishi, T Mizoguchi, E Blumberg, RS Bhan, AK AF Mizoguchi, Atsushi Ogawa, Atsushiro Takedatsu, Hidetoshi Sugimoto, Ken Shimomura, Yasuyo Shirane, Katsunori Nagahama, Kiyotaka Nagaishi, Takashi Mizoguchi, Emiko Blumberg, Richard S. Bhan, Atul K. TI Dependence of intestinal granuloma formation on unique myeloid DC-like cells SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; MESENTERIC LYMPH-NODES; TOLL-LIKE RECEPTORS; DENDRITIC CELLS; IN-VIVO; EXPERIMENTAL COLITIS; DEFICIENT MICE; T-CELLS; MYCOBACTERIUM-TUBERCULOSIS; EPITHELIAL-CELLS AB Granulomas represent a localized inflammatory reaction that is characteristically observed in many inflammatory conditions. However, the mechanisms of granuloma formation have not been fully defined. Herein we , by using experimental models of intestinal inflammation, that a unique CD11c(+) DC-like cell subset that exhibits phenotypic and functional features of immature myeloid DCs and is characterized by the expression of a macrophage marker (F4/80) produces large amounts of IL-23 and directly induces the development of granulomas under a Th1-predominant intestinal inflammatory condition. Importantly, both IL-4 and IgG contribute to the suppression of F4/80(+) DC-like cell-mediated granuloma formation by regulating the function and differentiation of this cell subset. In addition, enteric flora is required for the F4/80(+) DC-like cell-mediated granuloma formation. Collectively, our data provide what we believe are novel insights into the involvement of 174/80(+) DC-like cells in intestinal granuloma formation and demonstrate the role of host (IL-4 and IgG) and environmental (enteric flora) factors that regulate this function. C1 Massachusetts Gen Hosp, Dept Pathol Serv, Immunopathol Unit, Boston, MA 02114 USA. Massachusetts Gen Hosp, Gastrointestinal Unit, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA. RP Mizoguchi, E (reprint author), Massachusetts Gen Hosp, Dept Pathol Serv, Immunopathol Unit, Simches 8234,185 Cambridge St, Boston, MA 02114 USA. EM amizoguchi@partners.org FU NIDDK NIH HHS [R01 DK044319, DK47677, R37 DK044319, DK53056, R01 DK051362, DK44319, K08 DK064289, DK64289, DK51362, DK064351, R01 DK064351, R01 DK053056, R01 DK047677] NR 61 TC 38 Z9 39 U1 0 U2 0 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD MAR PY 2007 VL 117 IS 3 BP 605 EP 615 DI 10.1172/JCI30150 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 142PR UT WOS:000244662500020 PM 17318261 ER PT J AU Zhang, HB Bajraszewski, N Wu, EX Wang, HW Moseman, AP Dabora, SL Griffin, JD Kwiatkowski, DJ AF Zhang, Hongbing Bajraszewski, Natalia Wu, Erxi Wang, Hongwei Moseman, Annie P. Dabora, Sandra L. Griffin, James D. Kwiatkowski, David J. TI PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID TUBEROUS SCLEROSIS COMPLEX; GROWTH-FACTOR-RECEPTOR; SIGNALING PATHWAYS; BETA-RECEPTOR; BINDING PARTNER; MOUSE MODELS; IFN-GAMMA; C-MYC; CANCER; RAPAMYCIN AB The receptor tyrosine kinase/PI3K/Akt/mammalian target of rapamycin (RTK/PI3K/Akt/mTOR) pathway is frequently altered in tumors. Inactivating mutations of either the TSC1 or the TSC2 tumor-suppressor genes cause tuberous sclerosis complex (TSC), a benign tumor syndrome in which there is both hyperactivation of mTOR and inhibition of RTK/PI3K/Akt signaling, partially due to reduced PDGFR expression. We report here that activation of PI3K or Akt, or deletion of phosphatase and tensin homolog (PTEN) in mouse embryonic fibroblasts (MEFs) also suppresses PDGFR expression. This was a direct effect of mTOR activation, since rapamycin restored PDGFR expression and PDGF-sensitive Akt activation in Tsc1(-/-) and Tsc2(-/-) cells. Akt activation in response to EGF in Tsc2(-/-) cells was also reduced. Furthermore, Akt activation in response to each of EGF, IGF, and PMA was reduced in cells lacking both PDGFR alpha and PDGFR beta, implying a role for PDGFR in transmission of growth signals downstream of these stimuli. Consistent with the reduction in PI3K/Akt signaling, in a nude mouse model both Tsc1(-/-) and Tsc2(-/-) cells had reduced tumorigenic potential in comparison to control cells, which was enhanced by expression of either active Akt or PDGFR beta. In conclusion, PDGFR is a major target of negative feedback regulation in cells with activated mTOR, which limits the growth potential of TSC tumors. C1 Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Dept Physiol, Beijing 100005, Peoples R China. Peking Union Med Coll, Beijing, Peoples R China. Brigham & Womens Hosp, Div Translat Med, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Childrens Hosp Informat Program, Boston, MA 02115 USA. RP Zhang, HB (reprint author), Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Dept Physiol, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China. EM hbzhang2006@gmail.com FU NINDS NIH HHS [R37 NS031535, NS24279, NS31535, P01 NS024279, R01 NS031535]; NLM NIH HHS [T15 LM007092, LM07092] NR 49 TC 191 Z9 209 U1 1 U2 13 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD MAR PY 2007 VL 117 IS 3 BP 730 EP 738 DI 10.1172/JC128984 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 142PR UT WOS:000244662500032 PM 17290308 ER PT J AU Ng, AK Mauch, PM AF Ng, Andrea K. Mauch, Peter M. TI Role of radiation therapy in localized aggressive lymphoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Editorial Material ID B-CELL LYMPHOMA; CHEMOTHERAPY PLUS RITUXIMAB; NON-HODGKINS-LYMPHOMA; ONCOLOGY-GROUP; RADIOTHERAPY; CHOP; TRIAL; CARCINOMA; CANCER; ACVBP C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Radiat Oncol, Boston, MA 02115 USA. RP Ng, AK (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Radiat Oncol, Boston, MA 02115 USA. NR 14 TC 14 Z9 14 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 1 PY 2007 VL 25 IS 7 BP 757 EP 759 DI 10.1200/JCO.2006.09.5562 PG 3 WC Oncology SC Oncology GA 145SK UT WOS:000244884600004 PM 17228015 ER PT J AU Jackman, DM Yeap, BY Lindeman, NI Fidias, P Rabin, MS Temel, J Skarin, AT Meyerson, M Holmes, AJ Borras, AM Freidlin, B Ostler, PA Lucca, J Lynch, TJ Johnson, BE Janne, PA AF Jackman, David M. Yeap, Beow Y. Lindeman, Neal I. Fidias, Panos Rabin, Michael S. Temel, Jennifer Skarin, Arthur T. Meyerson, Matthew Holmes, Alison J. Borras, Ana M. Freidlin, Boris Ostler, Patricia A. Lucca, Joan Lynch, Thomas J. Johnson, Bruce E. Jaenne, Pasi A. TI Phase II clinical trial of chemotherapy-naive patients >= 70 years of age treated with erlotinib for advanced non-small-cell lung cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID GROWTH-FACTOR-RECEPTOR; SOUTHWEST-ONCOLOGY-GROUP; QUALITY-OF-LIFE; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; BRONCHIOLOALVEOLAR-CARCINOMA; GEFITINIB THERAPY; GENE-MUTATIONS; SINGLE-AGENT; SENSITIVITY AB Purpose This is a phase II, multicenter, open-label study of chemotherapy-naive patients with non-small-cell lung cancer (NSCLC) and age >= 70 years who were treated with erlotinib and evaluated to determine the median, 1-year, and 2-year Survival. The secondary end points include radiographic response rate, time to progression (TTP), toxicity, and symptom improvement. Patients and Methods Eligible patients with NSCLC were treated with erlotinib 150 mg/d until disease progression or significant toxicity. Tumor response was assessed every 8 weeks by computed tomography scan using Response Evaluation Criteria in Solid Tumors. Tumor samples were analyzed for the presence of somatic mutations in EGFR and KRAS. Results Eighty eligible patients initiated erlotinib therapy between March 2003 and May 2005. There were eight partial responses (10%), and an additional 33 patients (41%) had stable disease for 2 months or longer. The median TTP was 3.5 months (95% Cl, 2.0 to 5.5 months). The median survival time was 10.9 months (95% Cl, 7.8 to 14.6 months). The 1- and 2- year survival rates were 46% and 19%, respectively. The most common toxicities were acneiform rash (79%) and diarrhea (69%). Four patients developed interstitial lung disease of grade 3 or higher, with one treatment-related death. EGFR mutations were detected in nine of 43 patients studied. The presence of an EGFR mutation was strongly correlated with disease control, prolonged TTP, and survival. Conclusion Erlotinib monotherapy is active and relatively well tolerated in chemotherapy-naive elderly patients with advanced NSCLC. Erlotinib merits consideration for further investigation as a first-line therapeutic option in elderly patients. C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Janne, PA (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM pjianne@partners.org RI Meyerson, Matthew/E-7123-2012 FU NCI NIH HHS [P20CA90578-02, 1K12CA87723-01, 1R01CA114465-01] NR 35 TC 217 Z9 234 U1 3 U2 11 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 1 PY 2007 VL 25 IS 7 BP 760 EP 766 DI 10.1200/JCO.2006.07.5754 PG 7 WC Oncology SC Oncology GA 145SK UT WOS:000244884600005 PM 17228019 ER PT J AU Flinn, IW Neuberg, DS Grever, MR Dewald, GW Bennett, JM Paietta, EM Hussein, MA Appelbaum, FR Larson, RA Moore, DF Tallman, MS AF Flinn, Ian W. Neuberg, Donna S. Grever, Michael R. Dewald, Gordon W. Bennett, John M. Paietta, Elisabeth M. Hussein, Mohamad A. Appelbaum, Frederick R. Larson, Richard A. Moore, Dennis F., Jr. Tallman, Martin S. TI Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 46th Annual Meeting of the American-Society-of-Hematology CY DEC 04-07, 2004 CL San Diego, CA SP Amer Soc Hematol ID THERAPY; RITUXIMAB; COMBINATION; REGIMEN; CANCER; CAP AB Purpose The combination of fludarabine and cyclophosphamide is an effective regimen for patients with chronic lymphocytic leukemia (CLL). However, it may be accompanied by increased toxicity compared with fludarabine alone. E2997 is a phase III randomized Intergroup trial comparing fludarabine and cyclophosphamide (FC arm) versus fludarabine (F arm) alone in patients receiving their first chemotherapy regimen for CLL. Patients and Methods Symptomatic, previously untreated patients with CLL were randomly assigned to receive either fludarabine 25 mg/m(2) intravenously (IV) days 1 through 5 or cyclophosphamide 600 mg/m(2) IV day 1 and fludarabine 20 mg/m(2) IV days 1 through 5. These cycles were repeated every 28 days for a maximum of six cycles. Results A total of 278 patients were randomly assigned in this Intergroup study. Treatment with fludarabine and cyclophosphamide was associated with a significantly higher complete response (CR) rate (23.4% v 4.6%, P <.001) and a higher overall response (OR) rate (74.3% v 59.5%, P =.013) than treatment with fludarabine as a single agent. Progression-free survival (PFS) was also superior in patients treated with fludarabine and cyclophosphamide than those treated with fludarabine (31.6 v 19.2 months, P <.0001). Fludarabine and cyclophosphamide caused additional hematologic toxicity, including more severe thrombocytopenia (P =.046), but it did not increase the number of severe infections (P =.812). Conclusion Fludarabine and cyclophosphamide produced an increase in OR and CR, and it improved PFS in patients with previously untreated CLL compared with fludarabine alone and was not associated with an increase in infectious toxicity. C1 Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Ohio State Univ, Sch Med, Columbus, OH 43210 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Mayo Clin, Rochester, MN USA. Univ Rochester, Ctr Canc, Rochester, NY USA. Our Lady Mercy Med Ctr, Bronx, NY USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Univ Chicago, Canc & Leukemia Grp B, Feinberg Sch Med, Chicago, IL 60637 USA. Canc Ctr Kansas, Wichita, KS USA. RP Flinn, IW (reprint author), Sarah Cannon Res Inst, 250 25th Ave N,Suite 110, Nashville, TN 37203 USA. EM iflinn@tnone.com OI Larson, Richard/0000-0001-9168-3203 FU NCI NIH HHS [CA21115, CA11083, CA13650, CA15488, CA16116, CA23318, CA31946, CA49957, CA59307, CA66636] NR 18 TC 251 Z9 264 U1 0 U2 5 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 1 PY 2007 VL 25 IS 7 BP 793 EP 798 DI 10.1200/JCO.2006.08.0762 PG 6 WC Oncology SC Oncology GA 145SK UT WOS:000244884600010 PM 17283364 ER PT J AU Grever, MR Lucas, DM Dewald, GW Arenberg, DS Reed, JC Kitada, S Flinn, IW Tallman, MS Appelbaum, FR Larson, RA Paietta, E Jelinek, DF Gribben, JG Byrd, JC AF Grever, Michael R. Lucas, David M. Dewald, Gordon W. Arenberg, Donna S. Reed, John C. Kitada, Shinichi Flinn, Ian W. Tallman, Martin S. Appelbaum, Frederick R. Larson, Richard A. Paietta, Elisabeth Jelinek, Diane F. Gribben, John G. Byrd, John C. TI Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 42nd Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 02-06, 2006 CL Atlanta, GA SP Amer Soc Clin Oncol ID MUTATION STATUS; GENOMIC ABERRATIONS; CD38 EXPRESSION; DISEASE PROGRESSION; ZAP-70 EXPRESSION; FLUDARABINE; THERAPY; RITUXIMAB; SURVIVAL; REGION AB Purpose Genomic features including unmutated immunoglobulin variable region heavy chain (IgV(H)) genes, del(11q22.3), del(17p13.1), and p53 mutations have been reported to predict the clinical course and overall survival of patients with chronic lymphocytic leukemia (CLL). In addition, ZAP-70 and Bcl-2 family proteins have been explored as predictors of outcome. Patients and Methods We prospectively evaluated the prognostic significance of a comprehensive panel of laboratory factors on both response and progression-free survival (PFS) using samples and data from 235 patients enrolled onto a therapeutic trial. Patients received either fludarabine (FL; n = 113) or fludarabine plus cyclophosphamide (FC; n = 122) as part of a US Intergroup randomized trial for previously untreated CLL patients. Results Complete response (CB) rates were 24.6% for patients receiving FC and 5.3% for patients receiving FL (P =.00004). PFS was statistically significantly longer in patients receiving FC (median, 33.5 months for patients receiving FC and 19.9 months for patients receiving FL, P<.0001). The occurrence of del(17p13.1) (hazard ratio, 3.428; P=.0002) or del(11q22.3) (hazard ratio, 1.904; P =.006) was associated with reduced PFS. CR and overall response rates were not significantly different based on cytogenetics, IgVH mutational status, CD38 expression, or p53 mutational status. Expression of ZAP-70, Bcl-2, Bax, Mcl-1, XIAP, Caspase-3, and Traf-1 was not associated with either clinical response or PFS. Conclusion These results support the use of interphase cytogenetic analysis, but not IgV(H), CD38 expression, or ZAP-70 status, to predict outcome of FL-based chemotherapy. Patients with high-risk cytogenetic features should be considered for alternative therapies. C1 Ohio State Univ, Dept Internal Med, Div Hematol Oncol, Columbus, OH 43210 USA. Ohio State Univ, Eastern Cooperat Oncol Grp, Columbus, OH 43210 USA. Ohio State Univ, Canc & Leukemia Grp B, Columbus, OH 43210 USA. Ohio State Univ, SW Oncol Grp, Columbus, OH 43210 USA. Mayo Clin Coll Med, Rochester, MN USA. Mayo Clin, Dept Cytogenet, Rochester, MN USA. Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. Burnham Inst Med Res, La Jolla, CA USA. Johns Hopkins Univ, Dept Oncol, Baltimore, MD USA. Univ Chicago, Chicago, IL 60637 USA. Northwestern Univ, Feinberg Sch Med, Div Hematol & Oncol, Chicago, IL 60611 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Our Lady Mercy Comprehens Canc Ctr, Bronx, NY USA. Barts & London Sch Med, London, England. RP Grever, MR (reprint author), 215 Means Hall,1654 Upham Dr, Columbus, OH 43210 USA. EM michael.grever@osumc.edu RI Lucas, David/E-3555-2011; OI Larson, Richard/0000-0001-9168-3203 FU NCI NIH HHS [R01 CA 88647, R21 CA 101332, U10 CA 101140] NR 35 TC 210 Z9 214 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 1 PY 2007 VL 25 IS 7 BP 799 EP 804 DI 10.1200/JCO.2006.08.3089 PG 6 WC Oncology SC Oncology GA 145SK UT WOS:000244884600011 PM 17283363 ER PT J AU de Jong, D Rosenwald, A Chhanabhai, M Gaulard, P Klapper, W Lee, A Sander, B Thorns, C Campo, E Molina, T Norton, A Hagenbeek, A Horning, S Lister, A Raemaekers, J Gascoyne, RD Salles, G Weller, E AF de Jong, Daphne Rosenwald, Andreas Chhanabhai, Mukesh Gaulard, Philippe Klapper, Wolfram Lee, Abigail Sander, Birgitta Thorns, Christoph Campo, Elias Molina, Thierry Norton, Andrew Hagenbeek, Anton Horning, Sandra Lister, Andrew Raemaekers, John Gascoyne, Randy D. Salles, Gilles Weller, Edie TI Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - A study from the Lunenburg Lymphoma Biomarker Consortium SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID NON-HODGKINS-LYMPHOMA; BCL-2 PROTEIN EXPRESSION; GERMINAL-CENTER; GENE; SURVIVAL; DLBCL; REARRANGEMENT; CHEMOTHERAPY; CORRELATE; SUBTYPES AB Purpose The results of immunohistochemical class prediction and prognostic stratification of diffuse large B-cell lymphoma (DLBCL) have been remarkably various thus far. Apart from biologic variations, this may be caused by differences in laboratory techniques, scoring definitions, and inter- and intraobserver variations. In this study, an international collaboration of clinical lymphoma research groups from Europe, United States, and Canada concentrated on validation and standardization of immunohistochemistry of the currently potentially interesting prognostic markers in DLBCL. Patients and Methods Sections of a tissue microarray from 36 patients with DLBCL were stained in eight laboratories with antibodies to CD20, CD5, bcl-2, bcl-6, CD10, HLA-DR, MUM1, and MIB-1 according to local methods. The study was performed in two rounds firstly focused on the evaluation of laboratory staining variation and secondly on the scoring variation. Results Different laboratory staining techniques resulted in unexpectedly highly variable results and very poor reproducibility in scoring for almost all markers. No single laboratory stood out as uniformly poor or excellent. With elimination of variation due to staining, high agreement was found for CD20, HLA-DR, and CD10. Poor agreement was found for bcl-6 and Ki-67. Optimization of techniques and uniformly agreed on scoring criteria improved reproducibility. Conclusion This study shows that semiquantitative immunohistochemistry for subclassification of DLBCL is feasible and reproducible, but exhibits varying rates of concordance for different markers. These findings may explain the wide variation of biomarker prognostic impact reported in the literature. Harmonization of techniques and centralized consensus review appears mandatory when using immunohistochemical biomarkers for treatment stratification. C1 Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands. Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands. Univ Med Ctr Nijmegen, Nijmegen, Netherlands. Univ Wurzburg, Inst Pathol, D-8700 Wurzburg, Germany. Univ Hosp Schleswig Holstein, Dept Pathol, Hematopathol Sect, Kiel, Germany. Univ Clin Schleswig Holstein, Kiel, Germany. Univ British Columbia, British Columbia Canc Agcy, Dept Pathol & Med Oncol, Vancouver, BC V5Z 1M9, Canada. Hop Henri Mondor, INSERM, U617, Dept Pathol, F-94010 Creteil, France. Univ Paris Descartes, APHP, Hotel Dieu, Paris, France. Hospices Civils Lyon, Lyon, France. Univ Lyon 1, F-69365 Lyon, France. St Bartholomews Hosp, CRUK Med Oncol Unit, London, England. Karolinska Inst, Stockholm, Sweden. Univ Barcelona, Hosp Clin, Barcelona, Spain. Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RP de Jong, D (reprint author), Netherlands Canc Inst, Dept Pathol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands. EM d.d.jong@nki.nl RI Klapper, Wolfram/D-2516-2010; Thorns, Christoph/E-2945-2010; Klapper, Wolfram/S-6314-2016; OI Campo, elias/0000-0001-9850-9793 NR 29 TC 179 Z9 180 U1 2 U2 7 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 1 PY 2007 VL 25 IS 7 BP 805 EP 812 DI 10.1200/JCO.2006.09.4490 PG 8 WC Oncology SC Oncology GA 145SK UT WOS:000244884600012 PM 17327602 ER PT J AU Barry, E DeAngelo, DJ Neuberg, D Stevenson, K Loh, ML Asselin, BL Barr, RD Clavell, LA Hurwitz, CA Moghrabi, A Samson, Y Schorin, M Cohen, HJ Sallan, SE Silverman, LB AF Barry, Elly DeAngelo, Daniel J. Neuberg, Donna Stevenson, Kristen Loh, Mignon L. Asselin, Barbara L. Barr, Ronald D. Clavell, Luis A. Hurwitz, Craig A. Moghrabi, Albert Samson, Yvan Schorin, Marshall Cohen, Harvey J. Sallan, Stephen E. Silverman, Lewis B. TI Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 42nd Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 02-06, 2006 CL Atlanta, GA SP Amer Soc Clin Oncol ID BONE-MARROW-TRANSPLANTATION; YOUNG-ADULTS; LONG-TERM; CHILDREN; TRIALS; THERAPY; AGE; EXPERIENCE; IMPACT AB Purpose Historically, adolescents with acute lymphoblastic leukemia (ALL) have had inferior outcomes when compared with younger children. We report the outcome of adolescents treated on Dana-Farber Cancer Institute (DFCI; Boston, MA) ALL Consortium Protocols conducted between 1991 and 2000. Patients and Methods A total of 844 patients aged 1 to 18 years, with newly diagnosed ALL were enrolled onto two consecutive DFCI-ALL Consortium Protocols. We compared outcomes in three age groups: children aged 1 to 10 years (n = 685), young adolescents aged 10 to 15 years (n = 108), and older adolescents aged 15 to 18 years (n = 51). Results With a median follow-up of 6.5 years, the 5-year event-free survival (EFS) for those aged 1 to 10 years was 85% (SE, 1 %), compared with 77% (SE, 4%) for those aged 10 to 15 years, and 78% (SE, 6%) for those aged 15 to 18 years (P =.09). Adolescents were more likely to present with T-cell phenotype (P <.001) and less likely to have the TEL-AML1 fusion (P =.05). The incidence of pancreatitis and thromboembolic complications, but not asparaginase allergy, was higher in patients : 10 years of age compared with those younger than 10 years. However, there was no difference in the rate of treatment-related complications between the 10- to 15-year and 15- to 18-year age groups. Conclusion Adolescents were more likely to present at diagnosis with biologically higher risk disease (T-cell phenotype and absence of the TEL-AML1 fusion) and more likely to experience treatment-related complications than younger children. However, the 5-year EFS for older adolescents was 78% +/- 6%, which is superior to published outcomes for similarly aged patients treated with other pediatric and adult ALL regimens. Based on this experience, we currently are piloting our regimen in patients aged 18 to 50 years. C1 Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Childrens Hosp, Dept Pediat, Boston, MA 02115 USA. Univ Calif San Francisco, Dept Pediat Hematol Oncol, San Francisco, CA 94143 USA. Lucile Packard Childrens Hosp, Dept Pediat, Palo Alto, CA USA. Hosp St Justine, Dept Pediat Hematol Oncol, Montreal, PQ, Canada. Ctr Hosp Quebec, Dept Pediat, Quebec City, PQ, Canada. McMaster Univ, Dept Pediat, Hamilton, ON, Canada. Univ Rochester, Med Ctr, Dept Pediat Hematol Oncol, Rochester, NY 14642 USA. San Jorge Childrens Hosp, Dept Pediat Oncol, San Juan, PR USA. Maine Med Ctr, Maine Childrens Canc Program, Dept Pediat Oncol, Portland, ME USA. Tulane Hosp Children, Dept Pediat, New Orleans, LA USA. RP Barry, E (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA. EM elly_barry@dfci.harvard.edu FU NCI NIH HHS [CA 68484] NR 25 TC 94 Z9 100 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 1 PY 2007 VL 25 IS 7 BP 813 EP 819 DI 10.1200/JCO.2006.08.6397 PG 7 WC Oncology SC Oncology GA 145SK UT WOS:000244884600013 PM 17327603 ER PT J AU Chen, YB Rahemtullah, A Breeden, E Hochberg, EP AF Chen, Yi-Bin Rahemtullah, Ahyah Breeden, Eric Hochberg, Ephraim P. TI Bleomycin-induced flagellate erythema SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID PULMONARY TOXICITY C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Chen, YB (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 9 TC 16 Z9 16 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 1 PY 2007 VL 25 IS 7 BP 898 EP 900 DI 10.1200/JCO.2006.09.7691 PG 3 WC Oncology SC Oncology GA 145SK UT WOS:000244884600024 PM 17327612 ER PT J AU Baker, P Oliva, E AF Baker, Patricia Oliva, Esther TI Endometrial stromal tumours of the uterus: a practical approach using conventional morphology and ancillary techniques SO JOURNAL OF CLINICAL PATHOLOGY LA English DT Review ID SMOOTH-MUSCLE TUMORS; SEX-CORD TUMORS; UNUSUAL HISTOLOGIC FEATURES; JAZF1-JJAZ1 GENE FUSION; EPITHELIOID CELL TUMOR; MESENCHYMAL TUMORS; IMMUNOHISTOCHEMICAL ANALYSIS; INTRAVENOUS LEIOMYOMATOSIS; CLINICOPATHOLOGIC ANALYSIS; GLANDULAR DIFFERENTIATION AB Endometrial stromal tumours (ESTs) are diagnosed in most instances by light microscopy. Often, the greatest challenge is to distinguish between the different subtypes of these tumours. Furthermore, a handful of new or relatively new entities have been described in the literature, which may cause problems in the differential diagnosis; highly cellular leiomyoma is the most common. In addition, new antibodies have been developed to help in the distinction of ESTs from their mimics, as there are prognostic and therapeutic implications. A practical approach is provided for the diagnosis of ESTs on the basis of systematic assessment of histological and immunohistochemical parameters, and recent developments related to these tumours are highlighted. C1 Massachusetts Gen Hosp, Pathol Dept Warren 2, Boston, MA 02114 USA. Hlth Sci Ctr, Pathol Dept, Winnipeg, MB, Canada. RP Oliva, E (reprint author), Massachusetts Gen Hosp, Pathol Dept Warren 2, 55 Fruit St, Boston, MA 02114 USA. EM eoliva@partners.org NR 85 TC 40 Z9 42 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0021-9746 J9 J CLIN PATHOL JI J. Clin. Pathol. PD MAR PY 2007 VL 60 IS 3 BP 235 EP 243 DI 10.1136/jcp.2005.031203 PG 9 WC Pathology SC Pathology GA 143UA UT WOS:000244750100002 PM 17347285 ER PT J AU Aas, JA Barbuto, SM Alpagot, T Olsen, I Dewhirst, FE Paster, BJ AF Aas, J. A. Barbuto, S. M. Alpagot, T. Olsen, I. Dewhirst, F. E. Paster, B. J. TI Subgingival plaque microbiota in HIV positive patients SO JOURNAL OF CLINICAL PERIODONTOLOGY LA English DT Article DE 16S and 18S rDNA; HIV positive; periodontitis; subgingival plaque ID SACCHAROMYCES-CEREVISIAE; DIALISTER-PNEUMOSINTES; PERIODONTAL LESIONS; ORAL-CAVITY; ENDOCARDITIS; MICROFLORA; GINGIVITIS; DIVERSITY; INFECTION; BACTERIA AB Aim: To describe and compare the predominant bacterial and fungal species associated with gingivitis, periodontitis, and linear gingival erythema (LGE), in HIV positive subjects with different immune status. Methods: Viral loads and CD4 levels determined HIV disease status. From pooled subgingival plaque, 16S and 18S rDNA were cloned and sequenced to determine species identity. Results: One hundred and nine bacterial species were identified from 14 subjects. Nearly half of the species were not cultivable. Notably, the classical putative periodontal pathogens, Treponema denticola, Porphyromonas gingivalis and Tannerella forsythia were below the limit of detection and were not detected. Species of Gemella, Dialister, Streptococcus and Veillonella were predominant. In one HIV positive subject with periodontitis and low viral load, Gemella morbillorum, a known opportunistic pathogen, constituted 84% of the clones. Saccharomyces cerevisiae was the only fungal species detected in an LGE subject and in periodontitis subjects with high viral loads. In periodontitis patients with low viral loads, Candida albicans was predominant, while S. cerevisiae was only a minor component. Conclusion: These case studies suggest that other bacterial species, rather than the classical periodontal pathogens, may be involved in periodontal diseases of subjects with HIV. These data are indicative of opportunistic infections in a highly susceptible immunocompromised host. C1 Univ Oslo, Fac Dent, Inst Oral Biol, N-0316 Oslo, Norway. Forsyth Inst, Boston, MA USA. Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. Univ Pacific, Sch Dent, San Francisco, CA 94115 USA. RP Aas, JA (reprint author), Univ Oslo, Fac Dent, Inst Oral Biol, POB 1052, N-0316 Oslo, Norway. EM jornaaas@odont.uio.no RI Aas, Jorn /A-3805-2008 FU NCRR NIH HHS [M01-RR01032]; NIDCR NIH HHS [DE11443, U01 DE016937, DE15077] NR 44 TC 57 Z9 60 U1 0 U2 6 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6979 J9 J CLIN PERIODONTOL JI J. Clin. Periodontol. PD MAR PY 2007 VL 34 IS 3 BP 189 EP 195 DI 10.1111/j.1600-051X.2006.01034.x PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 134US UT WOS:000244110300001 PM 17309593 ER PT J AU Haffajee, AD Torresyap, G Socransky, SS AF Haffajee, Anne D. Torresyap, G. Socransky, Sigmund S. TI Clinical changes following four different periodontal therapies for the treatment of chronic periodontitis: 1-year results SO JOURNAL OF CLINICAL PERIODONTOLOGY LA English DT Article DE antibiotics; attachment level; azithromycin; chronic periodontitis; metronidazole; periodontal therapy; pocket depth; scaling and root planing; subantimicrobial dose doxycycline ID SUBANTIMICROBIAL DOSE DOXYCYCLINE; GENERALIZED AGGRESSIVE PERIODONTITIS; ADULT PERIODONTITIS; NONSURGICAL TREATMENT; DOUBLE-BLIND; ADJUNCTIVE TREATMENT; SYSTEMIC METRONIDAZOLE; AMOXICILLIN; PARAMETERS; GINGIVAL AB Objective: To compare clinical changes occurring in chronic periodontitis subjects receiving SRP alone or with systemically administered azithromycin, metronidazole or a sub-antimicrobial dose of doxycycline. Material and Methods: 92 chronic periodontitis subjects were randomly assigned to receive SRP alone (N=23) or combined with 500 mg azithromycin per day for 3 days (N=25), 250 mg metronidazole tid for 14 days (N=24) or 20 mg doxycycline bid for 3 months (N=20). Gingival redness, bleeding on probing, suppuration, pocket depth and attachment level were measured at baseline and 3, 6 and 12 months post therapy. The significance of changes in clinical parameters within groups over time was sought using the Friedman test and among groups using ANCOVA or the Kruskal Wallis test. Results: All groups showed clinical improvements at 12 months, with subjects receiving adjunctive agents showing a somewhat better response. Sites with initial pocket depth > 6 mm showed significantly greater pocket depth reduction and greater attachment gain in subjects receiving metronidazole or azithromycin than subjects in the other groups. Some subjects showed attachment loss at 12 months in each group ranging from 15% to 39% of subjects in the SDD and SRP only groups respectively. Conclusion: This study, demonstrated that periodontal therapy provides clinical benefits and that antibiotics provide a clinical benefit over SRP alone, particularly at initially deeper periodontal pockets. C1 Forsyth Inst, Dept Periodontol, Boston, MA 02115 USA. RP Haffajee, AD (reprint author), Forsyth Inst, Dept Periodontol, 140 Fenway, Boston, MA 02115 USA. EM ahaffajee@forsyth.org FU NIDCR NIH HHS [DE-13232] NR 43 TC 72 Z9 80 U1 1 U2 12 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6979 J9 J CLIN PERIODONTOL JI J. Clin. Periodontol. PD MAR PY 2007 VL 34 IS 3 BP 243 EP 253 DI 10.1111/j.1600-051X.2006.01040.x PG 11 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 134US UT WOS:000244110300009 PM 17309596 ER PT J AU Caroff, SN Walker, P Campbell, EC Lorry, A Petro, C Lynch, K Gallop, R AF Caroff, Stanley N. Walker, Patricia Campbell, E. Cabrina Lorry, Alan Petro, Christopher Lynch, Kevin Gallop, Robert TI Treatment of tardive dyskinesia with galantamine: A randomized controlled crossover trial SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID DOPA-INDUCED DYSKINESIAS; MOVEMENT-DISORDERS; CHOLINERGIC NEURONS; ALZHEIMERS-DISEASE; RATING-SCALE; DOUBLE-BLIND; SCHIZOPHRENIA; DONEPEZIL; HALOPERIDOL; RATS AB Objective: Recent evidence suggests that tardive dyskinesia may result from antipsychotic-induced damage to striatal cholinergic neurons. To test whether cholinesterase inhibitors compensate for diminished cholinergic activity, we conducted a 30-week randomized, double-blind, placebo-controlled crossover trial of galantamine in patients with tardive dyskinesia. Method: Patients with tardive dyskinesia were recruited between June 2001 and June 2004. After a 2-week baseline period, 35 male schizophrenia patients, on stable doses of antipsychotics, were randomly assigned to receive galantamine (8-24 mg) or placebo for two 12-week phases separated by a 4-week washout period. Patients were evaluated every 2 weeks for changes in extrapyramidal symptoms and before and after each treatment for effects on psychiatric symptoms and cognition. Results: Galantamine reduced mean total Abnormal Involuntary Movement Scale (AIMS) scores more than placebo, but this difference was not statistically significant (p =.08). However, patients initially randomly assigned to galantamine showed a reversal of AIMS scores after switching to placebo. Simpson-Angus Scale ratings of parkinsonism were significantly higher with galantamine than placebo (p =.0005) and correlated with age. There were no significant differences between groups in akathisia, cognition, or psychiatric symptoms. More patients dropped out while receiving galantamine, but this outcome did not significantly influence the results. Conclusions: In contrast to previous reports, reductions in tardive dyskinesia associated with galantamine were not statistically significant compared with placebo in this trial. However, galantamine was associated with a modest rebound in dyskinesia scores after discontinuation and clinically minor but statistically higher ratings of parkinsonism. These findings support the need for further investigations of cholinergic mechanisms underlying tardive dyskinesia and extrapyramidal effects of cholinesterase inhibitors when used in combination with antipsychotics in susceptible patients. C1 Univ Penn, Sch Med, Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. W Chester Univ, Dept Appl Math & Stat, W Chester, PA 19380 USA. RP Caroff, SN (reprint author), Vet Affairs Med Ctr, 116A,Univ Ave, Philadelphia, PA 19104 USA. EM stanley.caroff@va.gov NR 55 TC 16 Z9 16 U1 1 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD MAR PY 2007 VL 68 IS 3 BP 410 EP 415 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 152CK UT WOS:000245338200009 PM 17388711 ER PT J AU Adler, LA Barkley, RA Newcorn, JH Spencer, TJ Weiss, MD AF Adler, Lenard A. Barkley, Russell A. Newcorn, Jeffrey H. Spencer, Thomas J. Weiss, Margaret D. TI Managing ADHD in children, adolescents, and adults with comorbid anxiety SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; OBSESSIVE-COMPULSIVE DISORDER; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CLINICAL-TRIAL; PSYCHIATRIC COMORBIDITY; MULTIMODAL-TREATMENT; DOUBLE-BLIND; MEDICATION ALGORITHM; STIMULANT MEDICATION C1 NYU, Sch Med, Dept Psychiat, New York, NY 10012 USA. NYU, Sch Med, Dept Neurol, New York, NY USA. SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. Mt Sinai Sch Med, Div Child & Adolescent Psychiat, New York, NY USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA USA. Massachusetts Gen Hosp, Dept Pediat Psychopharmacol, Boston, MA 02114 USA. Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada. Childrens & Womens Hlth Ctr British Columbia, Prov ADHD Program, Vancouver, BC, Canada. RP Adler, LA (reprint author), NYU, Sch Med, Dept Psychiat, 550 1st Ave, New York, NY 10012 USA. OI Newcorn, Jeffrey /0000-0001-8993-9337 NR 63 TC 5 Z9 5 U1 3 U2 9 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD MAR PY 2007 VL 68 IS 3 BP 451 EP 462 PG 12 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 152CK UT WOS:000245338200016 ER PT J AU Tamietto, M Geminiani, G Genero, R de Gelder, B AF Tamietto, Marco Geminiani, Giuliano Genero, Rosanna de Gelder, Beatrice TI Seeing fearful body language overcomes attentional deficits in patients with neglect SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Article ID EMOTIONAL FACIAL EXPRESSIONS; MEDIAL PREFRONTAL CORTEX; EVENT-RELATED FMRI; HUMAN AMYGDALA; NEUROPSYCHOLOGICAL EVIDENCE; PARIETAL EXTINCTION; VISUAL EXTINCTION; CAPTURE ATTENTION; SPATIAL ATTENTION; MACAQUE MONKEYS AB Survival depends to some extent on the ability to detect salient signals and prepare an appropriate response even when attention is engaged elsewhere. Fearful body language is a salient signal of imminent danger, easily observable from a distance and indicating to the observer which adaptive action to prepare for. Here we investigated for the first time whether fearful body language modulates the spatial distribution of attention and enhances visual awareness in neurological patients with severe attentional disorders. Patients with visual extinction and hemispatial neglect following right parietal injury have a rightward attentional bias accompanied by loss of awareness for contralesional left stimuli, especially when competing stimuli appear to the right. Three such patients were tested with pictures of fearful, happy, and neutral bodily expressions briefly presented either unilaterally in the left or right visual field, or to both fields simultaneously. On bilateral trials, unattended and task-irrelevant fearful bodily expressions modulated attentional selection and visual awareness. Fearful bodily expressions presented in the contralesional unattended visual field simultaneously with neutral bodies in the ipsilesional field were detected more often than left-side neutral or happy bodies. This demonstrates that despite pathological inattention and parietal damage, emotion and action-related information in fearful body language may be extracted automatically, biasing attentional selection and visual awareness. Our findings open new perspectives on the role of bodily expressions in attentional selection and suggest that a neural network in intact fronto-limbic and visual areas may still mediate reorienting of attention and preparation for action upon perceiving fear in others. C1 Univ Turin, Dipartimento Psicol, I-10123 Turin, Italy. Papa Giovanni XXIII Hosp, Pianezza, Italy. Tilburg Univ, NL-5000 LE Tilburg, Netherlands. RP de Gelder, B (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Biomed Imaging, 1st St Bldg 36, Charlestown, MA 02129 USA. EM tamietto@psych.unito.it; degelder@nmr.mgh.harvard.edu OI Tamietto, Marco/0000-0002-8815-8499 NR 55 TC 50 Z9 51 U1 4 U2 10 PU M I T PRESS PI CAMBRIDGE PA 238 MAIN STREET, STE 500, CAMBRIDGE, MA 02142-1046 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PD MAR PY 2007 VL 19 IS 3 BP 445 EP 454 DI 10.1162/jocn.2007.19.3.445 PG 10 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 148NE UT WOS:000245081100009 PM 17335393 ER PT J AU Sugawara, M Murtie, JC Stankovic, KM Liberman, MC Corfas, G AF Sugawara, Mitsuru Murtie, Joshua C. Stankovic, Konstantina M. Liberman, M. Charles Corfas, Gabriel TI Dynamic patterns of neurotrophin 3 expression in the postnatal mouse inner ear SO JOURNAL OF COMPARATIVE NEUROLOGY LA English DT Article DE NT3; postnatal; cochlea; utricle; saccule; ampulla; spiral ganglion ID SPIRAL GANGLION NEURONS; GUINEA-PIG COCHLEA; REISSNERS MEMBRANE; INNERVATION; CELLS; LOCALIZATION; MICE; PERIPHERY; RECEPTORS; ROLES AB Recent studies indicate that neurotrophin 3 (NT3) may be important for the maintenance and function of the adult inner ear, but the pattern of postnatal NT3 expression in this organ has not been characterized. We used a reporter mouse in which cells expressing NT3 also express P-galactosidase, allowing for their histochemical visualization, to determine the pattern of NT3 expression in cochlear and vestibular organs. We analyzed animals from birth (PO) to adult (P135). At PO, NT3 was strongly expressed in supporting cells and hair cells of all vestibular and cochlear sense organs, Reissner's membrane, saccular membrane, and the dark cells adjacent to canal organs. With increasing age, staining disappeared in most cell types but remained relatively high in inner hair cells (IHCs) and to a lesser extent in IHC supporting cells. In the cochlea, by PO there is a longitudinal gradient (apex > base) that persists into adulthood. In vestibular maculae, staining gradients are: striolar > extrastriolar regions and supporting cells > hair cells. By P135, cochlear staining is restricted to IHCs and their supporting cells, with stronger expression in the apex than the base. By the same age, in the vestibular organs, NT3 expression is weak and restricted to saccular and utricular supporting cells. These results suggest that NT3 might play a long-term role in the maintenance and functioning of the adult auditory and vestibular systems and that supporting cells are the main source of this factor in the adult. C1 Harvard Univ, Div Neurosci, Childrens Hosp, Sch Med,Neurobiol Program, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. Tohoku Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Sendai, Miyagi 9808574, Japan. RP Corfas, G (reprint author), Harvard Univ, Div Neurosci, Childrens Hosp, Sch Med,Neurobiol Program, 300 Longwood Ave, Boston, MA 02115 USA. EM gabriel.corfas@childrens.harvard.edu FU NICHD NIH HHS [P30-HD 018655]; NIDCD NIH HHS [R01 DC0188, P30 DC05209, P30 DC005209, R01 DC004820] NR 30 TC 44 Z9 46 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9967 J9 J COMP NEUROL JI J. Comp. Neurol. PD MAR 1 PY 2007 VL 501 IS 1 BP 30 EP 37 DI 10.1002/cne.21227 PG 8 WC Neurosciences; Zoology SC Neurosciences & Neurology; Zoology GA 129AJ UT WOS:000243700500003 PM 17206617 ER PT J AU Waters, EA Weinstein, ND Colditz, GA Emmons, KA AF Waters, Erika A. Weinstein, Neil D. Colditz, Graham A. Emmons, Karen A. TI Reducing aversion to side effects in preventive medical treatment decisions SO JOURNAL OF EXPERIMENTAL PSYCHOLOGY-APPLIED LA English DT Article DE decision making; risk perception; risk communication; visual display; graphical display ID RISK COMMUNICATION; GRAPHICAL PERCEPTION; PROSPECT-THEORY; FORMATS; INFORMATION; DISPLAYS; CHOICE; UNCERTAINTY; AVOIDANCE; FREQUENCY AB Laypeople tend to be overly sensitive to side effects of treatments that prevent illness, possibly leading them to refuse beneficial therapies. This Internet-based study attempted to reduce such side effect aversion by adding graphic displays to the numerical risk probabilities. It also explored whether graphics reduce side effect aversion by making it easier for respondents to determine how the treatment might change their net cancer risk. Participants (N = 4,248) were presented with a hypothetical preventive treatment situation that was or was not accompanied by a small side effect. In both conditions, the net absolute risk reduction was 12%. Adding an array of stick figures to risk probabilities reduced side effect aversion substantially, but adding a bar graph was not beneficial. The ability of arrays to reduce side effect aversion was not attributable to greater accuracy in evaluating the treatment's net benefit. C1 Rutgers State Univ, Dept Psychol, Piscataway, NJ 08855 USA. Rutgers State Univ, Dept Human Ecol, Piscataway, NJ 08855 USA. Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Waters, EA (reprint author), NCI, Canc Prevent Fellowship Program, Div Canc Prevent, 6130 Execut Blvd, Bethesda, MD 20892 USA. EM erika.a.waters@gmail.com RI Colditz, Graham/A-3963-2009; OI Colditz, Graham/0000-0002-7307-0291; Waters, Erika/0000-0001-7402-0133 NR 38 TC 45 Z9 45 U1 3 U2 12 PU AMER PSYCHOLOGICAL ASSOC/EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1076-898X J9 J EXP PSYCHOL-APPL JI J. Exp. Psychol.-Appl. PD MAR PY 2007 VL 13 IS 1 BP 11 EP 21 DI 10.1037/1076-898X.13.1.11 PG 11 WC Psychology, Applied SC Psychology GA 148GV UT WOS:000245063600002 PM 17385998 ER PT J AU Owens, DK Sundaram, V Lazzeroni, LC Douglass, LR Tempio, P Holodniy, M Sanders, GD Shadle, VM McWhorter, VC Agoncillo, T Haren, N Chavis, D Borowsky, LH Yano, EM Jensen, P Simberkoff, MS Bozzette, SA AF Owens, Douglas K. Sundaram, Vandana Lazzeroni, Lauro C. Douglass, Lena R. Tempio, Patricia Holodniy, Mark Sanders, Gillian D. Shadle, Vera M. McWhorter, Valerie C. Agoncillo, Teodoro Haren, Noreen Chavis, Darlene Borowsky, Leila H. Yano, Elizabeth M. Jensen, Peter Simberkoff, Michael S. Bozzette, Samuel A. TI HIV testing of at risk patients in a large integrated health care system SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE HIV; screening; risk factors ID HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-CARE; ANTIRETROVIRAL THERAPY; COST-EFFECTIVENESS; UNITED-STATES; INFECTION; BEHAVIORS; WOMEN AB OBJECTIVE: Early identification of HIV infection is critical for patients to receive life-prolonging treatment and risk-reduction counseling. Understanding HIV screening practices and barriers to HIV testing is an important prelude to designing successful HIV screening programs. Our objective was to evaluate current practice patterns for identification of HIV. METHODS: We used a retrospective cohort analysis of 13,991 at-risk patients seen at 4 large Department of Veterans Affairs (VA) health-care systems. We also reviewed 1, 100 medical records of tested patients. We assessed HIV testing rates among at-risk patients, the rationale for HIV testing, and predictors of HIV testing and of HIV infection. RESULTS: Of the 13,991 patients at risk for HM only 36% had been HIV-tested. The prevalence of HTV ranged from 1% to 20% among tested patients at the 4 sites. Approximately 90% of patients who were tested had a documented reason for testing. CONCLUSION. One-half to two-thirds of patients at risk for HIV had not been tested within our selected VA sites. Among tested patients, the rationale for HIV testing was well documented. Further testing of at-risk patients could clearly benefit patients who have unidentified HIV infection by providing earlier access to life-prolonging therapy. C1 VA Palo Alto Healthcare Syst, Palo Alto, CA USA. Stanford Univ, Ctr Primary Care & Outcomes Res, Dept Med, Stanford, CA 94305 USA. Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA. Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA. Duke Univ, Duke Clin Res Inst, Durham, NC 27706 USA. VA San Francisco Healthcare Syst, San Francisco, CA USA. VA San Diego Healthcare Syst, San Diego, CA USA. VA New York Harbor Healthcare Syst, New York, NY USA. VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. RP Owens, DK (reprint author), VA Palo Alto Healthcare Syst, Palo Alto, CA USA. EM owens@stanford.edu RI Lazzeroni, Laura/F-2903-2010; OI Lazzeroni, Laura/0000-0002-1846-6920 FU NIDA NIH HHS [R01 DA015612, R01 DA15612-01] NR 26 TC 16 Z9 16 U1 2 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2007 VL 22 IS 3 BP 315 EP 320 DI 10.1007/s11606-006-0028-9 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 143JX UT WOS:000244718600005 PM 17356961 ER PT J AU Simpson, SA Long, JA AF Simpson, Scott A. Long, Judith A. TI Medical student-run health clinics: Important contributors to patient care and medical education SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE medical student-run clinics-underserved population; medical education; community health ID HOMELESS; SERVICES; CENTERS; ACCESS AB BACKGROUND: Despite the popularity of medical student-run health clinics among U.S. medical schools, there is no information about how many clinics exist, how many students volunteer there, or how many patients they see and what services they offer. OBJECTIVE: We describe, for the first time, the prevalence and operation of medical student-run health clinics nationwide. DESIGN AND PARTICIPANTS: A web-based survey was sent to all 124 Association of American Medical Colleges allopathic schools in the 50 states. RESULTS: Ninety-four schools responded (76%); 49 schools had at least 1 student-run clinic (52%). Fiftynine student-run clinics provided detailed data on their operation. The average clinic had 16 student volunteers a week, and most incorporated preclinical students (56/59, 93%). Nationally, clinics reported more than 36,000. annual patient-physician visits, in addition to more nonvisit encounters. Patients were predominantly minority: 31% Hispanic; 3 1 % Black/African American; 25% White; 11% Asian; and 3% Native American or other. Most student-run health clinics had resources both to treat acute illness and also to manage chronic conditions. Clinics were most often funded by private grants (42/59, 71%); among 27 clinics disclosing finances, a median annual operating budget of $12,000 was reported. CONCLUSIONS: Medical student-run health clinics offer myriad services to disadvantaged patients and are also a notable phenomenon in medical education. Wider considerations of community health and medical education should not neglect the local role of a studentrun health clinic. C1 Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Ctr Hlth Equ Res & Promo, Philadelphia, PA USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Simpson, SA (reprint author), Univ Penn, Sch Med, 1201 Blockley Hall 423 Guardian Dr, Philadelphia, PA 19104 USA. EM ss@mail.med.upenn.edu NR 21 TC 86 Z9 86 U1 1 U2 14 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2007 VL 22 IS 3 BP 352 EP 356 DI 10.1007/s11606-006-0073-4 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 143JX UT WOS:000244718600011 PM 17356967 ER PT J AU Dhaliwal, G Chou, CL AF Dhaliwal, Gurpreet Chou, Calvin L. TI A brief educational intervention in personal finance for medical residents SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med DE curriculum program/evaluation; financial management; medical student and residency education ID STRESS AB INTRODUCTION. Although medical educational debt continues to escalate, residents receive little guidance in financial planning. AIM. To educate interns about long-term investment strategies. SETTING: University-based medicine internship program. PROGRAM DESCRIPTION. An unselected cohort of interns (n=52; 84% of all interns) underwent a 90minute interactive seminar on personal finance, focusing on retirement savings. Participants completed a preseminar investor literacy test to assess baseline financial knowledge. Afterward, interns rated the seminar and expressed their intention to make changes to their long-term retirement accounts. After 37 interns had attended the seminar, a survey was administered to all interns to compare actual changes to these accounts between seminar attendees and nonattendees. MEASUREMENTS AND MAIN RESULTS: Interns' average score on the investor literacy test was 40% ' equal to the general population. Interns strongly agreed that the seminar was valuable (average 5.0 on 5-point Likert scale). Of the 46 respondents to the account allocation survey, interns who had already attended the seminar (n=25) were more likely than interns who had not yet attended (n=21) to have switched their investments from low to high-yield accounts at the university hospital (64 vs 19%, P= 0.003) and to enroll in the county hospital retirement plan (64 vs 33%, P=0.07). CONCLUSIONS: One 90-minute seminar on personal finances leads to significant changes in allocation of tax-deferred retirement savings. We calculate that these changes can lead to substantial long-term financial benefits and suggest that programs consider automatically enrolling trainees into higher yield retirement plans. C1 San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94131 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94131 USA. RP Dhaliwal, G (reprint author), San Francisco VA Med Ctr, Dept Med, 4150 Clement St,111, San Francisco, CA 94131 USA. EM gurpreet.dhaliwal@va.gov NR 12 TC 5 Z9 5 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2007 VL 22 IS 3 BP 374 EP 377 DI 10.1007/s11606-006-0078-z PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 143JX UT WOS:000244718600015 PM 17356971 ER PT J AU Takahashi, TA Baernstein, A Binswanger, I Bradley, K Merrill, JO AF Takahashi, Traci A. Baernstein, Amy Binswanger, Ingrid Bradley, Katharine Merrill, Joseph O. TI Predictors of hospitalization for injection drug users seeking care for soft tissue infections SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med DE injection drug use; soft tissue infection; cellulitis; abscess; substance abuse ID RESISTANT STAPHYLOCOCCUS-AUREUS; SAN-FRANCISCO; HIGH PREVALENCE; AUDIT-C; POPULATION; ABSCESSES; DRINKING; SKIN AB BACKGROUND: Soft tissue infections (STIs) from injection drug use are a common cause of Emergency Department visits, hospitalizations, and operating room procedures, yet little is known about factors that may predict the need for these costly medical services. OBJECTIVE: To describe a cohort of injection drug users seeking Emergency Department care for STIs and to identify risk factors associated with hospitalization. We hypothesized that participants who delayed seeking care would be hospitalized more often than those who did not. DESIGN: Cohort study using in-person structured interviews and medical record review. Logistic regression assessed the association between hospital admission and delay in seeking care as well as other demographic, clinical, and psychosocial factors. PARTICIPANTS: Injection drug users who sought Emergency Department care for STIs from May 2001 to March 2002. RESULTS: Of the 136 participants, 55 (40%) were admitted to the hospital. Delay in seeking care was not associated with hospital admission. Participants admitted for their infection were significantly more likely to be living in a shelter (P=.01) and to report being hospitalized 2 or more times in the past year (P <.01). CONCLUSIONS: We identified a subpopulation of injection drug users, mostly living in shelters, who were hospitalized frequently in the past year and who were more likely to be hospitalized for their current infections compared to others. As members of this subpopulation can be easily identified and located, they may benefit from interventions to reduce the health care utilization resulting from these infections. C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. Univ Washington, Sch Med, Seattle, WA 98104 USA. Univ Colorado, Denver, CO 80202 USA. Hlth & Sci Ctr, Denver, CO USA. RP Takahashi, TA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM traci@u.washington.edu OI Binswanger, Ingrid/0000-0001-8862-8078 FU NIAAA NIH HHS [K23 AA000313, K23AA00313]; NIDA NIH HHS [R03DA14518] NR 20 TC 21 Z9 21 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2007 VL 22 IS 3 BP 382 EP 388 DI 10.1007/s11606-006-0079-y PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 143JX UT WOS:000244718600017 PM 17356973 ER PT J AU Haas, JS Earle, CC Orav, JE Brawarsky, P Neville, BA Acevedo-Garcia, D Williams, DR AF Haas, Jennifer S. Earle, Craig C. Orav, John E. Brawarsky, Phyllis Neville, Bridget A. Acevedo-Garcia, Dolores Williams, David R. TI Lower use of hospice by cancer patients who live in minority versus white areas SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE race; ethnicity; hospice; segregation ID OF-LIFE CARE; MEDICARE PATIENTS; DEATH; DISPARITIES; TECHNOLOGY; PHARMACIES; COMMUNITY; CLOSURES AB BACKGROUND: Although hospice care can alleviate suffering at the end of life for patients with cancer, it remains underutilized, particularly by African Americans and Hispanics. OBJECTIVE: To examine whether the racial composition of the census tract where an individual resides is associated with hospice use. DESIGN. Retrospective analysis of the Surveillance, Epidemiology, and End Results-Medicare file for individuals dying from breast, colorectal, lung, or prostate cancer (n=70,669). MEASUREMENTS: Hospice use during the 12 months before death. RESULTS: Hospice was most commonly used by individuals who lived in areas with fewer Affican-American and Hispanic residents (47%), and was least commonly used by individuals who lived in areas with a high percentage of African-American and Hispanic residents (35%). Hispanics (odds ratio 0.51, 95% confidence interval 0.290.9 1) and African Americans (0. 56, 0.44-0.7 1) were less likely to use hospice if they lived in a census tract with a high percentage of both African Americans and Hispanics than if they lived in a low minority tract. African Americans and whites were less likely to receive hospice care if they lived in a census tract with a high percentage of Hispanics than if they lived in a low minority area. CONCLUSIONS: Increasing hospice use may require interventions to improve the delivery of hospice care in minority communities. C1 Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Gen Med & Primary Care, Boston, MA 02120 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. Univ Michigan, Inst Social Res, Dept Sociol, Ann Arbor, MI 48109 USA. Univ Michigan, Inst Social Res, Dept Epidemiol, Ann Arbor, MI 48109 USA. RP Haas, JS (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Gen Med & Primary Care, 1620 Tremont St, Boston, MA 02120 USA. EM jhaas@partners.org FU AHRQ HHS [P01 HS010856]; NCI NIH HHS [R01 CA112451, R01 CA112451-03] NR 24 TC 34 Z9 34 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2007 VL 22 IS 3 BP 396 EP 399 DI 10.1007/s11606-006-0034-y PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 143JX UT WOS:000244718600019 PM 17356975 ER PT J AU Goroll, AH Berenson, RA Schoenbaum, SC Gardner, LB AF Goroll, Allan H. Berenson, Robert A. Schoenbaum, Stephen C. Gardner, Laurence B. TI Fundamental reform of payment for adult primary care: Comprehensive payment for comprehensive care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE primary care; comprehensive payment; capitation; resource-based relative value scale (RBRVS); compensation ID INFORMATION-TECHNOLOGY; FINANCIAL INCENTIVES; INTERNAL-MEDICINE; RISK ADJUSTMENT; HEALTH; PHYSICIANS; QUALITY; ORGANIZATIONS; PERFORMANCE; MEDICARE AB Primary care is essential to the effective and efficient functioning of health care delivery systems, yet there is an impending crisis in the field due in part to a dysfunctional payment system. We present a fundamentally new model of payment for primary care, replacing encounter-based imbursement with comprehensive payment for comprehensive care. Unlike former iterations of primary care capitation (which simply bundled inadequate fee-for-service payments), our comprehensive payment model represents new investment in adult primary care, with substantial increases in payment over current levels. The comprehensive payment is directed to practices to include support for the modern systems and teams essential to the delivery of comprehensive, coordinated care. Income to primary physicians is increased commensurate with the high level of responsibility expected. To ensure optimal allocation of resources and the rewarding of desired outcomes, the comprehensive payment is needs /risk-adjusted and performance-based. Our model establishes a new social contract with the primary care community, substantially increasing payment in return for achieving important societal health system goals, including improved accessibility, quality, safety, and efficiency. Attainment of these goals should help offset and justify the costs of the investment. Field tests of this and other new models of payment for primary care are urgently needed. C1 Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. Urban Inst, Washington, DC 20037 USA. Commonwealth Fund, New York, NY USA. Univ Miami, Sch Med, Dept Med, Miami, FL 33152 USA. RP Goroll, AH (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. EM ahgoroll@partners.org NR 66 TC 100 Z9 100 U1 6 U2 19 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2007 VL 22 IS 3 BP 410 EP 415 DI 10.1007/s11606-006-0083-2 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 143JX UT WOS:000244718600021 PM 17356977 ER PT J AU Souer, JS Rutgers, M Andermahr, J Jupiter, JB Ring, D AF Souer, J. Sebastiaan Rutgers, Marijn Andermahr, Jonas Jupiter, Jesse B. Ring, David TI Perilunate fracture-dislocations of the wrist: Comparison of temporary screw versus K-wire fixation SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE perilunate injury; K-wire fixation; screw fixation ID DORSAL APPROACH; MANAGEMENT; REPAIR AB Purpose: Temporary intercarpal screw fixation has been suggested as an alternative to temporary K-wire fixation in the treatment of perilunate wrist dislocations. We compared the 2 treatment methods in 2 retrospective cohorts with a null hypothesis that there would be no difference in final wrist motion. Methods: Eighteen patients with surgically treated perilunate wrist dislocations (9 treated with intercarpal screws, 9 with intercarpal K-wires) were evaluated an average of 44 months after injury. The intercarpal screws were removed an average of 5 months and the K-wires an average of 3 months after the initial procedure. Complications included 3 pin track infections (1 with wrist sepsis), 2 scaphoid nonunions (screw fixation), and 2 patients with loss of reduction (K-wire fixation) treated with repeat surgery. Results: Four patients (2 in each cohort) had wrist arthrodesis with poor results. Among the 14 remaining patients the final flexion arc was 97 degrees for patients treated with screw fixation compared with 73 degrees for patients treated with K-wires. The mean grip strength was 74% (screw fixation) and 67% (K-wire) that of the uninjured arm. According to the Mayo Modified Wrist Score, the functional result was excellent in 1 patient (screw), good in 2 patients (1 each group), fair in 6 patients (3 in each group), and poor in 9 patients (4 screws, 5 K-wire). Seven patients (2 screws, 5 K-wires) had grade 2 or 3 midcarpal arthritis according to the criteria of Knirk and Jupiter, but none had more than mild radiocarpal arthritis. Conclusions: The results of treatment with, temporary screws are comparable to the results of treatment with temporary K-wires. C1 Massachusetts Gen Hosp, Hand & Upper Extrem Serv, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Yawkey Ctr, Ste 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org NR 15 TC 26 Z9 28 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD MAR PY 2007 VL 32A IS 3 BP 318 EP 325 DI 10.1016/j.jhsa.2007.01.008 PG 8 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 148FK UT WOS:000245059800003 PM 17336837 ER PT J AU Bonkovsky, HL Snow, KK Malet, PF Back-Madruga, C Fontana, RJ Sterling, RK Kulig, CC Di Bisceglie, AM Morgan, TR Dienstag, JL Ghany, MG Gretch, DR AF Bonkovsky, Herbert L. Snow, Kristin K. Malet, Peter F. Back-Madruga, Carla Fontana, Robert J. Sterling, Richard K. Kulig, Clark C. Di Bisceglie, Adrian M. Morgan, Timothy R. Dienstag, Jules L. Ghany, Marc G. Gretch, David R. CA HALT-C Trial Grp TI Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis SO JOURNAL OF HEPATOLOGY LA English DT Article DE cirrhosis; fibrosis; health-related quality of life; hepatitis; viral type C; sexual functioning; sustained virological response ID VIRUS-INFECTION; PEGINTERFERON ALPHA-2A; SURVEY SF-36; WORK PRODUCTIVITY; PLUS RIBAVIRIN; INTERFERON; THERAPY; RELIABILITY; COMBINATION; REDUCTION AB Background/Aims: Although the antiviral and histological benefits of peginterferon/ribavirin therapy are well established, the effects on health-related quality of life (HRQOL) and sexual health are less certain. This study assessed HRQOL and sexual health in patients with advanced fibrosis or cirrhosis in the HALT-C Trial. Methods: Subjects completed SF-36 and sexual health questionnaires prior to and after 24 weeks of peginterferon/ribavirin therapy (n = 1144). Three hundred and seventy-three (33%) subjects were HCV RNA negative at week 20 and continued therapy through week 48; 258 were seen at week 72. One hundred and eighty achieved sustained virological responses (SVR) and 78 relapsed. Results: At baseline, patients had poorer scores for all eight SF-36 domains compared to healthy controls. Patients with cirrhosis had lower HRQOL scores than those with bridging fibrosis, as did patients with higher depression scores. SVR patients had significant improvements in seven domains, whereas relapsers had significant worsening in one domain. Sexual scores improved in SVR patients and decreased in relapsers (p = 0.03). In multivariate analyses, improvements in HRQOL and sexual scores were significantly associated with SVR but were less striking in patients with lower depression scores. Conclusions: Achievement of SVR after peginterferon/ribavirin therapy improves HRQOL and sexual health in chronic hepatitis C patients with advanced fibrosis or cirrhosis. (c) 2006 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. C1 Univ Connecticut, Ctr Hlth, Liver Biliary Pancreat Ctr, Farmington, CT USA. Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT USA. Univ Connecticut, Ctr Hlth, Dept Microbial & Struct Biol, Farmington, CT USA. New England Res Inst, Watertown, MA 02172 USA. Univ Texas, SW Med Ctr, Div Digest & Liver Dis, Dallas, TX USA. Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90089 USA. Univ Michigan, Med Ctr, Div Gastroenterol, Ann Arbor, MI USA. Virginia Commonwealth Univ, Hlth Syst, Div Gastroenterol Hepatol & Nutr, Hepatol Sect, Richmond, VA USA. Univ Colorado, Sch Med, Sect Hepatol, Div Gastroenterol & Hepatol, Denver, CO USA. St Louis Univ, Sch Med, Div Gastroenterol & Hepatol, St Louis, MO 63103 USA. Univ Calif Irvine, Div Gastroenterol, Irvine, CA 92717 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA USA. Massachusetts Gen Hosp, Gastrointestinal Unit, Med Serv, Boston, MA USA. NIDDKD, Liver Dis Branch, Div Digest Dis & Nutr, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Bonkovsky, HL (reprint author), Univ Connecticut, Ctr Hlth, Liver Biliary Pancreat Ctr, Farmington, CT USA. EM bonkovsky@uchc.edu FU NCRR NIH HHS [M01 RR000042, M01 RR000043, M01 RR000051, M01 RR000065, M01 RR000633, M01 RR000827, M01 RR001066, M01 RR006192, M01RR-00042, M01RR-00043, M01RR-00051, M01RR-00065, M01RR-00633, M01RR-00827, M01RR-01066, M01RR-06192]; NIDDK NIH HHS [N01-DK-9-2320, N01-DK-9-2318, N01-DK-9-2319, N01-DK-9-2321, N01-DK-9-2322, N01-DK-9-2323, N01-DK-9-2324, N01-DK-9-2325, N01-DK-9-2326, N01-DK-9-2327, N01-DK-9-2328] NR 50 TC 71 Z9 72 U1 2 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PD MAR PY 2007 VL 46 IS 3 BP 420 EP 431 DI 10.1016/j.jhep.2006.10.009 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 144QU UT WOS:000244811900011 PM 17196293 ER PT J AU Maier, H Isogawa, M Freeman, GJ Chisari, FV AF Maier, Holly Isogawa, Masanori Freeman, Gordon J. Chisari, Francis V. TI PD-1 : PD-L1 interactions contribute to the functional suppression of virus-specific CD8(+) T lymphocytes in the liver SO JOURNAL OF IMMUNOLOGY LA English DT Article ID HEPATITIS-B-VIRUS; CELL-ACTIVATION; TRANSGENIC MICE; CYTOKINE PRODUCTION; ENDOTHELIAL-CELLS; INTERFERON-GAMMA; VIRAL-INFECTION; SURFACE-ANTIGEN; EFFECTOR PHASE; PD-1 AB Mechanisms contributing to the development of chronic viral infections, including chronic hepatitis B virus (HBV) infections, are not well understood. We have shown recently that production of IFN-gamma, an important antiviral cytokine, by HBV-specific CTLs is rapidly induced when they enter the liver of HBV transgenic mice, and then rapidly suppressed, despite the continued presence of Ag. Suppression of IFN-gamma production by the CTLs coincides with the up-regulation of programmed cell death (PD)-1, a cell surface signaling molecule known to inhibit T cell function. To determine whether PD-1 plays a role in the functional suppression of IFN-gamma secretion by CTLs, we treated HBV transgenic mice with blocking Abs specific for PD ligand (PD-L)1, the most widely expressed PD-1 ligand, and adoptively transferred HBV-specific CTLs. Treatment with anti-PD-L1 Abs resulted in a delay in the suppression of IFN-gamma-producing CTLs and a concomitant increase in the absolute number of IFN-gamma-producing CTLs in the liver. These results indicate that PD-1:PD-L1 interactions contribute to the suppression of IFN-gamma secretion observed following Ag recognition in the liver. Blockade of inhibitory pathways such as PD-1:PD-L1 may reverse viral persistence and chronic infection in cases in which the CTL response is suppressed by this mechanism. C1 Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. RP Chisari, FV (reprint author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,SBR10, La Jolla, CA 92037 USA. EM fchisari@scripps.edu RI Chisari, Francis/A-3086-2008; OI Chisari, Francis/0000-0002-4832-1044 FU NCI NIH HHS [R01 CA 40489-21]; NIAID NIH HHS [T32 AI 07244-22, P01 AI 56299] NR 44 TC 135 Z9 150 U1 0 U2 15 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD MAR 1 PY 2007 VL 178 IS 5 BP 2714 EP 2720 PG 7 WC Immunology SC Immunology GA 143PH UT WOS:000244734500022 PM 17312113 ER PT J AU Sailer, CA Pott, GB Dinarello, CA Whinney, SM Forster, JE Larson-Duran, JK Landay, A Al-Harthi, L Schooley, RT Benson, CA Judson, FN Thompson, M Palella, FJ Shapiro, L AF Sailer, Carrie A. Pott, Gregory B. Dinarello, Charles A. Whinney, Samantha Ma Forster, Jeri E. Larson-Duran, Jacqueline K. Landay, Alan Al-Harthi, Lena Schooley, Robert T. Benson, Constance A. Judson, Franklyn N. Thompson, Melanie Palella, Frank J. Shapiro, Leland TI Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon-gamma levels SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 12th Conference on Retroviruses and Opportunistic Infections CY FEB 22-25, 2005 CL Boston, MA ID HIV-1-INFECTED PATIENTS; DISEASE PROGRESSION; MONONUCLEAR-CELLS; PATHOGENESIS AB Interleukin ( IL)-18 generates T helper 1-type immunity and inhibits human immunodeficiency virus type 1 ( HIV-1) in primary cells in vitro. Because IL-18 may participate in HIV-1 containment, whole-blood IL-18 levels were measured in 20 healthy control subjects and longitudinally in 28 subjects with early HIV-1 infection. Compared with those in control subjects, IL-18 levels were higher during early HIV-1 infection, and IL-18 levels predicted reduced CXCR4 HIV-1 coreceptor expression and diminished interferon ( IFN)-gamma levels. By contrast, a direct association between IL-18 and IFN-gamma levels was observed in blood stimulated with lipopolysaccharide. During early HIV-1 infection, IL-18 may regulate HIV-1 coreceptor expression and have antiretroviral activity. C1 Hlth Sci Ctr, Denver, CO USA. Denver Vet Affairs Med Ctr, Denver, CO USA. Denver Publ Hlth Dept, Denver, CO USA. Rush Univ, Med Ctr, Chicago, IL 60612 USA. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. AIDS Res Consortium Atlanta, Atlanta, GA USA. RP Shapiro, L (reprint author), Univ Colorado, Div Infect Dis, Dept Med, 4200 E 9th Ave,B168, Denver, CO 80262 USA. EM Leland.Shapiro@uchsc.edu FU NIAID NIH HHS [5 P01 AI055356-02, AI 15614] NR 15 TC 9 Z9 10 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 1 PY 2007 VL 195 IS 5 BP 734 EP 738 DI 10.1086/511435 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 136RV UT WOS:000244242700020 PM 17262717 ER PT J AU Dallalio, G Brunson, CY Means, RT AF Dallalio, Gail Brunson, Chris Y. Means, Robert T., Jr. TI Cytokine concentrations in bone marrow of stable sickle cell anemia patients SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Article; Proceedings Paper CT Meeting of the Southern-Society-for-Clinical-Research CY FEB 24, 2005 CL New Orleans, LA SP So Soc Clin Res DE sickle cell anemia; inflammation; erythropoiesis; cytokines; placental growth factor; apoptosis ID SERUM TRANSFERRIN RECEPTOR; PLACENTA GROWTH-FACTOR; CFU-E; STEADY-STATE; DISEASE; ERYTHROPOIETIN; INFLAMMATION; ACTIVATION; CHILDREN; CULTURE AB Inflammation plays a significant role in the clinical manifestations of sickle cell anemia, In studies of anemic patients with other clinical syndromes, measurement of the concentrations of cytokine mediators of inflammation in bone marrow aspirates has provided unique correlations with clinical and laboratory parameters. We determined concentrations of interleukin (IL)-1, IL-6, tumor necrosis factor (TNF), and placental growth factor (PIGF) in bone marrow aspirates from six homozygous sickle cell (SS) patients who were not acutely ill and who were not receiving hydroxyurea, erythropoietin, or chronic transfusion and compared them with specimens from seven healthy controls. We also measured concentrations of soluble transferrin receptor (sTfR) and of marrow erythroid colony-forming units (CFU-E) as markers of erythropoietic activity. sTfR concentration was significantly higher in SS patients (p = .024). CFU-E concentration was not significantly different between the two groups. Bone marrow concentrations of IL-6 and IL-1 did not differ between the study groups. TNF was undetectable in all specimens, plasma or marrow. Bone marrow PIGF concentrations were significantly higher in SS patients (p = .004). Since PIGF is a product of erythroid cells, the ratio of marrow PIGF to marrow sTfR was determined and found to be significantly greater in SS patients. This suggests that the observed difference in marrow PIGF concentrations does not reflect increased erythropoiesis but rather represents increased PIGF production per erythroid unit. C1 Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY USA. Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. Vet Affairs Med Ctr, Div Hematol, Lexington, KY USA. Vet Affairs Med Ctr, Div Oncol, Lexington, KY USA. RP Means, RT (reprint author), VA Med Ctr, Med Serv 111, Room A429,1101 Vet Dr, Lexington, KY 40502 USA. EM robert.means@uky.edu RI Means, Robert/A-4454-2008 FU NHLBI NIH HHS [HL69418] NR 28 TC 3 Z9 3 U1 1 U2 2 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD MAR PY 2007 VL 55 IS 2 SU S BP 69 EP 74 DI 10.2310/6650.2007.06029 PG 6 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 191JX UT WOS:000248128600016 PM 17362693 ER PT J AU Kis, J Engelmann, P Farkas, K Richman, G Eck, S Lolley, J Jalahej, H Borowiec, M Kent, SC Treszl, A Orban, T AF Kis, Janos Engelmann, Peter Farkas, Klara Richman, Geoffrey Eck, Shawn Lolley, James Jalahej, Heyam Borowiec, Maciej Kent, Sally C. Treszl, Andras Orban, Tihamer TI Reduced CD4+ subset and Th1 bias of the human iNKT cells in Type 1 diabetes mellitus SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE autoimmunity; V alpha 24+6B11+cells; cytokines ID KILLER T-CELLS; NKT CELLS; ALPHA-GALACTOSYLCERAMIDE; HUMAN LIVER; TCR ALPHA; RECOGNITION; AUTOIMMUNITY; ACTIVATION; EXPRESSION; DISTINCT AB Invariant NKT (iNKT) cells are considered to be important in some autoimmune diseases including Type I diabetes mellitus (T1DM). So far, the published data are contradictory in regard to the role of iNKT cells in T1DM. We aimed to study iNKT cell frequency and the function of different iNKT cell subgroups in T1DM. We compared the results of four subject groups: healthy (H), long-term T2DM (ItT2DM; more than I year), newly diagnosed T1DM (ndT1DM; less than 3 months), and ItT1DM (more than I year) individuals. We measured the iNKT cell frequencies by costaining for the invariant TCR alpha-chain with 6B11-FITC and V alpha 24-PE. After sorting the V alpha 24+6B11+ cells, the generated iNKT clones were characterized. We tested CD4, CD8, and CD161 expression and IL-4 and IFN-gamma production on TCR stimulation. The CD4+ population among the iNKT cells was decreased significantly in ItT1DM versus ndT1DM, ItT2DM, or H individuals. The T1DM iNKT cell cytokine profile markedly shifted to the Th1 direction. There was no difference in the frequency of iNKT cells in PBMC among the different patient groups. The decrease in the CD4+ population among the iNKT cells and their Th1 shift indicates dysfunction of these potentially important regulatory cells in T1DM. C1 Joslin Diabet Ctr, Sect Immunol & Immungenet, Boston, MA 02215 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA USA. Polyclin Hosp Brothers St John, Dept Internal Med, Budapest, Hungary. Univ Pecs, Fac Med, Dept Immunol & Biotechnol, Pecs, Hungary. Hosp Brothers St John, Dept Internal Med, Polyclin, Budapest, Hungary. Bajcsy Zsilinszky Hosp, Dept Med 3, Budapest, Hungary. RP Orban, T (reprint author), Joslin Diabet Ctr, Sect Immunol & Immungenet, 1 Joslin Pl, Boston, MA 02215 USA. EM tihamer.orban@joslin.harvard.edu FU NIAID NIH HHS [N01 AI15416] NR 36 TC 32 Z9 33 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD MAR PY 2007 VL 81 IS 3 BP 654 EP 662 DI 10.1189/jlb.1106654 PG 9 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 140LE UT WOS:000244505800012 PM 17151140 ER PT J AU Odegaard, JI Vats, D Zhang, L Ricardo-Gonzalez, R Smith, KL Sykes, DB Kamps, MP Chawla, A AF Odegaard, Justin I. Vats, Divya Zhang, Lina Ricardo-Gonzalez, Roberto Smith, Kristi L. Sykes, David B. Kamps, Mark P. Chawla, Ajay TI Quantitative expansion of ES cell-derived myeloid progenitors capable of differentiating into macrophages SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE cell line; alternative activation; classical activation ID TOLL-LIKE RECEPTORS; PPAR-GAMMA; ALTERNATIVE ACTIVATION; CHRONIC ENTEROCOLITIS; INFLAMMATION; ATHEROSCLEROSIS; NEUTROPHILS; METABOLISM; EXPRESSION; MODEL AB Macrophages participate in physiologic and pathologic processes through elaboration of distinct activation programs. Studies with macrophage cell systems have revealed much concerning the importance of this pleiotropic cell; however, these studies are inherently limited by three factors: heterogeneity of the target cell population, poor capacity to elaborate various activation programs, and lack of a genetically tractable model system for loss- and gain-of-function studies. Although definitive, hematopoietic lineages can be isolated from embryonic stem (ES) cells, these isolation procedures are inefficient and time-consuming and require elaborate cell-sorting protocols. We therefore examined whether myeloid precursors, capable of differentiating into macrophages, could be conditionally expanded in vitro. Here, we report methods for selective isolation and immortalization of ES cell-derived myeloid precursors by estrogen-regulated HoxA9 protein. Using this new macrophage differentiation system, an unlimited number of custom-designed macrophages with defined functional characteristics can be generated from any targeted ES cell. In combination with knockout or small interfering RNA knockdown technologies, this macrophage differentiation system provides a powerful tool for high throughput analysis of regulatory mechanisms controlling macrophage activation in health and disease. C1 Stanford Univ, Sch Med, Div Endocrinol Metab & Gerontol, Dept Med, Stanford, CA 94305 USA. Stanford Univ, Sch Med, Grad Program Immunol, Stanford, CA 94305 USA. Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA. Univ Calif San Diego, Mol Pathol Grad Program, La Jolla, CA 92093 USA. Harvard Univ, Massachusetts Gen Hosp, Dept Med, Boston, MA USA. RP Chawla, A (reprint author), Stanford Univ, Sch Med, Div Endocrinol Metab & Gerontol, Dept Med, Stanford, CA 94305 USA. EM achawla@stanford.edu FU NHLBI NIH HHS [HL076746, R01 HL076746]; NIAID NIH HHS [T32 AI007290, F31 AI066402, AI066402]; NIDDK NIH HHS [K08 DK062386, DK062386] NR 35 TC 15 Z9 15 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD MAR PY 2007 VL 81 IS 3 BP 711 EP 719 DI 10.1189/jlb.0906590 PG 9 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 140LE UT WOS:000244505800017 PM 17158607 ER PT J AU Kelly, KA Allport, JR Yu, AM Sinh, S Sage, EH Gerszten, RE Weissleder, R AF Kelly, Kimberly A. Allport, Jennifer R. Yu, Amy M. Sinh, Sumita Sage, E. Helene Gerszten, Robert E. Weissleder, Ralph TI SPARC is a VCAM-1 counter-ligand that medicates leukocyte transmigration SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE adhesion molecules; cell trafficking; phage display ID ACTIVATED VASCULAR ENDOTHELIUM; TRANSENDOTHELIAL MIGRATION; CELL-ADHESION; IN-VITRO; EF-HAND; FLOW; SELECTIN; CADHERIN; BINDING; ICAM-1 AB VCAM-1 is a cell surface molecule, which has been shown to mediate leukocyte adhesion to the endothelium and subsequent transmigration. Although VCAM-1 regulates adhesion through its interaction with VLA-4, VLA-4 does not play a role in VCAM-I-dependent diapedesis, an observation suggesting the presence of a second ligand for VCAM-1. We now report a novel interaction between VCAM-1 and secreted protein acidic and rich in cysteine (SPARC), which induces actin cytoskeletal rearrangement and intercellular gaps, physiological processes known to be important for leukocyte transmigration. The binding of leukocyte-derived SPARC to VCAM-1 was demonstrated to be necessary for leukocyte transmigration through endothelial monolayers (diapedesis) in vitro, and furthermore, SPARC null mice have abnormalities in leukocyte recruitment to the inflamed peritoneum in vivo. These findings provide new insight into the mechanisms of transendothelial leukocyte migration and suggest a potential, targetable interaction for therapeutic intervention. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA USA. Virginia Mason, Hope Heart Program, Benaroya Res Inst, Seattle, WA USA. Massachusetts Gen Hosp, Dept Cardiol, Charlestown, MA USA. RP Kelly, KA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, 149 13th St,Room 5420, Charlestown, MA 02129 USA. EM kkelly9@partners.org NR 32 TC 41 Z9 42 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD MAR PY 2007 VL 81 IS 3 BP 748 EP 756 DI 10.1189/jlb.1105664 PG 9 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 140LE UT WOS:000244505800021 PM 17178915 ER PT J AU Shirernan, PK Contreras-Shannon, V Ochoa, O Karia, BP Michalek, JE McManus, LM AF Shirernan, Paula K. Contreras-Shannon, Veronica Ochoa, Oscar Karia, Bijal P. Michalek, Joel E. McManus, Linda M. TI MCP-1 deficiency causes altered inflammation with impaired skeletal muscle regeneration SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE CCL2; macrophage; neutrophils; chemokines; ischemia ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; CC-CHEMOKINE RECEPTOR-2; SATELLITE CELLS; MYOGENIC CELLS; MICE DEFICIENT; SNAKE-VENOM; P-SELECTIN; INJURY; MACROPHAGES; DIFFERENTIATION AB We examined the role of MCP-1, a potent chemotactic and activating factor for macrophages, in perfusion, inflammation, and skeletal muscle regeneration post-ischemic injury. MCP-1-/- or C57Bl/6J control mice [wild-type (WT)] underwent femoral artery excision (FAE). Muscles were collected for histology, assessment of tissue chemokines, and activity measurements of lactate dehydrogenase (LDH) and myeloperoxidase. In MCP-1-/- mice, restoration of perfusion was delayed, and LDH and fiber size, indicators of muscle regeneration, were decreased. Altered inflammation was observed with increased neutrophil accumulation in MCP-1-/- versus WT mice at Days I and 3 (P <= 0.003), whereas fewer macrophages were present in MCP-1-/- mice at Day 3. As necrotic tissue was removed in ViT mice, macrophages decreased (Day 7). In contrast, macrophage accumulation in MCP-1-/- was increased in association with residual necrotic tissue and impaired muscle regeneration. Consistent with altered inflammation, neutrophil chemotactic factors (keratinocyte-derived chemokine mid macrophage inflammatory protein-2) were increased at Day I post-FAE. The macrophage cheniotactic factor MCP-5 was increased significantly in WT juice at Day 3 compared with MCP-1-/- mice. However, at post-FAE Day 7, MCP-5 was significantly elevated in MCP-1-/- mice versus WT mice. Addition of exogenous MCP-1 did not induce proliferation in murine myoblasts (C2C12 cells) in vitro. MCP-1 is essential for reperfusion and the successful completion of normal skeletal muscle regeneration after ischemic tissue injury. Impaired muscle regeneration in MCP-1-/- mice suggests an important role for macrophages and MCP-1 in tissue reparative processes. C1 Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Periodont, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Shirernan, PK (reprint author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr,MC 7741, San Antonio, TX 78229 USA. EM shireman@uthscsa.edu FU NHLBI NIH HHS [HL070158, HL04776, HL074236]; NIAMS NIH HHS [AR052610] NR 61 TC 99 Z9 102 U1 0 U2 4 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD MAR PY 2007 VL 81 IS 3 BP 775 EP 785 DI 10.1189/jlb.0506356 PG 11 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 140LE UT WOS:000244505800024 PM 17135576 ER PT J AU Fitzgerald, ML Xavier, R Haley, KJ Welti, R Goss, JL Brown, CE Zhuang, DZ Bell, SA Lu, NF Mckee, M Seed, B Freeman, MW AF Fitzgerald, Michael L. Xavier, Ramnik Haley, Kathleen J. Welti, Ruth Goss, Julie L. Brown, Cari E. Zhuang, Debbie Z. Bell, Susan A. Lu, Naifang Mckee, Mary Seed, Brian Freeman, Mason W. TI ABCA3 inactivation in mice causes respiratory failure, loss of pulmonary surfactant, and depletion of lung phosphatidylglycerol SO JOURNAL OF LIPID RESEARCH LA English DT Article DE ATP cassette binding transporterA1; lipid transporter; lamellar body ID TANDEM MASS-SPECTROMETRY; PROTEIN-B; MEMBRANE-PROTEIN; GENE ABCR; II CELLS; MUTATIONS; DISEASE; DEFICIENCY; ARABIDOPSIS; CHOLESTEROL AB The highly branched mammalian lung relies on surfactant, a mixture of phospholipids, cholesterol, and hydrophobic proteins, to reduce intraalveolar surface tension and prevent lung collapse. Human mutations in the ABCA3 transporter have been associated with childhood respiratory disease of variable severity and onset. Here, we report the generation of Abca3 null mice, which became lethargic and cyanotic and died within 1 h of birth. Tissue blots found ABCA3 expression was highest in lung but was also detectable in other tissues, including the kidney. Gross development of kidney and lung was normal in neonatal Abca3(-/-) pups, but the mice failed to inflate their lungs, leading to death from atelectatic respiratory failure. Ultrastructural analysis of the Abca3-/- lungs revealed an absence of surfactant from the alveolar space and a profound loss of mature lamellar bodies, the intracellular storage organelle for surfactant. Mass spectrometry measurement of > 300 phospholipids in lung tissue taken from Abca3(-/-) mice showed a dramatic reduction of phosphatidylglycerol (PG) levels as well as selective reductions in phosphatidylcholine species containing short acyl chains. These results establish a requirement of ABCA3 for lamellar body formation and pulmonary surfactant secretion and suggest a unique and critical role for the transporter in the metabolism of pulmonary PG. They also demonstrate the utility of the Abca3 null mouse as a model for a devastating human disease. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lipid Metab Unit, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Programe Membrane Biol, Boston, MA 02114 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Pulm & Crit Care Med, Boston, MA 02364 USA. Kansas State Univ, Div Biol, Manhattan, KS 66506 USA. RP Freeman, MW (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lipid Metab Unit, Boston, MA 02114 USA. EM freeman@molbio.mgh.harvard.edu FU NCRR NIH HHS [P20 RR-16475]; NHLBI NIH HHS [HL-72358, HL-45098, HL-074136, HL-68988]; NIDDK NIH HHS [DK-43351, DK-57521, P30 DK040561, P30 DK040561-11] NR 29 TC 90 Z9 91 U1 0 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD MAR PY 2007 VL 48 IS 3 BP 621 EP 632 DI 10.1194/jlr.M600449-JLR200 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 142JO UT WOS:000244645800014 PM 17142808 ER PT J AU Lorenz, C Benner, T Chen, PJ AF Lorenz, C. Benner, T. Chen, P. J. TI Automated perfusion-weighted MRI using localized arterial input functions. (vol 24, pg 1133, 2006) SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Correction C1 Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. Harvard MIT, Div Hlth Sci & Technol, Charlestown, MA USA. MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA. MIT, Dept Nucl Engn, Cambridge, MA 02139 USA. Massachusetts Gen Hosp, Stroke Serv, Boston, MA 02114 USA. Univ Helsinki, Cent Hosp, Funct Brain Imaging Unit, Helsinki Brain Res Ctr, Helsinki, Finland. Finnish Def Forces, Ctr Mil Med, Helsinki, Finland. Univ Turku, Dept Diagnost Radiol, Turku, Finland. Kuopio Univ Hosp, Dept Clin Radiol, Kuopio, Finland. Kuopio Univ Hosp, Dept Neurol, Kuopio, Finland. RP Lorenz, C (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD MAR PY 2007 VL 25 IS 3 BP 666 EP 666 DI 10.1002/jmri.20869 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 143CY UT WOS:000244698800028 ER PT J AU Kilbourne, AM Bauer, MS Nossek, A Drill, LJ Cooley, S Post, EP AF Kilbourne, Amy M. Bauer, Mark S. Nossek, Agnes Drill, Larry J. Cooley, Susan Post, Edward P. TI Improving general medical care for patients with bipolar disorder: A randomized, controlled effectiveness trial SO JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS LA English DT Meeting Abstract C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. VA Pittsburgh, Pittsburgh, PA 15240 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU INT CENTER MENTAL HEALTH POLICY & ECONOMICS-ICMPE PI MILANO PA VIA DANIELE CRESPI 7, MILANO, 20123, ITALY SN 1091-4358 J9 J MENT HEALTH POLICY JI J. Ment. Health Policy Econ. PD MAR PY 2007 VL 10 SU 1 BP S21 EP S22 PG 2 WC Health Policy & Services; Psychiatry SC Health Care Sciences & Services; Psychiatry GA 166OQ UT WOS:000246388800048 ER PT J AU Kilbourne, AM Biswas, K Sajatovic, M Pirraglia, PA Williford, WO Bauer, MS AF Kilbourne, Amy M. Biswas, Kousick Sajatovic, Martha Pirraglia, Paul A. Williford, William O. Bauer, Mark S. TI Is the chronic care model effective for complex patients?: Analyzing moderators of treatment effect in bipolar disorder SO JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS LA English DT Meeting Abstract C1 Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. VA Pittsburgh, Pittsburgh, PA 15240 USA. RI Sajatovic, Martha/I-8001-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT CENTER MENTAL HEALTH POLICY & ECONOMICS-ICMPE PI MILANO PA VIA DANIELE CRESPI 7, MILANO, 20123, ITALY SN 1091-4358 J9 J MENT HEALTH POLICY JI J. Ment. Health Policy Econ. PD MAR PY 2007 VL 10 SU 1 BP S22 EP S22 PG 1 WC Health Policy & Services; Psychiatry SC Health Care Sciences & Services; Psychiatry GA 166OQ UT WOS:000246388800049 ER PT J AU Wisniewski, SR Rush, AJ Bryan, C Shelton, R Trivedi, MH Marcus, S Husain, MM Hollon, SD Fava, M AF Wisniewski, Stephen R. Rush, A. John Bryan, Charlene Shelton, Richard Trivedi, Madhukar H. Marcus, Sheila Husain, Mustafa M. Hollon, Steven D. Fava, Maurizio CA STAR D Investigators TI Comparison of quality of life measures in a depressed population SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE quality of life; depression; function; satisfaction ID ILLNESS RATING-SCALE; REPORT QIDS-SR; PSYCHOMETRIC EVALUATION; SYMPTOMATOLOGY IDS; QUICK INVENTORY AB Measures of quality of life have been increasingly used in clinical trials. When designing a study, researchers must decide which quality of life measure to use. Some literature provides guidance through general recommendations, though lacks quantitative comparisons. In this report, 2 general quality of life measures, the 12-Item Short Form Health Survey (SF-12) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), are compared in a depressed population. STAR*D data were used to analyze the associations among the SF-12 and the Q-LES-Q. Each measure covers 6 domains, overlapping on 5 (health, self-esteem/ well-being, community/productivity, social/love relationships, leisure/creativity), with the SF-12 addressing family and the Q-LES-Q addressing living situations. Strong item-by-item associations exist only between the Q-LES-Q and the SF-12 physical health items. The 2 measures overlap on the domains covered while the lack of correlation between the 2 measures may be attributed to the perspective of each question as the Q-LES-Q measures satisfaction while the SF-12 measures the patient's perception of function. C1 Univ Pittsburgh, Epidemiol Data Ctr, Pittsburgh, PA 15261 USA. Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75230 USA. Vanderbilt Univ, Med Ctr, Dept Psychiat, Nashville, TN USA. Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. RP Wisniewski, SR (reprint author), Univ Pittsburgh, Epidemiol Data Ctr, 127 Parran Hall,130 DeSoto St, Pittsburgh, PA 15261 USA. EM wisniew@edc.pitt.edu OI Wisniewski, Stephen/0000-0002-3877-9860; Rush, Augustus/0000-0003-2004-2382 FU NIMH NIH HHS [N01MH90003] NR 22 TC 18 Z9 18 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD MAR PY 2007 VL 195 IS 3 BP 219 EP 225 DI 10.1097/01.nmd.0000258229.38212.6f PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 146MP UT WOS:000244938900006 PM 17468681 ER PT J AU Biederman, J Petty, CR Fried, R Fontanella, J Doyle, AE Seidman, LJ Faraone, SV AF Biederman, Joseph Petty, Carter R. Fried, Ronna Fontanella, Jessie Doyle, Alysa E. Seidman, Larry J. Faraone, Stephen V. TI Can self-reported Behavioral scales assess executive function deficits? A controlled study of adults with ADHD SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE self-reported executive function deficits; Barkley scales; EFDs ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; HYPERACTIVITY DISORDER; CHILDREN; NEUROPSYCHOLOGY; PERFORMANCE; DIAGNOSIS; IMPACT AB One of the suspected sources of negative outcomes associated with attention-deficit/hyperactivity disorder (ADHD) has been a deficit in executive functions (EFD). Although self-report questionnaires purport to assess behavioral concomitants of EFDs, little is known about their informativeness. The aim was to examine the association between self-reported behavioral concomitants of EFDs and functional outcomes among adults with ADHD. Subjects were adults with (N = 200) and without (N = 138) DSM-IV criteria for ADHD. The Current Behavior Scale (CBS) was used as a proxy for EFDs. The 50th percentile of the ADHD subjects' total CBS scores explained the most variance in the functional outcomes compared with other cutoffs, and it identified subjects with more impaired global functioning, more comorbidities, and lower socioeconomic status. Scores on the CBS above the 50th percentile identify adults with ADHD at significantly higher risk for functional morbidity beyond that conferred by the diagnosis of ADHD alone. C1 Massachusetts Gen Hosp, Dept Psychiat, Pediat Psychopharmacol Unit, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Psychiat, ADHD Program, Boston, MA 02114 USA. SUNY Syracuse, Dept Psychiat & Behav Sci, Syracuse, NY USA. RP Biederman, J (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Pediat Psychopharmacol Unit, Warren 705,55 Sfuit St, Boston, MA 02114 USA. EM biederman@helix.mgh.harvard.edu OI Faraone, Stephen/0000-0002-9217-3982 FU NIMH NIH HHS [R01MH57934] NR 29 TC 15 Z9 17 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD MAR PY 2007 VL 195 IS 3 BP 240 EP 246 DI 10.1097/01.nmd.0000243968.06789.73 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 146MP UT WOS:000244938900009 PM 17468684 ER PT J AU Jensen, RJ Rizzo, JF AF Jensen, Ralph J. Rizzo, Joseph F., III TI Responses of ganglion cells to repetitive electrical stimulation of the retina SO JOURNAL OF NEURAL ENGINEERING LA English DT Article; Proceedings Paper CT Eye and the Chip World Congress on Artificial Vision CY JUN 15-17, 2006 CL Detroit Inst Ophthalmol, Detroit, MI HO Detroit Inst Ophthalmol ID PAIRED-PULSE DEPRESSION; RABBIT; THRESHOLDS; ACTIVATION; PLASTICITY; SYNAPSE; VISION AB Retinal ganglion cells (RGCs) can be activated electrically either directly or indirectly (via the retinal neural network). Previous studies have shown that RGCs can follow high stimulus rates (>= 200 pulses s(-1)) when directly activated. In the present study, we investigated how well RGCs can follow repetitive stimulation of the neural network. We studied the responses (spike activity) of RGCs in isolated rabbit retina to stimulation with paired pulses applied at different interpulse intervals and trains of pulses applied at different frequencies. We found that the response amplitude of a RGC to a current pulse applied soon (<= 400 ms) after a preceding current pulse is diminished. This depression in response amplitude became greater as the interval between pulses became shorter. At an interpulse interval of 15 ms (shortest tested), the response amplitude to the second current pulse was reduced on average 94%. When a train of ten stimulus pulses was applied, further depression was observed, particularly at high stimulation frequencies. The depression with each successive pulse was relatively moderate compared to the depression to the second pulse. The results of this study have implications for the design of electrical stimulation strategies in a retinal prosthesis. C1 VA Boston Healthcare Syst, Ctr Innovat Visual Rehabil, Boston, MA 02130 USA. Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA. RP Jensen, RJ (reprint author), VA Boston Healthcare Syst, Ctr Innovat Visual Rehabil, Mail Stop 151E,150 S Huntington Ave, Boston, MA 02130 USA. EM Ralph.Jensen@med.va.gov NR 19 TC 64 Z9 64 U1 1 U2 6 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 1741-2560 J9 J NEURAL ENG JI J. Neural Eng. PD MAR PY 2007 VL 4 IS 1 SI SI BP S1 EP S6 DI 10.1088/1741-2560/4/1/S01 PG 6 WC Engineering, Biomedical; Neurosciences SC Engineering; Neurosciences & Neurology GA 155XT UT WOS:000245612700002 PM 17325407 ER PT J AU Merabet, LB Rizzo, JF Pascual-Leone, A Fernandez, E AF Merabet, Lotfi B. Rizzo, Joseph F., III Pascual-Leone, Alvaro Fernandez, Eduardo TI Who is the ideal candidate? Decisions and issues relating to visual neuroprosthesis development, patient testing and neuroplasticity SO JOURNAL OF NEURAL ENGINEERING LA English DT Article; Proceedings Paper CT Eye and the Chip World Congress on Artificial Vision CY JUN 15-17, 2006 CL Detroit Inst Ophthalmol, Detroit, MI HO Detroit Inst Ophthalmol ID CROSS-MODAL PLASTICITY; TRANSCRANIAL MAGNETIC STIMULATION; ELECTRICAL-STIMULATION; BLIND HUMANS; VISION; CORTEX; PERCEPTION; RECOGNITION; DISEASES; RETINA AB Appropriate delivery of electrical stimulation to intact visual structures can evoke patterned sensations of light in individuals who have been blind for many years. This pivotal finding has lent credibility to the concept of restoring functional vision by artificial means. As numerous groups worldwide pursue human clinical testing with visual prosthetic devices, it is becoming increasingly clear that there remains a considerable gap between the challenges of prosthetic device development and the rehabilitative strategies needed to implement this new technology in patients. An important area of future work will be the development of appropriate pre- and post-implantation measures of performance and establishing candidate selection criteria in order to quantify technical advances, guide future device design and optimize therapeutic success. We propose that the selection of an 'ideal' candidate should also be considered within the context of the variable neuroplastic changes that follow vision loss. Specifically, an understanding of the adaptive and compensatory changes that occur within the brain could assist in guiding the development of post-implantation rehabilitative strategies and optimize behavioral outcomes. C1 Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Noninvas Brain Stimulat,Dept Neurol, Boston, MA 02115 USA. Univ Miguel Hernandez, Inst Bioingn, Elche, Spain. Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Merabet, LB (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Noninvas Brain Stimulat,Dept Neurol, Boston, MA 02115 USA. EM lmerabet@bidmc.harvard.edu RI Fernandez, Eduardo/S-8206-2016 NR 28 TC 14 Z9 14 U1 0 U2 2 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 1741-2560 J9 J NEURAL ENG JI J. Neural Eng. PD MAR PY 2007 VL 4 IS 1 SI SI BP S130 EP S135 DI 10.1088/1741-2560/4/1/S15 PG 6 WC Engineering, Biomedical; Neurosciences SC Engineering; Neurosciences & Neurology GA 155XT UT WOS:000245612700016 PM 17325411 ER PT J AU Hessburg, PC Rizzo, JF AF Hessburg, Philip C. Rizzo, Joseph F., III TI The Eye and the Chip. World Congress on Artificial Vision 2006 SO JOURNAL OF NEURAL ENGINEERING LA English DT Editorial Material C1 Detroit Inst Ophthalmol, Grosse Pointe Pk, MI 48230 USA. Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Hessburg, PC (reprint author), Detroit Inst Ophthalmol, Grosse Pointe Pk, MI 48230 USA. NR 0 TC 3 Z9 3 U1 0 U2 1 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 1741-2560 J9 J NEURAL ENG JI J. Neural Eng. PD MAR PY 2007 VL 4 IS 1 SI SI DI 10.1088/1741-2560/4/1/E01 PG 2 WC Engineering, Biomedical; Neurosciences SC Engineering; Neurosciences & Neurology GA 155XT UT WOS:000245612700001 ER PT J AU Klucken, J McLean, PJ Winkler, J Hyman, BT AF Klucken, J. McLean, P. J. Winkler, J. Hyman, B. T. TI Lysosomal degradation in Lewy bodies and alpha-synuclein aggregation SO JOURNAL OF NEURAL TRANSMISSION LA English DT Meeting Abstract CT 5th Congress Deutsche-Parkinson-Gesellschaft CY MAR 07-10, 2007 CL Ulm, GERMANY SP Deutsch Parkinson Gesell C1 Univ Klin Regensburg, Regensburg, Germany. Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0300-9564 J9 J NEURAL TRANSM JI J. Neural Transm. PD MAR PY 2007 VL 114 IS 3 BP X EP XI PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 140DU UT WOS:000244485200049 ER PT J AU Zucker, B Kama, JA Cantuti-Castelvetri, I Kuhn, A Weiller, C Young, AB Luthi-Carter, R AF Zucker, B. Kama, J. A. Cantuti-Castelvetri, I. Kuhn, A. Weiller, C. Young, A. B. Luthi-Carter, R. TI Regional dysfunction of laser-dissected corticostriatal neurons in Huntington's disease transgenic mice and human brains SO JOURNAL OF NEURAL TRANSMISSION LA English DT Meeting Abstract CT 5th Congress Deutsche-Parkinson-Gesellschaft CY MAR 07-10, 2007 CL Ulm, GERMANY SP Deutsch Parkinson Gesell C1 Freiburg Univ Hosp, Freiburg, Germany. Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. Ecole Polytechn Fed Lausanne, Lausanne, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0300-9564 J9 J NEURAL TRANSM JI J. Neural Transm. PD MAR PY 2007 VL 114 IS 3 BP XXVII EP XXVIII PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 140DU UT WOS:000244485200107 ER PT J AU Turner, CD Chi, S Marcus, KJ MacDonald, T Packer, RJ Poussaint, TY Vajapeyam, S Ullrich, N Goumnerova, LC Scott, RM Briody, C Chordas, C Zimmerman, MA Kieran, MW AF Turner, Christopher D. Chi, Susan Marcus, Karen J. MacDonald, Tobey Packer, Roger J. Poussaint, Tina Young Vajapeyam, Sridhar Ullrich, Nicole Goumnerova, Liliana C. Scott, R. Michael Briody, Caitlin Chordas, Christine Zimmerman, Mary Ann Kieran, Mark W. TI Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE thalidomide; radiation therapy; children; brain stem glioma; glioblastoma multiforme; advanced MR techniques; biologic correlative studies ID HIGH-GRADE GLIOMAS; CANCER GROUP; TRIAL; CHEMOTHERAPY; THERAPY; RADIOTHERAPY; TEMOZOLOMIDE; CHILDHOOD; ANALOGS; AGENT AB A phase II study was conducted to assess the efficacy of administering daily thalidomide concomitantly with radiation and continuing for up to 1 year following radiation in children with brain stem gliomas (BSG) or glioblastoma multiforme (GBM). Secondary objectives were to obtain preliminary evidence of biologic activity of thalidomide and to evaluate toxicities from chronic administration of thalidomide in this population. Thirteen patients (2-14 years old) with newly diagnosed BSG (12 patients) or GBM (one patient) were enrolled between July 1999 and June 2000. All patients received focal radiotherapy to a total dose of 5,580 cGy. Thalidomide was administered once daily beginning on the first day of radiation and continued for 12 months or until the patient came off study. The starting dose was 12 mg/kg (rounded down to the nearest 50 mg) and was increased by 20% weekly, if tolerated, to 24 mg/kg or 1,000 mg (whichever was lower). Advanced imaging techniques and urine and serum analysis for anti-angiogenic markers were performed in some patients in an attempt to correlate changes with clinical effect of therapy. No patients completed the planned 12 months of thalidomide therapy and all have since died of disease progression. The median duration of therapy was 5 months (range 2-11 months). Nine patients came off study for progressive disease (PD), three patients due to toxicity and one patient withdrew consent. Several patients on this study required more extended courses of high dose steroids than would have been otherwise expected for this population due to significant peritumoral edema and necrosis. No consistent pattern emerged from the biologic correlative studies from 11 patients. However, advanced imaging with techniques such as MR spectroscopy, MR perfusion and 18-fluorodeoxyglucose positron emission tomography (FDG-PET) were helpful in distinguishing growing tumor from treatment effect and necrosis in some patients. The median time to progression (TTP) was 5 months (range 2-11 months) and the median time to death (TTD) was 9 months (range 5-17 months). In this small patient sample adding thalidomide to radiation did not improve TTP or TTD from historical controls, however, toxicity appeared to be increased. C1 Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. Childrens Hosp, Dept Med, Div Radiat Oncol, Boston, MA 02115 USA. Childrens Natl Med Ctr, Dept Neurol, Washington, DC 20010 USA. Childrens Natl Med Ctr, Dept Hematol Oncol, Washington, DC 20010 USA. Childrens Hosp, Dept Radiol, Boston, MA 02115 USA. Childrens Hosp, Dept Neurol, Boston, MA 02115 USA. Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA. RP Turner, CD (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St,SW 331, Boston, MA 02115 USA. EM christopher_turner@dfci.harvard.edu RI MacDonald, Tobey/D-4554-2013; OI Kieran, Mark/0000-0003-2184-7692 NR 23 TC 42 Z9 43 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD MAR PY 2007 VL 82 IS 1 BP 95 EP 101 DI 10.1007/s11060-006-9251-9 PG 7 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 136CA UT WOS:000244199000014 PM 17031553 ER PT J AU Ramesh, V Thatte, HS McCarley, RW Basheer, R AF Ramesh, Vijay Thatte, Hemant S. McCarley, Robert W. Basheer, Radhika TI Adenosine and sleep deprivation promote NF-kappa B nuclear translocation in cholinergic basal forebrain SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE adenosine; cholinergic basal forebrain; EEG delta activity; NF-kappa B; sleep deprivation ID FOS-LIKE IMMUNOREACTIVITY; RAT-BRAIN; PROLONGED WAKEFULNESS; RECEPTOR EXPRESSION; GENE-EXPRESSION; RECOVERY SLEEP; MESSENGER-RNAS; A(1) RECEPTOR; NEURONS; INCREASES AB In our investigations related to the homeostatic sleep factor adenosine (AD), we previously demonstrated that the DNA-binding activity of the transcription factor NF-kappa B in rat cholinergic basal forebrain increased following 3 h of sleep deprivation (SD). However, the neurotransmitter nature of the cells and the SD-induced stimuli responsible for NF-kappa B activation were not defined. In this report, we demonstrate, using double labeling immunohistochemistry, that nuclear translocation of NF-kappa B occurs almost exclusively in the cholinergic neurons of the basal forebrain following 3 h of SD. Furthermore, cholinergic basal forebrain microinjection of AD (25 nmol/L) or the A(1) receptor agonist N-6-cyclo-hexyladenosine (100 nmol/L) induced nuclear translocation of NF-kappa B, thus suggesting that SD-induced increased extracellular concentrations of AD, acting via the A(1) AD receptor, may be responsible for the nuclear translocation of NF-kappa B in cholinergic neurons. Moreover, blocking the nuclear translocation of NF-kappa B by injection of inhibitor peptide, SN50, immediately prior to 6 h SD significantly reduced delta activity (1-4 Hz) during the first two hours of recovery sleep. Together, these data suggest a role in sleep homeostasis for the SD-induced activation of NF-kappa B in cholinergic basal forebrain, and that transcription factor NF-kappa B may code for factor(s) that play a role in sleep homeostasis. C1 Dept Psychiat, Boston, MA 02132 USA. Harvard Univ, Sch Med, W Roxbury, MA USA. VA Boston Healthcare Syst, Dept Psychiat, W Roxbury, MA USA. VA Boston Healthcare Syst, Dept Surg, W Roxbury, MA USA. RP Basheer, R (reprint author), Dept Psychiat, 1400 VFW Pkwy,Bldg 3,Room 2A101, Boston, MA 02132 USA. EM radhika_basheer@hms.harvard.edu RI McCarley, Robert/N-5562-2014 OI McCarley, Robert/0000-0001-5705-7495 FU NIMH NIH HHS [MH39683] NR 46 TC 23 Z9 24 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD MAR PY 2007 VL 100 IS 5 BP 1351 EP 1363 DI 10.1111/j.1471-4159.2006.04314.x PG 13 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 134WN UT WOS:000244115200019 PM 17316404 ER PT J AU St Martin, JL Klucken, J Outeiro, TF Nguyen, P Keller-McGandy, C Cantuti-Castelvetri, I Grammatopoulos, TN Standaert, DG Hyman, BT McLean, PJ AF St Martin, Jessie L. Klucken, Jochen Outeiro, Tiago F. Nguyen, Paul Keller-McGandy, Christine Cantuti-Castelvetri, Ippolita Grammatopoulos, Tom N. Standaert, David G. Hyman, Bradley T. McLean, Pamela J. TI Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE adeno-associated virus; heat shock proteins; laser capture microdissection; Parkinson's disease; substantia nigra; alpha-synuclein ID PARKINSONS-DISEASE; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; MOLECULAR CHAPERONES; LEWY BODIES; TOXICITY; RAT; OVEREXPRESSION; AGGREGATION; SUPPRESSION; MICE AB Several transgenic mouse lines with altered alpha-synuclein expression have been developed that show a variety of Parkinson's disease-like symptoms without specific loss of dopaminergic neurons. Targeted over-expression of human alpha-synuclein using viral-vector mediated gene delivery into the substantia nigra of rats and non-human primates leads to dopaminergic cell loss and the formation of alpha-synuclein aggregates reminiscent of Lewy bodies. In the context of these recent findings, we used adeno-associated virus (AAV) to over-express wild type human alpha-synuclein in the substantia nigra of mice. We hypothesized that this over-expression would recapitulate pathological hallmarks of Parkinson's disease, creating a mouse model to further characterize the disease pathogenesis. Recombinant AAV expressing alpha-synuclein was stereotaxically injected into the substantia nigra of mice, leading to a 25% reduction of dopaminergic neurons after 24 weeks of transduction. Furthermore, examination of mRNA levels of stress-related proteins using laser capture microdissection and quantitative PCR revealed a positive correlation of Hsp27 expression with the extent of viral transduction at 4 weeks and a positive correlation of Hsp40, Hsp70 and caspase 9 with the extent of viral transduction at 24 weeks. Taken together, our findings suggest that targeted over-expression of alpha-synuclein can induce pathology at the gross anatomical and molecular level in the substantia nigra, providing a mouse model in which upstream changes in Parkinson's disease pathogenesis can be further elucidated. C1 Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Alzheimer Res Unit, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Neurol Serv, Charlestown, MA 02129 USA. RP McLean, PJ (reprint author), Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Alzheimer Res Unit, 114 16th St, Charlestown, MA 02129 USA. EM pmclean@partners.org RI Outeiro, Tiago/C-1067-2008; OI Outeiro, Tiago/0000-0003-1679-1727; Grammatopoulos, Tom/0000-0001-7175-051X; Standaert, David/0000-0003-2921-8348 FU NINDS NIH HHS [P50 NS038372, P50 NS38372] NR 32 TC 75 Z9 77 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD MAR PY 2007 VL 100 IS 6 BP 1449 EP 1457 DI 10.1111/j.1471-4159.2006.04310.x PG 9 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 143KS UT WOS:000244720700002 PM 17241127 ER PT J AU Johnson, KA Moran, EK Becker, JA Blacker, D Fischman, AJ Albert, MS AF Johnson, K. A. Moran, E. K. Becker, J. A. Blacker, D. Fischman, A. J. Albert, M. S. TI Single photon emission computed tomography perfusion differences in mild cognitive impairment SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY LA English DT Article ID EARLY ALZHEIMERS-DISEASE; PRECLINICAL PREDICTION; GLUCOSE-METABOLISM; FDG-PET; SPECT; DEMENTIA; AD; HYPOMETABOLISM; CONVERSION; DIAGNOSIS AB Objective: To relate cerebral perfusion abnormalities to subsequent changes in clinical status among patients with mild cognitive impairment (MCI). Methods: Perfusion single photon emission computed tomography (SPECT) images were acquired in 105 elderly patients without dementia with MCI, using 99mTc-HMPAO. Clinical outcome after a 5-year follow-up period was heterogeneous. Results: Baseline SPECT data differed in those patients with MCI who were later diagnosed with Alzheimer's disease (the converter group) from those patients with MCI who experienced clinically evident decline but did not progress to a diagnosis of Alzheimer's disease within the follow-up period (the decliner group), from patients with MCI who had no clinical evidence of progression (the stable group), and from a group of 19 normal subjects (the control group). The most consistent decreases in relative perfusion in converters compared with the normal, stable and decliner groups were observed in the caudal anterior cingulate, and in the posterior cingulate. In addition, converters showed increased relative perfusion in the rostral anterior cingulate in comparison to the stable and decliner groups. A group of patients with Alzheimer's disease were also included for purposes of comparison. The group of patients with Alzheimer's disease at baseline differed from each of the other groups, with temporoparietal regions showing the most significant reductions in perfusion. Conclusions: These results suggest that clinical heterogeneity in MCI is reflected in SPECT perfusion differences, and that the pattern of perfusion abnormalities evolves with increasing clinical severity. C1 Massachusetts Gen Hosp, Dept Radiol Nucl Med, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. RP Johnson, KA (reprint author), Massachusetts Gen Hosp, Dept Radiol Nucl Med, Fruit St, Boston, MA 02114 USA. EM kajohnson@partners.org FU NIA NIH HHS [P01-AG04953] NR 41 TC 31 Z9 34 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-3050 J9 J NEUROL NEUROSUR PS JI J. Neurol. Neurosurg. Psychiatry PD MAR PY 2007 VL 78 IS 3 BP 240 EP 247 DI 10.1136/jnnp.2006.096800 PG 8 WC Clinical Neurology; Psychiatry; Surgery SC Neurosciences & Neurology; Psychiatry; Surgery GA 137EZ UT WOS:000244277100006 PM 17056633 ER PT J AU Einevoll, GT Pettersen, KH Devor, A Ulbert, I Halgren, E Dale, AM AF Einevoll, Gaute T. Pettersen, Klas H. Devor, Anna Ulbert, Istvan Halgren, Eric Dale, Anders M. TI Laminar population analysis: Estimating firing rates and evoked synaptic activity from multielectrode recordings in rat barrel cortex SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article ID CURRENT-SOURCE-DENSITY; FIELD POTENTIALS; CORTICAL COLUMN; CEREBRAL-CORTEX; IN-VITRO; LAYER 4; NEURONS; CONNECTIONS; NEOCORTEX; ORGANIZATION AB We present a new method, laminar population analysis (LPA), for analysis of laminar-electrode ( linear multielectrode) data, where physiological constraints are explicitly incorporated in the mathematical model: the high-frequency band [multiunit activity (MUA)] is modeled as a sum over contributions from firing activity of multiple cortical populations, whereas the low-frequency band [ local field potential (LFP)] is assumed to reflect the dendritic currents caused by synaptic inputs evoked by this firing. The method is applied to stimulus-averaged laminar-electrode data from barrel cortex of anesthetized rat after single whisker flicks. Two sample data sets, distinguished by stimulus paradigm, type of applied anesthesia, and electrical boundary conditions, are studied in detail. These data sets are well accounted for by a model with four cortical populations: one supragranular, one granular, and two infragranular populations. Population current source densities (CSDs; the CSD signatures after firing in a particular population) provided by LPA are further used to estimate the synaptic connection pattern between the various populations using a new LFP template-fitting technique, where LFP population templates are found by the electrostatic forward solution based on results from compartmental modeling of morphologically reconstructed neurons. Our analysis confirms previous experimental findings regarding the synaptic connections from neurons in the granular layer onto neurons in the supragranular layers and provides predictions about other synaptic connections. Furthermore, the time dependence of the stimulus-evoked population firing activity is predicted, and the temporal ordering of response onset is found to be compatible with earlier findings. C1 Norwegian Univ Life Sci, Dept Math Sci & Technol, N-1432 As, Norway. Norwegian Univ Life Sci, Ctr Integrat Genet, N-1432 As, Norway. Massachusetts Gen Hosp, Athinoula A Martinos Ctr, Charlestown, MA USA. Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA. Hungarian Acad Sci, Inst Psychol, Budapest, Hungary. RP Einevoll, GT (reprint author), Norwegian Univ Life Sci, Dept Math Sci & Technol, POB 5003, N-1432 As, Norway. EM Gaute.Einevoll@umb.no RI Ulbert, Istvan/F-2213-2010; Dale, Anders/A-5180-2010 FU NIBIB NIH HHS [R01 EB-00790, R01 EB000790]; NINDS NIH HHS [NS-051188, NS-1874, R01 NS018741, R01 NS051188] NR 39 TC 79 Z9 80 U1 0 U2 14 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD MAR PY 2007 VL 97 IS 3 BP 2174 EP 2190 DI 10.1152/jn.00845.2006 PG 17 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 145KW UT WOS:000244864900033 PM 17182911 ER PT J AU Wilson, EC Melcher, JR Micheyl, C Gutschalk, A Oxenham, AJ AF Wilson, E. Courtenay Melcher, Jennifer R. Micheyl, Christophe Gutschalk, Alexander Oxenham, Andrew J. TI Cortical fMRI activation to sequences of tones alternating in frequency: Relationship to perceived rate and streaming SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article ID PRIMARY AUDITORY-CORTEX; SOUND-LEVEL; PERCEPTUAL ORGANIZATION; SONGBIRD FOREBRAIN; TIME INTERVALS; ACOUSTIC NOISE; STIMULUS RATE; HUMAN BRAIN; SEGREGATION; MODULATION AB Human listeners were functionally imaged while reporting their perception of sequences of alternating-frequency tone bursts separated by 0, 1/8, 1, or 20 semitones. Our goal was to determine whether functional magnetic resonance imaging ( fMRI) activation of auditory cortex changes with frequency separation in a manner predictable from the perceived rate of the stimulus. At the null and small separations, the tones were generally heard as a single stream with a perceived rate equal to the physical tone presentation rate. fMRI activation in auditory cortex was appreciably phasic, showing prominent peaks at the sequence onset and offset. At larger-frequency separations, the higher- and lower-frequency tones perceptually separated into two streams, each with a rate equal to half the overall tone presentation rate. Under those conditions, fMRI activation in auditory cortex was more sustained throughout the sequence duration and was larger in magnitude and extent. Phasic to sustained changes in fMRI activation with changes in frequency separation and perceived rate are comparable to, and consistent with, those produced by changes in the physical rate of a sequence and are far greater than the effects produced by changing other physical stimulus variables, such as sound level or bandwidth. We suggest that the neural activity underlying the changes in fMRI activation with frequency separation contribute to the coding of the co-occurring changes in perceived rate and perceptual organization of the sound sequences into auditory streams. C1 Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. MIT, Elect Res Lab, Cambridge, MA 02139 USA. MIT, Harvard Mit Div Hlth Sci & Technol, Speech & Hearing Biosci & Technol Program, Cambridge, MA 02139 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Wilson, EC (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charlest St, Boston, MA 02114 USA. EM ecwilson@mit.edu OI Oxenham, Andrew/0000-0002-9365-1157 FU NCRR NIH HHS [P41-RR-14075, P41 RR014075]; NIDCD NIH HHS [P01 DC000119, P01 DC000119-260023, P01-DC-00119, P30 DC005209, P30-DC-005209, R01 DC005216, R01-DC-05216] NR 38 TC 53 Z9 53 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD MAR PY 2007 VL 97 IS 3 BP 2230 EP 2238 DI 10.1152/jn.00788.2006 PG 9 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 145KW UT WOS:000244864900037 PM 17202231 ER PT J AU Smith, AC Wirth, S Suzuki, WA Brown, EN AF Smith, Anne C. Wirth, Sylvia Suzuki, Wendy A. Brown, Emery N. TI Bayesian an alysis of interleaved learning and response bias in behavioral experiments SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article ID MODELS; REPRESENTATIONS; ACQUISITION; NEURONS; CHOICE; TIME AB Bayesian analysis of interleaved learning and response bias in behavioral experiments. J Neurophysiol 97: 2516-2524, 2007. First published December 20, 2006; doi:10.1152/jn. 00946.2006. Accurate characterizations of behavior during learning experiments are essential for understanding the neural bases of learning. Whereas learning experiments often give subjects multiple tasks to learn simultaneously, most analyze subject performance separately on each individual task. This analysis strategy ignores the true interleaved presentation order of the tasks and cannot distinguish learning behavior from response preferences that may represent a subject's biases or strategies. We present a Bayesian analysis of a state-space model for characterizing simultaneous learning of multiple tasks and for assessing behavioral biases in learning experiments with interleaved task presentations. Under the Bayesian analysis the posterior probability densities of the model parameters and the learning state are computed using Monte Carlo Markov Chain methods. Measures of learning, including the learning curve, the ideal observer curve, and the learning trial translate directly from our previous likelihood-based state-space model analyses. We compare the Bayesian and current likelihood - based approaches in the analysis of a simulated conditioned T-maze task and of an actual object-place association task. Modeling the interleaved learning feature of the experiments along with the animal's response sequences allows us to disambiguate actual learning from response biases. The implementation of the Bayesian analysis using the WinBUGS software provides an efficient way to test different models without developing a new algorithm for each model. The new state-space model and the Bayesian estimation procedure suggest an improved, computationally efficient approach for accurately characterizing learning in behavioral experiments. C1 Univ Calif Davis, Dept Anesthesiol & Pain Med, Davis, CA 95616 USA. Inst Cognit Sci, Bron, France. NYU, Ctr Neural Sci, New York, NY 10003 USA. Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neurosci Stat Res Lab, Boston, MA 02114 USA. Harvard Univ, MIT, Div Hlth Sci & Technol, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. RP Smith, AC (reprint author), Univ Calif Davis, Dept Anesthesiol & Pain Med, TB-170,1 Shields Ave, Davis, CA 95616 USA. EM annesmith@ucdavis.edu FU NIDA NIH HHS [DA-015644]; NIMH NIH HHS [MH-071847, MH-58847] NR 39 TC 30 Z9 30 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD MAR PY 2007 VL 97 IS 3 BP 2516 EP 2524 DI 10.1152/jn.00946.2006 PG 9 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 145KW UT WOS:000244864900061 PM 17182907 ER PT J AU Bandyopadhyay, S Jeong, KH Hansen, JT Vassilev, PM Brown, EM Chattopadhyay, N AF Bandyopadhyay, Sanghamitra Jeong, Kyeong-Hoon Hansen, Jacob Tfelt Vassilev, Peter M. Brown, Edward M. Chattopadhyay, Naibedya TI Calcium-sensing receptor stimulates secretion of an interferon-gamma-induced monokine (CXCL10) and monocyte chemoattractant protein-3 in immortalized GnRH neurons SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE chemokine; G-protein-coupled receptor; chemotaxis; CXCR3; preoptic hypothalamus ID OUTWARD K+ CHANNEL; GONADOTROPIN-RELEASING-HORMONE; CENTRAL-NERVOUS-SYSTEM; CA2+-SENSING RECEPTOR; CHEMOKINE RECEPTORS; CELL-LINE; HUMAN ASTROCYTES; GENE-EXPRESSION; MESSENGER-RNA; MAST-CELLS AB Biology of GnRH neurons is critically dependent on extracellular Ca2+ (Ca-o(2+)). We evaluated differences in gene expression patterns with low and high Ca 0 in an immortalized GnRH neuron line, GT1-7 cells. Mouse global oligonucleotide microarray was used to evaluate transcriptional differences among the genes regulated by elevated Ca-o(2+). Our result identified two interferon-gamma (IFN gamma)-inducible chemokines, CXCL9 and CXCL10, and a beta chemokine, monocyte chemoattractant protein-3 (MCP-3/CCL7), being up-regulated in GT1-7 cells treated with high Ca-o(2+) (3.0 mM) compared with low Ca-o(2+) (0.5 mM). Up-regulation of these mRNAs by elevated Ca-o(2+) was confirmed by quantitative PCR. Elevated Ca-o(2+) stimulated secretion of CXCL10 and MCP but not CXCL9 in GT1-7 cells, and this effect was mediated by an extracellular calcium-sensing receptor (CaR) as the dominant negative CaR attenuated secretion of CXCL10 and MCP-3. CXCL10 and MCP-3 were localized in mouse GnRH neurons in the preoptic hypothalamus. Suppression of K+ channels (BK channels) with 25 nM charybdotoxin inhibited high-Ca-o(2+)-stimulated CXCL10 release. Accordingly, CaR activation by a specific CaR agonist, NPS-467, resulted in the activation of a Ca2+-activated K+ channel in these cells. CaR-mediated MCP-3 secretion involves the PI3 kinase pathway in GT1-7 cells. MCP-3 stimulated chernotaxis of astrocytes treated with transforming growth factor-p (TGF beta). With TGF beta-treated astrocytes, we next observed that conditioned medium from GT1-7 cells treated with high Ca2+ promoted chemotaxis of astrocytes, and this effect was attenuated by a neutralizing antibody to MCP-3. These results implicate CaR as an important regulator of GnRH neuron function in vivo by stimulating secretion of heretofore unsuspected cytokines, i.e.,CXCL10 and MCP-3. (c) 2007Wiley-Liss,inc. C1 Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurochem Lab,Dept Psychiat & Genet, Boston, MA 02115 USA. Brigham & Womens Hosp, Membrane Biol Program, Boston, MA 02115 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Aging Res Unit, Charlestown, MA USA. Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA USA. RP Chattopadhyay, N (reprint author), Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Dept Med, 221 Longwood Ave, Boston, MA 02115 USA. EM naibedya@rics.bwh.harvard.edu OI Bandyopadhyay, Sanghamitra /0000-0002-1490-3599; Chattopadhyay, Naibedya/0000-0003-2473-0246 FU NIAMS NIH HHS [AR02115]; NIDDK NIH HHS [DK48330, DK52005, DK67111, DK67155] NR 49 TC 11 Z9 11 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD MAR PY 2007 VL 85 IS 4 BP 882 EP 895 DI 10.1002/jnr.21177 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 149PK UT WOS:000245158800021 PM 17285630 ER PT J AU Ishizuka, K Oaklander, AL Chiocca, EA AF Ishizuka, Kelly Oaklander, Anne Louise Chiocca, E. Antonio TI A retrospective analysis of reasons for reoperation following initially successful peripheral nerve stimulation SO JOURNAL OF NEUROSURGERY LA English DT Article DE complex regional pain syndrome; complication; neurosurgery; pain; migration; peripheral nerve ID ELECTRICAL-STIMULATION; PAIN; RESPONSES; EPILEPSY; NEUROMA; FIBERS AB Object. The authors investigated the causes for surgical reexploration in patients with complex regional pain syndrome Type 11 who received initial relief of pain from implantation of a peripheral nerve stimulator (PNS). Methods. The authors reviewed the charts of 11 consecutive patients who underwent a total of 27 PNS-related operations at one institution. Duration of follow up ranged from 5 days to more than 24 months. Of 11 patients who received PNS implants, seven (64%) required one or more additional surgeries to relocate the PNS because initial pain relief following stimulation was lost and not restored by changing pulse generator settings. Loss of analgesia was attributed to migration of the sutured electrode strip paddle (nine [33%] of 27 surgeries), infection (four [15%] of 27), and the need for placement in an alternative location (three [11%] of 27). Conclusions. Although infection is attributable to surgical technique, most complications requiring repeated surgery (nine [33%] of 27) are caused by equipment design. Changes in PNS design or in implantation technique might substantially reduce the need for reoperation after PNS implantation. C1 Ohio State Univ, James Canc Hosp, Dept Neurol Surg, Columbus, OH 43210 USA. Solove Res Inst, Columbus, OH 43210 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia,Nerve Injury Unit, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Nerve Injury Unit, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol,Nerve Injury Unit, Boston, MA USA. RP Chiocca, EA (reprint author), Ohio State Univ, James Canc Hosp, Dept Neurol Surg, N-1017 Doan Hall,410 W 10th Ave, Columbus, OH 43210 USA. EM EA.Chiocca@osumc.edu NR 18 TC 9 Z9 11 U1 0 U2 1 PU AMER ASSOC NEUROLOGICAL SURGEONS PI CHARLOTTESVILLE PA UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA SN 0022-3085 J9 J NEUROSURG JI J. Neurosurg. PD MAR PY 2007 VL 106 IS 3 BP 388 EP 390 DI 10.3171/jns.2007.106.3.388 PG 3 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 145KV UT WOS:000244864700005 PM 17367060 ER PT J AU O'Sullivan, JC Yao, XL Alam, H McCabe, JT AF O'Sullivan, Joseph C. Yao, Xiang-Lan Alam, Hasan McCabe, Joseph T. TI Diazoxide, as a postconditioning and delayed preconditioning trigger, increases HSP25 and HSP70 in the central nervous system following combined cerebral stroke and hemorrhagic shock SO JOURNAL OF NEUROTRAUMA LA English DT Article DE HSP; ischemia; ischemic preconditioning; postconditioning; shock ID K-ATP CHANNELS; TRAUMATIC BRAIN-INJURY; RAT-BRAIN; ISCHEMIA-REPERFUSION; CYTOCHROME-C; CELL-DEATH; PROTEINS; EXPRESSION; TOLERANCE; MYOCARDIUM AB Combined hemorrhagic shock (Shock) and unilateral common carotid artery occlusion (Stroke) results in a decrease of oxygen availability to peripheral tissues and organs and the central nervous system (CNS). A variety of biochemical processes ensue, including organ failure, cellular apoptosis, and necrosis. The present study used male, Sprague-Dawley rats to assess the impact of cerebral insult. Using heat-shock protein 25 and 70 (HSP25, HSP70) as biomarkers, measured 24 h after injury, we tested the hypothesis that pharmacological induction of preconditioning can offer cytoprotection from combined Stroke and Shock. The compound, diazoxide (DZ), is known to induce preconditioning through its effect as a mitochondrial potassium ATP (mK(ATP)) channel opener and succinate dehydrogenase inhibitor. When administered 24 h prior to Stroke and Shock (delayed preconditioning), DZ increased cerebral cortical and hippocampal levels of HSP25 and HSP70. A more clinically relevant treatment paradigm was tested, where DZ was administered after the induction of Stroke and Shock (postconditioning). When administered 60 min (but not 10 min) after the induction of Stroke and Shock, DZ significantly increased HSP25 and HSP70 expression in the ipsilateral cerebral cortex and hippocampus. Taken together, these results suggest that DZ treatment may be efficacious for CNS injury resulting from blood loss and anoxia from combined cerebral ischemia and hemorrhagic shock. "Postconditioning" triggered by DZ, immediately before resuscitation, is a potentially effective treatment for ischemia-reperfusion injury from combined Stroke and Shock. C1 Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA. Uniformed Serv Univ Hlth Sci, Grad Program Neurosci, Bethesda, MD 20814 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02115 USA. RP McCabe, JT (reprint author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. EM JMcCabe@usuhs.mil NR 45 TC 9 Z9 13 U1 2 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD MAR PY 2007 VL 24 IS 3 BP 532 EP 546 DI 10.1089/neu.2006.0128 PG 15 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 152RQ UT WOS:000245379900009 PM 17402858 ER PT J AU Aqel, R Zoghbi, GJ Bender, LW Scott, JW Baldwin, JA Heo, J Iskandrian, AE AF Aqel, Raed Zoghbi, Gilbert J. Bender, Luvenia W. Scott, Johnny W. Baldwin, Jon A. Heo, Jaekyeong Iskandrian, Ami E. TI Myocardial perfusion imaging after transient balloon occlusion during percutaneous coronary interventions SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article DE myocardial perfusion imaging; single photon emission computed tomography; ischemia; percutaneous coronary intervention ID HEXAKIS 2-METHOXYISOBUTYL ISONITRILE; VENTRICULAR-FUNCTION; TC-99M SESTAMIBI; BLOOD-FLOW; ISCHEMIA; ANGIOPLASTY; REPERFUSION; AREA; MITOCHONDRIAL; RESERVE AB Background. Myocardial perfusion imaging (MPI) is highly sensitive in detecting rest ischemia when the radiotracer is injected during the episode of ischemia. The frequency of abnormal MPI results after resolution of ischemia is not well defined. The aim of this study was to determine how long MPI results remain abnormal after transient coronary artery occlusion. Methods and Results. Patients undergoing single-vessel percutaneous coronary intervention were injected with technetium 99m sestamibi at 30 to 60 minutes (group 1) (n = 20) or 90 to 120 minutes (group 2) (n = 10) after the last balloon inflation and 24 hours later. There were 30 men aged 59 8 years. The culprit vessel was the left anterior descending artery in 14 patients and the right coronary artery in 13. The diameter stenosis was reduced from 76.1% 8.7% to 3.0% +/- 6.4% (P < .001). The duration of balloon inflation was 40.3 +/- 12.5 seconds. Chest pain or ST shifts occurred in 66% of patients. A perfusion defect in the territory of the culprit artery was detected in 3 of 20 patients (15%) in group 1 and in 0 of 10 patients (0%) in group 2 (P = .3). One of those three patients had a perfusion defect on MPI done 24 hours later, along with a regional wall motion abnormality on the 2 sets of images. Conclusions. Abnormal perfusion is seen in a small percentage of patients at 30 to 60 minutes and in none at 90 to 120 minutes after a brief transient balloon occlusion. These results might have important implications in patient care. C1 Univ Alabama, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. Univ Alabama, Dept Radiol, Birmingham, AL 35294 USA. RP Zoghbi, GJ (reprint author), Univ Alabama, Birmingham VA Med Ctr, LHRB 306,1530 3rd Ave S, Birmingham, AL 35294 USA. EM gzoghbi@uab.edu NR 24 TC 2 Z9 2 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1071-3581 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD MAR-APR PY 2007 VL 14 IS 2 BP 221 EP 228 DI 10.1016/j.nuclcard.2006.11.012 PG 8 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 152WF UT WOS:000245392100013 PM 17386385 ER PT J AU Cury, RC Nieman, K Shapiro, MD Nasir, K Cury, RC Brady, TJ AF Cury, Ricardo C. Nieman, Koen Shapiro, Michael D. Nasir, Khurram Cury, Roberto C. Brady, Thomas J. TI Comprehensive cardiac CT study: Evaluation of coronary arteries, left ventricular function, and myocardial perfusion - Is it possible? SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Review ID SPIRAL COMPUTED-TOMOGRAPHY; MULTIDETECTOR ROW CT; CARDIOVASCULAR MAGNETIC-RESONANCE; AMERICAN-HEART-ASSOCIATION; IN-STENT RESTENOSIS; DIAGNOSTIC-ACCURACY; INTRAVASCULAR ULTRASOUND; NONINVASIVE ASSESSMENT; BYPASS GRAFTS; CHEST-PAIN AB With advances in multidetector computed tomography (MDCT) technology, the new generation of 64-slice MDCT scanners with submillimeter collimation and a faster gantry rotation allows imaging of the entire heart in a single breath-hold with excellent temporal and spatial resolution. This potentially permits a comprehensive assessment of coronary anatomy, left ventricular function, and myocardial perfusion. As will be seen in this review of the current literature regarding 16- and 64-slice MDCT, there is great promise for a comprehensive cardiac computed tomography (CT) study. The available data support the notion that CT coronary angiography may be an alternative to invasive coronary angiography in symptomatic patients with a low to intermediate likelihood of having coronary artery disease. By use of the same data acquired for CT coronary angiography, evaluation of global and regional left ventricular function and myocardial perfusion can be added to the MDCT evaluation without additional exposure to contrast medium or radiation and may provide a more conclusive cardiac workup in these patients. The potential applications and limitations of coronary stenosis detection, global and regional left ventricular function, and myocardial perfusion assessment by MDCT will be reviewed. The full potential of cardiac MDCT is just beginning to be realized. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Cardiac MRI PET CT Program, Boston, MA 02114 USA. Erasmus MC, Dept Cardiol, Ctr Thorax, Rotterdam, Netherlands. Univ Sao Paulo, Dept Cardiol, Heart Inst InCor, Sao Paulo, Brazil. RP Cury, RC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, 165 Cambridge St,Suite 400, Boston, MA 02114 USA. EM rcury@partners.org; rcury@partners.org NR 108 TC 30 Z9 34 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD MAR-APR PY 2007 VL 14 IS 2 BP 229 EP 243 DI 10.1016/j.nuclcard.2007.01.035 PG 15 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 152WF UT WOS:000245392100014 PM 17386386 ER PT J AU Schroeder, T Melo, MFV Musch, G Harris, RS Winkler, T Venegas, JG AF Schroeder, Tobias Melo, Marcos F. Vidal Musch, Guido Harris, R. Scott Winkler, Tilo Venegas, Jose G. TI PET imaging of regional F-18-FDG uptake and lung function after cigarette smoke inhalation SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE positron emission tomography; FDG; pulmonary gas exchange; inflammation; smoke inhalation injury ID OBSTRUCTIVE PULMONARY-DISEASE; POSITRON-EMISSION-TOMOGRAPHY; NEUTROPHIL KINETICS; INJURY; INFLAMMATION; VENTILATION; PERFUSION; SHEEP AB Cigarette smoke is thought to promote local lung inflammation that leads to lung dysfunction. Lung neutrophilic inflammation is known to result in increased pulmonary uptake of F-18-FDG Using a sheep model of localized exposure to cigarette smoke , in this study we tested whether PET-imaged changes in regional intrapulmonary distribution of F-18-FDG uptake are related to changes in regional lung function as assessed with the infused (NN)-N-13-saline method. Methods: Five anesthetized, mechanically ventilated sheep were exposed to unilateral inhalation of smoke from 10 tobacco cigarettes while the contralateral lung was ventilated with smoke-free gas. Two hours after the exposure, regional gas content was measured from a transmission scan; regional ventilation, perfusion, and shunt were measured from the kinetics of (NN)-N-13-saline; and regional F-18-FDG influx constant (K) was calculated with the Patlak algorithm applied at a voxel-by-voxel level. Results: K-i was higher and more heterogeneous in the smoke-exposed lungs than in the control lungs (P < 0.05). Spatial heterogeneity of Ki and impairment in regional lung function were quite variable among animals despite similar levels of smoke exposure. However, increases in mean Ki correlated linearly with its spatial heterogeneity (Spearman correlation, r(s) = 0.94), and the highest levels of regional Ki in smoke-exposed lungs and control lungs correlated with regional shunt fraction (r(s) = 0.78). Also, the heterogeneity of the ventilation-perfus ion (V/Q) distribution of the smoke-exposed lungs was 10 times greater than that of the control lungs but correlated strongly with that of the control lungs (r = 0.998). Conclusion: Substantial interanimal variability and spatial heterogeneity in lung function and F-18-FDG uptake seem to characterize the response to smoke exposure. The highest levels of local F-18-FDG uptake were associated with differences in V/Q matching and shunt fraction among animals. The data also suggest that preexisting heterogeneity in V/Q could have been responsible for the large interanimal variability by affecting the heterogeneity and strength of the acute response to smoke inhalation. C1 Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Venegas, JG (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, CLN 255,55 Fruit St, Boston, MA 02114 USA. EM jvenegas@vqpet.mgh.harvard.edu RI Winkler, Tilo/B-5337-2009 OI Winkler, Tilo/0000-0002-7276-5550 FU NHLBI NIH HHS [HL-068011, HL-56879, R01 HL086827] NR 21 TC 28 Z9 28 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD MAR PY 2007 VL 48 IS 3 BP 413 EP 419 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 146MB UT WOS:000244937400022 PM 17332619 ER PT J AU Fitzgibbon, M Gans, KM Evans, WD Viswanath, K Johnson-Taylor, WL Krebs-Smith, SM Rodgers, AB Yaroch, AL AF Fitzgibbon, Marian Gans, Kim M. Evans, W. Douglas Viswanath, K. Johnson-Taylor, Wendy L. Krebs-Smith, Susan M. Rodgers, Anne B. Yaroch, Amy L. TI Communicating healthy eating: Lessons learned and future directions SO JOURNAL OF NUTRITION EDUCATION AND BEHAVIOR LA English DT Article; Proceedings Paper CT Workshop on Diet and Communication - What Can Communication Science Tell Us about Promoting Optimal Dietary Behavior CY JUL, 2005 CL Bethesda, MD DE nutrition; communication; diet; behavior change ID VEGETABLE CONSUMPTION; PUBLIC-HEALTH; PLANNED BEHAVIOR; SOCIAL ECOLOGY; NUTRITION; PROMOTION; POLICY; FRUIT; CAMPAIGNS; INTERVENTION AB Achieving and maintaining wide-scale positive dietary change is a complex and formidable endeavor, given the current food environment. Moreover, for positive change to occur, nutrition messages should be communicated in a scientifically precise, yet practical and motivating manner. This challenge was the impetus for the organization of a 2-day workshop hosted by the National Cancer Institute (NCI) and the Division of Nutrition Research Coordination (DNRC), both of the National Institutes of Health (NIH). The conference included communication, nutrition, and behavioral scientists, market researchers, media advocates, journalists, and public policy experts. Discussions regarding communication efforts and the best methods to craft, deliver, and evaluate the impact of nutrition messages illustrated both the challenges and the opportunities we face. During the discussions, important recommendations for nutrition communicators and interventionists emerged, based on existing knowledge from the communications field, lessons learned thus far, and noted gaps in our knowledge. C1 Univ Illinois, Jesse Brown VA Med Ctr, Chicago, IL 60608 USA. Univ Illinois, Dept Med, Chicago, IL 60608 USA. Brown Univ, Inst Community Hlth Promot, Providence, RI 02912 USA. RTI Int, Washington, DC USA. Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NIH, Div Nutr Res Coordinat, Bethesda, MD 20892 USA. NIH, Natl Canc Inst, Risk Factor Monitoring & Methods Branch, Bethesda, MD 20892 USA. NIH, Natl Canc Inst, Hlth Promot Res Branch, Bethesda, MD 20892 USA. RP Fitzgibbon, M (reprint author), Univ Illinois, Jesse Brown VA Med Ctr, 1747 W Roosevelt Rd, Chicago, IL 60608 USA. EM mlf@uic.edu NR 70 TC 23 Z9 23 U1 5 U2 25 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1499-4046 J9 J NUTR EDUC BEHAV JI J. Nutr. Educ. Behav. PD MAR-APR PY 2007 VL 39 IS 2 SU S BP S63 EP S71 DI 10.1016/j.jneb.2006.08.017 PG 9 WC Education, Scientific Disciplines; Nutrition & Dietetics SC Education & Educational Research; Nutrition & Dietetics GA 151JZ UT WOS:000245287600013 PM 17336811 ER PT J AU Viswanath, K Bond, K AF Viswanath, K. Bond, Kathleen TI Social determinants and nutrition: Reflections on the role of communication SO JOURNAL OF NUTRITION EDUCATION AND BEHAVIOR LA English DT Article CT Workshop on Diet and Communication - What Can Communication Science Tell Us about Promoting Optimal Dietary Behavior CY JUL, 2005 CL Bethesda, MD DE diet and communication; communication disparities and nutrition; social determinants and nutrition; social determinants and diet ID PUBLIC-HEALTH; PREVENTION PROGRAMS; CANCER PREVENTION; BASE-LINE; FAST-FOOD; FRUIT; INTERVENTIONS; DISPARITIES; STRATEGIES; KNOWLEDGE AB A healthy diet is considered a critical pathway in influencing chronic conditions such as hypertension, diabetes, cardiovascular disease, cancer, and obesity. The current information environment around diet and nutrition is complex and often confusing to the public. Though considerable evidence suggests that successful public health communication campaigns can promote health and prevent disease, studies also show that this success is subject to the influence of social determinants, such as social class, social networks, race and ethnicity, and neighborhood. Through a critical and selective review of literature on social epidemiology and public health communication, this paper explores how social determinants may mediate nutrition communication effects. C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. RP Bond, K (reprint author), Dana Farber Canc Inst, SM 251,44 Binney St, Boston, MA 02115 USA. EM vish_viswanath@dfci.harvard.edu NR 61 TC 20 Z9 22 U1 2 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1499-4046 J9 J NUTR EDUC BEHAV JI J. Nutr. Educ. Behav. PD MAR-APR PY 2007 VL 39 IS 2 BP S20 EP S24 DI 10.1016/j.jneb.2006.07.008 PG 5 WC Education, Scientific Disciplines; Nutrition & Dietetics SC Education & Educational Research; Nutrition & Dietetics GA 151JZ UT WOS:000245287600004 PM 17336801 ER PT J AU Counter, SA Buchanan, LH Ortega, F AF Counter, S. Allen Buchanan, Leo H. Ortega, Fernando TI Lead concentrations in maternal blood and breast milk and pediatric blood of Andean villagers: 2006 follow-up investigation SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CHILDREN; EXPOSURE; LEVEL AB Objective: To determine the current lead (Pb) concentration in blood (PbB) and breast milk (PbM) of mothers and the PbB of children living in Andean Ecuadorian villages with high Pb contamination. Methods: Samples of whole blood from 93 participants (74 children and 19 adult women) were analyzed for Pb concentration by graphite furnace atomic absorption spectroscopy with Zeeman background correction, and milk samples from nursing mothers were analyzed by inductively coupled plasma-mass spectrometry (ICP-MS). Results: Mean PbB concentration in children in 2006 was 26.7 mu g/dL (SD: 23.0), and significantly lower than the mean PbB level in 1996 to 2000, but similar to the PbB level found in 2003. The mean PbB level of 22.0 mu g/dL (SD: 20.6) for the 19 women in the 2006 study group did not differ significantly from the women in the 1996 to 2000 or 2003 study group. The PbM levels (range: 1-49 mu g/L) of nursing mothers in the 2006 group were similar to the PbM values observed in the breast milk of nursing mothers in the same study area in 2003, and matched high PbB levels in some mother-infant pairs. Conclusion: This study found elevated, but stable, PbB and PbM levels in mothers and elevated, but stable, PbB levels in children in 2006 that were consistent with the levels observed in 2003 in the same Andean villages. C1 Harvard Univ, Sch Med, Biol Labs, Dept Neurol, Cambridge, MA 02138 USA. Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. Univ Massachusetts, Sch Med, Shriver Ctr, Dept Pediat, Waltham, MA USA. Harvard Univ, Dept Otolaryngol, Hlth Serv, Cambridge, MA 02138 USA. Univ San Francisco Quito, Dept Med, Quito, Ecuador. RP Counter, SA (reprint author), Harvard Univ, Sch Med, Biol Labs, Dept Neurol, 16 Divin Ave, Cambridge, MA 02138 USA. EM allen_Counter@harvard.edu NR 27 TC 12 Z9 12 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD MAR PY 2007 VL 49 IS 3 BP 302 EP 309 DI 10.1097/jom.0b01301803225b0 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 148PM UT WOS:000245087100008 PM 17351516 ER PT J AU Levine, MH Goddard, AL Dodson, TB AF Levine, Marci H. Goddard, Allison L. Dodson, Thomas B. TI Inferior alveolar nerve canal position: A clinical and radiographic study SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article AB Purpose: To document a clinically relevant position of the inferior alveolar nerve (IAN) in dentate patients and identify patient factors associated with IAN position. Materials and Methods: The investigators used a cross-sectional study design and a study sample of subjects who had a radiographically identifiable IAN canal and at least I mandibular first molar was enrolled. Predictor variables were age, gender, and race. Outcome variables were the linear distances between the buccal aspect of the IAN canal and the outer buccal cortical margin of the mandible, and the superior aspect of the IAN canal and the alveolar crest. Appropriate uni-, bi-, and multivariate statistics were computed. Results: The study sample was composed of 50 patients with a mean age of 42 years, 42.0% were male, and 73.2% were white. On average, the buccal aspect of the canal was 4.9 mm from the buccal cortical margin of the mandible. The superior aspect of the IAN canal was 17.4 mm inferior from the alveolar crest. Age and race were statistically associated with IAN position relative to the buccal cortical mandibular margin (P <.05). None of the demographic variables were associated with vertical position. Conclusions: The IAN canal was 4.9 mm and 17.4 mm from the buccal and superior cortical surfaces of the mandible, respectively. The bucco-lingual IAN canal position was associated with age and race. Older patients and white patients, on average, have less distance between the buccal aspect of the canal and the buccal mandibular border. To minimize the risk of IAN injury, these variables should be considered when planning mandibular osteotomies or using monocortical plates. (C) 2007 American Association of Oral and Maxillofacial Surgeons. C1 Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA. RP Dodson, TB (reprint author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, 55 Fruit St,1201 Warren Bldg, Boston, MA 02114 USA. EM tbdodson@partners.org FU NIDCR NIH HHS [K24 DE00048] NR 6 TC 32 Z9 38 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD MAR PY 2007 VL 65 IS 3 BP 470 EP 474 DI 10.1016/j.joms.2006.05.056 PG 5 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 144XU UT WOS:000244830600017 PM 17307595 ER PT J AU Salleh, NM Fueki, K Garrett, NR Ohyama, T AF Salleh, N. M. Fueki, K. Garrett, N. R. Ohyama, T. TI Objective and subjective hardness of a test item used for evaluating food mixing ability SO JOURNAL OF ORAL REHABILITATION LA English DT Article DE food texture; hardness; food mixing ability; masticatory function ID REMOVABLE PARTIAL DENTURES; MASTICATORY FUNCTION; NATURAL FOODS; CHEWING GUM; MUSCLE-ACTIVITY; IMPLANT; TEXTURE; WEARERS; ELECTROMYOGRAPHY; OVERDENTURES AB The aim of this study was to compare objective and subjective hardness of selected common foods with a wax cube used as a test item in a mixing ability test. Objective hardness was determined for 11 foods (cream cheese, boiled fish paste, boiled beef, apple, raw carrot, peanut, soft/hard rice cracker, jelly, plain chocolate and chewing gum) and the wax cube. Peak force (N) to compress each item was obtained from force-time curves generated with the Tensipresser. Perceived hardness ratings of each item were made by 30 dentate subjects (mean age 26.9 years) using a visual analogue scale (100 mm). These subjective assessments were given twice with a 1 week interval. High intraclass correlation coefficients (ICCs) for test-retest reliability were seen for all foods (ICC > 0.68; P < 0.001). One-way ANOVA found a significant effect of food type on both the objective hardness score and the subjective hardness rating (P < 0.001). The wax cube showed significant lower objective hardness score (32.6 N) and subjective hardness rating (47.7) than peanut (45.3 N, 63.5) and raw carrot (82.5 N, 78.4) [P < 0.05; Ryan-Einot-Gabriel-Welsch (REGW)-F]. A significant semilogarithmic relationship was found between the logarithm of objective hardness scores and subjective hardness ratings across twelve test items (r = 0.90; P < 0.001). These results suggest the wax cube has a softer texture compared with test foods traditionally used for masticatory performance test, such as peanut and raw carrot. The hardness of the wax cube could be modified to simulate a range of test foods by changing mixture ratio of soft and hard paraffin wax. C1 Tokyo Med & Dent Univ, Grad Sch, Bunkyo Ku, Tokyo 1138549, Japan. Univ Calif Los Angeles, Sch Dent, Jane & Jerry Weintraub Ctr Reconstruct Biotechnol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Dent, Div Adv Prosthodont Biomat & Hosp Dent, Los Angeles, CA 90024 USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Fueki, K (reprint author), Tokyo Med & Dent Univ, Grad Sch, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan. EM kunfu.rpro@tmd.ac.jp RI Fueki, Kenji/A-9909-2008 OI Fueki, Kenji/0000-0002-5885-2447 FU NCRR NIH HHS [C06 RR-14529-01] NR 46 TC 24 Z9 24 U1 1 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0305-182X J9 J ORAL REHABIL JI J. Oral Rehabil. PD MAR PY 2007 VL 34 IS 3 BP 174 EP 183 DI 10.1111/j.1365-2842.2006.01645.x PG 10 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 134WP UT WOS:000244115400003 PM 17302945 ER PT J AU Gordon, GJ Mani, M Mukhopadhyay, L Dong, L Yeap, BY Sugarbaker, DJ Bueno, R AF Gordon, G. J. Mani, M. Mukhopadhyay, L. Dong, L. Yeap, B. Y. Sugarbaker, D. J. Bueno, R. TI Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma SO JOURNAL OF PATHOLOGY LA English DT Article ID NF-KAPPA-B; CANCER-CELLS; PYRROLIDINE-DITHIOCARBAMATE; CANDIDATE ONCOGENES; EXPRESSION; GROWTH; SUPPRESSORS; ACTIVATION; CISPLATIN; CASPASE-8 AB Inhibitor of apoptosis proteins (IAPs) are overexpressed by most neoplasms and promote tumour cell survival after a wide variety of apoptotic stimuli elicited via intrinsic (ie mitochondrial) and extrinsic (ie death receptor) pathways. It has previously been reported that one of these proteins, IAP-1(MIHC/cIAP2), is overexpressed in malignant pleural mesothelioma (MPM) and is responsible for a large degree of the resistance of cultured MPM cells to cisplatin. Subsequent analysis in a larger number of human tumours revealed that additional IAPs (eg IAP-2/MIHB/cIAP1, livin/NlL-IAP/KIAP, survivin, and XIAP/MIHA/hILP) are also overexpressed in MPM and, with the exception of IAP-2, have expression patterns that correlate with prognosis. In the present study, potential regulatory mechanisms of IAP genes in MPM were investigated and it was found that tumour necrosis factor-alpha (TNF-alpha) can increase mRNA and protein levels of IAP-1, IAP-2, and XIAP, but not livin or survivin in MPM cell lines (n = 4). It was also found that IAP gene expression levels are increased concomitantly with translocation to the nucleus of the TNF-responsive transcription factor NF-kappa B. Co-incubation of MPM cells with TNF-alpha and pyrrolidine dithiocarbamate (PDTC), an NF-kappa B inhibitor, prevented TNF-mediated up-regulation of IAP gene expression levels. In survival studies, TNF-alpha was not toxic to MPM cells at any concentration examined. However, MPM cells exposed to TNF-alpha were twice as resistant to cisplatin in dose response survival assays compared with unstimulated controls and were found to have a significantly greater fraction of surviving cells at multiple cisplatin concentrations (p < 0.0087). Finally, it was found that levels of circulating TNF-alpha were statistically significantly (p = 0.031) (median 312.5 pg/ml) higher in MPM patients (n = 6) prior to surgical tumour debulking compared with those after surgery (median 0 pg/ml). These results when combined with previous observations by our laboratory and others strongly suggest that IAPs act synergistically with TNF family members to promote survival of MPM tumour cells after exposure to cisplatin and possibly other chemotherapeutic drugs. Copyright (c) 2007 Pathological Society of Great Britain and Ireland. C1 Harvard Univ, Sch Med, Brigham & Womens Hosp, Thorac Surg Oncol Lab, Boston, MA 02115 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Gordon, GJ (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Thorac Surg Oncol Lab, BLI Bldg,Room 137,221 Longwood Ave,75 Francis St, Boston, MA 02115 USA. EM ggordon@partners.org FU NCI NIH HHS [CA-100315, CA-102591, CA-105249] NR 40 TC 39 Z9 43 U1 0 U2 2 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0022-3417 J9 J PATHOL JI J. Pathol. PD MAR PY 2007 VL 211 IS 4 BP 439 EP 446 DI 10.1002/path.2120 PG 8 WC Oncology; Pathology SC Oncology; Pathology GA 141YL UT WOS:000244615000007 PM 17253597 ER PT J AU Gordon, GJ Mani, M Mukhopadhyay, L Dong, L Edenfield, HR Glickman, JN Yeap, BY Sugarbaker, DJ Bueno, R AF Gordon, G. J. Mani, M. Mukhopadhyay, L. Dong, L. Edenfield, H. R. Glickman, J. N. Yeap, B. Y. Sugarbaker, D. J. Bueno, R. TI Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma SO JOURNAL OF PATHOLOGY LA English DT Article ID SURVIVAL; CANCER; CELLS; LOCALIZATION; THERAPY; IAPS AB Inhibitor of apoptosis proteins (IAPs) comprise a family of structurally similar proteins, five of which are widely studied in the context of cancer: IAP-1/MIHC/cIAP2, IAP2/MIHB/cIAP1, livin/ML-IAP/KIAP, survivin, and XIAP/MIHA/hILP. IAPs are overexpressed by most neoplasms, promote tumour cell survival after a wide variety of apoptotic stimuli, and frequently have gene and/or protein expression patterns associated with a relatively poor prognosis. However, many IAPs are also expressed by normal tissues, can facilitate apoptotic cell death, and have expression patterns associated with a relatively favourable prognosis in some cases. The result is that the precise role(s) of IAPs in human tumours is not exactly known. It has been previously reported that IAP-1 is overexpressed in malignant pleural mesothelioma (MPM) and is responsible for a large degree of the resistance of cultured MPM cells to cisplatin. Given the high homology of IAP family members, it is likely that other IAPs will be important in MPM. In the present study, the gene and protein expression patterns of IAP-1, IAP-2, survivin, livin, and XIAP have been determined in MPM cell lines (n = 9) and a large number of MPM tumours using high-density oligonucleotide microarrays (it = 40) and an MPM tissue array (n = 66). Human tumours were linked to clinical data and it was found that IAP-1 and survivin mRNA expression patterns were associated with a relatively shorter patient survival, while those of XIAP and livin were associated with a relatively longer patient survival. Abundant protein for all IAPs was also detected in MPM tumours, where they were expressed primarily in the cytoplasm. Only IAP-1 and livin protein was expressed in the nucleus of MPM tumours. These results provide the rationale for additional study of this gene family in MPM and cancer in general. Copyright (c) 2007 Pathological Society of Great Britain and Ireland. C1 Harvard Univ, Sch Med, Brigham & Womens Hosp, Thorac Surg Oncol Lab, Boston, MA 02115 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Gordon, GJ (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Thorac Surg Oncol Lab, BLI Bldg,Room 137,221 Longwood Ave,75 Francis St, Boston, MA 02115 USA. EM ggordon@partners.org FU NCI NIH HHS [CA-100315, CA-102591, CA-105249] NR 25 TC 46 Z9 47 U1 0 U2 2 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0022-3417 J9 J PATHOL JI J. Pathol. PD MAR PY 2007 VL 211 IS 4 BP 447 EP 454 DI 10.1002/path.2121 PG 8 WC Oncology; Pathology SC Oncology; Pathology GA 141YL UT WOS:000244615000008 PM 17253596 ER PT J AU Fanjiang, G Russell, GH Katz, AJ AF Fanjiang, Gary Russell, George H. Katz, Aubrey J. TI Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION LA English DT Article DE ulcerative colitis; Crohn disease; infliximab; Lichtiger Colitis Activity Index; pediatric patients ID INFLAMMATORY-BOWEL-DISEASE; POUCH-ANAL ANASTOMOSIS; CROHNS-DISEASE; INTRAVENOUS CYCLOSPORINE; FOLLOW-UP; EFFICACY; CHILDHOOD; CHILDREN; SAFETY; EXPERIENCE AB Objectives: We evaluated the response to infliximab in pediatric patients with ulcerative colitis (UC) and their long-term follow-up. We expanded our previous study of 14 patients and furthermore evaluated the success of weaning patients from infliximab. Patients and Methods: We reviewed the charts of 27 pediatric patients with UC who were treated with infliximab instead of undergoing a colectomy. Patients with new-onset UC refractory to intravenous steroids for 5 to 10 days and patients with nonsteroid-dependent UC with an acute exacerbation were classified as acutely ill (n = 16); patients with chronic steroid-dependent UC were classified as chronically ill (n = 11). The Lichtiger Colitis Activity Index (LCAI) was measured for all patients at baseline and at I and 2 months after treatment with infliximab was initiated. Patients were regarded as successfully treated if they remained off steroids and avoided colectomy. Results: The acutely ill group had a mean LCAI score of 11.4 at induction and 0.3 after 2 months. The chronically ill group had a mean LCAI score of 11.2 at induction and 5.5 after 2 months. Treatment with infliximab was successful in 75% of acutely ill patients and in 27% of chronically ill patients. Infliximab was discontinued in 80% of successfully treated patients (83% of acutely ill, 67% of chronically ill). These patients had an average of 10 infusions and a mean follow-up time of 10 months from their last infliximab infusion. Conclusions: Our results suggest that infliximab is more effective in acutely ill UC patients than in patients with chronic steroid-dependent UC. In addition, some patients treated with infliximab can be weaned from infliximab and maintain remission. C1 Massachusetts Gen Hosp, Pediat Gastroenterol & Nutr, Boston, MA 02114 USA. RP Fanjiang, G (reprint author), Massachusetts Gen Hosp, Pediat Gastroenterol & Nutr, 55 Fruit St,VBK 107, Boston, MA 02114 USA. EM gfanjiang@partners.org FU AHRQ HHS [T32-HS00060] NR 50 TC 34 Z9 38 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-2116 J9 J PEDIATR GASTR NUTR JI J. Pediatr. Gastroenterol. Nutr. PD MAR PY 2007 VL 44 IS 3 BP 312 EP 317 DI 10.1097/MPG.0b013e31802e98d4 PG 6 WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics GA 141BI UT WOS:000244550900004 PM 17325550 ER PT J AU Saad, AG Sachs, J Turner, CD Proctor, M Marcus, KJ Wang, L Lidov, H Ullrich, NJ AF Saad, Ali G. Sachs, Jessica Turner, Christopher D. Proctor, Mark Marcus, Karen J. Wang, Larry Lidov, Hart Ullrich, Nicole J. TI Extracranial metastases of glioblastoma in a child - Case report and review of the literature SO JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY LA English DT Review DE glioblastoma; glioma; metastasis ID CENTRAL NERVOUS-SYSTEM; EXTRANEURAL METASTASES; PERITONEAL-CAVITY; MULTIFORME; TUMORS; ASTROCYTOMA AB Glioblastoma (GBM) is the most common adult malignant brain tumor but is notably less common in children. Primary brain tumors rarely metastasize outside the central nervous system and when metastases occur, it is often in patients with diversionary shunting of the cerebrospinal fluid. This report details the case of a 13(1)/(2)-year-old boy who was diagnosed with GBM. He survived 10 months after diagnosis. At autopsy, the tumor was found to extensively infiltrate the leptomeninges as well as the cranial skin and soft tissue. Further examination disclosed multiple liver and lung metastatic GBM nodules. This pattern of spread is very uncharacteristic of gliomas and emphasizes the importance of adequate metastatic evaluation. C1 Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Hematol Oncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. Brigham & Womens Hosp, Childrens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Pediat Brain Tumor Program, Boston, MA 02115 USA. RP Saad, AG (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St,Amory 3, Boston, MA 02115 USA. EM asaad@partners.org NR 20 TC 15 Z9 15 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1077-4114 J9 J PEDIAT HEMATOL ONC JI J. Pediatr. Hematol. Oncol. PD MAR PY 2007 VL 29 IS 3 BP 190 EP 194 DI 10.1097/MPH.0b013e31803350a7 PG 5 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 151NG UT WOS:000245296700014 PM 17356401 ER PT J AU Mocan, MC Ament, C Azar, NF AF Mocan, Mehmet C. Ament, Christine Azar, Nathalie F. TI The characteristics and surgical outcomes of medial rectus recessions in Graves' ophthalmopathy SO JOURNAL OF PEDIATRIC OPHTHALMOLOGY & STRABISMUS LA English DT Article ID STRABISMUS SURGERY; THYROID OPHTHALMOPATHY; MOTILITY AB Purpose: To evaluate the clinical characteristics and surgical outcomes of medial rectus (MR) recessions in patients with Graves' ophthalmopathy. Patients and. Methods: The clinical records of 32 patients with Graves' ophthalmopathy who underwent MR recessions with adjustable sutures for restrictive esotropia were reviewed. The clinical characteristics of patients, the size of the esodeviations, the limitations of ductions, the surgical doses, and observed responses to surgery were recorded and analyzed. Main outcome measures included the ratio of predicted to observed correction for MR recessions, improvement in ductions, and restoration of binocular status. Results: The mean age of the 32 patients (20 women, 12 men) at surgery was 54.1 +/- 11.4 years. The mean duration of thyroid eye disease was 4.3 +/- 5.4 years (range, 1 to 24 years). The ratios of predicted to observed correction for esodeviations at distance and near, respectively, were 2.21 +/- 1.24 and 2.16 +/- 1.81 at the time of adjustment and 1.61 +/- 0.37 and 1.84 +/- 0.90 at final follow-up. The limitation of abduction improved from -2.3 +/- 1.3 to -0.75 +/- 0.98. Binocular single vision was achieved in 73% of patients, and a further 10% of patients were able to fuse with prisms. A history of decompression was present in 75% of cases. Patients with a history of decompression had more restriction in abduction (-2.49 vs -1.78, P = .061), more frequently required bilateral surgery (75% vs. 62.5%), and had a higher ratio of predicted to observed correction (1.71 +/- 0.37 vs 1.37 0.28, P = .043). Conclusions: Patients with Graves' ophthalmopathy who undergo MR recession for restrictive esotropia are prone to undercorrection. A history of decompression is associated with a less favorable clinical outcome. Augmented surgery, adjustable sutures, or both are recommended for improved surgical outcomes. C1 Massachusetts Eye & Ear Infirm, Pediat Ophthalmol & Strabismus Serv, Boston, MA 02114 USA. RP Azar, NF (reprint author), Massachusetts Eye & Ear Infirm, Pediat Ophthalmol & Strabismus Serv, Floor 1,243 Charles St, Boston, MA 02114 USA. OI Mocan, Cem/0000-0002-3419-9105 NR 15 TC 5 Z9 5 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0191-3913 J9 J PEDIAT OPHTH STRAB JI J. Pediatr. Ophthalmol. Strabismus. PD MAR-APR PY 2007 VL 44 IS 2 BP 93 EP 100 PG 8 WC Ophthalmology; Pediatrics SC Ophthalmology; Pediatrics GA 152SB UT WOS:000245381000007 PM 17410960 ER PT J AU Svoren, BM Volkening, LK Butler, DA Moreland, EC Anderson, BJ Laffel, LMB AF Svoren, Britta M. Volkening, Lisa K. Butler, Deborah A. Moreland, Elaine C. Anderson, Barbara J. Laffel, Lori M. B. TI Temporal trends in the treatment of pediatric type I diabetes and impact on acute outcomes SO JOURNAL OF PEDIATRICS LA English DT Article ID SUBCUTANEOUS INSULIN INFUSION; GLYCEMIC CONTROL; SEVERE HYPOGLYCEMIA; COMPLICATIONS TRIAL; METABOLIC-CONTROL; ADVERSE OUTCOMES; CHILDREN; MELLITUS; ADOLESCENTS; THERAPY AB Objective To evaluate temporal trends in pediatric type 1 diabetes (T1DM) management and resultant effects on outcomes. Study design Two pediatric T1DM cohorts were followed prospectively for 2 years and compared; Cohort 1 (N = 299) was enrolled in 1997 and Cohort 2 (N = 152) was enrolled in 2002. In both cohorts, eligible participants were identified and sequentially approached at regularly scheduled clinic visits until the target number of participants was reached. Main outcome measures were hemoglobin A1c (A1c), body mass index Z score and incidence rate (IR; per 100 patient-years) of hypoglycemia, hospitalizations, and emergency room (ER) visits. Results At baseline, Cohort 2 monitored blood glucose more frequently than Cohort 1 (>= 4 times/day: 72% vs 39%, P < .001) and was prescribed more intensive therapy than Cohort 4 (>= 3 injections/day or pump: 85% vs 65%, P <.001). A1c was lower in Cohort 2 than Cohort 1 at baseline (8.4% vs 8.7%, P = .03) and study's end (8.7% vs 9.0%, P = .04). The cohorts did not differ in Z-BMI (0.83 vs 0.79, P = .57) or IR of hospitalizations (11.2 vs 12.9, P = .38). Cohort 2 had lower IR of total severe hypoglycemic events (29.4 vs 55.4, P < .001) and ER visits (22.0 vs 29.3, P = .02). Conclusions T1DM management intensified during 5 years between cohorts and was accompanied by improved A1c and stable Z-BMI. Along with improved control, IR of severe hypoglycemia and ER visits decreased by almost 50% and 25%. respectively. C1 Joslin Diabet Ctr, Pediat & Adolescent Sect, Boston, MA 02215 USA. Joslin Diabet Ctr, Genet & Epidemiol Sect, Boston, MA 02215 USA. Joslin Diabet Ctr, Behav & Mental Hlth Sect, Boston, MA 02215 USA. Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Med,Div Endocrinol, Boston, MA 02115 USA. Univ Alabama Birmingham, Childrens Hosp, Div Pediat Endocrinol, Birmingham, AL USA. Baylor Coll Med, Houston, TX 77030 USA. RP Laffel, LMB (reprint author), Joslin Diabet Ctr, Pediat & Adolescent Sect, 1 Joslin Pl, Boston, MA 02215 USA. EM Lori.Laffel@joslin.harvard.edu FU NIDDK NIH HHS [5T32DK063702, R01 DK046887, R01DK046887, T32 DK063702] NR 45 TC 44 Z9 46 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD MAR PY 2007 VL 150 IS 3 BP 279 EP 285 DI 10.1016/j.jpeds.2006.12.009 PG 7 WC Pediatrics SC Pediatrics GA 142DP UT WOS:000244629700019 PM 17307546 ER PT J AU Otomo-Corgel, J AF Otomo-Corgel, Joan TI Implants and oral bisphosphonates: Risky business? SO JOURNAL OF PERIODONTOLOGY LA English DT Editorial Material ID EXPERIMENTAL PERIODONTITIS; BEAGLE DOGS; OSTEONECROSIS; THERAPY; BONE; JAWS; OSTEOPOROSIS; ALENDRONATE; PREVENTION; RECOGNITION C1 Univ Calif Los Angeles, Los Angeles, CA 90024 USA. Sch Dent, Dept Periodont, Los Angeles, CA 90024 USA. Greater Los Angeles Vet Adm Hlth Care Syst, Los Angeles, CA USA. RP Otomo-Corgel, J (reprint author), 1127 Wilshire Blvd,Suite 1110, Los Angeles, CA 90017 USA. EM Joan@corgels.com NR 25 TC 7 Z9 7 U1 0 U2 1 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 J9 J PERIODONTOL JI J. Periodont. PD MAR PY 2007 VL 78 IS 3 BP 373 EP 376 DI 10.1902/jop.2007.073001 PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 146GW UT WOS:000244923500001 PM 17335360 ER PT J AU Hinton, DE Sinclair, SJ Chung, RCY Pollack, MH AF Hinton, Devon E. Sinclair, Samuel J. Chung, Rita C. -Y. Pollack, Mark H. TI The SF-36 among cambodian and vietnamese refugees: An examination of psychometric properties SO JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT LA English DT Article DE Southeast Asians; Cambodians; Vietnamese; refugees; SF-36; health status; culture; stress disorder; posttraumatic ID QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS-DISORDER; HEALTH SURVEY; SCALING ASSUMPTIONS; PANIC DISORDER; IQOLA PROJECT; CONSTRUCT-VALIDITY; CLINICAL-TESTS; TRANSLATION; PREVALENCE AB Among traumatized Cambodian (N=90) and Vietnamese (N=94) refugees attending a psychiatric clinic, the study examined the validity and psychometric properties of the Short Form-36 Health Survey (SF-36), a measure of self-perceived mental and physical health. In both patient samples, all eight SF-36 scales displayed excellent internal consistency (item-scale correlations and Cronbach's alpha). But, similar to other studies of Asian samples, (a) the Vitality (VT) scale did not separate from the Mental Health (MH) and General Health (GH) scales, as evidenced by item-scale and interscale correlations, and (b) the VT scale loaded as strongly (Vietnamese sample) or more strongly (Cambodian sample) than the MH scale on the so-called Mental Factor in a two-factor solution of the eight scales (with the GH scale also loading heavily on the same factor). C1 Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. SE Asian Clin, Arbour Counseling Serv, Lowell, MA USA. Hlth Assessment Lab, Boston, MA USA. George Mason Univ, Fairfax, VA 22030 USA. RP Hinton, DE (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 15 Parkman St,WACC 812, Boston, MA 02114 USA. EM devon_hinton@hms.harvard.edu NR 37 TC 0 Z9 0 U1 19 U2 20 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0882-2689 J9 J PSYCHOPATHOL BEHAV JI J. Psychopathol. Behav. Assess. PD MAR PY 2007 VL 29 IS 1 BP 39 EP 46 DI 10.1007/s10862-006-9022-0 PG 8 WC Psychology, Clinical SC Psychology GA 128WS UT WOS:000243691000005 ER PT J AU Sharp, GC Lu, HM Trofimov, A Tang, XL Jiang, SB Turcotte, J Gierga, DP Chen, GTY Hong, TS AF Sharp, Gregory C. Lu, Hsiao Ming Trofimov, Alexei Tang, Xiaoli Jiang, Steve B. Turcotte, Julie Gierga, David P. Chen, George T. Y. Hong, Theodore S. TI Assessing residual motion for gated proton-beam radiotherapy SO JOURNAL OF RADIATION RESEARCH LA English DT Article; Proceedings Paper CT NIRS-CNAO Joint Symposium on Carbon Ion Radiotherapy CY NOV 27-28, 2006 CL Milan, ITALY SP Natl Inst Radiol Sci, Centro Nazl Adroterapia Oncol DE liver cancer; organ motion; proton radiotherapy ID INSPIRATION BREATH-HOLD; EXTERNAL MARKER; ORGAN MOTION; TUMOR MOTION; RESPIRATION; TRACKING; SYSTEM AB Gated radiation therapy is a promising method for improving the dose conformality of treatments to moving targets and reducing the total volume of irradiated tissue. Target motion is of particular concern in proton beam radiotherapy, due to the finite range of proton dose deposition in tissue. Gating allows one to reduce the extent of variation, due to respiration, of the radiological depth to target during treatment delivery. However, respiratory surrogates typically used for gating do not always accurately reflect the position of the internal target. For instance, a phase delay often exists between the internal motion and the motion of the surrogate. Another phenomenon, baseline drafting refers to a gradual change in the exhale position over time, which generally affects the external and internal markers differently. This study examines the influence of these two physiological phenomena on gated radiotherapy using an external surrogate. C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Sharp, GC (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St, Boston, MA 02114 USA. EM gcsharp@partners.org NR 16 TC 8 Z9 8 U1 0 U2 2 PU JAPAN RADIATION RESEARCH SOC PI CHIBA PA C/O NAT INST RADIOLOGICAL SCI 9-1 ANAGAWA-4-CHOME INAGE-KU, CHIBA, 263, JAPAN SN 0449-3060 J9 J RADIAT RES JI J. Radiat. Res. PD MAR PY 2007 VL 48 SU A BP A55 EP A59 DI 10.1269/jrr.48.A55 PG 5 WC Biology; Radiology, Nuclear Medicine & Medical Imaging SC Life Sciences & Biomedicine - Other Topics; Radiology, Nuclear Medicine & Medical Imaging GA 188RL UT WOS:000247936900006 PM 17513900 ER PT J AU Giles, JT Mease, P Boers, M Bresnihan, B Conaghan, PG Heald, A Maksymowych, WP Maillefert, JF Simon, L Tsuji, W Wakefield, R Woodworth, T Schumacher, HR Bingham, CO AF Giles, Jon T. Mease, Philip Boers, Maarten Bresnihan, Barry Conaghan, Philip G. Heald, Alison Maksymowych, Walter P. Maillefert, Jean-Francis Simon, Lee Tsuji, Wayne Wakefield, Richard Woodworth, Thasia Schumacher, H. Ralph Bingham, Clifton O., III TI Assessing single joints in arthritis clinical trials SO JOURNAL OF RHEUMATOLOGY LA English DT Article; Proceedings Paper CT 8th International Consensus Conference on Outcome Measures in Rheumatology Clinical Trails CY MAY 10-14, 2006 CL Valletta, MALTA DE outcome assessment; arthritis; validity; reliability; responsiveness; joint examination ID OSTEOARTHRITIS INDEX WOMAC; WESTERN ONTARIO; KNEE OSTEOARTHRITIS; RHEUMATOID-ARTHRITIS; PHYSICAL-EXAMINATION; OUTCOME MEASURES; VALIDATION; ULTRASONOGRAPHY; RELIABILITY; HIP AB Endpoints and outcome measurements to detect changes in joint structure for the assessment of single joints are needed to enable rheumatology clinical trials of therapies targeting preservation of joint structure, especially via locally applied therapies. While the assessment of certain aspects of single joint inflammation and function is accepted in the evaluation of osteoarthritis (OA) using the WOMAC, it tends to be limited to the knee and hip. The advent of therapies that are directed toward a single joint in inflammatory arthritis, including intraarticular cytokine antagonists and gene therapeutics, requires reliable measures to assess change over time in single joints and the clinical meaningfulness of such change. Traditionally, clinical trials for inflammatory arthritis have used composite response indices such as American College of Rheumatology response or improvement in Disease Activity Score as outcomes based on multiple joint clinical measures, acute phase reactants, and functional status. However, it is not known whether these will appropriately detect changes referable to single joint intervention. This Special Interest Group was developed to bring together interested individuals to identify and evaluate outcome measurements for single joints. The knee was the initial focus, as clinical, radiographic, and functional assessments have been well developed for knee OA. A PubMed English language review was conducted before OMERACT 8, evaluating existing clinical instruments in the context of the OMERACT filter. At OMERACT 8, the group developed a research agenda to perform additional validation studies of clinical and functional indices, imaging, synovial histopathology, and soluble biomarkers. C1 Johns Hopkins Univ, Div Rheumatol, Baltimore, MD 21224 USA. Univ Washington, Div Rheumatol Res, Seattle, WA 98195 USA. Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands. Univ Coll Dublin, Dept Rheumatol, St Vincents Hosp, Dublin 4, Ireland. Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland. Univ Leeds, Leeds, W Yorkshire, England. Targeted Genet Corp, Seattle, WA USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA. Univ Alberta, Dept Med, Edmonton, AB, Canada. Univ Burgundy, INSERM, ERM 0207, Dijon Univ Hosp, Dijon, France. Amgen Inc, Seattle, WA USA. Univ Leeds, Acad Unit Musculoskeletal Dis, Leeds, W Yorkshire, England. Roche Pharmaceut, Welwyn Garden City, Herts, England. Vet Affairs Med Ctr, Philadelphia, PA USA. Johns Hopkins Univ, Div Rheumatol, Baltimore, MD USA. Johns Hopkins Univ, Div Clin Immunol & Allergy, Baltimore, MD USA. RP Giles, JT (reprint author), Johns Hopkins Univ, Div Rheumatol, 5501 Hopkins Bayview Circle,Suite 1B-1, Baltimore, MD 21224 USA. EM gilesjont@jhmi.edu NR 37 TC 13 Z9 13 U1 0 U2 3 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD MAR PY 2007 VL 34 IS 3 BP 641 EP 647 PG 7 WC Rheumatology SC Rheumatology GA 141YA UT WOS:000244613800031 PM 17343312 ER PT J AU Demay, MB MacDonald, PN Skorija, K Dowd, DR Cianferotti, L Cox, M AF Demay, Marie B. MacDonald, Paul N. Skorija, Kristi Dowd, Diane R. Cianferotti, Luisella Cox, Megan TI Role of the vitamin D receptor in hair follicle biology SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY LA English DT Article; Proceedings Paper CT 13th Workshop on Vitamin D CY APR 07-12, 2006 CL Victoria, CANADA SP Novacea Inc, Solvay Pharmaceut BV, Teijin Ltd DE nuclear receptor; hair follicle; transgene; knockout; anagen ID RICKETS TYPE-II; KNOCKOUT MICE; EPIDERMAL DIFFERENTIATION; RESISTANT RICKETS; ALOPECIA; EXPRESSION; CALCIUM; GROWTH; GENE AB The vitamin D receptor (VDR) is expressed in numerous cells and tissues, including the skin. The critical requirement for cutaneous expression of the VDR has been proven by investigations in mice and humans lacking functional receptors. These studies demonstrate that absence of the VDR leads to the development of alopecia. The hair follicle is formed by reciprocal interactions between an epidermal placode, which gives rise to the hair follicle keratinocytes and the underlying mesoderm which gives rise to the dermal papilla. Hair follicle morphogenesis ends the second week of life in mice. Studies in VDR null mice have failed to demonstrate a cutaneous abnormality during this period of hair follicle morphogenesis. However, VDR null mice are unable to initiate a new hair cycle after the period of morphogenesis is complete, therefore, do not grow new hair. Investigations in transgenic mice have demonstrated that restricted expression of the VDR to keratinocytes is capable of preventing alopecia. in the VDR null mice, thus demonstrating that the epidermal component of the hair follicle requires VDR expression to maintain normal hair follicle homeostasis. Studies were then performed to determine which regions of the VDR were required for these actions. Investigations in mice lacking the first zinc finger of the VDR have demonstrated that they express a truncated receptor containing an intact ligand binding and AF2 domain. These mice are a phenocopy of mice lacking the VDR, thus demonstrate the critical requirement of the DNA binding domain for hair follicle homeostasis. Transgenic mice expressing VDRs with mutations in either the ligand-binding domain or the AF2 domain were generated. These investigations demonstrated that mutant VDRs incapable of ligand-dependent transactivation were able to prevent alopecia. Investigations are currently underway to define the mechanism by which the unliganded VDR maintains hair follicle homeostasis. (c) 2006 Elsevier Ltd. All rights reserved. C1 Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA. RP Demay, MB (reprint author), Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St,Their 501, Boston, MA 02114 USA. EM demay@helix.mgh.harvard.edu FU NIDDK NIH HHS [R01 DK046974] NR 18 TC 13 Z9 15 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-0760 J9 J STEROID BIOCHEM JI J. Steroid Biochem. Mol. Biol. PD MAR PY 2007 VL 103 IS 3-5 SI SI BP 344 EP 346 DI 10.1016/j.jsbmb.2006.12.036 PG 3 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 158WU UT WOS:000245826800025 PM 17223342 ER PT J AU Bikle, D Teichert, A Hawker, N Xie, Z Oda, Y AF Bikle, D. Teichert, A. Hawker, N. Xie, Z. Oda, Y. TI Sequential regulation of keratinocyte differentiation by 1,25(OH)(2)D-3, VDR, and its coregulators SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY LA English DT Article; Proceedings Paper CT 13th Workshop on Vitamin D CY APR 07-12, 2006 CL Victoria, CANADA SP Novacea Inc, Solvay Pharmaceut BV, Teijin Ltd DE keratinocytes; differentiation; vitamin D; gene transcription; heat shock proteins; coactivators; hairless ID VITAMIN-D-RECEPTOR; 1,25-DIHYDROXYVITAMIN-D3; HAIRLESS; COACTIVATORS; COMPLEXES; CALCIUM; CELLS; SKIN; 1-ALPHA,25-DIHYDROXYVITAMIN-D3; TRANSACTIVATION AB Keratinocyte differentiation requires the sequential regulation of gene expression. We have explored the role of 1,25(OH)(2)D-3 and its receptor (VDR) in this process. VDR sequentially binds to coactivator complexes such as Vitamin D receptor interacting protein (DRIP) and steroid receptor coactivator (SRC) during differentiation. Different genes respond differently to the VDR/coactivator complexes as determined by knockdown studies. The binding of DRIP205 and SRC to VDR is ligand (i.e. 1,25(OH)(2)D-3) dependent. LXXLL motifs in these coactivators are critical for this binding; however, the affinity for VDR of the different LXXLL motifs in these coactivators varies. Hairless is an inhibitor of 1,25(OH)(2)D-3 dependent gene transcription. A phi XX phi phi motif in hairless is crucial for hairless binding to VDR, and its binding is ligand independent. 1,25(OH)(2)D-3 displaces hairless and recruits the coactivators to VDREs. Hsp90 and p23 are chaperone proteins recruited to the DRIP/VDR complex, where they block the binding of the complex to VDREs and block 1,25(OH)(2)D-3 stimulated transcription. Thus four mechanisms explain the ability of 1,25(OH)(2)D-3 to sequentially regulate gene transcription during differentiation: changes in coregulator levels, their differential binding to VDR, differential gene responsiveness to the VDR/coregulator complexes, and chaperone proteins facilitating the cycling of VDR/coregulator complexes on and off the VDREs. Published by Elsevier Ltd. C1 San Francisco VA Med Ctr, Endocrine Res Unit, San Francisco, CA 94121 USA. Univ Calif San Francisco, Vet Affairs Med Ctr, San Francisco, CA 94121 USA. RP Bikle, D (reprint author), San Francisco VA Med Ctr, Endocrine Res Unit, 111N,4150 Clement St, San Francisco, CA 94121 USA. EM Daniel.Bikle@ucsf.edu FU NIAMS NIH HHS [R01 AR038386] NR 28 TC 15 Z9 16 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-0760 J9 J STEROID BIOCHEM JI J. Steroid Biochem. Mol. Biol. PD MAR PY 2007 VL 103 IS 3-5 SI SI BP 396 EP 404 DI 10.1016/j.jsbmb.2006.12.063 PG 9 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 158WU UT WOS:000245826800034 PM 17229570 ER PT J AU Wolf, M Thadhani, R AF Wolf, Myles Thadhani, Ravi TI Vitamin D in patients with renal failure: A summary of observational mortality studies and steps moving forward SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY LA English DT Article; Proceedings Paper CT 13th Workshop on Vitamin D CY APR 07-12, 2006 CL Victoria, CANADA SP Novacea Inc, Solvay Pharmaceut BV, Teijin Ltd DE vitamin D; survival; hemodialysis ID SECONDARY HYPERPARATHYROIDISM; HEMODIALYSIS-PATIENTS; THERAPY; RISK; ASSOCIATION; PRODUCT; DISEASE; ANALOGS AB Although approximately half of patients undergoing hemodialysis receive activated forms of Vitamin D, the primary reason to initiate this therapy has rested solely on the management of secondary hyperparathyroidism. Secondary hyperparathyroidism is likely one of several consequences of Vitamin D deficiency, and only now have other consequences of Vitamin D deficiency emerged. Although previously viewed as a contributor to hypercalcemia and hyperphosphatemia, recent studies suggest Vitamin D may improve cardiovascular structure and function, improve vascular compliance, and reduce pro-inflammatory cytokines, all of which may contribute to the improved survival observed in retrospective studies examining the outcome of patients treated with activated Vitamin D compared to those who were not. The current review examines two recent large-scale studies of hemodialysis patients: one that demonstrated a survival advantage of paricalcitol over calcitriol, and a second that demonstrated a significant survival advantage of any intravenous Vitamin D formulation versus none. In both studies, the findings were independent of mineral and parathyroid hormone levels, suggesting "non-traditional" actions of Vitamin D contributed to the observed survival advantage. Potential steps moving forward in light of these observational studies are subsequently discussed. (c) 2006 Elsevier Ltd. All rights reserved. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Renal Unit,Dept Med, Boston, MA 02114 USA. RP Thadhani, R (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Renal Unit,Dept Med, Bullfinch 127,55 Fruit St, Boston, MA 02114 USA. EM rthadhani@partners.org FU NIDDK NIH HHS [R21 DK071674, DK 71674] NR 25 TC 26 Z9 28 U1 1 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-0760 J9 J STEROID BIOCHEM JI J. Steroid Biochem. Mol. Biol. PD MAR PY 2007 VL 103 IS 3-5 SI SI BP 487 EP 490 DI 10.1016/j.jsbmb.2006.11.009 PG 4 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 158WU UT WOS:000245826800052 PM 17197169 ER PT J AU Bray, JW Zarkin, GA Miller, WR Mitra, D Kivlahan, DR Martin, DJ Couper, DJ Cisler, RA AF Bray, Jeremy W. Zarkin, Gary A. Miller, William R. Mitra, Debanjali Kivlahan, Daniel R. Martin, Daniel J. Couper, David J. Cisler, Ron A. TI Measuring economic outcomes of alcohol treatment using the economic form 90 SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID HEALTH-CARE UTILIZATION; PROJECT-MATCH; COSTS; VALIDATION; DEPENDENCE; ACCURACY; PHARMACOTHERAPIES; RELIABILITY; INSTRUMENT; VALIDITY AB Objective: This article assesses the ability of the economic outcome measures in the Economic Form 90 to detect differences across levels of alcohol dependence as measured by the Alcohol Dependence Scale. Method: We used baseline data from the Combining Medications and Behavioral Interventions (COMBINE) Study, a large, multisite clinical trial, to assess the extent to which the economic items on the Economic Form 90 instrument can detect differences across levels of alcohol dependence. Results: After adjusting for differences in demographic characteristics, the Economic Form 90 can detect significant differences across a range of dependence severity levels for the economic outcomes of inpatient medical care, emergency-department medical care, behavioral health care, being on parole or probation, and missed workdays, conditional on being employed. We did not detect significant differences across dependence severity for employment status, outpatient medical care, other criminal justice involvement, or motor vehicle accidents. Conclusions: The Economic Form 90 can identify differences in many economic outcomes associated with differing levels of alcohol dependence. This suggests that the Economic Form 90 may be useful in assessing changes in economic outcomes that result from changes in alcohol dependence. C1 RTI Int, Res Triangle Pk, NC 27709 USA. Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA. Vet Affairs Puget Sound, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. Univ N Carolina, Dept Biostat, Chapel Hill, NC USA. Univ Wisconsin, Sch Med & Publ Hlth, Ctr Urban Populat Hlth, Aurora Sinai Med Ctr, Milwaukee, WI 53201 USA. RP Bray, JW (reprint author), RTI Int, 3040 Cornwallis Rd, Res Triangle Pk, NC 27709 USA. EM bray@rti.org FU NIAAA NIH HHS [1-R01-AA12788] NR 35 TC 9 Z9 9 U1 5 U2 10 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 EI 1938-4114 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD MAR PY 2007 VL 68 IS 2 BP 248 EP 255 PG 8 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA 199RK UT WOS:000248712700010 PM 17286343 ER PT J AU Chang, SB Miron, P Miron, A Iglehart, JD AF Chang, Sharon B. Miron, Penelope Miron, Alexander Iglehart, J. Dirk TI Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells SO JOURNAL OF SURGICAL RESEARCH LA English DT Article; Proceedings Paper CT 1st Annual Academic Surgical Congress of the Association-for-Academic-Surgery CY FEB 07-11, 2006 CL San Diego, CA SP Assoc Acad Surg DE rapamycin; estrogen receptor; breast cancer; tamoxifen ID PHOSPHATIDYLINOSITOL-3-OH KINASE; MTOR INHIBITOR; TARGET; AKT; RESISTANCE; NEOPLASIA; MECHANISM; PATHWAY AB Background. Estrogen-receptor (ER)-positive breast cancers comprise the majority of sporadic breast cancers. Although 50% respond to antibormonal treatment, both primary and acquired resistance limit the utility of this therapy, and other agents are needed. Rapamycin, an inhibitor of the mammalian Target of Rapamycin (mTOR), possesses antitumor activity against many tumors including breast tumors, and particularly against ER-positive breast cancer cell lines. The sensitivity of these cells to rapamycin has been attributed to activation of the PI3K/Akt/mTOR pathway by nongenomic ER signaling. The purpose of this study was to evaluate the efficacy of rapamycin against ER-positive breast cancer, particularly under 17 beta-estradiol (E2)-dependent conditions, and to investigate mechanisms of rapamycin-sensitivity in ER-positive cells. Materials and methods. Breast cancer cell lines were tested for sensitivity to rapamycin. Antiproliferative effects of rapamycin, alone and in combination with tamoxifen, were assessed under E2-dependent conditions. Western blot analysis was used to detect activation of mTOR by nongenomic ER signaling. Results. Rapamycin effectively inhibits proliferation of the ER-positive MCF-7 cell line. In our system, this sensitivity is probably not due to nongenomic ER activation of the PI3K/Akt/mTOR pathway; rapid stimulation of mTOR occurred nonspecifically after medium replacement, and addition of E2 stimulated mTOR only after 1 h. Combining rapamycin and tamoxifen under E2-dependent conditions yielded additive/ synergistic effects at effective concentrations. Conclusions. These results suggest that rapamycin may be an effective treatment for ER-positive breast cancer, either alone or in combination with tamoxifen, and also may be a potential therapy for tamoxifen-resistant cancers. (c) 2007 Elsevier Inc. All rights reserved. C1 Univ Calif Davis, Med Ctr, Dept Surg, Sacramento, CA 95817 USA. Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. RP Chang, SB (reprint author), Univ Calif Davis, Med Ctr, Dept Surg, 2315 Stockton Blvd 6309, Sacramento, CA 95817 USA. EM sharon.chang@ucdmc.ucdavis.edu FU NCI NIH HHS [F32 CA110616-01] NR 24 TC 43 Z9 45 U1 1 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD MAR PY 2007 VL 138 IS 1 BP 37 EP 44 DI 10.1016/j.jss.2006.07.003 PG 8 WC Surgery SC Surgery GA 145CC UT WOS:000244841900007 PM 17109887 ER PT J AU Shera, CA Tubis, A Talmadge, CL de Boer, E Fahey, PF Guinan, JJ AF Shera, Christopher A. Tubis, Arnold Talmadge, Carrick L. de Boer, Egbert Fahey, Paul F. Guinan, John J., Jr. TI Allen-Fahey and related experiments support the predominance of cochlear slow-wave otoacoustic emissions SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article ID BASILAR-MEMBRANE; 2-TONE DISTORTION; AUDITORY-NERVE; INTRACOCHLEAR PRESSURE; 3-DIMENSIONAL MODEL; MAMMALIAN COCHLEA; PRODUCTS; STIMULUS; PHENOMENOLOGY; NONLINEARITY AB Originally proposed as a method for measuring the power gain of the cochlear amplifier, Allen-Fahey experiments compare intracochlear distortion products and ear-canal otoacoustic emissions (OAEs) under tightly controlled conditions. In this paper Allen-Fahey experiments are shown to place significant constraints on the dominant mode of reverse energy propagation within the cochlea. Existing Allen-Fahey experiments are reviewed and shown to contradict the predictions of compression-wave OAE models recently proposed in the literature. In compression-wave models, distortion products propagate from their site of generation to the stapes via longitudinal compression waves in the cochlear fluids (fast waves); in transverse traveling-wave, models, by contrast, distortion products propagate primarily via pressure-difference waves whose velocity and other characteristics depend on the mechanical properties of the cochlear partition (slow waves). Compression-wave models predict that the distortion-product OAEs (DPOAEs) measured in the Allen-Fahey paradigm increase at close primary-frequency ratios (or remain constant in the hypothetical absence of tuned suppression), The behavior observed experimentally is just the opposite-a pronounced decrease in DPOAE amplitude at close ratios. Since neither compression-wave nor simple conceptual "hybrid-wave" models can account for the experimental results-whereas slow-wave models can, via systematic changes in distortion-source directionality arising from wave-interference effects-Allen-Fahey and related experiments provide compelling evidence against the predominance of compression-wave OAEs in mammalian cochlear mechanics. (c) 2007 Acoustical Society of America. C1 Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. Purdue Univ, Dept Phys, W Lafayette, IN 47907 USA. Univ Calif San Diego, Inst Nonlinear Sci, La Jolla, CA 92093 USA. Univ Mississippi, Natl Ctr Phys Acoust, University, MS 38677 USA. Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands. Univ Scranton, Dept Phys, Scranton, PA 18510 USA. RP Shera, CA (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA. EM shera@epl.meei.harvard.edu FU NIDCD NIH HHS [R01 DC03687, R01 DC00235, R01 DC003687] NR 59 TC 26 Z9 27 U1 0 U2 1 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD MAR PY 2007 VL 121 IS 3 BP 1564 EP 1575 DI 10.1121/1.2405891 PG 12 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA 147VT UT WOS:000245031600033 PM 17407894 ER PT J AU Irwin, B Mauriello, D Hemminger, L Pappert, A Kimball, AB AF Irwin, Blair Mauriello, Dana Hemminger, Laura Pappert, Amy Kimball, Alexandra B. TI Skin sun-acne tutorial evaluation among middle- and high-school students in central New Jersey SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article ID CANCER PREVENTION; EDUCATION AB Background: Because of the perception that a tan is healthy and attractive, it has been difficult to educate adolescents about sun protection. Objective: We sought to examine whether the skin sun-acne tutorial, all hour-long, hands-on educational intervention that combined acne education with sun-protection education, increased knowledge of skin care, sun protection, and acne Methods: in all, 1214 middle- and, high-school students were taught, tested, and surveyed. Outcomes were determined based on comparing performance on a pretest and posttest. Results: All students, regardless of sex, ethnicity, age, or race, improved significantly from their pretest to posttest scores (P <.001). Limitations: This study only used one health educator and was restricted to public schools in central New Jersey. Conclusions: The skin sun-acne tutorial significantly improved knowledge of skin care including knowledge of sun protection and acne among students of different grades, sexes, ages, ethnicities, and races. C1 Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA. Univ Med & Dent New Jersey, Sch Publ Hlth, New Brunswick, NJ USA. Stanford Univ, Stanford, CA 94305 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Kimball, AB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Clin Unit Res Trials Skin, 50 Staniford St,246, Boston, MA 02114 USA. EM harvardskinstudies@partners.org NR 16 TC 6 Z9 6 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAR PY 2007 VL 56 IS 3 BP 407 EP 412 DI 10.1016/j.jaad.2006.11.028 PG 6 WC Dermatology SC Dermatology GA 141XP UT WOS:000244612700007 PM 17239985 ER PT J AU Avram, MM Avram, AS James, WD AF Avram, Mathew M. Avram, Alison Sharpe James, William D. TI Subcutaneous fat in normal and diseased states - 3. Adipogenesis: From stem cell to fat cell SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Review ID ADIPOCYTE PRECURSOR CELLS; GROWTH-FACTOR-I; WHITE ADIPOSE-TISSUE; ACTIVATED RECEPTOR-GAMMA; STROMAL-VASCULAR CELLS; TUMOR-NECROSIS-FACTOR; SERUM-FREE MEDIUM; BINDING PROTEIN-BETA; EXTRACELLULAR-MATRIX SUBSTRATA; GATA TRANSCRIPTION FACTORS AB The quest for effective strategies to treat obesity has propelled fat research into an exploration of the molecular processes that drive adipocyte formation, and hence body fat mass. The development of obesity is dependent on the coordinated interplay of adipocyte hypertrophy (increased fat cell size), adipocyte hyperplasia (increased fat cell number), and angiogenesis. Evidence suggests that adipocyte hyperplasia, or adipogenesis, occurs throughout life, both in response to normal cell turnover as well as in response to the need for additional fat mass stores that arises when caloric intake exceeds nutritional requirements. Adipogenesis involves two major events-the recruitment and proliferation of adipocyte precursor cells, called preadipocytes, followed by the subsequent conversion of preadipocytes, or differentiation, into mature fat cells. in vitro studies using experimental and primary preadipocyte cell lines have uncovered the mechanisms that drive the adipogenic process, a tightly controlled sequence of events guided by the strict temporal regulation of multiple inhibitory and stimulatory signaling events involving regulators of cell-cycle functions and differentiation factors. This article reviews the current understanding of adipogenesis with emphasis on the various stages of adipocyte development; on key hormonal, nutritional, paracrine, and neuronal control signals; as well as on the components involved in cell-cell or cell-matrix interactions that are pivotal in regulating fat cell formation. Special consideration is given to clinical applications derived from adipogenesis research with impact on medical, surgical and cosmetic fields. C1 Massachusetts Gen Hosp, Dermatol Laser & Cosmet Ctr, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. RP Avram, AS (reprint author), 4 Longfellow Pl,Apt 3405, Boston, MA 02114 USA. EM asaderm@aol.com NR 254 TC 91 Z9 96 U1 0 U2 10 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAR PY 2007 VL 56 IS 3 BP 472 EP 492 DI 10.1016/j.jaad.2006.06.022 PG 21 WC Dermatology SC Dermatology GA 141XP UT WOS:000244612700020 PM 17317490 ER PT J AU Pickens, S Naik, AD Burnett, J Kelly, PA Gleason, M Dyer, CB AF Pickens, Sabrina Naik, Aanand D. Burnett, Jason Kelly, P. A. Gleason, Mary Dyer, Carmel B. TI The utility of the Kohlman evaluation of living skills test is associated with substantiated cases of elder self-neglect SO JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS LA English DT Article DE activities of daily living; instrumental activities of daily living; KELS test; elder self-neglect; Adult Protective Services ID DWELLING OLDER PERSONS; FUNCTIONAL STATUS; PHYSICAL FUNCTION; ABUSE; MISTREATMENT; DISABILITY; MORTALITY; COMPARE; ADULTS AB Purpose: Self-neglect is the most prevalent finding among cases reported to Adult Protective Services (APS) and is characterized by an inability to meet one's own basic needs. The Kohlman evaluation of living skills (KELS) has been validated in geriatric populations to assess performance with both instrumental and basic activities of daily living and as an assessment tool for the capacity to live independently; therefore, the purpose of this analysis was to compare the scores of the KELS between substantiated cases of self-neglect and matched community-dwelling elders. Data sources: This is a cross-sectional pilot study of 50 adults aged 65 years and older who were recruited from APS as documented cases of self-neglect and 50 control participants recruited from Harris County Hospital District outpatient clinics. Control participants were matched for age, race, gender, and ZIP code. A geriatric nurse practitioner (NP)-led team administered a comprehensive geriatric assessment in homes of all study participants. The assessment included the KELS and mini-mental state examination (MMSE) tests. Chi-square analyses were used to determine if cases of self-neglect were significantly more likely to fail the KELS test than matched controls. Conclusions: The analyses revealed that self-neglectors were significantly more likely to fail the KELS than non-self-neglectors (50% vs. 30%, p = .025). When stratified by MMSE scores, self-neglectors with intact cognitive function remained significantly more likely to fail the KELS compared to matched, cognitively intact controls (45% vs. 17%, p = .013). Abnormal results using an in-home KELS test were significantly associated with substantiated cases of self-neglect. Implications for practice: There is currently no gold-standard measure for identifying capacity with self-care behaviors among cases of self-neglect. As a result, self-neglect may remain unidentified in many clinical settings. The KELS provides clinicians with an objective measure of an individual's capacity and performance with everyday life-supporting tasks and thus, provides information that can help NPs identify elders at risk for self-neglect. These findings suggest that the KELS test has significant utility as part of a comprehensive geriatric assessment to aid clinicians in suspected cases of self-neglect. C1 Baylor Coll Med, Quentin Mease Hosp, Dept Internal Med, Div Geriatr, Houston, TX 77004 USA. Baylor Coll Med, Vet Affairs Med Ctr 152, Dept Internal Med, Div Geriatr,Sect Hlth Serv Res, Houston, TX 77030 USA. Baylor Coll Med, Vet Affairs Med Ctr 152, Dept Internal Med, Div Geriatr,Sect Geriatr, Houston, TX 77030 USA. Baylor Coll Med, Vet Affairs Med Ctr 152, Dept Internal Med, Div Geriatr,Sect Endocrinol, Houston, TX 77030 USA. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Internal Med, Div Geriatr,Sect Endocrinol, Houston, TX 77030 USA. RP Pickens, S (reprint author), Baylor Coll Med, Quentin Mease Hosp, Dept Internal Med, Div Geriatr, 3601 N MacGregor Way, Houston, TX 77004 USA. EM sabrina_pickens@hchd.tmc.edu FU NCRR NIH HHS [P20 RR020626-02, P-20-RR020626-02]; NIA NIH HHS [K23 AG027144-01A1, K23 AG027144] NR 37 TC 22 Z9 22 U1 0 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1041-2972 J9 J AM ACAD NURSE PRAC JI J. Am. Acad. Nurse Pract. PD MAR PY 2007 VL 19 IS 3 BP 137 EP 142 DI 10.1111/j.1745-7599.2007.00205.x PG 6 WC Health Care Sciences & Services; Nursing SC Health Care Sciences & Services; Nursing GA 141JE UT WOS:000244573800005 PM 17341281 ER PT J AU Itani, KMF Morris, PJ Macias, FC Bevilacqua, RG Cheng, SWK Ladipo, JK Brennan, MF AF Itani, Kamal M. F. Morris, Peter J. Macias, Francisco Cardoza Bevilacqua, Ruy G. Cheng, Stephen W. K. Ladipo, J. K. Brennan, Murray F. TI Training of a surgeon: An international perspective SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID MEDICAL-STUDENTS; EDUCATION C1 VA Boston Healthcare Syst, Dept Surg, W Roxbury, MA 02132 USA. Boston Univ, Boston, MA 02215 USA. Royal Coll Surgeons England, Oxford, England. Univ Nacl Autonoma Mexico, La Paz, Mexico. Univ Sao Paulo, Sao Paulo, Brazil. Univ Hong Kong, Hong Kong, Peoples R China. Univ Ibadan, Ibadan, Nigeria. Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA. RP Itani, KMF (reprint author), VA Boston Healthcare Syst, Dept Surg, 1400 VFW Pkwy, W Roxbury, MA 02132 USA. EM kitani@med.va.gov OI Brennan, Murray/0000-0003-2358-4371 NR 7 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD MAR PY 2007 VL 204 IS 3 BP 478 EP 485 DI 10.1016/j.jamcollsurg.2006.12.004 PG 8 WC Surgery SC Surgery GA 144VT UT WOS:000244825200020 PM 17324785 ER PT J AU Dorr, D Bonner, LM Cohen, AN Shoai, RS Perrin, R Chaney, E Young, AS AF Dorr, David Bonner, Laura M. Cohen, Amy N. Shoai, Rebecca S. Perrin, Ruth Chaney, Edmund Young, Alexander S. TI Informatics systems to promote improved care for chronic illness: A literature review SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Review ID RANDOMIZED CONTROLLED-TRIALS; DISEASE MANAGEMENT PROGRAMS; DECISION-SUPPORT-SYSTEMS; HEALTH-CARE; COMPUTERIZED REMINDERS; CLINICAL-TRIALS; METAANALYSIS; QUALITY; TECHNOLOGY; STANDARDS AB Objective: To understand information systems components important in supporting team-based care of chronic illness through a literature search. Design: Systematic search of literature from 1996-2005 for evaluations of information systems used in the care of chronic illness. Measurements: The relationship of design, quality, information systems components, setting, and other factors with process, quality outcomes, and health care costs was evaluated. Results: In all, 109 articles were reviewed involving 112 information system descriptions. Chronic diseases targeted included diabetes (42.9% of reviewed articles), heart disease (36.6%), and mental illness (23.2%), among others. System users were primarily physicians, nurses, and patients. Sixty-seven percent of reviewed experiments had positive outcomes; 94% of uncontrolled, observational studies claimed positive results. Components closely correlated with positive experimental results were connection to an electronic medical record, computerized prompts, population management (including reports and feedback), specialized decision support, electronic scheduling, and personal health records. Barriers identified included costs, data privacy and security concerns, and failure to consider workflow. Conclusion: The majority of published studies revealed a positive impact of specific health information technology components on chronic illness care. Implications for future research and system designs are discussed. C1 Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR USA. VA Puget Sound Healthcare Syst, NW HSR&D Ctr Excellence, Seattle, WA USA. VA Desert Pacific Mental Illness Res Educ & Clin, Los Angeles, CA USA. VA Informat Resource Ctr, Hines, IL USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. RP Dorr, D (reprint author), 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM dorrd@ohsu.edu RI Young, Alexander/A-1523-2009 OI Young, Alexander/0000-0002-9367-9213 FU NLM NIH HHS [K22 LM 8427-01, K22 LM008427] NR 40 TC 121 Z9 123 U1 0 U2 30 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD MAR-APR PY 2007 VL 14 IS 2 BP 156 EP 163 DI 10.1197/jamia.M2255 PG 8 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 155FF UT WOS:000245562600003 PM 17213491 ER PT J AU Hung, J Lang, R Flachskampf, F Shernan, SK McCulloch, ML Adams, DB Thomas, J Vannan, M Ryan, T AF Hung, Judy Lang, Roberto Flachskampf, Frank Shernan, Stanton K. McCulloch, Marti L. Adams, David B. Thomas, James Vannan, Mani Ryan, Thomas TI 3D echocardiography: A review of the current status and future directions SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY LA English DT Review ID TIME 3-DIMENSIONAL ECHOCARDIOGRAPHY; LEFT-VENTRICULAR VOLUME; CONGENITAL HEART-DISEASE; IN-VIVO VALIDATION; MITRAL-VALVE-PROLAPSE; DOBUTAMINE-STRESS-ECHOCARDIOGRAPHY; INITIAL CLINICAL-EXPERIENCE; ATRIOVENTRICULAR SEPTAL-DEFECTS; WALL-MOTION ABNORMALITIES; LEFT ATRIAL VOLUME C1 Duke Univ, Med Ctr, Durham, NC 27710 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Chicago, Med Ctr, Chicago, IL 60637 USA. Univ Erlangen Nurnberg, Erlangen, Germany. Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Texas, Med Branch, Galveston, TX 77550 USA. Cleveland Clin, Cleveland, OH 44106 USA. Univ Calif Irvine, Med Ctr, Orange, CA USA. RP Ryan, T (reprint author), Duke Univ, Med Ctr, Box 3975, Durham, NC 27710 USA. EM ryan0013@mc.duke.edu NR 133 TC 160 Z9 168 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0894-7317 J9 J AM SOC ECHOCARDIOG JI J. Am. Soc. Echocardiogr. PD MAR PY 2007 VL 20 IS 3 BP 213 EP 233 DI 10.1016/j.echo.2007.01.010 PG 21 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 144SO UT WOS:000244816600002 PM 17336747 ER PT J AU Varghese, SA Powell, TB Budisavljevic, MN Oates, JC Raymond, JR Almeida, JS Arthur, JM AF Varghese, Sanju A. Powell, T. Brian Budisavljevic, Milos N. Oates, Jim C. Raymond, John R. Almeida, Jonas S. Arthur, John M. TI Urine biomarkers predict the cause of glomerular disease SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; ENDOTHELIAL GROWTH-FACTOR; IDIOPATHIC MEMBRANOUS GLOMERULONEPHRITIS; CAPILLARY-ELECTROPHORESIS; DIABETIC-NEPHROPATHY; MASS-SPECTROMETRY; IGA NEPHROPATHY; DIAGNOSTIC MARKERS; EXCRETION; PROTEIN AB Diagnosis of the type of glomerular disease that causes the nephrotic syndrome is necessary for appropriate treatment and typically requires a renal biopsy. The goal of this study was to identify candidate protein biomarkers to diagnose glomerular diseases. Proteomic methods and informatic analysis were used to identify patterns of urine proteins that are characteristic of the diseases. Urine proteins were separated by two-dimensional electrophoresis in 32 patients with FSGS, lupus nephritis, membranous nephropathy, or diabetic nephropathy. Protein abundances from 16 patients were used to train an artificial neural network to create a prediction algorithm. The remaining 16 patients were used as an external validation set to test the accuracy of the prediction algorithm. In the validation set, the model predicted the presence of the diseases with sensitivities between 75 and 86% and specificities from 92 to 67%. The probability of obtaining these results in the novel set by chance is 5 X 10(-8). Twenty-one gel spots were most important for the differentiation of the diseases. The spots were cut from the gel, and 20 were identified by mass spectrometry as charge forms of 11 plasma proteins: Orosomucoid, transferrin, alpha-1 microglobulin, zinc alpha-2 glycoprotein, alpha-1 antitrypsin, complement factor B, haptoglobin, transthyretin, plasma retinol binding protein, albumin, and hemopexin. These data show that diseases that cause nephrotic syndrome change glomerular protein permeability in characteristic patterns. The fingerprint of urine protein charge forms identifies the glomerular disease. The identified proteins are candidate biomarkers that can be tested in assays that are more amenable to clinical testing. C1 Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. Ralph H Jonshon VA Med Ctr, Dept Med, Charleston, SC USA. Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA. RP Arthur, JM (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,POB 250623, Charleston, SC 29425 USA. EM arthur@musc.edu FU NCRR NIH HHS [M01 RR001070]; NHLBI NIH HHS [N01 HV 28181, N01HV28181]; NIAMS NIH HHS [R21 AR051719, R21 AR051719-02] NR 44 TC 132 Z9 144 U1 0 U2 9 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD MAR PY 2007 VL 18 IS 3 BP 913 EP 922 DI 10.1681/ASN.2006070767 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 159NS UT WOS:000245873400030 PM 17301191 ER PT J AU Kosson, DS Miller, SK Byrnes, KA Leveroni, CL AF Kosson, David S. Miller, Sarah K. Byrnes, Katherine A. Leveroni, Catherine L. TI Testing neuropsychological hypotheses for cognitive deficits in psychopathic criminals: A study of global-local processing SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE personality disorder; antisocial personality disorder; crime; behavior; reaction time; frontal lobes ID ANTISOCIAL PERSONALITY-DISORDER; LEFT-HEMISPHERE ACTIVATION; SOMATIC MARKER HYPOTHESIS; DIVIDED VISUAL-ATTENTION; CARD SORTING TEST; NONPSYCHOPATHIC OFFENDERS; ORBITOFRONTAL CORTEX; RESPONSE MODULATION; PCL-R; PERFORMANCE AB Competing hypotheses about neuropsychological mechanisms underlying psychopathy are seldom examined in the same study. We tested the left hemisphere activation hypothesis and the response modulation hypothesis of psychopathy in 172 inmates completing a global-local processing task under local bias, global bias, and neutral conditions. Consistent with the left hemisphere activation hypothesis, planned comparisons showed that psychopathic inmates classified local targets more slowly than nonpsychopathic inmates in a local bias condition and exhibited a trend toward similar deficits for global targets in this condition. However, contrary to the response modulation hypothesis, psychopaths were no slower to respond to local targets in a global bias condition. Because psychopathic inmates were not generally slower to respond to local targets, results are also not consistent with a general left hemisphere dysfunction account. Correlational analyses also indicated deficits specific to conditions presenting most targets at the local level initially. Implications for neuropsychological conceptualizations of psychopathy are considered. C1 Rosalind Franklin Univ Med & Sci, Dept Psychol, N Chicago, IL 60064 USA. Med Coll Wisconsin, Dept Neurol Neuropsychol, Milwaukee, WI 53226 USA. Massachusetts Gen Hosp, Psychol Assessment Ctr, Boston, MA 02114 USA. RP Kosson, DS (reprint author), Rosalind Franklin Univ Med & Sci, Dept Psychol, 3333 Green Bay Rd, N Chicago, IL 60064 USA. EM david.kosson@rosalindfranklin.edu FU NIMH NIH HHS [MH57714, MH49111] NR 70 TC 10 Z9 10 U1 2 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD MAR PY 2007 VL 13 IS 2 BP 267 EP 276 DI 10.1017/S1355617707070294 PG 10 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 144XD UT WOS:000244828800010 PM 17286884 ER PT J AU Vagefi, PA Choudhry, M Hilgenberg, AD AF Vagefi, Parsia A. Choudhry, Modassir Hilgenberg, Alan D. TI Excision of an aneurysm of the left atrial appendage SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Editorial Material C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiac Surg, Boston, MA 02114 USA. RP Vagefi, PA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiac Surg, 55 Fruit St,GRB-425, Boston, MA 02114 USA. EM pvagefi@partners.org NR 5 TC 4 Z9 5 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD MAR PY 2007 VL 133 IS 3 BP 822 EP U134 DI 10.1016/j.jtcvs.2006.11.025 PG 3 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 139OO UT WOS:000244441800047 PM 17320601 ER PT J AU Chauhan, AK Goerge, T Schneider, SW Wagner, DD AF Chauhan, A. K. Goerge, T. Schneider, S. W. Wagner, D. D. TI Formation of platelet strings and microthrombi in the presence of ADAMTS-13 inhibitor does not require P-selectin or beta(3) integrin SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Article DE ADAMTS-13; beta 3; INF> integrin; platelet strings; P-selectin; ULVWF ID VON-WILLEBRAND-FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; WEIBEL-PALADE BODIES; REGULATED SECRETORY PATHWAY; HUMAN VONWILLEBRAND-FACTOR; FACTOR-CLEAVING PROTEASE; FACTOR MULTIMERS; ENDOTHELIAL-CELLS; ADHESION; STORAGE AB Background: Ultra-large von Willebrand factor (ULVWF) and the receptor P-selectin are released from endothelial Weibel-Palade bodies during injury or inflammation. VWF mediates platelet adhesion and P-selectin promotes leukocyte rolling. ADAMTS-13 limits the duration of platelet adhesion by cleaving the ULVWF. In the absence of ADAMTS-13, long VWF filaments decorated with platelets form. Recent in vitro studies suggested that P-selectin might anchor these platelet strings to endothelium, but whether the same mechanism exists in vivo remains to be elucidated. Methods: We address the role of P-selectin and beta(3) integrin in platelet string formation in vivo using intravital microscopy by infusing inhibitory ADAMTS-13 antibody in P-selectin-/- and beta(3)-deficient mice and activating the endothelium by injecting histamine. Results: We show that inhibition of ADAMTS-13 combined with endothelial activation leads to similar extents of platelet string formation in wild-type, P-selectin- and integrin beta(3)-deficient mice. Further, in venules the platelet strings can coalesce into VWF-platelet aggregates. This process utilizes neither the platelet beta(3) integrin nor P-selectin. We also show in vitro that platelets can act as a bridge between the VWF fibers and that VWF can self-associate even in areas devoid of platelets. Conclusions: The formation or retention of the platelet strings does not require P-selectin or the endothelial VWF receptor alpha(v)beta(3). Furthermore, in the presence of low ADAMTS-13 activity, VWF-dependent and alpha(IIb)beta(3)-independent platelet clustering occurs in veins, as has been shown at high arterial shear rates. Our study further supports the importance of regulation of VWF multimer size upon secretion from Weibel-Palade bodies. C1 Harvard Univ, CBR Inst Biomed Res & Dev Pathol, Sch Med, Boston, MA 02115 USA. Harvard Univ, Dept Pathol, Sch Med, Boston, MA 02115 USA. Univ Munster, Dept Dermatol, D-4400 Munster, Germany. RP Wagner, DD (reprint author), Harvard Univ, CBR Inst Biomed Res & Dev Pathol, Sch Med, 800 Huntington Ave, Boston, MA 02115 USA. EM wagner@cbr.med.harvard.edu FU NHLBI NIH HHS [R37 HL41002, R37 HL041002] NR 33 TC 31 Z9 31 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1538-7933 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD MAR PY 2007 VL 5 IS 3 BP 583 EP 589 DI 10.1111/j.1538-7836.2007.02361.x PG 7 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 137FG UT WOS:000244277800023 PM 17166247 ER PT J AU Nathens, AB McMurray, MK Cuschieri, J Durr, EA Moore, EE Bankey, PE Freeman, B Harbrecht, BG Johnson, JL Minei, JP McKinley, BA Moore, FA Shapiro, MB West, MA Tompkins, RG Maier, RV AF Nathens, Avery B. McMurray, Megan K. Cuschieri, Joseph Durr, Emily A. Moore, Ernest E. Bankey, Paul E. Freeman, Brad Harbrecht, Brian G. Johnson, Jeffrey L. Minei, Joseph P. McKinley, Bruce A. Moore, Frederick A. Shapiro, Michael B. West, Michael A. Tompkins, Ronald G. Maier, Ronald V. TI The practice of venous thromboembolism prophylaxis in the major trauma patient SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article; Proceedings Paper CT 65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma CY SEP 28-30, 2006 CL New Orleans, LA SP Amer Assoc Surg Trauma DE venous thromboembolism; prophylaxis; deep venous thrombosis; pulmonary embolism; knowledge translation ID PULMONARY-EMBOLISM; PREVENTION; INJURY; FILTERS; CARE AB Background: The incidence of venous thromboembolism (VTE) without prophylaxis is as high as 80% after major trauma. Initiation of prophylaxis is often delayed because of concerns of injury-associated bleeding. As the effect of delays in the initiation of prophylaxis on VTE rates is unknown, we set out to evaluate the relationship between late initiation of prophylaxis and VTE. Methods: Data were derived from a multicenter prospective cohort study evaluating clinical outcomes in adults with hemorrhagic shock after injury. Analyses were limited to patients with an Intensive Care Unit length of stay >= 7 days. The rate of VTE was estimated as a function of the time to initiation of pharmacologic pro-phylaxis. A multivariate stepwise logistic regression model was used to evaluate factors associated with late initiation. Results: There were 315 subjects who met inclusion criteria; 34 patients (11%) experienced a VTE within the first 28 days. Prophylaxis was initiated within 48 hours of injury in 25% of patients, and another one-quarter had no prophylaxis for at least 7 days after injury. Early prophylaxis was associated with a 5% risk of VTE, whereas delay beyond 4 days was associated with three times that risk (risk ratio, 3.0, 95% CI [1.4-6.5]). Factors associated with late (> 4 days) initiation of prophylaxis included severe head injury, absence of comorbidities, and massive transfusion, whereas the presence of a severe lower extremity fracture was associated with early prophylaxis. Conclusions: Clinicians are reticent to begin timely VTE prophylaxis in critically injured patients. Patients are without VTE prophylaxis for half of all days within the first week of admission and this delay in the initiation of prophylaxis is associated with a threefold greater risk of VTE. The relative risks and benefits of early VTE prophylaxis need to be defined to better direct practice in this high-risk population. C1 Univ Toronto, Dept Surg, Toronto, ON, Canada. Univ Washington, Dept Surg, Seattle, WA 98195 USA. Univ Colorado, Hlth Sci Ctr, Dept Surg, Denver, CO 80262 USA. SW Texas State Univ, Dept Surg, Dallas, TX USA. Univ Rochester, Med Ctr, Dept Surg, Rochester, NY 14642 USA. Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA. Methodist Hosp, Dept Surg, Houston, TX 77030 USA. Massachusetts Gen Hosp, Div Burn Surg, Boston, MA 02114 USA. RP Nathens, AB (reprint author), St Michaels Hosp, 3-073 Queen Wing,30 Bond St, Toronto, ON M5B 1W8, Canada. EM nathensa@smh.toronto.on.ca FU NIGMS NIH HHS [U54 GM062119-1, U54 GM062119] NR 18 TC 53 Z9 61 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0022-5282 EI 1529-8809 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD MAR PY 2007 VL 62 IS 3 BP 557 EP 562 DI 10.1097/TA.0b013e318031b5f5 PG 6 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 145PP UT WOS:000244877300002 PM 17414328 ER PT J AU Cohen, SP Villena, F Mao, JR AF Cohen, Steven P. Villena, Felipe Mao, Jianren TI Two unusual cases of postamputation pain from Operation Iraqi Freedom SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article ID PHANTOM-LIMB PAIN; AMERICAN VETERANS; AMPUTATION; AMPUTEES; STUMP C1 Johns Hopkins Med Inst, Pain Management Ctr, Dept Anesthesiol, Baltimore, MD 21205 USA. Johns Hopkins Med Inst, Dept Crit Care Med, Baltimore, MD 21205 USA. Walter Reed Army Med Ctr, Pain Management Ctr, Washington, DC 20307 USA. Landstuhl Reg Army Med Ctr, Dept Surg, Anesthesia Serv, Landstuhl, Germany. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesiol & Crit Care,Pain Ctr, Boston, MA 02115 USA. RP Cohen, SP (reprint author), Johns Hopkins Med Inst, Pain Management Ctr, Dept Anesthesiol, 550 N Broadway,Suite 301, Baltimore, MD 21205 USA. EM scohen40@jhmi.edu NR 18 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD MAR PY 2007 VL 62 IS 3 BP 759 EP 761 DI 10.1097/01.ta.0000235268.32690.8b PG 3 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 145PP UT WOS:000244877300041 PM 17414361 ER PT J AU Jensen, ME McGraw, JK Cardella, JF Hirsch, JA AF Jensen, Mary E. McGraw, J. Kevin Cardella, John F. Hirsch, Joshua A. TI Position statement on percutaneous vertebral augmentation: A consensus statement developed by the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, American Association of Neurological Surgeons/Congress of Neurological Surgeons, and American Society of Spine Radiology SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID OSTEOPOROTIC COMPRESSION FRACTURES; BALLOON KYPHOPLASTY; FOLLOW-UP; POLYMETHYLMETHACRYLATE VERTEBROPLASTY; PULMONARY-EMBOLISM; CLINICAL-OUTCOMES; ACRYLIC CEMENT; PAIN RELIEF; BED REST; COMPLICATIONS C1 Riverside Methodist Hosp, Riverside Intervent Consultants, Columbus, OH 43214 USA. Univ Virginia Hlth Syst, Dept Radiol, Charlottesville, VA USA. Univ Colorado, Hlth Sci Ctr, Dept Radiol, Denver, CO 80262 USA. Massachusetts Gen Hosp, Dept Intervent Neuroradiol & Endovasc Neurosurg, Boston, MA 02114 USA. RP McGraw, JK (reprint author), Riverside Methodist Hosp, Riverside Intervent Consultants, 3525 Olentangy River Rd,Ste 5362, Columbus, OH 43214 USA. EM jkmcgraw@hotmail.com NR 68 TC 32 Z9 34 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD MAR PY 2007 VL 18 IS 3 BP 325 EP 330 DI 10.1016/j.jvir.2007.01.014 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA 150ED UT WOS:000245197500001 PM 17377175 ER PT J AU Perron, MJ Stremlau, M Lee, M Javanbakht, H Song, B Sodroski, J AF Perron, Michel J. Stremlau, Matthew Lee, Mark Javanbakht, Hassan Song, Byeongwoon Sodroski, Joseph TI The human TRIM5 alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid SO JOURNAL OF VIROLOGY LA English DT Article ID RETROVIRUS RESTRICTION; REVERSE TRANSCRIPTION; HOST-RANGE; MONKEY TRIM5-ALPHA; HIV-1 INFECTION; OLD-WORLD; CELLS; REPLICATION; PROTEIN; DOMAIN AB The host cell factors TRIM5 alpha(hu) and Fv-1 restrict N-tropic murine leukemia virus (N-MLV) infection at an early postentry step before or after reverse transcription, respectively. Interestingly, the identity of residue 110 of the MLV capsid determines susceptibility to both TRIM5 alpha(hu) and Fv-1. In this study, we investigate the fate of the MLV capsid in cells expressing either the TRIM5 alpha(hu) or Fv-1 restriction factor. The expression of TRIM5 alpha(hu), but not Fv-1, specifically promoted the premature conversion of particulate N-MLV capsids within infected cells to soluble capsid proteins. The TRIM5 alpha(hu)-mediated disassembly of particulate N-MLV capsids was dependent upon residue 110 of the viral capsid. Furthermore, the deletion or disruption of TRIM5 alpha(hu). domains necessary for potent N-MLV restriction completely abrogated the disappearance of particulate N-MLV capsids observed with wild-type TRIM5 alpha(hu). These results suggest that premature disassembly of the viral capsid contributes to the restriction of N-MLV infection by TRIM alpha(hu), but not by Fv-1. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Div AIDS,Dept Canc Immunol & AIDS, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Immunol & Infect Dis, Boston, MA 02115 USA. RP Sodroski, J (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div AIDS,Dept Canc Immunol & AIDS, 44 Binney St,JFB 824, Boston, MA 02115 USA. EM joseph_sodroski@dfci.harvard.edu FU NIAID NIH HHS [AI 063987, P30 AI060354, R01 AI063987, AI 60354] NR 42 TC 105 Z9 105 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAR PY 2007 VL 81 IS 5 BP 2138 EP 2148 DI 10.1128/JVI.02318-06 PG 11 WC Virology SC Virology GA 138RM UT WOS:000244380000005 PM 17135314 ER PT J AU Radziewicz, H Ibegbu, CC Fernandez, ML Workowski, KA Obideen, K Wehbi, M Hanson, HL Steinberg, JP Masopust, D Wherry, EJ Altman, JD Rouse, BT Freeman, GJ Ahmed, R Grakoui, A AF Radziewicz, Henry Ibegbu, Chris C. Fernandez, Marina L. Workowski, Kimberly A. Obideen, Kamil Wehbi, Mohammad Hanson, Holly L. Steinberg, James P. Masopust, David Wherry, E. John Altman, John D. Rouse, Barry T. Freeman, Gordon J. Ahmed, Rafi Grakoui, Arash TI Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression SO JOURNAL OF VIROLOGY LA English DT Article ID CD8(+) T-CELLS; CHRONIC VIRAL-INFECTION; PROGRAMMED DEATH-1; EFFECTOR FUNCTION; IMMUNE-RESPONSE; RECEPTOR-ALPHA; UNITED-STATES; HIV; STIMULATION; ACTIVATION AB The majority of people infected with hepatitis C virus (HCV) fail to generate or maintain a T-cell response effective for viral clearance. Evidence from murine chronic viral infections shows that expression of the coinhibitory molecule PD-1 predicts CD8(+) antiviral T-cell exhaustion and may contribute to inadequate pathogen control. To investigate whether human CD8+ T cells express PD-1 and demonstrate a dysfunctional phenotype during chronic HCV infection, peripheral and intrahepatic HCV-specific CD8(+) T cells were examined. We found that in chronic HCV infection, peripheral HCV-specific T cells express high levels of PD-1 and that blockade of the PD-1/PD-L1 interaction led to an enhanced proliferative capacity. Importantly, intrahepatic HCV-specific T cells, in contrast to those in the periphery, express not only high levels of PD-1 but also decreased interleukin-7 receptor alpha (CD127), an exhausted phenotype that was HCV antigen specific and compartmentalized to the liver, the site of viral replication. C1 Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30329 USA. Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30329 USA. Emory Univ, Sch Med, Dept Med, Atlanta, GA 30329 USA. Wistar Inst Anat & Biol, Program Immunol, Philadelphia, PA 19104 USA. Univ Tennessee, Coll Vet Med, Knoxville, TN 37996 USA. Harvard Univ, Sch Med, Dept Med, Dana Farber Canc Inst,Dept Med Oncol, Boston, MA 02115 USA. RP Grakoui, A (reprint author), Emory Univ, Sch Med, Emory Vaccine Ctr, 954 Gatewood Rd,NE, Atlanta, GA 30329 USA. EM arash.grakoui@emory.edu RI masopust, david/B-5027-2008 FU NCRR NIH HHS [K12 RR 017643, K12 RR017643, P51 RR000165, RR 00165]; NIAID NIH HHS [AI 070101, AI 56299, P01 AI056299, R01 AI070101, R56 AI070101] NR 50 TC 274 Z9 284 U1 1 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAR PY 2007 VL 81 IS 6 BP 2545 EP 2553 DI 10.1128/JVI.02021-06 PG 9 WC Virology SC Virology GA 145FN UT WOS:000244850800001 PM 17182670 ER PT J AU Sarfaty, S Kolb, D Barnett, R Szalacha, L Caswell, C Inui, T Carr, PL AF Sarfaty, Suzanne Kolb, Deborah Barnett, Rosalind Szalacha, Laura Caswell, Cheryl Inui, Thomas Carr, Phyllis L. TI Negotiation in academic medicine: A necessary career skill SO JOURNAL OF WOMENS HEALTH LA English DT Article ID GENDER; OUTCOMES AB Aims: Negotiation and its use in academic medicine have not been studied. Little is known about faculty experience with negotiation or its potential benefits for academe. Barriers to negotiation and how they can be addressed, especially for faculty without perceived skill in negotiation, are unknown. Methods: To better understand the problems that such faculty experience, we completed in-depth, individual telephone interviews of 20 academic medical faculty at 11 of the 24 medical schools in the National Faculty Survey, all of whom perceived difficulty in negotiation. Faculty were stratified by rank, gender, and degree. Semistructured interviews were audiotaped, transcribed, and analyzed by five reviewers. We explored the role of negotiation in academe, barriers to negotiation, what faculty and institutions can do to improve the use of negotiation, and possible differences in negotiation by gender. Results: Faculty were relatively unaware of the possible uses of negotiation to advance their work in academe. Women tended to see negotiation as less important to an academic career than did their male colleagues. The perceived hierarchy and secrecy of many academic medical centers was believed to create a difficult environment for negotiation. For effective negotiation to occur, faculty stated the need to prepare, gather information, especially on compensation and resources, and to know their priorities. Preparation was particularly important for women, correlating with greater comfort with the degree of aggressiveness in the negotiation and greater self-confidence after the negotiation. These informants suggested that institutions need to provide more transparent information on salary and promotion guidelines. Further, institutions need to empower faculty with a solid understanding of institutional policy, goals, and resource needs of academic life. Conclusions: Many medical faculty are insufficiently aware of, or skilled in, the negotiation process and find significant barriers to negotiate in academe. Medical centers need to improve the climate for negotiation in academic medicine to maximize the potential contributions of negotiation to the institution. C1 Boston Univ, Sch Med, Div Internal Med, Boston, MA 02118 USA. Simmons Grad Sch Management, Boston, MA USA. Womens Studies Res Ctr Brandeis, Waltham, MA USA. Harvard Univ, Sch Educ, Boston, MA 02115 USA. New England Res Inst, Boston, MA USA. Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gen Internal Med, Boston, MA USA. RP Carr, PL (reprint author), Boston Univ, Sch Med, Div Internal Med, 715 Albany St,Room L-109, Boston, MA 02118 USA. EM plcarr@bu.edu NR 12 TC 16 Z9 16 U1 1 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2007 VL 16 IS 2 BP 235 EP 244 DI 10.1089/jwh.2006.0037 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 155SO UT WOS:000245598600010 PM 17388740 ER PT J AU Chang, J Cornell, JE Van Remmen, H Hakala, K Ward, WF Richardson, A AF Chang, Jinsook Cornell, John E. Van Remmen, Holly Hakala, Kevin Ward, Walter F. Richardson, Arlan TI Effect of aging and caloric restriction on the mitochondrial proteome SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID RESPIRATORY-CHAIN ACTIVITY; AGE-DEPENDENT IMPAIRMENT; HUMAN SKELETAL-MUSCLE; FREE FATTY-ACIDS; OXIDATIVE STRESS; RAT-HEART; OXYGEN-CONSUMPTION; PERMEABILITY TRANSITION; DIETARY RESTRICTION; RADICAL GENERATION AB The rat mitochondrial proteome was analyzed using two-dimensional polyacrylamide gel electrophoresis (2-D PAGE), and proteins altered by age or caloric restriction (CR) were identified using mass spectrometry. Of 2061 mitochondrial proteins analyzed in the three tissues, a significant change with age occurred in 25 liver proteins (19 increased, 6 decreased), 3 heart proteins (1 increased, 2 decreased), and 5 skeletal muscle proteins (all increased). CR prevented the age-related change in the level of one liver mitochondrial protein, altered the levels of four proteins (one increased, three decreased) from heart, and one protein (decreased) from skeletal muscle. Identification of the proteins that changed with age or CR revealed that they were varied among the three tissues, that is, not one mitochondrial protein was changed, in common, by age or CR in any tissue studied. Thus, the effect of age on the mitochondrial proteome appears to be tissue-specific, and CR has a minor effect on age-related protein changes. C1 Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Barshop Inst Longev & Aging Studies, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. RP Ward, WF (reprint author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 7703 Floyd Curl Dr,MSC 7756, San Antonio, TX 78229 USA. EM wardw@uthscsa.edu FU NCI NIH HHS [CA54174]; NIA NIH HHS [R01 AG23843, R01 AG025362-01] NR 67 TC 25 Z9 25 U1 0 U2 7 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAR PY 2007 VL 62 IS 3 BP 223 EP 234 PG 12 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 228WM UT WOS:000250763300001 PM 17389719 ER PT J AU Yancik, R Ershler, W Satariano, W Hazzard, W Cohen, HJ Ferruci, L AF Yancik, Rosemary Ershler, William Satariano, William Hazzard, William Cohen, Harvey J. Ferruci, Luigi TI Report of the National Institute on Aging Task Force on Comorbidity SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Editorial Material C1 NIA, NIH, Geriat & Clin Gerontol Program, Geriatr Branch, Bethesda, MD 20892 USA. NIA, Clin Res Branch, Baltimore, MD 21224 USA. Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Duke Univ, Med Ctr, Ctr Study Aging, Durham, NC USA. RP Yancik, R (reprint author), NIA, NIH, Geriat & Clin Gerontol Program, Geriatr Branch, 7201 Wisconsin Ave,Suite 3C307, Bethesda, MD 20892 USA. EM yancikr@nia.nih.gov FU Intramural NIH HHS [Z99 AG999999] NR 4 TC 78 Z9 78 U1 1 U2 4 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAR PY 2007 VL 62 IS 3 BP 275 EP 280 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 228WM UT WOS:000250763300006 PM 17389724 ER PT J AU Yao, J Gutierrez, OM Reiser, J AF Yao, J. Gutierrez, O. M. Reiser, J. TI Emphysematous pyelonephritis SO KIDNEY INTERNATIONAL LA English DT Article ID PERCUTANEOUS DRAINAGE; MEDICAL THERAPY; DIABETIC-PATIENTS; MANAGEMENT; GAS; EXPERIENCE AB A 58-year-old woman with a past medical history of hypertension and arthritis presented to the Emergency Department of the Massachusetts General Hospital complaining of 1 week of progressive fatigue. The patient had visited her primary care physician 1 week before a 'water pill refill' and general medical examination. Results of the examination were an elevated blood glucose level and the diagnosis of diabetes mellitus. She was not started on medication at that time, and was instructed to return to the clinic in 1 week for follow-up. During the ensuing week, she reported feeling increasingly tired and depressed, to the point that she stopped eating and drinking for approximately 4 days. Subsequently, she developed mild right upper quadrant abdominal discomfort, and noted that the color of her urine had turned very dark. Her family became concerned about her condition and decided to bring her to the hospital for evaluation. C1 Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Reiser, J (reprint author), Massachusetts Gen Hosp, Dept Med, Div Nephrol, 149 13th St, Boston, MA 02114 USA. EM jreiser@partners.org NR 27 TC 4 Z9 4 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD MAR PY 2007 VL 71 IS 5 BP 462 EP 465 DI 10.1038/sj.ki.5002001 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 138TY UT WOS:000244387400018 PM 17136032 ER PT J AU Russo, LM Sandoval, RM McKee, M Osicka, TM Collins, AB Brown, D Molitoris, BA Comper, WD AF Russo, L. M. Sandoval, R. M. McKee, M. Osicka, T. M. Collins, A. B. Brown, D. Molitoris, B. A. Comper, W. D. TI The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: Retrieval is disrupted in nephrotic states SO KIDNEY INTERNATIONAL LA English DT Article DE albuminuria; proximal tubule; glomerular filtration barrier; nephropathy; pathophysiology of renal disease and progression ID NEGATIVELY CHARGED FICOLL; FRACTIONAL CLEARANCE; GLOMERULAR PERMSELECTIVITY; 2-PHOTON MICROSCOPY; BINDING PROTEIN; IN-VIVO; RAT; MICROPUNCTURE; PERMEABILITY; DEGRADATION AB The origin of albuminuria remains controversial owing to difficulties in quantifying the actual amount of albumin filtered by the kidney. Here we use fluorescently labeled albumin, together with the powerful technique of intravital 2-photon microscopy to show that renal albumin filtration in non-proteinuric rats is B50 times greater than previously measured and is followed by rapid endocytosis into proximal tubule cells (PTCs). The endocytosed albumin appears to undergo transcytosis in large vesicles (500 nm in diameter), identified by immunogold staining of endogenous albumin by electron microscopy, to the basolateral membrane where the albumin is disgorged back to the peritubular blood supply. In nephrotic rats, the rate of uptake of albumin by the proximal tubule (PT) is decreased. This is consistent with reduced expression of clathrin, megalin, and vacuolar H+-ATPase A subunit, proteins that are critical components of the PT endocytotic machinery. These findings strongly support the paradigm-shifting concept that the glomerular filter normally leaks albumin at nephrotic levels. Albuminuria does not occur as this filtered albumin load is avidly bound and retrieved by PTCs. Dysfunction of this retrieval pathway leads to albuminuria. Thus, restoration of the defective endocytotic and processing function of PT epithelial cells might represent an effective strategy to limit urinary albumin loss, at least in some types of nephrotic syndrome. C1 Univ Melbourne, Dept Med, Austin Hlth, Heidelberg, Vic 3084, Australia. Massachusetts Gen Hosp, Program Membrane Biol, Renal Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Indiana Univ, Sch Med, Div Nephrol, Dept Med, Indianapolis, IN 46204 USA. Indiana Univ, Sch Med, Indiana Ctr Biol Microscopy, Indianapolis, IN 46204 USA. Massachusetts Gen Hosp, Pathol Unit, Boston, MA 02114 USA. Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN USA. RP Comper, WD (reprint author), Univ Melbourne, Dept Med, Austin Hlth, Heidelberg, Vic 3084, Australia. EM wcomper@hotmail.com FU NIDDK NIH HHS [DK 061594, DK 42956] NR 31 TC 213 Z9 219 U1 1 U2 9 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD MAR PY 2007 VL 71 IS 6 BP 504 EP 513 DI 10.1038/sj.ki.5002041 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 143TV UT WOS:000244748900009 PM 17228368 ER PT J AU O'Hare, AM Bertenthal, D Walter, LC Garg, AX Covinsky, K Kaufman, JS Rodriguez, RA Allon, M AF O'Hare, A. M. Bertenthal, D. Walter, L. C. Garg, A. X. Covinsky, K. Kaufman, J. S. Rodriguez, R. A. Allon, M. TI When to refer patients with chronic kidney disease for vascular access surgery: Should age be a consideration? SO KIDNEY INTERNATIONAL LA English DT Article DE elderly; permanent vascular access; hemodialysis; timing; Department of Veterans Affairs; chronic kidney disease ID HEMODIALYSIS-PATIENTS; ARTERIOVENOUS-FISTULAS; OUTCOMES; MANAGEMENT; MORTALITY; FAILURE; CHOICE; COHORT; RISK AB To determine whether age should inform our approach toward permanent vascular access placement in patients with chronic kidney disease, we conducted a retrospective cohort study among 11 290 non-dialysis patients with an estimated glomerular filtration rate (eGFR) < 25 ml/min/ 1.73m(2) based on 2000 - 2001 outpatient creatinine measurements in the Department of Veterans Affairs. For each age group, we examined the percentage of patients that had and had not received a permanent access by 1 year after cohort entry, and the percentage in each of these groups that died, started dialysis, or survived without dialysis. We also modeled the number of unnecessary procedures that would have occurred in theoretical scenarios based on existing vascular access guidelines. The mean eGFR was 17.7 ml/min/1.73 m(2) at cohort entry. Twenty-five percent (n = 2870) of patients initiated dialysis within a year of cohort entry. Among these, only 39% (n = 1104) had undergone surgery to place a permanent access beforehand. As compared with younger patients, older patients were less likely to undergo permanent access surgery, but also less likely to start dialysis. In all theoretical scenarios examined, older patients would have been more likely than younger patients to receive unnecessary procedures. If all patients had been referred for permanent access surgery at cohort entry, the ratio of unnecessary to necessary procedures after 2 years of follow-up would have been 5:1 for patients aged 85 - 100 years but only 0.5:1 for those aged 18 - 44 years. Currently recommended approaches to permanent access placement based on a single threshold level of renal function for patients of all ages are not appropriate. C1 Univ Calif San Francisco, Vet Adm Med Ctr, Dept Med, San Francisco, CA 94121 USA. VA San Francisco REAP, San Francisco, CA USA. Univ Western Ontario, Dept Med, London, ON, Canada. VA Boston Healthcare Syst, Renal Sect, Boston, MA USA. San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA. Univ Alabama Stata Stat Software, Stata Corp, Dept Med, College Stn, TX USA. RP O'Hare, AM (reprint author), Univ Calif San Francisco, Vet Adm Med Ctr, Dept Med, 111J Nephrol,4150 Clement St, San Francisco, CA 94121 USA. EM Ann.O'Hare@va.gov FU NIA NIH HHS [K23 AG28980-01]; NIDDK NIH HHS [K24 DK59818-01] NR 20 TC 74 Z9 74 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD MAR PY 2007 VL 71 IS 6 BP 555 EP 561 DI 10.1038/sj.ki.5002078 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 143TV UT WOS:000244748900014 PM 17245396 ER PT J AU Georgoulis, AD Kiapidou, IS Velogianni, L Stergiou, N Boland, A AF Georgoulis, Anastasios D. Kiapidou, Irini-Solia Velogianni, Lamprini Stergiou, Nicholas Boland, Arthur TI Herodicus, the father of sports medicine SO KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY LA English DT Article DE sports medicine; history of medicine; physical activity; herodicus; training; diet AB Herodicus (fifth century BC) is the first person in the history of medicine who actually combined sports with medicine. He used to be a sports teacher, who later studied medicine and managed to succeed Euryphon in the medical school of Cnidos, one of the most prominent in ancient Greece together with its neighbor medical school of Cos (Hippocrates' home). In Cnidos Herodicus formed his own theoretical perspective of medicine. He considered, namely, bad health to be the result of imbalance between diet and physical activity and for this reason he recommended strict diet, constant physical activity and regular training. He believed that this combination was the ideal way to maintain good standards of health and he applied this type of treatment method to his patients. Unfortunately, Herodicus' works are lost today. However, excerpts of his medical system, which can be traced in ancient texts, support the fact that Herodicus can be considered as the father of sports medicine. C1 Univ Ioannina, Orthopaed Sports Med Ctr Ioannina, Dept Orthopaed Surg, GR-45110 Ioannina, Greece. Univ Nebraska, HPER Biomech Lab, Omaha, NE 68182 USA. Massachusetts Gen Hosp, Sports Med Shoulder Serv, Boston, MA 02114 USA. RP Georgoulis, AD (reprint author), POB 1330, Ioannina 45110, Greece. EM oaki@cc.uoi.gr NR 19 TC 1 Z9 1 U1 2 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0942-2056 J9 KNEE SURG SPORT TR A JI Knee Surg. Sports Traumatol. Arthrosc. PD MAR PY 2007 VL 15 IS 3 BP 315 EP 318 DI 10.1007/s00167-006-0149-z PG 4 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA 159CE UT WOS:000245842200017 PM 16951976 ER PT J AU Antonescu, CR Hornick, JL Nielsen, GP Mino-Kenudson, M Wong, G Corless, C Fletcher, CDM AF Antonescu, C. R. Hornick, J. L. Nielsen, G. P. Mino-Kenudson, M. Wong, G. Corless, C. Fletcher, C. D. M. TI Dedifferentiation in gastrointestinal stromal tumor (GIST) to an anaplastic KIT negative phenotype - A diagnostic pitfall SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 30 BP 11A EP 11A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300031 ER PT J AU Deshpande, V Nielsen, GP Rosenberg, AE AF Deshpande, V. Nielsen, G. P. Rosenberg, A. E. TI Gnathic well differentiated osteosarcomas: A clinicopathologic study of 9 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 39 BP 13A EP 13A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300040 ER PT J AU Nielsen, GP Srivastava, A O'Connell, JX Mangham, C Rosenberg, AE AF Nielsen, G. P. Srivastava, A. O'Connell, J. X. Mangham, C. Rosenberg, A. E. TI Epithelioid hemangioma of bone. A study of 39 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. CJ Coady Assoicates, Surry, BC, Canada. Royal Orthopaed Hosp, Birmingham B31 2AP, W Midlands, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 69 BP 20A EP 20A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300070 ER PT J AU Brachtel, EF Rusby, JE Michaelson, JS Smith, BL Koerner, FC AF Brachtel, E. F. Rusby, J. E. Michaelson, J. S. Smith, B. L. Koerner, F. C. TI Patterns of nipple involvement by breast carcinoma in mastectomies SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 99 BP 26A EP 26A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300100 ER PT J AU Brachtel, EF Kawakubo, H Kish, JB Yeo, G Maheswaram, S AF Brachtel, E. F. Kawakubo, H. Kish, J. B. Yeo, G. Maheswaram, S. TI Cyclin D1 overexpression with CCND1 amplification is correlated with loss of BTG2 in estrogen-receptor positive human breast cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 98 BP 26A EP 26A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300099 ER PT J AU Martyniak, A Kandel, MJ Stadler, Z Masciari, S Harris, L Miron, A Richardson, A Schnitt, SJ Garber, JE Collins, LC AF Martyniak, A. Kandel, M. J. Stadler, Z. Masciari, S. Harris, L. Miron, A. Richardson, A. Schnitt, S. J. Garber, J. E. Collins, L. C. TI Is basal cytokeratin (CK) or epidermal growth factor receptor (EGFR) expression predictive of BRCA1 mutation status in women with triple negative breast cancers? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 165 BP 41A EP 41A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300166 ER PT J AU Bedri, S Cizek, SM Talusan, P Lee, H Stone, JR AF Bedri, S. Cizek, S. M. Talusan, P. Lee, H. Stone, J. R. TI Risk factors for atherosclerosis and the development of preatherosclerotic intimal hyperplasia SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 239 BP 57A EP 57A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300240 ER PT J AU Belsley, NA Lauwers, GY Pitman, MB Deshpande, V AF Belsley, N. A. Lauwers, G. Y. Pitman, M. B. Deshpande, V. TI Serous cystadenomas of the pancreas: Diagnostic performance of imaging and fine needle aspiration biopsy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 273 BP 64A EP 64A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300274 ER PT J AU Ko, V Tambouret, RH Wilbur, DC AF Ko, V. Tambouret, R. H. Wilbur, D. C. TI Low grade squamous intraepithelial lesion (LSIL) and high risk HPV status: Effect of age on follow-up with high grade cervical lesions SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 317 BP 73A EP 74A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300318 ER PT J AU Murphy, EE Deshpande, V AF Murphy, E. E. Deshpande, V. TI Pre-operative diagnostic assessment of pseudocysts of the pancreas: A multimodal approach SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 335 BP 77A EP 77A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300336 ER PT J AU Shah, SS Faquin, WC Khurana, KK AF Shah, S. S. Faquin, W. C. Khurana, K. K. TI FNA of misclassified primary malignant neoplasms of thyroid: Impact on patient management SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 SUNY Syracuse, Syracuse, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 359 BP 82A EP 83A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300360 ER PT J AU Smouse, J Cibas, E Janne, P Joshi, V Lindeman, N AF Smouse, J. Cibas, E. Janne, P. Joshi, V. Lindeman, N. TI Cytology specimens compare favorably with surgical specimens for EGFR mutation detection in patients with NSCLC SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Mol Med Lab, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 369 BP 85A EP 85A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300370 ER PT J AU Yuan, Q Wilbur, D AF Yuan, Q. Wilbur, D. TI Follow up of high risk human papillomavirus (HPV) tests with high viral loads: Correlation with original pap test interpretations and biopsy results SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 382 BP 87A EP 88A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300383 ER PT J AU Knoepp, SM Carney, JA Mihn, MC Bei, T Stergiopoulos, S Stratakis, CA Zembowicz, A AF Knoepp, S. M. Carney, J. A. Mihn, M. C. Bei, T. Stergiopoulos, S. Stratakis, C. A. Zembowicz, A. TI Loss of expression of a carney complex gene, protein kinase a regulatory subunit 1a, in sporadic and carney complex-associated pigmented epithelioid melanocytoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. Mayo Clin, Rochester, MN USA. NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 419 BP 95A EP 95A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300420 ER PT J AU Turbiner, J Zukerberg, L Harris, NL Flotte, T AF Turbiner, J. Zukerberg, L. Harris, N. L. Flotte, T. TI Cutaneous marginal zone lymphoma with marked plasmacytic differentiation and rare B cells SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 437 BP 99A EP 99A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300438 ER PT J AU Chen, JH Pinkus, GS Faquin, WC Lloyd, RV Nose, V AF Chen, J. H. Pinkus, G. S. Faquin, W. C. Lloyd, R. V. Nose, V. TI Papillary thyroid carcinoma, columnar cell variant: A clinicopathologic and molecular study SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 444 BP 100A EP 100A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300445 ER PT J AU Abreu-e-Lima, P Farraye, F Smith, T Swaroop, P Garner, L Lauwers, G Odze, RD AF Abreu-e-Lima, P. Farraye, F. Smith, T. Swaroop, P. Garner, L. Lauwers, G. Odze, R. D. TI Clinical and pathologic features of ulcerative colitis in primary sclerosing cholangitis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Boston Med Ctr, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. St Louis Univ Hosp, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 470 BP 106A EP 106A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300470 ER PT J AU Bailey, GP Wittner, BS Ramaswamy, S Redston, MS AF Bailey, G. P. Wittner, B. S. Ramaswamy, S. Redston, M. S. TI Differential gene expression profiling of MGMT deficient colorectal cancer reveals a carcinogenic pathway distinct from other mismatch repair intact tumors SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 478 BP 107A EP 107A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300478 ER PT J AU Deshpande, V Lauwers, GY AF Deshpande, V. Lauwers, G. Y. TI Isolated cecal focal active colitis (FAC) in the asymptomatic adult: A clinical, endoscopic and pathological study of 24 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 504 BP 113A EP 113A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300504 ER PT J AU Farris, AB Lauwers, GY Zukerberg, LR AF Farris, A. B. Lauwers, G. Y. Zukerberg, L. R. TI The rectal tonsil: Analysis of salient histologic features to recognize this important entity SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 508 BP 114A EP 114A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300508 ER PT J AU Hornick, JL Mino-Kenudson, M Lauwers, GY Odze, RD AF Hornick, J. L. Mino-Kenudson, M. Lauwers, G. Y. Odze, R. D. TI Biological properties of buried intestinal epithelium following photodynamic therapy for Barrett's esophagus SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 526 BP 118A EP 118A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300526 ER PT J AU Johnston, EI Lewin, DN Wang, HL Lauwers, GY Srivastava, A Shyr, Y Washington, MK AF Johnston, E. I. Lewin, D. N. Wang, H. L. Lauwers, G. Y. Srivastava, A. Shyr, Y. Washington, M. K. TI Lymphovascular invasion in colorectal cancer: An interobserver variability SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Vanderbilt Univ, Nashville, TN USA. St Louis Univ, St Louis, MO 63103 USA. Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 533 BP 119A EP 119A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300533 ER PT J AU Kawasaki, T Fuchs, CS Loda, M Ogino, S AF Kawasaki, T. Fuchs, C. S. Loda, M. Ogino, S. TI Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype (CIMP) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 534 BP 119A EP 119A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300534 ER PT J AU Mino-Kenudson, M Lauwers, GY AF Mino-Kenudson, M. Lauwers, G. Y. TI Duplicated muscularis mucosa in Barrett esophagus - Vascular characteristics of newly formed submucosa SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 551 BP 123A EP 123A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300551 ER PT J AU Mino-Kenudson, M Lauwers, GY AF Mino-Kenudson, M. Lauwers, G. Y. TI Pathology of Barrett esophagus after photodynamic therapy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 550 BP 123A EP 123A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300550 ER PT J AU Oble, DA Mino-Kenudson, M Goldsmith, J Mihm, MC Hodi, FS Dranoff, G Lauwers, GY AF Oble, D. A. Mino-Kenudson, M. Goldsmith, J. Mihm, M. C. Hodi, F. S. Dranoff, G. Lauwers, G. Y. TI Autoimmune enteropathy-like panenteritis is associated with the novel cancer therapy adjuvant a-CTLA-4 mAb SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Hosp, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 560 BP 125A EP 125A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300560 ER PT J AU Ogino, S Kawasaki, T Loda, M Fuchs, CS AF Ogino, S. Kawasaki, T. Loda, M. Fuchs, C. S. TI A large population-based colorectal cancer sample shows correlations of CpG island methylator phenotype-low (CIMP-Low) with male sex and KRAS mutations SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 563 BP 125A EP 125A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300563 ER PT J AU Ogino, S Loda, M Fuchs, CS AF Ogino, S. Loda, M. Fuchs, C. S. TI Do histopathologic features of colorectal carcinoma predict microsatellite instability (MSI) or CpG island methylator phenotype (CIMP) or both? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 564 BP 126A EP 126A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300564 ER PT J AU Park, DY Srivastava, A Kim, GH Mino-Kenudson, M Deshpand, V Zukerberg, LR Lauwers, GY AF Park, D. Y. Srivastava, A. Kim, G. H. Mino-Kenudson, M. Deshpand, V. Zukerberg, L. R. Lauwers, G. Y. TI Immunohistochemical expression of MUC stains, CD10 and CDX2 in morphological variants of gastric epithelial dysplasia with emphasis on type II (Foveolar type) dysplasia SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Pusan Natl Univ Hosp, Pusan, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 567 BP 126A EP 126A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300567 ER PT J AU Park, DY Srivastava, A Kim, GH Mino-Kenudson, M Deshpand, V Zukerberg, LR Lauwers, GY AF Park, D. Y. Srivastava, A. Kim, G. H. Mino-Kenudson, M. Deshpand, V. Zukerberg, L. R. Lauwers, G. Y. TI Gastric foveolar (Type II) dysplasia frequently arises from a background mucosa with a distinctive form of intestinal metaplasia SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Pusan Natl Univ Hosp, Pusan, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 566 BP 126A EP 126A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935300566 ER PT J AU Sepehr, A Iafrate, AJ Lauwers, GY Misdraji, J AF Sepehr, A. Iafrate, A. J. Lauwers, G. Y. Misdraji, J. TI Serrated epithelial proliferations of the appendix SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 584 BP 130A EP 130A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301007 ER PT J AU Zhang, X Huang, Q Goyal, R Odze, RD AF Zhang, X. Huang, Q. Goyal, R. Odze, R. D. TI High fidelity image cytometry in neoplastic lesions in Barrett's esophagus, including basal crypt dysplasia-like atypia with surface maturation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 VA Boston Hlth Care Syst, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 597 BP 133A EP 133A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301020 ER PT J AU Demichelis, F Fall, K Perner, S Andren, O Schmidt, FH Setlur, SR Hoshida, Y Mosquera, JM Pawitan, Y Lee, C Adami, HO Mucci, LA Kantoff, PW Andersson, SO Chinnaiyan, AM Johansson, JE Rubin, MA AF Demichelis, F. Fall, K. Perner, S. Andren, O. Schmidt, F. H. Setlur, S. R. Hoshida, Y. Mosquera, J. M. Pawitan, Y. Lee, C. Adami, H. O. Mucci, L. A. Kantoff, P. W. Andersson, S. O. Chinnaiyan, A. M. Johansson, J. E. Rubin, M. A. TI TMPRSS2 : ERG gene fusion associated with lethal prostate cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. MIT, Broad Inst Harvard, Cambridge, MA 02139 USA. Hosp Ulm, Ulm, Germany. Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA. Univ Hosp Orebro, Orebro, Sweden. Karolinska Inst, Stockholm, Sweden. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 643 BP 142A EP 143A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301066 ER PT J AU Fine, SW Trock, B Reuter, VE Ayala, G Cheville, JC Fearn, P Jenkins, RB Knudsen, BS Loda, M Netto, GJ Said, J Shah, RB Simko, J Troncoso, P True, LD Yang, XJ Rubin, MA DeMarzo, AM AF Fine, S. W. Trock, B. Reuter, V. E. Ayala, G. Cheville, J. C. Fearn, P. Jenkins, R. B. Knudsen, B. S. Loda, M. Netto, G. J. Said, J. Shah, R. B. Simko, J. Troncoso, P. True, L. D. Yang, X. J. Rubin, M. A. DeMarzo, A. M. TI Effects of tissue processing on biomarker analysis in prostate needle biopsies: A multi-institutional study SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Johns Hopkins Univ, Baltimore, MD USA. Baylor Coll Med, Houston, TX 77030 USA. Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. MD Anderson Canc Ctr, Houston, TX USA. Northwestern Univ, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 658 BP 146A EP 146A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301081 ER PT J AU Hansel, DE Cheville, J Berhescu, E Fine, S Young, RH Epstein, JI AF Hansel, D. E. Cheville, J. C. Berhescu, E. Fine, S. Young, R. H. Epstein, J. I. TI Renal carcinoid tumor: A clinicopathologic study of 21 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. Mayo Clin, Rochester, MN USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 680 BP 150A EP 151A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301103 ER PT J AU Jiang, Z Chu, PG Woda, BA Liu, Q Wu, CL AF Jiang, Z. Chu, P. G. Woda, B. A. Liu, Q. Wu, C-L TI The RNA-binding protein IMP3: A novel molecular marker predicts metastasis and progression of renal cell carcinomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Univ Massachusetts, Med Ctr, Worcester, MA USA. City Hope Natl Med Ctr, Los Angeles, CA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 694 BP 153A EP 154A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301117 ER PT J AU Mosquera, JM Perner, S Demichelis, F Hoffer, MD Mertz, KD Paris, P Sinko, J Collins, C Bismar, T Rubin, MA AF Mosquera, J. M. Perner, S. Demichelis, F. Hoffer, M. D. Mertz, K. D. Paris, P. Sinko, J. Collins, C. Bismar, T. Rubin, M. A. TI Morphological features of TMPRSS2: ERG fusion prostate cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Harvard Univ, Sch Med, Boston, MA USA. Univ Ulm, Ulm, Germany. SRA Div Bioinformat Grp, Trento, Italy. Univ Calif San Francisco, San Francisco, CA 94143 USA. McGill Univ, Montreal, PQ, Canada. Harvard Univ, Sch Med, MIT, Cambridge, MA 02138 USA. Dana Farber Harvard Comprehens Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 748 BP 165A EP 165A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301171 ER PT J AU Oliva, E Kaufman, DS Shipley, WU Spicer, B Paner, G Gown, AM Amin, MB AF Oliva, E. Kaufman, D. S. Shipley, W. U. Spicer, B. Paner, G. Gown, A. M. Amin, M. B. TI Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia vs carcinoma in situ (CIS) of the bladder. A study of 48 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. PhenoPath Lab, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 760 BP 167A EP 167A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301183 ER PT J AU Perner, S Mosquera, JM Demichelis, F Hofer, MD Paris, PL Simko, J Collins, C Bismar, T Chinnaiyan, AM De Marzo, AM Rubin, MA AF Perner, S. Mosquera, J-M Demichelis, F. Hofer, M. D. Paris, P. L. Simko, J. Collins, C. Bismar, T. Chinnaiyan, A. M. De Marzo, A. M. Rubin, M. A. TI TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA. Univ Ulm, Ulm, Germany. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. McGill Univ, Fac Med, Montreal, PQ, Canada. Johns Hopkins Univ, Sch Med, Bloomberg Sch Publ Hlth, Baltimore, MD USA. ITC Irst, Trento, Italy. Univ Michigan, Sch Med, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 769 BP 169A EP 170A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301192 ER PT J AU Saenz, AJ Nielsen, GP Campbell, S Oliva, E AF Saenz, A. J. Nielsen, G. P. Campbell, S. Oliva, E. TI OCT-4 expression in malignant epithelial tumors of the genitourinary tract SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 787 BP 173A EP 173A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301210 ER PT J AU Westfall, D Folpe, AL Paner, GP Oliva, E Goldstein, LC Gown, AM Amin, MB AF Westfall, D. Folpe, A. L. Paner, G. P. Oliva, E. Goldstein, L. C. Gown, A. M. Amin, M. B. TI Utility of a comprehensive immunohistochemical (lHC) panel in the differential diagnosis of spindle cell lesions of the urinary bladder SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. Mayo Clin, Rochester, MN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Phenopath Labs, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 834 BP 183A EP 183A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301257 ER PT J AU Dahiya, S Carney, E Lopez-Varela, E Oliva, E Ma, XJ Sgroi, DC AF Dahiya, S. Carney, E. Lopez-Varela, E. Oliva, E. Ma, X-J Sgroi, D. C. TI Estrogen receptor (ER) co-activators and co-repressors in endometrial carcinoma associated with tamoxifen therapy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. AviaraDx Inc, Carlsbad, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 884 BP 194A EP 194A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301307 ER PT J AU Dahiya, S Felix, A Branton, P Campbell, S Sgroi, DC Oliva, E AF Dahiya, S. Felix, A. Branton, P. Campbell, S. Sgroi, D. C. Oliva, E. TI Low-grade endometrial stromal sarcoma (LG-ESS): Is there an immunophenotype, predictive of clinical behavior? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Portuguese Oncol Inst, Lisbon, Portugal. Inova Fairfax Hosp, Falls Church, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 883 BP 194A EP 194A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301306 ER PT J AU Dionigi, A Oliva, E Iafrate, AD Bell, DA AF Dionigi, A. Oliva, E. Iafrate, A. D. Bell, D. A. TI A wide spectrum of serous carcinomas arise in ovarian serous borderline tumors: A report of 25 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 887 BP 194A EP 195A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301310 ER PT J AU Irving, JA Young, RH AF Irving, J. A. Young, R. H. TI Granulosa cell tumors of the ovary with a pseudopapillary pattern: A study of 12 cases of an unusual morphologic variant emphasizing their distinction from transitional cell neoplasms and other papillary ovarian tumors SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Vancouver Gen Hosp, Vancouver, BC, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 919 BP 202A EP 202A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301342 ER PT J AU Jarboe, E Lee, Y Drapkin, R McKeon, FD Crum, CP AF Jarboe, E. Lee, Y. Drapkin, R. McKeon, F. D. Crum, C. P. TI The morphologic and immunophenotypic spectrum of a candidate precursor to pelvic serous carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Res Inst, Boston, MA USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 921 BP 202A EP 202A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301344 ER PT J AU McCluggage, WG Young, RH AF McCluggage, W. G. Young, R. H. TI Tubulo-squamous polyp: A report of ten cases of a distinctive hitherto uncharacterised vaginal polyp SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Royal Grp Hosp Trust, Belfast, Antrim, North Ireland. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 948 BP 207A EP 208A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301371 ER PT J AU Post, MD Carinelli, SG Campbell, S Soslow, RA Oliva, E AF Post, M. D. Carinelli, S. G. Campbell, S. Soslow, R. A. Oliva, E. TI p16 expression in squamous and trophoblastic lesions of the upper female genital tract SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Fdn Osped Policlin, Mangiagalli Regina Elena, Milan, Italy. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 963 BP 210A EP 211A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301386 ER PT J AU Rollins, SE Clement, PB Young, RH AF Rollins, S. E. Clement, P. B. Young, R. H. TI Uterine tumors resembling ovarian sex cord tumors frequently have incorporated mature smooth muscle imparting a pseudoinfiltrative appearance SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ British Columbia, Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 971 BP 212A EP 212A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301394 ER PT J AU Staats, PN McCluggage, WG Clement, PB Young, RH AF Staats, P. N. McCluggage, W. G. Clement, P. B. Young, R. H. TI Re-exploration of the distinctive ovarian lesion associated with sclerosing peritonitis: An analysis of 25 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Royal Grp Hosp Trust, Belfast, Antrim, North Ireland. Vancouver Gen Hosp, Vancouver, BC, Canada. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 984 BP 215A EP 215A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301407 ER PT J AU Wang, WL Soslow, RA Hensley, M Asad, H Zannoni, GF de Nictolis, M Branton, P Oliva, E AF Wang, W. L. Soslow, R. A. Hensley, M. Asad, H. Zannoni, G. F. de Nictolis, M. Branton, P. Oliva, E. TI Histopathologic prognostic factors in stage I uterine leiomyosarcomas (Ut-LMS); a clinicopathologic study of 28 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Cattolica, Rome, Italy. Ist Anat & Istol Patol, Ancona, Italy. Inova Fairfax Hosp, Church Falls, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 994 BP 217A EP 217A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301417 ER PT J AU Gang, Y Hutchinson, L Hassejian, R Galili, N Hao, S Raza, A Woda, B Wang, SA AF Gang, Y. Hutchinson, L. Hassejian, R. Galili, N. Hao, S. Raza, A. Woda, B. Wang, S. A. TI Myelodysplastic syndrome with erythroid Hypoplasia/Aplasia shows distinct clinicopathological features and clonal T cell expansion SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Univ Massachusetts, Med Ctr, Worcester, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 1100 BP 240A EP 240A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935301523 ER PT J AU Rahemtullah, A Harris, NL Ferry, JA AF Rahemtullah, A. Harris, N. L. Ferry, J. A. TI CD20+ T-Cell lymphoma: Clinicopathologic features of 5 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 1175 BP 256A EP 257A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935302009 ER PT J AU Cornell, LD Collins, AB Selig, MK Della Pelle, P Colvin, RB AF Cornell, L. D. Collins, A. B. Selig, M. K. Della Pelle, P. Colvin, R. B. TI De novo focal segmental glomerulosclerosis with collapse associated with sirolimus theraphy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 1244 BP 271A EP 272A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935302078 ER PT J AU Chung, SM Ferrone, CR Ferrone, S Klinstra, DS AF Chung, S. M. Ferrone, C. R. Ferrone, S. Klinstra, D. S. TI HLA class I antigen processing machinery (APM) is altered in short-term survivors (STS) of pancreatic adenocarcinoma (PAC) compared to long-term survivors (LTS) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Cornell Univ, Weill Med Coll, New York, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 1274 BP 278A EP 278A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935302108 ER PT J AU Deshpande, V Pitman, MB Lauwers, GY AF Deshpande, V. Pitman, M. B. Lauwers, G. Y. TI Endoscopic ultrasound (EUS)-Guided fine needle aspiration biopsy (FNAB) is a powerful predictor of malignancy in intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN) of the pancreas: A retrospective analysis of 110 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 1277 BP 278A EP 279A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935302111 ER PT J AU Sepehr, A Deshpande, V Lauwers, GY Mino-Kenudson, M AF Sepehr, A. Deshpande, V. Lauwers, G. Y. Mino-Kenudson, M. TI An IgG4+ to IgG+ plasma cells ratio in ampullary tissue as a marker to differentiate autoimmune pancreatitis from pancreatic cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 1338 BP 292A EP 292A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935302172 ER PT J AU Beheshti, J Mark, E Sabo, E Janne, P Sequist, L Jackman, D Joshi, V Iafrate, A Wang, L Meyerson, M Lindeman, N AF Beheshti, J. Mark, E. Sabo, E. Janne, P. Sequist, L. Jackman, D. Joshi, V. Iafrate, A. Wang, L. Meyerson, M. Lindeman, N. TI Correlation of papillary and bronchioloalveolar patterns in lung adenocarcinoma with EGFR mutation and response to tyrosine kinase inhibitors SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Rhode Isl Hosp, Providence, RI USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Mol Med Lab, Cambridge, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Brown Univ, Sch Med, Providence, RI 02912 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 1463 BP 318A EP 318A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935302297 ER PT J AU Beheshti, J Mark, E Sabo, E Janne, P Sequist, L Joshi, V Jackman, D Iafrate, AJ Wang, L Meyerson, M Lindeman, N AF Beheshti, J. Mark, E. Sabo, E. Janne, P. Sequist, L. Joshi, V. Jackman, D. Iafrate, A. J. Wang, L. Meyerson, M. Lindeman, N. TI Multimarker immunohistochemistry of non-small cell lung carcinomas: Correlation with EGFR mutation and response to treatment SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Rhode Isl Hosp, Providence, RI USA. Brown Univ, Sch Med, Providence, RI 02912 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Mol Med Lab, Cambridge, MA USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 1462 BP 318A EP 318A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935302296 ER PT J AU Koreishi, A Fidias, P Harris, NL Wright, C Hasserjian, RP AF Koreishi, A. Fidias, P. Harris, N. L. Wright, C. Hasserjian, R. P. TI Histologic changes in thymomas treated with neo-adjuvant chemoradiotherapy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 1494.5 BP 324A EP 325A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935302329 ER PT J AU Matsuhara, O Imazeki, N Tsuda, H Nakatani, Y Mark, EJ AF Matsuhara, O. Imazeki, N. Tsuda, H. Nakatani, Y. Mark, E. J. TI Differences of fibroblastic foci of UIP and intraalveolar buds of COP/BOOP, as measured by cellular markers and growth factors SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Natl Def Med Coll, Tokorozawa, Saitama 359, Japan. Chiba Univ, Chiba, Japan. Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 1502 BP 326A EP 326A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935302337 ER PT J AU Ruangchira-Urai, R Mark, FJ AF Ruangchira-urai, R. Mark, F. J. TI Bronchiolitis interstitial pneumonitis: A distinctive disease with clinical and pathological features intermediate between bronchiolitis obliterans organizing pneumonia and usual interstitial pneumonitis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Mahidol Univ, Siriraj Hosp, Fac Med, Bangkok 10700, Thailand. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 1517 BP 329A EP 329A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935302352 ER PT J AU Sholl, LM Iafrate, AJ Chou, YP Wu, MT Su, L Christiani, DC Chirieac, LR AF Sholl, L. M. Iafrate, A. J. Chou, Y. P. Wu, M. T. Su, L. Christiani, D. C. Chirieac, L. R. TI Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in non-small cell lung carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Vet Gen Hosp, Kaohsiung, Taiwan. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2007 VL 87 SU 1 MA 1522 BP 330A EP 331A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 146LG UT WOS:000244935302357 ER PT J AU Chen, J Jette, C Kanki, JP Aster, JC Look, AT Griffin, JD AF Chen, J. Jette, C. Kanki, J. P. Aster, J. C. Look, A. T. Griffin, J. D. TI NOTCH1-induced T-cell leukemia in transgenic zebrafish SO LEUKEMIA LA English DT Article DE notch; bcl2; T-ALL; zebrafish ID ACUTE LYMPHOBLASTIC-LEUKEMIA; CENTRAL-NERVOUS-SYSTEM; CHROMOSOMAL TRANSLOCATION; NOTCH1 MUTATIONS; C-MYC; V(D)J RECOMBINATION; HOMEOBOX GENE; EXPRESSION; TRANSFORMATION; PROTEIN AB Activating mutations in the NOTCH1 gene have been found in about 60% of patients with T-cell acute lymphoblastic leukemia (T-ALL). In order to study the molecular mechanisms by which altered Notch signaling induces leukemia, a zebrafish model of human NOTCH1-induced T-cell leukemia was generated. Seven of sixteen mosaic fish developed a T-cell lymphoproliferative disease at about 5 months. These neoplastic cells extensively invaded tissues throughout the fish and caused an aggressive and lethal leukemia when transplanted into irradiated recipient fish. However, stable transgenic fish exhibited a longer latency for leukemia onset. When the stable transgenic line was crossed with another line overexpressing the zebrafish bcl2 gene, the leukemia onset was dramatically accelerated, indicating synergy between the Notch pathway and the bcl2-mediated antiapoptotic pathway. Reverse transcription-polymerase chain reaction analysis showed that Notch target genes such as her6 and her9 were highly expressed in NOTCH1-induced leukemias. The ability of this model to detect a strong interaction between NOTCH1 and bcl2 suggests that genetic modifier screens have a high likelihood of revealing other genes that can cooperate with NOTCH1 to induce T-ALL. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. RP Griffin, JD (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM james_griffin@dfci.harvard.edu FU NCI NIH HHS [CA-36167, CA-68484] NR 62 TC 57 Z9 63 U1 1 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD MAR PY 2007 VL 21 IS 3 BP 462 EP 471 DI 10.1038/sj.leu.2404546 PG 10 WC Oncology; Hematology SC Oncology; Hematology GA 139BN UT WOS:000244407100012 PM 17252014 ER PT J AU Sherbenou, DW Wong, MJ Humayun, A McGreevey, LS Harrell, P Yang, R Mauro, M Heinrich, MC Press, RD Druker, BJ Deininger, MW AF Sherbenou, D. W. Wong, M. J. Humayun, A. McGreevey, L. S. Harrell, P. Yang, R. Mauro, M. Heinrich, M. C. Press, R. D. Druker, B. J. Deininger, M. W. TI Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib SO LEUKEMIA LA English DT Article DE chronic myeloid leukemia; CCR; D-HPLC; imatinib; kinase domain ID CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; CLINICAL RESISTANCE; MESYLATE TREATMENT; CHRONIC-PHASE; CML; REMISSION; THERAPY; STI571 AB Residual leukemia is demonstrable by reverse transcriptase-polymerase chain reaction in most patients with chronic myeloid leukemia who obtain a complete cytogenetic response (CCR) to imatinib. In patients who relapse during imatinib therapy, a high rate of mutations in the kinase domain of BCR-ABL have been identified, but the mechanisms underlying disease persistence in patients with a CCR are poorly characterized. To test whether kinase domain mutations are a common mechanism of disease persistence, we studied patients in stable CCR. Mutations were demonstrated in eight of 42 (19%) patients with successful amplification and sequencing of BCR-ABL. Mutation types were those commonly associated with acquired drug resistance. Four patients with mutations had a concomitant rise of BCR-ABL transcript levels, two of whom subsequently relapsed; the remaining four did not have an increase in transcript levels and follow-up samples, when amplifiable, were wild type. BCR-ABL-kinase domain mutations in patients with a stable CCR are infrequent, and their detection does not consistently predict relapse. Alternative mechanisms must be responsible for disease persistence in the majority of patients. C1 Oregon Hlth Sci Univ, Div Hematol & Med Oncol, Inst Canc, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Cell & Dev Biol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Howard Hughes Med Inst, Portland, OR 97201 USA. RP Deininger, MW (reprint author), Oregon Hlth Sci Univ, Div Hematol & Med Oncol, Inst Canc, L592,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. EM deininge@ohsu.edu FU NHLBI NIH HHS [HL082978-01] NR 18 TC 60 Z9 62 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD MAR PY 2007 VL 21 IS 3 BP 489 EP 493 DI 10.1038/sj.leu.2404554 PG 5 WC Oncology; Hematology SC Oncology; Hematology GA 139BN UT WOS:000244407100015 PM 17252009 ER PT J AU Yasui, H Hideshima, T Ikeda, H Ocio, EM Kiziltepe, T Vallet, S Okawa, Y Neri, P Sukhdeo, K Podar, K Chauhan, D Richardson, PG Raje, N Carrasco, DR Anderson, KC AF Yasui, H. Hideshima, T. Ikeda, H. Ocio, E. M. Kiziltepe, T. Vallet, S. Okawa, Y. Neri, P. Sukhdeo, K. Podar, K. Chauhan, D. Richardson, P. G. Raje, N. Carrasco, D. R. Anderson, K. C. TI Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway SO LEUKEMIA LA English DT Article DE multiple myeloma; beta-catenin/ TCF; NSAID; apoptosis ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; KAPPA-B; INDUCED APOPTOSIS; PROSTATE-CANCER; GENE-EXPRESSION; CARCINOMA-CELLS; BREAST-CANCER; R-ENANTIOMER AB We have reported previously that R-enantiomer of etodolac (R-etodolac), which is under investigation in phase 2 clinical trials in chronic lymphocytic leukemia, induces potent cytotoxicity at clinically relevant concentrations in multiple myeloma (MM) cells. In this study, we demonstrated that SDX-308 (CEP-18082), a novel analog of etodolac, has more potent cytotoxicity than R-etodolac against both MM cell lines and patient MM cells, including tumor cells resistant to conventional (dexamethasone, doxorubicine, melphalan) and novel (bortezomib) therapies. SDX-308-induced cytotoxicity is triggered by caspase-8/9/3 activation and poly (ADP-ribose) polymerase cleavage, followed by apoptosis. SDX-308 significantly inhibits beta-catenin/T-cell factor pathway by inhibiting nuclear translocation of beta-catenin, thereby downregulating transcription and expression of downstream target proteins including myc and survivin. Neither interleukin-6 nor insulin-like growth factor-1 protect against growth inhibition triggered by SDX-308. Importantly, growth of MM cells adherent to bone marrow (BM) stromal cells is also significantly inhibited by SDX-308. Our data therefore indicate that the novel etodolac analog SDX- 308 can target MM cells in the BM milieu. C1 Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido, Japan. Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA. RP Anderson, KC (reprint author), Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, 44 Binney St,Mayer 557, Boston, MA 02115 USA. EM kenneth_anderson@dfci.harvard.edu RI 2007, Secribsal/A-1556-2012 FU NCI NIH HHS [R0-1 CA 50947, IP50 CA10070]; PHS HHS [P0-1 78378] NR 56 TC 17 Z9 17 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD MAR PY 2007 VL 21 IS 3 BP 535 EP 540 DI 10.1038/sj.leu.2404561 PG 6 WC Oncology; Hematology SC Oncology; Hematology GA 139BN UT WOS:000244407100022 PM 17268521 ER PT J AU Henning, EC Azuma, C Sotak, CH Helmer, KG AF Henning, Erica C. Azuma, Chieko Sotak, Christopher H. Helmer, Karl G. TI Multispectral quantification of tissue types in a RIF-1 tumor model with histological validation. Part I SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article; Proceedings Paper CT 12th Annual Meeting of the International-Society-for-Magnetic-Resonance-in-Medicine CY MAY 15-21, 2004 CL Kyoto, JAPAN SP Int Soc Magnet Resonance Med DE RIF-1; tumor; diffusion; multispectral analysis; HIF-1 ID APPARENT DIFFUSION-COEFFICIENT; SQUAMOUS-CELL CARCINOMA; MAGNETIC-RESONANCE; BRAIN-TUMORS; CEREBRAL-ISCHEMIA; BREAST-CANCER; LESION VOLUME; RAT-BRAIN; HYPOXIA; RADIOTHERAPY AB Accurate assessments of therapeutic efficacy are confounded by intra- and intertumor heterogeneity. To address this issue we employed multispectral (MS) analysis using the apparent diffusion coefficient (ADC), T-2, proton density (M-0), and k-means (KM) clustering algorithm to identify multiple compartments within both viable and necrotic tissue in a radiation-induced fibrosarcoma (RIF-1) tumor model receiving single-dose (1000 cGy) radiotherapy. Optimization of the KM method was achieved through histological validation by hematoxylin-eosin (H&E) staining and hypoxia-inducible factor-1 alpha (HIF-1 alpha) immunohistochemistry. The optimum KM method was determined to be a two-feature (ADC, T-2) and four-cluster (two clusters each of viable tissue and necrosis) segmentation. KM volume estimates for both viable (r = 0.94, P < 0.01) and necrotic (r = 0.69, P = 0.07) tissue were highly correlated with their H&E counterparts. HIF-1 alpha immunohistochemistry showed that the intensity of HIF-1 alpha expression tended to be concentrated in perinecrotic regions, supporting the subdivision of the viable tissue into well-oxygenated and hypoxic regions. Since both necrosis and hypoxia have been implicated in poor treatment response and reduced patient survival, the ability to quantify the degree of necrosis and the severity of hypoxia with this method may aid in the planning and modification of treatment regimens. C1 Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA. Tufts Univ, Cummings Sch Vet Med, Dept Clin Sci, North Grafton, MA USA. Worcester Polytech Inst, Dept Chem & Biochem, Worcester, MA 01609 USA. Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA 01605 USA. RP Helmer, KG (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, 149 13th St,Room 2301, Charlestown, MA 02129 USA. EM helmer@nmr.mgh.harvard.edu RI Henning, Erica/E-8542-2010 NR 46 TC 20 Z9 20 U1 1 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0740-3194 J9 MAGN RESON MED JI Magn. Reson. Med. PD MAR PY 2007 VL 57 IS 3 BP 501 EP 512 DI 10.1002/mrm.21161 PG 12 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 142NR UT WOS:000244657200007 PM 17326181 ER PT J AU Henning, EC Azuma, C Sotak, CH Helmer, KG AF Henning, Erica C. Azuma, Chieko Sotak, Christopher H. Helmer, Karl G. TI Multispectral tissue characterization in a RIF-1 tumor model: Monitoring the ADC and T-2 responses to single-dose radiotherapy. Part II SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article; Proceedings Paper CT 12th Annual Meeting of the International-Society-for-Magnetic-Resonance-in-Medicine CY MAY 15-21, 2004 CL Kyoto, JAPAN SP Int Soc Magnet Resonance Med DE RIF-1; tumor; diffusion; multispectral analysis; radiotherapy ID HUMAN-MELANOMA XENOGRAFTS; BRAIN-TUMORS; DIFFUSION MRI; CANCER; CHEMOTHERAPY; THERAPY; RADIATION; FRACTION; NECROSIS AB A multispectral (MS) approach that combines apparent diffusion coefficient (ADC) and T-2 parameter maps with k-means (KM) clustering was employed to distinguish multiple compartments within viable tumor tissue (V1 and V2) and necrosis (N1 and N2) following single-dose (1000 cGy) radiotherapy in a radiation-induced fibrosarcoma (RIF-1) tumor model. The contributions of cell kill and tumor growth kinetics to the radiotherapy-induced response were investigated. A larger pretreatment V1 volume was correlated with decreased tumor growth delay (TGD) (r = 0.68) and cell kill (r = 0.71). There was no correlation for the pretreatment V2 volume. These results suggest that V1 tissue is well oxygenated and radiosensitive, whereas V2 tissue is hypoxic and therefore radioresistant. The relationship between an early ADC response and vasogenic edema and formation of necrosis was investigated. A trend for increased ADC was observed prior to an increase in the necrotic fraction (NF). Because there were no changes in T-2, these observations suggest that the early increase in ADC is more likely based on a slight reduction in cell density, rather than radiation-induced vasogenic edema. Quantitative assessments of individual tissue regions, tumor growth kinetics, and cell kill should provide a more accurate means of monitoring therapy in preclinical animal models because such assessments can minimize the issue of intertumor variability. C1 Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA. Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA 01609 USA. Worcester Polytech Inst, Dept Chem & Biochem, Worcester, MA 01609 USA. Tufts Univ, Cummings Sch Vet Med, Dept Clin Sci, North Grafton, MA 01536 USA. RP Helmer, KG (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Room 2301,149 13th St, Charlestown, MA 02129 USA. RI Henning, Erica/E-8542-2010 NR 27 TC 8 Z9 8 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0740-3194 J9 MAGN RESON MED JI Magn. Reson. Med. PD MAR PY 2007 VL 57 IS 3 BP 513 EP 519 DI 10.1002/mrm.21178 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 142NR UT WOS:000244657200008 PM 17326182 ER PT J AU Wu, YT Dai, GP Ackerman, JL Hrovat, MI Glimcher, MJ Snyder, BD Nazarian, A Chesler, DA AF Wu, Yaotang Dai, Guangping Ackerman, Jerome L. Hrovat, Mirko I. Glimcher, Melvin J. Snyder, Brian D. Nazarian, Ara Chesler, David A. TI Water- and fat-suppressed proton projection MRI (WASPI) of rat femur bone SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article DE bone; MRI; WASPI; ultrashort T-2 imaging; solid-state MR imaging ID MAGNETIC-RESONANCE; TRABECULAR BONE; MECHANICAL-PROPERTIES; MINERAL DENSITY; IN-VIVO; CORTICAL BONE; ARCHITECTURE; PHOSPHORUS; RESOLUTION; TURNOVER AB Investigators often study rats by mu CT to investigate the pathogenesis and treatment of skeletal disorders in humans. However, mu CT measurements provide information only on bone mineral content and not the solid matrix. CT scans are often carried out on cancellous bone, which contains a significant volume of marrow cells, stroma, water, and fat, and thus the apparent bone mineral density (BMD) does not reflect the mineral density within the matrix, where the mineral crystals are localized. Water- and fat-suppressed solid-state proton projection imaging (WASPI) was utilized in this study to image the solid matrix content (collagen, tightly bound water, and other immobile molecules) of rat femur specimens, and meet the challenges of small sample size and demanding submillimeter resolution. A method is introduced to recover the central region of k-space, which is always lost in the receiver dead time when free induction decays (FIDs) are acquired. With this approach, points near the k-space origin are sampled under a small number of radial projections at reduced gradient strength. The typical scan time for the current WASPI experiments was 2 hr. Proton solid-matrix images of rat femurs with 0.4-mm resolution and 12-mm field of view (FOV) were obtained. This method provides a noninvasive means of studying bone matrix in small animals. C1 Childrens Hosp, Dept Orthopaed Surg, Lab Study Skeletal Disorders & Rehabil, Boston, MA 02115 USA. Massachusetts Gen Hosp, Dept Radiol, Biomat Lab, Martinos Ctr, Charlestown, MA USA. Beth Israel Deaconess Med Ctr, Dept Orthopaed Surg, Orthoped Biomech Lab, Boston, MA 02115 USA. Mirtech Inc, Brockton, MA USA. MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Wu, YT (reprint author), Childrens Hosp, Dept Orthopaed Surg, Lab Study Skeletal Disorders & Rehabil, 300 Longwood Ave, Boston, MA 02115 USA. EM yaotang.wu@childrens.harvard.edu RI Ackerman, Jerome/E-2646-2015 OI Ackerman, Jerome/0000-0001-5176-7496 FU NCRR NIH HHS [S10-RR16811, P41-RR14075]; NIA NIH HHS [R01-AG014701]; NIBIB NIH HHS [R01-EB004012] NR 39 TC 31 Z9 32 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0740-3194 J9 MAGN RESON MED JI Magn. Reson. Med. PD MAR PY 2007 VL 57 IS 3 BP 554 EP 567 DI 10.1002/mrm.21174 PG 14 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 142NR UT WOS:000244657200013 PM 17326184 ER PT J AU Hinton, DE Nguyen, L Pollack, MH AF Hinton, Devon E. Nguyen, Lim Pollack, Mark H. TI Orthostatic panic as a key Vietnamese reaction to traumatic events - The case of September 11, 2001 SO MEDICAL ANTHROPOLOGY QUARTERLY LA English DT Article DE Vietnamese refugees; trauma-related disorder; panic attacks; orthostatic panic ID POSTTRAUMATIC-STRESS-DISORDER; TREATMENT-RESISTANT PTSD; CAMBODIAN REFUGEES; DYSREGULATION; PREVALENCE; SEVERITY; SYMPTOMS; ATTACKS; SCALE; WAR AB This article discusses a culturally specific response to traumatic events: orthostatic panic attacks among Vietnamese refugees. We compared the rate and severity of orthostatic panic as well as the rates and severity of associated flashbacks a month before and a month after September 11, 2001. After that date, the rate and severity of orthostatic panic greatly increased, as did the rate and severity of associated flashbacks. The central role of orthostatic panic as a response to traumatic events is illustrated through a patient's vignette. An explanation of why September 11 so profoundly influenced this population is adduced, including an explanation of why it resulted in considerable worsening of orthostatic panic. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA. Arbour Counseling, Lowell, MA USA. RP Hinton, DE (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA. NR 92 TC 3 Z9 3 U1 0 U2 0 PU AMER ANTHROPOLOGICAL ASSOC PI ARLINGTON PA 2200 WILSON BLVD, STE 600, ARLINGTON, VA 22201 USA SN 0745-5194 J9 MED ANTHROPOL Q JI Med. Anthropol. Q. PD MAR PY 2007 VL 21 IS 1 BP 81 EP 107 DI 10.1525/maq.2007.21.1.81 PG 27 WC Anthropology; Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Anthropology; Public, Environmental & Occupational Health; Biomedical Social Sciences GA 158SV UT WOS:000245815800005 PM 17405699 ER PT J AU Chang, G Chen, L Mao, JR AF Chang, Grace Chen, Lucy Mao, Jianren TI Opioid tolerance and hyperalgesia SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article ID MORPHINE-TOLERANCE; CHRONIC PAIN; ANTINOCICEPTIVE TOLERANCE; INTRATHECAL MORPHINE; IATROGENIC SYNDROME; CROSS-TOLERANCE; CANCER PAIN; RAT; INFUSION; REMIFENTANIL AB Opioids have been successfully used for the management of acute and cancer-related pain. Concerns regarding side effects, tolerance, dependence, addiction, and hyperalgesia have limited the use of opioids for the management of chronic nonmalignant pain. This article will review updated information from both clinical and preclinical studies regarding opioid-induced hyperalgesia, tolerance, and dependence. The implications of these issues in clinical opioid therapy also will be discussed. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pain Ctr,Div Pain Med,Dept Anesthesia & Crit Care, Boston, MA 02114 USA. RP Mao, JR (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pain Ctr,Div Pain Med,Dept Anesthesia & Crit Care, Boston, MA 02114 USA. EM jmao@partners.org NR 47 TC 98 Z9 102 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 J9 MED CLIN N AM JI Med. Clin. N. Am. PD MAR PY 2007 VL 91 IS 2 BP 199 EP + DI 10.1016/j.mcna.2006.10.003 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 147ZJ UT WOS:000245044000003 PM 17321281 ER PT J AU Meenan, RT Saha, S Chou, R Swarztrauber, K Krages, KP O'Keeffe-Rosetti, MC McDonagh, M Chan, BKS Hornbrook, MC Helfand, M AF Meenan, Richard T. Saha, Somnath Chou, Roger Swarztrauber, Karleen Krages, Kathryn Pyle O'Keeffe-Rosetti, Maureen C. McDonagh, Marian Chan, Benjamin K. S. Hornbrook, Mark C. Helfand, Mark TI Cost-effectiveness of echocardiography to identify intracardiac thrombus among patients with first stroke or transient ischemic attack SO MEDICAL DECISION MAKING LA English DT Review DE cost-effectiveness; decision analysis; stroke; transesophageal echocardiography; transthoracic echocardiography; diagnostic imaging ID TWO-DIMENSIONAL ECHOCARDIOGRAPHY; LEFT ATRIAL THROMBI; LEFT-VENTRICULAR THROMBUS; PATENT FORAMEN OVALE; POSITIVE BLOOD CULTURES; RHEUMATIC HEART-DISEASE; PERTH COMMUNITY STROKE; LONG-TERM RISK; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CEREBRAL-ISCHEMIA AB Background and Purpose. Echocardiography to select stroke patients for targeted treatments, such as anticoagulation (AC), to reduce recurrent stroke risk is controversial. The authors objective was to evaluate the cost-effectiveness of imaging strategies that use transthoracic (TTE) and transesophageal (TEE) echocardiography for identifying intracardiac thrombus in new stroke patients. Methods. Model-based cost-effectiveness analysis of 7 echocardiographic imaging strategies and 2 nontesting strategies with model parameters based on systematic evidence review related to effectiveness of echocardiography in newly diagnosed ischemic stroke patients (white males aged 65 years in base case). Primary, outcome was cost per quality-adjusted life year (QALY). Results. All strategies containing TTE were dominated by others and were eliminated from the analysis. Assuming that AC reduces recurrent stroke risk from intracardiac thrombus by 43% over 1 year, TEE generated a cost per QALY of $137,000 (relative to standard treatment) among patients with 5% thrombus prevalence. Cost per QALY dropped to $50,000 in patients with at least 15% intracardiac thrombus prevalence, or, if an 86% relative risk reduction with AC is assumed, in patients with thrombus prevalence of at least 6%. Probabilistic analyses indicate considerable uncertainty around the cost-effectiveness of echocardiography across a wide range of intracardiac thrombus prevalence (pretest probability). Conclusions. Current evidence on cost-effectiveness is insufficient to justify widespread use of echocardiography in stroke patients. Additional research on recurrent stroke risk in patients with intracardiac thrombus and on the efficacy of AC in reducing that risk may contribute to a better understanding of the circumstances under which echocardiography will be cost-effective. C1 Kaiser Permanente NW, Ctr Hlth Res, Portland, OR 97227 USA. Oregon Hlth & Sci Univ, Evidence Based Practice Ctr, Portland, OR 97201 USA. Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. RP Meenan, RT (reprint author), Kaiser Permanente NW, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA. EM Richard.meenan@kpchr.org FU PHS HHS [290-97-0018] NR 118 TC 20 Z9 20 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD MAR-APR PY 2007 VL 27 IS 2 BP 161 EP 177 DI 10.1177/0272989X06297388 PG 17 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 154ZL UT WOS:000245547200009 PM 17409366 ER PT J AU Thompson, BM Schneider, VF Haidet, P Levine, RE McMahon, KK Perkowski, LC Richards, BF AF Thompson, Britta M. Schneider, Virginia F. Haidet, Paul Levine, Ruth E. McMahon, Kathryn K. Perkowski, Linda C. Richards, Boyd F. TI Team-based learning at ten medical schools: two years later SO MEDICAL EDUCATION LA English DT Article DE education, medical, undergraduate, methods; teaching, methods; group processes; United States; faculty ID EDUCATION AB Purpose: In 2003, we described initial use of team-based learning (TBL) at 10 medical schools. The purpose of the present study was to review progress and understand factors affecting the use of TBL at these schools during the subsequent 2 years. Methods: Representatives from 10 schools evaluated in 2003 were again evaluated in 2005. They were interviewed by members of the Team Based Learning Collaborative using a semistructured interview process. Data were analysed by 2 researchers using the constant comparative method and were triangulated through sharing results with other interviewers at regular intervals to verify conclusions and form consensus. Results: TBL continued to be used in all but 1 school. At the 9 remaining schools, TBL was added to 18 courses, continued to be used in 19 and was discontinued in 13 courses. At some schools, it was discontinued in single courses in lieu of new, longitudinal integration courses in which TBL was a main instructional strategy. Faculty, student, course and institutional factors were associated with changes in TBL use. Conclusions: Faculty, administration/curriculum, students and characteristics of specific courses influence ongoing utilisation of TBL. Those who desire to implement TBL would do well to take these factors into account as they plan implementation efforts at their schools. C1 Baylor Coll Med, Off Curriculum, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. Univ Texas, Med Branch, Galveston, TX 77555 USA. Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79409 USA. Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. RP Thompson, BM (reprint author), Baylor Coll Med, Off Curriculum, M301, Houston, TX 77030 USA. EM brittat@bcm.tmc.edu RI Herring, Anna/L-7859-2014 NR 16 TC 79 Z9 82 U1 3 U2 13 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0308-0110 J9 MED EDUC JI Med. Educ. PD MAR PY 2007 VL 41 IS 3 BP 250 EP 257 DI 10.1111/j.1365-2929.2006.02684.x PG 8 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 138DD UT WOS:000244342400005 PM 17316209 ER PT J AU Seco, J Sharp, GC Turcotte, J Gierga, D Bortfeld, T Paganetti, H AF Seco, J. Sharp, G. C. Turcotte, J. Gierga, D. Bortfeld, T. Paganetti, H. TI Effects of organ motion on IMRT treatments with segments of few monitor units SO MEDICAL PHYSICS LA English DT Article DE organ motion; IGRT; motion average-dose; small MU segments; hypo-fractionation ID MULTILEAF COLLIMATOR; RADIOTHERAPY; DELIVERY; PROBABILITY; LUNG AB Interplay between organ (breathing) motion and leaf motion has been shown in the literature to have a small dosimetric impact for clinical conditions (over a 30 fraction treatment). However, previous studies did not consider the case of treatment beams made up of many few-monitor-unit (MU) segments, where the segment delivery time (1-2 s) is of the order of the breathing period (3-5 s). In this study we assess if breathing compromises the radiotherapy treatment with IMRT segments of low number of MUs. We assess (i) how delivered dose varies, from patient to patient, with the number of MU per segment, (ii) if this delivered dose is identical to the average dose calculated without motion over the path of the motion, and (iii) the impact of the daily variation of the delivered dose as a function of MU per segment. The organ motion was studied along two orthogonal directions, representing the left-right and cranial-caudal directions of organ movement for a patient setup in the supine position. Breathing motion was modeled as sin(x), sin(4)(x), and sin(6)(x), based on functions used in the literature to represent organ motion. Measurements were performed with an ionization chamber and films. For a systematic study of motion effects, a MATLAB simulation was written to model organ movement and dose delivery. In the case of a single beam made up of one single segment, the dose delivered to point in a moving target over 30 fractions can vary up to 20% and 10% for segments of 10 MU and 20 MU, respectively. This dose error occurs because the tumor spends most of the time near the edges of the radiation beam. In the case of a single beam made of multiple segments with low MU, we observed 2.4%, 3.3%, and 4.3% differences, respectively, for sin(x), sin(4)(x), and sin(6)(X) motion, between delivered dose and motion-averaged dose for points in the penumbra region of the beam and over 30 fractions. In approximately 5-10% of the cases, differences between the motion-averaged dose and the delivered 30-fraction dose could reach 6%, 8% and 10-12%, respectively for sin(x), sin(4)(x), and sin(6)(X) motion. To analyze a clinical IMRT beam, two patient plans were randomly selected. For one of the patients, the beams showed a likelihood of up to 25.6% that the delivered dose would deviate from the motion-averaged dose by more than 1%. For the second patient, there was a likelihood of up to 62.8% of delivering a dose that differs by more than 1% from the motion-averaged dose and a likelihood of up to similar to 30% for a 2% dose error. For the entire five-beam IMRT plan, statistical averaging over the beams reduces the overall dose error between the delivered dose and the motion-averaged dose. For both patients there was a likelihood of up to 7.0% and 33.9% that the dose error was greater than 1%, respectively. For one of the patients, there was a 12.6% likelihood of a 2% dose error. Daily intrafraction variation of the delivered dose of more than 10% is non-negligible and can potentially lead to biological effects. We observed [for sin(x), sin(4)(x), and sin(6)(x)] that below 10-15 MU leads to large daily variations of the order of 15-35%. Therefore, for small MU segments, non-negligible biological effects can be incurred. We conclude that for most clinical cases the effects may be small because of the use of many beams, it is desirable to avoid low-MU segments when treating moving targets. In addition, dose averaging may not work well for hypo-fractionation, where fewer fractions are used. For ypo-fractionation, PDF modeling of the tumor motion in IMRT optimization may not be adequate. (c) 2007 American Association of Physicists in Medicine. C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Seco, J (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RI Seco, Joao/J-4451-2012 FU NCI NIH HHS [R01 CA111590-02, R01-CA 111590, R01 CA111590] NR 13 TC 58 Z9 58 U1 0 U2 2 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD MAR PY 2007 VL 34 IS 3 BP 923 EP 934 DI 10.1118/1.2436972 PG 12 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 148NT UT WOS:000245082600008 PM 17441238 ER PT J AU Braun, RD Beatty, AL AF Braun, Rod D. Beatty, Alexis L. TI Modeling of oxygen transport across tumor multicellular layers SO MICROVASCULAR RESEARCH LA English DT Article DE oxygen transport; PO2; tumor; choroidal melanoma; cancer; multicellular layer; MCL; oxygen consumption ID ADVANCED CANCER; UTERINE CERVIX; EXTRAVASCULAR TRANSPORT; RADIATION-THERAPY; CELL-LINES; SPHEROIDS; DIFFUSION; HYPOXIA; CONSUMPTION; CARCINOMA AB Purpose: Tumor oxygen level plays a major role in the response of tumors to different treatments. The purpose of this study was to develop a method of determining oxygen transport properties in a recently developed 3D model of tumor parenchyma, the multicellular layer (MCL). Methods: OCM-1 human choroidal melanoma cells were grown as 3D MCLs on collagen-coated culture plate inserts. A recessed-cathode oxygen microelectrode was used to measure oxygen tension (PO2) profiles across 8 different MCL from the free surface to the insert membrane. The profiles were fitted to four different one-dimensional diffusion models: 1-, 2-, and 3-region models with uniform oxygen consumption (q) in each region and a modified 3-region model with a central region where q=0 and PO2=0. Results: Depending upon the presence of a central region of anoxia, the PO2 profiles were fitted best by either the two-region model or the modified 3-region model. Consumption of tumor cells near the insert membrane was higher than that of cells close to the free surface (33.1 +/- 13.6 x 10(-4) vs. 11.8 +/- 6.7 x 10(-4) mm Hg/mu m(2), respectively). Conclusions: The model is useful for determining oxygenation and consumption in MCL, especially for cell lines that cannot be grown as spheroids. In the future, this model will pen-nit the study of parameters important in tumor oxygenation in vitro. (c) 2006 Elsevier Inc. All rights reserved. C1 Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA. Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA. Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Braun, RD (reprint author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, 540 E Canfield Ave, Detroit, MI 48201 USA. EM rbraun@med.wayne.edu FU NEI NIH HHS [P30 EY004068, R29 EY011634, R29 EY 11634, P30 EY 04068] NR 28 TC 6 Z9 6 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0026-2862 J9 MICROVASC RES JI Microvasc. Res. PD MAR PY 2007 VL 73 IS 2 BP 113 EP 123 DI 10.1016/j.mvr.2006.11.001 PG 11 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 149XG UT WOS:000245179600006 PM 17196225 ER PT J AU Fitzsimons, MG Sparks, JW Jones, SF Crowley, JM Dalal, A Sunder, N AF Fitzsimons, Michael G. Sparks, J. William Jones, Sheri F. Crowley, Judith M. Dalal, Akshay Sunder, Neelakantan TI Anesthesia services during Operation Unified Assistance, aboard the USNS Mercy, after the tsunami in Southeast Asia SO MILITARY MEDICINE LA English DT Article ID TUBERCULOSIS; ETHICS; ISSUES AB The tsunami that struck Southeast Asia on December 26, 2004, resulted in the deaths of >300,000 individuals. The U.S. response included the formation of the first combined civilian/military peacetime humanitarian effort, directed by the National Command Authority as Operation Unified Assistance. This effort included military personnel from the U.S. Navy and civilians assembled by Project HOPE. Anesthesiologists and certified nurse anesthetists provided care in >150 cases. We discuss the initial response, medical and cultural planning, logistical support, procedures, and lessons learned in this unique opportunity. C1 Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Div Cardiac Anesthesia, Boston, MA 02114 USA. RP Fitzsimons, MG (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Div Cardiac Anesthesia, Boston, MA 02114 USA. NR 15 TC 3 Z9 3 U1 0 U2 1 PU ASSN MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD MAR PY 2007 VL 172 IS 3 BP 227 EP 231 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 146BH UT WOS:000244909000002 PM 17436763 ER PT J AU Antonescu, C Hornick, J Nielsen, G Mino-Kenudson, M Wong, G Corless, C Fletcher, CDM AF Antonescu, C. R. Hornick, J. L. Nielsen, G. P. Mino-Kenudson, M. Wong, G. Corless, C. Fletcher, C. D. M. TI Dedifferentiation in gastrointestinal stromal tumor (GIST) to an anaplastic KIT negative phenotype - A diagnostic pitfall SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 30 BP 11A EP 11A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400031 ER PT J AU Deshpande, V Nielsen, GP Rosenberg, AE AF Deshpande, V. Nielsen, G. P. Rosenberg, A. E. TI Gnathic well differentiated osteosarcomas: A clinicopathologic study of 9 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 39 BP 13A EP 13A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400040 ER PT J AU Nielsen, GP Srivastava, A O'Connell, JX Mangham, C Rosenberg, AE AF Nielsen, G. P. Srivastava, A. O'Connell, J. X. Mangham, C. Rosenberg, A. E. TI Epithelioid hemangioma of bone. A study of 39 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. CJ Coady Assoicates, Surry, BC, Canada. Royal Orthopaed Hosp, Birmingham B31 2AP, W Midlands, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 69 BP 20A EP 20A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400070 ER PT J AU Brachtel, EF Rusby, JE Michaelson, JS Smith, BL Koerner, F AF Brachtel, E. F. Rusby, J. E. Michaelson, J. S. Smith, B. L. Koerner, F. C. TI Patterns of nipple involvement by breast carcinoma in mastectomies SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 99 BP 26A EP 26A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400100 ER PT J AU Brachtel, EF Kawakubo, H Kish, JB Yeo, G Maheswaran, S AF Brachtel, E. F. Kawakubo, H. Kish, J. B. Yeo, G. Maheswaran, S. TI Cyclin D1 overexpression with CCND1 amplification is correlated with loss of BTG2 in estrogen-receptor positive human breast cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 98 BP 26A EP 26A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400099 ER PT J AU Martyniak, A Kandel, MJ Masciari, S Harris, L Miron, A Richardson, A Schnitt, SJ Garber, JE Collins, LC AF Martyniak, A. Kandel, M. J. Masciari, S. Harris, L. Miron, A. Richardson, A. Schnitt, S. J. Garber, J. E. Collins, L. C. TI Is basal cytokeratin (CK) or epidermal growth factor receptor (EGFR) expression predictive of BRCA1 mutation status in women with triple negative breast cancers? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 165 BP 41A EP 41A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400166 ER PT J AU Bedri, S Cizek, SM Talusan, P Lee, H Stone, JR AF Bedri, S. Cizek, S. M. Talusan, P. Lee, H. Stone, J. R. TI Risk factors for atherosclerosis and the development of preatherosclerotic intimal hyperplasia SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 239 BP 57A EP 57A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400240 ER PT J AU Belsley, NA Lauwers, GY Pitman, MB Deshpande, V AF Belsley, N. A. Lauwers, G. Y. Pitman, M. B. Deshpande, V. TI Serous cystadenomas of the pancreas: Diagnostic performance of imaging and fine needle aspiration biopsy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 273 BP 64A EP 64A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400274 ER PT J AU Ko, V Tambouret, RH Wilbur, DC AF Ko, V. Tambouret, R. H. Wilbur, D. C. TI Low grade squamous intraepithelial lesion (LSIL) and high risk HPV status: Effect of age on follow-up with high grade cervical lesions SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 317 BP 73A EP 74A PG 2 WC Pathology SC Pathology GA 146GL UT WOS:000244922400318 ER PT J AU Murphy, EE Deshpande, V AF Murphy, E. E. Deshpande, V. TI Pre-operative diagnostic assessment of pseudocysts of the pancreas: A multimodal approach SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 335 BP 77A EP 77A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400336 ER PT J AU Shah, SS Faquin, WC Khurana, KK AF Shah, S. S. Faquin, W. C. Khurana, K. K. TI FNA of misclassified primary malignant neoplasms of thyroid: Impact on patient management SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 SUNY Upstate Med Univ, Syracuse, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 359 BP 82A EP 83A PG 2 WC Pathology SC Pathology GA 146GL UT WOS:000244922400360 ER PT J AU Smouse, J Cibas, E Janne, P Joshi, V Lindeman, N AF Smouse, J. Cibas, E. Janne, P. Joshi, V. Lindeman, N. TI Cytology specimens compare favorably with surgical specimens for EGFR mutation detection in patients with NSCLC SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Mol Med Lab, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 369 BP 85A EP 85A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400370 ER PT J AU Yuan, Q Wilbur, D AF Yuan, Q. Wilbur, D. TI Follow up of high risk human papillornavirus (HPV) tests with high viral loads: Correlation with original pap test interpretations and biopsy results SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 382 BP 87A EP 88A PG 2 WC Pathology SC Pathology GA 146GL UT WOS:000244922400383 ER PT J AU Knoepp, SM Carney, JA Mihm, MC Bei, T Stergiopoulos, S Stratakis, CA Zembowicz, A AF Knoepp, S. M. Carney, J. A. Mihm, M. C. Bei, T. Stergiopoulos, S. Stratakis, C. A. Zembowicz, A. TI Loss of expression of a carney complex gene, protein kinase a regulatory subunit 1a, in sporadic and carney complex-associated pigmented epithelioid melanocytoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Mayo Clin, Rochester, MN USA. NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 419 BP 95A EP 95A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400420 ER PT J AU Turbiner, J Zukerberg, L Harris, NL Flotte, T AF Turbiner, J. Zukerberg, L. Harris, N. L. Flotte, T. TI Cutaneous marginal zone lymphoma with marked plasmacytic differentiation and rare B cells SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 437 BP 99A EP 99A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400438 ER PT J AU Chen, JH Pinkus, GS Faquin, WC Lloyd, RV Nose, V AF Chen, J-H Pinkus, G. S. Faquin, W. C. Lloyd, R. V. Nose, V. TI Papillary thyroid carcinoma, columnar cell variant: A clinicopathologic and molecular study SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 444 BP 100A EP 100A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400445 ER PT J AU Abreu-E-Lima, P Farraye, F Smith, T Swaroop, P Garner, L Lauwers, G Odze, RD AF Abreu-e-Lima, P. Farraye, F. Smith, T. Swaroop, P. Garner, L. Lauwers, G. Odze, R. D. TI Clinical and pathologic features of ulcerative colitis in primary sclerosing cholangitis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Boston Med Ctr, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. St Louis Univ Hosp, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 470 BP 106A EP 106A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400470 ER PT J AU Bailey, GP Wittner, BS Ramaswamy, S Redston, MS AF Bailey, G. P. Wittner, B. S. Ramaswamy, S. Redston, M. S. TI Differential gene expression profiling of MGMT deficient colorectal cancer reveals a carcinogenic pathway distinct from other mismatch repair intact tumors SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 478 BP 107A EP 107A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400478 ER PT J AU Deshpande, V Lauwers, GY AF Deshpande, V. Lauwers, G. Y. TI Isolated cecal focal active colitis (FAC) in the asymptomatic adult: A clinical, endoscopic and pathological study of 24 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 504 BP 113A EP 113A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400504 ER PT J AU Farris, AB Lauwers, GY Zukerberg, LR AF Farris, A. B. Lauwers, G. Y. Zukerberg, L. R. TI The rectal tonsil: Analysis of salient histologic features to recognize this important entity SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 508 BP 114A EP 114A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400508 ER PT J AU Hornick, JL Mino-Kenudson, M Lauwers, GY Odze, RD AF Hornick, J. L. Mino-Kenudson, M. Lauwers, G. Y. Odze, R. D. TI Biological properties of buried intestinal epithelium following photodynamic therapy for Barrett's esophagus SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 526 BP 118A EP 118A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400526 ER PT J AU Johnston, EI Lewin, DN Wang, HL Lauwers, GY Srivastava, A Shyr, Y Washington, MK AF Johnston, E. I. Lewin, D. N. Wang, H. L. Lauwers, G. Y. Srivastava, A. Shyr, Y. Washington, M. K. TI Lymphovascular invasion in colorectal cancer: An interobserver variability study SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Vanderbilt Univ, Nashville, TN USA. MUSC Med Ctr, Charleston, SC USA. Washington Univ, St Louis, MO USA. Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 533 BP 119A EP 119A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400533 ER PT J AU Kawasaki, T Fuchs, CS Loda, M Ogino, S AF Kawasaki, T. Fuchs, C. S. Loda, M. Ogino, S. TI Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype (CIMP) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 534 BP 119A EP 119A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400534 ER PT J AU Mino-Kenudson, M Lauwers, GY AF Mino-Kenudson, M. Lauwers, G. Y. TI Pathology of Barrett esophagus after photodynamic therapy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 550 BP 123A EP 123A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400550 ER PT J AU Mino-Kenudson, M Lauwers, GY AF Mino-Kenudson, M. Lauwers, G. Y. TI Duplicated muscularis mucosa in Barrett esophagus - Vascular characteristics of newly formed submucosa SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 551 BP 123A EP 123A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400551 ER PT J AU Gino, S Kawasaki, T Loda, M Fuchs, C AF Gino, S. Kawasaki, T. Loda, M. Fuchs, C. S. TI A large population-based colorectal cancer sample shows correlations of CpG island methylator phenotype-low (CIMP-Low) with male sex and KRAS mutations SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 563 BP 125A EP 125A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400563 ER PT J AU Oble, DA Mino-Kenudson, M Goldsmith, J Mihm, MC Hodi, FS Dranoff, G Lauwers, GY AF Oble, D. A. Mino-Kenudson, M. Goldsmith, J. Mihm, M. C. Hodi, F. S. Dranoff, G. Lauwers, G. Y. TI Autoimmune enteropathy-like panenteritis is associated with the novel cancer therapy adjuvant a-CTLA-4 mAb SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Hosp, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 560 BP 125A EP 125A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400560 ER PT J AU Ogino, S Kawasaki, T Kirkner, GJ Qgawa, A Loda, M Fuchs, C AF Ogino, S. Kawasaki, T. Kirkner, G. J. Qgawa, A. Loda, M. Fuchs, C. S. TI MSI-High CIMP-High colorectal cancers show frequent Down-Regulation of nuclear p27 (CDKN1B), while Non-MSI Non-CIMP-High tumors show frequent down-regulation of p21 (CDKN1A) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 562 BP 125A EP 125A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400562 ER PT J AU Ogino, S Loda, M Fuchs, CS AF Ogino, S. Loda, M. Fuchs, C. S. TI Do histopathologic features of colorectal carcinoma predict microsatellite instability (MSI) or CpG island methylator phenotype (CIMP) or both? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 564 BP 126A EP 126A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400564 ER PT J AU Park, DY Srivastava, A Kim, GH Mino-Kenudson, M Deshpand, V Zukerberg, LR Lauwers, GY AF Park, D. Y. Srivastava, A. Kim, G. H. Mino-Kenudson, M. Deshpand, V. Zukerberg, L. R. Lauwers, G. Y. TI Immunohistochemical expression of MUC stains, CD10 and CDX2 in morphological variants of gastric epithelial dysplasia with emphasis on type II (Foveolar type) dysplasia SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Pusan Natl Univ Hosp, Pusan, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 567 BP 126A EP 126A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400567 ER PT J AU Park, DY Srivastava, A Kim, GH Mino-Kenudson, M Deshpand, V Zukerberg, LR Lauwers, GY AF Park, D. Y. Srivastava, A. Kim, G. H. Mino-Kenudson, M. Deshpand, V. Zukerberg, L. R. Lauwers, G. Y. TI Gastric foveolar (Type II) dysplasia frequently arises from a background mucosa with a distinctive form of intestinal metaplasia SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Pusan Natl Univ Hosp, Pusan, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 566 BP 126A EP 126A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922400566 ER PT J AU Sepehr, A Iafrate, AJ Lauwers, GY Misdraji, J AF Sepehr, A. Iafrate, A. J. Lauwers, G. Y. Misdraji, J. TI Serrated epithelial proliferations of the appendix SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Harverd Med Sch, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 584 BP 130A EP 130A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922401007 ER PT J AU Zhang, X Huang, Q Goyal, R Odze, RD AF Zhang, X. Huang, Q. Goyal, R. Odze, R. D. TI High fidelity image cytometry in neoplastic lesions in Barrett's esophagus, including basal crypt dysplasia-like atypia with surface maturation SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 VA Boston Hlth Care Syst, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 597 BP 133A EP 133A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922401020 ER PT J AU Demichelis, F Fall, K Perner, S Andren, O Schmidt, FH Setlur, SR Hoshida, Y Mosquera, JM Pawitan, Y Adami, HO Mucci, LA Kantoff, PW Andersson, SO Chinnaiyan, AM Johansson, JE Rubin, MA AF Demichelis, F. Fall, K. Perner, S. Andren, O. Schmidt, F. H. Setlur, S. R. Hoshida, Y. Mosquera, J. M. Pawitan, Y. Adami, H. O. Mucci, L. A. Kantoff, P. W. Andersson, S. O. Chinnaiyan, A. M. Johansson, J. E. Rubin, M. A. TI TMPRSS2 : ERG gene fusion associated with lethal prostate cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. MIT, Broad Inst Harvard, Cambridge, MA 02139 USA. Univ Hosp, Ulm, Germany. Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA. Univ Hosp, Orebro, Sweden. Karolinska Inst, Stockholm, Sweden. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 643 BP 142A EP 143A PG 2 WC Pathology SC Pathology GA 146GL UT WOS:000244922401066 ER PT J AU Hansel, DE Clieville, JC Berbescu, E Fine, S Young, RH Epstein, JI AF Hansel, D. E. Clieville, J. C. Berbescu, E. Fine, S. Young, R. H. Epstein, J. I. TI Renal carcinoid tumor: A clinicopathologic study of 21 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. Mayo Clin, Rochester, MN USA. Mem Sloan Kettering, New York, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 680 BP 150A EP 151A PG 2 WC Pathology SC Pathology GA 146GL UT WOS:000244922401103 ER PT J AU Jiang, Z Chu, P Woda, B Liu, Q Li, C Rock, K Wu, CL AF Jiang, Z. Chu, P. G. Woda, B. A. Liu, Q. Li, C. Rock, K. L. Wu, C-L TI The RNA-Binding protein IMP3: A novel molecular marker predicts metastasis and progression of renal cell carcinomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Univ Massachusetts, Med Ctr, Worcester, MA USA. City Hope Natl Med Ctr, Los Angeles, CA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 694 BP 153A EP 154A PG 2 WC Pathology SC Pathology GA 146GL UT WOS:000244922401117 ER PT J AU Mosquera, JM Perner, S Demichelis, F Hoffer, MD Mertz, KD Paris, P Simko, J Collins, C Bismar, T Rubin, MA AF Mosquera, J. M. Perner, S. Demichelis, F. Hoffer, M. D. Mertz, K. D. Paris, P. Simko, J. Collins, C. Bismar, T. Rubin, M. A. TI Morphological features of TMPRSS2 : ERG fusion prostate cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Univ Ulm, Ulm, Germany. SRA Div & Bioinformat Grp, Povo, Italy. Univ Calif San Francisco, San Francisco, CA 94143 USA. McGill Univ, Montreal, PQ, Canada. Harvard Univ, MIT, Sch Med, Cambridge, MA 02139 USA. Dana Farber Harvard Comprehens Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 748 BP 165A EP 165A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922401171 ER PT J AU Oliva, E Kaufman, DF Shipley, WU Spicer, B Paner, GP Gown, AM Amin, MB AF Oliva, E. Kaufman, D. S. Shipley, W. U. Spicer, B. Paner, G. P. Gown, A. M. Amin, M. B. TI Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia vs carcinoma in situ (CIS) of the bladder. A study of 48 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. Phenopath Labs, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 760 BP 167A EP 167A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922401183 ER PT J AU Perner, S Mosquera, JM Demichelis, F Hofer, MD Paris, PL Simko, J Collins, C Bismar, TA Chinnaiyan, AM De Marzo, AM Rubin, MA AF Perner, S. Mosquera, J-M Demichelis, F. Hofer, M. D. Paris, P. L. Simko, J. Collins, C. Bismar, T. A. Chinnaiyan, A. M. De Marzo, A. M. Rubin, M. A. TI TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Ulm, Ulm, Germany. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. McGill Univ, Fac Med, Montreal, PQ, Canada. Johns Hopkins Univ, Sch Med, Bloomberg Sch Publ Hlth, Baltimore, MD USA. ITC Irst, Trento, Italy. Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 769 BP 169A EP 170A PG 2 WC Pathology SC Pathology GA 146GL UT WOS:000244922401192 ER PT J AU Saenz, AJ Nielsen, GP Campbell, S Oliva, E AF Saenz, A. J. Nielsen, G. P. Campbell, S. Oliva, E. TI OCT-4 expression in malignant epithelial tumors of the genitourinary tract SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 787 BP 173A EP 173A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922401210 ER PT J AU Westfall, D Folpe, AL Paner, GP Oliva, E Goldstein, LC Gown, AM Amin, MB AF Westfall, D. Folpe, A. L. Paner, G. P. Oliva, E. Goldstein, L. C. Gown, A. M. Amin, M. B. TI Utility of a comprehensive immunohistochemical (IHC) panel in the differential diagnosis of spindle cell lesions of the urinary bladder SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. Mayo Clin, Rochester, MN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. PhenoPath Labs, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 834 BP 183A EP 183A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922401257 ER PT J AU Dahiya, S Carney, E Lopez-Varela, E Oliva, E Ma, XJ Sgroi, DC AF Dahiya, S. Carney, E. Lopez-Varela, E. Oliva, E. Ma, X-J Sgroi, D. C. TI Estrogen receptor (ER) co-activators and co-repressors in endometrial carcinoma associated with tamoxifen therapy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. AviaraDx Inc, Carlsbad, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 884 BP 194A EP 194A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922401307 ER PT J AU Dahiya, S Felix, A Branton, P Campbell, S Sgroi, DC Oliva, E AF Dahiya, S. Felix, A. Branton, P. Campbell, S. Sgroi, D. C. Oliva, E. TI Low-grade endometrial stromal sarcoma (LG-ESS): Is there an immunophenotype predictive of clinical behavior? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Portuguese Oncol Inst, Lisbon, Portugal. Inova Faifax Hosp, Falls Church, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 883 BP 194A EP 194A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922401306 ER PT J AU Dionigi, A Oliva, E Iafrate, AJ Bell, DA AF Dionigi, A. Oliva, E. Iafrate, A. J. Bell, D. A. TI A wide spectrum of serous carcinomas arise in ovarian serous borderline tumors: A report of 25 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 887 BP 194A EP 195A PG 2 WC Pathology SC Pathology GA 146GL UT WOS:000244922401310 ER PT J AU Irving, J Young, R AF Irving, J. A. Young, R. H. TI Granulosa cell tumors of the ovary with a pseudopapillary pattern: A study of 12 cases of an unusual morphologic variant emphasizing their distinction from transitional cell neoplasms and other papillary ovarian tumors SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Vancouver Gen Hosp, Vancouver, BC, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 919 BP 202A EP 202A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922401342 ER PT J AU Jarboe, E Lee, Y Drapkin, R McKeon, FD Crum, CP AF Jarboe, E. Lee, Y. Drapkin, R. McKeon, F. D. Crum, C. P. TI The morphologic and immunophenotypic spectrum of a candidate precursor to pelvic serous carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. RI Drapkin, Ronny/E-9944-2016 OI Drapkin, Ronny/0000-0002-6912-6977 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 921 BP 202A EP 202A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922401344 ER PT J AU McCluggage, WG Young, RH AF McCluggage, W. G. Young, R. H. TI Tubulo-squamous polyp: A report of ten cases of a distinctive hitherto uncharacterised vaginal polyp SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Royal Grp Hosp Trust, Belfast, Antrim, North Ireland. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 948 BP 207A EP 208A PG 2 WC Pathology SC Pathology GA 146GL UT WOS:000244922401371 ER PT J AU Post, MD Carinelli, SG Campbell, S Soslow, RA Oliva, E AF Post, M. D. Carinelli, S. G. Campbell, S. Soslow, R. A. Oliva, E. TI p16 expression in squamous and trophoblastic lesions of the upper female genital tract SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Fdn Osped Policlin, Milan, Italy. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 963 BP 210A EP 211A PG 2 WC Pathology SC Pathology GA 146GL UT WOS:000244922401386 ER PT J AU Rollins, SE Clement, PB Young, RH AF Rollins, S. E. Clement, P. B. Young, R. H. TI Uterine tumors resembling ovarian sex cord tumors frequently have incorporated mature smooth muscle imparting a pseudoinfiltrative appearance SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ British Columbia, Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 971 BP 212A EP 212A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922401394 ER PT J AU Staats, PN McCluggage, WG Clement, PB Young, RH AF Staats, P. N. McCluggage, W. G. Clement, P. B. Young, R. H. TI Re-exploration of the distinctive ovarian lesion associated with sclerosing peritonitis: An analysis of 25 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Royal Grp Hosp Trusts, Belfast, Antrim, North Ireland. Vancouver Gen Hosp, Vancouver, BC, Canada. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 BP 215A EP 215A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922401407 ER PT J AU Mang, WL Soslow, RA Hensley, M Asad, H Zannoni, GF de Nictolis, A Branton, P Oliva, E AF Mang, W. L. Soslow, R. A. Hensley, M. Asad, H. Zannoni, G. F. de Nictolis, A. Branton, P. Oliva, E. TI Histopathologic prognostic factors in stage I uterine leiomyosarcomas (Ut-LMS); a clinicopathologic study of 28 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Cattolica, Rome, Italy. Ist Anat & Istol Patol, Ancona, Italy. Inova Fairfax Hosp, Church Falls, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 994 BP 217A EP 217A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922401417 ER PT J AU Gang, Y Hutchinson, L Hasserjian, R Galili, N Hao, S Raza, A Woda, B Wang, SA AF Gang, Y. Hutchinson, L. Hasserjian, R. Galili, N. Hao, S. Raza, A. Woda, B. Wang, S. A. TI Myelodysplastic syndrome with erythroid hypoplasi a/aplasia shows distinct clinicopathological features and clonal T cell expansion SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Univ Massachusetts, Med Ctr, Worcester, MA 01605 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 1100 BP 240A EP 240A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922401523 ER PT J AU Rahemtullah, A Harris, NL Ferry, JA AF Rahemtullah, A. Harris, N. L. Ferry, J. A. TI CD20+ T-cell lymphoma: Clinicopathologic features of 5 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 1175 BP 256A EP 257A PG 2 WC Pathology SC Pathology GA 146GL UT WOS:000244922402009 ER PT J AU Cornell, LD Collins, AB Selig, MK Della Pelle, P Colvin, RB AF Cornell, L. D. Collins, A. B. Selig, M. K. Della Pelle, P. Colvin, R. B. TI De novo focal segmental glomerulosclerosis with collapse associated with sirolimus therapy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 1244 BP 271A EP 272A PG 2 WC Pathology SC Pathology GA 146GL UT WOS:000244922402078 ER PT J AU Chung, SM Ferrone, CR Ferrone, S Klimstra, DS AF Chung, S. M. Ferrone, C. R. Ferrone, S. Klimstra, D. S. TI HLA class I antigen processing machinery (APM) is altered in short-term survivors (STS) of pancreatic adenocarcinoma (PAC) compared to long-term survivors (LTS) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Weill Cornell Med Coll, New York, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 1274 BP 278A EP 278A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922402108 ER PT J AU Deshpande, V Pitman, MB Lauwers, GY AF Deshpande, V. Pitman, M. B. Lauwers, G. Y. TI Endoscopic ultrasound (EUS)-guided fine needle aspiration biopsy (FNAB) is a powerful predictor of malignancy in intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN) of the pancreas: A retrospective analysis of 110 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 1277 BP 278A EP 279A PG 2 WC Pathology SC Pathology GA 146GL UT WOS:000244922402111 ER PT J AU Sepehr, A Deshpande, V Lauwers, GY Mino-Kenudson, M AF Sepehr, A. Deshpande, V. Lauwers, G. Y. Mino-Kenudson, M. TI An IgG4+ to IgG+ plasma cells ratio in ampullary tissue as a marker to differentiate autoimmune pancreatitis from pancreatic cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 1338 BP 292A EP 292A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922402172 ER PT J AU Beheshti, J Mark, E Sabo, E Janne, P Sequist, L Joshi, V Jackman, D Iafrate, AJ Wang, L Meyerson, M Lindeman, N AF Beheshti, J. Mark, E. Sabo, E. Janne, P. Sequist, L. Joshi, V. Jackman, D. Iafrate, A. J. Wang, L. Meyerson, M. Lindeman, N. TI Multimarker immunohistochemistry of non-small cell lung carcinomas: Correlation with EGFR mutation and response to treatment SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brown Univ, Rhode Isl Hosp, Sch Med, Providence, RI 02903 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Mol Med Lab, Cambridge, MA USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 1462 BP 318A EP 318A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922402296 ER PT J AU Beheshti, J Mark, E Sabo, E Janne, P Sequist, L Jackman, D Joshi, V Iafrate, A Wang, L Meyerson, M Lindeman, N AF Beheshti, J. Mark, E. Sabo, E. Janne, P. Sequist, L. Jackman, D. Joshi, V. Iafrate, A. Wang, L. Meyerson, M. Lindeman, N. TI Correlation of papillary and bronchioloalveolar patterns in lung adenocarcinoma with EGFR mutation and response to tyrosine kinase inhibitors SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Rhode Isl Hosp, Providence, RI USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Mol Med Lab, Cambridge, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Brown Univ, Sch Med, Providence, RI 02912 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 1463 BP 318A EP 318A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922402297 ER PT J AU Koreishi, A Fidias, P Harris, NL Wright, C Hasserjian, RP AF Koreishi, A. Fidias, P. Harris, N. L. Wright, C. Hasserjian, R. P. TI Histologic changes in thymomas treated with neo-adjuvant chemoradiotherapy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 1494 BP 324A EP 325A PG 2 WC Pathology SC Pathology GA 146GL UT WOS:000244922402329 ER PT J AU Matsubara, O Imazeki, N Tsuda, H Nakatani, Y Mark, EJ AF Matsubara, O. Imazeki, N. Tsuda, H. Nakatani, Y. Mark, E. J. TI Differences of fibroblastic foci of UIP and lntraalveolar buds of COP/BOOP, as measured by cellular markers and growth factors SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Natl Def Med Coll, Tokorozawa, Saitama 359, Japan. Chiba Univ, Chiba, Japan. Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 1502 BP 326A EP 326A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922402336 ER PT J AU Ruangchira-Urai, R Mark, EJ AF Ruangchira-urai, R. Mark, E. J. TI Bronchiolitis interstitial pneumonitis: A distinctive disease with clinical and pathological features intermediate between bronchiolitis obliterans organizing pneumonia and usual interstitial pneumonitis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. Mahidol Univ, Fac Med, Siriraj Hosp, Bangkok 10700, Thailand. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 1517 BP 329A EP 329A PG 1 WC Pathology SC Pathology GA 146GL UT WOS:000244922402351 ER PT J AU Sholl, LM Iafrate, AJ Chou, YP Wu, MT Su, L Christiani, DC Chirieac, LR AF Sholl, L. M. Iafrate, A. J. Chou, Y. P. Wu, M. T. Su, L. Christiani, D. C. Chirieac, L. R. TI Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in non-small cell lung carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Kaohsiung Vet Gen Hosp, Kaohsiung, Taiwan. Harvard Sch Publ Hlth, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD MAR PY 2007 VL 20 SU 2 MA 1522 BP 330A EP 331A PG 2 WC Pathology SC Pathology GA 146GL UT WOS:000244922402356 ER PT J AU Laustsen, PG Russell, SJ Cui, L Entingh-Pearsall, A Holzenberger, M Liao, RL Kahn, CR AF Laustsen, Palle G. Russell, Steven J. Cui, Lei Entingh-Pearsall, Amelia Holzenberger, Martin Liao, Ronglih Kahn, C. Ronald TI Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID GROWTH-FACTOR-I; ANKYRIN REPEAT PROTEIN; GENE-EXPRESSION; HEART-FAILURE; DIABETES-MELLITUS; SKELETAL-MUSCLE; RECEPTOR GENE; CELL-SIZE; IGF-I; MYOCARDIAL-CONTRACTILITY AB Cardiovascular disease is the leading cause of death in people with type 2 diabetes and is linked to insulin resistance even in the absence of diabetes. Here we show that mice with combined deficiency of the insulin receptor and insulin-like growth factor 1 (IGF-1) receptor in cardiac and skeletal muscle develop early-onset dilated cardiomyopathy and die from heart failure within the first month of life despite having a normal glucose homeostasis. Mice lacking the insulin receptor show impaired cardiac performance at 6 months, and mice lacking the insulin receptor plus one Igf1r allele have slightly increased mortality. By contrast, mice lacking the IGF-1 receptor or the IGF-1 receptor plus one Ir allele appear normal. Morphological characterization and oligonucleotide array analysis of gene expression demonstrate that prior to development of these physiological defects, mice with combined deficiency of both insulin and IGF-1 receptors have a coordinated down-regulation of genes encoding components of the electron transport chain and mitochondrial fatty acid beta-oxidation pathways and altered expression of contractile proteins. Thus, while neither the insulin receptor nor IGF-1 receptor in muscle is critical for glucose homeostasis during the first month of life, signaling from these receptors, particularly the insulin receptor, is required for normal cardiac metabolism and function. C1 Joslin Diabet Ctr, Boston, MA 02215 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA. Boston Univ, Sch Med, Boston, MA 02218 USA. Hop St Antoine, INSERM, U515, F-75571 Paris, France. RP Kahn, CR (reprint author), Joslin Diabet Ctr, Boston, MA 02215 USA. EM c.ronald.kahn@joslin.harvard.edu FU NIDDK NIH HHS [DK 31036, R01 DK031036, R37 DK031036] NR 57 TC 80 Z9 87 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD MAR PY 2007 VL 27 IS 5 BP 1649 EP 1664 DI 10.1128/MCB.01110-06 PG 16 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 137PW UT WOS:000244305500009 PM 17189427 ER PT J AU Zheng, Q Davis, EC Richardson, JA Starcher, BC Li, TS Gerard, RD Yanagisawa, H AF Zheng, Qian Davis, Elaine C. Richardson, James A. Starcher, Barry C. Li, Tiansen Gerard, Robert D. Yanagisawa, Hiromi TI Molecular amalysis of fibulin-5 function during de novo synthesis of elastic fibers (vol 27, pg 1083, 2007) SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Correction C1 Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX USA. Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA. Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX USA. McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada. Univ Texas, Hlth Ctr, Dept Biochem, Tyler, TX USA. Harvard Univ, Med Sch, Dept Opthamol, Boston, MA USA. Massachusetts Eye & Ear Infirm, Boston, MA USA. RP Zheng, Q (reprint author), Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD MAR PY 2007 VL 27 IS 5 BP 1990 EP 1990 DI 10.1128/MCB.00111-07 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 137PW UT WOS:000244305500036 ER PT J AU Kim, M Murphy, K Liu, F Parker, SE Dowling, ML Baff, W Kao, GD AF Kim, Mijin Murphy, Katie Liu, Fang Parker, Sharon E. Dowling, Melissa L. Baff, Wesley Kao, Gary D. TI Caspase-mediated specific cleavage of BubR1 is a determinant of mitotic progression (vol 25, pg 9232, 2007) SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Correction C1 Philadelphia Vet Affairs Med Ctr, Dept Radiat Oncol, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Kim, M (reprint author), Philadelphia Vet Affairs Med Ctr, Dept Radiat Oncol, Philadelphia, PA 19104 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD MAR PY 2007 VL 27 IS 5 BP 1991 EP 1991 DI 10.1128/MCB.02381-06 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 137PW UT WOS:000244305500037 ER PT J AU Yan, Q Bartz, S Mao, M Li, LJ Kaelin, WG AF Yan, Qin Bartz, Steven Mao, Mao Li, Lianjie Kaelin, William G., Jr. TI The hypoxia-inducible factor 2 alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID HYPOXIA-INDUCIBLE FACTOR; VON-HIPPEL-LINDAU; TRANSCRIPTIONAL ACTIVITY; TUMOR-GROWTH; FACTOR HIF; ENDOTHELIAL-CELLS; STRUCTURAL BASIS; BINDING-PROTEIN; GENE-EXPRESSION; TARGET GENES AB Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor, consisting of an alpha subunit and a beta subunit, that controls cellular responses to hypoxia. HIF alpha contains two transcriptional activation domains called the N-terminal transactivation domain (NTAD) and the C-terminal transactivation domain (CTAD). HIF alpha is destabilized by prolyl hydroxylation catalyzed by EgIN family members. In addition, CTAD function is inhibited by asparagine hydroxylation catalyzed by FIH1. Both hydroxylation reactions are linked to oxygen availability. The von Hippel-Lindau tumor suppressor protein (pVHL) is frequently mutated in kidney cancer and is part of the ubiquitin ligase complex that targets prolyl hydroxylated HIF alpha for destruction. Recent studies suggest that HIF2 alpha plays an especially important role in promoting tumor formation by pVHL-defective renal carcinoma cells among the three HIF alpha paralogs. Here we dissected the relative contribution of the two HIF2 alpha transactivation domains to hypoxic gene activation and renal carcinogenesis and investigated the regulation of the HIF2a CTAD by FIHI. We found that the HIF2a NTAD is capable of activating both artificial and naturally occurring HIF-responsive promoters in the absence of the CTAD. Moreover, we found that the HIF2 alpha CTAD, in contrast to the HIF1 alpha CTAD, is relatively resistant to the inhibitory effects of FIHI under normoxic conditions and that, perhaps as a result, both the NTAD and CTAD cooperate to promote renal carcinogenesis in vivo. C1 Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. Rosetta Inpharmat, LLC, Seattle, WA 98109 USA. RP Kaelin, WG (reprint author), Howard Hughes Med Inst, Boston, MA 02115 USA. EM william_kaelin@dfci.harvard.edu RI Yan, Qin/E-8893-2012 OI Yan, Qin/0000-0003-4077-453X NR 56 TC 86 Z9 86 U1 2 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD MAR PY 2007 VL 27 IS 6 BP 2092 EP 2102 DI 10.1128/MCB.01514-06 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 147LD UT WOS:000245003600010 PM 17220275 ER PT J AU Maser, RS Wong, KK Sahin, E Xia, HL Naylor, M Hedberg, HM Artandi, SE DePinho, RA AF Maser, Richard S. Wong, Kwok-Kin Sahin, Erguen Xia, Huili Naylor, Maria Hedberg, H. Mason Artandi, Steven E. DePinho, Ronald A. TI DNA-dependent protein kinase catalytic subunit is not required for dysfunctional telomere fusion and checkpoint response in the telomerase-deficient mouse SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID SEVERE COMBINED IMMUNODEFICIENCY; STRAND BREAK REPAIR; TO-END FUSIONS; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; LIGASE-IV; IONIZING-RADIATION; MAMMALIAN TELOMERES; GENOMIC INSTABILITY AB Telomeres are key structural elements for the protection and maintenance of linear chromosomes, and they function to prevent recognition of chromosomal ends as DNA double-stranded breaks. Loss of telomere capping function brought about by tellomerase deficiency and gradual erosion of telomere ends or by experimental disruption of higher-order telomere structure culminates in the fusion of defective telomeres and/or the activation of DNA damage checkpoints. Previous work has implicated the nonhomologous end-joining (NHEJ) DNA repair pathway as a critical mediator of these biological processes. Here, employing the telomerase-deficient mouse model, we tested whether the NHEJ component DNA-dependent protein kinase catalytic subunit (DNA-PKcs) was required for fusion of eroded/dysfunctional telomere ends and the telomere checkpoint responses. In late-generation mTerc(-/-) DNA-PKcs(-/-) cells and tissues, chromosomal end-to-end fusions and anaphase bridges were readily evident. Notably, nullizygosity for DNA Ligase4 (Lig4)-an additional crucial NHEJ component-was also permissive for chromosome fusions in mTerc(-/-) cells, indicating that, in contrast to results seen with experimental disruption of telomere structure, telomere dysfunction in the context of gradual telomere erosion can engage additional DNA repair pathways. Furthermore, we found that DNA-PKcs deficiency does not reduce apoptosis, tissue atrophy, or p53 activation in late-generation mTerc(-/-) tissues but rather moderately exacerbates germ cell apoptosis and testicular degeneration. Thus, our studies indicate that the NHEJ components, DNA-PKcs and Lig4, are not required for fusion of critically shortened telomeric ends and that DNA-PKcs is not required for sensing and executing the telomere checkpoint response, findings consistent with the consensus view of the limited role of DNA-PKcs in DNA damage signaling in general. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Mol Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. Stanford Univ, Sch Med, Dept Med, Div Hematol, Stanford, CA 94305 USA. Stanford Univ, Sch Med, Canc Biol Program, Stanford, CA 94305 USA. Dana Farber Canc Inst, Ctr Appl Canc Sci, Boston, MA 02115 USA. Dana Farber Canc Inst, Belfer Fdn Inst Innovat Canc Sci, Boston, MA 02115 USA. RP DePinho, RA (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Mol Oncol, 44 Binney St,M413, Boston, MA 02115 USA. EM ron_depinho@dfci.harvard.edu RI Maser, Richard/B-2970-2012; OI wong, kwok kin/0000-0001-6323-235X FU NCI NIH HHS [P01CA95616, P01 CA095616, R01 CA084628, R01CA84628, U01 CA084313, U01CA84313]; NIA NIH HHS [K08AG 2400401] NR 96 TC 48 Z9 48 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD MAR PY 2007 VL 27 IS 6 BP 2253 EP 2265 DI 10.1128/MCB.01354-06 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 147LD UT WOS:000245003600023 PM 17145779 ER PT J AU Egles, C Claudepierre, T Manglapus, MK Champliaud, MF Brunken, WJ Hunter, DD AF Egles, Christophe Claudepierre, Thomas Manglapus, Mary K. Champliaud, Marie-France Brunken, William J. Hunter, Dale D. TI Laminins containing the beta 2 chain modulate the precise organization of CNS synapses SO MOLECULAR AND CELLULAR NEUROSCIENCE LA English DT Article DE synapse stabilization; extracellular matrix; hippocampus; brain; laminin ID CENTRAL-NERVOUS-SYSTEM; ADULT-MOUSE BRAIN; S-LAMININ; HIPPOCAMPAL-NEURONS; SYNAPTIC CLEFT; NEUROMUSCULAR-JUNCTION; DEVELOPING RETINAE; DEFICIENT MICE; GLIAL-CELLS; EXPRESSION AB Synapses are formed and stabilized by concerted interactions of pre-, intra-, and post-synaptic components; however, the precise nature of the intrasynaptic components in the CNS remains obscure. Potential intrasynaptic components include extracellular matrix molecules such as laminins; here, we isolate P2-containing laminins, including perhaps laminins 13 (alpha 3 beta 2 gamma 3) and 14 (alpha 4 beta 2 gamma 3), from CNS synaptosomes suggesting a role for these molecules in synaptic organization. Indeed, hippocampal synapses that form in vivo in the absence of these laminins are malformed at the ultrastructural level and this malformation is replicated in synapses formed in vitro, where laminins are provided largely by the post-synaptic neuron. This recapitulation of the in vivo function of laminins in vitro suggests that the malformations are a direct consequence of the removal of laminins from the synapse. Together, these results support a role for neuronal laminins in the structural integrity of central synapses. (c) 2006 Elsevier Inc. All rights reserved. C1 Tufts Ctr Vis Res, Dept Neurosci, Boston, MA 02111 USA. Tufts Ctr Vis Res, Dept Anat & Cellular Biol, Boston, MA 02111 USA. Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Dept Dermatol, Charlestown, MA 02129 USA. Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA. RP Brunken, WJ (reprint author), Tufts Univ, Sch Med, Dept Anat & Cellular Biol, 136 Harrison Ave, Boston, MA 02111 USA. EM bill.brunken@tufts.edu; dale.hunter@tufts.edu OI Brunken, William J/0000-0001-7330-1814; EGLES, Christophe/0000-0003-0982-7752 FU NEI NIH HHS [EY012037, EY013078]; NINDS NIH HHS [NS039502] NR 57 TC 31 Z9 31 U1 1 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1044-7431 J9 MOL CELL NEUROSCI JI Mol. Cell. Neurosci. PD MAR PY 2007 VL 34 IS 3 BP 288 EP 298 DI 10.1016/j.mcn.2006.11.004 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 146BJ UT WOS:000244909200002 PM 17189701 ER PT J AU Mitsiades, CS Negri, J McMullan, C McMillin, DW Sozopoulos, E Fanourakis, G Voutsinas, G Tseleni-Balafouta, S Poulaki, V Batt, D Mitsiades, N AF Mitsiades, Constantine S. Negri, Joseph McMullan, Ciaran McMillin, Douglas W. Sozopoulos, Elias Fanourakis, Galinos Voutsinas, Gerassimos Tseleni-Balafouta, Sophia Poulaki, Vassiliki Batt, David Mitsiades, Nicholas TI Targeting BRAF(V600E) in thyroid carcinoma: therapeutic implications SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID POORLY DIFFERENTIATED CARCINOMAS; PROTEIN-KINASE ACTIVATION; APOPTOSIS-INDUCING LIGAND; BRAF MUTATIONS; CELL-LINES; HIGH PREVALENCE; HUMAN-MELANOMA; CANCER; RET/PTC; GROWTH AB B-Raf is an important mediator of cell proliferation and survival signals transduced via the Ras-Raf-MEK-ERK cascade. BRAF mutations have been detected in several tumors, including papillary thyroid carcinoma, but the precise role of B-Raf as a therapeutic target for thyroid carcinoma is still under investigation. We analyzed a panel of 93 specimens and 14 thyroid carcinoma cell lines for the presence of BRAF mutations and activation of the mitogen-activated protein/ERK kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway. We also compared the effect of a B-Raf small inhibitory RNA construct and the B-Raf kinase inhibitor AAL881 on both B-Raf wild-type and mutant thyroid carcinoma cell lines. We found a high prevalence of the T1799A (V600E) mutation in papillary and anaplastic carcinoma specimens and cell lines. There was no difference in patient age, B-Raf expression, Ki67 immunostaining, or clinical stage at presentation between wild-type and BRAF(V600E) specimens. Immunodetection of phosphorylated and total forms of MEK and ERK revealed no difference in their phosphorylation between wild-type and BRAF(V600E) patient specimens or cell lines. Furthermore, a small inhibitory RNA construct targeting the expression of both wild-type B-Raf and B-Raf(V600E) induced a comparable reduction of viability in both wild-type and BRAF(V600E) mutant cancer cells. Interestingly, AAL881 inhibited MEK and ERK phosphorylation and induced apoptosis preferentially in BRAF(V600E)-harboring cells than wild-type ones, possibly because of better inhibitory activity against B-Raf(V600E). We conclude that B-Raf is important for the pathophysiology of thyroid carcinomas irrespective of mutational status. Small molecule inhibitors that selectively target B-Raf(V600E) may provide clinical benefit for patients with thyroid cancer. C1 Harvard Univ, Dept Med Oncol, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. Univ Athens, Dept Pathol, Athens, Greece. Natl Ctr Sci Res Demokritos, Inst Biol, Lab Environm Mutagenesis & Carcinogenesis, GR-15310 Athens, Greece. Novartis Inst BioMed Res Inc, Oncol Res, Cambridge, MA USA. RP Mitsiades, CS (reprint author), Harvard Univ, Dept Med Oncol, Dana Farber Canc Inst, Sch Med, Mayer Bldg,Room M555,44 Binney St, Boston, MA 02115 USA. EM Constantine_Mitsiades@dfci.harvard.edu NR 45 TC 42 Z9 44 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD MAR PY 2007 VL 6 IS 3 BP 1070 EP 1078 DI 10.1158/1535-7163.MCT-06-0449 PG 9 WC Oncology SC Oncology GA 148NO UT WOS:000245082100030 PM 17363500 ER PT J AU Dimmock, DP Zhang, Q Shieh, J Chou, PC Truong, C Schmitt, E Sifry-Plat, M Ficicioglu, CH Enns, GM Arch, EM Longo, N Lipson, MH Craigen, WJ Wong, LJ AF Dimmock, D. P. Zhang, Q. Shieh, J. Chou, P. C. Truong, C. Schmitt, E. Sifry-Plat, M. Ficicioglu, C. H. Enns, G. M. Arch, E. M. Longo, N. Lipson, M. H. Craigen, W. J. Wong, L. -J. TI The clinical features and molecular genetics of deoxyguanosine kinase deficiency. SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Inherited-Metabolic-Disorders (SIMD 2007) CY MAR 25-28, 2007 CL Nashville, TN SP Soc Inherited Metabol Disorders C1 Baylor Coll Med, Houston, TX 77030 USA. Univ Calif San Francisco, J David Gladstone Inst, San Francisco, CA 94143 USA. Kaiser Permanente, Dept Med Genet, Sacramento, CA USA. Childrens Hosp Philadelphia, Dept Metab, Philadelphia, PA 19104 USA. Stanford Univ, Sch Med, Div Med Genet, Stanford, CA 94305 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Utah, Div Med Genet, Dept Peds, Salt Lake City, UT 84112 USA. RI Dimmock, David/I-7913-2015 OI Dimmock, David/0000-0001-6690-2523 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD MAR PY 2007 VL 90 IS 3 MA 18 BP 250 EP 250 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 149XF UT WOS:000245179500038 ER PT J AU Garofalakis, A Zacharakis, G Meyer, H Economou, EN Mamalaki, C Papamatheakis, J Kioussis, D Ntziachristos, V Ripoll, J AF Garofalakis, Anikitos Zacharakis, Giannis Meyer, Heiko Economou, Eleftherios N. Mamalaki, Clio Papamatheakis, Joseph Kioussis, Dimitris Ntziachristos, Vasilis Ripoll, Jorge TI Three-dimensional in vivo imaging of green fluorescent protein-expressing T cells in mice with noncontact fluorescence molecular tomography SO MOLECULAR IMAGING LA English DT Article ID DIFFUSE OPTICAL TOMOGRAPHY; SINGULAR-VALUE ANALYSIS; GENE-EXPRESSION; INDOCYANINE GREEN; SCATTERING MEDIA; BREAST-CANCER; TURBID MEDIA; MOUSE MODELS; TUMORS; MICROSCOPY AB Given that optical tomography is capable of quantitatively imaging the distribution of several important chromophores and fluorophores in vivo, there has been a great deal of interest in developing optical imaging systems with increased numbers of measurements under optimal experimental conditions. In this article, we present a novel system that enables three-dimensional imaging of fluorescent probes in whole animals using a noncontact setup, in parallel with a three-dimensional surface reconstruction algorithm. This approach is directed toward the in vivo imaging of fluorophore or fluorescent protein concentration in small animals. The system consists of a rotating sample holder and a lens-coupled charge-coupled device camera in combination with a fiber-coupled laser scanning device. By measuring multiple projections, large data sets can be obtained, thus improving the accuracy of the inversion models used for quantitative three-dimensional reconstruction of fluorochrome distribution, as well as facilitating a higher spatial resolution. In this study, the system was applied to determining the distribution of green fluorescent protein (GFP)expressing T lymphocytes in a transgenic mouse model, thus demonstrating the potential of the system for studying immune system function. The technique was used to image and reconstruct fluorescence originating from 32 X 10(6) T cells in the thymus and 3 X 10(5) T cells in the spleen. C1 Fdn Res & Technol Hellas, Inst Elect Struct & Laser, Iraklion 71110, Greece. Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion 71110, Greece. Natl Inst Med Res, Div Mol Immunol, London NW7 1AA, England. Harvard Univ, Sch Med, Lab Bioopt & Mol Imaging, Massachusetts Gen Hosp,Ctr Mol Imaging Res, Charlestown, MA USA. RP Garofalakis, A (reprint author), Fdn Res & Technol Hellas, Inst Elect Struct & Laser, POB 1527, Iraklion 71110, Greece. EM agarof@ieslforth.gr RI Economou, Eleftherios /E-6374-2010; Zacharakis, Giannis/A-2544-2014; Ripoll, Jorge/J-8134-2012 OI Zacharakis, Giannis/0000-0002-6438-0773; Ripoll, Jorge/0000-0001-8856-7738 FU Medical Research Council [MC_U117512796]; NCI NIH HHS [R24 CA 92782, P50 CA 86355, R33 CA 91807]; NIBIB NIH HHS [R01 EB000750-1] NR 62 TC 43 Z9 43 U1 0 U2 7 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1535-3508 J9 MOL IMAGING JI Mol. Imaging PD MAR-APR PY 2007 VL 6 IS 2 BP 96 EP 107 DI 10.2310/7290.2007.00007 PG 12 WC Biochemical Research Methods; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Radiology, Nuclear Medicine & Medical Imaging GA 186NN UT WOS:000247785500003 PM 17445504 ER PT J AU Ishiguro, K Ando, T Goto, H Xavier, R AF Ishiguro, Kazuhiro Ando, Takafumi Goto, Hidemi Xavier, Ramnik TI Bcl10 is phosphorylated on Ser138 by Ca2+/calmodulin-dependent protein kinase II SO MOLECULAR IMMUNOLOGY LA English DT Article DE Ca2+/calmodulin-dependent protein kinase; phosphorylation; signal transduction; NF-kappa B; synapses ID NF-KAPPA-B; T-CELL; LYMPHOCYTE-ACTIVATION; CARMA1; RECRUITMENT; DOMAIN; MALT1; REQUIREMENT; REGULATOR; APOPTOSIS AB Ordered assembly of scaffold proteins Carma1-Bc11O-Malt1 determines NF-kappa B activation following T cell receptor (TCR) engagement. Carmal-Bc110 interaction and the signaling pathway are controlled by Carma1 phosphorylation, which are induced by PKC theta and Ca2,/calmodulin-dependent protein kinase 11 (CaMKII). In addition to Carma1 phosphorylation, previous studies have demonstrated that Bc110 is phosphorylated in the C-terminal Ser/Thr rich region following TCR engagement. However the kinases that phosphorylate Be] 10 are incompletely understood. Here we show that CaMKII phosphorylates Bc110 on Ser138. Furthermore, a CaMKII inhibitor, KN93, and CaMKII siRNA substantially reduce Bc110 phosphorylation induced by phorbol myristate acetate/ionomycin. S138A mutation prolongs Bc110-induced NF-kappa B activation, suggesting that Bc110 phosphorylation is involved in attenuation of NF-kappa B activation. These findings suggest that CaMKII modulates NF-kappa B activation via phosphorylating Bc110 as well as Carma1. (c) 2006 Elsevier Ltd. All rights reserved. C1 Nagoya Univ, Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan. Nagoya Univ, Grad Sch Med, Dept Gastroenterol, Showa Ku, Nagoya, Aichi 4668550, Japan. Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. RP Ishiguro, K (reprint author), Nagoya Univ, Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan. EM kio@med.nagoya-u.ac.jp OI Ishiguro, Kazuhiro/0000-0003-1776-2805 FU NIDDK NIH HHS [P30 DK040561, P30 DK040561-11] NR 27 TC 21 Z9 23 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD MAR PY 2007 VL 44 IS 8 BP 2095 EP 2100 DI 10.1016/j.molimm.2006.09.012 PG 6 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA 138GQ UT WOS:000244351500031 PM 17052756 ER PT J AU Lim, SD Stallcup, W Lefkove, B Govindarajan, B Au, KS Northrup, H Lang, D Fisher, DE Patel, A Amin, MB Arbiser, JL AF Lim, So Dug Stallcup, William Lefkove, Benjamin Govindarajan, Baskaran Au, Kit Sing Northrup, Hope Lang, Deborah Fisher, David E. Patel, Avani Amin, Mahul B. Arbiser, Jack L. TI Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: Are angiomyolipomas neoplasms of stem cells? SO MOLECULAR MEDICINE LA English DT Article ID GROWTH-FACTOR RECEPTOR; PDGF ALPHA-RECEPTOR; TUBEROUS SCLEROSIS; RENAL ANGIOMYOLIPOMA; DEVELOPING RAT; PROTEOGLYCAN; KIDNEY; GENE; BRAIN; TFE3 AB Angiomyolipomas are benign tumors of the kidney which express phenotypes of smooth muscle, fat, and melanocytes. These tumors appear with increased frequency in the autosomal dominant disorder tuberous sclerosis and are the leading cause of morbidity in adults with tuberous sclerosis. While benign, these tumors are capable of provoking life threatening hemorrhage and replacement of the kidney parenchyma, resulting in renal failure. The histogenesis of these tumors is currently unclear, although currently, we believe these tumors arise from "perivascular epithelioid cells" of which no normal counterpart has been convincingly demonstrated. Recently, stem cell precursors have been recognized that can give rise to smooth muscle and melanocytes. These precursors have been shown to express the neural stem cell marker NG2 and L1. In order to determine whether angiomyolipomas, which exhibit smooth muscle and melanocytic phenotypes, express NG2 and L1, we performed immunocytochemistry on a cell line derived from a human angiomyolipoma, and found that these cells are uniformly positive. Immunohistochemistry of human angiomyolipoma specimens revealed uniform staining of tumor cells, while renal cell carcinomas revealed positivity only of angiogenic vessels. These results support a novel histogenesis of angiomyolipoma as a defect in differentiation of stem cell precursors. C1 Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA. Emory Univ, Sch Med, Dept Urol, Atlanta, GA 30322 USA. Atlanta VA Med Ctr, Burham Inst Med Res, Canc Res Ctr, La Jolla, CA USA. Univ Texas, Sch Med, Dept Pediat, Div Med Genet, Houston, TX USA. Univ Penn, Hlth Syst, Div Cardiovasc, Philadelphia, PA 19104 USA. Dana Farber Canc Inst, Dept Pediat Hematol & Oncol, Boston, MA 02115 USA. RP Arbiser, JL (reprint author), Emory Univ, Sch Med, Dept Dermatol, 1639 Pierce Dr,WMB 5309, Atlanta, GA 30322 USA. EM jarbise@emory.edu FU NIAMS NIH HHS [P30 AR 42687, P30 AR042687, R01 AR 050727, R01 AR047901, R01 AR050727, R01AR 47901] NR 35 TC 22 Z9 22 U1 0 U2 1 PU FEINSTEIN INSTITUTE MED RES PI MANHASSET PA 350 COMMUNITY DRIVE, MANHASSET, NY 11030 USA SN 1076-1551 J9 MOL MED JI Mol. Med. PD MAR-APR PY 2007 VL 13 IS 3-4 BP 160 EP 165 DI 10.2119/2006-00070.Lim PG 6 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 179KD UT WOS:000247287500005 PM 17592550 ER PT J AU Reese, AJ Yoneda, A Breger, JA Beauvais, A Liu, H Griffith, CL Bose, I Kim, MJ Skau, C Yang, S Sefko, JA Osumi, M Latge, JP Mylonakis, E Doering, TL AF Reese, Amy J. Yoneda, Aki Breger, Julia A. Beauvais, Anne Liu, Hong Griffith, Cara L. Bose, Indrani Kim, Myoung-Ju Skau, Colleen Yang, Sarah Sefko, Julianne A. Osumi, Masako Latge, Jean-Paul Mylonakis, Eleftherios Doering, Tamara L. TI Loss of cell wall alpha(1-3) glucan affects Cryptococcus neoformans from ultrastructure to virulence SO MOLECULAR MICROBIOLOGY LA English DT Article ID FISSION YEAST; CAENORHABDITIS-ELEGANS; ASPERGILLUS-FUMIGATUS; SCHIZOSACCHAROMYCES-POMBE; ELECTRON-MICROSCOPY; SYNTHASE; GENE; HOMOLOG; CAPSULE; PROTEIN AB Yeast cell walls are critical for maintaining cell integrity, particularly in the face of challenges such as growth in mammalian hosts. The pathogenic fungus Cryptococcus neoformans additionally anchors its polysaccharide capsule to the cell surface via alpha(1-3) glucan in the wall. Cryptococcal cells disrupted in their alpha glucan synthase gene were sensitive to stresses, including temperature, and showed difficulty dividing. These cells lacked surface capsule, although they continued to shed capsule material into the environment. Electron microscopy showed that the alpha glucan that is usually localized to the outer portion of the cell wall was absent, the outer region of the wall was highly disorganized, and the inner region was hypertrophic. Analysis of cell wall composition demonstrated complete loss of alpha glucan accompanied by a compensatory increase in chitin/chitosan and a redistribution of beta glucan between cell wall fractions. The mutants were unable to grow in a mouse model of infection, but caused death in nematodes. These studies integrate morphological and biochemical investigations of the role of alpha glucan in the cryptococcal cell wall. C1 Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA. Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. Inst Pasteur, Unite Aspergillus, F-7501 Paris, France. Japan Womens Univ, Dept Biol, Tokyo 112, Japan. RP Doering, TL (reprint author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA. EM doering@wustl.edu RI Beauvais, Anne/A-6358-2012; Latge, Jean Paul/C-9846-2014 FU NIAID NIH HHS [K08 AI063084, K08 AI63084]; NIGMS NIH HHS [R01 GM71007, R01 GM071007] NR 64 TC 69 Z9 70 U1 1 U2 8 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0950-382X J9 MOL MICROBIOL JI Mol. Microbiol. PD MAR PY 2007 VL 63 IS 5 BP 1385 EP 1398 DI 10.1111/j.1365-2958.2006.05551.x PG 14 WC Biochemistry & Molecular Biology; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA 136SY UT WOS:000244245600011 PM 17244196 ER PT J AU O'Connor, KC McLaughlin, KA De Jager, PL Chitnis, T Bar-Or, A Banwell, B Fukaura, H Tenembaum, S Wong, SL Tavakoli, NP Rostasy, K Dale, RC Freedman, MS Wucherpfennig, KW Hafler, DA AF O'Connor, K. C. McLaughlin, K. A. De Jager, P. L. Chitnis, T. Bar-Or, A. Banwell, B. Fukaura, H. Tenembaum, S. Wong, S. L. Tavakoli, N. P. Rostasy, K. Dale, R. C. Freedman, M. S. Wucherpfennig, K. W. Hafler, D. A. TI Autoantibodies recognizing myelin oligodendrocyte glycoprotein are rarely present in the serum or CSF of patients with multiple sclerosis SO MULTIPLE SCLEROSIS LA English DT Meeting Abstract CT 11th Annual Meeting of the Americas-Committee-for-Treatment-and-Research-in- Multiple-Sclerosis CY OCT 08, 2006 CL Chicago, IL SP Amer Comm Treatment & Res Multiple Scleros C1 Brigham & Womens Hosp, Lab Mol Immunol, Ctr Neurol Dis, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. Harvard Univ, Broad Inst, Boston, MA 02115 USA. MIT, Cambridge, MA 02139 USA. McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada. Hosp Sick Children, Dept Paediat Neurol, Toronto, ON M5G 1X8, Canada. Hokkaido Univ, Dept Neurol, Sapporo, Hokkaido 060, Japan. Natl Pediat Hosp Dr JP Garrahan, Dept Pediat Neurol, Buenos Aires, DF, Argentina. New York State Dept Hlth, Diagnost Immunol Lab, Wadsworth Ctr, Albany, NY 12201 USA. Univ Gottingen, Dept Pediat & Pediat Neurol, D-3400 Gottingen, Germany. Great Ormond St Hosp Sick Children, Dept Neurol, London WC1N 3JH, England. Ottawa Gen Hosp, Dept Neurol, Ottawa, ON K1H 8L6, Canada. RI Bar-Or, Amit/C-4213-2011 NR 6 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 J9 MULT SCLER JI Mult. Scler. PD MAR PY 2007 VL 13 IS 2 BP 284 EP 285 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 158LK UT WOS:000245792800028 ER PT J AU Pellman, D AF Pellman, David TI Cell biology - Aneuploidy and cancer SO NATURE LA English DT Editorial Material ID MITOTIC CHECKPOINT; CHROMOSOMES; TUMORIGENESIS; MICE C1 Harvard Univ, Sch Med, Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Pellman, D (reprint author), Harvard Univ, Sch Med, Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. EM david_pellman@dfci.harvard.edu NR 13 TC 53 Z9 58 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD MAR 1 PY 2007 VL 446 IS 7131 BP 38 EP 39 DI 10.1038/446038a PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 140RY UT WOS:000244525600029 PM 17330036 ER PT J AU Wang, ZZ Au, P Chen, T Shao, Y Daheron, LM Bai, H Arzigian, M Fukumura, D Jain, RK Scadden, DT AF Wang, Zack Z. Au, Patrick Chen, Tong Shao, Ying Daheron, Laurence M. Bai, Hao Arzigian, Melanie Fukumura, Dai Jain, Rakesh K. Scadden, David T. TI Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo SO NATURE BIOTECHNOLOGY LA English DT Article ID CD34(+) CELLS; DIFFERENTIATION; ANGIOGENESIS AB We describe the differentiation of human embryonic stem (hES) cells into endothelial cells using a scalable two-dimensional method that avoids an embryoid-body intermediate. After transplantation into severe combined immunodeficient (SCID) mice, the differentiated cells contributed to arborized blood vessels that integrated into the host circulatory system and served as blood conduits for 150 d. C1 Maine Med Ctr, Res Inst, Scarborough, ME 04074 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol,Edwin L Steele Lab, Boston, MA 02114 USA. Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. Fudan Univ, Shanghai Huashan Hosp, Dept Hematol, Shanghai 200040, Peoples R China. Harvard Univ, Stem Cell Inst, Cambridge, MA 02138 USA. RP Wang, ZZ (reprint author), Maine Med Ctr, Res Inst, Scarborough, ME 04074 USA. EM wangz@mmc.org; jain@steele.mgh.harvard.edu; scadden.david@mgh.harvard.edu FU NCI NIH HHS [P01CA80124, R01CA115767, R01CA96915]; NCRR NIH HHS [P20RR018789]; NIDDK NIH HHS [K01DK064696] NR 13 TC 174 Z9 183 U1 1 U2 16 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1087-0156 J9 NAT BIOTECHNOL JI Nat. Biotechnol. PD MAR PY 2007 VL 25 IS 3 BP 317 EP 318 DI 10.1038/nbt1287 PG 2 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA 143TP UT WOS:000244748300023 PM 17322871 ER PT J AU Li, JY Brieher, WM Scimone, ML Kang, SJ Zhu, H Yin, H von Andrian, UH Mitchison, T Yuan, JY AF Li, Juying Brieher, William M. Scimone, M. Lucila Kang, Shin Jung Zhu, Hong Yin, Helen von Andrian, Ulrich H. Mitchison, Timothy Yuan, Junying TI Caspase-11 regulates cell migration by promoting Aip1-Cofilin-mediated actin depolymerization SO NATURE CELL BIOLOGY LA English DT Article ID INTERACTING PROTEIN-1; FILAMENTS; COFILIN; FACTOR/COFILIN; IDENTIFICATION; REQUIREMENTS; ACTIVATION; DYNAMICS; EFFECTOR; MOTILITY AB Coordinated regulation of cell migration, cytokine maturation and apoptosis is critical in inflammatory responses. Caspases, a family of cysteine proteases, are known to regulate cytokine maturation and apoptosis. Here, we show that caspase-11, a mammalian pro-inflammatory caspase, regulates cell migration during inflammation. Caspase-11-deficient lymphocytes exhibit a cell-autonomous migration defect in vitro and in vivo. We demonstrate that caspase-11 interacts physically and functionally with actin interacting protein 1 ( Aip1),an activator of cofilin-mediated actin depolymerization. The caspase-recruitment domain ( CARD) of caspase-11 interacts with the carboxy-terminal WD40 propeller domain of Aip1 to promote cofilin-mediated actin depolymerization. Cells with Aip1 or caspase-11 deficiency exhibit defects in actin dynamics. Using in vitro actin depolymerization assays, we found that caspase-11 and Aip1 work cooperatively to promote cofilin-mediated actin depolymerization. These data demonstrate a novel cell autonomous caspase-mediated mechanism that regulates actin dynamics and mammalian cell migration distinct from the receptor mediated Rho-Rac-Cdc42 pathway. C1 Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA. Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA. RP Li, JY (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. EM jyuan@hms.harvard.edu RI von Andrian, Ulrich/A-5775-2008 FU NIA NIH HHS [R37 AG12859] NR 28 TC 73 Z9 74 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1465-7392 J9 NAT CELL BIOL JI Nat. Cell Biol. PD MAR PY 2007 VL 9 IS 3 BP 276 EP + DI 10.1038/ncb1541 PG 20 WC Cell Biology SC Cell Biology GA 141DT UT WOS:000244558600012 PM 17293856 ER PT J AU Jackman, DM Janne, PA AF Jackman, David M. Jaenne, Pasi A. TI Does erlotinib improve symptoms in patients with lung cancer? Commentary SO NATURE CLINICAL PRACTICE ONCOLOGY LA English DT Editorial Material DE erlotinib; lung cancer; quality of life; symptoms ID CLINICAL-TRIALS; QLQ-C30 C1 Dana Farber Canc Inst, Lowe Ctr thorac Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Janne, PA (reprint author), Dana Farber Canc Inst, Lowe Ctr thorac Oncol, 44 Binney St, Boston, MA 02115 USA. EM pjanne@partners.org NR 5 TC 2 Z9 2 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1743-4254 J9 NAT CLIN PRACT ONCOL JI Nat. Clin. Pract. Oncol. PD MAR PY 2007 VL 4 IS 3 BP 146 EP 147 DI 10.1038/ncponc0738 PG 2 WC Oncology SC Oncology GA 141MC UT WOS:000244581700004 PM 17262089 ER PT J AU Wright, JL Porter, MP AF Wright, Jonathan L. Porter, Michael P. TI Quality-of-life assessment in patients with bladder cancer SO NATURE CLINICAL PRACTICE UROLOGY LA English DT Review DE bladder cancer; cystectomy; quality of life; urinary bladder neoplasm; urinary diversion ID CONTINENT CUTANEOUS DIVERSION; CALMETTE-GUERIN THERAPY; RADICAL CYSTECTOMY; URINARY-DIVERSION; ILEAL CONDUIT; ORTHOTOPIC NEOBLADDER; SF-36 SURVEY; CARCINOMA; RECONSTRUCTION; QUESTIONNAIRE AB Health-related quality of life (HRQOL) in patients with bladder cancer is important, because radical cystectomy and urinary diversion significantly affect urinary and sexual function, and lead to associated sex-specific morbidity. This article reviews the current methods for defining HRQOL, describes the specific challenges in measuring HRQOL in patients with bladder cancer, and critically analyzes the existing literature on bladder cancer HRQOL. Previous studies have been limited by study design, generalizability, and by the different instruments used, namely nonvalidated questionnaires that are not specific for bladder cancer. To date, only two prospective studies with baseline HRQOL data have been published and few conclusions can be drawn from these cross-sectional, retrospective studies. On the basis of the published literature, there is no convincing evidence that superior HRQOL is achieved with a particular type of urinary diversion after cystectomy for bladder cancer. Patients should be counseled on all reconstructive alternatives and a diversion chosen on the basis of patient preference, patient anatomy and tumor status, rather than on a potential difference in HRQOL. Prospective studies with appropriate adjustment for confounding factors, which use validated and disease-specific questionnaires, are needed for HRQOL research on bladder cancer. C1 Univ Washington, Dept Urol, Seattle, WA 98108 USA. Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Porter, MP (reprint author), Univ Washington, Dept Urol, 1660 S Columbian Way S-112-GU, Seattle, WA 98108 USA. EM mporter@u.washington.edu NR 42 TC 31 Z9 33 U1 2 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1743-4270 J9 NAT CLIN PRACT UROL JI Nat. Clin. Pract. Urol. PD MAR PY 2007 VL 4 IS 3 BP 147 EP 154 DI 10.1038/ncpuro0750 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 143UT UT WOS:000244752600012 PM 17347659 ER PT J AU Szatmari, P Paterson, AD Zwaigenbaum, L Roberts, W Brian, J Liu, XQ Vincent, JB Skaug, JL Thompson, AP Senman, L Feuk, L Qian, C Bryson, SE Jones, MB Marshall, CR Scherer, SW Vieland, VJ Bartlett, C Mangin, LV Goedken, R Segre, A Pericak-Vance, MA Cuccaro, ML Gilbert, JR Wright, HH Abramson, RK Betancur, C Bourgeron, T Gillberg, C Leboyer, M Buxbaum, JD Davis, KL Hollander, E Silverman, JM Hallmayer, J Lotspeich, L Sutcliffe, JS Haines, JL Folstein, SE Piven, J Wassink, TH Sheffield, V Geschwind, DH Bucan, M Brown, WT Cantor, RM Constantino, JN Gilliam, TC Herbert, M LaJonchere, C Ledbetter, DH Lese-Martin, C Miller, J Nelson, S Samango-Sprouse, CA Spence, S State, M Tanzi, RE Coon, H Dawson, G Devlin, B Estes, A Flodman, P Klei, L McMahon, WM Minshew, N Munson, J Korvatska, E Rodier, PM Schellenberg, GD Smith, M Spence, MA Stodgell, C Tepper, PG Wijsman, EM Yu, CE Roge, B Mantoulan, C Wittemeyer, K Poustka, A Felder, B Klauck, SM Schuster, C Poustka, F Bolte, S Feineis-Matthews, S Herbrecht, E Schmotzer, G Tsiantis, J Papanikolaou, K Maestrini, E Bacchelli, E Blasi, F Carone, S Toma, C Van Engeland, H de Jonge, M Kemner, C Koop, F Langemeijer, M Hijimans, C Staal, WG Baird, G Bolton, PF Rutter, ML Weisblatt, E Green, J Aldred, C Wilkinson, JA Pickles, A Le Couteur, A Berney, T McConachie, H Bailey, AJ Francis, K Honeyman, G Hutchinson, A Parr, JR Wallace, S Monaco, AP Barnby, G Kobayashi, K Lamb, JA Sousa, I Sykes, N Cook, EH Guter, SJ Leventhal, BL Salt, J Lord, C Corsello, C Hus, V Weeks, DE Volkmar, F Tauber, M Fombonne, E Shih, A AF Szatmari, Peter Paterson, Andrew D. Zwaigenbaum, Lonnie Roberts, Wendy Brian, Jessica Liu, Xiao-Qing Vincent, John B. Skaug, Jennifer L. Thompson, Ann P. Senman, Lili Feuk, Lars Qian, Cheng Bryson, Susan E. Jones, Marshall B. Marshall, Christian R. Scherer, Stephen W. Vieland, Veronica J. Bartlett, Christopher Mangin, La Vonne Goedken, Rhinda Segre, Alberto Pericak-Vance, Margaret A. Cuccaro, Michael L. Gilbert, John R. Wright, Harry H. Abramson, Ruth K. Betancur, Catalina Bourgeron, Thomas Gillberg, Christopher Leboyer, Marion Buxbaum, Joseph D. Davis, Kenneth L. Hollander, Eric Silverman, Jeremy M. Hallmayer, Joachim Lotspeich, Linda Sutcliffe, James S. Haines, Jonathan L. Folstein, Susan E. Piven, Joseph Wassink, Thomas H. Sheffield, Val Geschwind, Daniel H. Bucan, Maja Brown, W. Ted Cantor, Rita M. Constantino, John N. Gilliam, T. Conrad Herbert, Martha LaJonchere, Clara Ledbetter, David H. Lese-Martin, Christa Miller, Janet Nelson, Stan Samango-Sprouse, Carol A. Spence, Sarah State, Matthew Tanzi, Rudolph E. Coon, Hilary Dawson, Geraldine Devlin, Bernie Estes, Annette Flodman, Pamela Klei, Lambertus McMahon, William M. Minshew, Nancy Munson, Jeff Korvatska, Elena Rodier, Patricia M. Schellenberg, Gerard D. Smith, Moyra Spence, M. Anne Stodgell, Chris Tepper, Ping Guo Wijsman, Ellen M. Yu, Chang-En Roge, Bernadette Mantoulan, Carine Wittemeyer, Kerstin Poustka, Annemarie Felder, Barbel Klauck, Sabine M. Schuster, Claudia Poustka, Fritz Boelte, Sven Feineis-Matthews, Sabine Herbrecht, Evelyn Schmoetzer, Gabi Tsiantis, John Papanikolaou, Katerina Maestrini, Elena Bacchelli, Elena Blasi, Francesca Carone, Simona Toma, Claudio Van Engeland, Herman de Jonge, Maretha Kemner, Chantal Koop, Frederike Langemeijer, Marjolijn Hijimans, Channa Staal, Wouter G. Baird, Gillian Bolton, Patrick F. Rutter, Michael L. Weisblatt, Emma Green, Jonathan Aldred, Catherine Wilkinson, Julie-Anne Pickles, Andrew Le Couteur, Ann Berney, Tom McConachie, Helen Bailey, Anthony J. Francis, Kostas Honeyman, Gemma Hutchinson, Aislinn Parr, Jeremy R. Wallace, Simon Monaco, Anthony P. Barnby, Gabrielle Kobayashi, Kazuhiro Lamb, Janine A. Sousa, Ines Sykes, Nuala Cook, Edwin H. Guter, Stephen J. Leventhal, Bennett L. Salt, Jeff Lord, Catherine Corsello, Christina Hus, Vanessa Weeks, Daniel E. Volkmar, Fred Tauber, Maite Fombonne, Eric Shih, Andy TI Mapping autism risk loci using genetic linkage and chromosomal rearrangements SO NATURE GENETICS LA English DT Article ID HUMAN GENOME; SPECTRUM DISORDERS; MENTAL-RETARDATION; GLUTAMATE; NEUROLIGINS; FAMILY; TWIN; ASSOCIATION; PREVALENCE; DISSECTION AB Autism spectrum disorders (ASDs) are common, heritable neurodevelopmental conditions. The genetic architecture of ASDs is complex, requiring large samples to overcome heterogeneity. Here we broaden coverage and sample size relative to other studies of ASDs by using Affymetrix 10K SNP arrays and 1,168 families with at least two affected individuals, performing the largest linkage scan to date while also analyzing copy number variation in these families. Linkage and copy number variation analyses implicate chromosome 11p12-p13 and neurexins, respectively, among other candidate loci. Neurexins team with previously implicated neuroligins for glutamatergic synaptogenesis, highlighting glutamate-related genes as promising candidates for contributing to ASDs. C1 McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON L8N 3Z5, Canada. Hosp Sick Children, Ctr Appl Genom, Toronto, ON M5G 1X8, Canada. Hosp Sick Children, Program Genet & Genome Biol, Toronto, ON M5G 1X8, Canada. McMaster Univ, Dept Pediat, Hamilton, ON L8N 3Z5, Canada. Hosp Sick Children, Autism Res Unit, Toronto, ON M5G 1X8, Canada. Univ Toronto, Clarke Inst, Ctr Addist & Mental Hlth, Toronto, ON M5G 1X8, Canada. Univ Toronto, Clarke Inst, Dept Psychiat, Toronto, ON M5G 1X8, Canada. Dalhousie Univ, Izaak Walton Killam Hlth Ctr, Dept Pediat, Halifax, NS B3K 6R8, Canada. Dalhousie Univ, Izaak Walton Killam Hlth Ctr, Dept Psychol, Halifax, NS B3K 6R8, Canada. Penn State Univ, Coll Med, Dept Neural & Behav Sci, Hershey, PA 17033 USA. Columbus Childrens Res Inst, Ctr Quantitat & Computat Biol, Columbus, OH 43205 USA. Univ Iowa, Dept Comp Sci, Iowa City, IA 52242 USA. Univ Miami, Miller Sch Med, Inst Human Genet, Miami, FL 33101 USA. Univ S Carolina, Columbia, SC 29208 USA. Univ Paris 12, INSERM, U513, F-94000 Creteil, France. Inst Pasteur, F-75013 Paris, France. Univ Gothenburg, Dept Child & Adolescent Psychiat, S-41119 Gothenburg, Sweden. Grp Hosp Henri Mondor Albert Chenevier, APHP, Dept Psychiat, F-94000 Creteil, France. Mt Sinai Sch Med, Seaver Autism Res Ctr, Dept Psychiat, New York, NY 10029 USA. Mt Sinai Sch Med, Greater New York Autism Ctr Excellence, Dept Psychiat, New York, NY 10029 USA. Stanford Univ, Dept Psychiat, Palo Alto, CA 94304 USA. Vanderbilt Univ, Ctr Mol Neurosci, Nashville, TN 37232 USA. Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN 37232 USA. Johns Hopkins Univ, Dept Psychiat, Baltimore, MD 21287 USA. Univ N Carolina, Chapel Hill, NC 27599 USA. Univ Iowa, Iowa City, IA 52242 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. Univ Penn, Philadelphia, PA 19104 USA. New York State Inst Basic Res Dev Disabil, Staten Isl, NY 10314 USA. Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA. Washington Univ, Sch Med, St Louis, MO 63130 USA. Univ Chicago, Chicago, IL 60637 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Cure Autism Now, Los Angeles, CA 90036 USA. Emory Univ, Atlanta, GA 30322 USA. George Washington Univ, Washington, DC 20052 USA. Univ Calif Los Angeles, Los Angeles, CA 90095 USA. Yale Univ, Ctr Child Study, New Haven, CT 06520 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA. Univ Washington, Dept Psychol, Seattle, WA 98195 USA. Univ Washington, Ctr Human Dev & Disabil, Seattle, WA 98195 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. Univ Calif Irvine, Dept Pediat, Irvine, CA 92697 USA. Pugent Sound VA Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA 98104 USA. Univ Rochester, Med Ctr, Dept OB GYN, Rochester, NY 14642 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Toulouse Le Mirail, Ctr Etud & Rech Psychopathol, CERPP, F-31058 Toulouse, France. Deutsch Krebsforschungszentrum, Div Mol Genome Anal, DKFZ, D-69120 Heidelberg, Germany. Goethe Univ Frankfurt, Klin Psychiat & Psychotherapy Kindes & Jugendalte, D-60528 Frankfurt, Germany. Univ Athens, Aghia Sophia Childrens Hosp, Dept Child Psychiat, Athens 11526, Greece. Univ Bologna, Dept Biol, I-40126 Bologna, Italy. Univ Utrecht, Med Ctr, Dept Child & Adolescent Psychiat, NL-3508 GA Utrecht, Netherlands. Guys Hosp, Newcomen Ctr, London SE1 9RT, England. Inst Psychiat, Dept Child & Adolescent Psychiat, London, England. SGDP, Inst Psychiat, London SE5 8AF, England. Univ Cambridge, Sch Clin, Cambridge CB2 2AH, England. Univ Manchester, Booth Hall Childrens Hosp, Dept Child Psychiat, Manchester M9 7AA, Lancs, England. Univ Manchester, Sch Epidemiol & Hlth Sci, Manchester M13 9P, Lancs, England. Univ Newcastle, Sir James Space Inst, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England. Univ Oxford, Dept Psychiat, Oxford OX3 7LQ, England. Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England. Univ Illinois, Inst Juvenile Res, Dept Psychiat, Chicago, IL 60608 USA. Univ Michigan, Autism & Communicat Disorders Ctr, UMACC, Ann Arbor, MI 48109 USA. Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15213 USA. CHU Toulouse, Serv Pediat & Genet Med, Toulouse, France. McGill Univ, Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada. Autism Speeks, New York, NY 10016 USA. RP Scherer, SW (reprint author), McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON L8N 3Z5, Canada. EM swscherer@sickkids.ca; devlinbj@upmc.edu RI Bolton, Patrick/E-8501-2010; Bailey, Anthony/J-2860-2014; Toma, Claudio/L-7853-2014; Staal, Wouter/A-3099-2013; Paterson, Andrew/A-4088-2011; Stodgell, Christopher/A-1161-2007; Haines, Jonathan/C-3374-2012; Howe, Jennifer/I-9013-2012; Maestrini, Elena/K-7508-2012; Scherer, Stephen /B-3785-2013; Rutter, Michael/C-8570-2013; Sutcliffe, James/C-1348-2012; Segre, Alberto/B-1734-2009; Bartlett, Christopher/B-4958-2009; Monaco, Anthony/A-4495-2010; Pickles, Andrew/A-9625-2011; Nelson, Stanley/D-4771-2009; Weeks, Daniel/B-2995-2012 OI Liu, Xiao-Qing/0000-0002-4034-5156; Buxbaum, Joseph/0000-0001-8898-8313; Weeks, Daniel/0000-0001-9410-7228; Betancur, Catalina/0000-0002-3327-4804; Bourgeron, Thomas/0000-0001-8164-9220; Fombonne, Eric/0000-0002-8605-3538; Bolton, Patrick/0000-0002-5270-6262; Bailey, Anthony/0000-0003-4257-972X; Toma, Claudio/0000-0003-3901-7507; Paterson, Andrew/0000-0002-9169-118X; Girao Meireles de Sousa, Ines/0000-0001-6983-8870; Stodgell, Christopher/0000-0002-1666-5299; Wijsman, Ellen/0000-0002-2725-6669; Green, Jonathan/0000-0002-0143-181X; Scherer, Stephen /0000-0002-8326-1999; Sutcliffe, James/0000-0001-5200-6007; Bartlett, Christopher/0000-0001-7837-6348; Monaco, Anthony/0000-0001-7480-3197; Pickles, Andrew/0000-0003-1283-0346; FU Fondazione Telethon NR 50 TC 821 Z9 845 U1 16 U2 115 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD MAR PY 2007 VL 39 IS 3 BP 319 EP 328 DI 10.1038/ng1985 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA 140CK UT WOS:000244480000013 ER PT J AU Thomas, RK Baker, AC DeBiasi, RM Winckler, W LaFramboise, T Lin, WM Wang, M Feng, W Zander, T MacConnaill, LE Lee, JC Nicoletti, R Hatton, C Goyette, M Girard, L Majmudar, K Ziaugra, L Wong, KK Gabriel, S Beroukhim, R Peyton, M Barretina, J Dutt, A Emery, C Greulich, H Shah, K Sasaki, H Gazdar, A Minna, J Armstrong, SA Mellinghoff, IK Hodi, FS Dranoff, G Mischel, PS Cloughesy, TF Nelson, SF Liau, LM Mertz, K Rubin, MA Moch, H Loda, M Catalona, W Fletcher, J Signoretti, S Kaye, F Anderson, KC Demetri, GD Dummer, R Wagner, S Herlyn, M Sellers, WR Meyerson, M Garraway, LA AF Thomas, Roman K. Baker, Alissa C. DeBiasi, Ralph M. Winckler, Wendy LaFramboise, Thomas Lin, William M. Wang, Meng Feng, Whei Zander, Thomas MacConnaill, Laura E. Lee, Jeffrey C. Nicoletti, Rick Hatton, Charlie Goyette, Mary Girard, Luc Majmudar, Kuntal Ziaugra, Liuda Wong, Kwok-Kin Gabriel, Stacey Beroukhim, Rameen Peyton, Michael Barretina, Jordi Dutt, Amit Emery, Caroline Greulich, Heidi Shah, Kinjal Sasaki, Hidefumi Gazdar, Adi Minna, John Armstrong, Scott A. Mellinghoff, Ingo K. Hodi, F. Stephen Dranoff, Glenn Mischel, Paul S. Cloughesy, Tim F. Nelson, Stan F. Liau, Linda M. Mertz, Kirsten Rubin, Mark A. Moch, Holger Loda, Massimo Catalona, William Fletcher, Jonathan Signoretti, Sabina Kaye, Frederic Anderson, Kenneth C. Demetri, George D. Dummer, Reinhard Wagner, Stephan Herlyn, Meenhard Sellers, William R. Meyerson, Matthew Garraway, Levi A. TI High-throughput oncogene mutation profiling in human cancer SO NATURE GENETICS LA English DT Article ID GASTROINTESTINAL STROMAL TUMORS; TYROSINE KINASE JAK2; OF-FUNCTION MUTATION; MYELOPROLIFERATIVE DISORDERS; ACTIVATING MUTATIONS; LUNG ADENOCARCINOMA; POLYCYTHEMIA-VERA; GENE; SENSITIVITY; GEFITINIB AB Systematic efforts are underway to decipher the genetic changes associated with tumor initiation and progression(1,2). However, widespread clinical application of this information is hampered by an inability to identify critical genetic events across the spectrum of human tumors with adequate sensitivity and scalability. Here, we have adapted high-throughput genotyping to query 238 known oncogene mutations across 1,000 human tumor samples. This approach established robust mutation distributions spanning 17 cancer types. Of 17 oncogenes analyzed, we found 14 to be mutated at least once, and 298 (30%) samples carried at least one mutation. Moreover, we identified previously unrecognized oncogene mutations in several tumor types and observed an unexpectedly high number of co-occurring mutations. These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. MIT, Broad Inst, Cambridge, MA 02142 USA. Harvard Univ, Broad Inst, Cambridge, MA 02142 USA. Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA. Nagoya City Univ, Sch Med, Dept Surg 2, Nagoya, Aichi 4678601, Japan. Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA. Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA. Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol & Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60637 USA. NCI, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA. USN, Natl Med Ctr, Bethesda, MD 20084 USA. Dana Farber Canc Inst, Ludwig Ctr Canc Res, Boston, MA 02115 USA. Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland. Med Univ Vienna, Austrian Acad Sci, Dept Dermatol, Div Immunol Allergy & Infect Dis, A-1090 Vienna, Austria. Austrian Acad Sci, Ctr Mol Med, A-1090 Vienna, Austria. Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA. Novartis Inst BioMed Res, Cambridge, MA 02139 USA. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Melanoma Program Med Oncol, Boston, MA 02115 USA. Max Planck Soc, Max Planck Inst Neurol Res, Klaus Joachim Zulch Labs, D-50931 Cologne, Germany. Univ Cologne, Fac Med, D-50931 Cologne, Germany. Univ Cologne, Ctr Integrated Oncol, D-50931 Cologne, Germany. Univ Cologne, Dept Internal Med 1, D-50931 Cologne, Germany. RP Garraway, LA (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM levi_garraway@dfci.harvard.edu RI Peyton, Michael/A-8728-2008; Nelson, Stanley/D-4771-2009; kaye, frederic/E-2437-2011; Meyerson, Matthew/E-7123-2012; Dutt, Amit/I-1911-2013; OI Dutt, Amit/0000-0002-1119-4774; Wagner, Stephan/0000-0003-4941-7029; Rubin, Mark/0000-0002-8321-9950; wong, kwok kin/0000-0001-6323-235X FU NCI NIH HHS [P50 CA070907, P50CA70907] NR 27 TC 616 Z9 633 U1 7 U2 25 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD MAR PY 2007 VL 39 IS 3 BP 347 EP 351 DI 10.1038/ng1975 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA 140CK UT WOS:000244480000016 PM 17293865 ER PT J AU Chen, TP Hevi, S Gay, F Tsujimoto, N He, T Zhang, BL Ueda, Y Li, E AF Chen, Taiping Hevi, Sarah Gay, Frederique Tsujimoto, Naomi He, Timothy Zhang, Bailin Ueda, Yoshihide Li, En TI Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells SO NATURE GENETICS LA English DT Article ID EMBRYONIC STEM-CELLS; METHYLATION PATTERNS; MAMMALIAN-CELLS; CPG METHYLATION; DNA; P53; PHOSPHORYLATION; EXPRESSION; COOPERATE; DAMAGE AB Studies have shown that DNA (cytosine-5-)-methyltransferase 1 (DNMT1) is the principal enzyme responsible for maintaining CpG methylation and is required for embryonic development and survival of somatic cells in mice(1-3). The role of DNMT1 in human cancer cells, however, remains highly controversial(4-7). Using homologous recombination, here we have generated a DNMT1 conditional allele in the human colorectal carcinoma cell line HCT116 in which several exons encoding the catalytic domain are flanked by loxP sites. Cre recombinase-mediated disruption of this allele results in hemimethylation of similar to 20% of CpG-CpG dyads in the genome, coupled with activation of the G2/M checkpoint, leading to arrest in the G2 phase of the cell cycle. Although cells gradually escape from this arrest, they show severe mitotic defects and undergo cell death either during mitosis or after arresting in a tetraploid G1 state. Our results thus show that DNMT1 is required for faithfully maintaining DNA methylation patterns in human cancer cells and is essential for their proliferation and survival. C1 Novartis Inst Biomed Res, Epigenet Program, Cambridge, MA 02139 USA. Novartis Inst Biomed Res, Cent Technol, Cambridge, MA 02139 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Charlestown, MA 02129 USA. RP Li, E (reprint author), Novartis Inst Biomed Res, Epigenet Program, 250 Massachusette Ave, Cambridge, MA 02139 USA. EM en.li@novartis.com OI Ueda, Yoshihide/0000-0003-3196-3494 NR 23 TC 177 Z9 187 U1 2 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD MAR PY 2007 VL 39 IS 3 BP 391 EP 396 DI 10.1038/ng1982 PG 6 WC Genetics & Heredity SC Genetics & Heredity GA 140CK UT WOS:000244480000023 PM 17322882 ER PT J AU Sharpe, AH Wherry, EJ Ahmed, R Freeman, GJ AF Sharpe, Arlene H. Wherry, E. John Ahmed, Rafi Freeman, Gordon J. TI The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection SO NATURE IMMUNOLOGY LA English DT Review ID T-CELL-ACTIVATION; SYSTEMIC-LUPUS-ERYTHEMATOSUS; HELICOBACTER-PYLORI INFECTION; RESPIRATORY SYNCYTIAL VIRUS; DEATH-1 PD-1 PATHWAY; DENDRITIC CELLS; RHEUMATOID-ARTHRITIS; VIRAL-INFECTION; B7 FAMILY; DISEASE PROGRESSION AB The programmed cell death 1 (PD-1) surface receptor binds to two ligands, PD-L1 and PD-L2. Studies have shown that PD-1-PD-L interactions control the induction and maintenance of peripheral T cell tolerance and indicate a previously unknown function for PD-L1 on nonhematopoietic cells in protecting tissues from autoimmune attack. PD-1 and its ligands have also been exploited by a variety of microorganisms to attenuate antimicrobial immunity and facilitate chronic infection. Here we examine the functions of PD-1 and its ligands in regulating antimicrobial and self-reactive T cell responses and discuss the therapeutic potential of manipulating this pathway. C1 Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Wistar Inst Anat & Biol, Program Immunol, Philadelphia, PA 19104 USA. Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA. Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA. Harvard Univ, Sch Med, Dept Med,Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Sharpe, AH (reprint author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. EM arlene_sharpe@hms.harvard.edu NR 90 TC 580 Z9 624 U1 13 U2 70 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1529-2908 J9 NAT IMMUNOL JI Nat. Immunol. PD MAR PY 2007 VL 8 IS 3 BP 239 EP 245 DI 10.1038/ni1443 PG 7 WC Immunology SC Immunology GA 137EF UT WOS:000244275100009 PM 17304234 ER PT J AU Medarova, Z Pham, W Farrar, C Petkova, V Moore, A AF Medarova, Zdravka Pham, Wellington Farrar, Christian Petkova, Victoria Moore, Anna TI In vivo imaging of siRNA delivery and silencing in tumors SO NATURE MEDICINE LA English DT Article ID SMALL INTERFERING RNA; FAS PROTECTS MICE; GENE-EXPRESSION; EFFICIENT DELIVERY; LENTIVIRAL VECTORS; SEQUENCE; MODEL; INHIBITION; KNOCKDOWN; POTENT AB With the increased potential of RNA interference (RNAi) as a therapeutic strategy, new noninvasive methods for detection of siRNA delivery and silencing are urgently needed. Here we describe the development of dual-purpose probes for in vivo transfer of siRNA and the simultaneous imaging of its accumulation in tumors by high-resolution magnetic resonance imaging (MRI) and near-infrared in vivo optical imaging (NIRF). These probes consisted of magnetic nanoparticles labeled with a near-infrared dye and covalently linked to siRNA molecules specific for model or therapeutic targets. Additionally, these nanoparticles were modified with a membrane translocation peptide for intracellular delivery. We show the feasibility of in vivo tracking of tumor uptake of these probes by MRI and optical imaging in two separate tumor models. We also used proof-of-principle optical imaging to corroborate the efficiency of the silencing process. These studies represent the first step toward the advancement of siRNA delivery and imaging strategies, essential for cancer therapeutic product development and optimization. C1 Harvard Univ, Sch Med, MIT,Athinoula A Martinos Ctr Biomed Imaging, Massachusetts Gen Hosp,Dept Radiol, Boston, MA 02129 USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Moore, A (reprint author), Harvard Univ, Sch Med, MIT,Athinoula A Martinos Ctr Biomed Imaging, Massachusetts Gen Hosp,Dept Radiol, Room 2301,Bldg 149,13th St, Boston, MA 02129 USA. EM amoore@helix.mgh.harvard.edu FU NIA NIH HHS [K25 AG029415-01A1, K25 AG029415, K25 AG029415-02, K25 AG029415-03, K25 AG029415-04, K25 AG029415-05] NR 35 TC 443 Z9 461 U1 11 U2 113 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD MAR PY 2007 VL 13 IS 3 BP 372 EP 377 DI 10.1038/nm1486 PG 6 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 143JC UT WOS:000244715700052 PM 17322898 ER PT J AU Sharma, SV Bell, DW Settleman, J Haber, DA AF Sharma, Sreenath V. Bell, Daphne W. Settleman, Jeffrey Haber, Daniel A. TI Epidermal growth factor receptor mutations in lung cancer SO NATURE REVIEWS CANCER LA English DT Review ID TYROSINE KINASE INHIBITOR; GENE COPY NUMBER; PREVIOUSLY TREATED PATIENTS; SQUAMOUS-CELL CARCINOMA; PHASE-II TRIAL; ACQUIRED-RESISTANCE; EGFR MUTATIONS; IRREVERSIBLE INHIBITOR; ACTIVATING MUTATIONS; SOMATIC MUTATIONS AB The development and clinical application of inhibitors that target the epidermal growth factor receptor ( EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies. We review the results of genetic, biochemical and clinical studies focused on somatic mutations of EGFR that are associated with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors. Understanding the genetic heterogeneity of epithelial tumours and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers. C1 Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Haber, DA (reprint author), Massachusetts Gen Hosp, Ctr Canc, 149 13th St, Charlestown, MA 02129 USA. EM haber@helix.mgh.harvard.edu RI Mendez, Pedro /J-8955-2016; Tang, Amy/L-3226-2016 OI Mendez, Pedro /0000-0001-6713-7907; Tang, Amy/0000-0002-5772-2878 NR 180 TC 1226 Z9 1291 U1 25 U2 223 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-175X J9 NAT REV CANCER JI Nat. Rev. Cancer PD MAR PY 2007 VL 7 IS 3 BP 169 EP 181 DI 10.1038/nrc2088 PG 13 WC Oncology SC Oncology GA 140QK UT WOS:000244520500013 PM 17318210 ER PT J AU Zurn, A Zabel, U Vilardaga, JP Lohse, MJ Hoffmann, C AF Zuern, A. Zabel, U. Vilardaga, J. -P. Lohse, M. J. Hoffmann, C. TI Optical recording of differential conformational changes within the 3(rd) intracellular loop of the alpha 2a-adrenergic receptor for full and partial agonists in living cells SO NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY LA English DT Meeting Abstract CT 48th Spring Meeting of the Deutsche-Gesellschaft-fur Experimentelle-ung-Klinische-Pharmakologie-und-Toxikologie CY MAR 13-15, 2007 CL Mainz, GERMANY SP Deutsch Gesell Experimentelle & Klinische Pharmakol & Toxikol C1 Univ Wurzburg, Inst Pharmakol & Toxikol, D-97078 Wurzburg, Germany. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Endocrine Unit,Div Nephrol, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0028-1298 J9 N-S ARCH PHARMACOL JI Naunyn-Schmiedebergs Arch. Pharmacol. PD MAR PY 2007 VL 375 SU 1 MA 24 BP 16 EP 17 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 161EK UT WOS:000245997000025 ER PT J AU Mertz, KD Setlur, SR Dhanasekaran, SM Demichelis, F Perner, S Tomlins, S Tchinda, J Laxman, B Vessella, RL Beroukhim, R Lee, C Chinnaiyan, AM Rubin, MA AF Mertz, Kirsten D. Setlur, Sunita R. Dhanasekaran, Saravana M. Demichelis, Francesca Perner, Sven Tomlins, Scott Tchinda, Joelle Laxman, Bharathi Vessella, Robert L. Beroukhim, Rameen Lee, Charles Chinnaiyan, Arul M. Rubin, Mark A. TI Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: A new perspective for an old model SO NEOPLASIA LA English DT Article DE TMPRSS2-ERG; prostate cancer; cell line; gene fusion; translocation ID EXPRESSION; AUTOPSY AB Recent studies have established that a significant fraction of prostate cancers harbor a signature gene fusion between the 5' region of androgen-regulated TMPRSS2 and an ETS family transcription factor, most commonly ERG. Studies on the molecular mechanisms and functional consequences of this important chromosomal rearrangement are currently limited to the VCaP cell line derived from a vertebral bone metastasis of a hormone-refractory prostate tumor. Here we report on the NCI-H660 cell line, derived from a metastatic site of an extrapulmonary small cell carcinoma arising from the prostate. NCI-H660 harbors TMPRSS2-ERG fusion with a homozygous intronic deletion between TMPRSS2 and ERG. We demonstrate this by real-time quantitative polymerase chain reaction, a two-stage dual-color interphase fluorescence in situ hybridization ( FISH) assay testing for TMPRSS2 and ERG break-aparts, and single-nucleotide polymorphism oligonucleotide arrays. The deletion is consistent with the common intronic deletion found on chromosome 21q22.2-3 in human prostate cancer samples. We demonstrate the physical juxtaposition of TMPRSS2 and ERG on the DNA level by fiber FISH. The androgen receptor-negative NCI-H660 cell line expresses ERG in an androgen-independent fashion. This in vitro model system has the potential to provide important pathobiologic insights into TMPRSS2-ERG fusion prostate cancer. C1 Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland. Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA. ITC Irst, SRA Div, Bioinformat Grp, Trento, Italy. Univ Ulm, Dept Pathol, Ulm, Germany. Univ Washington, Seattle, WA 98195 USA. Puget Sound VA Med Ctr, Seattle, WA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. MIT, Broad Inst, Cambridge, MA 02139 USA. Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA. RP Rubin, MA (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, 221 Longwood Ave,EBRC 442A, Boston, MA 02115 USA. EM marubin@partners.org OI Rubin, Mark/0000-0002-8321-9950; Demichelis, Francesca/0000-0002-8266-8631 FU NCI NIH HHS [NCI P50 CA090381, NCI P50 CA69568, P50 CA069568, P50 CA090381]; NIA NIH HHS [R01 AG021404, R01AG21404] NR 21 TC 55 Z9 57 U1 0 U2 0 PU NEOPLASIA PRESS PI ANN ARBOR PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648 USA SN 1522-8002 J9 NEOPLASIA JI Neoplasia PD MAR PY 2007 VL 9 IS 3 BP 200 EP U3 DI 10.1593/neo.07103 PG 8 WC Oncology SC Oncology GA 149AP UT WOS:000245119000004 PM 17401460 ER PT J AU Bartzokis, G Tishler, TA Lu, PH Villablanca, P Altshuler, LL Carter, M Huang, D Edwards, N Mintz, J AF Bartzokis, George Tishler, Todd A. Lu, Po H. Villablanca, Pablo Altshuler, Lori L. Carter, Michele Huang, Danny Edwards, Nancy Mintz, Jim TI Brain ferritin iron may influence age- and gender-related risks of neurodegeneration SO NEUROBIOLOGY OF AGING LA English DT Article; Proceedings Paper CT International Conference on Prevention of Dementia of the Alzheimers-Association CY JUN 18-21, 2005 CL Washington, DC SP Alzheimers Assoc DE brain; iron; ferritin; MRI; FDRI; gender; sex; dementia; risk; age; onset; neurodegeneration; hemochromatosis; free radicals; treatment; prevention; myelin; white matter; oligodendrocytes; hippocampus; frontal lobe; protemopathy ID MATTER STRUCTURAL INTEGRITY; HALLERVORDEN-SPATZ-SYNDROME; HEMOCHROMATOSIS GENE HFE; ONSET PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; RAT-BRAIN; IN-VIVO; LEWY BODIES; HEREDITARY HEMOCHROMATOSIS AB Background: Brain iron promotes oxidative damage and protein oligornerization that result in highly prevalent age-related proteinopathies such as Alzheimer's disease (AD), Parkinson's disease (PD), and Dementia with Lewy Bodies (DLB). Men are more likely to develop such diseases at earlier ages than women but brain iron levels increase with age in both genders. We hypothesized that brain iron may influence both the age- and gender-related risks of developing these diseases. Methods: The amount of iron in ferritin molecules (ferritin iron) was measured in vivo with MRI by utilizing the field dependent relaxation rate increase (FDRI) method. Ferritin iron was measured in four subcortical nuclei [caudate (C), putamen (P), globus pallidus (G), thalamus (T)], three white matter regions [frontal lobe (Fwm), genu and splenium of the corpus callosum (Gwm, Swm)] and hippocampus (Hipp) in 165 healthy adults aged 19-82. Results: There was a high correlation (r > 0.99) between published post-mortem brain iron levels and FDRI. There were significant age-related changes in ferritin iron (increases in Hipp, C, P, G, and decreases in Fwm). Women had significantly lower ferritin iron than men in five regions (C, T, Fwm, Gwm, Swm). Conclusions: This is the first demonstration of gender differences in brain ferritin iron levels. It is possible that brain iron accumulation is a risk factor that can be modified. MRI provides the opportunity to assess brain iron levels in vivo and may be useful in targeting individuals or groups for preventive therapeutic interventions. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, Alzheimers Dis Res Ctr, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Lab Neuroimaging, Dept Neurol,Div Brain Mapping, Los Angeles, CA 90095 USA. Greater Los Angeles VA Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Neurosci Interdept Grad Program, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA. RP Bartzokis, G (reprint author), Univ Calif Los Angeles, Alzheimers Dis Res Ctr, 710 Westwood Pl,Room 2-238, Los Angeles, CA 90095 USA. EM gbar@ucla.edu RI Bartzokis, George/K-2409-2013 FU NIA NIH HHS [AG 16570, R01 AG027342]; NIMH NIH HHS [MH066029-01A2, MH51928, MH6357-01A1] NR 123 TC 176 Z9 182 U1 3 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD MAR PY 2007 VL 28 IS 3 BP 414 EP 423 DI 10.1016/j.neurobiolaging.2006.02.005 PG 10 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 137CG UT WOS:000244269800011 PM 16563566 ER PT J AU Gourcerol, G Tache, Y AF Gourcerol, G. Tache, Y. TI Obestatin - a ghrelin-associated peptide that does not hold its promise to suppress food intake and motility SO NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Editorial Material DE food intake; gastric emptying; ghrelin; GPR39; obestatin ID COUPLED RECEPTOR GPR39; GROWTH-HORMONE; ENERGY-BALANCE; BODY-WEIGHT; RODENTS; RATS; SECRETION; MODIFY; LEPTIN; PLAYER AB Ghrelin is a gut peptide well established to induce prokinetic and appetite stimulatory actions. Obestatin is a novel 23-amino acid peptide derived from the processing of the ghrelin gene. The peptide name was in keeping with its initially reported actions to suppress food intake and digestive motility and to antagonize ghrelin's stimulatory effect through interaction with the orphan GPR-39 receptor. However, subsequently, these findings have been questioned because obestatin actions to reduce food intake and to inhibit gastrointestinal (GI) motility in vivo and in vitro have not been reproduced by several groups. Furthermore, while GPR-39 appears to be involved in gut motor functions, convergent reports showed that obestatin is not the cognate ligand for this receptor. In light of recent controversy over the effects of obestatin, the present findings from De Smet et al. provides additional evidence that obestatin does not influence food intake and GI motility in vivo and in vitro. Taken together, existing reports curtail the initial promise that obestatin is a new regulator of appetite and digestive motility. Therefore, it is proposed to rename obestatin as ghrelin-associated peptide. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, CURE Digest Dis Res Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA USA. RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu NR 34 TC 52 Z9 55 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1350-1925 J9 NEUROGASTROENT MOTIL JI Neurogastroenterol. Motil. PD MAR PY 2007 VL 19 IS 3 BP 161 EP 165 DI 10.1111/j.1365-2982.2007.00916.x PG 5 WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences SC Gastroenterology & Hepatology; Neurosciences & Neurology GA 134QJ UT WOS:000244098400001 PM 17300284 ER PT J AU Hillman, EMC Devor, A Bouchard, MB Dunn, AK Krauss, GW Skoch, J Bacskai, BJ Dale, AM Boas, DA AF Hillman, Elizabeth M. C. Devor, Anna Bouchard, Matthew B. Dunn, Andrew K. Krauss, G. W. Skoch, Jesse Bacskai, Brian J. Dale, Anders M. Boas, David A. TI Depth-resolved optical imaging and microscopy of vascular compartment dynamics during somatosensory stimulation SO NEUROIMAGE LA English DT Article ID CEREBRAL BLOOD-VOLUME; RAT FOREPAW STIMULATION; RODENT BARREL CORTEX; LAMINAR SPECIFICITY; BRAIN ACTIVATION; NEURAL ACTIVITY; IN-VIVO; HEMOGLOBIN CONCENTRATION; CEREBROVASCULAR TONE; OXYGENATION CHANGES AB The cortical hemodynamic response to somatosensory stimulus is investigated at the level of individual vascular compartments using both depth-resolved optical imaging and in-vivo two-photon microscopy. We utilize a new imaging and spatiotemporal analysis approach that exploits the different characteristic dynamics of responding arteries, arterioles, capillaries and veins to isolate their three-dimensional spatial extent within the cortex. This spatial delineation is validated using vascular casts. Temporal delineation is supported by in-vivo two-photon microscopy of the temporal dynamics and vascular mechanisms of the arteriolar and venous responses. Using these techniques we have been able to characterize the roles of the different vascular compartments in generating and controlling the hemodynamic response to somatosensory stimulus. We find that changes in arteriolar total hemoglobin concentration agree well with arteriolar dilation dynamics, which in turn correspond closely with changes in venous blood flow. For 4-s stimuli, we see only small changes in venous hemoglobin concentration, and do not detect measurable dilation or ballooning in the veins. Instead, we see significant evidence of capillary hyperemia. We compare our findings to historical observations of the composite hemodynamic response from other modalities including functional magnetic resonance imaging. Implications of our results are discussed with respect to mathematical models of cortical hemodynamics, and to current theories on the mechanisms underlying neurovascular coupling. We also conclude that our spatiotemporal analysis approach is capable of isolating and localizing signals from the capillary bed local to neuronal activation, and holds promise for improving the specificity of other hemodynamic imaging modalities. (c) 2006 Elsevier Inc. All rights reserved. C1 Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. Univ Calif San Diego, La Jolla, CA 92093 USA. Univ Texas, Austin, TX 78712 USA. RP Hillman, EMC (reprint author), Columbia Univ, Dept Biomed Engn, 351L Engn Terrace,1210 Amsterdam Ave, New York, NY 10027 USA. EM eh2245@columbia.edu RI Hillman, Elizabeth/B-9854-2009; Dale, Anders/A-5180-2010; Dunn, Andrew/I-9527-2014; OI Hillman, Elizabeth M. C./0000-0001-5511-1451 FU NIBIB NIH HHS [R01 EB000768, R01 EB000790, R01EB000768, R01EB000790]; NINDS NIH HHS [R01 NS051188, K25 NS041291, K25NS41291, R01NS05118, R21 NS053684, R21NS053684] NR 82 TC 155 Z9 155 U1 3 U2 16 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD MAR PY 2007 VL 35 IS 1 BP 89 EP 104 DI 10.1016/j.neuroimage.2006.11.032 PG 16 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 145VN UT WOS:000244894000010 PM 17222567 ER PT J AU Wright, CI Feczko, E Dickerson, B Williams, D AF Wright, Christopher I. Feczko, Eric Dickerson, Bradford Williams, Danielle TI Neuroanatomical correlates of personality in the elderly SO NEUROIMAGE LA English DT Article DE amygdala; emotion; aging; magnetic resonance imaging; personality; prefrontal cortex ID DORSOLATERAL PREFRONTAL CORTEX; HUMAN CEREBRAL-CORTEX; PRIMARY-CARE PATIENTS; LATE-LIFE DEPRESSION; 5-FACTOR MODEL; INDIVIDUAL-DIFFERENCES; BEHAVIORAL-INHIBITION; GERIATRIC DEPRESSION; ORBITOFRONTAL CORTEX; EMOTIONAL EXPERIENCE AB Extraversion and neuroticism are two important and frequently studied dimensions of human personality. They describe individual differences in emotional responding that are quite stable across the adult lifespan. Neuroimaging research has begun to provide evidence that neuroticism and extraversion have specific neuroanatomical correlates within the cerebral cortex and amygdala of young adults. However, these brain areas undergo alterations in size with aging, which may influence the nature of these personality factor-brain structure associations in the elderly. One study in the elderly demonstrated associations between perisylvian cortex structure and measures of self transcendence [Kaasinen, V., Maguire, R.P., Kurki, T., Bruck, A., Rinne, J.O., 2005. Mapping brain structure and personality in late adulthood. Neurolmage 24, 315-322], but the neuroanatomical correlates of extraversion and neuroticism, or other measures of the Five Factor Model of personality have not been explored. The purpose of the present study was to investigate the structural correlates of neuroticism and extraversion in healthy elderly subjects (n = 29) using neuroanatomic measures of the cerebral cortex and amygdala. We observed that the thickness of specific lateral prefrontal cortex (PFC) regions, but not amygdala volume, correlates with measures of extraversion and neuroticism. The results suggest differences in the regional neuroanatomic correlates of specific personality traits with aging. We speculate that this relates to the influences of age-related structural changes in the PFC. (c) 2006 Elsevier Inc. All rights reserved. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Psychiat Neuroimaging Res Program,Lab Aging & Emo, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gerontol Res Unit, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. Brigham & Womens Hosp, Dept Neurol, Div Cognit & Behav Neurol, Boston, MA 02115 USA. RP Wright, CI (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Psychiat Neuroimaging Res Program,Lab Aging & Emo, 13th St,Bldg 149,CNY-2628, Charlestown, MA 02129 USA. EM ciwright@partners.org FU NCRR NIH HHS [P41-RR14075, P41 RR014075]; NIA NIH HHS [R01 AG030311, R01AG030311, R01 AG030311-01]; NIMH NIH HHS [K23 MH064806-05, K23 MH064806, K23MH64806] NR 97 TC 56 Z9 56 U1 2 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD MAR PY 2007 VL 35 IS 1 BP 263 EP 272 DI 10.1016/j.neuroimage.2006.11.039 PG 10 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 145VN UT WOS:000244894000026 PM 17229578 ER PT J AU Han, SD Nestor, PG Hale-Spencer, M Cohen, A Niznikiewicz, M McCarley, RW Wible, CG AF Han, S. Duke Nestor, Paul G. Hale-Spencer, Magdalena Cohen, Adam Niznikiewicz, Margaret McCarley, Robert W. Wible, Cynthia G. TI Functional neuroimaging of word priming in males with chronic schizophrenia SO NEUROIMAGE LA English DT Article ID AUDITORY HALLUCINATIONS; THOUGHT-DISORDER; SPREADING ACTIVATION; SPEECH-PERCEPTION; SEMANTIC NETWORK; BRAIN; FMRI; ABNORMALITIES; NEUROANATOMY; VOICES AB Word-priming studies have suggested that the associative disturbance of schizophrenia may reflect aberrant spread of activation through the lexicon of the brain. To explore this, we examined lexical activation using a semantic word-priming paradigm coupled with functional magnetic resonance imaging (fMRI). We also wanted to determine whether brain activation to this paradigm correlated with relevant clinical symptom measures. In addition to completing clinical symptom measures, twelve chronic patients and twelve demographically matched control subjects completed a lexical-decision semantic-priming paradigm developed as an event-related BOLD fMRI task. This paradigm consisted of words that differed in connectivity. Words with many connections between shared semantic associates are considered high in connectivity and produce the largest behavioral semantic priming effects in control subjects, while words with few connections between shared semantic associates are considered low in connectivity and produce a relatively smaller amount of semantic priming. In fMRI, a respective step-wise increase in activation from high connectivity to low connectivity to unrelated word pairs was expected for normal subjects. Controls showed the expected pattern of activation to word connectivity; however, patients showed a less robust pattern of activation to word connectivity. Furthermore, this aberrant response correlated with measures of Auditory Hallucinations, Distractive Speech, Illogicality, and Incoherence. The patients did not display left frontal and temporal activation as a function of the degree of word connectivity as seen in healthy controls. This may reflect a disease-related disturbance in functional connectivity of lexical activation, which in turn may be associated with clinical symptomatology. (c) 2006 Elsevier Inc. All rights reserved. C1 Loyola Univ, Dept Psychol, Chicago, IL 60626 USA. VA Boston Healthcare Syst, Brockton, MA USA. Univ Massachusetts, Dept Psychol, Boston, MA 02125 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Surg Planning Lab, Boston, MA USA. Harvard Univ, Sch Med, Brockton VA Med Ctr, Dept Psychiat, Brockton, MA 02401 USA. RP Han, SD (reprint author), Loyola Univ, Dept Psychol, 6525 N Sheridan Rd, Chicago, IL 60626 USA. EM dhan2@luc.edu RI McCarley, Robert/N-5562-2014; OI McCarley, Robert/0000-0001-5705-7495; Cohen, Adam/0000-0003-2719-3351 FU NIMH NIH HHS [1 R01 MH067080-01A2, R01 MH067080, R01 MH067080-01A2] NR 63 TC 29 Z9 29 U1 1 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD MAR PY 2007 VL 35 IS 1 BP 273 EP 282 DI 10.1016/j.neuroimage.2006.11.029 PG 10 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 145VN UT WOS:000244894000027 PM 17215145 ER PT J AU Singhal, AB AF Singhal, Aneesh B. TI A review of oxygen therapy in ischemic stroke SO NEUROLOGICAL RESEARCH LA English DT Review DE hyperbaric oxygen therapy; normobaric oxygen therapy; neuroprotection; acute stroke therapy; hypoxic-ischemic encephalopathy ID FOCAL CEREBRAL-ISCHEMIA; FREE-RADICAL PRODUCTION; GLOBAL BRAIN ISCHEMIA; SPINAL-CORD ISCHEMIA; HYPERBARIC-OXYGEN; RAT MODEL; CARDIAC-ARREST; NORMOBARIC HYPEROXIA; BLOOD-FLOW; ARTERY OCCLUSION AB Neuroprotective drugs have so far failed clinical trials, at high cost, and intravenous tissue plasminogen activator (i.v. tPA) remains the only FDA- approved acute stroke therapy. Hyperoxia, acting via multiple direct and indirect mechanisms, may be a powerful neuroprotective strategy to salvage acutely ischemic brain tissue and extend the time window for acute stroke treatment. Of the available oxygen delivery methods, hyperbaric oxygen therapy (HBO) appears to be the most potent, while even normobaric oxygen therapy (NBO) may be effective if started promptly after stroke onset. HBO has so far failed to show efficacy in three clinical trials. The failure of these trials is probably attributable to factors such as delayed time to therapy, inadequate sample size and use of excessive chamber pressures. Previous trials did not assess long-term benefit in patients with tissue reperfusion. In this modern era of stroke thrombolysis and advanced neuroimaging, oxygen therapy may have renewed significance. If applied within the first few hours after stroke onset or in patients with imaging evidence of salvageable brain tissue, oxygen therapy could be used to 'buy time' for the administration of thrombolytic or neuroprotective drugs. This article reviews the history and current rationale for using oxygen therapy in stroke, the mechanisms of action of HBO and the results of animal and human studies of hyperoxia in cerebrovascular diseases. C1 Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Singhal, AB (reprint author), Massachusetts Gen Hosp, Dept Neurol, 175 Cambridge St,Suite 300, Boston, MA 02114 USA. EM asinghal@partners.org NR 114 TC 67 Z9 77 U1 0 U2 15 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 0161-6412 J9 NEUROL RES JI Neurol. Res. PD MAR PY 2007 VL 29 IS 2 BP 173 EP 183 DI 10.1179/016164107X181815 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 165JI UT WOS:000246301000009 PM 17439702 ER PT J AU Zhu, ZT Munhall, AC Johnson, SW AF Zhu, Zi-Tao Munhall, Adam C. Johnson, Steven W. TI Tyramine excites rat subthalamic neurons in vitro by a dopamine-dependent mechanism SO NEUROPHARMACOLOGY LA English DT Article; Proceedings Paper CT 34th Annual Meeting of the Society-for-Neuroscience CY OCT 23-27, 2004 CL San Diego, CA SP Soc Neurosci DE tyramine; dopamine; subthalamic neurons; inward current; synaptic current; subthalamic nucleus; brain slices; trace amine; electrophysiology ID CENTRAL-NERVOUS-SYSTEM; TRACE AMINES; SUBSTANTIA-NIGRA; NUCLEUS NEURONS; PARKINSONS-DISEASE; BASAL GANGLIA; AMPHETAMINE; RECEPTORS; RELEASE; BRAIN AB Tyramine. an endogenous ligand for mammalian trace amin e-associated receptors, may act as a neuromodulator that regulates neuronal activity in basal ganglia. Using whole-cell patch recordings of subthalamic nucleus (STN) neurons in rat brain slices, we found that bath application of tyramine evoked an inward current in voltage-clamp in over 60% of all STN neurons. The inward current induced by tyramine was mimicked by the D-2-like dopamine receptor agonist quinpirole, but was only partially blocked by the D-2-like receptor antagonist sulpiride. In contrast, the D-1-like receptor agonist SKF38393 evoked no current in STN neurons. Inward current evoked by tyramine was significantly reduced by the catecholamine uptake inhibitor nomifensine, and by exhausting catecholamines in the brain via pretreatment with reserpine. Tyramine also reduced the amplitude of GABA(A) receptor-mediated IPSCs that were evoked by focal electrical stimulation of the slice. Inhibition of IPSCs by tyramine was mimicked by quinpirole and was blocked by sulpiride but not by SCH23390, a D-1 receptor antagonist. Moreover, tyramine-induced inhibition of IPSCs was reduced in slices pretreated with reserpine, and this inhibition could be restored by briefly superfusing the slice with dopamine. These results suggest that tyramine acts as an indirect dopamine agonist in the STN. Although inhibition of IPSCs is mediated by D-2-like receptors, the dopamine-dependent inward currents evoked by tyramine do not fit a typical dopamine receptor pharmacological profile. (c) 2007 Elsevier Ltd. All rights reserved. C1 Portland VA Med Ctr, R&D 61, Dept Neurol Res, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. RP Johnson, SW (reprint author), Portland VA Med Ctr, R&D 61, Dept Neurol Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM johnsost@ohsu.edu FU NINDS NIH HHS [NS38715, R01 NS038715] NR 40 TC 8 Z9 8 U1 2 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3908 J9 NEUROPHARMACOLOGY JI Neuropharmacology PD MAR PY 2007 VL 52 IS 4 BP 1169 EP 1178 DI 10.1016/j.neuropharm.2006.12.005 PG 10 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 153ZQ UT WOS:000245477000012 PM 17291545 ER PT J AU Albert, M Blacker, D Moss, MB Tanzi, R McArdle, JJ AF Albert, Marilyn Blacker, Deborah Moss, Mark B. Tanzi, Rudolph McArdle, John J. TI Longitudinal change in cognitive performance among individuals with mild cognitive impairment SO NEUROPSYCHOLOGY LA English DT Article DE longitudinal cognition; prodromal AD; MCI; memory; executive function ID PRECLINICAL ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; INTELLECTUAL ABILITIES; NATURAL-HISTORY; VERBAL MEMORY; OLDER PERSONS; DECLINE; DEMENTIA; PREDICTION; ONSET AB The authors used mixed-effects growth models to examine longitudinal change in neuropsychological performance over a 4-year period among 197 individuals who were either normal or had mild cognitive impairment (MCI) at baseline. At follow-up, the participants were divided into 4 groups: (a) controls: participants who were normal at both baseline and follow-up (n = 33), (b) stables: participants with MCI whose Clinical Dementia Rating-Sum of Boxes (CDR-SB) score did not differ between the first and last evaluations (n = 22), (c) decliners: participants with MCI whose CDR-SB score declined between the first and last evaluations (n = 95), and (d) converters: participants who received a clinical diagnosis of Alzheimer's disease during the follow-up period (n = 47). Only the Episodic Memory factor showed a significantly greater rate of decline over the follow-up period among the converters. Two other factors were significantly lower in converters at baseline in comparison with other groups (the executive function factor and the general knowledge factor), but the rate of decline over time did not differ. Individuals with an APOE epsilon 4 allele scored lower on the episodic memory and executive function factors at baseline. C1 Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21218 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA. Boston Univ, Dept Anat & Neurobiol, Boston, MA 02215 USA. Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA. RP Albert, M (reprint author), 1620 McElderry St,Reed Hall E 2, Baltimore, MD 21205 USA. EM malbert9@jhmi.edu OI Moss, Mark/0000-0001-7330-3836 NR 66 TC 93 Z9 93 U1 3 U2 18 PU AMER PSYCHOLOGICAL ASSOC/EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0894-4105 J9 NEUROPSYCHOLOGY JI Neuropsychology PD MAR PY 2007 VL 21 IS 2 BP 158 EP 169 DI 10.1037/0894-4105.21.2.158 PG 12 WC Psychology, Clinical; Neurosciences; Psychology SC Psychology; Neurosciences & Neurology GA 146YJ UT WOS:000244970300002 PM 17402816 ER PT J AU Ecker, JL Frigoletto, FD AF Ecker, Jeffrey L. Frigoletto, Fredric D., Jr. TI Cesarean delivery and the risk-benefit calculus SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID SECTION C1 Harvard Univ, Sch Med, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Ecker, JL (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 5 TC 86 Z9 92 U1 0 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 1 PY 2007 VL 356 IS 9 BP 885 EP 888 DI 10.1056/NEJMp068290 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 140HV UT WOS:000244496400001 PM 17329693 ER PT J AU Buerhaus, PI Donelan, K Ulrich, BT DesRoches, C Dittus, R AF Buerhaus, Peter I. Donelan, Karen Ulrich, Beth T. DesRoches, Catherine Dittus, Robert TI Trends in the experiences of hospital-employed registered nurses: Results from the three national surveys SO NURSING ECONOMICS LA English DT Article ID WORKFORCE AB In an analysis of surveys conducted in 2002, 2004, and 2006, RN responses reveal perceived trends in aspects of the labor shortage and its effect on the work environment, quality of care, and their own professional outlook. The 2006 data revealed the highest rate (93%) of RNs perceiving that overall demand for nurses is less than supply; however, these perceptions were less severe in their local communities than was reported in 2004. While low wages rank highest as a causative factor of the shortage, the percent of RN agreement with this cause has dropped considerably since 2002. The 2006 survey data includes a new assessment of how RNs spend their time at work and if this time is appropriate including functions like direct care, documentation, and time with families. Only 25% of RNs rated "Magnet-like" characteristics of their hospital highly such as aspects of autonomy, opportunity for professional advancement, and recognition. While improvements are noted since 2004, RNs still perceive the shortage as causing delays in care, patient complaints, as well as interfering with staff communication. While improvements in some aspects of RN perceptions have improved in the short-term, the absence of a coordinated national strategy will make significant and sustained improvement in these issues challenging. C1 Vanderbilt Univ, Med Ctr, Inst Med & Publ Hlth, Ctr Interdisciplinary Hlth Workforce Studies, Nashville, TN 37240 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Gannett Healthcare Grp, Pearland, TX USA. Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. VA Tennessee Valley Healthcare Syst, Geriatr Res Educ & Clin Ctr, Nashville, TN USA. RP Buerhaus, PI (reprint author), Vanderbilt Univ, Med Ctr, Inst Med & Publ Hlth, Ctr Interdisciplinary Hlth Workforce Studies, 221 Kirkland Hall, Nashville, TN 37240 USA. NR 4 TC 25 Z9 25 U1 0 U2 4 PU JANNETTI PUBLICATIONS, INC PI PITMAN PA EAST HOLLY AVENUE, BOX 56, PITMAN, NJ 08071-0056 USA SN 0746-1739 J9 NURS ECON JI Nurs. Econ. PD MAR-APR PY 2007 VL 25 IS 2 BP 69 EP 79 PG 11 WC Nursing SC Nursing GA 159ET UT WOS:000245848900003 PM 17500491 ER PT J AU Cordero-Coma, M Anzaar, F Sobrin, L Foster, CS AF Cordero-Coma, Miguel Anzaar, Fahd Sobrin, Lucia Foster, C. Stephen TI Systemic immunomodulatory therapy in severe dry eye secondary to inflammation SO OCULAR IMMUNOLOGY AND INFLAMMATION LA English DT Article DE dry eye disease; immunosuppressive agents; keratitis sicca; Sjogren's syndrome; ocular surface inflammation; lacrimal gland ID VERSUS-HOST-DISEASE; SJOGRENS-SYNDROME; AUTOANTIBODIES; PATHOGENESIS; PREVALENCE; FK506; WOMEN AB Purpose: To report four patients with unusually severe acute keratitis sicca secondary to lacrimal tissue and ocular surface inflammation who eventually required systemic immunosuppressive therapy. Methods: Observational case series of four patients with extremely severe acute dry eye syndrome who were profoundly disabled by pain and photophobla (to the extent of staying in dark rooms) despite aggressive conventional therapy. Clinical data including visual acuities, other treatments administered for dry eye, systemic medical conditions, Schirmer and rose bcngal staining results, degree of conjunctival injection, and medications were recorded. All four patients were treated with systemic immunomodulatory therapy. Results: All four patients were female with a mean age at presentation of 40 years (range 22-58 years), and all had systemic autoimmune diseases: systemic lupus erythematosus (SLE) and Sjogren's syndrome (n = 2), Sjogren's syndrome (n = 1), rheumatoid arthritis (RA) and psoriasis (n = 1). Schirmer test values at onset ranged from 0 to 2 mm. All patients had failed aggressive lubrication, topical cyclosporine, lid care, and punctual plugs. In two patients, serum tears and hyphrecation punctal occlusion were tried without success. Various systemic immunosuppressive agents were used to control inflammation of the lacrimal glands: methotrexate and cyclosporine A (patient 1), cyclosporine A (patient 2), prednisone (patient 3), and methotrexate and infliximab (patient 4). Treatment with systemic immunomodulatory agents resulted in resolution of the acute inflammatory assault on the lacrimal glands and control of signs and symptoms of keratoconjunctivitis sicca in all four patients, and visual acuities improved in all of them. Post-treatment Schirmer values ranged from 7 to 10 mm. Conclusion: Systemic immunosuppressive agents may be required in the treatment of recalcitrant primary and secondary Sjogren's syndrome caused by systemic autolmmune conditions. We show that systemic immunomodulatory therapy leads to significantly improved tear production and resolution of the keratoconjunctivitis in these rare but severe cases. C1 Massachusetts Eye Res & Surg Inst, Cambridge, MA 02142 USA. Hosp Leon, Dept Ophthalmol, Leon, Spain. Harvard Univ, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Ocular Immunol & Uveitis Fdn, Cambridge, MA USA. RP Foster, CS (reprint author), Massachusetts Eye Res & Surg Inst, 8th Floor,5 Cambridge Ctr, Cambridge, MA 02142 USA. EM fosters@uveitis.org NR 19 TC 22 Z9 24 U1 2 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0927-3948 J9 OCUL IMMUNOL INFLAMM JI Ocul. Immunol. Inflamm. PD MAR-APR PY 2007 VL 15 IS 2 BP 99 EP 104 DI 10.1080/09273940701299354 PG 6 WC Ophthalmology SC Ophthalmology GA 174UC UT WOS:000246967300006 PM 17558834 ER PT J AU Wang, F Liu, R Lee, SW Sloss, CM Couget, J Cusack, JC AF Wang, F. Liu, R. Lee, S. W. Sloss, C. M. Couget, J. Cusack, J. C. TI Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance SO ONCOGENE LA English DT Article DE HB-EGF; EGFR; NF-kappa B; c-fos; chemotherapy resistance ID NF-KAPPA-B; HB-EGF; PROHB-EGF; METALLOPROTEINASE-CLEAVAGE; CELL-PROLIFERATION; SIGNALING CASCADES; CARCINOMA-CELLS; INHIBITION; CHEMORESISTANCE; ACTIVATION AB We have shown that one of the principle mechanisms of chemotherapy resistance involves the activation of nuclear factor kappa-B (NF-kappa B). In an effort to identify NF- kappa-B-regulated chemotherapy response genes, we performed a microarray assay and observed that heparin-binding EGF-like growth factor (HB-EGF) was significantly upregulated by SN38 (a strong inducer of NF-kappa B activity) in colon cancer cells. Further studies revealed that HB-EGF was rapidly induced following a variety of chemotherapy treatments. Using RNA interference, we demonstrated that the chemotherapy-induced HB-EGF was largely dependent on activator protein-1 (AP-1) and NF-kappa B activation. Constitutive HB-EGF expression rescued AP-1/NF-kappa B small interfering RNA (siRNA) cells from chemotherapy-induced apoptosis. Meanwhile, we found that the enzymatic shedding of HB-EGF was also regulated by chemotherapy treatment, resulting in the elevated release of soluble HB-EGF from the cellular membrane. Induction of HB-EGF expression and ectodomain shedding synergistically led to robust epidermal growth factor receptor (EGFR) phosphorylation, whereas inhibition of HB-EGF expression by use of the HB-EGF inhibitor (CRM197) or siRNA resulted in the suppression of chemotherapyinduced EGFR phosphorylation. These results suggest that the chemotherapy-induced EGFR activation is regulated by HB-EGF. Finally, we demonstrated that overexpression of HB-EGF led to apoptotic resistance to chemotherapy, whereas suppression of HB-EGF expression by siRNA resulted in a dramatic increase in cell death. In summary, our study suggests that chemotherapy-induced HB-EGF activation represents a critical mechanism of inducible chemotherapy resistance. Therefore, therapeutic intervention aimed at inhibiting HB-EGF activity may be useful in cancer prevention and treatments. C1 Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Boston, MA 02114 USA. Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA. RP Cusack, JC (reprint author), Massachusetts Gen Hosp, Div Surg Oncol, 55 Fruit St,7th Floor, Boston, MA 02114 USA. EM jcusack@partners.org FU NCI NIH HHS [CA77278-01A1, CA98871-01] NR 26 TC 58 Z9 60 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 J9 ONCOGENE JI Oncogene PD MAR PY 2007 VL 26 IS 14 BP 2006 EP 2016 DI 10.1038/sj.onc.1209999 PG 11 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 151TJ UT WOS:000245313400003 PM 17001310 ER PT J AU Houldin, AD AF Houldin, Arlene D. TI A qualitative study of caregivers' experiences with newly diagnosed advanced colorectal cancer SO ONCOLOGY NURSING FORUM LA English DT Article ID COLON-CANCER; ADJUSTMENT; DEPRESSION; COUPLES; BURDEN AB Purpose/Objectives: To report on a descriptive, qualitative study of 14 caregivers of patients newly diagnosed with advanced colorectal cancer. Research Approach: Qualitative. Setting: One urban ambulatory cancer center in the northeastern United States. Participants: 14 identified caregivers of patients newly diagnosed with stage III or IV colorectal cancer. Methodologic Approach: Sernistructured interviews were taped recorded. Interviewers asked participants to describe their experiences caring for a loved one with colorectal cancer. Thematic content analysis with inductive coding was used to code the transcribed interview data. Throughout the data-coding process, emics in each category were compared within and between categories to maximize the fit of participants' data. Categories were reviewed in a final stage of analysis and further organized into domains from which the core category was derived. Main Research Variables: Caregiver experiences of living with a person with colorectal cancer, effect on daily living, coping strategies used, and effect on children. Findings: The coded interview data yielded three domains: Experiencing Total Disruption of My Life, Staying Positive, and Attempting to Keep Family and Children's Routines as Normal as Possible. The core category that explained study participants' caregiving experiences was "balancing caregiving activities and disruptions while dealing positively with daily demands and personal impact." Conclusions: The dominant experiences of the participants focused on coming to terms with the disease's disruption in their lives, attempting to deal positively with the effect of the disease, and maintaining normalcy in family life. Interpretation: Targeted assessment of caregivers' needs is important in the three dimensions of the study domains. Clinicians who work with caregivers of patients with cancer should offer direct support because caregivers cope with the care of their loved one and struggle with their own distress and with maintaining normal family life. Findings suggest the importance of offering psychosocial support to caregivers and providing guidance to caregivers for support of their children and families. C1 Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Palliat Care Serv, Philadelphia, PA USA. RP Houldin, AD (reprint author), Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. EM houldin@nursing.upenn.edu NR 23 TC 32 Z9 34 U1 6 U2 10 PU ONCOLOGY NURSING SOCIETY PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAR PY 2007 VL 34 IS 2 BP 323 EP 330 DI 10.1188/07.ONF.323-330 PG 8 WC Oncology; Nursing SC Oncology; Nursing GA 146QP UT WOS:000244949700022 PM 17573296 ER PT J AU Stamatis, D Brown, S AF Stamatis, Donna Brown, Sheila TI Development of a teaching tool for patients receiving brachytherapy radiation and non-radiation nurses. SO ONCOLOGY NURSING FORUM LA English DT Meeting Abstract C1 Mass Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ONCOLOGY NURSING SOCIETY PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAR PY 2007 VL 34 IS 2 MA 1881 BP 476 EP 476 PG 1 WC Oncology; Nursing SC Oncology; Nursing GA 146QP UT WOS:000244949700046 ER PT J AU Stanghellini, E Carnie, M Gadkari, M Mahan, N Benedict, C Leonard, C AF Stanghellini, Escel Carnie, Martie Gadkari, Mrinalini Mahan, Nancy Benedict, Catherine Leonard, Christine TI An evidence-based approach to reducing nighttime noise on oncology inpatient units. SO ONCOLOGY NURSING FORUM LA English DT Meeting Abstract C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Brigham & Womens Canc Ctr, Patient & Family Advisory Council, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ONCOLOGY NURSING SOCIETY PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAR PY 2007 VL 34 IS 2 MA 1953 BP 484 EP 484 PG 1 WC Oncology; Nursing SC Oncology; Nursing GA 146QP UT WOS:000244949700071 ER PT J AU Stanghellini, E Carnie, M Gadkari, M Tatarouns, L McDonald, S Deary, J AF Stanghellini, Escel Carnie, Martie Gadkari, Mrinalini Tatarouns, Lela McDonald, Susan Deary, Joan TI An innovative approach for decreasing the incidence of falls in oncology patients: The patient/family falls prevention video. SO ONCOLOGY NURSING FORUM LA English DT Meeting Abstract C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Brigham & Womens Canc Ctr, Volunteer Patient & Family Advisory Council, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ONCOLOGY NURSING SOCIETY PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAR PY 2007 VL 34 IS 2 MA 1952 BP 484 EP 484 PG 1 WC Oncology; Nursing SC Oncology; Nursing GA 146QP UT WOS:000244949700070 ER PT J AU Pedulla, L Fonteyn, M McDonough, K AF Pedulla, Lillian Fonteyn, Marsha McDonough, Katherine TI Addressing the challenge of increasing frontline oncology nurses' involvement in committee work. SO ONCOLOGY NURSING FORUM LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. McDonough Grp, Norwood, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ONCOLOGY NURSING SOCIETY PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAR PY 2007 VL 34 IS 2 MA 1990 BP 489 EP 489 PG 1 WC Oncology; Nursing SC Oncology; Nursing GA 146QP UT WOS:000244949700085 ER PT J AU Fonteyn, M Healey, M Suzuki, N Bauer-Wu, S AF Fonteyn, Marsha Healey, Martha Suzuki, Naoe Bauer-Wu, Susan TI The clinical scholar: Formal recognition of nurse clinicians' collaborative activities. SO ONCOLOGY NURSING FORUM LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ONCOLOGY NURSING SOCIETY PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAR PY 2007 VL 34 IS 2 MA 2016 BP 494 EP 494 PG 1 WC Oncology; Nursing SC Oncology; Nursing GA 146QP UT WOS:000244949700099 ER PT J AU Fonteyn, M Bauer-Wu, S AF Fonteyn, Marsha Bauer-Wu, Susan TI Strategies to support oncology nurses' scholarly activities. SO ONCOLOGY NURSING FORUM LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ONCOLOGY NURSING SOCIETY PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAR PY 2007 VL 34 IS 2 MA 2031 BP 495 EP 496 PG 2 WC Oncology; Nursing SC Oncology; Nursing GA 146QP UT WOS:000244949700104 ER PT J AU O'Donnell, S Robertson, H Harrington, C Brown, L Audette, G Vasquez, A AF O'Donnell, Susan Robertson, Heather Harrington, Cynthia Brown, Laura Audette, Ginette Vasquez, Aura TI Staff nurse implementation of an evidence-based practice standard: Caring for oncology patients with alteration in skin integrity related to incontinence. SO ONCOLOGY NURSING FORUM LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ONCOLOGY NURSING SOCIETY PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAR PY 2007 VL 34 IS 2 MA 2033 BP 496 EP 496 PG 1 WC Oncology; Nursing SC Oncology; Nursing GA 146QP UT WOS:000244949700105 ER PT J AU Kelley, E Rosato, E Finn, S LaFrancesca, JP Perry, D AF Kelley, Elaine Rosato, Erika Finn, Susan LaFrancesca, Joanne P. Perry, Donna TI Administration of chemotherapy across the continuum of care: Building nursing competence in a long term acute care facility. SO ONCOLOGY NURSING FORUM LA English DT Meeting Abstract C1 Youville Hosp, Cambridge, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ONCOLOGY NURSING SOCIETY PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAR PY 2007 VL 34 IS 2 MA 2113 BP 512 EP 512 PG 1 WC Oncology; Nursing SC Oncology; Nursing GA 146QP UT WOS:000244949700153 ER PT J AU Johnson, E AF Johnson, Elizabeth TI Oncology nurses' perceptions of common patient problems encountered in care. SO ONCOLOGY NURSING FORUM LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ONCOLOGY NURSING SOCIETY PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAR PY 2007 VL 34 IS 2 MA 2202 BP 529 EP 529 PG 1 WC Oncology; Nursing SC Oncology; Nursing GA 146QP UT WOS:000244949700201 ER PT J AU Grover, M Krumm, S Wenzel, J Shaha, M Bauer-Wu, S Snyder, D AF Grover, Michelle Krumm, Sharon Wenzel, Jennifer Shaha, Maya Bauer-Wu, Susan Snyder, Diann TI Professional bereavement and resiliency: What does this mean to oncology nurses? SO ONCOLOGY NURSING FORUM LA English DT Meeting Abstract C1 Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ONCOLOGY NURSING SOCIETY PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAR PY 2007 VL 34 IS 2 MA 2204 BP 530 EP 530 PG 1 WC Oncology; Nursing SC Oncology; Nursing GA 146QP UT WOS:000244949700203 ER PT J AU Johnson, E Haverly, M Sennott, S Hoinowski-Diaz, P AF Johnson, Elizabeth Haverly, Martha Sennott, Shelley Hoinowski-Diaz, Patricia TI Human papilloma virus and cervical cancer: An educational program. SO ONCOLOGY NURSING FORUM LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ONCOLOGY NURSING SOCIETY PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAR PY 2007 VL 34 IS 2 MA 2208 BP 531 EP 531 PG 1 WC Oncology; Nursing SC Oncology; Nursing GA 146QP UT WOS:000244949700206 ER PT J AU Saint-Eloi, S Pedulla, LV Tracey, E Singh, P Thompson, L Souza, R AF Saint-Eloi, Suzelle Pedulla, Lillian Vitale Tracey, Elizabeth Singh, Prabhjyot Thompson, Lynn Souza, Robyn TI Development of a nursing telephone triage program in an oncology ambulatory setting. SO ONCOLOGY NURSING FORUM LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ONCOLOGY NURSING SOCIETY PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAR PY 2007 VL 34 IS 2 MA 2216 BP 532 EP 532 PG 1 WC Oncology; Nursing SC Oncology; Nursing GA 146QP UT WOS:000244949700211 ER PT J AU Ponte, PR Glazer, G Ellenbecker, C Cooley, M Fonteyn, M AF Ponte, Patricia Reid Glazer, Greer Ellenbecker, Carol Cooley, Mary Fonteyn, Marsha TI Developing and implementing a fast-track BS-PhD nursing program in health policy research to address diversity issues in oncology practice, education and research. SO ONCOLOGY NURSING FORUM LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Massachusetts, Boston, MA 02125 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ONCOLOGY NURSING SOCIETY PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAR PY 2007 VL 34 IS 2 MA 2220 BP 533 EP 533 PG 1 WC Oncology; Nursing SC Oncology; Nursing GA 146QP UT WOS:000244949700213 ER PT J AU Gross, A Branowicki, P Rozanski, S Nixon, C AF Gross, Anne Branowicki, Patricia Rozanski, Sheila Nixon, Colleen TI Nursing council model of shared governance spanning three academic medical centers. SO ONCOLOGY NURSING FORUM LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Childrens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ONCOLOGY NURSING SOCIETY PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAR PY 2007 VL 34 IS 2 MA 2349 BP 559 EP 560 PG 2 WC Oncology; Nursing SC Oncology; Nursing GA 146QP UT WOS:000244949700290 ER PT J AU Sonis, S Haddad, R Posner, M Watkins, B Fey, E Morgan, TV Mookanamparambil, L Ramoni, M AF Sonis, S. Haddad, R. Posner, M. Watkins, B. Fey, E. Morgan, T. V. Mookanamparambil, L. Ramoni, M. TI Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers SO ORAL ONCOLOGY LA English DT Article DE gene expression; radiation; toxicity; head and neck cancer ID SIGNALING PATHWAY; SMALL-INTESTINE; ORAL MUCOSITIS; RECEPTOR; STRESS; IL-6; RADIOTHERAPY; INFLAMMATION; ACTIVATION; KINASES AB Patients treated with radiotherapy are prone to a constellation of local and systemic toxicities including mucositis, xerostomia, fatigue and anorexia. The biological complexities and similarities underlying the development of toxicities have recently been realized. Mucosal barrier injury is one of the best studied" and gene expression patterns, based on animal tissue samples, have added to its understanding. While investigations gene expression based on tissue samples was valuable, its use precludes more generalizable conclusions relative to common pathogenic mechanisms., Additionally, attempting to define the kinetics of changes in gene expression by sequential sampling is pragmatically unrealistic. Our objectives were: 1. to determine if changes in gene expression could be detected during toxicity development using PBM from patients receiving chemoradiation; 2. to characterize the relationship of expressed genes using graph theory and pathway analysis; and 3. to evaluate potential relationships between the expression of particular genes, canonical pathways, and functional networks in explaining the pathogenesis of regimen-related toxicities. DESIGN: Microarray analysis was performed using PBM-derived cRNA obtained before and 2 weeks after the initiation of chemoradiation in five patients with head and neck cancer who developed documented regimen-related toxicities. We created a database of those genes newly expressed at 2 weeks and evaluated their potential significance relative to toxicity, by canonical pathway analysis, compilation of regional networks around focus genes, and development of a model globalizing the individual functional networks. There was strong concordance between known pathogenic mechanisms of toxicity and the genes, pathways, and networks developed by our data. A rote was elicited for unsuspected genes in toxicity development. Our results support the concept that radiation induced toxicities have common underlying mechanisms and demonstrate the utility of PBM as an RNA source for genetic studies. This methodology could be broadly applicable to the study of regimen-related toxicities. (c) 2006 Elsevier Ltd. All rights reserved. C1 Dana Farber Canc Inst, Div Oral Med & Head & Neck Canc, Boston, MA 02115 USA. Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. Harvard Partners Ctr Genet & Genom, Boston, MA 02115 USA. Biomodels LLC, Boston, MA USA. MIT, Boston, MA USA. Harvard Univ, Sch Med, Div Hlth Sci & Technol, Childrens Hosp Informat Program, Boston, MA USA. RP Sonis, S (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. EM ssonis@partners.org NR 31 TC 37 Z9 39 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1368-8375 J9 ORAL ONCOL JI Oral Oncol. PD MAR PY 2007 VL 43 IS 3 BP 289 EP 300 DI 10.1016/j.oraloncology.2006.03.014 PG 12 WC Oncology; Dentistry, Oral Surgery & Medicine SC Oncology; Dentistry, Oral Surgery & Medicine GA 146YA UT WOS:000244969400012 PM 16920386 ER PT J AU Munoz, AA Haddad, RI Woo, SB Bhattacharyya, N AF Munoz, Amanda A. Haddad, Robert I. Woo, Sook-Bin Bhattacharyya, Neil TI Behavior of oral squamous cell carcinoma in subjects with prior lichen planus SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article; Proceedings Paper CT 110th Annual Meeting of the American-Academy-of-Otolaryngology-Head-and-Neck-Surgery CY SEP 17-20, 2006 CL Toronto, CANADA SP Amer Acad Otolaryngol Head & Neck Surg AB OBJECTIVE: To characterize the clinical behavior of oral squamous cell carcinomas (OSCCA) arising in patients with pre-existing oral lichen planus (OLP). STUDY DESIGN AND SETTING: Retrospective case-control study. Disease-free interval, time to first recurrence, subsequent therapy, and overall survival were calculated and compared between cases and controls matched for age, gender, primary site, and tumor stage. RESULTS: In 10 identified subjects with OLP/OSCCA, mean time from OLP diagnosis to OSCCA was 5.5 years. Three subjects suffered a local recurrence and two developed a second primary OSCCA. Mean actuarial survival for OLP patients was 119 months vs 42 months for the control patients, though this difference was not significant (P = 0.201, log-rank). CONCLUSIONS: OLP/SCCA subjects may exhibit better actuarial survival than SCCA patients despite a somewhat higher rate of local recurrence and second primary SCCA. Further study is required to characterize the behavior of OSCCA arising in preexisting OLP. (c) 2007 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved. C1 Stanford Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Stanford, CA 94305 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Oral Med, Boston, MA 02115 USA. Brigham & Womens Hosp, Div Otolaryngol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Cambridge, MA 02138 USA. RP Bhattacharyya, N (reprint author), FACS, Div Otolaryngol, 45 Francis St, Boston, MA 02115 USA. EM neiloy@massmed.org NR 9 TC 5 Z9 5 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD MAR PY 2007 VL 136 IS 3 BP 401 EP 404 DI 10.1016/j.otohns.2006.09.023 PG 4 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 144JV UT WOS:000244793200012 PM 17321867 ER PT J AU Tubman, VN Smoot, L Heeney, MM AF Tubman, Venee N. Smoot, Leslie Heeney, Matthew M. TI Acquired immune cytopenias post-cardiac transplantation respond to rituximab SO PEDIATRIC BLOOD & CANCER LA English DT Article DE autoimmune hemolytic anemia; autoimmune thrombocytopenia; cardiac transplantation; Glanzmann thrombasthenia; rituximab (anti-C020) ID MONOCLONAL-ANTIBODY THERAPY; AUTOIMMUNE HEMOLYTIC-ANEMIA; BONE-MARROW TRANSPLANTATION; GLANZMANNS-THROMBASTHENIA; HEART-TRANSPLANTATION; EVANS-SYNDROME; THROMBOCYTOPENIA; LYMPHOMA; PATIENT AB Hematologic abnormalities following solid organ transplantation are infrequently autoimmune in origin. We present a series of autoimmune cytopenias developing as a late complication of pediatric cardiac transplantation. Autoimmune cytopenias represented include autoimmune hemolytic anemia, acquired Glanzmann thrombasthenia, and idiopathic thrombocytopenic purpura. Standard therapies were used in each patient without sustainable results. Eventually, each patient was treated with and responded to rituximab. In this report, we review these cases, propose potential mechanisms for development of autoimmune cytopenias, and discuss our experience with rituximab in managing refractory autoimmune cytopenias. C1 Childrens Hosp, Div Hematol Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Heeney, MM (reprint author), Childrens Hosp, Div Hematol Oncol, Dana Farber Canc Inst, Fegan 704,300 Longwood Ave, Boston, MA 02115 USA. EM matthew.heeney@childrens.harvard.edu RI Heeney, Matthew/J-6838-2015 OI Heeney, Matthew/0000-0002-1104-6843 NR 17 TC 10 Z9 10 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD MAR PY 2007 VL 48 IS 3 BP 339 EP 344 DI 10.1002/pbc.20761 PG 6 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 131FQ UT WOS:000243854200016 PM 16435382 ER PT J AU Lewis, CM Caruso, P Cunningham, MJ AF Lewis, Carol M. Caruso, Paul Cunningham, Michael J. TI Parapharyngeal space lymphadenopathy SO PEDIATRIC RADIOLOGY LA English DT Article DE parapharyngeal space; mass; pediatric ID TUMORS AB Parapharyngeal space masses are rare in the pediatric population and have a higher incidence of malignancy than those in adults, although the differential diagnosis is similar. We present the work-up and treatment of a child with a parapharyngeal space mass discovered incidentally on CT imaging. C1 Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. Massachusetts Eye & Ear Infirm, Dept Radiol, Boston, MA 02114 USA. RP Lewis, CM (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM carol_lewis@meei.harvard.edu NR 8 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0301-0449 J9 PEDIATR RADIOL JI Pediatr. Radiol. PD MAR PY 2007 VL 37 IS 3 BP 313 EP 316 DI 10.1007/s00247-006-0383-z PG 4 WC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging SC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging GA 136CO UT WOS:000244200400012 PM 17211602 ER PT J AU Heneghan, AM Chaudron, LH Storfer-Isser, A Park, ER Kelleher, KJ Stein, REK Hoagwood, KE O'Connor, KG Horwitz, SM AF Heneghan, Amy M. Chaudron, Linda H. Storfer-Isser, Amy Park, Elyse R. Kelleher, Kelly J. Stein, Ruth E. K. Hoagwood, Kimberly Eaton O'Connor, Karen G. Horwitz, Sarah McCue TI Factors associated with identification and management of maternal depression by pediatricians SO PEDIATRICS LA English DT Article DE maternal depression; pediatrician; practice patterns ID PRIMARY-CARE PHYSICIANS; WELL-CHILD VISITS; POSTPARTUM DEPRESSION; RESPONSE RATES; PSYCHOSOCIAL PROBLEMS; MENTAL-DISORDERS; HEALTH; SYMPTOMS; PARENTS; MOTHERS AB OBJECTIVE. We sought to identify characteristics of pediatricians that were associated with identification or management (referral and/or treatment) of mothers with depression. METHODS. A cross-sectional survey was mailed to a random sample of 1600 of the 50 818 US nonretired members of the American Academy of Pediatrics. Overall, 832 responded, with 745 responses from nontrainee members. The 662 fellow nontrainee members who engaged in direct patient care and completed information on identifying, referring, and treating maternal depression were included in the analyses. RESULTS. A total of 511 of 662 respondents reported identifying maternal depression; of those who reported identifying maternal depression, 421 indicated they referred and 29 that they treated maternal depression in their practices. Pediatricians who are older, work in practices that provide child mental health services, see primarily (>= 75%) white patients, use >= 1 method to address maternal depression, agree that pediatricians should be responsible for identifying maternal depression, think that maternal depression has an extreme effect on children's mental health, and are attitudinally more inclined to identify or manage maternal depression had significantly higher odds of reporting identification of maternal depression. Positive correlates of identification and management of maternal depression included practicing in the Midwest, using >= 1 method to address maternal depression, working in a practice that provides child mental health services, thinking that caregiving problems attributable to maternal health have an extreme effect on children's physical health, having attitudes that are more inclined to identify and to manage maternal depression, and usually inquiring about symptoms routinely to identify maternal depression. CONCLUSIONS. Pediatricians' practice characteristics and attitudes are associated with their identification and management of mothers with depression. C1 Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA. Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA. Univ Rochester, Dept Psychiat, Rochester, NY USA. Univ Rochester, Dept Psychol, Rochester, NY 14627 USA. Univ Rochester, Dept Obstet & Gynecol, Rochester, NY USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA. Ohio State Univ, Dept Pediat, Coll Med & Publ Hlth, Columbus, OH 43210 USA. Childrens Hosp, Dept Pediat, Albert Einstein Coll Med, Bronx, NY USA. Columbia Univ, Dept Psychiat, New York, NY USA. Amer Acad Pediat, Dept Res, Elk Grove Village, IL USA. RP Heneghan, AM (reprint author), Case Western Reserve Univ, Dept Pediat, Rainbow Babies & Childrens Hosp, 11100 Euclid Ave, Cleveland, OH 44106 USA. EM axh65@case.edu RI Kelleher, Kelly/E-3361-2011 NR 69 TC 28 Z9 28 U1 3 U2 7 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD MAR PY 2007 VL 119 IS 3 BP 444 EP 454 DI 10.1542/peds.2006-0765 PG 11 WC Pediatrics SC Pediatrics GA 141LK UT WOS:000244579800003 PM 17332196 ER PT J AU Demay, MB Sabbagh, Y Carpenter, TO AF Demay, Marie B. Sabbagh, Yves Carpenter, Thomas O. TI Calcium and vitamin D: What is known about the effects on growing bone SO PEDIATRICS LA English DT Article; Proceedings Paper CT Workshop on Skeletal Effects of Pharmacologic Agents in Children CY APR 14, 2005 CL Natl Inst Hlth, Bethesda, MD SP Amer Soc Bone & Mineral Res, Natl Inst Child Hlth & Human Dev HO Natl Inst Hlth DE vitamin D receptor; ablation; hypophosphatemia; rickets ID MINERAL ION HOMEOSTASIS; RECEPTOR-ABLATED MICE; PHOSPHATE IONS; HYPERTROPHIC CHONDROCYTES; APOPTOSIS; RICKETS; HYPERPARATHYROIDISM; ALOPECIA AB The objective of these investigations was to determine if the receptor- dependent effects of 1,25-dihydroxyvitamin D were essential for normal skeletal growth. Mice with targeted ablation of the vitamin D receptor were engineered, and the skeletal consequences of vitamin D receptor ablation were studied in the presence of normal and abnormal mineral ion homeostasis. Prevention of abnormal mineral ion homeostasis resulted in the development of a normal skeleton in the absence of a functional vitamin D receptor. The metabolic cause of rickets was found to be hypophosphatemia. The major receptor-dependent actions of 1,25-dihydroxyvitamin D on skeletal development are indirect and are a reflection of the role of this hormone on intestinal calcium absorption. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02115 USA. Yale Univ, Dept Pediat, New Haven, CT 06520 USA. RP Demay, MB (reprint author), 50 Blossom St,Thier 11, Boston, MA 02114 USA. EM demay@helix.mgh.harvard.edu OI Sabbagh, Yves/0000-0001-5339-6705 FU NIDDK NIH HHS [R01 DK046974, DK46974] NR 17 TC 15 Z9 19 U1 0 U2 5 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD MAR PY 2007 VL 119 SU S BP S141 EP S144 DI 10.1542/peds.2006-2023F PG 4 WC Pediatrics SC Pediatrics GA 186DS UT WOS:000247759900004 PM 17332234 ER PT J AU Ochala, J Dorer, DD Frontera, WR Krivickas, LS AF Ochala, Julien Dorer, David D. Frontera, Walter R. Krivickas, Lisa S. TI Single skeletal muscle fiber behavior after a quick stretch in young and older men: a possible explanation of the relative preservation of eccentric force in old age (vol 452, pg 464, 2006) SO PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY LA English DT Correction C1 Univ Hosp, Dept Neurosci, S-75185 Uppsala, Sweden. Spaulding Rehabil Hosp, Muscle Cell Physiol Lab, Dept Phys Med & Rehabil, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Bourgogne, Fac Sci Sport, Equipe INSERM, ERM 207, Dijon, France. Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. RP Ochala, J (reprint author), Univ Hosp, Dept Neurosci, Entrance 85,Room 6511, S-75185 Uppsala, Sweden. EM julien.ochala@neurofys.uu.se NR 1 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0031-6768 J9 PFLUG ARCH EUR J PHY JI Pflugers Arch. PD MAR PY 2007 VL 453 IS 6 BP 923 EP 923 DI 10.1007/s00424-006-0167-1 PG 1 WC Physiology SC Physiology GA 137PC UT WOS:000244303500018 ER PT J AU Kealey, C Chen, Z Christie, J Thorn, CF Whitehead, AS Price, M Samaha, FF Kimmel, SE AF Kealey, Canel Chen, Zhen Christie, Jason Thorn, Caroline F. Whitehead, Alexander S. Price, Maureen Samaha, Frederick F. Kimmel, Stephen E. TI Warfarin and cytochrome P4502C9 genotype: possible ethnic variation in warfarin sensitivity SO PHARMACOGENOMICS LA English DT Article DE anticoagulation; cytochrome P4502C9; polymorphisms; race; warfarin ID POLYMORPHISMS; ANTICOAGULATION; CYP2C9; ASSOCIATION; METABOLISM; VARIANTS; THERAPY; RISK; 2C9 AB Introduction: Warfarin is a widely prescribed, efficacious oral anticoagulant. S-warfarin, the more active form, is metabolized by the cytochrome P450 (CYP)2C9 enzyme. The aim was to evaluate the influence of two CYP2C9 functional polymorphisms (*2 and *3) on warfarin dose in African-Americans, an unstudied population and Caucasians, and also to assess the effect of these polymorphisms on anticoagulation response after accounting for nongenetic factors and genetic factors that might also impact the dose-response relationship of warfarin. Patients and methods: A prospective cohort of 362 patients with a target international normalized ratio of between 2.0 and 3.0 were genotyped. Warfarin sensitivity stratified by genotype was investigated using univariate and multivariate analyses. Results: The maintenance dose of warfarin was significantly related to genotype (p < 0.01) (variant carriers: 31.25 mg/week; wild-type: 37.5 mg/week), even after adjustment for possible confounding factors (p = 0.046). However, the effect of genotype was restricted to Caucasians, in whom variant carriers had a significantly lower maintenance dose compared with wild-type homozygotes (unadjusted: p < 0.01; adjusted: p = 0.02). There was a greater risk of over-anticoagulation among Caucasian variant carriers, although this was only observed prior to reaching maintenance dose. For African-American variant carriers, there was no difference in warfarin response based on CYP2C9 genotype. Discussion: CYP2C9 *2 and *3 variants provide predictive information in anticoagulation response. However, these variants may not be useful in African-Americans or as a marker of long-term over-anticoagulation once a stable dose is reached. C1 Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Dept Med, Div Cardiovasc Med, Sch Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Pharmacogenet, Philadelphia, PA 19104 USA. RP Kimmel, SE (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. FU NCRR NIH HHS [P20RR020741]; NHLBI NIH HHS [R01HL066176-04] NR 23 TC 43 Z9 44 U1 0 U2 2 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1462-2416 J9 PHARMACOGENOMICS JI Pharmacogenomics PD MAR PY 2007 VL 8 IS 3 BP 217 EP 225 DI 10.2217/14622416.8.3.217 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 145OS UT WOS:000244875000006 PM 17324110 ER PT J AU Boudsocq, M Droillard, MJ Barbier-Brygoo, H Lauriere, C AF Boudsocq, Marie Droillard, Marie-Jo Barbier-Brygoo, Helene Lauriere, Christiane TI Different phosphorylation mechanisms are involved in the activation of sucrose non-fermenting 1 related protein kinases 2 by osmotic stresses and abscisic acid SO PLANT MOLECULAR BIOLOGY LA English DT Article DE abscisic acid; Arabidopsis thaliana; osmotic stresses; phosphorylation; Pro-Q Diamond; SnRK2 ID DEPENDENT PROTEIN-KINASE; ARABIDOPSIS-THALIANA; SALT STRESS; HYPEROSMOTIC STRESS; SIGNAL-TRANSDUCTION; STOMATAL CLOSURE; GENE; ABA; TOLERANCE; RICE AB In Arabidopsis cell suspension, hyperosmotic stresses (mannitol and NaCl) were previously shown to activate nine sucrose non-fermenting 1 related protein kinases 2 (SnRK2s) whereas only five of them were also activated by abscisic acid (ABA) treatment. Here, the possible activation by phosphorylation/dephosphorylation of each kinase was investigated by studying their phosphorylation state after osmotic stress, using the Pro-Q Diamond, a specific dye for phosphoproteins. All the activated kinases were phosphorylated after osmotic stress but the induced phosphorylation changes were clearly different depending on the kinase. In addition, the increase of the global phosphorylation level induced by ABA application was lower, suggesting that different mechanisms may be involved in SnRK2 activation by hyperosmolarity and ABA. On the other hand, SnRK2 kinases remain activated by hyperosmotic stress in ABA-deficient and ABA-insensitive mutants, indicating that SnRK2 osmotic activation is independent of ABA. Moreover, using a mutant form of SnRK2s, a specific serine in the activation loop was shown to be phosphorylated after stress treatments and essential for activity and/or activation. Finally, SnRK2 activity was sensitive to staurosporine, whereas SnRK2 activation by hyperosmolarity or ABA was not, indicating that SnRK2 activation by phosphorylation is mediated by an upstream staurosporine-insensitive kinase, in both signalling pathways. All together, these results indicate that different phosphorylation mechanisms and at least three signalling pathways are involved in the activation of SnRK2 proteins in response to osmotic stress and ABA. C1 CNRS, UPR 2355, Inst Sci Vegetal, F-91198 Gif Sur Yvette, France. Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. RP Lauriere, C (reprint author), CNRS, UPR 2355, Inst Sci Vegetal, 1 Av Terrasse, F-91198 Gif Sur Yvette, France. EM Christiane.Lauriere@isv.cnrs-gif.fr RI BARBIER-BRYGOO, HELENE/A-8435-2013 NR 40 TC 88 Z9 103 U1 0 U2 12 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0167-4412 EI 1573-5028 J9 PLANT MOL BIOL JI Plant Mol.Biol. PD MAR PY 2007 VL 63 IS 4 BP 491 EP 503 DI 10.1007/s11103-006-9103-1 PG 13 WC Biochemistry & Molecular Biology; Plant Sciences SC Biochemistry & Molecular Biology; Plant Sciences GA 137UG UT WOS:000244317200004 PM 17103012 ER PT J AU Chehab, EW Patharkar, OR Cushman, JC AF Chehab, E. Wassim Patharkar, O. Rahul Cushman, John C. TI Isolation and characterization of a novel v-SNARE family protein that interacts with a calcium-dependent protein kinase from the common ice plant, Mesembryanthemum crystallinum SO PLANTA LA English DT Article DE calcium-dependent protein kinase; yeast two-hybrid; coiled-coil protein; v-SNARE; vesicular trafficking ID CALMODULIN-LIKE DOMAIN; TRANS-GOLGI NETWORK; COILED COILS; GENE FAMILY; RICE PLANTS; PSI-BLAST; IN-VIVO; DATABASE; STRESS; CDPK AB McCPK1 (Mesembryanthemum crystallinum calcium-dependent protein kinase 1) mRNA expression is transiently salinity- and dehydration-stress responsive. The enzyme also undergoes dynamic subcellular localization changes in response to these same stresses. Using the yeast-two hybrid system, we have isolated and characterized a M. crystallinum CPK1 Adaptor Protein 2 (McCAP2). We show that McCPK1 interacts with the C-terminal, coiled-coil containing region of McCAP2 in the yeast two-hybrid system. This interaction was confirmed in vitro between the purified recombinant forms of each of the proteins and in vivo by coimmunoprecipitation experiments from plant extracts. McCAP2, however, was not a substrate for McCPK1. Computational threading analysis suggested that McCAP2 is a member of a novel family of proteins with unknown function also found in rice and Arabidopsis. These proteins contain coiled-coil spectrin repeat domains present in the syntaxin superfamily that participate in vesicular and protein trafficking. Consistent with the interaction data, subcellular localization and fractionation studies showed that McCAP2 colocalizes with McCPK1 to vesicular structures located on the actin cytoskeleton and within the endoplasmic reticulum in cells subjected to low humidity stress. McCAP2 also colocalizes with AtVTI1a, an Arabidopsis v-SNARE [vesicle-soluble N-ethyl maleimide-sensitive factor (NSF) attachment protein (SNAP) receptor] present in the trans-Golgi network (TGN) and prevacuolar compartments (PVCs). Both interaction and subcellular localization studies suggest that McCAP2 may possibly serve as an adaptor protein responsible for vesicle-mediated trafficking of McCPK1 to or from the plasma membrane along actin microfilaments of the cytoskeleton. C1 Univ Nevada, Dept Biochem & Mol Biol MS200, Reno, NV 89557 USA. Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA. Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. RP Cushman, JC (reprint author), Univ Nevada, Dept Biochem & Mol Biol MS200, 311 Fleischmann Agr, Reno, NV 89557 USA. EM jcushman@unr.edu NR 59 TC 7 Z9 7 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0032-0935 EI 1432-2048 J9 PLANTA JI Planta PD MAR PY 2007 VL 225 IS 4 BP 783 EP 799 DI 10.1007/s00425-006-0371-4 PG 17 WC Plant Sciences SC Plant Sciences GA 137PG UT WOS:000244303900001 PM 16947054 ER PT J AU Dingli, D Traulsen, A Michor, F AF Dingli, David Traulsen, Arne Michor, Fransizka TI (A) symmetric stem cell replication and cancer SO PLOS COMPUTATIONAL BIOLOGY LA English DT Article ID COLORECTAL-CANCER; SELF-RENEWAL; MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR; DIFFERENTIATION; IDENTIFICATION; PROLIFERATION; DYNAMICS; COLON; LGL AB Most tissues in metazoans undergo continuous turnover due to cell death or epithelial shedding. Since cellular replication is associated with an inherent risk of mutagenesis, tissues are maintained by a small group of stem cells (SCs) that replicate slowly to maintain their own population and that give rise to differentiated cells. There is increasing evidence that many tumors are also maintained by a small population of cancer stem cells that may arise by mutations from normal SCs. SC replication can be either symmetric or asymmetric. The former can lead to expansion of the SC pool. We describe a simple model to evaluate the impact of (a) symmetric SC replication on the expansion of mutant SCs and to show that mutations that increase the probability of asymmetric replication can lead to rapid mutant SC expansion in the absence of a selective fitness advantage. Mutations in several genes can lead to this process and may be at the root of the carcinogenic process. C1 Harvard Univ, Program Evolutionary Dynam, Cambridge, MA 02138 USA. Mayo Clin, Coll Med, Div Hematol, Rochester, MN USA. Harvard Univ, Soc Fellows, Cambridge, MA 02138 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RP Dingli, D (reprint author), Harvard Univ, Program Evolutionary Dynam, Cambridge, MA 02138 USA. EM dingli@fas.harvard.edu RI Dingli, David/B-6355-2008; Traulsen, Arne/A-4955-2009 OI Traulsen, Arne/0000-0002-0669-5267 NR 48 TC 60 Z9 61 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-734X J9 PLOS COMPUT BIOL JI PLoS Comput. Biol. PD MAR PY 2007 VL 3 IS 3 BP 482 EP 487 AR e53 DI 10.1371/journal.pcbi.0030053 PG 6 WC Biochemical Research Methods; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Mathematical & Computational Biology GA 163VJ UT WOS:000246191000014 PM 17367205 ER PT J AU Gasser, O Bihl, FK Wolbers, M Loggi, E Steffen, I Hirsch, HH Gunthard, HF Walker, BD Brander, C Battegay, M Hess, C AF Gasser, Olivier Bihl, Florian K. Wolbers, Marcel Loggi, Elisabetta Steffen, Ingrid Hirsch, Hans H. Guenthard, Huldrych F. Walker, Bruce D. Brander, Christian Battegay, Manuel Hess, Christoph TI HIV patients developing primary CNS lymphoma lack EBV-specific CD4(+) T cell function irrespective of absolute CD4(+) T cell counts SO PLOS MEDICINE LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; EPSTEIN-BARR-VIRUS; NERVOUS-SYSTEM LYMPHOMA; CYTOMEGALOVIRUS RETINITIS; PERSISTENT INFECTION; IMMUNODEFICIENCY; ERA; PROLIFERATION; RESPONSES; RECOVERY AB Background In chronic HIV infection, antiretroviral therapy-induced normalization of CD4(+) T cell counts (immune reconstitution [IR]) is associated with a decreased incidence of opportunistic diseases. However, some individuals remain at risk for opportunistic diseases despite prolonged normalization of CD4(+) T cell counts. Deficient Epstein-Barr virus (EBV)-specific CD4(+) T cell function may explain the occurrence of EBV-associated opportunistic malignancy-such as primary central nervous system (PCNS) lymphoma-despite recovery of absolute CD4(+) T cell counts. Methods and Findings Absolute CD4(+) T cell counts and EBV-specific CD4(+) T cell-dependent interferon-c production were assessed in six HIV-positive individuals prior to development of PCNS lymphoma ("cases''), and these values were compared with those in 16 HIV-infected matched participants with no sign of EBV-associated pathology ("matched controls'') and 11 nonmatched HIV-negative blood donors. Half of the PCNS lymphoma patients fulfilled IR criteria (defined here as CD4(+) T cell counts >= 500/mu l blood). EBV-specific CD4(+) T cells were assessed 0.5-4.7 y prior to diagnosis of lymphoma. In 0/6 cases versus 13/16 matched controls an EBV-specific CD4(+) T cell response was detected (p = 0.007; confidence interval for odds ratio [0-0.40]). PCNS lymphoma patients also differed with regards to this response significantly from HIV-negative blood donors (p < 0.001, confidence interval for odds ratio [0-0.14]), but there was no evidence for a difference between HIV-negative participants and the HIV-positive matched controls (p = 0.47). Conclusions Irrespective of absolute CD4(+) T cell counts, HIV-positive patients who subsequently developed PCNS lymphoma lacked EBV-specific CD4(+) T cell function. Larger, ideally prospective studies are needed to confirm these preliminary data, and clarify the impact of pathogenspecific versus surrogate marker-based assessment of IR on clinical outcome. C1 Univ Basel Hosp, Dept Res, Immunobiol Lab, CH-4031 Basel, Switzerland. Massachusetts Gen Hosp, Partners Aids Res Ctr, Boston, MA 02114 USA. Univ Basel Hosp, Inst Clin Epidemiol, CH-4031 Basel, Switzerland. Univ Basel, Inst Med Microbiol, CH-4003 Basel, Switzerland. Univ Zurich Hosp, Div Infect Dis, CH-8091 Zurich, Switzerland. Univ Zurich Hosp, Hosp Epidemiol, CH-8091 Zurich, Switzerland. Univ Basel Hosp, Hosp Epidemiol, CH-4031 Basel, Switzerland. Univ Basel Hosp, Div Infect Dis, CH-4031 Basel, Switzerland. RP Hess, C (reprint author), Univ Basel Hosp, Dept Res, Immunobiol Lab, CH-4031 Basel, Switzerland. EM chess@uhbs.ch RI gunthard, huldrych/F-1724-2011; SHCS, only/G-4080-2011; Gasser, Olivier/I-3663-2013; Infektiologie, USZ/A-6921-2011; SHCS, all/G-4072-2011; SHCS, ch/G-4077-2011; Loggi, Elisabetta/K-7848-2016; OI gunthard, huldrych/0000-0002-1142-6723; Loggi, Elisabetta/0000-0003-4985-9783; Brander, Christian/0000-0002-0548-5778 NR 23 TC 50 Z9 52 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD MAR PY 2007 VL 4 IS 3 BP 556 EP 561 AR e96 DI 10.1371/journal.pmed.0040096 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 150TY UT WOS:000245243700023 PM 17388662 ER PT J AU Li, HJ Stampfer, MJ Hollis, JBW Mucci, LA Gaziano, JM Hunter, D Giovannucci, EL Ma, J AF Li, Haojie Stampfer, Meir J. Hollis, J. Bruce W. Mucci, Lorelei A. Gaziano, J. Michael Hunter, David Giovannucci, Edward L. Ma, Jing TI A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer SO PLOS MEDICINE LA English DT Article ID START CODON POLYMORPHISM; BONE-MINERAL DENSITY; GENE POLYMORPHISMS; UNITED-STATES; 1,25-DIHYDROXYVITAMIN D-3; SUBSEQUENT DEVELOPMENT; ULTRAVIOLET-RADIATION; GROWTH-INHIBITION; IN-VIVO; RISK AB Background Vitamin D insufficiency is a common public health problem nationwide. Circulating 25-hydroxyvitamin D-3 (25[ OH] D), the most commonly used index of vitamin D status, is converted to the active hormone 1,25 dihydroxyvitamin D-3 (1,25[OH](2)D), which, operating through the vitamin D receptor (VDR), inhibits in vitro cell proliferation, induces differentiation and apoptosis, and may protect against prostate cancer. Despite intriguing results from laboratory studies, previous epidemiological studies showed inconsistent associations of circulating levels of 25(OH) D, 1,25(OH) 2D, and several VDR polymorphisms with prostate cancer risk. Few studies have explored the joint association of circulating vitamin D levels with VDR polymorphisms. Methods and Findings During 18 y of follow-up of 14,916 men initially free of diagnosed cancer, we identified 1,066 men with incident prostate cancer (including 496 with aggressive disease, defined as stage C or D, Gleason 7-10, metastatic, and fatal prostate cancer) and 1,618 cancer-free, age-and smoking-matched control participants in the Physicians' Health Study. We examined the associations of prediagnostic plasma levels of 25(OH) D and 1,25(OH) 2D, individually and jointly, with total and aggressive disease, and explored whether relations between vitamin D metabolites and prostate cancer were modified by the functional VDR FokI polymorphism, using conditional logistic regression. Among these US physicians, the median plasma 25(OH) D levels were 25 ng/ml in the blood samples collected during the winter or spring and 32 ng/ml in samples collected during the summer or fall. Nearly 13% (summer/fall) to 36% (winter/spring) of the control participants were deficient in 25(OH) D (< 20 ng/ml) and 51% (summer/fall) and 77% (winter/spring) had insufficient plasma 25(OH) D levels (< 32 ng/ml). Plasma levels of 1,25(OH) 2D did not vary by season. Men whose levels for both 25(OH) D and 1,25(OH) 2D were below (versus above) the median had a significantly increased risk of aggressive prostate cancer (odds ratio [OR] 2.1, 95% confidence interval [CI] 1.2-3.4), although the interaction between the two vitamin D metabolites was not statistically significant (p(interaction) = 0.23). We observed a significant interaction between circulating 25(OH) D levels and the VDR FokI genotype (p(interaction) < 0.05). Compared with those with plasma 25(OH) D levels above the median and with the Fokl FF or Ff genotype, men who had low 25(OH) D levels and the less functional FokI ff genotype had increased risks of total (OR = 1.9, 95% CI 1.1-3.3) and aggressive prostate cancer (OR 2.5, 95% CI 1.1-5.8). Among men with plasma 25(OH) D levels above the median, the ff genotype was no longer associated with risk. Conversely, among men with the ff genotype, high plasma 25(OH) D level (above versus below the median) was related to significant 60% similar to 70% lower risks of total and aggressive prostate cancer. Conclusions Our data suggest that a large proportion of the US men had suboptimal vitamin D status (especially during the winter/spring season), and both 25(OH) D and 1,25(OH) 2D may play an important role in preventing prostate cancer progression. Moreover, vitamin D status, measured by 25(OH) D in plasma, interacts with the VDR FokI polymorphism and modifies prostate cancer risk. Men with the less functional FokI ff genotype (14% in the European-descent population of this cohort) are more susceptible to this cancer in the presence of low 25(OH) D status. C1 Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Channing Lab, Cambridge, MA 02138 USA. Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Cambridge, MA 02138 USA. Harvard Univ, Sch Publ Hlth, Dept Nutr, Cambridge, MA 02138 USA. Harvard Univ, Sch Med, Div Prevent Med, Brigham & Womens Hosp, Cambridge, MA 02138 USA. VA boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA. Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. RP Li, HJ (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Channing Lab, Cambridge, MA 02138 USA. EM haojie.li@channing.havard.edu FU NCI NIH HHS [CA-42182, CA-58684, R01 CA042182, R01 CA058684, R01 CA097193] NR 51 TC 148 Z9 153 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD MAR PY 2007 VL 4 IS 3 BP 562 EP 571 AR e103 DI 10.1371/journal.pmed.0040103 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 150TY UT WOS:000245243700024 PM 17388667 ER PT J AU Park, ER Quinn, VP Chang, YC Regan, S Loudin, B Cummins, S Perry, K Rigotti, NA AF Park, Elyse R. Quinn, Virginia P. Chang, Yuchiao Regan, Susan Loudin, Beverly Cummins, Sharon Perry, Kristin Rigotti, Nancy A. TI Recruiting pregnant smokers into a clinical trial: Using a network-model managed care organization versus community-based practices SO PREVENTIVE MEDICINE LA English DT Article DE smoking cessation; pregnant women; health care systems; recruitment ID SMOKING CESSATION INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; WOMEN; PROGRAM; SUPPORT AB Objectives: Recruiting pregnant smokers into smoking cessation intervention trials is challenging. Changes in health care systems offer new opportunities to overcome many of the obstacles encountered by researchers attempting to address the significant harm from maternal smoking. Investigators could facilitate smoking cessation study recruitment by collaborating with health care systems that systematically collect patient smoking status and record it in a centralized, retrievable fashion. This paper reports the results of utilizing this novel approach and compares it with a typical decentralized practice-based recruitment strategy. Methods: The study was conducted at Massachusetts General Hospital, in Boston, Massachusetts, from 2000 to 2005. Four hundred forty-two pregnant smokers were recruited for a randomized controlled trial of telephone-delivered smoking counseling from two sources: a network-model managed care health plan and community-based practices (CBP). At the health plan, study recruitment was built on an existing system that permitted pregnant smokers to be identified centrally. At the CBPs, identification and referral systems had to be developed at each practice specifically for the study. The two strategies were compared on the efficiency of recruitment, characteristics of enrollees, and study outcome and process measures. Results: The health plan strategy generated referrals nearly twice as fast as the CBP strategy (30.4 vs. 17.0 per month), but because referrals were not timely, a large proportion of women from the plan were too advanced in pregnancy to be eligible to enroll in the study. As a result, the two strategies yielded a comparable enrollment rate. Participants from the health plan were older, better educated, less racially diverse, more likely to be living with the baby's father, and less likely to have smokers in their environment. These differences were largely explained by the socioeconomic diversity of women recruited from the CBPs. Smoking cessation outcomes did not differ by recruitment source. Conclusions: A recruitment strategy using a health plan's centralized system was more efficient than a practice-based recruitment strategy at identifying potential study participants, but less efficient at generating study participants from the referrals received. Importantly, participants recruited by the two strategies differed by socioeconomic, but not cessation-related, characteristics. To date, recruiting pregnant smokers into intervention studies remains resource intensive and time consuming. Participant identification and recruitment will be greatly enhanced by health system innovations such as implementation of electronic medical records. (c) 2006 Elsevier Inc. All rights reserved. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. Univ Calif San Diego, La Jolla, CA 92093 USA. RP Park, ER (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM epark@partners.org OI Regan, Susan/0000-0003-0940-2017 FU NHLBI NIH HHS [K24 HL04440] NR 28 TC 13 Z9 13 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD MAR PY 2007 VL 44 IS 3 BP 223 EP 229 DI 10.1016/j.ypmed.2006.10.008 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 154AU UT WOS:000245480000008 PM 17204318 ER PT J AU Ross, JS Bernheim, SM Bradley, EH Teng, HM Gallo, WT AF Ross, Joseph S. Bernheim, Susannah M. Bradley, Elizabeth H. Teng, Hsun-Mei Gallo, William T. TI Use of preventive care by the working poor in the United States SO PREVENTIVE MEDICINE LA English DT Article DE poverty; socioeconomic factors; prevention and control; health promotion; mass screening/utilization; health services/utilization; United States ID HEALTH-CARE; UNINSURED ADULTS; SERVICES; INSURANCE; COVERAGE; CANCER; ACCESS; DISPARITIES; BEHAVIORS; OUTCOMES AB Objective. Examine the association between poverty and preventive care use among older working adults. Method. Cross-sectional analysis of the pooled 1996, 1998 and 2000 waves of the Health and Retirement Study, a nationally representative sample of older community-dwelling adults, studying self-reported use of cervical, breast, and prostate cancer screening, as well as serum cholesterol screening and influenza vaccination. Adults with incomes within 200% of the federal poverty level were defined as poor. Results. Among 10,088 older working adults, overall preventive care use ranged from 38% (influenza vaccination) to 76% (breast cancer screening). In unadjusted analyses, the working poor were significantly less likely to receive preventive care. After adjustment for insurance coverage, education, and other socio-demographic characteristics, the working poor remained significantly less likely to receive breast cancer (RR 0.92, 95% CI, 0.86-0.96), prostate cancer (RR 0.89, 95% CI, 0.81-0.97), and cholesterol screening (RR 0.91, 95% CI, 0.86-0.96) than the working non-poor, but were not significantly less likely to receive cervical cancer screening (RR 0.96, 95% CI, 0.90-1.01) or influenza vaccination (RR 0.92, 95% CI, 0.84-1.01). Conclusion. The older working poor are at modestly increased risk for not receiving preventive care. (c) 2006 Elsevier Inc. All rights reserved. C1 CUNY Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA. James J Peters Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Div Hlth Policy & Adm, New Haven, CT 06510 USA. Yale Univ, Sch Med, Dept Internal Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA. RP Ross, JS (reprint author), CUNY Mt Sinai Sch Med, Dept Geriatr & Adult Dev, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM joseph.ross@mssm.edu FU NIA NIH HHS [K01 AG021983, T32 AG1934, P30 AG21342, P30 AG021342] NR 43 TC 18 Z9 18 U1 2 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD MAR PY 2007 VL 44 IS 3 BP 254 EP 259 DI 10.1016/j.ypmed.2006.11.006 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 154AU UT WOS:000245480000013 PM 17196642 ER PT J AU Velicer, CM Dublin, S White, E AF Velicer, C. M. Dublin, S. White, E. TI Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications SO PROSTATE CANCER AND PROSTATIC DISEASES LA English DT Article DE diabetes; insulin; VITAL; cohort; leptin; insulin-like growth factor ID BINDING PROTEIN-1 IGFBP-1; IGF-I; CARDIOVASCULAR RISK; GROWTH-FACTORS; UNITED-STATES; MELLITUS; INSULIN; LEPTIN; MEN; DISEASE AB Epidemiologic evidence suggests diabetic men have a slightly lower prostate cancer risk than nondiabetic men. We examined this association in a prospective cohort study of 35 239 men, 50-76 years old, in Washington State who completed a baseline questionnaire between 2000 and 2002. Incident prostate cancers as of 31 December 2004 were identified through the SEER registry. Diabetic men had a slightly lower risk of prostate cancer than non-diabetic men ( hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.64-1.07). Insulin users overall and insulin users with diabetic complications had decreased risks, compared to non-diabetic men ( HR 0.49, 95% CI 0.26-0.92) and ( HR 0.36, 95% CI 0.15-0.87), respectively. Oral medication use for diabetes was not associated with prostate cancer. Insulin is likely a marker of severity of diabetes. Future studies of this association should consider diabetes type, treatment, severity, complications and biomarkers. C1 Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98109 USA. VA Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Velicer, CM (reprint author), Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Mail Stop M4-B402, Seattle, WA 98109 USA. EM cvelicer@fhcrc.org NR 26 TC 23 Z9 23 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1365-7852 J9 PROSTATE CANCER P D JI Prostate Cancer Prostatic Dis. PD MAR PY 2007 VL 10 IS 1 BP 46 EP 51 DI 10.1038/sj.pcan.4500914 PG 6 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 141UR UT WOS:000244604800006 PM 17033617 ER PT J AU Brusic, V Marina, O Wu, CJ Reinherz, EL AF Brusic, Vladimir Marina, Ovidiu Wu, Catherine J. Reinherz, Ellis L. TI Proteome informatics for cancer research: From molecules to clinic SO PROTEOMICS LA English DT Review DE bioinformatics; melanoma; software ID GENE-EXPRESSION; DENDRITIC CELLS; BREAST-CANCER; MASS-SPECTROMETRY; TUMOR MICROENVIRONMENT; BIOINFORMATICS TOOLS; COLORECTAL-CANCER; BINDING PEPTIDES; SYSTEMS BIOLOGY; PROSTATE-CANCER AB Proteomics offers the most direct approach to understand disease and its molecular biomarkers. Biomarkers denote the biological states of tissues, cells, or body fluids that are useful for disease detection and classification. Clinical proteomics is used for early disease detection, molecular diagnosis of disease, identification and formulation of therapies, and disease monitoring and prognostics. Bioinformatics tools are essential for converting raw proteornics data into knowledge and subsequently into useful applications. These tools are used for the collection, processing, analysis, and interpretation of the vast amounts of proteomics data. Management, analysis, and interpretation of large quantities of raw and processed data require a combination of various informatics technologies such as databases, sequence comparison, predictive models, and statistical tools. We have demonstrated the utility of bioinformatics in clinical proteornics through the analysis of the cancer antigen survivin and its suitability as a target for cancer immunotherapy. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA. RP Brusic, V (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. EM vladimir_brusic@dfci.harvard.edu FU NCI NIH HHS [5 R21 CA115043-2] NR 111 TC 18 Z9 21 U1 1 U2 6 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY SN 1615-9853 J9 PROTEOMICS JI Proteomics PD MAR PY 2007 VL 7 IS 6 BP 976 EP 991 DI 10.1002/pmic.200600965 PG 16 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 151ZY UT WOS:000245331000016 PM 17370257 ER PT J AU Iosifescu, DV Nierenberg, AA AF Iosifescu, Dan V. Nierenberg, Andrew A. TI New developments in depression research - Preface SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Editorial Material ID COMORBIDITY SURVEY REPLICATION; DSM-IV DISORDERS; PREVALENCE C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Iosifescu, DV (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 50 Staniford St,Suite 401, Boston, MA 02114 USA. EM diosifescu@partners.org; aanierenberg@partners.org NR 3 TC 3 Z9 3 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD MAR PY 2007 VL 30 IS 1 BP XI EP XIII DI 10.1016/j.psc.2007.01.002 PG 3 WC Psychiatry SC Psychiatry GA 156GL UT WOS:000245636000001 ER PT J AU Nierenberg, AA Katz, J Fava, M AF Nierenberg, Andrew A. Katz, Judith Fava, Maurizio TI A critical overview of the pharmacologic management of treatment-resistant depression SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Review ID SEROTONIN REUPTAKE INHIBITORS; STAR-ASTERISK-D; COMORBIDITY SURVEY REPLICATION; PLACEBO-CONTROLLED TRIAL; SEQUENCED TREATMENT ALTERNATIVES; TREATMENT-REFRACTORY DEPRESSION; FAILED MEDICATION TREATMENTS; BUPROPION SUSTAINED-RELEASE; OPEN-LABEL TREATMENT; DSM-IV DISORDERS AB Major depressive disorder is a frequent, serious disorder that usually responds partially to treatment and leaves many patients with treatment resistance. This article reviews and critically evaluates the evidence for the management of treatment-resistant depression and examines pharmacologic approaches to alleviate the suffering of patients who benefit insufficiently from initial treatment. C1 Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. RP Nierenberg, AA (reprint author), Suite 580,50 Staniford St, Boston, MA 02114 USA. EM anierenberg@partners.org NR 141 TC 26 Z9 29 U1 4 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X EI 1558-3147 J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD MAR PY 2007 VL 30 IS 1 BP 13 EP + DI 10.1016/j.psc.2007.01.001 PG 18 WC Psychiatry SC Psychiatry GA 156GL UT WOS:000245636000003 PM 17362800 ER PT J AU Dougherty, DD Rauch, SL AF Dougherty, Darin D. Rauch, Scott L. TI Somatic therapies for treatment-resistant depression: New neurotherapeutic interventions SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article ID TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE-STIMULATION; OBSESSIVE-COMPULSIVE DISORDER; DEEP BRAIN-STIMULATION; ELECTROCONVULSIVE-THERAPY; ANTERIOR CINGULOTOMY; POTENTIAL PREDICTORS; FOLLOW-UP; METAANALYSIS; DISEASE AB Until recently, few treatments for major depression other than pharmacotherapy, psychotherapy, and electroconvulsive therapy have been available. This article reviews recent data from the field of somatic therapies for treatment-resistant depression. Examples of neurotherapeutic interventions for major depression include ablative limbic system surgeries (eg, anterior cingulotomy and subcaudate tractotomy), vagus nerve stimulation, transcranial magnetic stimulation, and deep brain stimulation. The article briefly discusses the role of each of these neurotherapeutic interventions in treating depression. It concludes with thoughts on the future potential of neurotherapeutic interventions in the treatment of depression. C1 Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. McLean Hosp, Dept Psychiat, Belmont, MA 02478 USA. RP Dougherty, DD (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 15 Parkman St, Boston, MA 02114 USA. EM ddougherty@partners.org NR 29 TC 16 Z9 16 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD MAR PY 2007 VL 30 IS 1 BP 31 EP + DI 10.1016/j.psc.2006.12.006 PG 8 WC Psychiatry SC Psychiatry GA 156GL UT WOS:000245636000004 PM 17362801 ER PT J AU Feldman, G AF Feldman, Greg TI Cognitive and behavioral therapies for depression: Overview, new directions, and practical recommendations for dissemination SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; COLLABORATIVE RESEARCH-PROGRAM; MENTAL-HEALTH TREATMENT; STAR-ASTERISK-D; MAJOR DEPRESSION; PRIMARY-CARE; NATIONAL-INSTITUTE; RELAPSE PREVENTION; MARITAL-THERAPY; SELF-HELP AB Cognitive-behavioral therapy (GBT) is a nonpharmacologic strategy for depression treatment that has received considerable empirical support. This article provides an overview of the history and core techniques of CBT and discusses recently developed techniques and augmentations to CBT for depression. It reviews empirical studies comparing the relative efficacy of CBT and antidepressant medication as well as their combination. Studies highlighting the relapse-prevention properties of CBT are reviewed also. The article concludes with a discussion of practical recommendations for integrating GBT into a depression treatment plan. C1 Simmons Coll, Dept Psychol, Boston, MA 02115 USA. Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. RP Feldman, G (reprint author), Simmons Coll, Dept Psychol, 300 Fenway, Boston, MA 02115 USA. EM greg.feldman@simmons.edu NR 65 TC 21 Z9 21 U1 2 U2 18 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD MAR PY 2007 VL 30 IS 1 BP 39 EP + DI 10.1016/j.psc.2006.12.001 PG 13 WC Psychiatry SC Psychiatry GA 156GL UT WOS:000245636000005 PM 17362802 ER PT J AU Mischoulon, D AF Mischoulon, David TI Update and critique of natural remedies as antidepressant treatments SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article ID ST-JOHNS-WORT; PLACEBO-CONTROLLED TRIAL; MAJOR DEPRESSIVE DISORDER; ETHYL-EICOSAPENTAENOIC ACID; RANDOMIZED CONTROLLED TRIAL; TO-MODERATE DEPRESSION; ADENOSYL-L-METHIONINE; DOUBLE-BLIND TRIAL; HYPERICUM-PERFORATUM; BIPOLAR DEPRESSION AB The popularity of natural or "alternative" remedies to treat medical and psychiatric disorders has accelerated dramatically over the past decade, in the United States and worldwide. This article reviews the evidence for clinical efficacy, active ingredients, mechanisms of action, recommended dosages, and toxicities of the three best-studied putative natural antidepressants, St. John's Wort (hypenicum), S-adenosyl methionine, and the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid. Despite growing evidence for efficacy and safety, more comprehensive studies are required before these remedies can be recommended as safe and effective alternatives or adjuncts to conventional psychotropic agents. C1 Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Mischoulon, D (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, WAC-812,15 Parkman St, Boston, MA 02114 USA. EM dmischoulon@partners.org FU NCCIH NIH HHS [K23AT001129-05] NR 97 TC 15 Z9 15 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD MAR PY 2007 VL 30 IS 1 BP 51 EP + DI 10.1016/j.psc.2006.12.003 PG 19 WC Psychiatry SC Psychiatry GA 156GL UT WOS:000245636000006 PM 17362803 ER PT J AU Ostacher, MJ AF Ostacher, Michael J. TI Comorbid alcohol and substance abuse dependence in depression: Impact on the outcome of antidepressant treatment SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article ID NATIONAL EPIDEMIOLOGIC SURVEY; PLACEBO-CONTROLLED-TRIAL; MAJOR DEPRESSION; IMIPRAMINE TREATMENT; ANXIETY DISORDERS; FOLLOW-UP; ASSOCIATION; PREVALENCE; MOOD AB Major depressive disorder often co-occurs with substance use disorders, especially alcohol use disorders, and the course of each of these problems seems be complicated by the other. Diagnosing and treating these patients is challenging. A significant difficulty for clinicians is deciding whether to treat a mood episode in a patient who has current substance use or a substance use disorder, and what is the optimal treatment for that patient. This article discusses the prevalence of depressive and substance use disorder, the course of illness of comorbid depression and substance use disorders, and treatment response. C1 Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Ostacher, MJ (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 50 Staniford St,Suite 580, Boston, MA 02114 USA. EM mostacher@partners.org OI Ostacher, Michael/0000-0003-0353-7535 NR 23 TC 33 Z9 34 U1 2 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD MAR PY 2007 VL 30 IS 1 BP 69 EP + DI 10.1016/j.psc.2006.12.009 PG 9 WC Psychiatry SC Psychiatry GA 156GL UT WOS:000245636000007 PM 17362804 ER PT J AU Iosifescu, DV AF Iosifescu, Dan V. TI Treating depression in the medically ill SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Review ID PLACEBO-CONTROLLED TRIAL; DEXAMETHASONE SUPPRESSION TEST; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY-DISEASE; QUALITY-OF-LIFE; MAJOR DEPRESSION; DOUBLE-BLIND; POSTSTROKE DEPRESSION; FOLLOW-UP; RHEUMATOID-ARTHRITIS AB This article assesses the course of depressive disorders in persons who have comorbid medical illness. The article reviews a series of randomized, controlled studies of antidepressant treatment in subjects who have major depressive disorder (MDD) and selected medical illnesses. It also reviews a series of studies that compare the outcome of antidepressant treatment in subjects who have MDD with and without comorbid medical illness. It reviews hypotheses on the mechanism of the interaction between medical illness and clinical response in MDD. It concludes with clinical strategies recommended in depressed subjects who have medical comorbidity. C1 Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Iosifescu, DV (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, 50 Staniford St,Suite 401, Boston, MA 02114 USA. EM diosifescu@partners.org FU NIMH NIH HHS [K23MH067111] NR 125 TC 28 Z9 29 U1 7 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD MAR PY 2007 VL 30 IS 1 BP 77 EP + DI 10.1016/j.psc.2006.12.008 PG 15 WC Psychiatry SC Psychiatry GA 156GL UT WOS:000245636000008 PM 17362805 ER PT J AU Dougherty, DD Rauch, SL AF Dougherty, Darin D. Rauch, Scott L. TI Brain correlates of antidepressant treatment outcome from neuroimaging studies in depression SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Review ID POSITRON-EMISSION-TOMOGRAPHY; ANTERIOR CINGULATE CORTEX; CEREBRAL-BLOOD-FLOW; TREATMENT-RESISTANT DEPRESSION; SUBGENUAL PREFRONTAL CORTEX; RECURRENT MAJOR DEPRESSION; BIPOLAR AFFECTIVE-DISORDER; LATE-LIFE DEPRESSION; EVENT-RELATED FMRI; UNIPOLAR DEPRESSION AB The ultimate goal of psychiatric research in major depressive disorder, including postmortem and neuroimaging studies, is better diagnosis and treatment of afflicted individuals.A growing number of neuroiniaging studies have focused on correlates of treatment response. This article reviews findings from psychiatric research involving subjects who have major depression. It then discusses general issues involved in conducting neuroiniaging studies that seek to identify correlates of treatment response. It concludes with a review of neuromiaging studies of treatment response in depression and integrates these findings into current models regarding the pathophysiology of major depression. C1 Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. McLean Hosp, Dept Psychiat, Belmont, MA 02478 USA. RP Dougherty, DD (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 15 Parkman St, Boston, MA 02114 USA. EM ddougherty@partners.org NR 104 TC 24 Z9 24 U1 15 U2 17 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD MAR PY 2007 VL 30 IS 1 BP 91 EP + DI 10.1016/j.psc.2006.12.007 PG 14 WC Psychiatry SC Psychiatry GA 156GL UT WOS:000245636000009 PM 17362806 ER PT J AU Perlis, RH AF Perlis, Roy H. TI Pharmacogenetic studies of antidepressant response: How far from the clinic? SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article ID SEROTONIN TRANSPORTER GENE; INDUCED WEIGHT-GAIN; MAJOR DEPRESSIVE DISORDER; CHARCOAL-BROILED BEEF; 5-HT2C RECEPTOR GENE; FUNCTIONAL POLYMORPHISM; PROMOTER REGION; DRUG RESPONSE; PHENACETIN METABOLISM; BIPOLAR DEPRESSION AB Both the popular and the scientific press have embraced the idea of personalized medicine, in which genetic testing will allow precise matching of patients with optimal treatment. The first portion of this article briefly defines basic concepts in pharmacogenetics as they pertain to psychiatry and then discusses their potential application in antidepressant pharmacogenetics. The second portion of the article addresses key obstacles to the development and application of such tests, so that clinicians can understand how to evaluate and apply new tests as they are developed. C1 Massachusetts Gen Hosp, Pharmacogenet Res Unit, Depress & Biopolar Clin Program, Boston, MA 02114 USA. Massachusetts Gen Hosp, Res Program, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. RP Perlis, RH (reprint author), Massachusetts Gen Hosp, Pharmacogenet Res Unit, Depress & Biopolar Clin Program, 15 Parkman St,WACC 812, Boston, MA 02114 USA. EM rperlis@partners.org NR 78 TC 20 Z9 21 U1 1 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD MAR PY 2007 VL 30 IS 1 BP 125 EP + DI 10.1016/j.psc.2006.12.004 PG 15 WC Psychiatry SC Psychiatry GA 156GL UT WOS:000245636000011 PM 17362808 ER PT J AU Simpson, SM Krishnan, LL Kunik, ME Ruiz, P AF Simpson, Sherri M. Krishnan, Laura L. Kunik, Mark E. Ruiz, Pedro TI Racial disparities in diagnosis and treatment of depression: A literature review SO PSYCHIATRIC QUARTERLY LA English DT Review DE depression; racial disparities; diagnosis of depression; treatment of depression ID PRIMARY-CARE PATIENTS; ANTIDEPRESSANT TREATMENT; MAJOR DEPRESSION; UNITED-STATES; POPULATION; PREDICTORS; QUALITY; ILLNESS; ADULTS; TRENDS AB The purpose of this study was to systematically review the literature to determine whether racial disparities exist in the diagnosis and treatment of depression in the United States. A literature search using PubMed of potentially relevant articles in English that include data from population-based studies examining the diagnosis and/or treatment of depression; or data from prospective studies stratifying the rates of diagnosis and/or treatment of depression by race/ethnicity and ethnic comparisons between Caucasians, African Americans and/or Hispanics. Initial searches identified 2,396 articles. On the basis of our criteria, 14 articles were eligible for inclusion in this review. Four included data on the diagnosis of depression in different ethnic groups; their results were not consistent. Twelve included data on treatment variability in the treatment of depression; overall these suggested lower rates of treatment for African Americans and Hispanics than for Caucasians. More research is needed focusing on ethnic variation in the diagnosis of depression. Racial disparities exist in the treatment of depression. C1 Univ Texas, Sch Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Vet Affairs S Cent Mental Illness Res Educ & Clin, Little Rock, AR USA. Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Ruiz, P (reprint author), Univ Texas, Sch Med, Dept Psychiat & Behav Sci, 1300 Moursund,MSI 102, Houston, TX 77030 USA. EM Pedro.Ruiz@uth.tmc.edu NR 20 TC 65 Z9 66 U1 2 U2 9 PU KLUWER ACADEMIC-HUMAN SCIENCES PRESS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA SN 0033-2720 J9 PSYCHIAT QUART JI Psychiatr. Q. PD MAR PY 2007 VL 78 IS 1 BP 3 EP 14 DI 10.1007/s11126-006-9022-y PG 12 WC Psychiatry SC Psychiatry GA 136EU UT WOS:000244206200002 PM 17102936 ER PT J AU Pollard, R Yanasak, EV Rogers, SA Tapp, A AF Pollard, Richard Yanasak, Elisia V. Rogers, Steven A. Tapp, Andre TI Organizational and unit factors contributing to reduction in the use of seclusion and restraint procedures on an acute psychiatric inpatient unit SO PSYCHIATRIC QUARTERLY LA English DT Article; Proceedings Paper CT 38th Annual Meeting of the Association-for-the-Advancement-of-Behavior-Therapy CY NOV, 2004 CL New Orleans, LA SP Assoc Advancement Behav Therapy DE seclusion; restraint; inpatient psychiatry ID MILIEU AB Objective: The use of seclusion or restraint (S/R) as an emergency medical intervention to assist patients in regaining behavioral control continues to be an area of interest and concern for the Joint Commission on the Accreditation of Healthcare Organizations (JCAHO), consistent with the ongoing concerns in the medical, patient advocate, legislative and legal communities. This study examined unit characteristics and the use of S/R in a VA facility with a secured, acute mental health unit before and after the promulgation of the JCAHO 2000 standards for utilization of S/R for behavioral health reasons. Methods: Variables examined include patient acuity, patient census, number of admits, number of discharges, length of stay, number of nursing staff on duty, critical incidents and S/R hours per month. Results: Results indicated S/R use began showing a notable decrease corresponding to the time that senior unit management began discussions of the new JCAHO standards. These reductions maintained statistical significance even after controlling for changes in unit environmental variables. C1 VA Puget Sound Hlth Care Syst, Amer Lake Div, Mental Hlth Serv, Tacoma, WA 98493 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Yanasak, EV (reprint author), VA Puget Sound Hlth Care Syst, Amer Lake Div, Mental Hlth Serv, A-116-R,9600 Vet Dr SW, Tacoma, WA 98493 USA. EM Elisia.Yanasak@med.va.gov NR 25 TC 26 Z9 26 U1 2 U2 4 PU KLUWER ACADEMIC-HUMAN SCIENCES PRESS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA SN 0033-2720 J9 PSYCHIAT QUART JI Psychiatr. Q. PD MAR PY 2007 VL 78 IS 1 BP 73 EP 81 DI 10.1007/s11126-006-9028-5 PG 9 WC Psychiatry SC Psychiatry GA 136EU UT WOS:000244206200008 PM 17102932 ER PT J AU Bauer-Wu, S Norris, R Healey, M Powell, M Habin, K Partridge, A Schapira, L AF Bauer-Wu, S. Norris, R. Healey, M. Powell, Mark Habin, K. Partridge, A. Schapira, L. TI An innovative expressive writing intervention for young breast cancer patients: Feasibility, preference and psychological effects SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Massachusetts, Boston, MA 02125 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 2 Z9 2 U1 2 U2 4 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9249 J9 PSYCHO-ONCOL JI Psycho-Oncol. PD MAR PY 2007 VL 16 IS 3 SU S BP S78 EP S79 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 147ZS UT WOS:000245044900150 ER PT J AU Bober, S Park, E Diller, L AF Bober, S. Park, E. Diller, L. TI Re-engaging the disconnected: Educational intervention with long-term female Hodgkin's survivors at high risk for breast cancer SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9249 J9 PSYCHO-ONCOL JI Psycho-Oncol. PD MAR PY 2007 VL 16 IS 3 SU S BP S71 EP S71 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 147ZS UT WOS:000245044900136 ER PT J AU Fineberg, I Asch, S Golden, J AF Fineberg, I Asch, S. Golden, J. TI A research-based model for family conferences in palliative care SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 Univ Lancaster, Inst Hlth Res, Int Observ End Life Care, Lancaster, England. VA Greater Los Angeles Hlthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9249 J9 PSYCHO-ONCOL JI Psycho-Oncol. PD MAR PY 2007 VL 16 IS 3 SU S BP S67 EP S67 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 147ZS UT WOS:000245044900128 ER PT J AU Green, GL Carter, DN Latini, DM Devadoss, R Kaniu-Mwaniki, P Barker, JC Sands, LP Chren, MM Knight, SJ AF Green, G. L. DN, Carter Latini, D. M. Devadoss, R. Kaniu-Mwaniki, P. Barker, J. C. Sands, L. P. Chren, M-M Knight, S. J. TI Symptoms following prostate cancer diagnosis and care: Expanding the range and identifying needs for symptom management SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 San Francisco VA Med Ctr, San Francisco, CA USA. Baylor Coll Med, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Purdue Univ, W Lafayette, IN 47907 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9249 J9 PSYCHO-ONCOL JI Psycho-Oncol. PD MAR PY 2007 VL 16 IS 3 SU S BP S69 EP S70 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 147ZS UT WOS:000245044900133 ER PT J AU Greer, J Temel, J Pirl, W Lynch, T AF Greer, J. Temel, J. Pirl, W. Lynch, T. TI Anxiety, quality of life and chemotherapy adherence among patients with advanced non-small cell lung cancer SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9249 J9 PSYCHO-ONCOL JI Psycho-Oncol. PD MAR PY 2007 VL 16 IS 3 SU S BP S13 EP S13 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 147ZS UT WOS:000245044900023 ER PT J AU Hamilton, J Bauer-Wu, S Liem, J Levandowski, K AF Hamilton, J. Bauer-Wu, S. Liem, J. Levandowski, K. TI Visitors: Social support during bone marrow transplantation SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 Univ Massachusetts, Boston, MA 02125 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9249 J9 PSYCHO-ONCOL JI Psycho-Oncol. PD MAR PY 2007 VL 16 IS 3 SU S BP S75 EP S76 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 147ZS UT WOS:000245044900144 ER PT J AU Kornblith, AB Powell, M Regan, MM Bennett, S Krasner, C Moy, B Younger, J Goodman, A Berkowitz, R Winer, E AF Kornblith, A. B. Powell, M. Regan, M. M. Bennett, S. Krasner, C. Moy, B. Younger, J. Goodman, A. Berkowitz, R. Winer, E. TI Long-term psychosocial adjustment of older versus younger survivors of breast and endometrial cancer SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9249 J9 PSYCHO-ONCOL JI Psycho-Oncol. PD MAR PY 2007 VL 16 IS 3 SU S BP S24 EP S24 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 147ZS UT WOS:000245044900043 ER PT J AU Lannen, P Kreicbergs, U Onelov, E Wolfe, J AF Lannen, P. Kreicbergs, U. Onelov, E. Wolfe, J. TI Support from healthcare staff can facilitate parental grieving following the loss of a child to cancer: A nationwide study SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Phillis F Cantor Ctr, Boston, MA 02115 USA. Karolinska Inst, Dept Women & Childs Hlth, Stockholm, Sweden. Childrens Hosp, Dept Med, Boston, MA 02115 USA. Univ Bern, Dept Psychol, Bern, Switzerland. Dana Farber Canc Inst, Dept Pediat Oncol, Ctr Outcomes & Policy Res, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9249 J9 PSYCHO-ONCOL JI Psycho-Oncol. PD MAR PY 2007 VL 16 IS 3 SU S BP S45 EP S45 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 147ZS UT WOS:000245044900083 ER PT J AU Pirl, W Temel, J Cashavelly, B Lynch, T AF Pirl, W. Temel, J. Cashavelly, B. Lynch, T. TI Parsing depression from fatigue in cancer patients using the fatigue symptom inventory SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9249 J9 PSYCHO-ONCOL JI Psycho-Oncol. PD MAR PY 2007 VL 16 IS 3 SU S BP S48 EP S48 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 147ZS UT WOS:000245044900089 ER PT J AU West, L Bauer-Wu, S Liem, J Powell, M AF West, L. Bauer-Wu, S. Liem, J. Powell, M. TI Factors associated with anxiety and depression in young women recently diagnosed with breast cancer SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 Univ Massachusetts, Boston, MA 02125 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9249 J9 PSYCHO-ONCOL JI Psycho-Oncol. PD MAR PY 2007 VL 16 IS 3 SU S BP S92 EP S93 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 147ZS UT WOS:000245044900178 ER PT J AU Zebrack, B Bleyer, A Albritton, K Medearis, S Tang, J AF Zebrack, B. Bleyer, A. Albritton, K. Medearis, S. Tang, J. TI Assessing the health care needs of adolescent and young adult cancer patients and survivors SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 Univ So Calif, Sch Social Work, Los Angeles, CA 90089 USA. St Charles Hosp, Bend, OR USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9249 J9 PSYCHO-ONCOL JI Psycho-Oncol. PD MAR PY 2007 VL 16 IS 3 SU S BP S6 EP S6 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 147ZS UT WOS:000245044900010 ER PT J AU Guo, S Chen, DF Zhou, DF Sun, HQ Wu, GY Haile, CN Kosten, TA Kosten, TR Zhang, XY AF Guo, Song Chen, Da Fang Zhou, Dong Feng Sun, Hong Qiang Wu, Gui Ying Haile, Colin N. Kosten, Therese A. Kosten, Thomas R. Zhang, Xiang Yang TI Association of functional catechol O-methyl transferase (COMT) Val108Met polymorphism with smoking severity and age of smoking initiation in Chinese male smokers SO PSYCHOPHARMACOLOGY LA English DT Article DE COMT; polymorphism; nicotine; smoker; dependence ID METHYLTRANSFERASE COMT; NICOTINE DEPENDENCE; GENETIC-VARIATION; TRANSPORTER GENE; POPULATION; BEHAVIOR; WOMEN; CONSUMPTION; CESSATION; JAPANESE AB Rationale Catechol-O-methyltransferase (COMT) is an enzyme involved in the degradation and inactivation of the neurotransmitter dopamine, which is important in mediating drug reward such as nicotine in tobacco smoke. Different COMT alleles encode enzyme whose activity varies from three- to fourfold that may affect dopamine levels and alter subjective effects of nicotine. Recent evidence also suggests that a COMT polymorphism may be especially important in determining an individual's predisposition to developing nicotine dependence. Subjects and Methods We studied the COMT Val108Met polymorphism in a male population of 203 current smokers, 66 former smokers, and 102 non-smokers. The age-adjusted odds ratios were estimated by multiple logistic regression models. Results The results showed no significant association of the COMT Val108Met with initiation, persistent smoking, or smoking cessation. However, current smokers with the Met allele had significantly higher Fagerstrom Test for Nicotine Dependence scores (7.5 +/- 2.1 vs 6.8 +/- 1.8, p = 0.018) and started smoking significantly earlier (18.4 +/- 4.9 vs 20.1 +/- 5.9 years, p = 0.036). Conclusions These results suggest that the COMT Val108Met polymorphism may not influence smoking status in a Chinese male population but may influence the age at which smoking started and smoking severity among smokers. However, the findings must be regarded as preliminary because of the relatively small sample size and marginal associations and should be replicated in a larger cohort. C1 Peking Univ, Int Mental Hlth, Beijing 100083, Peoples R China. Peking Univ, Sch Publ Hlth, Dept Epidemiol & Stat, Beijing 100083, Peoples R China. Beijing Anding Hosp Capital Univ Med Sci, Natl Drug Dependence Treatment Ctr, Beijing, Peoples R China. Beijing Huilongguan Hosp, Ctr Biol Psychait, Beijing, Peoples R China. Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Zhang, XY (reprint author), Peking Univ, Int Mental Hlth, Beijing 100083, Peoples R China. EM dafangchen@bjmu.edu.cn; zhoudf@bjmu.edu.cn; xyzhang@bcm.edu OI Haile, Colin/0000-0001-8293-7291 FU NIDA NIH HHS [K05-DA0454, P50-DA18827] NR 32 TC 30 Z9 32 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD MAR PY 2007 VL 190 IS 4 BP 449 EP 456 DI 10.1007/s00213-006-0628-4 PG 8 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 132FC UT WOS:000243926900005 PM 17206495 ER PT J AU Porcerelli, JH Dauphin, VB Ablon, JS Leitman, S Bambery, M AF Porcerelli, John H. Dauphin, V. Barry Ablon, J. Stuart Leitman, Susan Bambery, Michael TI Psychoanalysis with avoidant personality disorder: A systematic case study SO PSYCHOTHERAPY LA English DT Article DE psychoanalysis; avoidant; personality disorder; case study; treatment outcome ID COLLABORATIVE RESEARCH-PROGRAM; MENTAL-HEALTH TREATMENT; ASSESSING AXIS II; NATIONAL INSTITUTE; DYNAMIC PSYCHOTHERAPY; CLINICAL-SIGNIFICANCE; MAJOR DEPRESSION; COMMUNITY SAMPLE; OBJECT RELATIONS; DSM-IV AB This case study of process and outcome is based upon data obtained during a 5-year psychoanalysis of an adult male with avoidant personality disorder (AVPD). To date, no known systematic case studies, effectiveness studies, or randomized control trials exist for psychoanalysis in the treatment of AVPD. In this study, self-reported symptoms and observer-rated personality disorder (PD), global functioning, object relations, and psychological health were gathered at intake, after each year of treatment, and at 1-year follow-up. Process data was gathered to determine the extent to which the treatment adhered to prototypes of psychodynamic, cognitive-behavioral, and interpersonal therapy. Results indicated that the patient achieved clinically significant reductions in PD, symptom severity, and relational pathology. Gains were maintained at 1-year follow-up. The treatment significantly adhered to psychodynamic principles throughout, with some use of cognitive-behavioral and interpersonal principles in the third year of treatment. These findings warrant further investigation of psychoanalysis for AVPD and demonstrate the usefulness of assessing multiple domains of patient functioning and treatment process. C1 Wayne State Univ, Sch Med, Dept Family Med & Publ Hlth Sci, Detroit, MI 48235 USA. Univ Detroit Mercy, Dept Psychol, Detroit, MI 48221 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Porcerelli, JH (reprint author), Wayne State Univ, Sch Med, Dept Family Med & Publ Hlth Sci, 15400 W McNichols,Room 210, Detroit, MI 48235 USA. EM jporcer@med.wayne.edu NR 54 TC 14 Z9 15 U1 2 U2 11 PU AMER PSYCHOLOGICAL ASSOC, DIV PSYCHOTHERAPY PI CORAL GABLES PA 1390 SOUTH DIXIE HIGHWAY, STE 2222, CORAL GABLES, FL 33146-2946 USA SN 0033-3204 J9 PSYCHOTHERAPY JI Psychotherapy PD MAR PY 2007 VL 44 IS 1 BP 1 EP 13 DI 10.1037/0033-3204.44.1.1 PG 13 WC Psychology, Clinical SC Psychology GA 151MA UT WOS:000245293300001 PM 22122163 ER PT J AU Blendon, RJ Benson, JM DesRoches, CM Lyon-Daniel, K Mitchell, EW Pollard, WE AF Blendon, Robert J. Benson, John M. DesRoches, Catherine M. Lyon-Daniel, Katherine Mitchell, Elizabeth W. Pollard, William E. TI The public's preparedness for hurricanes in four affected regions SO PUBLIC HEALTH REPORTS LA English DT Article ID KATRINA AB Objectives. The purpose of this article is to look at how prepared people in communities outside the main areas devastated by Hurricanes Katrina and Rita thought they were for those storms and for major hurricanes in the near future, what factors were related to why people did not evacuate, and what concerns people had in communities that took in evacuees from the hurricanes. Methods. Telephone interviews were conducted with randomly selected adults in Baton Rouge, Houston, Dallas, and Mississippi/Alabama (excluding the immediate Gulf Coast) to assess respondents' knowledge, attitudes, and behaviors about hurricane preparedness and response to Hurricanes Katrina and Rita. Results. The surveys found a sizeable proportion of respondents who might not, for a number of reasons, comply with future orders to evacuate. A substantial proportion reported that they were not prepared for another major hurricane and indicated a desire for more information about how to prepare for future hurricanes. In communities that reported taking in I urge numbers of evacuees, residents expressed concern about the impact of the evacuees on their community. Conclusion. Evacuating communities involves a number of concrete problems that were not adequately addressed in the cases of Hurricanes Katrina and Rita. Responses to these surveys indicate a need for more comprehensive hurricane disaster planning. C1 Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, HArvard Opin Res Program, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Natl Ctr Hlth Marketing, Ctr Dis Control & Prevent, Atlanta, GA USA. RP Blendon, RJ (reprint author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave,4th Fl, Boston, MA 02115 USA. EM rblendon@hsph.harvard.edu NR 15 TC 10 Z9 10 U1 1 U2 5 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2007 VL 122 IS 2 BP 167 EP 176 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 135BU UT WOS:000244129600006 PM 17357359 ER PT J AU Uppot, RN AF Uppot, Raul N. TI Impact of obesity on radiology SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Article ID IMAGE QUALITY; SCREENING MAMMOGRAPHY; LIMITATIONS; ASSOCIATION; SONOGRAPHY; OUTCOMES; SURGERY; FATNESS; WEIGHT AB Obesity is impacting radiology departments throughout the country. Increasingly, the ability to acquire and interpret images is compromised by a patient's body habitus. This article provides radiologists with background information about obesity including the definition of obesity the prevalence of obesity and the health and economic implications; describes current problems and provides specific solutions related to imaging obese patients using various modalities; and discusses the future of medical imaging and obesity. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent Radiol,Dept Rad, Boston, MA 02114 USA. RP Uppot, RN (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent Radiol,Dept Rad, 55 Fruit St,White 270, Boston, MA 02114 USA. EM ruppot@partners.org NR 34 TC 36 Z9 36 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD MAR PY 2007 VL 45 IS 2 BP 231 EP + DI 10.1016/j.rcl.2007.03.001 PG 17 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 179KO UT WOS:000247288600002 PM 17502214 ER PT J AU Montet, X Figueiredo, JL Alencar, H Ntziachristos, V Mahmood, U Weissleder, R AF Montet, Xavier Figueiredo, Jose-Luiz Alencar, Herlen Ntziachristos, Vasilis Mahmood, Umar Weissleder, Ralph TI Tomographic fluorescence imaging of tumor vascular volume in mice SO RADIOLOGY LA English DT Article ID IN-VIVO; PHASE-I; ANGIOGENESIS; CANCER; MOUSE; CONJUGATE; MODEL; SIZE AB Purpose: To prospectively determine the feasibility of imaging vascular volume fraction ( VVF) and its therapeutic inhibition in mouse models of cancer with three-dimensional fluorescence molecular tomography ( FMT). Materials and Methods: All studies were approved by the institutional animal review committee and were in accordance with National Institutes of Health guidelines. CT26 colon tumor-bearing mice were imaged with FMT after intravenous administration of long-circulating near-infrared fluorescent bloodpool agents optimized for two nonoverlapping excitation wavelengths ( 680 and 750 nm). A total of 58 mice were used for imaging VVF to evaluate the following: ( a) differences in ectopically and orthotopically implanted tumors ( n = 10), ( b) cohorts of mice ( n = 24) treated with anti-vascular endothelial growth factor ( VEGF) antibody, ( c) serial imaging in same animal to determine natural course of angiogenesis ( n = 4), and ( d) dose response to anti-VEGF therapy ( n = 20). To compare groups receiving antiangiogenic chemotherapy, analysis of variance was used. Results: Fluorochrome concentrations derived from FMT measurements were reconstructed with an accuracy of +/- 10% at 680 nm and +/- 7% at 750 nm and in a depth-independent manner, unlike at reflectance imaging. FMT measurements of vascular fluorescent probes were linear, with concentration over several orders of magnitude ( r > 0.98). VVFs of colonic tumors, which varied considerably among animals ( 3.5% +/- 1.5 [ standard deviation]), could be depicted with in vivo imaging in three dimensions with less than 5 minutes of imaging and less than 3 minutes of analysis. The natural course of angiogenesis and its inhibition could be reliably imaged and depicted serially in different experimental setups. Conclusion: FMT is a tomographic optical imaging technique that, in conjunction with appropriate fluorescent probes, allows quantitative visualization of biologic processes. C1 Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Weissleder, R (reprint author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, Bldg 149,13th St,Room 5403, Charlestown, MA 02129 USA. EM weissleder@helix.mgh.harvard.edu OI Montet, Xavier/0000-0003-2442-5866 FU NCI NIH HHS [R33 CA91807, P01 CA69246, P50 CA86355, R24 CA92782] NR 29 TC 88 Z9 91 U1 0 U2 6 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD MAR PY 2007 VL 242 IS 3 BP 751 EP 758 DI 10.1148/radiol.2423052065 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 142VR UT WOS:000244679200013 PM 17325064 ER PT J AU Lee, SI Saokar, A Dreyer, KJ Weilburg, JB Thrall, JH Hahn, PF AF Lee, Susanna I. Saokar, Anuradha Dreyer, Keith J. Weilburg, Jeffrey B. Thrall, James H. Hahn, Peter F. TI Does radiologist recommendation for follow-up with the same imaging modality contribute substantially to high-cost imaging volume? SO RADIOLOGY LA English DT Article; Proceedings Paper CT 90th Scientific Assembly and Annual Meeting of the Radiological-Society-of-North-America CY NOV 28-DEC 03, 2004 CL Chicago, IL SP Radiol Soc N Amer ID UNITED-STATES AB Purpose: To retrospectively measure repeat rates for high-cost imaging studies, determining their causes and trends, and the impact of radiologist recommendations for a repeat examination on imaging volume. Materials and Methods: This HIPAA-compliant study had institutional review board approval, with waiver of informed consent. Repeat examination was defined as a same-modality examination performed in the same patient within 0 days to 7 months of a first examination. From a database of all radiology examinations ( > 2.9 million) at one institution from May 1996 to June 2003, a computerized search identified head, spine, chest, and abdominal computed tomographic ( CT), brain and spine magnetic resonance ( MR) imaging, pelvic ultrasonography ( US), and nuclear cardiology examinations with a prior examination of the same type within 7 months. Examination pairs were subdivided into studies repeated at less than 2 weeks, between 2 weeks and 2 months, or between 2 and 7 months. Automated classification of radiology reports revealed whether a repeat examination from June 2002 to June 2003 had been preceded by a radiologist recommendation on the prior report. Trends over time were analyzed with linear regression, and 95% confidence intervals were calculated. Results: Between July 2002 and June 2003, 31 111 of 100 335 examinations ( 31%) were repeat examinations. Body CT ( 9057 of 20 177 [ 45%] chest and 8319 of 22 438 [ 37%] abdomen) and brain imaging ( 6823 of 18 378 [ 37%] CT and 3427 of 11 455 [ 30%] MR imaging) represented the highest repeat categories. Among five high-cost, high-volume imaging examinations, 6426 of 85 014 ( 8%) followed a report with a radiologist recommendation. Most common indications for examination repetition were neurologic surveillance within 2 weeks and cancer follow-up at 2-7 months. From 1997 to mid-2003, MR imaging and CT repeat rates increased ( 0.71% per year [ P < .01] and 1.87% per year [ P < .01], respectively). Conclusion: Repeat examinations account for nearly one-third of high-cost radiology examinations and represent an increasing proportion of such examinations. Most repeat examinations are initiated clinically without a recommendation by a radiologist. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Massachusetts Gen Phys Org, Boston, MA 02114 USA. RP Lee, SI (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA. NR 20 TC 25 Z9 25 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD MAR PY 2007 VL 242 IS 3 BP 857 EP 864 DI 10.1148/radoil.2423051754 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 142VR UT WOS:000244679200026 PM 17325070 ER PT J AU Pelley, CJ Kwo, J Hess, DR AF Pelley, Carolyn J. Kwo, Jean Hess, Dean R. TI Tracheomalacia in an adult with respiratory failure and Morquio syndrome SO RESPIRATORY CARE LA English DT Article; Proceedings Paper CT 50th International Respiratory Congress of the American-Association-for-Respiratory-Care CY DEC 04, 2004-DEC 07, 2006 CL New Orleans, LA SP Amer Assoc Respiratory Care DE Morquio syndrome; tracheomalacia; tracheostomy; respiratory failure ID POSITIVE AIRWAY PRESSURE; ACQUIRED TRACHEOBRONCHOMALACIA; INFANTS; MUCOPOLYSACCHARIDOSES; OBSTRUCTION; MANAGEMENT; DISORDERS; TRACHEAL; COLLAPSE; DISEASE AB Patients with Morquio syndrome can develop respiratory failure secondary to reduced chest wall compliance and airway collapse from irregularly shaped vocal cords and trachea. We report the case of a patient with Morquio syndrome whose clinical course was complicated by tracheomalacia. An obese 29-year-old female with Morquio syndrome presented with severe wheezing and tachycardia. One month prior to admission, she underwent elective spinal stabilization surgery, which resulted in fixed head flexion. The surgery was complicated by paraplegia and the need for mechanical ventilation via tracheostomy. Initial bronchoscopy revealed severe tracheomalacia, and the tracheostomy tube was changed to one with an adjustable flange. On 3 occasions over the next 20 days she had labored breathing with dramatically decreased V-T. Each time, bronchoscopy revealed almost complete occlusion of the distal end of the tracheostomy tube. Ventilation became much easier when the tracheostomy tube was advanced past the obstruction. After one month, she became febrile, severely hypoxemic, and her family decided to withdraw care. In patients with Morquio syndrome, close attention must be given to the patient's abnormal airways and malformed chest cage. Mechanical ventilation may be difficult because of upper-airway obstruction or low compliance imposed by the restrictive chest wall. Complete tracheal collapse can occur in these patients, especially with fixed head flexion. C1 Massachusetts Gen Hosp, Resp Care Dept, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Hess, DR (reprint author), Massachusetts Gen Hosp, Resp Care Dept, Ellison 401,55 Fruit St, Boston, MA 02114 USA. EM dhess@partners.org NR 18 TC 13 Z9 14 U1 0 U2 3 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESPIR CARE JI Respir. Care PD MAR PY 2007 VL 52 IS 3 BP 278 EP 282 PG 5 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 146FN UT WOS:000244920000004 PM 17328826 ER PT J AU Miravitlles, M Anzueto, A Legnani, D Forstmeier, L Fargel, M AF Miravitlles, Marc Anzueto, Antonio Legnani, Delfino Forstmeier, Leonhard Fargel, Matthias TI Patient's perception of exacerbations of COPD - the PERCEIVE study SO RESPIRATORY MEDICINE LA English DT Article DE COPD; chronic bronchitis; patient-reported outcomes; respiratory symptoms ID OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; CHRONIC-BRONCHITIS; INTERNATIONAL SURVEY; UNITED-STATES; HEALTH; POPULATION; RECOVERY; COSTS; PERSPECTIVE AB The evaluation of therapies requires the development of patient-reported outcomes (PROs) that help clinicians to understanding the symptoms, perceptions and feelings of patients with exacerbations of chronic obstructive pulmonary disease (COPD). With the aim of obtaining information on the perceptions of patients with COPD, their exacerbations and expectations of treatment, a random telephone contact survey in six countries was performed. From 83,592 households screened, 1100 subjects with symptoms compatible with COPD were identified. The most frequent symptom was shortness of breath (78%). The most frequent complaint was that due to their COPD: "they could not complete the activities they like to do" (54%); 17% (187) of individuals were afraid that their COPD would cripple, or eventually kill them. Exacerbations generated a mean of 5.1 medical visits/year (SD=4.6) with the mean duration of exacerbation symptoms being 10.5 days. Increased coughing was the exacerbation symptom having the strongest impact on well-being (42%). Fifty-five percent of patients declared that quicker symptom relief was the most desired requirement for treatment. New data are provided on the impact of COPD and its exacerbations on the daily life of patients. These data will help to develop PROs designed to evaluate the effectiveness of different therapies for exacerbated COPD. (c) 2006 Elsevier Ltd. All rights reserved. C1 Hosp Clin Barcelona, Inst Clin Torax IDIBAPS, Serv Pneumol, Barcelona, Spain. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Milan, Inst Resp Dis, Milan, Italy. Bayer HealthCare, Wuppertal, Germany. Psyma Int Med Mkt Res GmbH, Rueckersdorf Nuernberg, Germany. RP Miravitlles, M (reprint author), Hosp Clin Barcelona, Inst Clin Torax IDIBAPS, Serv Pneumol, Barcelona, Spain. EM marcm@clinic.ub.es OI Miravitlles, Marc/0000-0002-9850-9520 NR 40 TC 54 Z9 55 U1 0 U2 3 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 J9 RESP MED JI Respir. Med. PD MAR PY 2007 VL 101 IS 3 BP 453 EP 460 DI 10.1016/j.rmed.2006.07.010 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA 144XJ UT WOS:000244829500010 PM 16938447 ER PT J AU Cerrato, F Seminara, SB AF Cerrato, Felecia Seminara, Stephanie B. TI Human genetics of GPR54 SO REVIEWS IN ENDOCRINE & METABOLIC DISORDERS LA English DT Article DE puberty; kisspeptin; metastin; GPR54; gonadotropin-releasing hormone (GnRH); hypognadotropic hypogonadism ID IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; PROTEIN-COUPLED RECEPTOR; METASTASIS SUPPRESSOR GENE; HORMONE-RELEASING ACTIVITY; PITUITARY-GONADAL AXIS; KISS-1 MESSENGER-RNA; GNRH RECEPTOR; GONADOTROPIN-SECRETION; REPRODUCTIVE AXIS; KALLMANN-SYNDROME AB Idiopathic hypogonadotropic hypogonadism (IHH) is a condition characterized by absence of sexual maturation in the setting of low sex steroids and low/ normal gonadotropins. Despite its rarity, considerable genetic heterogeneity and phenotypic variability exists in this disorder. Loss of function mutations in a G protein coupled receptor, GPR54, have been shown to cause IHH. Although mutations in GPR54 are not a common cause of this condition, patients bearing mutations are critical to explore genotype-phenotype correlations and gene function. In this review, we will examine the human genetics studies of GPR54, the phenotypic implications of mutations in this gene, and the emerging roles of the kisspeptin/GPR54 pathway. C1 Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA. RP Cerrato, F (reprint author), Massachusetts Gen Hosp, Reprod Endocrine Unit, Bartlett Hall Extens 5, Boston, MA 02114 USA. EM sseminara@partners.org FU NICHD NIH HHS [U54 HD028138, R01 HD043341] NR 59 TC 12 Z9 15 U1 0 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1389-9155 J9 REV ENDOCR METAB DIS JI Rev. Endocr. Metab. Disord. PD MAR PY 2007 VL 8 IS 1 BP 47 EP 55 DI 10.1007/s11154-007-9027-3 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 165KL UT WOS:000246304300006 PM 17334928 ER PT J AU MacIntyre, N Crapo, RO Viegi, G Johnson, DC van der Grinten, CPM Brusasco, V Burgos, F Casaburi, R Coates, A Enright, P Gustafsson, P Hankinson, J Jensen, R Mckay, R Miller, MR Navajas, D Pedersen, OF Pellegrino, R Wanger, J AF MacIntyre, N. Crapo, R. O. Viegi, G. Johnson, D. C. van der Grinten, C. P. M. Brusasco, V. Burgos, F. Casaburi, R. Coates, A. Enright, P. Gustafsson, P. Hankinson, J. Jensen, R. McKay, R. Miller, M. R. Navajas, D. Pedersen, O. F. Pellegrino, R. Wanger, J. TI Standardisation of the single-breath determination of carbon monoxide uptake in the lung SO REVUE DES MALADIES RESPIRATOIRES LA French DT Review ID PULMONARY DIFFUSING-CAPACITY; AIR-FLOW LIMITATION; GENERAL-POPULATION SAMPLE; TRANSFER-COEFFICIENT KCO; CAPILLARY BLOOD-VOLUME; ALVEOLAR VOLUME; CIGARETTE-SMOKING; VENTILATION INHOMOGENEITY; IMPAIRMENT DISABILITY; FUNCTION LABORATORIES C1 Univ Genoa, I-16132 Genoa, Italy. Duke Univ, Med Ctr, Durham, NC 27706 USA. LDS Hosp, Salt Lake City, UT USA. CNR, Inst Clin Physiol, I-56100 Pisa, Italy. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Hop Univ Maastricht, Maastricht, Netherlands. Hosp Clin Villarroel, Barcelona, Spain. Harbor UCLA Med Ctr, Torrance, CA 90509 USA. Hosp Sick Children, Toronto, ON M5G 1X8, Canada. Queen Silvias Childrens Hosp, Gothenburg, Sweden. Hankinson Consulting Inc, Valdosta, GA USA. Occupat Med, Cincinnati, OH USA. Univ Hosp Birmingham NHS Trust, Birmingham, W Midlands, England. Lab Biofis & Bioengn, Barcelona, Spain. Univ Aarhus, Aarhus, Denmark. Azienda Osped S Croce & Carle, Cuneo, Italy. Pharmaceut Res Associates Inc, Lenexa, KS USA. RP Brusasco, V (reprint author), Univ Genoa, Vle Benedetto 15,6, I-16132 Genoa, Italy. EM vito.brusasco@unige.it RI Burgos, Felip/E-5734-2015 OI Burgos, Felip/0000-0002-4938-4581 NR 112 TC 3 Z9 3 U1 0 U2 4 PU MASSON EDITEUR PI MOULINEAUX CEDEX 9 PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE SN 0761-8425 J9 REV MAL RESPIR JI Rev. Mal. Respir. PD MAR PY 2007 VL 24 IS 3 BP S65 EP S82 DI 10.1019/200720006 PN 2 PG 18 WC Respiratory System SC Respiratory System GA 162RP UT WOS:000246107500008 ER PT J AU Miller, MR Hankinson, J Brusasco, V Burgos, F Casaburi, R Coates, A Crapo, R Enright, P van der Grinten, CPM Gustafsson, P Jensen, R Johnson, DC MacIntyre, N Mckay, R Navajas, D Pedersen, OF Pellegrino, R Viegi, G Wanger, J AF Miller, M. R. Hankinson, J. Brusasco, V. Burgos, F. Casaburi, R. Coates, A. Crapo, R. Enright, P. van der Grinten, C. P. M. Gustafsson, P. Jensen, R. Johnson, D. C. MacIntyre, N. McKay, R. Navajas, D. Pedersen, O. F. Pellegrino, R. Viegi, G. Wanger, J. TI Standardisation of spirometry SO REVUE DES MALADIES RESPIRATOIRES LA French DT Article ID PEAK EXPIRATORY FLOW; CHRONIC AIRWAY-OBSTRUCTION; AMERICAN-THORACIC-SOCIETY; PULMONARY-FUNCTION; PRESCHOOL-CHILDREN; GENERAL-POPULATION; JET NEBULIZATION; HARMONIC CONTENT; VOLUME CURVES; TEMPERATURE C1 Univ Genoa, I-16132 Genoa, Italy. Univ Hosp Birmingham, NHS Trust, Birmingham, W Midlands, England. Hankinson Consulting Inc, Valdosta, GA USA. Hosp Clin Villarroel, Villarroel, Barcelona, Spain. Harbor UCLA Med Ctr, Torrance, CA 90509 USA. Hosp Sick Children, Toronto, ON M5G 1X8, Canada. LDS Hosp, Salt Lake City, UT USA. Univ Hosp Maastricht, Maastricht, Les Pays Bas, Netherlands. Queen Silvias Childrens Hosp, Gothenburg, Sweden. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Duke Univ, Med Ctr, Durham, NC USA. Occupat Med, Cincinnati, OH USA. Univ Barcelona, IDI BAPS, Barcelona, Spain. Univ Aarhus, Aarhus, Denmark. Azienda Osped S Croce & Carle, Cuneo, Italy. CNR, Inst Clin Physiol, I-56100 Pisa, Italy. Pharmaceut Res Associates Inc, Lenexa, KS USA. RP Brusasco, V (reprint author), Univ Genoa, Vle Benedetto 15,6, I-16132 Genoa, Italy. EM vito.brusasco@unige.it NR 69 TC 4 Z9 4 U1 2 U2 20 PU MASSON EDITEUR PI MOULINEAUX CEDEX 9 PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE SN 0761-8425 J9 REV MAL RESPIR JI Rev. Mal. Respir. PD MAR PY 2007 VL 24 IS 3 BP S27 EP S49 DI 10.1019/200720004 PN 2 PG 23 WC Respiratory System SC Respiratory System GA 162RP UT WOS:000246107500006 ER PT J AU Miller, MR Crapo, R Hankinson, J Brusasco, V Burgos, F Casaburi, R Coates, A Enright, P van der Grinten, CPM Gustafsson, P Jensen, R Johnson, DC MacIntyre, N Mckay, R Navajas, D Pedersen, OF Pellegrino, R Viegi, G Wenger, J AF Miller, M. R. Crapo, R. Hankinson, J. Brusasco, V. Burgos, F. Casaburi, R. Coates, A. Enright, P. van der Grinten, C. P. M. Gustafsson, P. Jensen, R. Johnson, D. C. MacIntyre, N. McKay, R. Navajas, D. Pedersen, O. F. Pellegrino, R. Viegi, G. Wenger, J. TI General considerations for lung function testing SO REVUE DES MALADIES RESPIRATOIRES LA French DT Article ID WORKING PARTY STANDARDIZATION; MYCOBACTERIUM-AVIUM; EUROPEAN-COMMUNITY; INFECTION-CONTROL; REFERENCE VALUES; CROSS-INFECTION; ARM SPAN; SPIROMETRY; VOLUMES; POPULATION C1 Univ Genes, I-16132 Genoa, Italy. Univ Hosp Birmingham, NHS Trust, Birmingham, W Midlands, England. LDS Hosp, Salt Lake City, UT USA. Hankinson Consulting Inc, Valdosta, GA USA. Hosp Clin Villarroel, Barcelona, Spain. Harbor UCLA Med Ctr, Torrance, CA USA. Hosp Sick Children, Toronto, ON M5G 1X8, Canada. Univ Hosp Maastricht, Maastricht, Netherlands. Queen Silvias Childrens Hosp, Gothenburg, Sweden. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Duke Univ, Med Ctr, Durham, NC USA. Occupat Med, Cincinnati, OH USA. Lab Biofis & Bioengn, Barcelona, Spain. Univ Aarhus, Aarhus, Denmark. Azienda Osped S Croce & Carle, Cuneo, Italy. CNR, Inst Clin Physiol, I-56100 Pisa, Italy. Pharmaceut Res Associates Inc, Lenexa, KS USA. RP Brusasco, V (reprint author), Univ Genes, Vle Benedetto 15,6, I-16132 Genoa, Italy. EM vito.brusasco@unige.it NR 44 TC 0 Z9 0 U1 0 U2 6 PU MASSON EDITEUR PI MOULINEAUX CEDEX 9 PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE SN 0761-8425 J9 REV MAL RESPIR JI Rev. Mal. Respir. PD MAR PY 2007 VL 24 IS 3 BP S15 EP S25 DI 10.1019/200720003 PN 2 PG 11 WC Respiratory System SC Respiratory System GA 162RP UT WOS:000246107500005 ER PT J AU Pellegrino, R Viegi, G Brusasco, V Crapo, RO Burgos, F Casaburi, R Coates, A van der Grinten, CPM Gustafsson, P Hankinson, J Jensen, R Johnson, DC MacIntyre, N Mckay, R Miller, MR Navajas, D Pedersen, OF Wanger, J AF Pellegrino, R. Viegi, G. Brusasco, V. Crapo, R. O. Burgos, F. Casaburi, R. Coates, A. van der Grinten, C. P. M. Gustafsson, P. Hankinson, J. Jensen, R. Johnson, D. C. MacIntyre, N. McKay, R. Miller, M. R. Navajas, D. Pedersen, O. F. Wanger, J. TI Interpretative strategies for lung function tests SO REVUE DES MALADIES RESPIRATOIRES LA French DT Review ID OBSTRUCTIVE PULMONARY-DISEASE; MONOXIDE DIFFUSING-CAPACITY; AIR-FLOW OBSTRUCTION; TRANSFER-COEFFICIENT KCO; MAXIMAL EXPIRATORY FLOW; SPIROMETRY REFERENCE VALUES; CARBON-MONOXIDE; ALVEOLAR VOLUME; INDUCED BRONCHOCONSTRICTION; BRONCHODILATOR RESPONSE C1 Univ Genoa, I-16132 Genoa, Italy. Azienda Osped S Croce & Carle, Cuneo, Italy. CNR, Inst Clin Physiol, I-56100 Pisa, Italy. LDS Hosp, Salt Lake City, UT USA. Hosp Clin Villarroel, Barcelona, Spain. Harbor UCLA Med Ctr, Torrance, CA 90509 USA. Hosp Sick Children, Toronto, ON M5G 1X8, Canada. Univ Hosp Maastricht, Maastricht, Netherlands. Queen Silvias Childrens Hosp, Gothenburg, Sweden. Hankinson Consulting Inc, Valdosta, GA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Duke Univ, Med Ctr, Durham, NC USA. Occupat Med, Cincinnati, OH USA. Univ Hosp Birmingham NHS Trust, Birmingham, W Midlands, England. Lab Biofis & Bioengn, Barcelona, Spain. Univ Aarhus, Aarhus, Denmark. Pharmaceut Res Associates Inc, Lenexa, KS USA. RP Brusasco, V (reprint author), Univ Genoa, Vle Benedetto 15,6, I-16132 Genoa, Italy. EM vito.brusasco@unige.it NR 159 TC 2 Z9 2 U1 2 U2 15 PU MASSON EDITEUR PI MOULINEAUX CEDEX 9 PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE SN 0761-8425 EI 1776-2588 J9 REV MAL RESPIR JI Rev. Mal. Respir. PD MAR PY 2007 VL 24 IS 3 BP S83 EP S108 DI 10.1019/200720007 PN 2 PG 26 WC Respiratory System SC Respiratory System GA 162RP UT WOS:000246107500009 ER PT J AU Wanger, J Clausen, JL Coates, A Pedersen, OF Brusasco, V Burgos, F Casaburi, R Crapo, R Enright, P van der Grinten, CPM Gustafsson, P Hankinson, J Jensen, R Johnson, D MacIntyre, N Mckay, R Miller, MR Navajas, D Pellegrino, R Viegi, G AF Wanger, J. Clausen, J. L. Coates, A. Pedersen, O. F. Brusasco, V. Burgos, F. Casaburi, R. Crapo, R. Enright, P. van der Grinten, C. P. M. Gustafsson, P. Hankinson, J. Jensen, R. Johnson, D. MacIntyre, N. McKay, R. Miller, M. R. Navajas, D. Pellegrino, R. Viegi, G. TI Standardisation of the measurement of lung volumes SO REVUE DES MALADIES RESPIRATOIRES LA French DT Article ID FUNCTIONAL RESIDUAL CAPACITY; THORACIC GAS VOLUME; PULMONARY; PLETHYSMOGRAPHY; QUANTIFICATION; ABBREVIATIONS; FREQUENCY; SYMBOLS; UNITS C1 Univ Genoa, I-16132 Genoa, Italy. Pharmaceut Res Associates Inc, Lenexa, KS USA. Univ Calif San Diego, San Diego, CA 92103 USA. Hosp Sick Children, Toronto, ON M5G 1X8, Canada. Univ Aarhus, Aarhus, Denmark. Hosp Clin Villarroel, Barcelona, Spain. Harbor UCLA Med Ctr, Torrance, CA 90509 USA. LDS Hosp, Salt Lake City, UT USA. Univ Hosp Maastricht, Maastricht, Netherlands. Queen Silvias Childrens Hosp, Gothenburg, Sweden. Hankinson Consulting Inc, Valdosta, GA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Duke Univ, Med Ctr, Durham, NC USA. Occupat Med, Cincinnati, OH USA. Univ Hosp Birmingham, NHS Trust, Birmingham, W Midlands, England. Univ Barcelona, IDIBAPS, Barcelona, Spain. Azienda Osped S Croce & Carle, Cuneo, Italy. CNR, Inst Clin Physiol, I-56100 Pisa, Italy. RP Brusasco, V (reprint author), Univ Genoa, Vle Benedetto 15,6, I-16132 Genoa, Italy. EM vito.brusasco@unige.it RI Burgos, Felip/E-5734-2015 OI Burgos, Felip/0000-0002-4938-4581 NR 41 TC 2 Z9 2 U1 0 U2 5 PU MASSON EDITEUR PI MOULINEAUX CEDEX 9 PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE SN 0761-8425 J9 REV MAL RESPIR JI Rev. Mal. Respir. PD MAR PY 2007 VL 24 IS 3 BP S51 EP S64 DI 10.1019/200720005 PN 2 PG 14 WC Respiratory System SC Respiratory System GA 162RP UT WOS:000246107500007 ER PT J AU Leung, WW Blanchard, JJ AF Leung, W. W. Blanchard, J. J. TI Experience and expression of emotion in social anhedonia: An examination of social affiliative state in schizotypy SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 Bronx Vet Adm Med Ctr, Educ & Clin Ctr, Mental Illness Res, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 220 EP 220 PG 1 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506600053 ER PT J AU Copeland, LA Lawrence, VA Zeber, JE Mortensen, EM AF Copeland, L. A. Lawrence, V. A. Zeber, J. E. Mortensen, E. M. TI Surgery rates among veterans with schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 S Texas Vet Hlth Care Syst, Verdict HSRD, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 230 EP 231 PG 2 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506600083 ER PT J AU Roffman, JL Weiss, AP Deckersbach, T Purcell, S Freudenreich, O Henderson, DS Ellis, C Duff, M Wong, DH Halsted, CH Goff, DC AF Roffman, J. L. Weiss, A. P. Deckersbach, T. Purcell, S. Freudenreich, O. Henderson, D. S. Ellis, C. Duff, M. Wong, D. H. Halsted, C. H. Goff, D. C. TI Effects of the MTHFR C677T polymorphism on negative symptoms and cognition in schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 Massachusetts Gen Hosp, Harvard Med Sch, Dept Psychiat, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 288 EP 288 PG 1 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506600247 ER PT J AU Dougherty, GG van Kammen, DP Yao, JK AF Dougherty, G. G. van Kammen, D. P. Yao, J. K. TI Covariance analysis of CSF amino acids in healthy normal and schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 VA Pittsburgh Healthcare System, Med Res Serv, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 309 EP 309 PG 1 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506600309 ER PT J AU Freudenreich, O Brockman, MA Goff, DC AF Freudenreich, O. Brockman, M. A. Goff, D. C. TI Peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR) SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 309 EP 310 PG 2 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506600311 ER PT J AU Levitt, JJ Rosow, LK Khan, U Kikinis, R Jolesz, FA McCarley, RW Shenton, ME AF Levitt, J. J. Rosow, L. K. Khan, U. Kikinis, R. Jolesz, F. A. McCarley, R. W. Shenton, M. E. TI The ventral and dorsal striatum in schizophrenia: An MRI study SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 Harvard Med Sch, VA Boston Healthcare Syst, Brockton, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 342 EP 342 PG 1 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506600402 ER PT J AU Nakamura, M Nestor, PG McCarley, RW Niznikiewicz, MA Levitt, JJ Kawashima, T Hsu, L Cohen, A Shenton, ME AF Nakamura, M. Nestor, P. G. McCarley, R. W. Niznikiewicz, M. A. Levitt, J. J. Kawashima, T. Hsu, L. Cohen, A. Shenton, M. E. TI Altered orbitofrontal sulco-gyral pattern in schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 Harvard Med Sch, VA Boston Healthcare Syst, Brockton, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 348 EP 349 PG 2 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506600419 ER PT J AU Kuperberg, GR Lakshmanan, B West, C AF Kuperberg, G. R. Lakshmanan, B. West, C. TI Double dissociations in hemodynamic modulation during the build-up of concrete and abstract meaning in schizophrenia: Evidence from FMRI SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 375 EP + PG 2 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506600500 ER PT J AU Manoach, D AF Manoach, D. TI Multimodal neuroimaging investigations of executive dysfunction in schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 377 EP 377 PG 1 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506600504 ER PT J AU Weiss, AP Goff, DC Roffman, JL Ellis, CB Schacter, DL AF Weiss, A. P. Goff, D. C. Roffman, J. L. Ellis, C. B. Schacter, D. L. TI Neural correlates of source memory performance in schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 388 EP 388 PG 1 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506600535 ER PT J AU Martin, LF Hall, MH Ross, RG Zerbe, G Freedman, R Olincy, A AF Martin, L. F. Hall, M. H. Ross, R. G. Zerbe, G. Freedman, R. Olincy, A. TI Discrimination of bipolar disorder and schizophrenia by physiological measures SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 408 EP 408 PG 1 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506600589 ER PT J AU Barr, RS Culhane, MA Jubelt, LE Weiss, AP Dyer, MA Mufti, RS Evins, AE AF Barr, R. S. Culhane, M. A. Jubelt, L. E. Weiss, A. P. Dyer, M. A. Mufti, R. S. Evins, A. E. TI Nicotine reduces impulsivity in nonsmokers with schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 420 EP 420 PG 1 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506601022 ER PT J AU Kennedy, A Harvey, M Wood, AE Kilzieh, N Tapp, A AF Kennedy, A. Harvey, M. Wood, A. E. Kilzieh, N. Tapp, A. TI Adjunctive galantamine's effect on schizophrenic symptomatology: A case report SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 MIRECC, VA Puget Sound Hlth Care Syst, Tacoma, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 436 EP 436 PG 1 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506601067 ER PT J AU Tapp, A Wood, AE Kennedy, A AF Tapp, A. Wood, A. E. Kennedy, A. TI Incidence of tardive dyskinesia in first and second generation antipsychotic medications SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 VA Puget Sound Hlth Care Syst, Tacoma, WA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 507 EP 507 PG 1 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506601262 ER PT J AU Holland, C Vinogradov, S Merzenich, M AF Holland, C. Vinogradov, S. Merzenich, M. TI Neuroplasticity-based cognitive training in schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 524 EP 524 PG 1 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506601311 ER PT J AU Sitnikova, T Kuperberg, G AF Sitnikova, T. Kuperberg, G. TI Time-course and neuroanatomy of abnormal real-world comprehension in schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 Massachusetts Gen Hosp, Martinos Ctr, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 541 EP 542 PG 2 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506601363 ER PT J AU Vinogradov, S Holland, C Merzenich, M Mellon, S Wolkowitz, O AF Vinogradov, S. Holland, C. Merzenich, M. Mellon, S. Wolkowitz, O. TI Increased serum BDNF levels in schizophrenic subjects after intensive neuroplasticity-based cognitive training SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 10th International Congress on Schizophrenia Research CY APR 02-06, 2005 CL Savannah, GA C1 Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Psychiat, San Francisco, CA 94143 USA. RI Wolkowitz, Owen/J-6649-2013 OI Wolkowitz, Owen/0000-0003-0655-5042 NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2007 VL 33 IS 2 BP 547 EP 547 PG 1 WC Psychiatry SC Psychiatry GA 140LL UT WOS:000244506601380 ER PT J AU Ouellette, H Kassarjian, A Tetreault, P Palmer, W AF Ouellette, Hugue Kassarjian, Ara Tetreault, Patrice Palmer, William TI Imaging of the overhead throwing athlete (vol 9, pg 316, 2005) SO SEMINARS IN MUSCULOSKELETAL RADIOLOGY LA English DT Correction C1 Harvard Univ, Massachusetts Gen Hosp, Dept Radiobiochem, Sch Med, Boston, MA 02114 USA. CHUM Hop Notre Dame, Dept Orthoped Surg, Notre Dame, IN USA. RP Ouellette, H (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Radiobiochem, Sch Med, 55 Fruit St,Yawkey 6th Floor, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1089-7860 J9 SEMIN MUSCULOSKEL R JI Semin. Musculoskelet. Radiol. PD MAR PY 2007 VL 11 IS 1 BP 91 EP 91 DI 10.1055/s-2007-984733 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 195OS UT WOS:000248422100011 ER PT J AU Sundaram, M Rosenthal, DI Hodler, J AF Sundaram, M. Rosenthal, D. I. Hodler, J. TI Scientific misconduct SO SKELETAL RADIOLOGY LA English DT Editorial Material C1 Cleveland Clin Fdn, Cleveland, OH 44195 USA. Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. Orthoped Univ Hosp Balgrist, CH-8008 Zurich, Switzerland. RP Sundaram, M (reprint author), Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA. EM sundarm@ccf.org; dirosenthal@partners.org; juerg.hodler@balgrist.ch NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0364-2348 J9 SKELETAL RADIOL JI Skeletal Radiol. PD MAR PY 2007 VL 36 IS 3 BP 179 EP 179 DI 10.1007/s00256-006-0256-4 PG 1 WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging GA 134PL UT WOS:000244095200001 PM 17205322 ER PT J AU Hu, WP Li, JD Zhang, CK Boehmer, L Siegel, JM Zhou, QY AF Hu, Wang-Ping Li, Jia-Da Zhang, Chengkang Boehmer, Lisa Siegel, Jerome M. Zhou, Qun-Yong TI Altered circadian and homeostatic sleep regulation in prokineticin 2-deficient mice SO SLEEP LA English DT Article DE sleep; prokineticin 2; sleep homeostasis; circadian genes; EEG; behavioral challenge ID DORSAL RAPHE NUCLEUS; KNOCK-OUT MICE; SUPRACHIASMATIC NUCLEUS; BEHAVIORAL STATE; AROUSAL; CLOCK; EXPRESSION; DEPRIVATION; WAKEFULNESS; AMYGDALA AB Study Objectives: Sleep is regulated by circadian and homeostatic processes. Recent studies with mutant mice have indicated that circadian-related genes regulate sleep amount, as well as the timing of sleep. Thus a direct link between circadian and homeostatic regulation of sleep may exist, at least at the molecular level. Prokineticin 2 (PK2), which oscillates daily with high amplitude in the suprachiasmatic nuclei (SCN), has been postulated to be an SCN output molecule. In particular, mice lacking the PK2 gene (PK2-/-) have been shown to display significantly reduced rhythmicity for a variety of circadian physiological and behavioral parameters. We investigated the role of PK2 in sleep regulation. Design: EEG/EMG sleep-wake patterns were recorded in PK2-/- mice and their wild-type littermate controls under baseline and challenged conditions. Measurements and Results: PK24- mice exhibited reduced total sleep time under entrained light-dark and constant darkness conditions. The reduced sleep time in PK24- mice occurred predominantly during the light period and was entirely due to a decrease in non-rapid eye movement (NREM) sleep time. However, PK24- mice showed increased rapid eye movement (REM) sleep time in both light and dark periods. After sleep deprivation, compensatory rebound in NREM sleep, REM sleep, and EEG delta power was attenuated in PK24- mice. In addition, PK24- mice had an impaired response to sleep disturbance caused by cage change in the light phase. Conclusions: These results indicate that PK2 plays roles in both circathan and homeostatic regulation of sleep. PK2 may also be involved in maintaining the awake state in the presence of behavioral challenges. C1 Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA. Univ Calif Los Angeles, Sch Med, VA GLAHS Sepulveda, Dept Psychiat, North Hills, CA USA. Univ Calif Los Angeles, Sch Med, Brain Res Inst, North Hills, CA USA. RP Zhou, QY (reprint author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA. EM qzhou@uci.edu FU NIMH NIH HHS [R01 MH067753-05] NR 34 TC 47 Z9 50 U1 1 U2 2 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD MAR 1 PY 2007 VL 30 IS 3 BP 247 EP 256 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 151QP UT WOS:000245305900002 PM 17425220 ER PT J AU Powell, NB Schechtman, KB Riley, RW Guilleminault, C Chiang, RPY Weaver, EM AF Powell, Nelson B. Schechtman, Kenneth B. Riley, Robert W. Guilleminault, Christian Chiang, Rayleigh Ping-Ying Weaver, Edward M. TI Sleepy driver near-misses may predict accident risks SO SLEEP LA English DT Article DE sleepy driving; sleep disorders; sleepy near-miss accidents; driving accidents; driving risks; Epworth Sleepiness Scale ID EPWORTH SLEEPINESS SCALE; MOTOR-VEHICLE CRASHES; DAYTIME SLEEPINESS; TRAFFIC ACCIDENTS; SERIOUS INJURY; APNEA; MANAGEMENT; PATIENT AB Study Objectives: To quantify the prevalence of self-reported near-miss sleepy driving accidents and their association with self-reported actual driving accidents. Design: A prospective cross-sectional internet-linked survey on driving behaviors. Setting: Dateline NBC News website. Results: Results are given on 35,217 (88% of sample) individuals with a mean age of 37.2 +/- 13 years, 54.8% women, and 87% white. The risk of at least one accident increased monotonically from 23.2% if there were no near-miss sleepy accidents to 44.5% if there were >= 4 near-miss sleepy accidents (P < 0.0001). After covariate adjustments, subjects who reported at least one near-miss sleepy accident were 1.13 (95% Cl, 1.10 to 1.16) times as likely to have reported at least one actual accident as subjects reporting no near-miss sleepy accidents (P < 0.0001). The odds of reporting at least one actual accident in those reporting 4 near-miss sleepy accidents as compared to those reporting no near-miss sleepy accidents was 1.87 ( 95% Cl, 1.64 to 2.14). Furthermore, after adjustments, the summary Epworth Sleepiness Scale (ESS) score had an independent association with having a near-miss or actual accident. An increase of 1 unit of ESS was associated with a covariate adjusted 4.4% increase of having at least one accident (P < 0.0001). Conclusion: A statistically significant dose-response was seen between the numbers of self-reported sleepy near-miss accidents and an actual accident. These findings suggest that sleepy near-misses may be dangerous precursors to an actual accident. C1 Stanford Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Stanford, CA 94305 USA. Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. Washington Univ, Sch Med, Div Biostat, St Louis, MO 63130 USA. Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. Fu Jen Catholic Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Taipei, Taiwan. Shin Kong Wu Ho Su Mem Hosp, Dept Otolaryngol Head & Neck Surg, Taipei, Taiwan. Univ Washington, Sch Med, Sleep Disorders Ctr, Harborview Med Ctr, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Powell, NB (reprint author), 750 Welch Rd Suite 317, Palo Alto, CA 94304 USA. EM npowell@ix.netcom.com FU NHLBI NIH HHS [K23 HL068849, K23 HL068849-04] NR 26 TC 57 Z9 58 U1 1 U2 4 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD MAR 1 PY 2007 VL 30 IS 3 BP 331 EP 342 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 151QP UT WOS:000245305900012 PM 17425230 ER PT J AU Cheng, EM Asch, SM Brook, RH Vassar, SD Jacob, EL Lee, ML Chang, DS Sacco, RL Hsiao, AF Vickrey, BG AF Cheng, Eric M. Asch, Steve M. Brook, Robert H. Vassar, Stefanie D. Jacob, Erin L. Lee, Martin L. Chang, Donald S. Sacco, Ralph L. Hsiao, An-Fu Vickrey, Barbara G. TI Suboptimal control of atherosclerotic disease risk factors after cardiac and cerebrovascular procedures SO STROKE LA English DT Article DE cardiac procedurest; carotid prevention; secondary prevention ID CAROTID-ENDARTERECTOMY; MYOCARDIAL-INFARCTION; ADMINISTRATIVE DATA; STROKE; MANAGEMENT; CARE; PREVENTION; HYPERLIPIDEMIA; HYPERTENSION AB Background and Purpose - Undergoing a carotid endarterectomy, a coronary artery bypass graft, or a percutaneous coronary intervention provides an opportunity to optimize control of blood pressure and low-density lipoprotein. Methods - Using Veterans Administration databases, we determined whether patients who underwent a carotid endarterectomy (n = 252), coronary artery bypass graft ( n = 486), or percutaneous coronary intervention ( n = 720) in 2002 to 2003 at 5 Veterans Administration Healthcare Systems had guideline-recommended control of blood pressure and low-density lipoprotein in 12-month periods before and after a vascular procedure. Postprocedure control of risk factors across procedure groups was compared using chi(2) tests and multivariate logistic regression. Results - The proportion of patients undergoing carotid endarterectomy who had optimal control of both blood pressure and low-density lipoprotein increased from 23% before the procedure to 33% after the procedure ( P = 0.05) compared with increases from 32% to 43% for coronary artery bypass graft ( P = 0.001) and from 29% to 45% for percutaneous coronary intervention ( P = 0.002). Compared with the carotid endarterectomy group, the percutaneous coronary intervention group was more likely to achieve optimal control of blood pressure ( OR: 1.92, 95% CI: 1.42 to 2.59) or low-density lipoprotein ( OR: 1.51, 95% CI: 1.01 to 2.26) and the coronary artery bypass graft group was more likely to achieve optimal control of blood pressure ( OR: 1.53, 95% CI: 1.42 to 2.59). Postprocedure cardiology visits, increase in medication intensity, and greater frequency of outpatient visits were also associated with optimal postprocedure risk factor control. Conclusions - Although modest improvements in risk factor control were detected, a majority of patients in each vascular procedure group did not achieve optimal risk factor control. More effective risk factor control programs are needed among most vascular procedure patients. C1 VA Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA 90073 USA. VA Ctr Study Healthcare Provider Behav, Sepulveda, CA USA. Univ Calif Los Angeles, Div Cardiol, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Div Cardiol, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. RAND Corp, Hlth Program, Santa Monica, CA USA. Univ Calif Irvine, Ctr Hlth Policy Res, Irvine, CA 92717 USA. VA Long Beach Healthcare Syst, Med Healthcare Grp, Long Beach, CA USA. Columbia Univ, Dept Epidemiol, New York, NY 10027 USA. Columbia Univ, Dept Neurol, New York, NY 10027 USA. RP Cheng, EM (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Neurol, 11301 Wilshire Blvd,B500,ML 127, Los Angeles, CA 90073 USA. EM eric.cheng@va.gov NR 24 TC 8 Z9 8 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2007 VL 38 IS 3 BP 929 EP 934 DI 10.1161/01.STR.0000257310.08310.0f PG 6 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 140DB UT WOS:000244482500026 PM 17255549 ER PT J AU Yin, W Signore, AP Iwai, M Cao, GD Gao, YQ Johnnides, MJ Hickey, RW Chen, J AF Yin, Wei Signore, Armando P. Iwai, Masanori Cao, Guodong Gao, Yanqin Johnnides, Michael J. Hickey, Robert W. Chen, Jun TI Preconditioning suppresses inflammation in neonatal hypoxic ischemia via Akt activation SO STROKE LA English DT Article DE hypoxia-ischemia; inflammation; neonatal; p-Akt; preconditioning ID GLYCOGEN-SYNTHASE KINASE-3-BETA; BRAIN-INJURY; RAT-BRAIN; NEUROPROTECTION; DAMAGE; TOLERANCE; INHIBITION; EXPRESSION; MEDIATORS; RECEPTOR AB Background and Purpose - Hypoxic preconditioning ( PC) confers robust neuroprotection against neonatal hypoxic-ischemic brain injury (H-I), yet the underlying mechanism is poorly understood. In the adult brain, neuronal survival after ischemia is associated with the activation of the phosphatidylinositol 3-kinase (PI3-K)/Akt signaling pathway. Suppression of inflammation is a newly identified direct consequence of PI3-K/Akt signaling. We therefore investigated whether PI3-K/Akt suppresses inflammation and contributes to PC-induced neuroprotection. Methods - Postnatal day 7 rats were exposed for 3 hours to either ambient air or 8% oxygen, which induces hypoxic PC. H-I was produced 24 hours later by unilateral carotid artery ligation followed by 2.5 hours of hypoxia. Animals were euthanized 0 to 24 hours later for detecting Akt and glycogen synthetase kinase-3 beta phosphorylation (p-Akt, p-GSK-3 beta), 24 hours later for assessing cytokine expression and inflammatory markers, and 7 days later for measuring brain tissue loss. In addition, LY294002 was injected intracerebroventricularly to inhibit PI3-K/Akt. Results - Brains with H-I without PC showed delayed but sustained reduction in p-Akt. PC restored the levels of p-Akt and the Akt substrate GSK-3 beta, reduced proinflammatory markers (NF-kappa B, COX-2, CD68, myeloperoxidase, and microglial activation), and markedly ameliorated H-I-induced brain tissue loss. Inhibition of PI3-K/Akt using LY294002 attenuated PC neuroprotection and promoted the expression of NF-kappa B, COX-2, and CD68. Proteomic microarray analysis revealed that PC inhibited expression of proinflammatory cytokines induced by H-I or a dose of lipopolysaccharide that resulted in minimal tissue damage. Conclusions - Suppression of inflammatory responses may contribute to PC neuroprotection against neonatal H-I brain injury. This effect is mediated in part via upregulating PI3-K/Akt activity. C1 Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Med, Inst Neurodegenerat Dis, Pittsburgh, PA 15213 USA. Fudan Univ, Sch Med, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. Childrens Hosp Pittsburgh, Div Pediat Emergency Med, Pittsburgh, PA 15213 USA. Vet Affairs Pittsburgh Hlth Care Syst, Educ & Clin Ctr, Pittsburgh, PA USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S-507,Biomed Sci Tower, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU NINDS NIH HHS [NS43802, NS45048, NS36736] NR 28 TC 65 Z9 71 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2007 VL 38 IS 3 BP 1017 EP 1024 DI 10.1161/01.STR.0000258102.18836.ca PG 8 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 140DB UT WOS:000244482500040 PM 17272774 ER EF